Torsade B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
ventricular B-DISO-MISC B-ANAT-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
intermittent O-MISC B-CHED-MISC
dobutamine B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
dilated B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
congestive B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
heart B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
secondary O-MISC B-ACTI-MISC
to O-MISC I-CHED-MISC
dilated B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
arrhythmias I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
QT B-DISO-MISC I-DISO-MISC
prolongation I-DISO-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
torsade B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
ventricular B-DISO-MISC B-ANAT-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
cycle O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
intermittent O-MISC B-CHED-MISC
low O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mcg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
torsade B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ACTI-MISC
pointes I-DISO-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
intermittent O-MISC B-CHED-MISC
dobutamine B-CHED-MISC O-MISC
supports O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
unpredictable O-MISC B-CHED-MISC
fatal O-MISC B-CHED-MISC
arrhythmias B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
history O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
rhythm O-MISC I-ACTI-MISC
disturbances O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
proarrhythmic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
Dubutamine B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Positive O-MISC B-CONC-MISC
skin O-MISC I-CONC-MISC
tests O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
late O-MISC B-CHED-MISC
reactions O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
radiographic O-MISC B-OCCU-MISC
contrast B-CHED-MISC O-MISC
media I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
delayed O-MISC B-CHED-MISC
reactions O-MISC B-ANAT-MISC
several O-MISC I-ACTI-MISC
hours O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
radiographic O-MISC B-OBJC-MISC
and O-MISC B-ACTI-MISC
contrast B-CHED-MISC B-OBJC-MISC
materials I-CHED-MISC I-OBJC-MISC
( O-MISC B-ACTI-MISC
PRC B-CHED-MISC B-OBJC-MISC
) O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
frequency O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
report O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
delayed O-MISC B-CHED-MISC
reactions O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
intradermoreactions O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
IDR O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
patch O-MISC B-CONC-MISC
tests O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
series O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ionic O-MISC O-MISC
and O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
ionic O-MISC B-ACTI-MISC
PRC B-CHED-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
angiography O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
venous O-MISC B-CHED-MISC
route O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
n O-MISC B-CHED-MISC
degree O-MISC I-CHED-MISC
1 O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
biphasic O-MISC I-ACTI-MISC
reaction O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
immediate O-MISC B-CHED-MISC
reaction O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
dyspnea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
loss B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
consciousness I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
delayed O-MISC I-ACTI-MISC
macro B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
papular I-DISO-MISC B-ANAT-MISC
rash I-DISO-MISC B-ANAT-MISC
appeared O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whilst O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
n O-MISC B-CHED-MISC
degree O-MISC I-CHED-MISC
2 O-MISC I-CHED-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
generalised O-MISC B-CHED-MISC
sensation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heat O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
pain B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
site O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
immediately O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
generalised O-MISC B-CHED-MISC
macro O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
papular O-MISC B-ANAT-MISC
reaction O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
skin O-MISC B-CONC-MISC
tests O-MISC I-CONC-MISC
revealed O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
delayed O-MISC B-ANAT-MISC
reactions O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
IDR O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
patch O-MISC B-CONC-MISC
tests O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
PRC B-CHED-MISC I-GENE-MISC
with O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
chains O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
structures O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
positive O-MISC B-CONC-MISC
skin O-MISC I-CONC-MISC
tests O-MISC I-CONC-MISC
are O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
favour O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
immunological O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
help O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
allergy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
transient O-MISC B-CHED-MISC
hyperammonemic B-DISO-MISC I-ACTI-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
dehydration B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
infection B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

From O-MISC B-ACTI-MISC
1986 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
1998 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
episodes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
transient O-MISC B-CHED-MISC
hyperammonemic B-DISO-MISC I-ACTI-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

None O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
decompensated O-MISC B-CHED-MISC
liver B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Onset O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyperammonemic B-DISO-MISC I-ACTI-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
varied O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Plasma O-MISC I-GENE-MISC
ammonium B-CHED-MISC B-OCCU-MISC
level O-MISC I-OCCU-MISC
ranged O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
248 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2387 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
626 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
431 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
episodes O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
various O-MISC B-CHED-MISC
degrees O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
azotemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
occurred O-MISC B-DEVI-MISC
during O-MISC B-ACTI-MISC
bacterial B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
without O-MISC B-CHED-MISC
infection B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-DEVI-MISC
during O-MISC B-ACTI-MISC
periods O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dehydration B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Higher O-MISC B-ACTI-MISC
plasma O-MISC B-OCCU-MISC
ammonium B-CHED-MISC I-OCCU-MISC
levels O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
rapid O-MISC B-CHED-MISC
onset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hyperammonemia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
bacterial B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
003 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0006 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
daily O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
2600 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
1800 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
episodes O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
78 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
plasma O-MISC B-CONC-MISC
ammonium B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
mental O-MISC I-ACTI-MISC
status O-MISC B-ANAT-MISC
returned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
adequate O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
hyperammonemic B-DISO-MISC I-ACTI-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
can O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Azotemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
body O-MISC I-ACTI-MISC
fluid O-MISC B-ANAT-MISC
insufficiency O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
bacterial B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
recognize O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
condition O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
continuous O-MISC B-CHED-MISC
infusion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
quinine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
4 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminopyridine I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
conditioned O-MISC B-ACTI-MISC
place O-MISC B-CHED-MISC
preference O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
motor O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
two O-MISC B-ACTI-MISC
unselective O-MISC O-MISC
potassium B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
channel O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
quinine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
4 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminopyridine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
conditioned O-MISC B-ACTI-MISC
place O-MISC B-CHED-MISC
preference O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
biphasic O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
motor O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Quinine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
block O-MISC B-CHED-MISC
voltage O-MISC O-MISC
- O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
ATP B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
sensitive O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
while O-MISC B-ACTI-MISC
4 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminopyridine I-CHED-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
block O-MISC B-CHED-MISC
voltage O-MISC O-MISC
- O-MISC B-DISO-MISC
sensitive O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
counterbalanced O-MISC B-ACTI-MISC
method O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
quinine B-CHED-MISC O-MISC
attenuated O-MISC B-DEVI-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
place O-MISC I-GENE-MISC
preference O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
4 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminopyridine I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
ineffective O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
motor O-MISC B-CONC-MISC
activity O-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
measured O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
Animex O-MISC O-MISC
- O-MISC B-ACTI-MISC
activity O-MISC B-OBJC-MISC
meter O-MISC I-OBJC-MISC
neither O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
K B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
channel O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
affected O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypoactivity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
K B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
channel O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
prevented O-MISC B-CHED-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
secondary O-MISC B-CHED-MISC
hyperactivity B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
involvement O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
quinine B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
sensitive O-MISC B-DISO-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
4 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminopyridine I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
sensitive O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
reward O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blockade O-MISC O-MISC
of O-MISC B-ACTI-MISC
K B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
sensitive O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
blockers O-MISC O-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
sufficient O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypoactivity B-DISO-MISC I-ACTI-MISC
whereas O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
seems O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
connected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
quinine B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
4 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminopyridine I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
sensitive O-MISC B-DISO-MISC
K B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Nociceptin B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
orphanin B-CHED-MISC O-MISC
FQ I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
nocistatin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
learning B-DISO-MISC I-DISO-MISC
and I-DISO-MISC B-ACTI-MISC
memory I-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Nociceptin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
orphanin B-CHED-MISC O-MISC
FQ I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
endogenous O-MISC B-CHED-MISC
ligand O-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
orphan O-MISC O-MISC
opioid O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
like O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ORL1 O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
involves O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
functions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
CNS O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
hand O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
nocistatin B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
precursor O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
nociceptin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
blocks O-MISC B-ACTI-MISC
nociceptin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
allodynia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hyperalgesia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
ORL1 O-MISC O-MISC
receptors O-MISC B-DISO-MISC
which O-MISC B-ACTI-MISC
display O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
degree O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sequence O-MISC B-LIVB-MISC
homology O-MISC I-PROC-MISC
with O-MISC B-ACTI-MISC
classical O-MISC B-ACTI-MISC
opioid O-MISC O-MISC
receptors O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
abundant O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
little O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
regarding O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
learning O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
designed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
whether O-MISC B-ACTI-MISC
nociceptin B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
orphanin B-CHED-MISC O-MISC
FQ I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
nocistatin B-CHED-MISC O-MISC
could O-MISC B-ACTI-MISC
modulate O-MISC B-CHED-MISC
impairment B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
learning I-DISO-MISC I-DISO-MISC
and I-DISO-MISC B-ACTI-MISC
memory I-DISO-MISC B-UnknownType-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
muscarinic O-MISC O-MISC
cholinergic O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
alternation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Y O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
maze O-MISC I-GEOG-MISC
and O-MISC B-ACTI-MISC
step O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
down O-MISC I-CONC-MISC
type O-MISC B-ACTI-MISC
passive O-MISC B-DEVI-MISC
avoidance O-MISC I-DISO-MISC
tasks O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

While O-MISC B-ACTI-MISC
nocistatin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
nmol O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
alternation O-MISC I-DISO-MISC
performance O-MISC B-DEVI-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
session O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
task O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
alternation O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
behaviours O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
cent O-MISC B-ACTI-MISC
alternation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
shorter O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
step O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
down O-MISC I-CHED-MISC
latency O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
retention O-MISC B-CONC-MISC
test O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
nociceptin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
nmol O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
normal O-MISC B-CHED-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
nocistatin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
nmol O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
alternation O-MISC I-DISO-MISC
performance O-MISC B-DEVI-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
session O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
task O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
impairment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
alternation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
behaviours O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
nocistatin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
biologically O-MISC O-MISC
active O-MISC B-DISO-MISC
peptide O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
ameliorates O-MISC B-ACTI-MISC
impairments O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
alternation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
peptides O-MISC O-MISC
play O-MISC B-ACTI-MISC
opposite O-MISC B-ACTI-MISC
roles O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
learning O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Meloxicam B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
liver B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
patient O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
rheumatoid B-DISO-MISC I-ACTI-MISC
arthritis I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
cytolytic O-MISC B-ANAT-MISC
hepatitis B-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
meloxicam B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
introduced O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Belgium O-MISC B-ORGA-MISC
, O-MISC B-ACTI-MISC
meloxicam B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
nonsteroidal O-MISC O-MISC
antiinflammatory O-MISC B-DISO-MISC
drug O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
selective O-MISC B-CHED-MISC
action O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inducible O-MISC B-CHED-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cyclooxygenase O-MISC O-MISC
2 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
cytolytic O-MISC B-ANAT-MISC
hepatitis B-DISO-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
rapidly O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
meloxicam B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
antinuclear O-MISC O-MISC
antibodies O-MISC B-DISO-MISC
suggesting O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hypersensitivity B-DISO-MISC I-ACTI-MISC
mechanism O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
meloxicam B-CHED-MISC O-MISC
related O-MISC B-ACTI-MISC
liver B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
demonstrates O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
drug O-MISC O-MISC
to O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
hepatic B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
remoxipride B-CHED-MISC O-MISC
metabolites O-MISC O-MISC
in O-MISC B-ACTI-MISC
HL60 O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
CD34 O-MISC I-GENE-MISC
+ O-MISC B-GEOG-MISC
/ O-MISC B-ACTI-MISC
CD19 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
human O-MISC I-ANAT-MISC
bone O-MISC I-GENE-MISC
marrow O-MISC B-GEOG-MISC
progenitor O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
: O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
relevance O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
remoxipride B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
aplastic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
antipsychotic O-MISC O-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
remoxipride B-CHED-MISC O-MISC
[ O-MISC O-MISC
( B-CHED-MISC B-DISO-MISC
S I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
bromo I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
N I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
[ I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
ethyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
pyrrolidinyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
methyl I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
6 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dimethoxybenz I-CHED-MISC B-DISO-MISC
amide I-CHED-MISC B-DISO-MISC
] O-MISC B-DISO-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
acquired O-MISC B-ACTI-MISC
aplastic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ability O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
remoxipride B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
pyrrolidine B-CHED-MISC O-MISC
ring O-MISC B-DISO-MISC
metabolites O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
aromatic O-MISC O-MISC
ring O-MISC B-DISO-MISC
metabolites O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
parent O-MISC B-ACTI-MISC
compound O-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
apoptosis O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
HL60 O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
human O-MISC I-GENE-MISC
bone O-MISC B-GEOG-MISC
marrow O-MISC B-GEOG-MISC
progenitor O-MISC B-GEOG-MISC
( O-MISC B-GEOG-MISC
HBMP O-MISC B-GEOG-MISC
) O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Cells O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
compound O-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
microM O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Apoptosis O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
fluorescence O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
Hoechst B-CHED-MISC O-MISC
33342 I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
propidium B-CHED-MISC O-MISC
iodide I-CHED-MISC B-DISO-MISC
stained O-MISC B-CONC-MISC
cell O-MISC I-GENE-MISC
samples O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Results O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
determination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
internucleosomal O-MISC I-DISO-MISC
DNA O-MISC I-LIVB-MISC
fragmentation O-MISC I-LIVB-MISC
using O-MISC B-ACTI-MISC
gel O-MISC B-CONC-MISC
electrophoresis O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
HL60 O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
samples O-MISC B-GENE-MISC
and O-MISC B-ACTI-MISC
terminal O-MISC B-CONC-MISC
deoxynucleotidyl O-MISC I-CONC-MISC
transferase O-MISC I-CONC-MISC
assay O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
HBMP O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
catechol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
hydroquinone B-CHED-MISC O-MISC
metabolites O-MISC O-MISC
, O-MISC B-ACTI-MISC
NCQ436 B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
NCQ344 B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
HL60 O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
HBMP O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
dependent O-MISC I-CHED-MISC
manner O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phenols B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
NCR181 O-MISC O-MISC
, O-MISC B-ACTI-MISC
FLA873 O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
FLA797 B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
derivatives O-MISC O-MISC
formed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
oxidation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pyrrolidine B-CHED-MISC O-MISC
ring O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
FLA838 O-MISC O-MISC
, O-MISC B-ACTI-MISC
NCM001 O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
NCL118 O-MISC O-MISC
, O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

No O-MISC I-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
NCQ436 B-CHED-MISC O-MISC
but O-MISC B-ACTI-MISC
NCQ344 B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
biphasic O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
cell O-MISC B-CHED-MISC
types O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
inducing O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
concentrations O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
concentrations O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
catechol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
hydroquinone B-CHED-MISC O-MISC
metabolites O-MISC O-MISC
of O-MISC B-ACTI-MISC
remoxipride B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
HL60 O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
HBMP O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phenol B-CHED-MISC O-MISC
metabolites O-MISC O-MISC
were O-MISC B-ACTI-MISC
inactive O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Similarly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
benzene B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
catechol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
hydroquinone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
phenol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
induce O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
HBMP O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
[ O-MISC B-ACTI-MISC
Moran O-MISC B-ACTI-MISC
et O-MISC B-ACTI-MISC
al O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Mol O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
Pharmacol O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1996 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
610 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
615 O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
propose O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
remoxipride B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
benzene B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
induce O-MISC B-ACTI-MISC
aplastic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
via O-MISC B-ACTI-MISC
production O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
reactive O-MISC O-MISC
metabolites O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ability O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NCQ436 B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
NCQ344 B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
induce O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
HBMP O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
may O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanism O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
acquired O-MISC B-ACTI-MISC
aplastic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
remoxipride B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Synthesis O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
preliminary O-MISC B-ACTI-MISC
pharmacological O-MISC B-CONC-MISC
investigations O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
1 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dihydro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
acenaphthylenyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
piperazine I-CHED-MISC B-DISO-MISC
derivatives O-MISC B-DISO-MISC
as O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
atypical O-MISC B-CHED-MISC
antipsychotic O-MISC O-MISC
agents O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
research O-MISC B-CONC-MISC
towards O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
atypical O-MISC B-CHED-MISC
antipsychotic O-MISC O-MISC
agents O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
strategy O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dopaminergic O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
modulated O-MISC B-CHED-MISC
through O-MISC B-ACTI-MISC
manipulation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serotonergic O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
synthesis O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
preliminary O-MISC B-ACTI-MISC
pharmacological O-MISC B-CONC-MISC
evaluation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
atypical O-MISC B-CHED-MISC
antipsychotic O-MISC O-MISC
agents O-MISC B-DISO-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
structure O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
1 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dihydro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
acenaphthylenyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
piperazine I-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
7 O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Compound O-MISC O-MISC
7e O-MISC O-MISC
, O-MISC B-DISO-MISC
5 B-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
{ I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
[ I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dihydro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
acenaphthylenyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
piperazinyl I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
ethyl I-CHED-MISC B-DISO-MISC
} I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dihy I-CHED-MISC B-DISO-MISC
dro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
1H I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
indol I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
one I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
affinities O-MISC B-OCCU-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
5 O-MISC O-MISC
- O-MISC B-DISO-MISC
HT1A O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
5 O-MISC O-MISC
- O-MISC B-DISO-MISC
HT2A O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
moderate O-MISC B-ACTI-MISC
affinity O-MISC B-OCCU-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
D2 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

7e O-MISC O-MISC
exhibits O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
reversal O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
indicating O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
atypical O-MISC B-CHED-MISC
antipsychotic O-MISC O-MISC
nature O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Sub O-MISC B-CHED-MISC
- O-MISC I-LIVB-MISC
chronic O-MISC I-CHED-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
nitric B-CHED-MISC I-DISO-MISC
- I-CHED-MISC I-LIVB-MISC
oxide I-CHED-MISC I-LIVB-MISC
synthesis O-MISC I-LIVB-MISC
modifies O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NADPH B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
diaphorase O-MISC B-DISO-MISC
neurons O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

RATIONALE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
NG B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
nitro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
L I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
arginine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NOARG I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inhibitor O-MISC O-MISC
of O-MISC B-ACTI-MISC
nitric B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
oxide I-CHED-MISC B-DISO-MISC
synthase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NOS O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
induces O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
effect O-MISC B-ACTI-MISC
undergoes O-MISC B-ACTI-MISC
rapid O-MISC B-ACTI-MISC
tolerance O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
sub O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
chronic O-MISC I-CHED-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NOARG I-CHED-MISC B-DISO-MISC
treatment O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Nitric B-CHED-MISC O-MISC
oxide I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NO B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
dopaminergic O-MISC I-DISO-MISC
neurotransmission O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
striatum O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Neuroleptic O-MISC O-MISC
drugs O-MISC B-DISO-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
block O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
receptors O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rodents O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
subchronic O-MISC B-CHED-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NOARG I-CHED-MISC B-DISO-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC I-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NOS O-MISC O-MISC
neurons O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
areas O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
motor O-MISC B-CHED-MISC
control O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Male O-MISC I-DISO-MISC
albino O-MISC I-ANAT-MISC
Swiss O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
sub O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
chronically O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
twice O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NOARG I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Catalepsy B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beginning O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
end O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Reduced O-MISC B-ACTI-MISC
nicotinamide B-CHED-MISC O-MISC
adenine I-CHED-MISC B-DISO-MISC
dinucleotide I-CHED-MISC B-DISO-MISC
phosphate I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
diaphorase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NADPH B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
d O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
histochemistry O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
employed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
visualize O-MISC B-ACTI-MISC
NOS O-MISC O-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
index O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
enzyme O-MISC O-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
brain O-MISC I-GENE-MISC
regions O-MISC B-GEOG-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
motor O-MISC B-CHED-MISC
control O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NOARG I-CHED-MISC B-DISO-MISC
sub O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
chronic O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
produced O-MISC B-ACTI-MISC
tolerance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NOARG I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC I-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NADPH B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
d O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
positive O-MISC B-DISO-MISC
cells O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dorsal O-MISC I-GENE-MISC
part O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
caudate O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
accumbens O-MISC I-GENE-MISC
nuclei O-MISC I-GENE-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pedunculopontine O-MISC I-GENE-MISC
tegmental O-MISC B-GEOG-MISC
nucleus O-MISC B-GEOG-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
NADPH B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
d O-MISC B-DISO-MISC
neuron O-MISC I-GENE-MISC
number O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
substantia O-MISC I-GENE-MISC
nigra O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
pars O-MISC I-GENE-MISC
compacta O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NOARG I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
give O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
support O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
NO B-CHED-MISC O-MISC
plays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
motor O-MISC B-DEVI-MISC
behavior O-MISC I-DEVI-MISC
control O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
suggest O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
take O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
synaptic O-MISC I-GENE-MISC
changes O-MISC B-CHED-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
antipsychotic O-MISC O-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Prolonged O-MISC B-CHED-MISC
left B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
occurs O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
induced O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
ischaemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
pharmacological O-MISC B-OCCU-MISC
stress O-MISC I-OCCU-MISC
leads O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
reversible O-MISC B-CHED-MISC
left B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
similar O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
randomised O-MISC B-CONC-MISC
crossover O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
recovery O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
systolic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
left O-MISC I-LIVB-MISC
ventricular O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
after O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
ischaemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

SUBJECTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
stable B-DISO-MISC I-ACTI-MISC
angina I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
angiographically O-MISC B-CHED-MISC
proven O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

INTERVENTIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Treadmill O-MISC B-CONC-MISC
exercise O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
stress O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
different O-MISC B-CHED-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Quantitative O-MISC B-CHED-MISC
assessment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
left O-MISC I-LIVB-MISC
ventricular O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
transthoracic O-MISC B-CONC-MISC
echocardiography O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
regular O-MISC B-CHED-MISC
intervals O-MISC I-CHED-MISC
after O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
test O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Both O-MISC B-ACTI-MISC
forms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
stress O-MISC I-ACTI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
reversible O-MISC B-CHED-MISC
systolic O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
diastolic O-MISC I-ACTI-MISC
dysfunction O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maximum O-MISC B-ACTI-MISC
double O-MISC B-ACTI-MISC
product O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
53 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
ST O-MISC I-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
63 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
stress O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
ejection O-MISC I-ACTI-MISC
fraction O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
SEM O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Regional O-MISC B-CONC-MISC
analysis O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
worst O-MISC B-CHED-MISC
affected O-MISC B-CHED-MISC
segment O-MISC B-CHED-MISC
15 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
isovolumic O-MISC B-CHED-MISC
relaxation O-MISC B-DEVI-MISC
period O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
45 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
stress O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
ischaemia B-DISO-MISC I-ACTI-MISC
results O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
reversible O-MISC B-CHED-MISC
left B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
presumed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
stunning I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Dobutamine B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
ischaemia B-DISO-MISC I-ACTI-MISC
could O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
pathophysiology O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
phenomenon O-MISC B-OCCU-MISC
further O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Anorexigens O-MISC O-MISC
and O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
United O-MISC B-ORGA-MISC
States O-MISC I-ORGA-MISC
: O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
surveillance O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
North O-MISC I-ACTI-MISC
American O-MISC B-ANAT-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
appetite O-MISC O-MISC
suppressants O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
Europe O-MISC B-ORGA-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
primary B-DISO-MISC I-ACTI-MISC
pulmonary I-DISO-MISC B-ANAT-MISC
hypertension I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PPH B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
fenfluramine B-CHED-MISC O-MISC
appetite O-MISC O-MISC
suppressants O-MISC B-DISO-MISC
became O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
United O-MISC B-ORGA-MISC
States O-MISC I-ORGA-MISC
but O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
withdrawn O-MISC B-PHEN-MISC
in O-MISC B-ACTI-MISC
September O-MISC B-ACTI-MISC
1997 O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
concerns O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

MATERIALS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prospective O-MISC B-ACTI-MISC
surveillance O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
diagnosed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
referral O-MISC B-PHYS-MISC
centers O-MISC I-PHYS-MISC
in O-MISC B-ACTI-MISC
North O-MISC B-ORGA-MISC
America O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

Data O-MISC B-CHED-MISC
collected O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
seen O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
September O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1996 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
December O-MISC B-CHED-MISC
31 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1997 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
identifiable O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
classed O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
PPH B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
history O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
also O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
special O-MISC B-ACTI-MISC
attention O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
antidepressants O-MISC O-MISC
, O-MISC B-ACTI-MISC
anorexigens O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
amphetamines B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Five O-MISC B-ACTI-MISC
hundred O-MISC B-ACTI-MISC
seventy O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
205 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
PPH B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
374 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
from O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
causes O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
secondary O-MISC I-ACTI-MISC
pulmonary B-DISO-MISC B-ANAT-MISC
hypertension I-DISO-MISC B-ANAT-MISC
[ O-MISC B-ACTI-MISC
SPH O-MISC I-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
anorexigens O-MISC O-MISC
was O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medications O-MISC B-CONC-MISC
surveyed O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fenfluramines B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
preferential O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
PPH B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
SPH O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
adjusted O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
> O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
stronger O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
longer O-MISC B-CHED-MISC
duration O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
use O-MISC I-CHED-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
shorter O-MISC B-CHED-MISC
duration O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
use O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
pronounced O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
recent O-MISC B-CHED-MISC
users O-MISC I-ANAT-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
remote O-MISC B-CHED-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
unexpectedly O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
SPH O-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
anorexigens O-MISC O-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
magnitude O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
PPH B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
specificity O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
fenfluramines B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
previous O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
indicating O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
fenfluramines B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
causally O-MISC B-ACTI-MISC
related O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
PPH B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
prevalence O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
anorexigen O-MISC O-MISC
use O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
SPH O-MISC I-ACTI-MISC
also O-MISC B-ACTI-MISC
raises O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
precipitate O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
conditions O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
SPH O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CHED-MISC
aspects O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Heparin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clotting O-MISC I-DISO-MISC
of O-MISC I-LIVB-MISC
blood O-MISC I-LIVB-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
clinically O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
treat O-MISC B-CONC-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
anticoagulant O-MISC O-MISC
drugs O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
development O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
remains O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anticoagulant O-MISC O-MISC
of O-MISC B-ACTI-MISC
choice O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
treat O-MISC B-CONC-MISC
acute O-MISC I-ACTI-MISC
thrombotic B-DISO-MISC B-ANAT-MISC
episodes O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
meritorious O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
do O-MISC B-ACTI-MISC
exist O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Bleeding B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
untoward O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Major O-MISC B-ACTI-MISC
bleeding B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
concern O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
heparin B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
untoward O-MISC B-PHEN-MISC
effects O-MISC I-DEVI-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
include O-MISC B-ACTI-MISC
heparin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
thrombocytopenia B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
heparin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
osteoporosis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
eosinophilia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
skin B-DISO-MISC I-DISO-MISC
reactions I-DISO-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
allergic B-DISO-MISC I-ACTI-MISC
reactions I-DISO-MISC B-ANAT-MISC
other O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
alopecia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
transaminasemia O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
hypoaldosteronism B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
priapism B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
relatively O-MISC B-CHED-MISC
rare O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
extremely O-MISC B-CHED-MISC
widespread O-MISC B-CHED-MISC
use O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
quite O-MISC B-CHED-MISC
common O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
HITT B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
osteoporosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
reasonable O-MISC B-ACTI-MISC
incidences O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
softly O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
deduced O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
reports O-MISC B-CHED-MISC
dealing O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
unfractionated O-MISC O-MISC
heparin B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidences O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
newer O-MISC B-CHED-MISC
low O-MISC O-MISC
molecular O-MISC B-DISO-MISC
weight O-MISC B-DISO-MISC
heparins B-CHED-MISC B-DISO-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
much O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
common O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
longer O-MISC B-ACTI-MISC
experience O-MISC B-ACTI-MISC
will O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
clearly O-MISC B-ACTI-MISC
define O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
molecular O-MISC B-GENE-MISC
weight O-MISC I-GEOG-MISC
preparations O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bilateral O-MISC I-ACTI-MISC
optic B-DISO-MISC B-ANAT-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
FK506 B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
after O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bilateral O-MISC I-ACTI-MISC
optic B-DISO-MISC B-ANAT-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
FK B-CHED-MISC O-MISC
506 I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
Prograf O-MISC O-MISC
; O-MISC B-ACTI-MISC
Fujisawa O-MISC B-PHYS-MISC
USA O-MISC I-PHYS-MISC
, O-MISC I-PHYS-MISC
Inc O-MISC I-PHYS-MISC
, O-MISC B-ACTI-MISC
Deerfield O-MISC B-ORGA-MISC
, O-MISC I-ORGA-MISC
Illinois O-MISC I-ORGA-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
immunosuppression O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
orthotropic O-MISC B-CONC-MISC
liver O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

METHOD O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
after O-MISC B-ACTI-MISC
orthotropic O-MISC B-CONC-MISC
liver O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
serial O-MISC B-ACTI-MISC
neuro O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
ophthalmologic O-MISC I-CONC-MISC
examinations O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
laboratory O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
episodic O-MISC B-CHED-MISC
deterioration O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
vision O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
eyes O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
features O-MISC B-CHED-MISC
resembling O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
optic I-DISO-MISC B-ANAT-MISC
neuropathies I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Deterioration B-DISO-MISC B-OCCU-MISC
of I-DISO-MISC B-ACTI-MISC
vision I-DISO-MISC I-DISO-MISC
occurred O-MISC B-ACTI-MISC
despite O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Tacrolimus B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
immunosuppressive O-MISC O-MISC
agents O-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
optic B-DISO-MISC I-GENE-MISC
nerve I-DISO-MISC B-GEOG-MISC
toxicity I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Hypercalcemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mood O-MISC I-ACTI-MISC
stabilizers O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Recent O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
bipolar B-DISO-MISC B-CHED-MISC
patient O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
maintenance O-MISC B-DEVI-MISC
lithium B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
hypercalcemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
bradyarrhythmia B-DISO-MISC I-ACTI-MISC
prompted O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
conduct O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
bipolar B-DISO-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
lithium B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
hypercalcemia B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
printout O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypercalcemia B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
generated O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
eliminating O-MISC B-ACTI-MISC
spurious O-MISC B-CHED-MISC
hypercalcemias B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
intravenous O-MISC B-CHED-MISC
fluids O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
identified O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
non O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hypercalcemias B-DISO-MISC I-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
malignancies B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
medical O-MISC I-ACTI-MISC
conditions O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
A O-MISC B-UnknownType-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
lithium B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
hypercalcemia B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
B O-MISC B-UnknownType-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
B O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
comparable O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
A O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
latter O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
medically O-MISC B-ACTI-MISC
compromised O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
pharmacotherapies O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
generated O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
C1 O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
comparable O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
normocalcemic O-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
C2 O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
normocalcemic O-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
anticonvulsant O-MISC O-MISC
mood O-MISC O-MISC
stabilizers O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
electrocardiographic O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
ECG O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
B O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
C1 O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
C2 O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
differ O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ECG O-MISC I-ACTI-MISC
abnormalities O-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
conduction O-MISC I-ACTI-MISC
defects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hypercalcemia B-DISO-MISC I-ACTI-MISC
resulting O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
medical O-MISC I-ACTI-MISC
diseases O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
bipolar B-DISO-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
hypercalcemia B-DISO-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
frequencies O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
conduction O-MISC I-ACTI-MISC
defects O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
A O-MISC I-CHED-MISC
had O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
mortality O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
2 O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
year O-MISC B-ANAT-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
zero O-MISC B-CHED-MISC
mortality O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
clinical O-MISC B-ACTI-MISC
implications O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Attenuation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
nanosphere O-MISC B-GENE-MISC
( O-MISC B-ACTI-MISC
NS O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
718 O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
incorporating O-MISC B-ACTI-MISC
amphotericin B-CHED-MISC O-MISC
B I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

NS O-MISC O-MISC
- O-MISC B-DISO-MISC
718 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
nanosphere O-MISC B-ACTI-MISC
incorporating O-MISC B-ACTI-MISC
amphotericin B-CHED-MISC O-MISC
B I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
pathogenic O-MISC I-ANAT-MISC
fungi O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
toxicity B-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
NS O-MISC O-MISC
- O-MISC B-DISO-MISC
718 O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Fungizone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
amphotericin B-CHED-MISC O-MISC
B I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sodium I-CHED-MISC B-DISO-MISC
deoxycholate I-CHED-MISC B-DISO-MISC
; O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
AmB I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
using O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cell O-MISC B-CONC-MISC
cultures O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
by O-MISC B-ACTI-MISC
biochemical O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
histopathological O-MISC B-CHED-MISC
study O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
pharmacokinetic O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
amphotericin B-CHED-MISC O-MISC
B I-CHED-MISC B-DISO-MISC
following O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
formulation O-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Incubation O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
NS O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
718 O-MISC I-PHEN-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
less O-MISC I-CHED-MISC
damage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cultured O-MISC I-GENE-MISC
human O-MISC I-ANAT-MISC
renal O-MISC I-GENE-MISC
proximal O-MISC I-GENE-MISC
tubular O-MISC B-GEOG-MISC
epithelial O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
AmB I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Serum O-MISC B-CONC-MISC
blood O-MISC I-CONC-MISC
urea B-CHED-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
creatinine B-CHED-MISC I-ACTI-MISC
concentrations O-MISC B-ANAT-MISC
increased O-MISC B-CHED-MISC
significantly O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
given O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
iv O-MISC B-CHED-MISC
infusion O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
AmB I-CHED-MISC B-DISO-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
NS O-MISC O-MISC
- O-MISC B-DISO-MISC
718 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Histopathological O-MISC B-CHED-MISC
examination O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
showed O-MISC B-ACTI-MISC
tubular B-DISO-MISC I-ACTI-MISC
necrosis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
AmB I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
but O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
change O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
NS O-MISC O-MISC
- O-MISC B-DISO-MISC
718 O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Amphotericin B-CHED-MISC O-MISC
B I-CHED-MISC B-DISO-MISC
concentrations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
NS O-MISC O-MISC
- O-MISC B-DISO-MISC
718 O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
AmB I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
results O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
incorporation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amphotericin B-CHED-MISC O-MISC
B I-CHED-MISC B-DISO-MISC
into O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
nanospheres O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
NS O-MISC O-MISC
- O-MISC B-DISO-MISC
718 O-MISC B-DISO-MISC
attenuates O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
amphotericin B-CHED-MISC O-MISC
B I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Patterns O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sulfadiazine B-CHED-MISC O-MISC
acute B-DISO-MISC B-ACTI-MISC
nephrotoxicity I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Sulfadiazine B-CHED-MISC O-MISC
acute B-DISO-MISC B-CHED-MISC
nephrotoxicity I-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
reviving O-MISC B-ACTI-MISC
specially O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
toxoplasmosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
HIV O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
positive O-MISC I-OCCU-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
person O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Under O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
sulfadiazine B-CHED-MISC O-MISC
they O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
oliguria B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
abdominal B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
multiple O-MISC B-ACTI-MISC
radiolucent O-MISC B-OCCU-MISC
renal B-DISO-MISC I-GENE-MISC
calculi I-DISO-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
echography O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
recovered O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
normal O-MISC I-DISO-MISC
renal O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
after O-MISC B-ACTI-MISC
adequate O-MISC B-CHED-MISC
hydration O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
alcalinization O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
nephrostomy O-MISC B-OBJC-MISC
tube O-MISC I-OBJC-MISC
had O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
placed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
ureteral B-DISO-MISC I-ACTI-MISC
lithiasis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
functional O-MISC B-GEOG-MISC
kidney O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

None O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
dialysis O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
biopsy O-MISC I-CONC-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
benign O-MISC B-CHED-MISC
course O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
sulfadiazine B-CHED-MISC O-MISC
requires O-MISC B-ACTI-MISC
exquisite O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
water O-MISC I-DISO-MISC
ingestion O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alcalinization O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
the O-MISC B-ANAT-MISC
urine O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
communicate O-MISC I-DISO-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
person O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fact O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Probably O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
detected O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
think O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
would O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Downbeat B-DISO-MISC I-ACTI-MISC
nystagmus I-DISO-MISC B-ANAT-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
patient O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

IMPLICATIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
documents O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
dizziness B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
downbeating B-DISO-MISC I-ACTI-MISC
nystagmus I-DISO-MISC B-ANAT-MISC
while O-MISC B-ACTI-MISC
receiving O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
large O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
IV O-MISC B-ACTI-MISC
patient O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
analgesia O-MISC I-CONC-MISC
morphine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
reports O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
epidural O-MISC I-GENE-MISC
morphine B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
and O-MISC B-ANAT-MISC
signs O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
IV O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
patient O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
analgesia O-MISC I-CONC-MISC
morphine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Hemodynamic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
antiadrenergic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
dronedarone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
healed O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hemodynamic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
antiadrenergic O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
dronedarone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
noniodinated O-MISC O-MISC
compound O-MISC B-DISO-MISC
structurally O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
after O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
oral O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
rest O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
sympathetic O-MISC I-GENE-MISC
stimulation O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
conscious O-MISC I-ANAT-MISC
dogs O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
healed O-MISC I-ACTI-MISC
myocardial B-DISO-MISC B-ANAT-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
randomly O-MISC B-CHED-MISC
received O-MISC B-CHED-MISC
orally O-MISC B-CHED-MISC
dronedarone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
twice O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
washout O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
treatments O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
HR O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MBP O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
rate O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
increase O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
left O-MISC B-ANAT-MISC
ventricular O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
LVdP O-MISC B-OCCU-MISC
/ O-MISC B-ACTI-MISC
dt O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
echocardiographically O-MISC B-CONC-MISC
assessed O-MISC B-DEVI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
ejection O-MISC I-LIVB-MISC
fraction O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
LVEF O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
fractional O-MISC I-ACTI-MISC
shortening O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
FS O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
chronotropic O-MISC B-CHED-MISC
response O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
sympathetic O-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
posttreatment O-MISC B-CHED-MISC
conditions O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Resting O-MISC B-CHED-MISC
values O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
LVEF O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
FS O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
LVdP O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
dt O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
MBP O-MISC I-DISO-MISC
remained O-MISC B-ACTI-MISC
unchanged O-MISC B-ACTI-MISC
whatever O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
regimen O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
resting O-MISC I-ACTI-MISC
HR O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependently O-MISC B-ACTI-MISC
lowered O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
dronedarone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lesser O-MISC B-ACTI-MISC
extent O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
dronedarone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
highest O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
dronedarone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
displayed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
antiadrenergic O-MISC I-DISO-MISC
effect O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
impair O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
resting O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Consequently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
dronedarone B-CHED-MISC O-MISC
might O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
suitable O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
prevention O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
arrhythmias B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
compromising O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Phase O-MISC B-CONC-MISC
2 O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
platinum B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
fallopian I-DISO-MISC I-ACTI-MISC
tube I-DISO-MISC B-ANAT-MISC
cancers I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
carcinoma B-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
peritoneum I-DISO-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Several O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
have O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Doxil B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
active O-MISC B-CHED-MISC
antineoplastic O-MISC O-MISC
agent O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
platinum B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
resistant O-MISC B-CHED-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
limiting O-MISC I-CHED-MISC
toxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
standard O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
regimen O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
q O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
erythrodysesthesia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
hand B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
foot I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
" O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
stomatitis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
wished O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
tolerable O-MISC B-CHED-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
treatment O-MISC B-CONC-MISC
regimen O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
document O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
platinum B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
MATERIALS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
or I-DISO-MISC B-ACTI-MISC
fallopian I-DISO-MISC I-ACTI-MISC
tube I-DISO-MISC B-ANAT-MISC
cancers I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
peritoneal B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
platinum B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
stable O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
progressive O-MISC I-ACTI-MISC
disease O-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
agents O-MISC O-MISC
or O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
objective O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
< O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
q O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
age O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
entered O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
2 O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
prior O-MISC B-CHED-MISC
regimens O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
experienced O-MISC B-ACTI-MISC
grade O-MISC I-ACTI-MISC
2 O-MISC B-ANAT-MISC
hand B-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
foot I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
stomatitis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
episodes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
grade O-MISC B-CHED-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
grade O-MISC I-ACTI-MISC
3 O-MISC B-ANAT-MISC
diarrhea B-DISO-MISC B-ANAT-MISC
requiring O-MISC B-ACTI-MISC
hospitalization O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
hydration O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
required O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
reductions O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
courses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
administered O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
protocol O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
evaluable O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
exhibited O-MISC B-ACTI-MISC
objective O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
subjective O-MISC B-CHED-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
antineoplastic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
modified O-MISC B-CHED-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
regimen O-MISC B-CONC-MISC
results O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
stomatitis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
hand B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
foot I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
standard O-MISC B-CHED-MISC
FDA O-MISC B-PHYS-MISC
- O-MISC I-CHED-MISC
approved O-MISC I-CHED-MISC
dose O-MISC B-CONC-MISC
schedule O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Definite O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
antineoplastic O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
platinum B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
bipolar B-DISO-MISC B-ANAT-MISC
mania I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Olanzipine B-CHED-MISC O-MISC
HGGW O-MISC I-PHYS-MISC
Study O-MISC I-PHYS-MISC
Group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
vs O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
bipolar B-DISO-MISC B-ANAT-MISC
mania I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Four O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
parallel O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
115 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
DSM O-MISC B-CHED-MISC
- O-MISC I-CONC-MISC
IV O-MISC I-CONC-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
manic B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
mixed O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
randomized O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
primary O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
measure O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Young O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
Mania B-DISO-MISC I-CHED-MISC
Rating O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
( O-MISC I-CHED-MISC
Y O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
MRS O-MISC I-CHED-MISC
) O-MISC I-CHED-MISC
total O-MISC I-CHED-MISC
score O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Response O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
euthymia O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
priori O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
end O-MISC B-CHED-MISC
point O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
score O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
end O-MISC B-CHED-MISC
point O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Y O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
MRS O-MISC I-CHED-MISC
total O-MISC I-CHED-MISC
score O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Safety O-MISC B-OCCU-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
using O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
Extrapyramidal B-DISO-MISC B-CHED-MISC
Symptom I-DISO-MISC I-CHED-MISC
( O-MISC I-CHED-MISC
EPS B-DISO-MISC B-CHED-MISC
) O-MISC I-CHED-MISC
rating O-MISC B-CHED-MISC
scales O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
laboratory O-MISC B-CHED-MISC
values O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
electrocardiograms O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
vital O-MISC I-DISO-MISC
signs O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
weight O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Olanzapine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
demonstrated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
greater O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SD O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
improvement O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Y O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
MRS O-MISC I-CHED-MISC
total O-MISC I-CHED-MISC
score O-MISC I-CHED-MISC
than O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
evident O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
postbaseline O-MISC B-CHED-MISC
observation O-MISC B-CONC-MISC
1 O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
randomization O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
maintained O-MISC B-ACTI-MISC
throughout O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
carried O-MISC B-ACTI-MISC
forward O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Olanzapine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
demonstrated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
euthymia O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
61 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
statistically O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
EPSs B-DISO-MISC I-ACTI-MISC
between O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
greater O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SD O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
weight B-DISO-MISC I-ACTI-MISC
gain I-DISO-MISC B-ANAT-MISC
than O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
experienced O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
emergent O-MISC B-ACTI-MISC
somnolence B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
[ O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Olanzapine B-CHED-MISC O-MISC
demonstrated O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
efficacy O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
bipolar B-DISO-MISC B-ANAT-MISC
mania I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pupil B-DISO-MISC I-ACTI-MISC
dilation I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
tropicamide B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
vision O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
driving O-MISC B-DEVI-MISC
simulator O-MISC B-OBJC-MISC
performance O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
assess O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pupil B-DISO-MISC I-ACTI-MISC
dilation I-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
vision O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
driving O-MISC I-DISO-MISC
ability O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
tests O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
parameters O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
visual O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
driving O-MISC B-GENE-MISC
simulator O-MISC B-OBJC-MISC
performance O-MISC B-DEVI-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
drivers O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
pupil B-DISO-MISC B-CONC-MISC
dilation I-DISO-MISC I-CONC-MISC
using O-MISC B-ACTI-MISC
guttae O-MISC I-GENE-MISC
tropicamide B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
driving O-MISC B-OBJC-MISC
simulator O-MISC I-OBJC-MISC
( O-MISC B-ACTI-MISC
Transport O-MISC B-GENE-MISC
Research O-MISC I-GEOG-MISC
Laboratory O-MISC I-GEOG-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
measure O-MISC B-CHED-MISC
reaction O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
RT O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
speed O-MISC B-CHED-MISC
maintenance O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
steering O-MISC B-CONC-MISC
accuracy O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Tests O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
visual O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
included O-MISC B-ACTI-MISC
high O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
low O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
contrast O-MISC I-LIVB-MISC
visual O-MISC I-LIVB-MISC
acuity O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
HCVA O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
LCVA O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Pelli O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
Robson O-MISC I-CONC-MISC
contrast O-MISC I-CONC-MISC
threshold O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Goldmann O-MISC B-CONC-MISC
perimetry O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
FIELDS O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Useful O-MISC B-CHED-MISC
Field O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
View O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
UFOV O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
test O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
visual O-MISC B-CHED-MISC
attention O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
undertaken O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
differences O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dilatation O-MISC B-ACTI-MISC
measurements O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
statistical O-MISC B-CHED-MISC
significance O-MISC I-CHED-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
one O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
tail O-MISC I-CHED-MISC
paired O-MISC I-CHED-MISC
t O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
tests O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Pupillary B-DISO-MISC I-DISO-MISC
dilation I-DISO-MISC I-LIVB-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
deterioration O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
HCVA O-MISC I-ANAT-MISC
only O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
drivers O-MISC I-ANAT-MISC
also O-MISC B-ACTI-MISC
exhibited O-MISC B-ACTI-MISC
deterioration O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
LCVA O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
RT O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Little O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
emerged O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
deterioration O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
FIELDS O-MISC B-GENE-MISC
and O-MISC B-ACTI-MISC
UFOV O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

Also O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
drivers O-MISC I-ANAT-MISC
appeared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
adjust O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
driving O-MISC B-DEVI-MISC
behaviour O-MISC I-DEVI-MISC
by O-MISC B-ACTI-MISC
reducing O-MISC B-CHED-MISC
their O-MISC B-ACTI-MISC
speed O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
driving O-MISC B-GENE-MISC
simulator O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
steering O-MISC I-ACTI-MISC
accuracy O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Pupillary B-DISO-MISC I-ACTI-MISC
dilation I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
vision O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
daylight O-MISC B-OCCU-MISC
driving O-MISC B-DEVI-MISC
performance O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
young O-MISC I-ANAT-MISC
people O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
larger O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
broader O-MISC B-ACTI-MISC
spectrum O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
warranted O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
guidelines O-MISC B-CHED-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
recommended O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
isotretinoin B-DISO-MISC I-ACTI-MISC
embryopathy I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
bilateral O-MISC I-ACTI-MISC
anotia B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
Taussig B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Bing I-DISO-MISC B-ANAT-MISC
malformation I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
newborn O-MISC I-ANAT-MISC
infant O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
multiple O-MISC I-ACTI-MISC
congenital O-MISC I-ACTI-MISC
anomalies O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
anotia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
Taussig B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Bing I-DISO-MISC B-ANAT-MISC
malformation I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
isotretinoin B-CHED-MISC O-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
trimester O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
paper O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
draw O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fact O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
caution O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
prescribing O-MISC B-CONC-MISC
vitamin B-CHED-MISC O-MISC
A I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
containing O-MISC B-DISO-MISC
drugs O-MISC O-MISC
to O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
childbearing O-MISC I-DISO-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
methoxamine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
urethral O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
genuine O-MISC I-ACTI-MISC
stress B-DISO-MISC I-ACTI-MISC
incontinence I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
crossover O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
alpha1 O-MISC O-MISC
- O-MISC B-DISO-MISC
adrenoceptor O-MISC B-DISO-MISC
agonist O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
urinary B-DISO-MISC I-ACTI-MISC
stress I-DISO-MISC B-ANAT-MISC
incontinence I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
randomised O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
crossover O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
design O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
employed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Half O-MISC B-ACTI-MISC
log O-MISC B-ACTI-MISC
incremental O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
methoxamine B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
( O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
genuine O-MISC B-ACTI-MISC
stress B-DISO-MISC I-ACTI-MISC
incontinence I-DISO-MISC B-ANAT-MISC
while O-MISC B-ACTI-MISC
measuring O-MISC B-CHED-MISC
maximum O-MISC I-ACTI-MISC
urethral O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MUP O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
symptomatic O-MISC B-CHED-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Methoxamine B-CHED-MISC O-MISC
evoked O-MISC B-CHED-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
MUP O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
but O-MISC B-ACTI-MISC
caused O-MISC B-CHED-MISC
a B-DISO-MISC B-ACTI-MISC
significant I-DISO-MISC B-CHED-MISC
rise I-DISO-MISC B-ACTI-MISC
in I-DISO-MISC B-ACTI-MISC
systolic I-DISO-MISC I-DISO-MISC
blood I-DISO-MISC I-LIVB-MISC
pressure I-DISO-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
fall O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
dosage O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Systemic O-MISC I-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
including O-MISC B-ACTI-MISC
piloerection O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
headache B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cold O-MISC I-ACTI-MISC
extremities O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
experienced O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
usefulness O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
peripherally O-MISC B-CHED-MISC
acting O-MISC B-ACTI-MISC
sub O-MISC O-MISC
- O-MISC B-DISO-MISC
type O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
selective O-MISC B-DISO-MISC
alpha1 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
adrenoceptor O-MISC B-DISO-MISC
agonists O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medical O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
stress B-DISO-MISC I-ACTI-MISC
incontinence I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
piloerection O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
cardiovascular O-MISC I-ACTI-MISC
side O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Hyperglycemic B-DISO-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
amino B-CHED-MISC O-MISC
compounds O-MISC B-DISO-MISC
structurally O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
caproate B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
feeding O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
amounts O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
diet O-MISC B-CHED-MISC
weight O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
amino B-CHED-MISC O-MISC
derivatives O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
caproate B-CHED-MISC O-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hyperglycemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
glucose B-CHED-MISC I-DISO-MISC
tolerance O-MISC I-LIVB-MISC
curve O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
occasionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
glucosuria B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Effective O-MISC B-ACTI-MISC
compounds O-MISC O-MISC
included O-MISC B-ACTI-MISC
norleucine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
norvaline B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
glutamate B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
epsilon B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminocaproate I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
methionine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
leucine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Toleration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
angiotensin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
converting I-CHED-MISC B-DISO-MISC
enzyme I-CHED-MISC B-DISO-MISC
inhibitors I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
heart B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATLAS O-MISC B-CONC-MISC
trial O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Assessment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
Treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
Lisinopril B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
Survival O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
angiotensin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
converting I-CHED-MISC B-DISO-MISC
enzyme I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
ACE I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
inhibitors I-CHED-MISC B-DISO-MISC
reduces O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
morbidity O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
heart B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CHF B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
agents O-MISC O-MISC
or O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
doses O-MISC B-CHED-MISC
lower O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
efficacious O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
trials O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
primarily O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
concerns O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
tolerability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
agents O-MISC O-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
examines O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
tolerability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
lisinopril B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
CHF B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
Assessment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
Lisinopril B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
Survival O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
multicenter O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
ACE B-CHED-MISC O-MISC
inhibitor I-CHED-MISC B-DISO-MISC
treatment O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
stabilized O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
medium O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
lisinopril B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
once O-MISC B-CHED-MISC
daily O-MISC I-CHED-MISC
[ O-MISC B-ACTI-MISC
OD O-MISC B-CHED-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
OD O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
OD O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
New O-MISC I-ACTI-MISC
York O-MISC B-ANAT-MISC
Heart O-MISC B-ANAT-MISC
Association O-MISC B-ANAT-MISC
classes O-MISC B-ANAT-MISC
II O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
IV O-MISC B-ACTI-MISC
CHF B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
ejection O-MISC I-LIVB-MISC
fractions O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
3164 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
followed O-MISC B-CONC-MISC
up O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
need O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
reduction O-MISC B-CHED-MISC
during O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
focus O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Of O-MISC B-ACTI-MISC
405 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
not O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
ACE B-CHED-MISC O-MISC
inhibitor I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
titrated O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medium O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
required O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
randomization O-MISC B-CONC-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
possibly O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Doses O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
patients O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
titrated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
assigned O-MISC B-ACTI-MISC
target O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
blinded O-MISC B-CONC-MISC
medication O-MISC O-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
remained O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
throughout O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Withdrawals O-MISC B-DEVI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Subgroups O-MISC B-CHED-MISC
presumed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
ACE B-CHED-MISC O-MISC
inhibitor I-CHED-MISC B-DISO-MISC
intolerance O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
120 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
creatinine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
132 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
dose O-MISC I-CONC-MISC
strategy O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
ACE B-CHED-MISC B-CONC-MISC
inhibitor I-CHED-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
CHF B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
successfully O-MISC B-ACTI-MISC
titrated O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
maintained O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
aggressive O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
agents O-MISC O-MISC
is O-MISC B-ACTI-MISC
warranted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Cocaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
ethanol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cocaethylene B-CHED-MISC O-MISC
cardiotoxity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
animal O-MISC I-ACTI-MISC
model O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
cocaine B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
ethanol I-DISO-MISC I-ACTI-MISC
abuse I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Simultaneous O-MISC B-CHED-MISC
abuse B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
cocaine I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
ethanol I-DISO-MISC O-MISC
affects O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
million O-MISC B-ACTI-MISC
Americans O-MISC I-ANAT-MISC
annually O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
substances O-MISC B-GENE-MISC
are O-MISC B-ACTI-MISC
substantially O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
toxic O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
drug O-MISC O-MISC
alone O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Their O-MISC B-ACTI-MISC
combined O-MISC B-CHED-MISC
cardiac B-DISO-MISC B-ANAT-MISC
toxicity I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
independent O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
drug O-MISC O-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cocaethylene B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CE B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
metabolite O-MISC O-MISC
formed O-MISC B-CHED-MISC
only O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ethanol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
delineate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CE B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combined O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
ethanol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
model O-MISC B-CHED-MISC
simulating O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
abuse O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
IV O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
boluses O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
ethanol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
IV O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
C O-MISC O-MISC
+ O-MISC B-ACTI-MISC
E O-MISC O-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
boluses O-MISC I-GENE-MISC
only O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
C O-MISC O-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
ethanol B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
only O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
E O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
boluses O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hemodynamic O-MISC B-CONC-MISC
measurements O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
electrocardiograms O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
drug O-MISC I-CONC-MISC
concentrations O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
fixed O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
intervals O-MISC I-CHED-MISC
after O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
drug O-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Two O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C O-MISC B-CONC-MISC
+ O-MISC B-ACTI-MISC
E O-MISC B-CONC-MISC
group O-MISC B-CHED-MISC
experienced O-MISC B-ACTI-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
collapse I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
dramatic O-MISC B-CHED-MISC
hemodynamic O-MISC I-DISO-MISC
changes O-MISC B-CHED-MISC
occurred O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
bolus O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C O-MISC B-DEVI-MISC
+ O-MISC I-DEVI-MISC
E O-MISC I-DEVI-MISC
and O-MISC B-ACTI-MISC
C O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
hemodynamic O-MISC I-DISO-MISC
changes O-MISC B-CHED-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C O-MISC B-DEVI-MISC
+ O-MISC I-DEVI-MISC
E O-MISC I-DEVI-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Peak O-MISC B-CHED-MISC
CE B-CHED-MISC B-CONC-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
SD O-MISC B-CHED-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
69 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
decrease B-DISO-MISC B-CHED-MISC
in I-DISO-MISC B-ACTI-MISC
cardiac I-DISO-MISC I-DISO-MISC
output I-DISO-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
SD O-MISC B-OCCU-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
dP O-MISC B-CHED-MISC
/ O-MISC I-CHED-MISC
dt O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
max O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
006 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
SD O-MISC B-CHED-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
SVO O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
025 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Ventricular B-DISO-MISC I-ACTI-MISC
arrhythmias I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
primarily O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C O-MISC I-DISO-MISC
+ O-MISC B-ACTI-MISC
E O-MISC I-DISO-MISC
group O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
experienced O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Cocaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
ethanol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
toxic O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
substance O-MISC B-GENE-MISC
alone O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Co O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
dysrhythmogenic O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Peak O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
cocaethylene B-CHED-MISC O-MISC
concentrations O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
prolonged O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
depression I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Worsening O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Parkinsonism B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
veralipride B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
menopause O-MISC I-DISO-MISC
: O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
female O-MISC I-ANAT-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
stable O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
worsening O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
motor O-MISC I-DISO-MISC
functions O-MISC I-LIVB-MISC
following O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
menopause O-MISC I-DISO-MISC
related O-MISC B-ANAT-MISC
symptoms O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
veralipride B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
back O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
emphasize O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anti O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
dopaminergic O-MISC B-ANAT-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
veralipride B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Viracept B-CHED-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
irregular B-DISO-MISC B-ACTI-MISC
heartbeat I-DISO-MISC I-DISO-MISC
warning O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
doctors O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
Boston O-MISC B-ORGA-MISC
warn O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protease O-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
Viracept B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
an O-MISC B-ACTI-MISC
irregular B-DISO-MISC B-CHED-MISC
heart I-DISO-MISC I-DISO-MISC
beat I-DISO-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
people O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
HIV O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Bradycardia B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
male O-MISC I-ANAT-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
Viracept B-CHED-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
HIV O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
ceased O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
switching O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
drug O-MISC O-MISC
combination O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Frequency O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
myeloperoxidase O-MISC O-MISC
- O-MISC B-DISO-MISC
antineutrophil O-MISC B-DISO-MISC
cytoplasmic O-MISC B-DISO-MISC
antibody O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MPO O-MISC O-MISC
- O-MISC B-DISO-MISC
ANCA O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Graves B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
propylthiouracil B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
MPO O-MISC O-MISC
- O-MISC B-DISO-MISC
ANCA O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
manifestations O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Myeloperoxidase O-MISC O-MISC
antineutrophil O-MISC B-DISO-MISC
cytoplasmic O-MISC B-DISO-MISC
antibody O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MPO O-MISC O-MISC
- O-MISC B-DISO-MISC
ANCA O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Graves B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
propylthiouracil B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
PTU B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MPO O-MISC O-MISC
- O-MISC B-DISO-MISC
ANCA O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
suspected O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
PTU B-CHED-MISC I-ACTI-MISC
because O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
titres O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
MPO O-MISC O-MISC
- O-MISC B-DISO-MISC
ANCA O-MISC B-DISO-MISC
decreased O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
PTU B-CHED-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
stopped O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Nevertheless O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
temporal O-MISC B-CHED-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MPO O-MISC B-OBJC-MISC
- O-MISC B-ACTI-MISC
ANCA O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
PTU B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
MPO O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
ANCA O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
Graves B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
sought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
address O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
parameters O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Graves B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

PATIENTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
102 O-MISC B-ACTI-MISC
untreated O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hyperthyroidism B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Graves B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
MPO O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
ANCA O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-ACTI-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
starting O-MISC B-ACTI-MISC
PTU B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
excluded O-MISC B-DEVI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
PTU B-CHED-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
period O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
remaining O-MISC B-ACTI-MISC
73 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
adopted O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subjects O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
investigation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
observation O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

MEASUREMENTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
MPO O-MISC O-MISC
- O-MISC B-ACTI-MISC
ANCA O-MISC O-MISC
was O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
intervals O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Before O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MPO O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
ANCA O-MISC I-CHED-MISC
titres O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
102 O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
Graves B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reference O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
below O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
73 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
positive O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
MPO O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
ANCA O-MISC O-MISC
at O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
start O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
PTU B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MPO O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
ANCA O-MISC O-MISC
titres O-MISC B-CHED-MISC
transiently O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
despite O-MISC B-ACTI-MISC
continued O-MISC B-ACTI-MISC
PTU B-CHED-MISC I-ACTI-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
vasculitic B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
developed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MPO O-MISC O-MISC
- O-MISC B-DISO-MISC
ANCA O-MISC B-DISO-MISC
titre O-MISC B-CHED-MISC
increased O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
204 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC I-ACTI-MISC
fever B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
oral B-DISO-MISC I-ACTI-MISC
ulcers I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
polyarthralgia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
resolved O-MISC I-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
stopping O-MISC B-ACTI-MISC
PTU B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MPO O-MISC O-MISC
- O-MISC B-DISO-MISC
ANCA O-MISC B-DISO-MISC
titre O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
discontinuing O-MISC B-ACTI-MISC
PTU B-CHED-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
PTU B-CHED-MISC I-ACTI-MISC
therapy O-MISC B-CONC-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MPO O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
ANCA O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
MPO O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
ANCA O-MISC B-ANAT-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
closely O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
asymptomatic O-MISC I-ACTI-MISC
chronic O-MISC I-ACTI-MISC
cocaine B-CHED-MISC B-ANAT-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
outpatient O-MISC I-ANAT-MISC
young O-MISC B-ACTI-MISC
asymptomatic O-MISC I-ACTI-MISC
chronic O-MISC I-ACTI-MISC
cocaine B-CHED-MISC B-ANAT-MISC
users O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
users O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
matched O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
underwent O-MISC B-ACTI-MISC
resting O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
electrocardiography O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
ECG O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Doppler O-MISC B-CONC-MISC
echocardiography O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Findings O-MISC I-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
detected O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Decreased O-MISC B-CHED-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
systolic O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
055 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Finally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
resting O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
peak O-MISC B-CHED-MISC
exercise O-MISC B-DEVI-MISC
abnormal B-DISO-MISC I-ACTI-MISC
left I-DISO-MISC B-CONC-MISC
ventricular I-DISO-MISC I-OCCU-MISC
filling I-DISO-MISC I-OCCU-MISC
was O-MISC B-ACTI-MISC
detected O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
or I-DISO-MISC B-ACTI-MISC
myocardial I-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
young O-MISC B-ACTI-MISC
asymptomatic O-MISC I-ACTI-MISC
chronic O-MISC I-ACTI-MISC
cocaine B-CHED-MISC B-ANAT-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
screening O-MISC B-CONC-MISC
ECG O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
echocardiography O-MISC B-CONC-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
warranted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Cardioprotective O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
Picrorrhiza O-MISC I-ANAT-MISC
kurroa O-MISC I-PHEN-MISC
against O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
myocardial O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cardioprotective O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ethanol B-CHED-MISC O-MISC
extract O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
Picrorrhiza O-MISC I-ANAT-MISC
kurroa O-MISC I-PHEN-MISC
rhizomes O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
roots O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
PK O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
respect O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
lipid O-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC I-GENE-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
PK O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
maintained O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
near O-MISC B-ACTI-MISC
normal O-MISC B-ANAT-MISC
status O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Phase O-MISC B-CHED-MISC
2 O-MISC I-CHED-MISC
early O-MISC B-ACTI-MISC
afterdepolarization O-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
trigger O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
polymorphic O-MISC I-ACTI-MISC
ventricular B-DISO-MISC B-ANAT-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
acquired O-MISC I-ACTI-MISC
long B-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
QT I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
intracellular O-MISC B-CHED-MISC
recordings O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
left O-MISC I-GENE-MISC
ventricular O-MISC B-GEOG-MISC
wall O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
examined O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
2 O-MISC I-LIVB-MISC
early O-MISC B-ACTI-MISC
afterdepolarization O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
EAD O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
producing O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
trigger O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
initiate O-MISC B-ACTI-MISC
torsade B-DISO-MISC O-MISC
de I-DISO-MISC B-DISO-MISC
pointes I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TdP B-DISO-MISC O-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
QT B-DISO-MISC I-DISO-MISC
prolongation I-DISO-MISC I-LIVB-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
dl O-MISC O-MISC
- O-MISC B-DISO-MISC
sotalol B-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
azimilide B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
contribution O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
transmural O-MISC I-DISO-MISC
dispersion O-MISC I-LIVB-MISC
of O-MISC I-LIVB-MISC
repolarization O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
TDR O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
transmural O-MISC B-CHED-MISC
propagation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
EAD O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maintenance O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
TdP B-DISO-MISC O-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Transmembrane O-MISC I-GENE-MISC
action O-MISC I-DISO-MISC
potentials O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
epicardium O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
midmyocardium O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
endocardium O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
simultaneously O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transmural O-MISC B-CHED-MISC
ECG O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
arterially O-MISC B-CHED-MISC
perfused O-MISC B-CONC-MISC
canine O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
rabbit O-MISC I-ANAT-MISC
left O-MISC B-CONC-MISC
ventricular O-MISC I-CONC-MISC
preparations O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

dl O-MISC O-MISC
- O-MISC B-DISO-MISC
Sotalol B-CHED-MISC B-DISO-MISC
preferentially O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
action O-MISC I-LIVB-MISC
potential O-MISC I-LIVB-MISC
duration O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
APD O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
M O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
dose O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependently O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
QT B-DISO-MISC I-DISO-MISC
prolongation I-DISO-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
TDR O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Azimilide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
prolonged O-MISC B-CHED-MISC
APD O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
QT O-MISC I-DISO-MISC
interval O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
concentrations O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
shortened O-MISC B-CHED-MISC
them O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Unlike O-MISC B-ACTI-MISC
dl O-MISC O-MISC
- O-MISC B-DISO-MISC
sotalol B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
azimilide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
epicardial O-MISC I-GENE-MISC
APD O-MISC I-ACTI-MISC
markedly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
diminished O-MISC B-CHED-MISC
TDR O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
dl O-MISC O-MISC
- O-MISC B-DISO-MISC
sotalol B-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
azimilide B-CHED-MISC O-MISC
rarely O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
EADs O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
canine O-MISC I-ANAT-MISC
left O-MISC I-GENE-MISC
ventricles O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
EADs O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rabbits O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
pronounced O-MISC B-ACTI-MISC
QT B-DISO-MISC I-DISO-MISC
prolongation I-DISO-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
TDR O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
dl O-MISC O-MISC
- O-MISC B-DISO-MISC
sotalol B-CHED-MISC B-DISO-MISC
facilitated O-MISC B-ACTI-MISC
transmural O-MISC I-DISO-MISC
propagation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
EADs O-MISC I-GENE-MISC
that O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
episodes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
TdP B-DISO-MISC O-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
rabbit O-MISC I-ANAT-MISC
left O-MISC I-GENE-MISC
ventricles O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
note O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
azimilide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
APD O-MISC I-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
dl O-MISC O-MISC
- O-MISC B-DISO-MISC
sotalol B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
EADs O-MISC I-GENE-MISC
often O-MISC B-ACTI-MISC
failed O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
propagate O-MISC B-DEVI-MISC
transmurally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
diminished O-MISC B-ACTI-MISC
TDR O-MISC B-PHEN-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
provides O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
intracellular O-MISC I-DISO-MISC
action O-MISC I-LIVB-MISC
potential O-MISC I-LIVB-MISC
recordings O-MISC B-CONC-MISC
that O-MISC B-ACTI-MISC
phase O-MISC I-ACTI-MISC
2 O-MISC B-ANAT-MISC
EAD O-MISC B-ANAT-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
generated O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
ventricular O-MISC I-GENE-MISC
wall O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
trigger O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
initiate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
TdP B-DISO-MISC O-MISC
under O-MISC B-ACTI-MISC
QT B-DISO-MISC I-DISO-MISC
prolongation I-DISO-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
pilot O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
stress O-MISC I-ACTI-MISC
echocardiography O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emergency O-MISC B-GENE-MISC
department O-MISC I-GEOG-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

STUDY O-MISC B-ACTI-MISC
OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
setting O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
poses O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
diagnostic O-MISC B-CHED-MISC
dilemma O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Dobutamine B-CHED-MISC B-CONC-MISC
stress O-MISC I-CONC-MISC
echocardiography O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
DSE O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sensitive O-MISC B-ACTI-MISC
test O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
evaluating O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
ischemia B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
theoretical O-MISC B-CHED-MISC
concern O-MISC B-ACTI-MISC
regarding O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
setting O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pilot O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
DSE O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
emergency O-MISC B-GENE-MISC
department O-MISC I-GEOG-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
case O-MISC I-CONC-MISC
series O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intensive O-MISC B-GENE-MISC
diagnostic O-MISC I-GEOG-MISC
and O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
unit O-MISC I-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ED O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
urban O-MISC B-ORGA-MISC
tertiary O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
care O-MISC I-GEOG-MISC
teaching O-MISC B-GENE-MISC
hospital O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
eligible O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
DSE O-MISC B-CONC-MISC
if O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
within O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
preceding O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
ECG O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
tropinin O-MISC O-MISC
I O-MISC B-DISO-MISC
level O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
exhibiting O-MISC B-ACTI-MISC
signs O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
continuing O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
toxicity B-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
excluded O-MISC B-DEVI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
admitted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hospital O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
serial O-MISC B-CONC-MISC
testing O-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DSE O-MISC B-CONC-MISC
testing O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intensive O-MISC B-CHED-MISC
diagnostic O-MISC B-GENE-MISC
and O-MISC B-ACTI-MISC
treatment O-MISC B-GENE-MISC
unit O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
inadequate O-MISC B-CHED-MISC
resting O-MISC B-CHED-MISC
images O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
DSE O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
terminated O-MISC B-CHED-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
inferior O-MISC B-CHED-MISC
hypokinesis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
DSE O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
terminated O-MISC B-CHED-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rate O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
related O-MISC B-ANAT-MISC
atrial O-MISC B-ANAT-MISC
conduction O-MISC B-ANAT-MISC
deficit O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
reach O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
target O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
completed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
DSE O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
reached O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
target O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rates O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

None O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
experienced O-MISC I-DISO-MISC
signs O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
exaggerated O-MISC B-CHED-MISC
adrenergic O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC O-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tachydysrhythmias B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
excluding O-MISC B-ACTI-MISC
sinus B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
exaggerated O-MISC B-CHED-MISC
adrenergic O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
required O-MISC B-ACTI-MISC
supplemental O-MISC O-MISC
atropine B-CHED-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
reach O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
target O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rates O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
No O-MISC I-ACTI-MISC
exaggerated O-MISC B-CHED-MISC
adrenergic O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
detected O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
related O-MISC B-ANAT-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Prenatal O-MISC B-CHED-MISC
cocaine B-CHED-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
cranial O-MISC B-CONC-MISC
sonographic O-MISC I-CHED-MISC
findings O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
preterm B-DISO-MISC I-ANAT-MISC
infants I-DISO-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Prenatal O-MISC I-ANAT-MISC
cocaine B-CHED-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
linked O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
subependymal O-MISC I-ACTI-MISC
hemorrhage B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
formation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cysts B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
detectable O-MISC I-DISO-MISC
on O-MISC B-ACTI-MISC
cranial O-MISC B-CONC-MISC
sonography O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
neonates O-MISC I-ANAT-MISC
born O-MISC I-DISO-MISC
at O-MISC I-LIVB-MISC
term O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
sought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
prenatal O-MISC B-CHED-MISC
cocaine B-CHED-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
increases O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
subependymal B-DISO-MISC I-ACTI-MISC
cysts I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
preterm B-DISO-MISC I-ANAT-MISC
infants I-DISO-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
retrospectively O-MISC B-CHED-MISC
reviewed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medical O-MISC B-CHED-MISC
records O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
cranial O-MISC B-CHED-MISC
sonograms O-MISC B-CONC-MISC
obtained O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
122 O-MISC B-ACTI-MISC
premature B-DISO-MISC I-ACTI-MISC
( I-DISO-MISC B-ANAT-MISC
< I-DISO-MISC B-ANAT-MISC
36 I-DISO-MISC B-ANAT-MISC
weeks I-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ANAT-MISC
gestation I-DISO-MISC B-ANAT-MISC
) I-DISO-MISC B-ANAT-MISC
infants I-DISO-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Infants O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
categorized O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
exposed O-MISC I-ACTI-MISC
to O-MISC B-ANAT-MISC
cocaine B-CHED-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
exposed O-MISC I-ACTI-MISC
to O-MISC B-ANAT-MISC
cocaine B-CHED-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Infants O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
assigned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
if O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
maternal O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
cocaine B-DISO-MISC I-ACTI-MISC
abuse I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
pregnancy O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
maternal O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
neonatal O-MISC B-CHED-MISC
urine O-MISC I-GENE-MISC
toxicology O-MISC B-PROC-MISC
results O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
delivery O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Five O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
122 O-MISC B-ACTI-MISC
infants O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
excluded O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
insufficient O-MISC B-CHED-MISC
medical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
histories O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
subependymal B-DISO-MISC I-ACTI-MISC
cysts I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
117 O-MISC B-ACTI-MISC
remaining O-MISC B-ACTI-MISC
infants O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
117 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
subependymal B-DISO-MISC I-ACTI-MISC
cysts I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
infants O-MISC I-ANAT-MISC
exposed O-MISC I-ACTI-MISC
to O-MISC B-ANAT-MISC
cocaine B-CHED-MISC O-MISC
prenatally O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
99 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unexposed O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
subependymal B-DISO-MISC I-ACTI-MISC
cyst I-DISO-MISC I-ACTI-MISC
formation O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
preterm B-DISO-MISC I-ANAT-MISC
infants I-DISO-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
cocaine B-CHED-MISC O-MISC
prenatally O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
results O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
term O-MISC I-ANAT-MISC
infants O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Thalidomide B-CHED-MISC I-ACTI-MISC
neuropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
metastatic O-MISC I-ACTI-MISC
prostate B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
prospectively O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
thalidomide B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
neuropathy B-DISO-MISC I-ACTI-MISC
using O-MISC B-ACTI-MISC
electrodiagnostic O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Sixty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
metastatic O-MISC I-ACTI-MISC
androgen B-CHED-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
independent O-MISC B-ANAT-MISC
prostate B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
label O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
oral O-MISC O-MISC
thalidomide B-CHED-MISC B-DISO-MISC
underwent O-MISC B-ACTI-MISC
neurologic O-MISC B-CONC-MISC
examinations O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
nerve O-MISC B-CONC-MISC
conduction O-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
NCS O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
month O-MISC B-CHED-MISC
intervals O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

NCS O-MISC B-CONC-MISC
included O-MISC B-ACTI-MISC
recording O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
sensory O-MISC I-DISO-MISC
nerve O-MISC I-LIVB-MISC
action O-MISC I-LIVB-MISC
potentials O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
SNAPs O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
median O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
radial O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
ulnar O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sural O-MISC I-GENE-MISC
nerves O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

SNAP O-MISC O-MISC
amplitudes O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
nerve O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
expressed O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
percentage O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
termed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SNAP O-MISC O-MISC
index O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
decline O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SNAP O-MISC B-CONC-MISC
index O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
clinically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Thalidomide B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
therapeutic O-MISC B-CONC-MISC
response O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
67 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
initially O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
remained O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
remained O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
remained O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
neuropathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC I-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decline O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SNAP O-MISC O-MISC
index O-MISC B-CHED-MISC
occurred O-MISC B-ACTI-MISC
concurrently O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Older O-MISC I-ANAT-MISC
age O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
contributing O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Neuropathy B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
thus O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
SNAP O-MISC O-MISC
index O-MISC B-CHED-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
monitor O-MISC B-CONC-MISC
peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
early O-MISC B-CONC-MISC
detection O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Overexpression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
copper B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
zinc B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
superoxide B-CHED-MISC B-DISO-MISC
dismutase O-MISC B-DISO-MISC
protects O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
kanamycin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hearing B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
participation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
reactive O-MISC O-MISC
oxygen B-CHED-MISC B-DISO-MISC
species O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
aminoglycoside B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ototoxicity B-DISO-MISC I-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
deduced O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
observations O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
aminoglycoside B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
iron B-CHED-MISC O-MISC
complexes O-MISC B-DISO-MISC
catalyze O-MISC B-OCCU-MISC
the O-MISC B-ACTI-MISC
formation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
superoxide B-CHED-MISC O-MISC
radicals O-MISC B-DISO-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
antioxidants O-MISC O-MISC
attenuate O-MISC B-DEVI-MISC
ototoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
hypothesized O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
overexpression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
Cu B-CHED-MISC O-MISC
/ O-MISC B-DISO-MISC
Zn B-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
superoxide B-CHED-MISC B-DISO-MISC
dismutase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
h O-MISC O-MISC
- O-MISC B-DISO-MISC
SOD1 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
protect O-MISC B-ACTI-MISC
transgenic O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
from O-MISC B-ACTI-MISC
ototoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Immunocytochemistry O-MISC B-CONC-MISC
confirmed O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
h O-MISC O-MISC
- O-MISC B-DISO-MISC
SOD1 O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
inner O-MISC I-GENE-MISC
ear O-MISC B-GEOG-MISC
tissues O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
transgenic O-MISC I-ANAT-MISC
C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6 O-MISC I-PHEN-MISC
- O-MISC I-PHEN-MISC
TgN O-MISC I-PHEN-MISC
[ O-MISC I-PHEN-MISC
SOD1 O-MISC I-PHEN-MISC
] O-MISC I-PHEN-MISC
3Cje O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Transgenic O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
nontransgenic O-MISC I-ANAT-MISC
littermates O-MISC I-PHEN-MISC
received O-MISC B-ACTI-MISC
kanamycin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
/ O-MISC B-ACTI-MISC
day O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
beginning O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
10 O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
birth O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Auditory O-MISC B-CHED-MISC
thresholds O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
evoked O-MISC B-CONC-MISC
auditory O-MISC B-CONC-MISC
brain O-MISC I-CONC-MISC
stem O-MISC I-CONC-MISC
responses O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
month O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
birth O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
nontransgenic O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
threshold O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kanamycin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
group O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
dB O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
- O-MISC B-ACTI-MISC
injected O-MISC I-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transgenic O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
kanamycin B-CHED-MISC O-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
threshold O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
dB O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
respective O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
kHz O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
protection O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
overexpression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
superoxide B-CHED-MISC O-MISC
dismutase O-MISC B-DISO-MISC
supports O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
oxidant O-MISC I-DISO-MISC
stress O-MISC I-LIVB-MISC
plays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
aminoglycoside B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ototoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC I-ACTI-MISC
also O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
transgenic O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
as O-MISC B-ACTI-MISC
suitable O-MISC B-ACTI-MISC
models O-MISC B-OBJC-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
strategies O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
prevention O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Fatty B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
tetracycline B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Dose O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
response O-MISC I-OCCU-MISC
relationships O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Dose O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
response O-MISC I-OCCU-MISC
relationships O-MISC I-OCCU-MISC
, O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
differences O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
fatty B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
tetracycline B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
rat O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
perfused O-MISC B-CONC-MISC
rat O-MISC I-ANAT-MISC
liver O-MISC I-GENE-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
male O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
rat O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
dose O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
tetracycline B-CHED-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
hepatic O-MISC I-ACTI-MISC
accumulation O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
triglyceride B-CHED-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
provision O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
adequate O-MISC B-CHED-MISC
oleic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
substrate O-MISC B-GENE-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
perfused O-MISC B-CONC-MISC
liver O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tetracycline B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
accumulation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
output O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
by O-MISC B-ACTI-MISC
livers O-MISC I-GENE-MISC
from O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Marked O-MISC I-DISO-MISC
differences O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
regard O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
base O-MISC I-GENE-MISC
line O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
control O-MISC B-GENE-MISC
) O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
output O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Accumulation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
triglyceride B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
cent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
values O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
response O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
graded O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
tetracycline B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
differ O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
pregnant O-MISC B-CHED-MISC
rat O-MISC I-ANAT-MISC
livers O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
livers O-MISC I-GENE-MISC
from O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
pregnant O-MISC I-DISO-MISC
female O-MISC I-LIVB-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
strikingly O-MISC B-ACTI-MISC
resistant O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tetracycline B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
depression B-DISO-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
output O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
under O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
conditions O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sexes O-MISC I-DISO-MISC
could O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
disposition O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
tetracycline B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
uptake O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
oleic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Depressed O-MISC B-CHED-MISC
hepatic O-MISC I-DISO-MISC
secretion O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
accounted O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
accumulated O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
triglyceride B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
production O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
rich O-MISC B-ACTI-MISC
fatty B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
response O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
tetracycline B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Prednisone B-CHED-MISC O-MISC
induces O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
glial O-MISC I-GENE-MISC
cerebral O-MISC B-ANAT-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
assess O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
prednisone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
PDN B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
cerebral O-MISC I-ACTI-MISC
glial O-MISC B-ANAT-MISC
changes O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Male O-MISC B-ACTI-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
formed O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
per O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
group O-MISC B-CHED-MISC
received O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
PDN B-CHED-MISC O-MISC
released O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
subcutaneous O-MISC B-OBJC-MISC
implant O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
group O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
implants O-MISC B-OBJC-MISC
containing O-MISC B-ACTI-MISC
PDN B-CHED-MISC O-MISC
equivalent O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
applied O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
implants O-MISC B-OBJC-MISC
contained O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
PDN B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Anxiety B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
open O-MISC B-OCCU-MISC
field O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
elevated O-MISC B-OBJC-MISC
plus O-MISC I-OBJC-MISC
- O-MISC I-OBJC-MISC
maze O-MISC I-OBJC-MISC
devices O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
number O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
cytoplasmic O-MISC I-GENE-MISC
transformation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
astrocytes O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
microglia O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
immunohistochemical O-MISC B-CONC-MISC
analyses O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Anxiety B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
PDN B-CHED-MISC I-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
magnitude O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
transformation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
microglia O-MISC I-GENE-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
intersections O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PDN B-CHED-MISC I-GENE-MISC
groups O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prefrontal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
controls O-MISC B-CHED-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
striatum O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
25 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
26 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
controls O-MISC B-CHED-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
stained O-MISC B-CONC-MISC
microglia O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PDN B-CHED-MISC I-ACTI-MISC
treated O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prefrontal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
per O-MISC B-ACTI-MISC
field O-MISC I-CHED-MISC
; O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Stained O-MISC B-ACTI-MISC
microglia O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
more O-MISC B-ACTI-MISC
numerous O-MISC I-CHED-MISC
striatum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
group O-MISC B-CHED-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Subacute O-MISC B-CHED-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
PDN B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
anxiety B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
reactivity O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
microglia O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
relevance O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
features O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
using O-MISC B-ACTI-MISC
PDN B-CHED-MISC I-ACTI-MISC
remains O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
elucidated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
carboplatin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
recurrent O-MISC B-CHED-MISC
squamous B-DISO-MISC I-ACTI-MISC
cell I-DISO-MISC B-ANAT-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
cervix I-DISO-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
activity O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
carboplatin B-CHED-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
recurrent O-MISC B-CHED-MISC
cervical B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
carboplatin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
area O-MISC B-CHED-MISC
under O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
concentration O-MISC I-CHED-MISC
curve O-MISC I-CHED-MISC
[ O-MISC B-ACTI-MISC
AUC O-MISC B-CHED-MISC
] O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Doxil B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
starting O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
intravenously O-MISC B-CHED-MISC
every O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
recurrent O-MISC B-CHED-MISC
squamous B-DISO-MISC I-ACTI-MISC
cell I-DISO-MISC B-ANAT-MISC
cervical I-DISO-MISC B-ANAT-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
antitumor O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
profile O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
assessable O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
assessable O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
overall O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
rate O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
response O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
survival O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
main O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
myelosuppression B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
Grade O-MISC I-ACTI-MISC
3 O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
anemia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
neutropenic B-DISO-MISC I-ACTI-MISC
fever I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
reactions O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
discontinuation O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Grade O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
nonhematologic O-MISC I-ACTI-MISC
toxicity B-DISO-MISC B-ANAT-MISC
included O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
emesis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
fatigue B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
mucositis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
stomatitis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
constipation B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
weight B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
hand B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
foot I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
skin B-DISO-MISC I-ACTI-MISC
reactions I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
carboplatin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
liposomal O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
has O-MISC B-ACTI-MISC
modest O-MISC B-ACTI-MISC
activity O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
recurrent O-MISC B-CHED-MISC
cervical B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Antimicrobial O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
mania B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
antibiomania B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
reports O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC B-ACTI-MISC
reviewed O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
antibiotic O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
manic B-DISO-MISC I-ACTI-MISC
episodes O-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
means O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
MEDLINE O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
PsychLit O-MISC B-CHED-MISC
search O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
reports O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
antibiotic O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
mania B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Unpublished O-MISC B-CHED-MISC
reports O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
requested O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
World O-MISC B-PHYS-MISC
Health O-MISC I-PHYS-MISC
Organization O-MISC I-PHYS-MISC
( O-MISC B-ACTI-MISC
WHO O-MISC B-PHYS-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Food O-MISC B-PHYS-MISC
and O-MISC I-PHYS-MISC
Drug O-MISC I-PHYS-MISC
Administration O-MISC I-PHYS-MISC
( O-MISC B-ACTI-MISC
FDA O-MISC B-PHYS-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
reports O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
antimicrobial O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
mania B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
implicating O-MISC B-ACTI-MISC
clarithromycin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
implicating O-MISC B-ACTI-MISC
isoniazid B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
each O-MISC B-ACTI-MISC
implicating O-MISC B-ACTI-MISC
erythromycin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
amoxicillin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
WHO O-MISC B-PHYS-MISC
reported O-MISC B-CONC-MISC
82 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
clarithromycin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
ciprofloxacin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ofloxacin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Cotrimoxazole B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
metronidazole B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
erythromycin B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
involved O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
manic B-DISO-MISC I-ACTI-MISC
episodes O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Cases O-MISC B-CHED-MISC
reported O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
FDA O-MISC B-PHYS-MISC
showed O-MISC B-ACTI-MISC
clarithromycin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
ciprofloxacin B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
mania B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Statistical O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
would O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
statistical O-MISC B-CHED-MISC
correlative O-MISC I-CHED-MISC
risk O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
undertaken O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
mania B-DISO-MISC I-ACTI-MISC
while O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
antimicrobials O-MISC O-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
risk O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
physicians O-MISC I-ANAT-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
reversibility O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
research O-MISC B-CONC-MISC
clearly O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
antimicrobial O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
mania B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relative O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-CHED-MISC
an O-MISC B-ACTI-MISC
antimicrobial O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
manic B-DISO-MISC I-ACTI-MISC
episode O-MISC B-CHED-MISC
among O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
demographic O-MISC B-CHED-MISC
populations O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
continue O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
affective O-MISC I-ACTI-MISC
disorders O-MISC B-ANAT-MISC
once O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initial O-MISC B-CHED-MISC
episode O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
occurs O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
antibiotics O-MISC O-MISC
, O-MISC B-ACTI-MISC
subsides O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
elected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
name O-MISC B-CHED-MISC
this O-MISC B-ACTI-MISC
syndrome O-MISC I-ACTI-MISC
" O-MISC B-ACTI-MISC
antibiomania B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC

Levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ocular B-DISO-MISC I-ACTI-MISC
dyskinesias I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ocular B-DISO-MISC I-ACTI-MISC
dyskinesias I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
uncommon O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Usually O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
simultaneously O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
limb O-MISC I-GENE-MISC
peak O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
dose O-MISC B-ANAT-MISC
choreatic B-DISO-MISC I-ACTI-MISC
dyskinesias I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
leftward O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
upward O-MISC B-CHED-MISC
deviations O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
gaze O-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
peak O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
hypothesize O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
dopaminergic O-MISC I-ACTI-MISC
denervation O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
caudate O-MISC I-GENE-MISC
nucleus O-MISC B-GEOG-MISC
is O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
ocular B-DISO-MISC I-ACTI-MISC
dyskinesias I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
comparison O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
glyceryl B-CHED-MISC O-MISC
trinitrate I-CHED-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
diclofenac B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
dysmenorrhea B-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
cross O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
over O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Primary O-MISC I-ACTI-MISC
dysmenorrhea B-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
syndrome O-MISC I-ACTI-MISC
characterized O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
painful O-MISC I-ACTI-MISC
uterine O-MISC I-ACTI-MISC
contractility O-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hypersecretion O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
endometrial O-MISC I-GENE-MISC
prostaglandins B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
steroidal O-MISC B-DISO-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
choice O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-CONC-MISC
vivo O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CONC-MISC
vitro O-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
myometrial O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
are O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
targets O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relaxant O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nitric B-CHED-MISC O-MISC
oxide I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NO B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
glyceryl B-CHED-MISC O-MISC
trinitrate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GTN B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
NO B-CHED-MISC O-MISC
donor O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
resolution O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
dysmenorrhea B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
comparison O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
diclofenac B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DCF B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
primary O-MISC I-ACTI-MISC
dysmenorrhea B-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
menstrual O-MISC I-DISO-MISC
cycles O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
open O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cross O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
over O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
controlled O-MISC B-CHED-MISC
design O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
receive O-MISC B-CHED-MISC
either O-MISC B-ACTI-MISC
DCF B-CHED-MISC B-CONC-MISC
per O-MISC I-CONC-MISC
os O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
GTN B-CHED-MISC B-OBJC-MISC
patches O-MISC B-OBJC-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
menses O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
menstrual O-MISC I-ACTI-MISC
cramps O-MISC B-ANAT-MISC
became O-MISC B-ACTI-MISC
unendurable O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
cycle O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
DCF B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
transdermal O-MISC I-GENE-MISC
GTN B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cycle O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
needs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
recorded O-MISC B-ACTI-MISC
menstrual O-MISC I-DISO-MISC
symptoms O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
120 O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
medication O-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cycle O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
pain B-DISO-MISC I-DISO-MISC
intensity O-MISC I-LIVB-MISC
score O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
DPI O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
main O-MISC B-ACTI-MISC
outcome O-MISC B-CHED-MISC
variable O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
significantly O-MISC B-CHED-MISC
reduced O-MISC I-CHED-MISC
DPI O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
30th O-MISC B-ACTI-MISC
minute O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
GTN B-CHED-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
DCF B-CHED-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
DCF B-CHED-MISC B-CONC-MISC
continued O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
reducing O-MISC B-CHED-MISC
pelvic B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
two O-MISC B-CHED-MISC
hours O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
GTN B-CHED-MISC I-ACTI-MISC
scores O-MISC B-CHED-MISC
remained O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
stable O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
DFC O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
after O-MISC B-CHED-MISC
one O-MISC B-CHED-MISC
hour O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
GTN B-CHED-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
DFC O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-CHED-MISC
two O-MISC I-CHED-MISC
hours O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
GTN B-CHED-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
DFC O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Low B-DISO-MISC I-ACTI-MISC
back I-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
relieved O-MISC B-CHED-MISC
by O-MISC I-CHED-MISC
both O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
. O-MISC B-ACTI-MISC

Headache B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
GTN B-CHED-MISC B-CONC-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
DCF B-CHED-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Eight O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
stopped O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
GTN B-CHED-MISC O-MISC
because O-MISC B-ACTI-MISC
headache B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
attributed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
became O-MISC B-ACTI-MISC
intolerable O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
GTN B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
tolerability O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
comparison O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
DCF B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
dysmenorrhea B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Temocapril B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC O-MISC
- O-MISC B-DISO-MISC
acting O-MISC B-DISO-MISC
non O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
SH O-MISC B-DISO-MISC
group O-MISC B-DISO-MISC
angiotensin B-CHED-MISC B-DISO-MISC
converting O-MISC B-DISO-MISC
enzyme O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
modulates O-MISC B-ACTI-MISC
glomerular B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
puromycin B-CHED-MISC O-MISC
aminonucleoside I-CHED-MISC O-MISC
nephrosis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
chronic O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
temocapril B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC O-MISC
- O-MISC B-DISO-MISC
acting O-MISC B-DISO-MISC
non O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
SH O-MISC B-DISO-MISC
group O-MISC B-DISO-MISC
angiotensin B-CHED-MISC B-DISO-MISC
converting O-MISC B-DISO-MISC
enzyme O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
ACE O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
proteinuria B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
inhibited O-MISC B-DEVI-MISC
glomerular O-MISC I-ACTI-MISC
hypertrophy B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
chronic O-MISC O-MISC
puromycin B-CHED-MISC B-DISO-MISC
aminonucleoside I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephrotic B-DISO-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Nephrosis B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
15mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
100g O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
Sprague O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Dawley O-MISC I-PHEN-MISC
( O-MISC I-PHEN-MISC
SD O-MISC I-PHEN-MISC
) O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
group O-MISC B-PHEN-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ii O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
temocapril B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
iii O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
temocapril B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
iv O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
untreated O-MISC B-CHED-MISC
controls O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Temocapril B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
killed O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
point O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
BP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
urinary O-MISC B-CHED-MISC
protein O-MISC O-MISC
excretion O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
histopathological O-MISC B-CHED-MISC
findings O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
morphometric O-MISC B-CONC-MISC
image O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
done O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Systolic O-MISC I-DISO-MISC
BP O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
temocapril B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Urinary O-MISC B-CHED-MISC
protein O-MISC B-DISO-MISC
excretion O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
group O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
significantly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
peaking O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
rose O-MISC B-ACTI-MISC
again O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Temocapril B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
attenuate O-MISC B-DEVI-MISC
proteinuria B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
markedly O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
it O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
index O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
GSI O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAN B-CHED-MISC I-ACTI-MISC
group O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
correlation O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
urinary O-MISC B-CHED-MISC
protein O-MISC O-MISC
excretion O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
GSI O-MISC O-MISC
( O-MISC B-ACTI-MISC
r O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
808 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ratio O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
glomerular O-MISC I-GENE-MISC
tuft O-MISC B-GEOG-MISC
area O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
area O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Bowman O-MISC I-GENE-MISC
' O-MISC B-GEOG-MISC
s O-MISC B-GEOG-MISC
capsules O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
GT O-MISC I-GENE-MISC
/ O-MISC B-ACTI-MISC
BC O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
lower O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
temocapril B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
appears O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
temocapril B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
retarding O-MISC B-CHED-MISC
renal O-MISC I-DISO-MISC
progression O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
protected O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
PAN B-CHED-MISC I-ACTI-MISC
neprotic B-DISO-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Pulmonary B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
prophylaxis O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
very O-MISC I-ANAT-MISC
preterm O-MISC I-PHEN-MISC
infants O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
hypoxaemia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
during O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
randomised O-MISC B-CONC-MISC
controlled O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
prophylactic O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
patent B-DISO-MISC I-ACTI-MISC
ductus I-DISO-MISC B-ANAT-MISC
arteriosus I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
premature O-MISC I-ACTI-MISC
infants O-MISC B-ANAT-MISC
born O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
28 O-MISC I-ACTI-MISC
weeks O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
gestation O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Echocardiography O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
severely O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
pulmonary O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
flow O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Hypoxaemia B-DISO-MISC I-ACTI-MISC
resolved O-MISC I-ACTI-MISC
quickly O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
inhaled O-MISC O-MISC
nitric B-CHED-MISC B-DISO-MISC
oxide I-CHED-MISC B-DISO-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
investigators O-MISC I-ANAT-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
trials O-MISC B-CONC-MISC
pay O-MISC B-ACTI-MISC
close O-MISC B-ACTI-MISC
attention O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
pulmonary O-MISC B-CONC-MISC
pressure O-MISC I-CONC-MISC
if O-MISC B-ACTI-MISC
hypoxaemia B-DISO-MISC I-ACTI-MISC
occurs O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
prophylactic O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Hyponatremia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
syndrome B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
inappropriate I-DISO-MISC B-ACTI-MISC
anti I-DISO-MISC O-MISC
- I-DISO-MISC B-DISO-MISC
diuretic I-DISO-MISC B-DISO-MISC
hormone I-DISO-MISC B-DISO-MISC
reported O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Vincristine B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
representation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Asians O-MISC I-ANAT-MISC
? O-MISC B-ACTI-MISC

PURPOSE O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
used O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pharmaceutical O-MISC B-PHYS-MISC
company O-MISC I-PHYS-MISC
' O-MISC I-PHYS-MISC
s O-MISC I-PHYS-MISC
global O-MISC B-CHED-MISC
safety O-MISC I-CHED-MISC
database O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reporting O-MISC B-CONC-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyponatremia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
syndrome B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
inappropriate I-DISO-MISC B-CHED-MISC
secretion I-DISO-MISC I-DISO-MISC
of I-DISO-MISC B-ACTI-MISC
anti I-DISO-MISC O-MISC
- I-DISO-MISC B-DISO-MISC
diuretic I-DISO-MISC B-DISO-MISC
hormone I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
SIADH B-DISO-MISC O-MISC
) O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
vincristine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
explore O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
at O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
risk O-MISC I-CHED-MISC
population O-MISC I-ANAT-MISC
subgroups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHOD O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
searched O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Eli O-MISC B-PHYS-MISC
Lilly O-MISC I-PHYS-MISC
and O-MISC I-PHYS-MISC
Company O-MISC I-PHYS-MISC
' O-MISC I-PHYS-MISC
s O-MISC I-PHYS-MISC
computerized O-MISC B-CHED-MISC
adverse O-MISC I-CHED-MISC
event O-MISC I-CHED-MISC
database O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyponatremia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
SIADH B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
November O-MISC B-ACTI-MISC
1999 O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-CONC-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
vincristine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hyponatremia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
SIADH B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
vincristine B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
reporting O-MISC B-CONC-MISC
rate O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
age O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
males O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Approximately O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
leukemia B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
reports O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
information O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
race O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
racial O-MISC B-CHED-MISC
distribution O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
Black O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
Caucasian O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
Asian O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
Asian O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyponatremia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
SIADH B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
vincristine B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
SIADH B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
vincristine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
physicians O-MISC I-ANAT-MISC
caring O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
Asian O-MISC I-ANAT-MISC
oncology O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
reversible O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
event O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Delayed O-MISC B-CHED-MISC
toxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
DBA O-MISC O-MISC
/ O-MISC I-PHEN-MISC
2 O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6 O-MISC I-PHEN-MISC
female O-MISC I-ANAT-MISC
mouse O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
describes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
delayed O-MISC B-CHED-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
bladder O-MISC I-GENE-MISC
pathology O-MISC B-PROC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
susceptible O-MISC B-CHED-MISC
strain O-MISC I-ANAT-MISC
of O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
DBA O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
2 O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
resistant O-MISC I-ANAT-MISC
strain O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6 O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CY B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Inbred O-MISC I-ANAT-MISC
DBA O-MISC I-PHEN-MISC
/ O-MISC I-PHEN-MISC
2 O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6 O-MISC I-PHEN-MISC
female O-MISC I-DISO-MISC
mice O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
CY B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
during O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
light O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
using O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
staining O-MISC B-CONC-MISC
procedures O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
conventional O-MISC B-CONC-MISC
electron O-MISC I-CONC-MISC
microscopy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Early O-MISC B-ACTI-MISC
CY B-CHED-MISC O-MISC
toxicity B-DISO-MISC I-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
haemorrhagic B-DISO-MISC I-ACTI-MISC
cystitis B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
strains O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
completely O-MISC B-ACTI-MISC
repaired O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CY B-CHED-MISC O-MISC
injection O-MISC O-MISC
ulcerous O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
ulcerous O-MISC B-ANAT-MISC
forms O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
cystitis B-DISO-MISC B-ANAT-MISC
appeared O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
DBA O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
2 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
but O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Delayed O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
characterized O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
infiltration O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
transepithelial O-MISC I-ACTI-MISC
passage O-MISC B-CHED-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lumen O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
inflammatory O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
exfoliation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urothelium O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Mast O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
appeared O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
connective O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
muscular O-MISC I-GENE-MISC
layers O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
much O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
DBA O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
2 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
or O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Electron O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
disclosed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
discoidal O-MISC I-GENE-MISC
vesicles O-MISC B-GEOG-MISC
normally O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cytoplasm O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
surface O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Instead O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
numerous O-MISC B-CHED-MISC
abnormal O-MISC I-ACTI-MISC
vesicles O-MISC I-GENE-MISC
containing O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
dark O-MISC I-ACTI-MISC
granules O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cytoplasm O-MISC I-GENE-MISC
of O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epithelial O-MISC I-GENE-MISC
layers O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Delayed O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
still O-MISC B-ACTI-MISC
persisted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
DBA O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
2 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
100 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
delayed O-MISC I-ACTI-MISC
toxicity B-DISO-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
CY B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
DBA O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
2 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
causes O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
pathology O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
pathology O-MISC B-CHED-MISC
resembles O-MISC B-ACTI-MISC
interstitial B-DISO-MISC I-ACTI-MISC
cystitis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
perhaps O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
model O-MISC I-PHEN-MISC
for O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

High O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
folinic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
three O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
weekly O-MISC I-CHED-MISC
mitomycin B-CHED-MISC O-MISC
C I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
advanced O-MISC I-ACTI-MISC
gastric B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
hour O-MISC B-CHED-MISC
continuous O-MISC B-CHED-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
folinic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
FA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
multidrug O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
regimens O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
advanced O-MISC I-ACTI-MISC
gastric B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AGC B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
toxicity B-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
weekly O-MISC B-ACTI-MISC
bolus O-MISC O-MISC
5 B-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
FA B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
mitomycin B-CHED-MISC O-MISC
C I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MMC B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
rate O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
response O-MISC B-CHED-MISC
rates O-MISC I-CHED-MISC
comparable O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
regimens O-MISC B-CONC-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
ELF O-MISC O-MISC
, O-MISC B-ACTI-MISC
FAM O-MISC O-MISC
or O-MISC B-ACTI-MISC
FAMTX O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
promising O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
overall O-MISC B-CHED-MISC
survival O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
improve O-MISC I-ACTI-MISC
this O-MISC B-ACTI-MISC
MMC B-CHED-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-ACTI-MISC
schedule O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
initiated O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
5 B-CHED-MISC B-ACTI-MISC
- I-CHED-MISC B-ACTI-MISC
FU I-CHED-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
FA B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
weekly O-MISC B-CHED-MISC
bolus O-MISC B-CONC-MISC
MMC B-CHED-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

PATIENTS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
From O-MISC B-ACTI-MISC
February O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1998 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
September O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2000 O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
recruited O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
AGC B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
weekly O-MISC B-CHED-MISC
24 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
hour O-MISC B-ACTI-MISC
5 B-CHED-MISC B-CONC-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
preceded O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
hour O-MISC B-ACTI-MISC
FA B-CHED-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
rest O-MISC B-ACTI-MISC
period O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Bolus O-MISC I-ACTI-MISC
MMC B-CHED-MISC B-ANAT-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
added O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
weekly O-MISC B-ACTI-MISC
intervals O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
given O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
outpatient O-MISC I-ANAT-MISC
basis O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
portable O-MISC B-OBJC-MISC
pump O-MISC B-OBJC-MISC
systems O-MISC I-OBJC-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
repeated O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
57 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
' O-MISC B-ACTI-MISC
characteristics O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
ratio O-MISC B-CHED-MISC
20 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
age O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
WHO O-MISC B-PHYS-MISC
status O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

18 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
AGC B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relapsed O-MISC B-OCCU-MISC
AGC B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-CONC-MISC
follow O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
surviving O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
evaluable O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
response O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
complete O-MISC B-ANAT-MISC
remission O-MISC B-ANAT-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
remission O-MISC I-ACTI-MISC
45 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
27 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
progressive O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
survival O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
[ O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
progression O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
free O-MISC I-CHED-MISC
survival O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
worst O-MISC B-CHED-MISC
toxicities B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
CTC O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
NCI O-MISC B-CONC-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
leukopenia B-DISO-MISC I-ACTI-MISC
45 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
33 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
vomitus B-DISO-MISC I-ACTI-MISC
24 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
diarrhea B-DISO-MISC I-ACTI-MISC
36 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
stomatitis B-DISO-MISC I-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
hand B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
foot I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
uremic I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HUS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
High O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
FA B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
MMC B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
outpatient O-MISC B-CONC-MISC
regimen O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
AGC B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
objective O-MISC B-ACTI-MISC
response O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
54 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
serve O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alternative O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
containing O-MISC B-CHED-MISC
regimens O-MISC B-CONC-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
HUS B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Persistent O-MISC B-ACTI-MISC
sterile O-MISC I-ACTI-MISC
leukocyturia B-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
impaired B-DISO-MISC B-CHED-MISC
renal I-DISO-MISC I-DISO-MISC
function I-DISO-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
human B-DISO-MISC I-ANAT-MISC
immunodeficiency I-DISO-MISC I-PHEN-MISC
virus I-DISO-MISC I-PHEN-MISC
type I-DISO-MISC I-PHEN-MISC
1 I-DISO-MISC I-PHEN-MISC
- I-DISO-MISC B-ACTI-MISC
infected I-DISO-MISC I-PHEN-MISC
children O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
indinavir B-CHED-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Prolonged O-MISC B-CHED-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
indinavir B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-ACTI-MISC
complications O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
well O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
documented O-MISC I-CONC-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
restricted O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
potent O-MISC B-ACTI-MISC
protease O-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
monitor O-MISC B-ACTI-MISC
indinavir B-CHED-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cohort O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
human B-DISO-MISC I-ANAT-MISC
immunodeficiency I-DISO-MISC I-PHEN-MISC
virus I-DISO-MISC I-PHEN-MISC
type I-DISO-MISC I-PHEN-MISC
1 I-DISO-MISC I-PHEN-MISC
- I-DISO-MISC B-ACTI-MISC
infected I-DISO-MISC I-ACTI-MISC
children O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
indinavir B-CHED-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Urinary O-MISC I-GENE-MISC
pH O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
albumin O-MISC O-MISC
, O-MISC B-ACTI-MISC
creatinine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
erythrocytes O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
leukocytes O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
bacteria O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
crystals O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
culture O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
every O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
96 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Serum O-MISC B-CONC-MISC
creatinine B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
routinely O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
points O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Steady O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
state O-MISC I-OCCU-MISC
pharmacokinetics O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
indinavir B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
done O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
indinavir B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
sterile O-MISC I-ACTI-MISC
leukocyturia B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
cells O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
micro O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
visits O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
96 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
53 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Persistent O-MISC B-ACTI-MISC
sterile O-MISC I-ACTI-MISC
leukocyturia B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
frequently O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
mild O-MISC B-CHED-MISC
increase O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urine O-MISC O-MISC
albumin O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
creatinine B-CHED-MISC O-MISC
ratio O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
microscopic O-MISC B-CONC-MISC
hematuria B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
creatinine B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
> O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
above O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
96 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
sterile O-MISC B-CHED-MISC
leukocyturia B-DISO-MISC I-ACTI-MISC
more O-MISC B-ACTI-MISC
frequently O-MISC B-CHED-MISC
had O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
creatinine B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
above O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
sterile O-MISC B-CHED-MISC
leukocyturia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
younger O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
persistent O-MISC B-ACTI-MISC
sterile O-MISC I-ACTI-MISC
leukocyturia B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
more O-MISC B-CHED-MISC
frequent O-MISC I-CHED-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
children O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
cumulative O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
leukocyturia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
area O-MISC B-CHED-MISC
under O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
curve O-MISC I-CHED-MISC
> O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
peak O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
indinavir B-CHED-MISC O-MISC
> O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
indinavir B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Subsequently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
levels O-MISC B-ANAT-MISC
decreased O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urine O-MISC B-OCCU-MISC
albumin O-MISC I-OCCU-MISC
/ O-MISC B-ACTI-MISC
creatinine B-CHED-MISC I-ACTI-MISC
ratios O-MISC I-OCCU-MISC
returned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
zero O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
leukocyturia B-DISO-MISC I-ACTI-MISC
disappeared O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Children O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
indinavir B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
sterile O-MISC B-CHED-MISC
leukocyturia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
sterile O-MISC B-CHED-MISC
leukocyturia B-DISO-MISC I-ACTI-MISC
more O-MISC B-ACTI-MISC
frequently O-MISC B-CHED-MISC
had O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
creatinine B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
above O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Younger O-MISC B-CHED-MISC
children O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
complications O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
impairment B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
renal I-DISO-MISC I-DISO-MISC
function I-DISO-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
nephrolithiasis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Indinavir B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
monitored O-MISC B-CONC-MISC
closely O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
sterile O-MISC I-ACTI-MISC
leukocyturia B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
< O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
area O-MISC B-CHED-MISC
under O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
curve O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
indinavir B-CHED-MISC O-MISC
> O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
C O-MISC B-CHED-MISC
( O-MISC I-CHED-MISC
max O-MISC I-CHED-MISC
) O-MISC I-CHED-MISC
> O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Utility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
troponin O-MISC O-MISC
I O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Baseline O-MISC B-CHED-MISC
electrocardiogram O-MISC I-ACTI-MISC
abnormalities O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
market O-MISC B-ORGA-MISC
elevations O-MISC B-CHED-MISC
not O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
necrosis I-DISO-MISC B-ANAT-MISC
make O-MISC B-ACTI-MISC
accurate O-MISC B-CHED-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
difficult O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Troponin O-MISC O-MISC
sampling O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
offer O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
diagnostic O-MISC B-CHED-MISC
utility O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
assess O-MISC B-DEVI-MISC
outcomes O-MISC I-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
troponin O-MISC O-MISC
positivity O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
admitted O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
exclusion O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Outcomes O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
admitted O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
possible O-MISC I-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
underwent O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rapid O-MISC B-CHED-MISC
rule O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
in O-MISC I-CHED-MISC
protocol O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
serial O-MISC B-ACTI-MISC
sampling O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
creatine B-CHED-MISC O-MISC
kinase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CK O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cardiac O-MISC O-MISC
troponin O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
cTnI O-MISC O-MISC
) O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Outcomes O-MISC B-CONC-MISC
included O-MISC B-ACTI-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
MI B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relative O-MISC B-ACTI-MISC
index O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
x O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
CK O-MISC O-MISC
] O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
death I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
coronary B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
246 O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
met O-MISC B-ACTI-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
criteria O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
cTnI O-MISC I-ACTI-MISC
elevations O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Angiography O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
cTnI O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
present O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
cTnI O-MISC B-CONC-MISC
elevations O-MISC B-CHED-MISC
met O-MISC B-ACTI-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
criteria O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
peak O-MISC B-CHED-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Sensitivities O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
specificities O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
likelihood O-MISC B-CHED-MISC
ratios O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
predicting O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
death I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
disease O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
MI B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
cTnI O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cTnI O-MISC I-ACTI-MISC
elevations O-MISC B-CHED-MISC
meet O-MISC B-ACTI-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
criteria O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Troponin O-MISC O-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
equivalent O-MISC B-ACTI-MISC
diagnostic O-MISC B-CHED-MISC
accuracy O-MISC I-CHED-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
CK O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MB O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
diagnosing O-MISC I-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
MI B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC B-CHED-MISC
interstitial B-DISO-MISC B-ANAT-MISC
nephritis I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
nicergoline B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Sermion B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
interstitial B-DISO-MISC B-ANAT-MISC
nephritis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AIN B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
nicergoline B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Sermion B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
hospital O-MISC B-GENE-MISC
for O-MISC B-ACTI-MISC
fever B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Before O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
nicergoline B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
bendazac B-CHED-MISC O-MISC
lysine I-CHED-MISC B-DISO-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
retinal B-DISO-MISC I-ACTI-MISC
vein I-DISO-MISC B-ANAT-MISC
occlusion I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
ophthalmologic O-MISC B-PHYS-MISC
department O-MISC I-PHYS-MISC
. O-MISC B-ACTI-MISC

Thereafter O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
experienced O-MISC B-ACTI-MISC
intermittent O-MISC I-ACTI-MISC
fever B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
skin B-DISO-MISC I-ACTI-MISC
rash I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
admission O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
arthralgia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
fever B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
laboratory O-MISC B-OCCU-MISC
findings O-MISC I-OCCU-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
eosinophilia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
AIN B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pathologic O-MISC B-CHED-MISC
findings O-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
biopsy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
lymphocyte O-MISC B-CONC-MISC
transformation O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
demonstrated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
result O-MISC B-CHED-MISC
against O-MISC B-ACTI-MISC
nicergoline B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
consisted O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
withdrawal O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
nicergoline B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
methylprednisolone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
completely O-MISC B-ANAT-MISC
recovered O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nicergoline B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
AIN B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
complicated O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
massive O-MISC I-ACTI-MISC
intestinal O-MISC I-ACTI-MISC
bleeding B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CRF B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
NMS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
levomepromazine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
NMS B-DISO-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
massive O-MISC I-ACTI-MISC
intestinal O-MISC B-ANAT-MISC
bleeding B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
episode O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
NMS B-DISO-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
CRF B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
complicated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
intestinal O-MISC I-ACTI-MISC
bleeding B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
needs O-MISC B-ACTI-MISC
special O-MISC B-ACTI-MISC
caution O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Blood O-MISC I-GENE-MISC
brain O-MISC B-GEOG-MISC
barrier O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
right O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
pawed O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
staining O-MISC B-CONC-MISC
method O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
asymmetrical O-MISC I-DISO-MISC
breakdown O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
brain O-MISC I-LIVB-MISC
barrier O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
BBB O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Paw O-MISC I-DISO-MISC
preference O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
food O-MISC B-CHED-MISC
reaching O-MISC I-CHED-MISC
test O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Adrenaline B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
destroy O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
BBB O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
triphenyltetrazolium B-CHED-MISC B-CONC-MISC
( O-MISC I-CONC-MISC
TTC B-CHED-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
staining O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
slices O-MISC B-GEOG-MISC
just O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
giving O-MISC B-ACTI-MISC
adrenaline B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
whole O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
sections O-MISC B-GEOG-MISC
exhibited O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
staining O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
TTC B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
adrenaline B-CHED-MISC B-CONC-MISC
infusion O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
unstained O-MISC I-ACTI-MISC
areas O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
brain O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
right O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
pawed O-MISC I-PHEN-MISC
animals O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
vice O-MISC B-ACTI-MISC
versa O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
left O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
pawed O-MISC I-PHEN-MISC
animals O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Similar O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
breakdown O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
BBB O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
explained O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
asymmetric O-MISC I-ACTI-MISC
cerebral O-MISC B-ANAT-MISC
blood O-MISC B-ANAT-MISC
flow O-MISC B-ANAT-MISC
depending O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
paw O-MISC I-GENE-MISC
preference O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
method O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
contralateral O-MISC B-CHED-MISC
motor O-MISC B-CHED-MISC
control O-MISC I-LIVB-MISC
that O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
determining O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dominant O-MISC B-CHED-MISC
cerebral O-MISC I-GENE-MISC
hemisphere O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Carvedilol B-CHED-MISC O-MISC
protects O-MISC I-ACTI-MISC
against O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
mitochondrial O-MISC I-ACTI-MISC
cardiomyopathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Several O-MISC B-ACTI-MISC
cytopathic O-MISC I-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
mediate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
limiting O-MISC I-CHED-MISC
cumulative O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
irreversible O-MISC I-ACTI-MISC
cardiomyopathy B-DISO-MISC B-ANAT-MISC
caused O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Recent O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
indicates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
key O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenic O-MISC I-ACTI-MISC
process O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
objective O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
investigation O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
test O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
carvedilol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nonselective O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
adrenergic O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
potent O-MISC B-ACTI-MISC
antioxidant O-MISC O-MISC
properties O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
protects O-MISC B-ACTI-MISC
against O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
mitochondrial O-MISC I-GENE-MISC
bioenergetic O-MISC I-DISO-MISC
dysfunction O-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
subchronic O-MISC I-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
toxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Heart O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
mitochondria O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
sc O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
carvedilol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
ip O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
. O-MISC B-ACTI-MISC

Heart O-MISC I-GENE-MISC
mitochondria O-MISC I-GENE-MISC
isolated O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
exhibited O-MISC B-ACTI-MISC
depressed O-MISC I-ACTI-MISC
rates O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
state O-MISC I-DISO-MISC
3 O-MISC I-LIVB-MISC
respiration O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
336 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
425 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
53 O-MISC B-ACTI-MISC
natom O-MISC B-ACTI-MISC
O O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
protein O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
respiratory O-MISC I-CHED-MISC
control O-MISC B-ANAT-MISC
ratio O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
RCR O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
mitochondria O-MISC I-GENE-MISC
isolated O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Mitochondrial O-MISC I-GENE-MISC
calcium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
loading O-MISC B-DEVI-MISC
capacity O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
NADH O-MISC O-MISC
- O-MISC B-DISO-MISC
dehydrogenase O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
suppressed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
mitochondria O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Doxorubicin B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
also O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
RCR O-MISC O-MISC
for O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
mitochondria O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
cytochrome O-MISC I-DISO-MISC
oxidase O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Coadministration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
carvedilol B-CHED-MISC O-MISC
decreased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
extent O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cellular O-MISC I-ACTI-MISC
vacuolization O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
myocytes O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
prevented O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
inhibitory O-MISC B-DEVI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
mitochondrial O-MISC I-GENE-MISC
respiration O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Carvedilol B-CHED-MISC O-MISC
also O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mitochondrial O-MISC I-GENE-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
loading O-MISC B-DEVI-MISC
capacity O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
respiratory O-MISC I-GENE-MISC
complexes O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
mitochondria O-MISC I-GENE-MISC
caused O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Carvedilol B-CHED-MISC O-MISC
by O-MISC B-ACTI-MISC
itself O-MISC B-ACTI-MISC
did O-MISC I-ACTI-MISC
not O-MISC B-ANAT-MISC
affect O-MISC B-CONC-MISC
any O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
parameters O-MISC I-ACTI-MISC
measured O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
mitochondria O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
protection O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
carvedilol B-CHED-MISC O-MISC
against O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
structural O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
cardiac O-MISC I-ACTI-MISC
tissue O-MISC B-ANAT-MISC
damage O-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
afford O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
clinical O-MISC B-PHEN-MISC
advantage O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
minimizing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
limiting O-MISC I-CHED-MISC
mitochondrial B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
cardiomyopathy B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
accompanies O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
doxorubicin B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
influenced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
agonists O-MISC O-MISC
than O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
agonists O-MISC O-MISC
and O-MISC B-ACTI-MISC
antagonists O-MISC O-MISC
on O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
agonists O-MISC O-MISC
significantly O-MISC B-ACTI-MISC
decreased B-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
locomotor I-DISO-MISC I-DISO-MISC
activity I-DISO-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
seems O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
A1 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
A2 O-MISC O-MISC
receptors O-MISC B-DISO-MISC
might O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
reaction O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
agonists O-MISC O-MISC
: O-MISC B-ACTI-MISC
2 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
p I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
carboxyethyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
phenethylamino I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
' I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
N I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
ethylcarboxamidoadenosine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CGS B-CHED-MISC O-MISC
21680 I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
A2A O-MISC O-MISC
receptor O-MISC B-DISO-MISC
agonist O-MISC O-MISC
, O-MISC B-ACTI-MISC
N6 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
cyclopentyladenosine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CPA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
A1 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
agonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
' I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
N I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
ethylcarboxamidoadenosine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NECA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
A2 O-MISC O-MISC
/ O-MISC B-DISO-MISC
A1 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
agonist O-MISC B-DISO-MISC
significantly O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependently O-MISC I-CHED-MISC
decreased O-MISC B-CHED-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
locomotor O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

CPA B-CHED-MISC O-MISC
reduced O-MISC B-CHED-MISC
cocaine B-CHED-MISC O-MISC
action O-MISC B-DEVI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
which O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
influence O-MISC B-ACTI-MISC
motility O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
CGS B-CHED-MISC O-MISC
21680 I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
NECA B-CHED-MISC O-MISC
decreased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
action O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
which O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
locomotor O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
involvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptors O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
action O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
although O-MISC B-ACTI-MISC
agonists O-MISC O-MISC
of O-MISC B-ACTI-MISC
A1 O-MISC O-MISC
receptors O-MISC B-DISO-MISC
seem O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
stronger O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
blockade O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
A2 O-MISC O-MISC
adenosine B-CHED-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
by O-MISC B-ACTI-MISC
DMPX B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
3 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
7 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dimethyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
propargylxanthine I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
locomotor O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Caffeine B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
similar O-MISC B-CHED-MISC
action O-MISC B-DEVI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CPT B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
8 B-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
cyclopentyltheophylline I-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
A1 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC O-MISC
, O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
test O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Similarly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
agonists O-MISC O-MISC
decreased O-MISC B-CHED-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
active O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
blockade O-MISC O-MISC
of O-MISC B-ACTI-MISC
A2 O-MISC O-MISC
adenosine B-CHED-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
DMPX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
selective O-MISC B-ANAT-MISC
blockade O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptors O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
increased O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
action O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
locomotor O-MISC B-CONC-MISC
activity O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
agonists O-MISC O-MISC
( O-MISC B-ACTI-MISC
A1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
A2 O-MISC O-MISC
) O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
locomotor O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
influenced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
agonists O-MISC O-MISC
( O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
A1 O-MISC O-MISC
receptors O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Amiodarone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bradyarrhythmia B-DISO-MISC I-ACTI-MISC
requiring O-MISC B-ACTI-MISC
permanent O-MISC B-OBJC-MISC
pacemaker O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AF B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bradyarrhythmia B-DISO-MISC I-ACTI-MISC
requiring O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
permanent O-MISC B-OBJC-MISC
pacemaker O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Reports O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
bradyarrhythmia B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
infrequent O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
assessing O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
' O-MISC I-CONC-MISC
s O-MISC I-CONC-MISC
use O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
arrhythmias I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
cohort O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
770 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
age O-MISC I-DISO-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
AF B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
provincewide O-MISC B-ORGA-MISC
database O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Quebec O-MISC B-ORGA-MISC
residents O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
1991 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1999 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nested O-MISC B-DEVI-MISC
case O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
design O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
477 O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bradyarrhythmia B-DISO-MISC I-ACTI-MISC
requiring O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
permanent O-MISC B-OBJC-MISC
pacemaker O-MISC I-OBJC-MISC
were O-MISC B-ACTI-MISC
matched O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
908 O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Multivariable O-MISC B-CONC-MISC
logistic O-MISC I-CONC-MISC
regression O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
estimate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pacemaker O-MISC B-CONC-MISC
insertion O-MISC I-CONC-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
amiodarone B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
controlling O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
sotalol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
Class O-MISC B-ACTI-MISC
I O-MISC B-ACTI-MISC
antiarrhythmic O-MISC O-MISC
agents O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
channel O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
digoxin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pacemaker O-MISC B-CONC-MISC
insertion O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
[ O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
] O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
modified O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
gender O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
versus O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
89 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Digoxin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
medication O-MISC B-CONC-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pacemaker O-MISC B-CONC-MISC
insertion O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
78 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
AF B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
increases O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bradyarrhythmia B-DISO-MISC I-ACTI-MISC
requiring O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
permanent O-MISC B-OBJC-MISC
pacemaker O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
finding O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
augmented O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pacemaker O-MISC B-CONC-MISC
insertion O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
women O-MISC I-PHEN-MISC
receiving O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
requires O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
investigation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Indomethacin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
morphologic O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
urinary O-MISC I-GENE-MISC
bladder O-MISC B-GEOG-MISC
epithelium O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
evaluate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
morphologic O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
urothelium O-MISC I-GENE-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Nonsteroidal O-MISC O-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drug O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
poorly O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
condition O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
tiaprofenic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
this O-MISC B-ACTI-MISC
condition O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Three O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
established O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
group O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
one O-MISC B-ACTI-MISC
intraperitoneal O-MISC B-CONC-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
group O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
oral O-MISC O-MISC
indomethacin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
daily O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
killed O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bladders O-MISC I-GENE-MISC
removed O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
light O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
electron O-MISC B-CONC-MISC
microscopic O-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
light O-MISC B-OCCU-MISC
microscopic O-MISC I-OCCU-MISC
findings O-MISC I-OCCU-MISC
showed O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
focal O-MISC I-ACTI-MISC
epithelial O-MISC B-ANAT-MISC
degeneration O-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
prominent O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
groups O-MISC B-CHED-MISC
revealed O-MISC B-CHED-MISC
statistically O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
numbers O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mast O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mucosa O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
penetration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lanthanum B-CHED-MISC O-MISC
nitrate I-CHED-MISC B-DISO-MISC
through O-MISC B-ACTI-MISC
intercellular O-MISC I-GENE-MISC
areas O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epithelium O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
difference O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mast O-MISC B-CONC-MISC
cell O-MISC I-CONC-MISC
counts O-MISC I-CONC-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Indomethacin B-CHED-MISC O-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
histopathologic O-MISC B-CHED-MISC
findings O-MISC I-ACTI-MISC
typical O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
interstitial B-DISO-MISC I-ACTI-MISC
cystitis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
leaky O-MISC B-CHED-MISC
bladder O-MISC I-GENE-MISC
epithelium O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
mucosal O-MISC I-ACTI-MISC
mastocytosis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
true O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nonsteroidal O-MISC O-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drug O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
clarified O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
prospective O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
label O-MISC I-CONC-MISC
phase O-MISC I-CONC-MISC
II O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
thalidomide B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
androgen B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
independent O-MISC B-ANAT-MISC
prostate B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
antiangiogenic O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
solid O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
haematological B-DISO-MISC I-ACTI-MISC
malignancies I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Thalidomide B-CHED-MISC O-MISC
blocks O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
angiogenic O-MISC O-MISC
agents O-MISC B-DISO-MISC
including O-MISC B-ACTI-MISC
bFGF O-MISC O-MISC
, O-MISC B-ACTI-MISC
VEGF O-MISC O-MISC
and O-MISC B-ACTI-MISC
IL O-MISC O-MISC
- O-MISC B-DISO-MISC
6 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
undertook O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
label O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
using O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
100 O-MISC B-DISO-MISC
mg O-MISC B-ACTI-MISC
once O-MISC B-CHED-MISC
daily O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
androgen B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
independent O-MISC B-ANAT-MISC
prostate B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
time O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
109 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
107 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
184 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
underwent O-MISC B-ACTI-MISC
regular O-MISC B-ACTI-MISC
measurement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
prostate O-MISC O-MISC
- O-MISC B-DISO-MISC
specific O-MISC B-DISO-MISC
antigen O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
PSA O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
urea B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
electrolytes O-MISC O-MISC
, O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
bFGF O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
VEGF O-MISC O-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decline O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
PSA O-MISC O-MISC
of O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
throughout O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fall O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
absolute O-MISC B-CHED-MISC
PSA O-MISC O-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Increasing O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
bFGF O-MISC O-MISC
and O-MISC B-ACTI-MISC
VEGF O-MISC O-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
progressive O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fall O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
PSA O-MISC O-MISC
also O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decline O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
bFGF O-MISC O-MISC
and O-MISC B-ACTI-MISC
VEGF O-MISC O-MISC
levels O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rising O-MISC B-CHED-MISC
PSA O-MISC O-MISC
showed O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
growth O-MISC O-MISC
factors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
included O-MISC B-ACTI-MISC
constipation B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
morning O-MISC I-ACTI-MISC
drowsiness B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
dizziness B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
rash B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
resulted O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
withdrawal O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
sensory I-DISO-MISC B-ANAT-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
before O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
completed O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
subclinical O-MISC B-CHED-MISC
evidence O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
repeat O-MISC B-ACTI-MISC
testing O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
findings O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
option O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
failed O-MISC B-CHED-MISC
other O-MISC B-ACTI-MISC
forms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
provided O-MISC B-ACTI-MISC
close O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
maintained O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Central B-DISO-MISC I-ACTI-MISC
nervous I-DISO-MISC B-ANAT-MISC
system I-DISO-MISC B-ANAT-MISC
toxicity I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
levobupivacaine B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
lumbar O-MISC I-ACTI-MISC
plexus O-MISC B-ANAT-MISC
block O-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Central B-DISO-MISC I-GENE-MISC
nervous I-DISO-MISC B-GEOG-MISC
system I-DISO-MISC B-GEOG-MISC
and I-DISO-MISC B-ACTI-MISC
cardiac I-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
local O-MISC O-MISC
anesthetics O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
regional O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Levobupivacaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pure O-MISC B-ACTI-MISC
S O-MISC O-MISC
( O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
enantiomer O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
improve O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
safety O-MISC I-CONC-MISC
profile O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
grand B-DISO-MISC B-ACTI-MISC
mal I-DISO-MISC I-ACTI-MISC
seizures I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
accidental O-MISC B-CHED-MISC
intravascular O-MISC B-CHED-MISC
injection O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
levobupivacaine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CASE O-MISC B-CHED-MISC
REPORT O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
Two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
presenting O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
elective O-MISC B-CONC-MISC
orthopedic O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lower O-MISC I-GENE-MISC
limb O-MISC B-GEOG-MISC
underwent O-MISC B-ACTI-MISC
blockade O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lumbar O-MISC I-GENE-MISC
plexus O-MISC B-GEOG-MISC
via O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
posterior O-MISC B-CHED-MISC
approach O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Immediately O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
levobupivacaine B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
microgram O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
grand B-DISO-MISC B-ACTI-MISC
mal I-DISO-MISC B-ANAT-MISC
seizures I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
despite O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
aspiration O-MISC I-DISO-MISC
for O-MISC I-LIVB-MISC
blood O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
clinical O-MISC I-ACTI-MISC
signs O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
epinephrine B-CHED-MISC O-MISC
administration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
successfully O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
thiopental I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
signs O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
preoperatively O-MISC B-CHED-MISC
with O-MISC I-CONC-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
adrenergic O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
medications O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
masked O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
signs O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unintentional O-MISC B-ACTI-MISC
intravascular O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
levobupivacaine B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Although O-MISC B-ACTI-MISC
levobupivacaine B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
safer O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
profile O-MISC B-CONC-MISC
than O-MISC B-ACTI-MISC
racemic O-MISC B-GENE-MISC
bupivacaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
adequate O-MISC B-CHED-MISC
amounts O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
levobupivacaine B-CHED-MISC O-MISC
reach O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
circulation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
will O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Plasma O-MISC I-GENE-MISC
concentrations O-MISC B-CHED-MISC
sufficient O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
central B-DISO-MISC I-GENE-MISC
nervous I-DISO-MISC B-GEOG-MISC
system I-DISO-MISC B-GEOG-MISC
toxicity I-DISO-MISC I-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
manifestations O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Amiodarone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
torsade B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
irrigation O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unusual O-MISC B-CHED-MISC
presentation O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
present O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
torsade B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
TdP B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
oral O-MISC B-CHED-MISC
amiodarone B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Consistent O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
reports O-MISC B-CHED-MISC
this O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
TdP B-DISO-MISC O-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
context O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
multiple O-MISC B-ACTI-MISC
exacerbating O-MISC I-ACTI-MISC
factors O-MISC B-CHED-MISC
including O-MISC B-ACTI-MISC
hypokalemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
digoxin B-CHED-MISC O-MISC
excess O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Transient O-MISC B-CHED-MISC
prolongation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
QT O-MISC I-DISO-MISC
during O-MISC B-ACTI-MISC
bladder O-MISC B-CONC-MISC
irrigation O-MISC I-CONC-MISC
prompted O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
episode O-MISC B-ACTI-MISC
of O-MISC I-CHED-MISC
TdP B-DISO-MISC O-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
exacerbates O-MISC I-ACTI-MISC
acquired O-MISC B-CHED-MISC
TdP B-DISO-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
speculate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
vagal O-MISC I-ACTI-MISC
tone O-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
irrigation O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
vagal O-MISC I-ACTI-MISC
maneuver O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
context O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
resulted O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
proarrhythmia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
irrigation O-MISC B-CONC-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
TdP B-DISO-MISC I-ACTI-MISC
despite O-MISC B-ACTI-MISC
hypokalemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hypomagnesemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Anaesthetic O-MISC I-ACTI-MISC
complications O-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
myotonia B-DISO-MISC I-ANAT-MISC
congenita I-DISO-MISC I-PHEN-MISC
: O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
study O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
comparison O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Myotonia B-DISO-MISC I-ANAT-MISC
congenita I-DISO-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
MC B-DISO-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
defect O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
skeletal O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
chloride B-CHED-MISC O-MISC
channel O-MISC B-DISO-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
sustained B-DISO-MISC B-ACTI-MISC
membrane I-DISO-MISC I-GENE-MISC
depolarisation I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
32 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
life O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
muscle B-DISO-MISC I-ACTI-MISC
spasm I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
secondary O-MISC B-CONC-MISC
ventilation O-MISC I-CONC-MISC
difficulties O-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
preoperative O-MISC B-CHED-MISC
injection O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
muscle B-DISO-MISC I-ACTI-MISC
spasms I-DISO-MISC B-ANAT-MISC
disappeared O-MISC B-ACTI-MISC
spontaneously O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
proceeded O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
further O-MISC B-CHED-MISC
problems O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
subsequently O-MISC B-ACTI-MISC
questioned O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
minor O-MISC B-CHED-MISC
symptoms O-MISC I-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
condition I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Myotonia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
examination O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
EMG O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
MC B-DISO-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
genetically O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
nor O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anaesthetist O-MISC O-MISC
were O-MISC B-ACTI-MISC
aware O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
before O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
potentially O-MISC B-CHED-MISC
lethal O-MISC I-ACTI-MISC
complication O-MISC I-ACTI-MISC
occurred O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
give O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
brief O-MISC B-ACTI-MISC
overview O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ion B-DISO-MISC I-ACTI-MISC
channel I-DISO-MISC B-ANAT-MISC
disorders I-DISO-MISC B-ANAT-MISC
including O-MISC B-ACTI-MISC
malignant B-DISO-MISC I-ACTI-MISC
hyperthermia I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
anaesthetic O-MISC I-ACTI-MISC
considerations O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Respiratory O-MISC B-CHED-MISC
pattern O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
model O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Apnea B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
systematic O-MISC B-CHED-MISC
studies O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
ictal O-MISC I-ACTI-MISC
respiratory O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Data O-MISC B-CHED-MISC
regarding O-MISC B-ACTI-MISC
respiratory O-MISC I-ACTI-MISC
pattern O-MISC B-ANAT-MISC
defects O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
interictal O-MISC B-CHED-MISC
periods O-MISC B-CHED-MISC
also O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
scarce O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
sought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
generate O-MISC B-ACTI-MISC
information O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
regard O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
interictal O-MISC I-ACTI-MISC
period O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Twelve O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
chronically O-MISC B-CHED-MISC
epileptic B-DISO-MISC I-ACTI-MISC
animals O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
anesthetized O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
tracheotomies O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
subjected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hyperventilation B-DISO-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
hypoventilation O-MISC I-ACTI-MISC
conditions O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Breathing O-MISC I-DISO-MISC
movements O-MISC I-LIVB-MISC
caused O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
thoracic O-MISC I-DISO-MISC
volume O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
forced O-MISC I-ACTI-MISC
air O-MISC B-GENE-MISC
to O-MISC B-ACTI-MISC
flow O-MISC B-OCCU-MISC
tidally O-MISC B-OCCU-MISC
through O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pneumotachograph O-MISC B-OBJC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
flow O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
differential O-MISC B-OBJC-MISC
pressure O-MISC I-OBJC-MISC
transducer O-MISC I-OBJC-MISC
, O-MISC B-ACTI-MISC
passed O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
polygraph O-MISC B-OBJC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
computer O-MISC B-GENE-MISC
with O-MISC B-ACTI-MISC
custom O-MISC B-GENE-MISC
software O-MISC I-GEOG-MISC
that O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
ventilation O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
VE O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
tidal O-MISC B-OCCU-MISC
volume O-MISC I-OCCU-MISC
( O-MISC B-ACTI-MISC
VT O-MISC B-OCCU-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
inspiratory O-MISC I-DISO-MISC
time O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
TI O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
expiratory O-MISC I-DISO-MISC
time O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
TE O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
breathing O-MISC I-DISO-MISC
frequency O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
f O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
inspiratory O-MISC I-DISO-MISC
flow O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
VT O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
TI O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
breath O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
breath O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
hyperventilation B-DISO-MISC I-ACTI-MISC
maneuver O-MISC B-DEVI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
ventilation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
VE O-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epileptic B-DISO-MISC I-ACTI-MISC
group O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
VE O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
TE O-MISC I-ACTI-MISC
peak O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
relation O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hypoventilation O-MISC I-ACTI-MISC
maneuver O-MISC B-DEVI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
arterial O-MISC I-GENE-MISC
Paco2 O-MISC O-MISC
, O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
VE O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epileptic B-DISO-MISC I-ACTI-MISC
group O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
VE O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
TE O-MISC I-ACTI-MISC
peak O-MISC B-CHED-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Systemic O-MISC B-CHED-MISC
application O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
KCN O-MISC O-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
peripheral O-MISC B-CHED-MISC
chemoreception O-MISC I-DISO-MISC
activation O-MISC B-DEVI-MISC
on O-MISC B-ACTI-MISC
ventilation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
VE O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
ability O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
react O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
compensate O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
blood O-MISC B-CONC-MISC
gas O-MISC I-CONC-MISC
changes O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
ventilation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
centrally O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
speculate O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
relation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
current O-MISC B-CHED-MISC
findings O-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
treating O-MISC B-CHED-MISC
different O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
conditions O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Fatal O-MISC I-ACTI-MISC
myeloencephalopathy B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
intrathecal O-MISC O-MISC
vincristine B-CHED-MISC B-DISO-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Vincristine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
accidentally O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
intrathecally O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
child O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
leukaemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
producing O-MISC B-ACTI-MISC
sensory B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
motor I-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Separate O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
administering O-MISC B-CONC-MISC
vincristine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
intrathecal O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
recommended O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Progesterone B-CHED-MISC I-DISO-MISC
potentiation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
arrhythmogenicity O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
pentobarbital B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
beating O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
heart O-MISC B-CONC-MISC
cell O-MISC I-CONC-MISC
cultures O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
progesterone B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
arrhythmogenicity O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
beating O-MISC B-CONC-MISC
rat O-MISC I-ANAT-MISC
heart O-MISC I-GENE-MISC
myocyte O-MISC B-GEOG-MISC
cultures O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
determining O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
AD50 O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
that O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
beating O-MISC B-ACTI-MISC
rat O-MISC I-GENE-MISC
heart O-MISC B-GEOG-MISC
myocyte O-MISC I-GENE-MISC
cultures O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
become O-MISC B-ACTI-MISC
arrhythmic B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC I-CHED-MISC
hour O-MISC I-CHED-MISC
progesterone B-CHED-MISC O-MISC
HCl B-CHED-MISC B-DISO-MISC
exposure O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
myocyte O-MISC I-GENE-MISC
contractile O-MISC I-DISO-MISC
rhythm O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Each O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
progesterone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
AD50 O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Estradiol B-CHED-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
also O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
arrhythmogenicity O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
myocyte O-MISC B-CONC-MISC
cultures O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
fourth O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
potent O-MISC B-OCCU-MISC
as O-MISC B-ACTI-MISC
progesterone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
progesterone B-CHED-MISC O-MISC
nor O-MISC B-ACTI-MISC
estradiol B-CHED-MISC O-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
arrhythmogenicity O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
potentiated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC O-MISC
progesterone B-CHED-MISC B-DISO-MISC
pretreatment O-MISC B-DEVI-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
arrhythmogenicity O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
intact O-MISC B-ACTI-MISC
pentobarbital B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
control O-MISC B-ACTI-MISC
nonprogesterone O-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SE O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
progesterone B-CHED-MISC O-MISC
can O-MISC B-ACTI-MISC
potentiate O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
arrhythmogenicity O-MISC I-ACTI-MISC
both O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Potentiation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
myocyte O-MISC B-CONC-MISC
cultures O-MISC I-CONC-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
partly O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocyte O-MISC I-GENE-MISC
level O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
soluble O-MISC B-CHED-MISC
Fas O-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
paracetamol B-CHED-MISC O-MISC
overdose B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
AIMS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Experimental O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
via O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Fas O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
Fas O-MISC I-DISO-MISC
Ligand O-MISC I-LIVB-MISC
signaling O-MISC I-LIVB-MISC
system O-MISC I-LIVB-MISC
may O-MISC B-ACTI-MISC
play O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
soluble O-MISC B-CHED-MISC
form O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
Fas O-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODOLOGY O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Serum O-MISC I-GENE-MISC
levels O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
sFas O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
soluble O-MISC B-CHED-MISC
Fas O-MISC O-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
ELISA O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
normal O-MISC I-ANAT-MISC
control O-MISC I-PHEN-MISC
subjects O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Serum O-MISC I-GENE-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tumor B-DISO-MISC O-MISC
necrosis B-DISO-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
alpha O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
interferon O-MISC O-MISC
- O-MISC B-DISO-MISC
gamma O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
determined O-MISC B-CHED-MISC
by O-MISC I-CHED-MISC
ELISA O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Serum O-MISC I-GENE-MISC
sFas O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
controls O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
greater O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
paracetamol B-CHED-MISC O-MISC
overdose B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
A O-MISC B-ANAT-MISC
to O-MISC B-ANAT-MISC
E O-MISC B-ANAT-MISC
hepatitis B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sFas O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
eventual O-MISC B-ACTI-MISC
outcome O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
correlation O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
sFas O-MISC O-MISC
levels O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
aspartate B-CHED-MISC O-MISC
aminotransferase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
r O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
613 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sFas O-MISC O-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
reflect O-MISC B-ACTI-MISC
activation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
Fas O-MISC O-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
tumor B-DISO-MISC O-MISC
necrosis B-DISO-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
alpha O-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-CHED-MISC
factor O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
loss O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Bilateral O-MISC B-CHED-MISC
subthalamic O-MISC I-GENE-MISC
nucleus O-MISC B-GEOG-MISC
stimulation O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

High O-MISC B-OCCU-MISC
frequency O-MISC I-OCCU-MISC
stimulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subthalamic O-MISC I-GENE-MISC
nucleus O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
STN O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
ameliorate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
signs O-MISC I-ACTI-MISC
and O-MISC B-ANAT-MISC
symptoms O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
advanced O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

AIM O-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
STN O-MISC I-GENE-MISC
stimulation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

METHOD O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
suffering O-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
Stages O-MISC B-CHED-MISC
III O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
V O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
Hoehn O-MISC B-CHED-MISC
and O-MISC I-CHED-MISC
Yahr O-MISC I-CHED-MISC
scale O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
bradykinesia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
rigidity B-DISO-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
underwent O-MISC B-ACTI-MISC
bilateral O-MISC B-CONC-MISC
implantation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
electrodes O-MISC B-OBJC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
STN O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Preoperative O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
postoperative O-MISC B-CONC-MISC
assessments O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
off O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
drug O-MISC O-MISC
conditions O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
Unified O-MISC B-CHED-MISC
Parkinson B-DISO-MISC I-CHED-MISC
' I-DISO-MISC I-CHED-MISC
s I-DISO-MISC I-CHED-MISC
Disease I-DISO-MISC I-CHED-MISC
Rating O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
Hoehn O-MISC B-CHED-MISC
and O-MISC I-CHED-MISC
Yahr O-MISC I-CHED-MISC
staging O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
England O-MISC B-ORGA-MISC
activities O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
living O-MISC I-CHED-MISC
score O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
video O-MISC B-GENE-MISC
recordings O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
After O-MISC B-ACTI-MISC
one O-MISC B-CHED-MISC
year O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
electrical O-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
STN O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
scores O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
activities O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
daily O-MISC I-DEVI-MISC
living O-MISC I-DEVI-MISC
and O-MISC B-ACTI-MISC
motor O-MISC B-CHED-MISC
examination O-MISC I-CHED-MISC
scores O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
Unified O-MISC B-CHED-MISC
Parkinson B-DISO-MISC I-CHED-MISC
' I-DISO-MISC I-CHED-MISC
s I-DISO-MISC I-CHED-MISC
Disease I-DISO-MISC I-CHED-MISC
Rating O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
parts O-MISC I-CHED-MISC
II O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
III O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
off O-MISC B-ACTI-MISC
medication O-MISC B-CONC-MISC
improved O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
61 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
subscores O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
akinesia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
rigidity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
tremor B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
gait O-MISC I-ACTI-MISC
also O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
813 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
359 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cognitive O-MISC I-DISO-MISC
functions O-MISC I-LIVB-MISC
remained O-MISC B-ACTI-MISC
unchanged O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
device O-MISC B-OBJC-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
experienced O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
weight O-MISC B-ANAT-MISC
gain O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Bilateral O-MISC B-CHED-MISC
subthalamic O-MISC I-GENE-MISC
nucleus O-MISC B-GEOG-MISC
stimulation O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
advanced O-MISC B-CHED-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
reduces O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
off O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
phase O-MISC B-CHED-MISC
symptoms O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
improves O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
axial O-MISC B-CHED-MISC
symptoms O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
reduces O-MISC B-CHED-MISC
levodopa B-CHED-MISC O-MISC
requirements O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
controlling O-MISC B-OCCU-MISC
drug B-DISO-MISC O-MISC
- I-DISO-MISC B-ACTI-MISC
induced I-DISO-MISC B-CHED-MISC
dyskinesias I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
occurring O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
desferrioxamine B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
recovery O-MISC I-DISO-MISC
after O-MISC B-ACTI-MISC
haemodialysis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
transfusion O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-ACTI-MISC
thalassemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
undergoing O-MISC B-ACTI-MISC
home O-MISC B-CONC-MISC
intravenous O-MISC I-CONC-MISC
desferrioxamine B-CHED-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
DFX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
means O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
totally O-MISC B-ACTI-MISC
implanted O-MISC B-OBJC-MISC
system O-MISC I-OBJC-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
poor O-MISC I-ACTI-MISC
compliance O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nightly O-MISC B-ACTI-MISC
subcutaneous O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
accidental O-MISC B-CHED-MISC
malfunctioning O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
infusion O-MISC B-OBJC-MISC
pump O-MISC I-OBJC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
inadvertently O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
toxic O-MISC B-CHED-MISC
dosage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
which O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
insufficiency I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Given O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
deterioration O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
laboratory O-MISC B-CHED-MISC
values O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
despite O-MISC B-ACTI-MISC
adequate O-MISC B-ACTI-MISC
medical O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decision O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
made O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
introduce O-MISC B-CHED-MISC
haemodialytical O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
remove O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
and O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
reduce O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

From O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
haemodialysis O-MISC B-CONC-MISC
can O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
desferrioxamine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Ocular O-MISC I-DISO-MISC
motility O-MISC I-LIVB-MISC
changes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
subtenon O-MISC B-CONC-MISC
carboplatin B-CHED-MISC I-CONC-MISC
chemotherapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
retinoblastoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Focal O-MISC B-ACTI-MISC
subtenon O-MISC O-MISC
carboplatin B-CHED-MISC I-CONC-MISC
injections O-MISC B-CONC-MISC
have O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
presumably O-MISC B-ACTI-MISC
toxicity B-DISO-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
free O-MISC B-CHED-MISC
adjunct O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
systemic O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
intraocular O-MISC B-CHED-MISC
retinoblastoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
experience O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
abnormal B-DISO-MISC I-ACTI-MISC
ocular I-DISO-MISC I-DISO-MISC
motility I-DISO-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
subtenon O-MISC B-CONC-MISC
carboplatin B-CHED-MISC I-CONC-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
abnormal B-DISO-MISC I-ACTI-MISC
ocular I-DISO-MISC I-DISO-MISC
motility I-DISO-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
retinoblastoma B-DISO-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
subtenon O-MISC O-MISC
carboplatin B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
ocular O-MISC B-CONC-MISC
manipulation O-MISC I-CONC-MISC
under O-MISC B-ACTI-MISC
general O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
their O-MISC B-ACTI-MISC
eyes O-MISC I-GENE-MISC
by O-MISC B-ACTI-MISC
forced O-MISC B-CHED-MISC
duction O-MISC B-CONC-MISC
testing O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
comparing O-MISC B-DEVI-MISC
ocular O-MISC I-DISO-MISC
motility O-MISC I-LIVB-MISC
after O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
control O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
ocular O-MISC I-DISO-MISC
motility O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Eyes O-MISC I-GENE-MISC
subsequently O-MISC B-ACTI-MISC
enucleated O-MISC I-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC I-ACTI-MISC
failure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
histologically O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Limitation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ocular O-MISC I-DISO-MISC
motility O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
eyes O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
intraocular O-MISC B-CHED-MISC
retinoblastoma B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
injections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
subtenon O-MISC O-MISC
carboplatin B-CHED-MISC B-DISO-MISC
as O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
multimodality O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Histopathological O-MISC B-CHED-MISC
examination O-MISC B-CONC-MISC
revealed O-MISC B-CHED-MISC
many O-MISC B-ACTI-MISC
lipophages O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
periorbital O-MISC I-GENE-MISC
fat O-MISC B-GEOG-MISC
surrounding O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
optic O-MISC I-GENE-MISC
nerve O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
eye O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
indicative O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
phagocytosis O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
existing O-MISC B-ACTI-MISC
fat O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
fat O-MISC I-ACTI-MISC
necrosis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
enucleations O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
technically O-MISC B-ACTI-MISC
difficult O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
hazardous O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
globe O-MISC I-GENE-MISC
rupture B-DISO-MISC I-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
extensive O-MISC B-ACTI-MISC
orbital O-MISC I-GENE-MISC
soft O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
adhesions O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Subtenon O-MISC O-MISC
carboplatin B-CHED-MISC B-DISO-MISC
chemotherapy O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
significant O-MISC B-CHED-MISC
fibrosis B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
orbital O-MISC I-GENE-MISC
soft O-MISC B-GEOG-MISC
tissues O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
mechanical O-MISC B-CHED-MISC
restriction O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
eye O-MISC I-DISO-MISC
movements O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
making O-MISC B-ACTI-MISC
subsequent O-MISC B-CHED-MISC
enucleation O-MISC B-CONC-MISC
difficult O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Subtenon O-MISC O-MISC
carboplatin B-CHED-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
free O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
restricted O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
indications O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Ethambutol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
optic B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
ethambutol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
optic B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHOD O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Thirteen O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
optic B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
ethambutol B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
tuberculosis B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
lung I-DISO-MISC I-GENE-MISC
or I-DISO-MISC B-ACTI-MISC
lymph I-DISO-MISC I-GENE-MISC
node I-DISO-MISC B-GEOG-MISC
at O-MISC B-ACTI-MISC
Siriraj O-MISC B-GENE-MISC
Hospital O-MISC I-GEOG-MISC
between O-MISC B-ACTI-MISC
1997 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2001 O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
retrospectively O-MISC B-CHED-MISC
reviewed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
clinical O-MISC I-DISO-MISC
characteristics O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
final O-MISC B-ACTI-MISC
visual O-MISC I-DISO-MISC
acuity O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
visual O-MISC B-CHED-MISC
outcome O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
optic B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
between O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
starting O-MISC B-ACTI-MISC
ethambutol B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
ranging O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Seven O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
experienced O-MISC B-ACTI-MISC
visual O-MISC I-DISO-MISC
recovery O-MISC I-LIVB-MISC
after O-MISC B-ACTI-MISC
stopping O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
irreversible O-MISC I-ACTI-MISC
visual B-DISO-MISC B-ANAT-MISC
impairment I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
mellitus I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
glaucoma B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
heavy O-MISC I-ACTI-MISC
smoking O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Early O-MISC B-CONC-MISC
recognition O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
optic B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ethambutol B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
prompt O-MISC B-CHED-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
is O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
particularly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
mellitus I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
glaucoma B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
heavy O-MISC I-ACTI-MISC
smokers O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
compensatory O-MISC B-CHED-MISC
gustatory B-DISO-MISC I-ACTI-MISC
hyperhidrosis I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
topical O-MISC O-MISC
glycopyrrolate B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Gustatory B-DISO-MISC I-ACTI-MISC
hyperhidrosis I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
facial O-MISC I-GENE-MISC
sweating B-DISO-MISC I-ACTI-MISC
usually O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
eating O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
hot O-MISC B-GENE-MISC
spicy O-MISC B-GENE-MISC
food O-MISC I-GEOG-MISC
or O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
smelling O-MISC B-DEVI-MISC
this O-MISC B-ACTI-MISC
food O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

Current O-MISC B-ACTI-MISC
options O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
include O-MISC B-ACTI-MISC
oral O-MISC O-MISC
anticholinergic O-MISC O-MISC
drugs O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
topical O-MISC B-CONC-MISC
application O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
anticholinergics O-MISC O-MISC
or O-MISC B-ACTI-MISC
aluminum B-CHED-MISC O-MISC
chloride I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
botulinum O-MISC O-MISC
toxin O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Thirteen O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
date O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
topical O-MISC O-MISC
glycopyrrolate B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
gustatory B-DISO-MISC I-ACTI-MISC
hyperhidrosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
interfered O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
social O-MISC B-DEVI-MISC
activities O-MISC I-DEVI-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
transthroacic O-MISC B-CONC-MISC
endoscopic O-MISC I-CONC-MISC
sympathectomy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
compensatory O-MISC B-CHED-MISC
focal O-MISC I-ACTI-MISC
hyperhidrosis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
applying O-MISC B-ACTI-MISC
topical O-MISC O-MISC
glycopyrrolate B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subjective O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
excellent O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
sweating B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
eating O-MISC B-DEVI-MISC
hot O-MISC B-GENE-MISC
spicy O-MISC I-GEOG-MISC
food O-MISC I-GEOG-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
fair O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
clearly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
sweating B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
incidents O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
embarrassed O-MISC I-ACTI-MISC
whilst O-MISC B-ACTI-MISC
eating O-MISC B-DEVI-MISC
hot O-MISC B-GENE-MISC
spicy O-MISC I-GEOG-MISC
foods O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

Adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
included O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mildly O-MISC I-ACTI-MISC
dry B-DISO-MISC B-ANAT-MISC
mouth I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sore B-DISO-MISC I-ACTI-MISC
throat I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
glycopyrrolate B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
light O-MISC I-ACTI-MISC
headache B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
glycopyrrolate B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
topical O-MISC B-CHED-MISC
application O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
glycopyrrolate B-CHED-MISC O-MISC
pad O-MISC B-DISO-MISC
appeared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
efficacious O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
convenient O-MISC B-CHED-MISC
method O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
severe O-MISC I-CHED-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
gustatory B-DISO-MISC I-ACTI-MISC
hyperhidrosis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
transthoracic O-MISC B-CONC-MISC
endoscopic O-MISC I-CONC-MISC
sympathectomy O-MISC I-CONC-MISC
or O-MISC B-ACTI-MISC
sympathicotomy O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Neuroleptic B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Can O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
bromocriptine B-CHED-MISC O-MISC
? O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
stable O-MISC B-ACTI-MISC
psychiatric O-MISC I-ANAT-MISC
outpatients O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
amenorrhea B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
oligomenorrhea B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
their O-MISC B-ACTI-MISC
neuroleptic B-CHED-MISC O-MISC
medications I-CHED-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
bromocriptine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Daily O-MISC B-CHED-MISC
dosages O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
corrected O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
restored O-MISC B-CONC-MISC
menstruation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
worsened O-MISC I-ACTI-MISC
psychiatric B-DISO-MISC I-ACTI-MISC
symptoms I-DISO-MISC B-ANAT-MISC
while O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
bromocriptine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
menstrual O-MISC I-DISO-MISC
irregularity O-MISC I-LIVB-MISC
successfully O-MISC B-ACTI-MISC
corrected O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
bromocriptine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
bromocriptine B-CHED-MISC O-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
as O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
neuroleptic B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
amenorrhea B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
galactorrhea B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Ethacrynic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
neurotransmitters O-MISC O-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Intracerebroventricular O-MISC B-CHED-MISC
injection O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
ethacrynic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
convulsive B-DISO-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
; O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
accelerated O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
synthesis O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
turnover O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
hydroxytryptamine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
suppressed O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
synthesis O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminobutyric I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
acetylcholine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
brain O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
completely O-MISC B-ACTI-MISC
antagonized O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
glutamate B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
methyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
D I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
aspartate I-CHED-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
aminophosphonovaleric B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
ethacrynic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
convulsions B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
neurotransmitter O-MISC O-MISC
systems O-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
differentially O-MISC B-CHED-MISC
modulated O-MISC B-PHEN-MISC
, O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
activation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
glutaminergic O-MISC I-GENE-MISC
neurons O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Pharmacology O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminobutyric I-CHED-MISC B-DISO-MISC
acidA I-CHED-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
complex O-MISC B-DISO-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anxioselective O-MISC O-MISC
and O-MISC B-ACTI-MISC
anticonvulsant O-MISC B-DISO-MISC
beta B-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
carboline I-CHED-MISC B-DISO-MISC
derivative O-MISC B-DISO-MISC
abecarnil B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
rodents O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beta B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
carboline I-CHED-MISC B-DISO-MISC
derivative O-MISC B-DISO-MISC
isopropyl B-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
6 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
benzyloxy I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
methoxymethyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
beta I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
carboline I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
carboxylate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
abecarrnil B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
ligand O-MISC O-MISC
for O-MISC B-ACTI-MISC
benzodiazepine B-CHED-MISC O-MISC
receptors O-MISC B-DISO-MISC
possessing O-MISC B-ACTI-MISC
anxiolytic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
properties O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
function O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
central O-MISC O-MISC
gamma B-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
aminobutyric I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
GABA B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
complex O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Added O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
cortical O-MISC I-GENE-MISC
membrane O-MISC B-GEOG-MISC
preparation O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
abecarnil B-CHED-MISC I-GENE-MISC
increased O-MISC B-ACTI-MISC
[ O-MISC O-MISC
3H O-MISC B-DISO-MISC
] O-MISC B-DISO-MISC
GABA B-CHED-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
enhanced O-MISC B-ACTI-MISC
muscimol B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
stimulated O-MISC B-ACTI-MISC
36Cl O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
uptake O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
binding O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
t B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
[ I-CHED-MISC B-DISO-MISC
35S I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
butylbicyclophosphorothionate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
[ B-CHED-MISC O-MISC
35S I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
TBPS I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
partial O-MISC B-ACTI-MISC
agonist O-MISC O-MISC
Ro B-CHED-MISC O-MISC
16 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
6028 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
tert B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
butyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
S I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
bromo I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
11 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
12 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
13 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
13a I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
tetrahydro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
9 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
oxo I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
9H I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
imidazo I-CHED-MISC B-DISO-MISC
[ I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
a I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
pyrrolo I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
[ I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
c I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
[ I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
benzodiazepine I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
carboxylate I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
weak O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
biochemical O-MISC B-CONC-MISC
tests O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
i O-MISC B-CHED-MISC
. O-MISC I-CHED-MISC
p O-MISC I-CHED-MISC
. O-MISC I-CHED-MISC
injection O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
abecarnil B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
decreased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
related O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
manner O-MISC B-ACTI-MISC
[ B-CHED-MISC B-ACTI-MISC
35S I-CHED-MISC B-ACTI-MISC
] I-CHED-MISC B-ACTI-MISC
TBPS I-CHED-MISC O-MISC
binding O-MISC I-DISO-MISC
measured O-MISC B-CHED-MISC
ex O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebral O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
antagonized O-MISC O-MISC
completely O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
convulsant O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
[ B-CHED-MISC O-MISC
35S I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
TBPS I-CHED-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
isoniazide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
350 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
[ B-CHED-MISC O-MISC
35S I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
TBPS I-CHED-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
foot O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
shock O-MISC B-ANAT-MISC
stress O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
correlate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pharmacological O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
action O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
abecarnil B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
[ B-CHED-MISC O-MISC
35S I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
TBPS I-CHED-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
exploratory O-MISC B-ACTI-MISC
motility O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
isoniazid B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
biochemical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
pharmacological O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
abecarnil B-CHED-MISC O-MISC
produced O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
paralleled O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
motor O-MISC I-ACTI-MISC
behavior O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
cortical O-MISC I-GENE-MISC
[ O-MISC O-MISC
35S O-MISC B-DISO-MISC
] O-MISC B-DISO-MISC
TBPS O-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
beta B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
carboline I-CHED-MISC B-DISO-MISC
reduced O-MISC B-CHED-MISC
markedly O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
[ B-CHED-MISC O-MISC
35S I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
TBPS I-CHED-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
isoniazid B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
ABSTRACT O-MISC B-ACTI-MISC
TRUNCATED O-MISC B-ACTI-MISC
AT O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
WORDS O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC

Recurrent O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
postpartum O-MISC B-CHED-MISC
patient O-MISC I-ANAT-MISC
receiving O-MISC B-CHED-MISC
bromocriptine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
puerperium O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
infrequently O-MISC B-CHED-MISC
reported O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Spasm B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
coronary O-MISC I-ACTI-MISC
dissection O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
atheromatous O-MISC I-ACTI-MISC
etiology O-MISC B-CHED-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Bromocriptine B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
implicated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
reports O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
puerperium O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inadvertent O-MISC B-ACTI-MISC
rechallenge O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
regarded O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
cardiac O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
bromocriptine B-CHED-MISC O-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
acknowledged O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Asterixis B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
carbamazepine B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
reports O-MISC B-CHED-MISC
about O-MISC B-ACTI-MISC
asterixis B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
psychopharmacologic O-MISC O-MISC
agents O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
we O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
psychotropic O-MISC O-MISC
drugs O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
asterixis B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
triggered O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
adding O-MISC B-ACTI-MISC
carbamazepine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CBZ B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
regimen O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
its O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
nor O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
levels O-MISC I-CONC-MISC
of O-MISC I-CONC-MISC
CBZ B-CHED-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
range O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
consider O-MISC B-ACTI-MISC
asterixis B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
easily O-MISC B-ACTI-MISC
overlooked O-MISC B-ACTI-MISC
sign O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
dosage O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
as O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
CBZ B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Pharmacodynamics O-MISC B-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypotensive B-DISO-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
parkinsonian B-DISO-MISC O-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
effects O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
parkinsonian B-DISO-MISC O-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
stable O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
fluctuating O-MISC B-CHED-MISC
responses O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
magnitude O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypotensive B-DISO-MISC I-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
dependent O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
fit O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
Emax O-MISC B-OBJC-MISC
model O-MISC I-OBJC-MISC
in O-MISC B-ACTI-MISC
fluctuating O-MISC B-CHED-MISC
responders O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Stable O-MISC I-ANAT-MISC
responders O-MISC I-PHEN-MISC
demonstrated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
small O-MISC B-CHED-MISC
hypotensive B-DISO-MISC I-ACTI-MISC
response O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Baseline O-MISC B-CHED-MISC
blood O-MISC I-DISO-MISC
pressures O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
fluctuating O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
baseline O-MISC B-CHED-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
hypotensive B-DISO-MISC I-ACTI-MISC
effects O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Antiparkinsonian O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
temporally O-MISC B-ACTI-MISC
correlated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
changes O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Phenylalanine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
neutral O-MISC O-MISC
amino B-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
LNAA O-MISC O-MISC
) O-MISC B-ACTI-MISC
competing O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
transport O-MISC I-DISO-MISC
across O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
brain O-MISC B-GEOG-MISC
barrier O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypotensive B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
antiparkinsonian O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
central O-MISC I-ACTI-MISC
hypotensive B-DISO-MISC B-ANAT-MISC
action O-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
parallels O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
motor O-MISC I-GENE-MISC
effects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
fluctuating O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hypotensive B-DISO-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
baseline O-MISC B-CHED-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
we O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
fluctuating O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
relative O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
stable O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Syndrome B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
inappropriate I-DISO-MISC B-ACTI-MISC
secretion I-DISO-MISC B-OCCU-MISC
of I-DISO-MISC B-ACTI-MISC
antidiuretic I-DISO-MISC O-MISC
hormone I-DISO-MISC B-DISO-MISC
after O-MISC B-ACTI-MISC
infusional O-MISC B-CHED-MISC
vincristine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
multiple B-DISO-MISC B-ANAT-MISC
myeloma I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
a O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
intravenous O-MISC B-CONC-MISC
infusion O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
vincristine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
dexamethasone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Nine O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
cycle O-MISC I-CHED-MISC
she O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
lethargy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
weakness B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
hyponatremia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Evaluation O-MISC B-CONC-MISC
revealed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
syndrome B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
inappropriate I-DISO-MISC B-ACTI-MISC
secretion I-DISO-MISC B-OCCU-MISC
of I-DISO-MISC B-ACTI-MISC
antidiuretic I-DISO-MISC O-MISC
hormone I-DISO-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
attributed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vincristine B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
serum O-MISC B-OCCU-MISC
sodium B-CHED-MISC I-OCCU-MISC
levels O-MISC I-OCCU-MISC
returned O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC B-CONC-MISC
and O-MISC I-CONC-MISC
dexamethasone B-CHED-MISC I-CONC-MISC
chemotherapy O-MISC B-CONC-MISC
without O-MISC B-ACTI-MISC
vincristine B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Heart B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
digitalise O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
? O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
view O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Despite O-MISC B-ACTI-MISC
extensive O-MISC B-ACTI-MISC
clinical O-MISC I-DISO-MISC
experience O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
digoxin B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
still O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
digoxin B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
beneficial O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
ventricular O-MISC B-CHED-MISC
rate O-MISC I-LIVB-MISC
control O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
sinus O-MISC I-ACTI-MISC
rhythm O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
the O-MISC B-ACTI-MISC
situation O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
clear O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Digoxin B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
narrow O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
toxic O-MISC B-CHED-MISC
ratio O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
concentrations O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
. O-MISC B-ACTI-MISC

Also O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
digoxin B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
undesirable O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
peripheral O-MISC I-DISO-MISC
resistance O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
myocardial O-MISC I-DISO-MISC
demands O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
causing O-MISC B-CHED-MISC
arrhythmias B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
paucity O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
designed O-MISC B-ACTI-MISC
trials O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
trials O-MISC B-CONC-MISC
that O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
available O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
small O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
limitations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
design O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
variation O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patient O-MISC B-CONC-MISC
benefit O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

More O-MISC B-ACTI-MISC
convincing O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
digoxin B-CHED-MISC O-MISC
improves O-MISC I-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
capacity O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
trial O-MISC B-CONC-MISC
has O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
sufficient O-MISC B-ACTI-MISC
power O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
mortality O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Pooled O-MISC B-CHED-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
other O-MISC B-ACTI-MISC
inotropic O-MISC O-MISC
drugs O-MISC O-MISC
shows O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
excess O-MISC B-CHED-MISC
mortality O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
digoxin B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
mortality O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Angiotensin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
converting O-MISC B-DISO-MISC
enzyme O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
ACE O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
inhibitors O-MISC B-DISO-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
safer O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
do O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
require O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
level O-MISC I-LIVB-MISC
monitoring O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
modify O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
disease O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
relieve O-MISC B-CONC-MISC
symptoms O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
improve O-MISC B-ACTI-MISC
exercise O-MISC I-DISO-MISC
tolerance O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
reduce O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Caution O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
exercised O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
digoxin B-CHED-MISC O-MISC
until O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
trials O-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
completed O-MISC B-CHED-MISC
showing O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
benefit O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
harm O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Until O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
digoxin B-CHED-MISC O-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
third O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
line O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Isradipine B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
general O-MISC B-PROC-MISC
practice O-MISC I-UnknownType-MISC
in O-MISC B-ACTI-MISC
Hong O-MISC B-ORGA-MISC
Kong O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
open O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
introduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
isradipine B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
general O-MISC B-DEVI-MISC
practice O-MISC I-UnknownType-MISC
in O-MISC B-ACTI-MISC
Hong O-MISC B-ORGA-MISC
Kong O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

303 O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
mild O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
moderate O-MISC I-ACTI-MISC
hypertension B-DISO-MISC B-ANAT-MISC
entered O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
withdrawal O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
main O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
headache B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
dizziness B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
palpitation B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
flushing B-DISO-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
frequent O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
isradipine B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Supine O-MISC B-CHED-MISC
blood O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
170 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
102 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
153 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
92 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
147 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
88 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
144 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
87 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
respectively O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
evaluable O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Similar O-MISC B-ACTI-MISC
reductions O-MISC B-CONC-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
standing O-MISC I-ACTI-MISC
blood O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
evidence O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
postural B-DISO-MISC I-ACTI-MISC
hypotension I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Normalization O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
responder O-MISC I-ACTI-MISC
rates O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
69 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Dosage O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
b O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
b O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
remaining O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
b O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Pharmacological O-MISC B-CHED-MISC
characteristics O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
galenic O-MISC O-MISC
formulation O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
without O-MISC B-ACTI-MISC
soyabean O-MISC O-MISC
oil O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pharmacokinetics O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
pharmacodynamics O-MISC B-PROC-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-CONC-MISC
profile O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
galenic O-MISC O-MISC
formulation O-MISC O-MISC
of O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
AM149 O-MISC O-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
contain O-MISC B-ACTI-MISC
soyabean O-MISC O-MISC
oil O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
standard O-MISC B-ACTI-MISC
formulation O-MISC O-MISC
of O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Disoprivan B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
randomised O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
cross O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
over O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
volunteers O-MISC I-PHEN-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
bolus O-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Plasma O-MISC I-GENE-MISC
propofol B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
three O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
compartment O-MISC I-CHED-MISC
model O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pharmacodynamic O-MISC B-OCCU-MISC
parameters O-MISC B-CHED-MISC
assessed O-MISC B-DEVI-MISC
included O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
emergence O-MISC B-CHED-MISC
times O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
respiratory O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
effects O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
monitored O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
over O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Owing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
thrombophlebitis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
terminated O-MISC B-CHED-MISC
prematurely O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
parallel O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
groups O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
each O-MISC B-CHED-MISC
group O-MISC B-PHEN-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
analysed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Plasma O-MISC I-GENE-MISC
concentrations O-MISC B-CHED-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
differ O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
formulations O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Anaesthesia O-MISC B-CONC-MISC
induction O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
emergence O-MISC B-CHED-MISC
times O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
respiratory O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
variables O-MISC B-CHED-MISC
showed O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
differences O-MISC B-ANAT-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Pain B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
thrombophlebitis B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
93 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
AM149 O-MISC O-MISC
than O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
Disoprivan B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
formulations O-MISC O-MISC
had O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
pharmacokinetic O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
pharmacodynamic O-MISC B-CONC-MISC
profiles O-MISC I-CONC-MISC
the O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
formulation O-MISC O-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
suitable O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
use O-MISC I-CONC-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
thrombophlebitis B-DISO-MISC I-ACTI-MISC
produced O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Pure B-DISO-MISC I-ACTI-MISC
red I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
aplasia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
toxic B-DISO-MISC I-ACTI-MISC
dermatitis I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
lymphadenopathy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
diphenylhydantoin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
diphenylhydantoin B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
skin B-DISO-MISC B-ANAT-MISC
rash I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
lymphadenopathy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
pure B-DISO-MISC I-ACTI-MISC
red I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
aplasia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
withdrawal O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pharmacon O-MISC B-GENE-MISC
all O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
disappeared O-MISC B-ACTI-MISC
spontaneously O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Skin B-DISO-MISC I-ACTI-MISC
rash I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
diphenylhydantoin B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
as O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
benign O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
malignant O-MISC I-ACTI-MISC
lymphadenopathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Pure B-DISO-MISC I-ACTI-MISC
red I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
aplasia I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
diphenylhydantoin B-CHED-MISC O-MISC
medication O-MISC B-CONC-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
exact O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
diphenylhydantoin B-CHED-MISC O-MISC
exerts O-MISC I-DISO-MISC
its O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
relation O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ingestion O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
diphenylhydantoin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
skin B-DISO-MISC I-ACTI-MISC
rash I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
lymphadenopathy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
pure B-DISO-MISC I-ACTI-MISC
red I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
aplasia I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
suggestive O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-CHED-MISC
connection O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Vinorelbine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
meta O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
clinical O-MISC I-CONC-MISC
trials O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Several O-MISC B-CHED-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
adverse O-MISC B-ANAT-MISC
reactions O-MISC B-ANAT-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
vinorelbine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
VNR B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
quantify O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
performed O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
meta O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
comparing O-MISC B-ACTI-MISC
VNR B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
chemotherapeutic O-MISC O-MISC
agents O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
malignancies B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Randomized O-MISC B-CONC-MISC
clinical O-MISC I-CONC-MISC
trials O-MISC I-CONC-MISC
comparing O-MISC B-ACTI-MISC
VNR B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
searched O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Medline O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
Embase O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
Evidence O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
based O-MISC I-CHED-MISC
Medicine O-MISC I-CHED-MISC
Reviews O-MISC I-CHED-MISC
databases O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Cochrane O-MISC B-CHED-MISC
library O-MISC I-CHED-MISC
from O-MISC B-ACTI-MISC
1987 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2002 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Outcomes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
interest O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
cardiac O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
deaths O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
event O-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
deaths O-MISC I-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
publication O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
trials O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
involving O-MISC B-ACTI-MISC
2441 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
VNR B-CHED-MISC B-PHYS-MISC
and O-MISC B-ACTI-MISC
2050 O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
VNR B-CHED-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
67 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
difference O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
between O-MISC B-ACTI-MISC
VNR B-CHED-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
[ O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
92 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VNR B-CHED-MISC I-GENE-MISC
cardiac O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
vindesine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
VDS B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
cardiotoxic B-DISO-MISC O-MISC
drugs O-MISC B-DISO-MISC
[ O-MISC B-ACTI-MISC
fluorouracil B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
anthracyclines B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
gemcitabine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
GEM B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
em O-MISC B-ACTI-MISC
leader O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Even O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
reach O-MISC B-ACTI-MISC
statistical O-MISC B-CHED-MISC
significance O-MISC I-CHED-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
trials O-MISC B-CONC-MISC
excluding O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
seemed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
trials O-MISC B-CONC-MISC
including O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
existing O-MISC I-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Vinorelbine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
concern O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
VNR B-CHED-MISC I-ACTI-MISC
seems O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
chemotherapeutic O-MISC O-MISC
agents O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
indications O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

MRI O-MISC B-CONC-MISC
findings O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
hypoxic O-MISC I-ACTI-MISC
cortical O-MISC B-ANAT-MISC
laminar O-MISC B-ANAT-MISC
necrosis B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
child O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
crisis O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
findings O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
girl O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rapidly O-MISC B-ACTI-MISC
installing O-MISC B-ACTI-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
crisis O-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
trimethoprim B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
sulfomethoxazole I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
anoxia I-DISO-MISC B-ANAT-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
permanent O-MISC B-CHED-MISC
damage O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Magnetic O-MISC B-CONC-MISC
Resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
revealed O-MISC B-ACTI-MISC
cortical O-MISC I-ACTI-MISC
laminar O-MISC B-ANAT-MISC
necrosis B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
arterial O-MISC I-GENE-MISC
border O-MISC B-GEOG-MISC
zones O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
cerebral O-MISC I-GENE-MISC
hemispheres O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
ischemic O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
subcortical O-MISC I-GENE-MISC
white O-MISC I-GENE-MISC
matter O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
cerebral O-MISC B-GEOG-MISC
hemisphere O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
putamen O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
cortical O-MISC I-ACTI-MISC
laminar O-MISC B-ANAT-MISC
necrosis B-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
classic O-MISC B-ACTI-MISC
entity O-MISC B-GENE-MISC
in O-MISC B-ACTI-MISC
adulthood O-MISC B-CHED-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
conditions O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
energy O-MISC B-CHED-MISC
depletions O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
reports O-MISC B-CHED-MISC
available O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
wide O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
natural O-MISC B-PROC-MISC
history O-MISC I-UnknownType-MISC
of O-MISC B-ACTI-MISC
Vigabatrin B-CHED-MISC O-MISC
associated O-MISC B-ACTI-MISC
visual B-DISO-MISC B-CHED-MISC
field I-DISO-MISC I-CHED-MISC
defects I-DISO-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
electing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
continue O-MISC B-CHED-MISC
their O-MISC B-ACTI-MISC
medication O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
natural O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
field I-DISO-MISC B-ANAT-MISC
defects I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
Vigabatrin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
who O-MISC B-ACTI-MISC
elected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
continue O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
medication O-MISC B-CONC-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
good O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
control O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
Vigabatrin B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
antiepileptic O-MISC O-MISC
drugs O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
entered O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
visual O-MISC B-CONC-MISC
surveillance O-MISC I-CONC-MISC
programme O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
followed O-MISC B-CONC-MISC
up O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
monthly O-MISC B-CHED-MISC
intervals O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
unequivocal O-MISC I-ACTI-MISC
defects O-MISC B-CHED-MISC
continued O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medication O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Following O-MISC B-ACTI-MISC
already O-MISC B-ACTI-MISC
published O-MISC B-DEVI-MISC
methodology O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
Eye O-MISC B-ACTI-MISC
2002 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
567 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
571 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
monocular O-MISC B-CHED-MISC
mean O-MISC I-CHED-MISC
radial O-MISC I-CHED-MISC
degrees O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
MRDs O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
4e O-MISC I-GENE-MISC
isopter O-MISC B-PHEN-MISC
on O-MISC B-ACTI-MISC
Goldmann O-MISC B-CONC-MISC
perimetry O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
calculated O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
right O-MISC I-GENE-MISC
eye O-MISC B-GEOG-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
discovery O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
visual B-DISO-MISC I-DISO-MISC
field I-DISO-MISC I-LIVB-MISC
defect I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
again O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Mean O-MISC B-ACTI-MISC
right O-MISC I-GENE-MISC
eye O-MISC B-GEOG-MISC
MRD O-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
presentation O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
degrees O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
22 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
degrees O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
22 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
338 O-MISC B-ACTI-MISC
unpaired O-MISC B-CHED-MISC
t O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
test O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
demonstrated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
deterioration B-DISO-MISC B-OCCU-MISC
in I-DISO-MISC B-ACTI-MISC
visual I-DISO-MISC B-CHED-MISC
field I-DISO-MISC I-CHED-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
period O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
treatment O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Established O-MISC B-ACTI-MISC
visual B-DISO-MISC I-DISO-MISC
field I-DISO-MISC I-LIVB-MISC
defects I-DISO-MISC I-LIVB-MISC
presumed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Vigabatrin B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
progress O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
spite O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
continuing O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medication O-MISC O-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
give O-MISC B-ACTI-MISC
support O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
Vigabatrin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
field I-DISO-MISC B-ANAT-MISC
defects I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
idiosyncratic O-MISC I-ACTI-MISC
adverse O-MISC B-ANAT-MISC
drug O-MISC B-ANAT-MISC
reaction O-MISC B-ANAT-MISC
rather O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
toxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rosaceiform O-MISC I-ACTI-MISC
dermatitis B-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
facial B-DISO-MISC I-ACTI-MISC
inflammatory I-DISO-MISC B-ANAT-MISC
dermatoses I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
ointment O-MISC O-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Tacrolimus B-CHED-MISC O-MISC
ointment O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
increasingly O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
anti O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
inflammatory O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
areas O-MISC I-CHED-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
face O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
observations O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
steroid B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
aggravated O-MISC B-ANAT-MISC
rosacea B-DISO-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
perioral B-DISO-MISC I-ACTI-MISC
dermatitis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
rosaceiform O-MISC I-ACTI-MISC
dermatitis B-DISO-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
ointment O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

OBSERVATIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Six O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
inflammatory B-DISO-MISC I-ACTI-MISC
facial I-DISO-MISC B-ANAT-MISC
dermatoses I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
tacrolimus B-CHED-MISC O-MISC
ointment O-MISC B-DISO-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ineffectiveness O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
standard O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Within O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
initially O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
rosacea B-DISO-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
acne B-DISO-MISC I-ACTI-MISC
experienced O-MISC B-ACTI-MISC
sudden O-MISC B-CHED-MISC
worsening O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
pustular O-MISC B-CHED-MISC
rosaceiform O-MISC I-ACTI-MISC
lesions O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Biopsy O-MISC B-CONC-MISC
revealed O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
abundance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Demodex O-MISC I-ANAT-MISC
mites O-MISC I-PHEN-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
eyelid O-MISC I-ACTI-MISC
eczema B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
rosaceiform O-MISC I-ACTI-MISC
periocular B-DISO-MISC B-ANAT-MISC
dermatitis I-DISO-MISC B-ANAT-MISC
gradually O-MISC B-ACTI-MISC
appeared O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
atopic B-DISO-MISC I-ACTI-MISC
dermatitis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
telangiectatic O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
papular B-DISO-MISC I-GENE-MISC
rosacea I-DISO-MISC B-GEOG-MISC
insidiously O-MISC B-CHED-MISC
appeared O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
spectrum O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rosaceiform O-MISC I-ACTI-MISC
dermatitis B-DISO-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
ointment O-MISC O-MISC
is O-MISC B-ACTI-MISC
heterogeneous O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
vasoactive O-MISC I-DISO-MISC
properties O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
proliferation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
Demodex O-MISC O-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
local O-MISC B-ACTI-MISC
immunosuppression O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occlusive O-MISC B-CHED-MISC
properties O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ointment O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
phenomena O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

Future O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Intravascular O-MISC I-ACTI-MISC
hemolysis B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
intermittent O-MISC B-CONC-MISC
rifampin B-CHED-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
rifampin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Intravascular O-MISC I-ACTI-MISC
hemolysis B-DISO-MISC B-ANAT-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
rifampin B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
extremely O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
leprosy B-DISO-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
hemolysis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
rifampin B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Structural O-MISC I-ACTI-MISC
abnormalities O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brains O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
visualize O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
profile O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
structural B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
in I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
human I-DISO-MISC I-ANAT-MISC
brain I-DISO-MISC I-GENE-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
chronic O-MISC I-ACTI-MISC
methamphetamine B-CHED-MISC B-ANAT-MISC
( O-MISC B-ANAT-MISC
MA B-CHED-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
abuse O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Studies O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
subjects O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
MA B-CHED-MISC I-ACTI-MISC
chronically O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
revealed O-MISC B-ACTI-MISC
deficits O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
dopaminergic O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
serotonergic O-MISC I-GENE-MISC
systems O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
cerebral O-MISC I-ACTI-MISC
metabolic B-DISO-MISC B-ANAT-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Using O-MISC B-ACTI-MISC
magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
MRI O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
computational O-MISC B-DEVI-MISC
brain O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
mapping O-MISC I-CONC-MISC
techniques O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pattern O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
structural O-MISC B-CHED-MISC
brain O-MISC I-GENE-MISC
alterations O-MISC B-PHEN-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
MA B-CHED-MISC I-ACTI-MISC
abuse O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
subjects O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
deficits O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
high O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
resolution O-MISC I-CONC-MISC
MRI O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
surface O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
based O-MISC I-CONC-MISC
computational O-MISC I-CONC-MISC
image O-MISC I-CONC-MISC
analyses O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
map O-MISC B-DEVI-MISC
regional O-MISC B-CHED-MISC
abnormalities B-DISO-MISC I-ACTI-MISC
in I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
cortex I-DISO-MISC I-GENE-MISC
, I-DISO-MISC B-ACTI-MISC
hippocampus I-DISO-MISC I-GENE-MISC
, I-DISO-MISC B-ACTI-MISC
white I-DISO-MISC I-GENE-MISC
matter I-DISO-MISC B-GEOG-MISC
, I-DISO-MISC B-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
ventricles I-DISO-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
MA B-CHED-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
matched O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
controls O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Cortical O-MISC I-GENE-MISC
maps O-MISC B-GENE-MISC
revealed O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
gray O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
matter O-MISC B-GEOG-MISC
deficits O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cingulate O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
limbic O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
paralimbic O-MISC I-ACTI-MISC
cortices O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
MA B-CHED-MISC I-ACTI-MISC
abusers O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
averaging O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
below O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
MA B-CHED-MISC I-ACTI-MISC
abusers O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
smaller O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
volumes O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
left O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
right O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
white O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
matter O-MISC B-ANAT-MISC
hypertrophy B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hippocampal O-MISC I-GENE-MISC
deficits O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
mapped O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
performance O-MISC I-LIVB-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
word O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
recall O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

MRI O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
based O-MISC I-CONC-MISC
maps O-MISC I-CONC-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
methamphetamine B-CHED-MISC B-ANAT-MISC
abuse O-MISC B-ANAT-MISC
causes O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
pattern O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cerebral O-MISC I-ACTI-MISC
deterioration O-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
contributes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
impaired B-DISO-MISC B-CHED-MISC
memory I-DISO-MISC I-DISO-MISC
performance I-DISO-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

MA B-CHED-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
selectively O-MISC B-ACTI-MISC
damage O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
medial O-MISC I-GENE-MISC
temporal O-MISC B-GEOG-MISC
lobe O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
consistent O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
studies O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cingulate O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
limbic O-MISC B-GEOG-MISC
cortex O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
inducing O-MISC B-ACTI-MISC
neuroadaptation O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
neuropil O-MISC I-GENE-MISC
reduction O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
death O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Prominent O-MISC B-ACTI-MISC
white O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
matter O-MISC B-ANAT-MISC
hypertrophy B-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
altered O-MISC I-ACTI-MISC
myelination O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
adaptive O-MISC I-ACTI-MISC
glial O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
gliosis B-DISO-MISC I-ACTI-MISC
secondary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
neuronal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
substrates O-MISC B-GENE-MISC
may O-MISC B-ACTI-MISC
help O-MISC B-ACTI-MISC
account O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
MA B-CHED-MISC I-ACTI-MISC
abuse O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
providing O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
targets O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ANAT-MISC
brain B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Disruption O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
lipid O-MISC I-DISO-MISC
homeostasis O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
after O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
treatment O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
peroxisome O-MISC O-MISC
proliferator O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
activated O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
alpha O-MISC B-DISO-MISC
target O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
activation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Amiodarone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
efficacious O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
antiarrhythmic O-MISC O-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
hepatotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
gain O-MISC B-ACTI-MISC
insight O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanism O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
unwanted O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
various O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
histology O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
regulation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Amiodarone B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
hepatomegaly B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
hepatocyte O-MISC I-GENE-MISC
microvesicular O-MISC B-CHED-MISC
lipid O-MISC I-ACTI-MISC
accumulation O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
triglycerides B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
glucose B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Northern O-MISC B-CONC-MISC
blot O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
hepatic O-MISC O-MISC
RNA O-MISC B-DISO-MISC
revealed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
increase O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
critical O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
fatty B-CHED-MISC I-DISO-MISC
acid I-CHED-MISC I-LIVB-MISC
oxidation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
lipoprotein O-MISC I-DISO-MISC
assembly O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
lipid O-MISC I-DISO-MISC
transport O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Many O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
regulated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
peroxisome O-MISC O-MISC
proliferator O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
activated O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
alpha O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
PPARalpha O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
ligand O-MISC O-MISC
- O-MISC B-DISO-MISC
activated O-MISC B-DISO-MISC
nuclear O-MISC B-DISO-MISC
hormone O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
transcription O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
absence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
hepatomegaly B-DISO-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
PPARalpha O-MISC B-LIVB-MISC
knockout O-MISC I-ANAT-MISC
[ O-MISC I-PHEN-MISC
PPARalpha O-MISC I-PHEN-MISC
- O-MISC I-PHEN-MISC
/ O-MISC I-PHEN-MISC
- O-MISC I-PHEN-MISC
] O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
indicated O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
upon O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
PPARalpha O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
mice O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PPARalpha O-MISC O-MISC
- O-MISC I-PHEN-MISC
/ O-MISC I-PHEN-MISC
- O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
resulted O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
rate O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
extent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
total O-MISC I-ACTI-MISC
body O-MISC B-ANAT-MISC
weight B-DISO-MISC B-ANAT-MISC
loss I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
inability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
activate O-MISC B-DEVI-MISC
either O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
or O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
PPARalpha O-MISC O-MISC
transiently O-MISC I-DISO-MISC
expressed O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
HepG2 O-MISC I-GENE-MISC
hepatoma B-DISO-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
indicates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
function O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
receptor O-MISC O-MISC
were O-MISC B-ACTI-MISC
indirect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Based O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
disrupts O-MISC B-CHED-MISC
hepatic O-MISC I-GENE-MISC
lipid O-MISC I-DISO-MISC
homeostasis O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
PPARalpha O-MISC B-LIVB-MISC
target O-MISC B-LIVB-MISC
genes O-MISC I-PROC-MISC
is O-MISC B-ACTI-MISC
secondary O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
this O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
provide O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
mechanistic O-MISC B-ACTI-MISC
information O-MISC I-CHED-MISC
regarding O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hepatotoxic B-DISO-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
PPARalpha O-MISC O-MISC
protects O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hepatotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Safety O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
compliance O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
once O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
daily O-MISC I-CHED-MISC
niacin B-CHED-MISC O-MISC
extended I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
release I-CHED-MISC B-DISO-MISC
/ I-CHED-MISC B-ACTI-MISC
lovastatin I-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Impact O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Medical O-MISC B-CONC-MISC
Subspecialty O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
Patient O-MISC B-CONC-MISC
Compliance O-MISC I-CONC-MISC
to O-MISC I-CONC-MISC
Treatment O-MISC I-CONC-MISC
( O-MISC I-CONC-MISC
IMPACT O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Niacin B-CHED-MISC O-MISC
extended I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
release I-CHED-MISC B-DISO-MISC
/ I-CHED-MISC B-ACTI-MISC
lovastatin I-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
combination O-MISC O-MISC
product O-MISC B-DISO-MISC
approved O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
hypercholesterolemia B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
mixed O-MISC I-ACTI-MISC
dyslipidemia B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
labeled O-MISC I-CONC-MISC
, O-MISC I-CONC-MISC
multicenter O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
evaluated O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
bedtime O-MISC B-CHED-MISC
niacin B-CHED-MISC O-MISC
extended I-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
release I-CHED-MISC B-DISO-MISC
/ I-CHED-MISC B-ACTI-MISC
lovastatin I-CHED-MISC O-MISC
when O-MISC B-ACTI-MISC
dosed O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
compliance O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
clinical O-MISC B-DEVI-MISC
practice O-MISC I-DEVI-MISC
settings O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
499 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
dyslipidemia B-DISO-MISC I-ACTI-MISC
requiring O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
intervention O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
081 O-MISC B-ACTI-MISC
sites O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
1 O-MISC B-ACTI-MISC
tablet O-MISC O-MISC
( O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
niacin B-CHED-MISC O-MISC
extended O-MISC O-MISC
- O-MISC B-DISO-MISC
release O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lovastatin B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
once O-MISC B-ACTI-MISC
nightly O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
tablets O-MISC O-MISC
for O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
also O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
dietary O-MISC B-CONC-MISC
counseling O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
educational O-MISC B-GENE-MISC
materials O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
reminders O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
call O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
toll O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
free O-MISC I-CHED-MISC
number O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
provided O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
education O-MISC B-CONC-MISC
about O-MISC B-ACTI-MISC
dyslipidemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
niacin B-CHED-MISC O-MISC
extended I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
release I-CHED-MISC B-DISO-MISC
/ I-CHED-MISC B-ACTI-MISC
lovastatin I-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Primary O-MISC B-ACTI-MISC
end O-MISC B-ACTI-MISC
points O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
compliance O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
liver O-MISC I-ACTI-MISC
transaminases O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
upper O-MISC B-CHED-MISC
limit O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
normal O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
myopathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Final O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
status O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
217 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
94 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Compliance O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
niacin B-CHED-MISC O-MISC
extended I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
release I-CHED-MISC B-DISO-MISC
/ I-CHED-MISC B-ACTI-MISC
lovastatin I-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
245 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
completing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
southeast O-MISC B-ORGA-MISC
and O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
endocrinologists O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lowest O-MISC B-CHED-MISC
compliance O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
highest O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
event O-MISC B-ANAT-MISC
rates O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Flushing B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
event O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
aspartate B-CHED-MISC O-MISC
aminotransferase O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
alanine B-CHED-MISC O-MISC
aminotransferase O-MISC B-DISO-MISC
> O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
upper O-MISC B-CHED-MISC
limit O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
normal O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
creatine B-CHED-MISC O-MISC
phosphokinase O-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
upper O-MISC B-CHED-MISC
limit O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
normal O-MISC I-CHED-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
myopathy B-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Niacin B-CHED-MISC O-MISC
extended I-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
release I-CHED-MISC B-DISO-MISC
/ I-CHED-MISC B-ACTI-MISC
lovastatin I-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
dosed O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
good O-MISC B-ACTI-MISC
compliance O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
incidences O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
increased O-MISC I-ACTI-MISC
liver O-MISC B-ANAT-MISC
and O-MISC B-ANAT-MISC
muscle O-MISC I-ACTI-MISC
enzymes O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Protective O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
Terminalia B-CHED-MISC I-ANAT-MISC
chebula I-CHED-MISC I-PHEN-MISC
against O-MISC B-ACTI-MISC
experimental O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Cardioprotective O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
ethanolic B-CHED-MISC O-MISC
extract I-CHED-MISC B-GENE-MISC
of I-CHED-MISC B-ACTI-MISC
Terminalia I-CHED-MISC I-ANAT-MISC
chebula I-CHED-MISC I-PHEN-MISC
fruits I-CHED-MISC B-GENE-MISC
( O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
body O-MISC B-ACTI-MISC
wt O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
body O-MISC B-ACTI-MISC
wt O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
administered O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
peroxides B-CHED-MISC B-DISO-MISC
increased O-MISC B-CHED-MISC
significantly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardial O-MISC I-GENE-MISC
marker O-MISC O-MISC
enzymes O-MISC O-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
concomitant O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Histopathological O-MISC B-CHED-MISC
examination O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
confirm O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardial O-MISC I-ACTI-MISC
necrosis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

T B-CHED-MISC I-ANAT-MISC
. I-CHED-MISC I-PHEN-MISC
chebula I-CHED-MISC I-PHEN-MISC
extract I-CHED-MISC B-GENE-MISC
pretreatment O-MISC B-DEVI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
ameliorate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
peroxide B-CHED-MISC B-DISO-MISC
formation O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
retained O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activities O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diagnostic O-MISC I-DISO-MISC
marker O-MISC I-LIVB-MISC
enzymes O-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
postoperative O-MISC I-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
droperidol B-CHED-MISC O-MISC
used O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
patient O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
analgesia O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
multiparous O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
good O-MISC B-ACTI-MISC
psychological O-MISC I-DISO-MISC
health O-MISC I-LIVB-MISC
underwent O-MISC B-ACTI-MISC
urgent O-MISC B-CHED-MISC
caesarean O-MISC B-CONC-MISC
section O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
labour O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Postoperatively O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC B-OBJC-MISC
- O-MISC I-OBJC-MISC
controlled O-MISC I-OBJC-MISC
analgesia O-MISC I-OBJC-MISC
device O-MISC I-OBJC-MISC
delivering O-MISC B-ACTI-MISC
boluses O-MISC O-MISC
of O-MISC B-ACTI-MISC
diamorphine B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
droperidol B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
025 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Whilst O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
device O-MISC B-OBJC-MISC
she O-MISC B-ACTI-MISC
gradually O-MISC B-ACTI-MISC
became O-MISC B-ACTI-MISC
anxious O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
feeling O-MISC I-ACTI-MISC
worsening O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
bolus O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
droperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
psychological B-DISO-MISC I-ACTI-MISC
disturbance I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
made O-MISC B-ACTI-MISC
straight O-MISC B-ACTI-MISC
away O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
close O-MISC B-ACTI-MISC
questioning O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
gave O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
clear O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
droperidol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
syringe O-MISC O-MISC
containing O-MISC B-ACTI-MISC
diamorphine B-CHED-MISC O-MISC
only O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
substituted O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
unease O-MISC O-MISC
resolved O-MISC I-ACTI-MISC
completely O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
feel O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dramatic O-MISC B-ACTI-MISC
extrapyramidal O-MISC I-ACTI-MISC
side O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
dopaminergic O-MISC O-MISC
antiemetics O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
subtle O-MISC B-ACTI-MISC
manifestations O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
easily O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
overlooked O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Accurate O-MISC B-CHED-MISC
patient O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
contributes O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
differentiating O-MISC B-CHED-MISC
diabetes B-DISO-MISC I-ACTI-MISC
insipidus I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
study O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
study O-MISC I-CHED-MISC
highlights O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
contribution O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
nursing O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
obtaining O-MISC B-CHED-MISC
an O-MISC B-ACTI-MISC
accurate O-MISC B-CHED-MISC
health O-MISC B-CONC-MISC
history O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
herein O-MISC B-ACTI-MISC
initially O-MISC B-ACTI-MISC
appeared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
neurogenic B-DISO-MISC I-ACTI-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
secondary O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
traumatic B-DISO-MISC I-ACTI-MISC
brain I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
nursing O-MISC I-ANAT-MISC
staff O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
reviewing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
health O-MISC B-CHED-MISC
history O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
discovered O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
polydipsia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
long O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
standing O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Lithium B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephrogenic B-DISO-MISC I-ACTI-MISC
DI I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
since O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hospital O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
changed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
focus O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
nephrogenic B-DISO-MISC I-ACTI-MISC
DI I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
combining O-MISC B-ACTI-MISC
information O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
physical O-MISC B-CONC-MISC
examination O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
radiologic O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
laboratory O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
critical O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
team O-MISC I-ANAT-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
self O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
treating O-MISC I-CONC-MISC
his O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephrogenic B-DISO-MISC I-ACTI-MISC
DI I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
neurogenic B-DISO-MISC I-ACTI-MISC
DI I-DISO-MISC I-ACTI-MISC
secondary O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
brain B-DISO-MISC I-ACTI-MISC
trauma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
successful O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
required O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
nephrogenic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
neurogenic B-DISO-MISC I-DISO-MISC
DI I-DISO-MISC B-CONC-MISC
be O-MISC B-ACTI-MISC
treated O-MISC B-ACTI-MISC
concomitantly O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Factors O-MISC B-ACTI-MISC
contributing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
ribavirin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
anemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
AIM O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Interferon B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
ribavirin B-CHED-MISC O-MISC
combination O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
C I-DISO-MISC B-ANAT-MISC
produces O-MISC B-ACTI-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
contributing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
ribavirin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
anemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Eighty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
C I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
interferon B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
alpha I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2b I-CHED-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
MU O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
intramuscularly O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
ribavirin B-CHED-MISC O-MISC
administered O-MISC B-CONC-MISC
orally O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
800 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
participated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
hemoglobin O-MISC O-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
ribavirin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
anemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Ribavirin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
anemia B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
hemoglobin O-MISC O-MISC
concentrations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
anemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
start O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hemoglobin O-MISC O-MISC
concentration O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hemoglobin O-MISC O-MISC
concentrations O-MISC I-OCCU-MISC
at O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
anemia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Such O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
old O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ribavirin B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
univariate O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Careful O-MISC B-DEVI-MISC
administration O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
necessary O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
old O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
ribavirin B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
experience O-MISC I-DISO-MISC
a O-MISC B-ACTI-MISC
fall O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
hemoglobin O-MISC O-MISC
concentrations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
start O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
monitored O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
particular O-MISC B-ACTI-MISC
care O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Zidovudine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
hepatitis B-DISO-MISC B-ANAT-MISC
induced O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
zidovudine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
AIDS B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
whereby O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
tolerated O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
reverse O-MISC O-MISC
transcriptase O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
2 B-CHED-MISC O-MISC
' I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
' I-CHED-MISC B-DISO-MISC
dideoxyinosine I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Physicians O-MISC I-ANAT-MISC
caring O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
AIDS B-DISO-MISC I-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
hitherto O-MISC B-CHED-MISC
rarely O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Oxidative O-MISC B-CHED-MISC
damage O-MISC B-CHED-MISC
precedes O-MISC B-ACTI-MISC
nitrative O-MISC B-CHED-MISC
damage O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
adriamycin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac O-MISC I-GENE-MISC
mitochondrial B-DISO-MISC I-GENE-MISC
injury I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
reactive O-MISC O-MISC
oxygen B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ROS O-MISC O-MISC
) O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
nitrogen B-CHED-MISC O-MISC
species O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
RNS O-MISC O-MISC
) O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
present O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
adriamycin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
ADR B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
actually O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
oxidative O-MISC I-ACTI-MISC
/ O-MISC B-ANAT-MISC
nitrative O-MISC B-ANAT-MISC
damage O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
quantitatively O-MISC B-CHED-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
course O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
subcellular O-MISC I-GENE-MISC
localization O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
postulated O-MISC B-CHED-MISC
damage O-MISC B-CHED-MISC
products O-MISC B-GENE-MISC
using O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
approach O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

B6C3 O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
ADR B-CHED-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Ultrastructural O-MISC B-CHED-MISC
damage O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
4 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
hydroxy I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
nonenal I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
4HNE B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
protein O-MISC O-MISC
adducts O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
3 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
nitrotyrosine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
3NT B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Quantitative O-MISC B-CHED-MISC
ultrastructural O-MISC I-GENE-MISC
damage O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
computerized O-MISC B-CONC-MISC
image O-MISC I-CONC-MISC
techniques O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
injury O-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
mitochondria O-MISC I-GENE-MISC
being O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
extensively O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
progressively O-MISC B-CHED-MISC
injured O-MISC B-CHED-MISC
subcellular O-MISC I-GENE-MISC
organelle O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
4HNE B-CHED-MISC O-MISC
protein O-MISC B-DISO-MISC
adducts O-MISC O-MISC
by O-MISC B-ACTI-MISC
immunogold O-MISC B-CONC-MISC
electron O-MISC I-CONC-MISC
microscopy O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
4HNE B-CHED-MISC O-MISC
protein O-MISC B-DISO-MISC
adducts O-MISC O-MISC
in O-MISC B-ACTI-MISC
mitochondria O-MISC I-GENE-MISC
as O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
peak O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
decline O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

3NT B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
subcellular O-MISC I-GENE-MISC
compartments O-MISC B-GEOG-MISC
at O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
subsequently O-MISC B-ACTI-MISC
declined O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
showed O-MISC B-ACTI-MISC
ADR B-CHED-MISC I-DISO-MISC
induced O-MISC B-CHED-MISC
4HNE B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
adducts O-MISC O-MISC
in O-MISC B-ACTI-MISC
mitochondria O-MISC I-GENE-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
point O-MISC I-CHED-MISC
as O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
initially O-MISC B-ACTI-MISC
appeared O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC I-ACTI-MISC
document O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-GENE-MISC
oxidative I-DISO-MISC B-CHED-MISC
damage I-DISO-MISC I-ACTI-MISC
precedes O-MISC B-ACTI-MISC
nitrative O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
nature O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
mitochondria O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
subcellular O-MISC I-GENE-MISC
organelles O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
site O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
intracellular O-MISC I-ACTI-MISC
injury O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Sotalol B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
coronary B-DISO-MISC I-ACTI-MISC
spasm I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
dilated B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
sustained O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
left O-MISC I-ACTI-MISC
ventricular B-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
dilated B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
referred O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
hospital O-MISC B-GENE-MISC
for O-MISC B-ACTI-MISC
symptomatic O-MISC B-CHED-MISC
incessant O-MISC B-CHED-MISC
sustained O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
VT B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
nifekalant B-CHED-MISC O-MISC
hydrochloride I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
sustained O-MISC B-ACTI-MISC
VT B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
terminated O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
alternate O-MISC B-ACTI-MISC
class O-MISC B-DISO-MISC
III O-MISC B-DISO-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
sotalol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prevention O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
VT B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
month O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
switching O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
nifekalant B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
sotalol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
short O-MISC B-ACTI-MISC
duration O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ST O-MISC I-ACTI-MISC
elevation O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
ECG O-MISC I-ACTI-MISC
monitoring O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

ST O-MISC I-ACTI-MISC
elevation O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
chest O-MISC I-ACTI-MISC
discomfort O-MISC B-ANAT-MISC
disappeared O-MISC B-ACTI-MISC
since O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
began O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
long O-MISC O-MISC
- O-MISC B-DISO-MISC
acting O-MISC B-DISO-MISC
diltiazem B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Coronary B-DISO-MISC I-ACTI-MISC
vasospasm I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
beta O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
blocking O-MISC I-LIVB-MISC
properties O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
sotalol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
antidepressant O-MISC O-MISC
trazodone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
2A O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
2C O-MISC O-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
behaviors O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

RATIONALE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
Hydroxytryptamine I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
via O-MISC B-ACTI-MISC
stimulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
2C O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
exerts O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tonic O-MISC I-DISO-MISC
inhibitory O-MISC I-LIVB-MISC
influence O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
dopaminergic O-MISC I-DISO-MISC
neurotransmission O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
activation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
2A O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
enhances O-MISC B-ACTI-MISC
stimulated O-MISC B-ACTI-MISC
DAergic O-MISC I-DISO-MISC
neurotransmission O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
antidepressant O-MISC O-MISC
trazodone B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
2A O-MISC B-DISO-MISC
/ O-MISC B-DISO-MISC
2C O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
trazodone B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
behaviors O-MISC B-DEVI-MISC
dependent O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
functional O-MISC I-ACTI-MISC
status O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nigrostriatal O-MISC B-PHEN-MISC
DAergic O-MISC I-GENE-MISC
system O-MISC B-UnknownType-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
trazodone B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
dexamphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
oral B-DISO-MISC B-CONC-MISC
stereotypies I-DISO-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
ergometrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
wet O-MISC I-ACTI-MISC
dog O-MISC B-ANAT-MISC
shake O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
WDS O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
behavior O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
penile O-MISC I-ACTI-MISC
erections O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
whether O-MISC B-ACTI-MISC
trazodone B-CHED-MISC O-MISC
induces O-MISC B-CHED-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Trazodone B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
induce O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
antagonize O-MISC B-DEVI-MISC
apomorphine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
stereotypy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
catalepsy B-DISO-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
trazodone B-CHED-MISC O-MISC
enhanced O-MISC B-ACTI-MISC
dexamphetamine B-CHED-MISC O-MISC
stereotypy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
antagonized O-MISC O-MISC
haloperidol B-CHED-MISC B-CONC-MISC
catalepsy B-DISO-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
ergometrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
WDS O-MISC I-ACTI-MISC
behavior O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
penile O-MISC I-ACTI-MISC
erections O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Trazodone B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
catalepsy B-DISO-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
antagonized O-MISC O-MISC
apomorphine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
dexamphetamine B-CHED-MISC O-MISC
stereotypies O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
trazodone B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
block O-MISC B-CHED-MISC
pre O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
postsynaptic O-MISC B-ACTI-MISC
striatal O-MISC O-MISC
D2 O-MISC B-DISO-MISC
DA O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
blocks O-MISC B-CHED-MISC
postsynaptic O-MISC B-ACTI-MISC
striatal O-MISC O-MISC
D2 O-MISC O-MISC
DA O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
trazodone B-CHED-MISC O-MISC
blocks O-MISC B-CHED-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
2A O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
2C O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
trazodone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
blocking O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
2C O-MISC O-MISC
receptors O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
releases O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nigrostriatal O-MISC B-PHEN-MISC
DAergic O-MISC I-GENE-MISC
neurons O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
tonic O-MISC I-DISO-MISC
inhibition O-MISC B-DEVI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
thereby O-MISC B-ACTI-MISC
potentiates O-MISC B-ACTI-MISC
dexamphetamine B-CHED-MISC O-MISC
stereotypy O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
antagonizes O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC I-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Swallowing B-DISO-MISC I-DISO-MISC
abnormalities I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Gastrointestinal B-DISO-MISC I-ACTI-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
centuries O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
aspects O-MISC B-CHED-MISC
concerning O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
pathophysiology O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
completely O-MISC B-ACTI-MISC
clarified O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
characterize O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
oropharyngeal O-MISC I-ACTI-MISC
dynamics O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Fifteen O-MISC B-ACTI-MISC
dyskinetic B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
nondyskinetic O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
asked O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
dysphagia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Unified O-MISC B-CHED-MISC
Parkinson B-DISO-MISC I-CHED-MISC
' I-DISO-MISC I-CHED-MISC
s I-DISO-MISC I-CHED-MISC
Disease I-DISO-MISC I-CHED-MISC
Rating O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
Parts O-MISC I-CHED-MISC
II O-MISC I-CHED-MISC
and O-MISC I-CHED-MISC
III O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Hoehn O-MISC B-CHED-MISC
and O-MISC I-CHED-MISC
Yahr O-MISC I-CHED-MISC
scale O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Deglutition O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
using O-MISC B-ACTI-MISC
modified O-MISC B-CHED-MISC
barium B-CHED-MISC B-CONC-MISC
swallow O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
videofluoroscopy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Nondyskinetic O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dyskinetic B-DISO-MISC I-ACTI-MISC
ones O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
oropharyngeal O-MISC I-ACTI-MISC
swallowing O-MISC I-DISO-MISC
efficiency O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
OPSE O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
liquid O-MISC B-GENE-MISC
food O-MISC I-GEOG-MISC
than O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
Dunnett O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Dyskinetic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
tended O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
OPSE O-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
nondyskinetic O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
Dunnett O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
06 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
OPSE O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
trend O-MISC B-ACTI-MISC
toward O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
smaller O-MISC B-CHED-MISC
oral O-MISC B-CHED-MISC
transit O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
Pearson O-MISC B-CHED-MISC
' O-MISC I-CHED-MISC
s O-MISC I-CHED-MISC
correlation O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
08 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dysphagia B-DISO-MISC I-ACTI-MISC
nor O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
severity O-MISC B-CHED-MISC
parameters O-MISC I-ACTI-MISC
correlated O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
videofluoroscopic O-MISC B-CONC-MISC
variables O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
dyskinetic B-DISO-MISC B-OCCU-MISC
patients O-MISC I-ANAT-MISC
performed O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
swallowing O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
explained O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
phase O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
deglutition O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
confirm O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
dysphagia B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
good O-MISC B-ACTI-MISC
predictor O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
deglutition O-MISC I-DISO-MISC
alterations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
nuclear O-MISC O-MISC
factor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
kappaB O-MISC B-DISO-MISC
activation O-MISC B-DEVI-MISC
attenuates O-MISC B-DEVI-MISC
tubulointerstitial B-DISO-MISC I-ACTI-MISC
nephritis I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Animals O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
gentamicin B-CHED-MISC O-MISC
can O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
residual O-MISC B-CHED-MISC
areas O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
interstitial O-MISC I-ACTI-MISC
fibrosis B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
nuclear O-MISC O-MISC
factor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
kappaB O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NF O-MISC O-MISC
- O-MISC B-DISO-MISC
kappaB O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mitogen O-MISC O-MISC
- O-MISC B-DISO-MISC
activated O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
MAP O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
kinases O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
macrophages O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
structural O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
functional O-MISC I-ACTI-MISC
renal O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
pyrrolidine B-CHED-MISC O-MISC
dithiocarbamate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
PDTC B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
NF O-MISC O-MISC
- O-MISC B-DISO-MISC
kappaB O-MISC B-DISO-MISC
inhibitor O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
twice O-MISC B-CHED-MISC
a O-MISC I-CHED-MISC
day O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
PDTC B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
M O-MISC B-ACTI-MISC
NaCl B-CHED-MISC O-MISC
solution O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
killed O-MISC B-DEVI-MISC
5 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
injections O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidneys O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
removed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
histological O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
immunohistochemical O-MISC B-CONC-MISC
studies O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
immunohistochemical O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
scored O-MISC B-CHED-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
extent O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
staining O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
fractional O-MISC I-GENE-MISC
interstitial O-MISC I-GENE-MISC
area O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
morphometry O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transitory O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC I-CONC-MISC
plasma O-MISC I-CONC-MISC
creatinine B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-ACTI-MISC
ED O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
MAP O-MISC O-MISC
kinases O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
NF O-MISC O-MISC
- O-MISC B-DISO-MISC
kappaB O-MISC B-DISO-MISC
staining O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
compared O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
killed O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
30 O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
fibrosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
despite O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recovery O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
PDTC B-CHED-MISC O-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
structural O-MISC B-CHED-MISC
changes O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
These O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
NF O-MISC O-MISC
- O-MISC I-LIVB-MISC
kappaB O-MISC B-DISO-MISC
activation O-MISC I-DISO-MISC
attenuates O-MISC B-DEVI-MISC
tubulointerstitial B-DISO-MISC I-ACTI-MISC
nephritis I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Glucose B-CHED-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
atypical O-MISC B-CHED-MISC
antipsychotic O-MISC O-MISC
agents O-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
frequently O-MISC B-CHED-MISC
sampled O-MISC B-CONC-MISC
intravenous O-MISC B-CONC-MISC
glucose B-CHED-MISC B-CONC-MISC
tolerance O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
minimal O-MISC B-CONC-MISC
model O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
While O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
new O-MISC B-PHEN-MISC
- O-MISC B-UnknownType-MISC
onset O-MISC B-UnknownType-MISC
diabetes B-DISO-MISC B-UnknownType-MISC
mellitus I-DISO-MISC B-UnknownType-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
certain O-MISC B-ACTI-MISC
atypical O-MISC O-MISC
antipsychotic O-MISC O-MISC
agents O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
remains O-MISC B-ACTI-MISC
unclear O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
atypical O-MISC O-MISC
agents O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
affecting O-MISC B-CHED-MISC
glucose B-CHED-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
or O-MISC B-ACTI-MISC
simply O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
known O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
most O-MISC B-ACTI-MISC
clearly O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
sampled O-MISC B-ACTI-MISC
intravenous O-MISC B-CONC-MISC
glucose B-CHED-MISC I-CONC-MISC
tolerance O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
cross O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
sectional O-MISC I-CONC-MISC
design O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
stable O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
evaluated O-MISC B-CONC-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
sampled O-MISC B-ACTI-MISC
intravenous O-MISC B-CONC-MISC
glucose B-CHED-MISC I-CONC-MISC
tolerance O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Bergman O-MISC B-CONC-MISC
minimal O-MISC I-CONC-MISC
model O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

SETTING O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Subjects O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
recruited O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
urban O-MISC B-ORGA-MISC
community O-MISC I-ANAT-MISC
mental O-MISC B-GENE-MISC
health O-MISC I-GEOG-MISC
clinic O-MISC I-GEOG-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
general O-MISC B-GENE-MISC
clinical O-MISC I-GEOG-MISC
research O-MISC I-GEOG-MISC
center O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
Fifty O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
signed O-MISC I-ACTI-MISC
informed O-MISC B-ACTI-MISC
consent O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
sampled O-MISC B-ACTI-MISC
intravenous O-MISC B-CONC-MISC
glucose B-CHED-MISC I-CONC-MISC
tolerance O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Thirty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
nonobese O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
schizoaffective B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
matched O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
mass O-MISC I-LIVB-MISC
index O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
either O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

MAIN O-MISC B-CHED-MISC
OUTCOME O-MISC I-CHED-MISC
MEASURES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Fasting O-MISC B-CONC-MISC
plasma O-MISC I-CONC-MISC
glucose B-CHED-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
fasting O-MISC I-ACTI-MISC
serum O-MISC B-CONC-MISC
insulin O-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
insulin B-DISO-MISC I-ACTI-MISC
sensitivity I-DISO-MISC B-ANAT-MISC
index O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
homeostasis O-MISC B-OCCU-MISC
model O-MISC B-CONC-MISC
assessment O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
insulin B-DISO-MISC I-ACTI-MISC
resistance I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
glucose B-CHED-MISC I-DISO-MISC
effectiveness O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SD O-MISC B-CHED-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
atypical O-MISC O-MISC
antipsychotic O-MISC O-MISC
agent O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Fasting O-MISC I-ACTI-MISC
serum O-MISC B-CONC-MISC
insulin O-MISC I-CONC-MISC
concentrations O-MISC B-CHED-MISC
differed O-MISC B-CHED-MISC
among O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
F O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
047 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
> O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
> O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
differences O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
04 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
difference O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
insulin B-DISO-MISC I-ACTI-MISC
sensitivity I-DISO-MISC B-ANAT-MISC
index O-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
F O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
66 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
< O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
< O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
clozapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
exhibiting O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
insulin B-DISO-MISC I-ACTI-MISC
resistance I-DISO-MISC B-ANAT-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
risperidone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
vs O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
vs O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
homeostasis O-MISC B-OCCU-MISC
model O-MISC B-CHED-MISC
assessment O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
insulin B-DISO-MISC I-ACTI-MISC
resistance I-DISO-MISC B-ANAT-MISC
also O-MISC B-ACTI-MISC
differed O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
F O-MISC O-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
92 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
> O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
> O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
vs O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
94 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
006 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
vs O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
difference O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
glucose B-CHED-MISC I-DISO-MISC
effectiveness O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
F O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
< O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
< O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
differences O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Both O-MISC B-ACTI-MISC
nonobese O-MISC O-MISC
clozapine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
groups O-MISC I-ANAT-MISC
displayed O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
insulin B-DISO-MISC I-ACTI-MISC
resistance I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
impairment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
glucose B-CHED-MISC I-DISO-MISC
effectiveness O-MISC B-ANAT-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
subjects O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
insulin B-DISO-MISC I-ACTI-MISC
resistance I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
consequences O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Thoracic B-DISO-MISC I-ACTI-MISC
hematomyelia I-DISO-MISC B-ANAT-MISC
secondary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
coumadin B-CHED-MISC B-CONC-MISC
anticoagulant O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
thoracic B-DISO-MISC I-ACTI-MISC
hematomyelia I-DISO-MISC B-ANAT-MISC
secondary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
anticoagulant O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CHED-MISC
features O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
cases O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
index O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
suspicion O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
quick O-MISC B-ACTI-MISC
diagnostic O-MISC B-CONC-MISC
procedure O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
successful O-MISC B-CHED-MISC
decompressive O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Mania B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
fluoxetine B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
adolescents O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Fluoxetine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
serotonin B-CHED-MISC O-MISC
reuptake O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
gaining O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
acceptance O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
adolescent O-MISC I-ANAT-MISC
depression B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Generally O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
mania B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
depressed B-DISO-MISC I-ACTI-MISC
adolescents O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
age O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
mania B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
pharmacotherapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
reported O-MISC B-CHED-MISC
here O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Apparent O-MISC B-CHED-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
mania B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
hypomania B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC B-CONC-MISC
pharmacotherapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
attention B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
deficit I-DISO-MISC B-ANAT-MISC
hyperactivity I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
affective O-MISC I-ACTI-MISC
instability O-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
major O-MISC I-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
psychotic B-DISO-MISC I-ACTI-MISC
features O-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
family O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
affective B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
optimal O-MISC B-CHED-MISC
dosage O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
individual O-MISC I-ANAT-MISC
vulnerability O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
mania B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
adolescents O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
insufficiency I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
melphalan B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
primary B-DISO-MISC I-ACTI-MISC
systemic I-DISO-MISC B-ANAT-MISC
amyloidosis I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
stem O-MISC B-CONC-MISC
cell O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
primary B-DISO-MISC I-ACTI-MISC
systemic I-DISO-MISC B-ANAT-MISC
amyloidosis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AL B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
poor O-MISC I-ACTI-MISC
prognosis O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-CHED-MISC
survival O-MISC I-CHED-MISC
time O-MISC I-LIVB-MISC
from O-MISC B-ACTI-MISC
standard O-MISC B-CONC-MISC
treatments O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

High O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
intravenous O-MISC B-CHED-MISC
melphalan B-CHED-MISC O-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
peripheral O-MISC B-CONC-MISC
blood O-MISC I-CONC-MISC
stem O-MISC I-CONC-MISC
cell O-MISC I-CONC-MISC
transplant O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PBSCT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
promising O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
mortality O-MISC I-CHED-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
insufficiency I-DISO-MISC B-ANAT-MISC
immediately O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
melphalan B-CHED-MISC B-CONC-MISC
conditioning O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
undertaken O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
examine O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
impact O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
posttransplant O-MISC B-CHED-MISC
mortality O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Consecutive O-MISC B-CHED-MISC
AL B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
PBSCT O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
retrospectively O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
insufficiency I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ARI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
melphalan B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
minimum O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
level O-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
immediately O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
conditioning O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Urine O-MISC I-GENE-MISC
sediment O-MISC B-GEOG-MISC
score O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sum O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
individual O-MISC B-CHED-MISC
types O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
sediment O-MISC B-GENE-MISC
identified O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
urine O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
studied O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ARI B-DISO-MISC O-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
after O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
melphalan B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Univariate O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
identified O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
hypoalbuminemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
heavy O-MISC I-ACTI-MISC
proteinuria B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
diuretic O-MISC O-MISC
use O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
sediment O-MISC B-GEOG-MISC
score O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Age O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
sediment O-MISC B-GEOG-MISC
score O-MISC B-CHED-MISC
remained O-MISC B-ACTI-MISC
independently O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
multivariate O-MISC B-CHED-MISC
analysis O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
ARI B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
melphalan B-CHED-MISC O-MISC
underwent O-MISC B-ACTI-MISC
dialysis O-MISC B-CONC-MISC
more O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
007 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
worse O-MISC I-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
survival O-MISC B-DEVI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
timing O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
strongly O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
melphalan B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
causative O-MISC I-ACTI-MISC
agent O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Ongoing O-MISC B-ACTI-MISC
tubular B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prerequisite O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
melphalan B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
evidenced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
active O-MISC B-CHED-MISC
urinary O-MISC I-GENE-MISC
sediment O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ARI B-DISO-MISC I-ACTI-MISC
adversely O-MISC B-CHED-MISC
affected O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
outcome O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
PBSCT O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Effective O-MISC B-ACTI-MISC
preventive O-MISC B-CHED-MISC
measures O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
help O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
mortality O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
PBSCT O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
AL B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Focal O-MISC I-ACTI-MISC
cerebral B-DISO-MISC B-ANAT-MISC
ischemia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
phenylephrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
reperfusion O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
180 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
temporary O-MISC B-CHED-MISC
middle B-DISO-MISC I-ACTI-MISC
cerebral I-DISO-MISC B-ANAT-MISC
artery I-DISO-MISC B-ANAT-MISC
occlusion I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
spontaneously O-MISC I-ACTI-MISC
hypertensive B-DISO-MISC B-ANAT-MISC
rats O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
phenylephrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
brain I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
brain O-MISC B-GEOG-MISC
barrier O-MISC B-GEOG-MISC
permeability O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
manipulated O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
schedules O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
120 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
reperfusion O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
Control O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
normotensive O-MISC I-ACTI-MISC
reperfusion O-MISC B-CONC-MISC
; O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
HTN B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
reperfusion O-MISC B-CONC-MISC
only O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
HTN B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
normotensive O-MISC I-ACTI-MISC
reperfusion O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
normotension O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Part O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
brain B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
staining O-MISC B-CONC-MISC
tissue O-MISC I-GENE-MISC
using O-MISC B-ACTI-MISC
2 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
triphenyltetrazolium I-CHED-MISC B-DISO-MISC
chloride I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
edema B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
microgravimetry O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Part O-MISC B-ACTI-MISC
B O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
blood O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
brain O-MISC B-GEOG-MISC
barrier O-MISC B-GEOG-MISC
permeability O-MISC B-OCCU-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
measuring O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
amount O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
extent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
extravasation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
Evans O-MISC O-MISC
Blue O-MISC B-DISO-MISC
dye O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Brain B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
percentage O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
hemisphere I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
HTN B-DISO-MISC I-ACTI-MISC
group O-MISC B-PHEN-MISC
( O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SD O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
HTN B-DISO-MISC I-ACTI-MISC
group O-MISC B-PHEN-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
turn O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Specific O-MISC B-CHED-MISC
gravity O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
HTN B-DISO-MISC I-ACTI-MISC
group O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
043 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
002 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
HTN B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
036 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
003 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
037 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
003 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Evans B-CHED-MISC O-MISC
Blue I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
mug O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
HTN B-DISO-MISC I-ACTI-MISC
group O-MISC B-PHEN-MISC
( O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
turn O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
HTN B-DISO-MISC I-ACTI-MISC
group O-MISC B-PHEN-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
supports O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
reperfusion O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
short O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
decreases O-MISC B-CHED-MISC
brain B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
edema B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
increases O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
vasogenic B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

People O-MISC I-ANAT-MISC
aged O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
hemorrhage B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
- O-MISC I-CHED-MISC
years O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
major O-MISC I-ACTI-MISC
hemorrhage B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
people O-MISC I-ANAT-MISC
aged O-MISC I-DISO-MISC
76 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
adjusted O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
warfarin B-CHED-MISC O-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC I-CONC-MISC
hospital O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
retrospective O-MISC B-CHED-MISC
observational O-MISC B-CONC-MISC
cohort O-MISC B-CHED-MISC
study O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

SETTING O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
healthcare O-MISC B-PHYS-MISC
network O-MISC B-CHED-MISC
involving O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
tertiary O-MISC B-GENE-MISC
hospitals O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

PARTICIPANTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Two O-MISC B-ACTI-MISC
hundred O-MISC B-ACTI-MISC
thirty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
aged O-MISC I-DISO-MISC
76 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
admitted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
healthcare O-MISC B-PHYS-MISC
network O-MISC I-PHYS-MISC
between O-MISC B-ACTI-MISC
July O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2001 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
June O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2002 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

MEASUREMENTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Information O-MISC B-ACTI-MISC
regarding O-MISC B-ACTI-MISC
major O-MISC B-CHED-MISC
bleeding B-DISO-MISC I-ACTI-MISC
episodes O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
strokes B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
use O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
relatives O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
primary O-MISC I-ANAT-MISC
physicians O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
medical O-MISC B-CHED-MISC
records O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Two O-MISC B-ACTI-MISC
hundred O-MISC B-ACTI-MISC
twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
age O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
94 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Total O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
530 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
53 O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
hemorrhages B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
annual O-MISC B-CHED-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
life O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
bleeds O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
annual O-MISC B-CHED-MISC
stroke B-DISO-MISC I-ACTI-MISC
rate O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
major O-MISC I-ACTI-MISC
hemorrhage B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
frail O-MISC I-ACTI-MISC
group O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
excluding O-MISC B-ACTI-MISC
fatalities O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
resulted O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
sequelae O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
rate O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
demonstrating O-MISC B-ACTI-MISC
how O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
warfarin B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
celecoxib B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
skin B-DISO-MISC B-ANAT-MISC
reactions I-DISO-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
paracetamol B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nimesulide B-CHED-MISC O-MISC
associated O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
steroidal O-MISC B-DISO-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Acetaminophen B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
paracetamol B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
P B-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Nimesulide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
analgesic O-MISC O-MISC
- O-MISC B-DISO-MISC
antipyretic O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
hypersensitivity B-DISO-MISC B-ANAT-MISC
reactions O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
agents O-MISC O-MISC
is O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
contrary O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
steroidal O-MISC B-DISO-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
commonly O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
reactions O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Celecoxib B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CE B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
drug O-MISC O-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
selectivity O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
affinity O-MISC B-OCCU-MISC
for O-MISC B-ACTI-MISC
COX O-MISC O-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
enzyme O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
tolerability O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
CE B-CHED-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
documented O-MISC I-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
cutaneous B-DISO-MISC I-ACTI-MISC
reactions I-DISO-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
P B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
associated O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
classic O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hypersensitivity B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
P B-CHED-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
reactions O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
classic O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
P B-CHED-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
N B-CHED-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
skin B-DISO-MISC I-LIVB-MISC
reactions I-DISO-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
challenge O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
blindly O-MISC B-CONC-MISC
administered O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beginning O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
challenge O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
dosage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CE B-CHED-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
refracted O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
challenge O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
controlled O-MISC B-CHED-MISC
again O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
exclude O-MISC B-ACTI-MISC
delayed O-MISC B-CHED-MISC
reactions O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
challenge O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
if O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
appeared O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
erythema B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
rush O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
urticaria B-DISO-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
angioedema B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
No O-MISC I-ACTI-MISC
reaction O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
and O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
88 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
tolerated O-MISC B-CHED-MISC
CE B-CHED-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
angioedema B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lips O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Only O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
hypersensitivity B-DISO-MISC I-ACTI-MISC
reaction O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
CE B-CHED-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
among O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
P B-CHED-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
N B-CHED-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
intolerant O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
CE B-CHED-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reasonably O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
do O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
tolerate O-MISC B-ACTI-MISC
P B-CHED-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
N B-CHED-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
regular O-MISC B-ACTI-MISC
analgesic O-MISC O-MISC
and O-MISC B-ACTI-MISC
nonsteroidal O-MISC O-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
use O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
end B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
stage I-DISO-MISC B-ANAT-MISC
renal I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Studies O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
analgesic O-MISC O-MISC
and O-MISC B-ACTI-MISC
nonsteroidal O-MISC O-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
end B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
stage I-DISO-MISC B-ANAT-MISC
renal I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ESRD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
conflicting O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
examine O-MISC I-ACTI-MISC
this O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
incident O-MISC B-OCCU-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ESRD B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
entering O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
local O-MISC B-CONC-MISC
dialysis O-MISC I-CONC-MISC
program O-MISC I-CONC-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ESRD B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-ORGA-MISC
area O-MISC I-ORGA-MISC
between O-MISC B-ACTI-MISC
June O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1995 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
November O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1997 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

They O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
underlying O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
presumably O-MISC B-ACTI-MISC
led O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
ESRD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Controls O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
admitted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
hospitals O-MISC B-GENE-MISC
from O-MISC B-ACTI-MISC
where O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
arose O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
matched O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Odds O-MISC B-CHED-MISC
ratios O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
conditional O-MISC B-ACTI-MISC
logistic O-MISC B-CONC-MISC
model O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
confounding O-MISC B-CHED-MISC
factors O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
whole O-MISC B-ACTI-MISC
study O-MISC B-CHED-MISC
population O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
diseases O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Five O-MISC B-ACTI-MISC
hundred O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
eighty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
1190 O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
use O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
analgesic O-MISC O-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
89 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
66 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
specific O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risks O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
pyrazolones B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
63 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
paracetamol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
94 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
nonaspirin O-MISC O-MISC
NSAIDs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ESRD B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
aspirin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cumulated O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
use O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
vascular O-MISC I-ACTI-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
[ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
72 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nonaspirin O-MISC O-MISC
analgesic O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ESRD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
use O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ESRD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amisulpride B-CHED-MISC O-MISC
overdose B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
prolonged B-DISO-MISC B-CHED-MISC
QT I-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
deliberate O-MISC I-ACTI-MISC
self O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
poisoning B-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amisulpride B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
QT B-DISO-MISC I-ACTI-MISC
prolongation I-DISO-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
hypocalcaemia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
QT B-DISO-MISC B-DEVI-MISC
prolongation I-DISO-MISC B-CHED-MISC
appeared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
respond O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
gluconate I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Growth O-MISC O-MISC
- O-MISC B-DISO-MISC
associated O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
43 O-MISC B-DISO-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
molecular O-MISC I-GENE-MISC
layer O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
epileptic B-DISO-MISC B-ANAT-MISC
rats O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
cycloheximide B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
GAP43 O-MISC O-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
thought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
linked O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
mossy O-MISC I-GENE-MISC
fiber O-MISC B-GEOG-MISC
sprouting O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
MFS O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
models O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
investigate O-MISC B-ACTI-MISC
how O-MISC B-ACTI-MISC
GAP43 O-MISC O-MISC
expression O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
GAP43 O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
ir O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
correlates O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
MFS O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intensity O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
densitometry O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
extension O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
width O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
GAP43 O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
ir O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inner O-MISC I-GENE-MISC
molecular O-MISC B-GEOG-MISC
layer O-MISC B-GEOG-MISC
of O-MISC B-GEOG-MISC
the O-MISC B-GEOG-MISC
dentate O-MISC I-GENE-MISC
gyrus O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
IML O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
subject O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Pilo B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
cycloheximide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CHX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
inhibit O-MISC B-DEVI-MISC
MFS O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
CHX B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Pilo B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Pilo B-CHED-MISC O-MISC
group O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
, O-MISC B-ACTI-MISC
except O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
CHX B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
killed O-MISC B-DEVI-MISC
between O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
later O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
sections O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
processed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
GAP43 O-MISC O-MISC
immunohistochemistry O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Densitometry O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
difference O-MISC B-ANAT-MISC
regarding O-MISC B-ACTI-MISC
GAP43 O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
ir O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
IML O-MISC I-GENE-MISC
between O-MISC B-ACTI-MISC
Pilo B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
CHX B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
Pilo B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
width O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
GAP43 O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
ir O-MISC I-PROC-MISC
band O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
IML O-MISC I-GENE-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
CHX B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
Pilo B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
larger O-MISC I-CHED-MISC
band O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Pilo B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
finding O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CHX B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
Pilo B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
GAP43 O-MISC O-MISC
- O-MISC B-ACTI-MISC
ir O-MISC B-ACTI-MISC
band O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
IML O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
reinforces O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blockade O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MFS O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
change O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
GAP43 O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
ir O-MISC B-OCCU-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Pilo B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
thinning O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
band O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
narrow O-MISC B-CHED-MISC
layer O-MISC B-CHED-MISC
just O-MISC B-ACTI-MISC
above O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
granule O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
layer O-MISC B-GEOG-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
loss O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hilar O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
projections O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
express O-MISC B-ACTI-MISC
GAP O-MISC O-MISC
- O-MISC B-DISO-MISC
43 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Nicotine B-CHED-MISC O-MISC
antagonizes O-MISC I-ACTI-MISC
caffeine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
pentylenetetrazole B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
anxiogenic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

RATIONALE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Nicotine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
consumed O-MISC B-ACTI-MISC
licit O-MISC O-MISC
psychoactive O-MISC O-MISC
drugs O-MISC B-DISO-MISC
worldwide O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Epidemiological O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
concurrently O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
experimental O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
indicate O-MISC B-ACTI-MISC
clear O-MISC B-ACTI-MISC
pharmacological O-MISC B-CHED-MISC
interactions O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
have O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
interaction O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
responses O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
investigates O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
nicotine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
anxiogenic O-MISC O-MISC
drug O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
pentylenetetrazole B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
elevated O-MISC B-CONC-MISC
plus O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
maze O-MISC I-CONC-MISC
( O-MISC I-CONC-MISC
EPM O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
on O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Adult O-MISC I-ANAT-MISC
male O-MISC I-DISO-MISC
Swiss O-MISC I-ANAT-MISC
Webster O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
nicotine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
10 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
pentylenetetrazole B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
injections O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
open O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
closed O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
arm O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
entries O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
EPM O-MISC B-GENE-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
session O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Locomotor O-MISC B-DEVI-MISC
activity O-MISC I-DEVI-MISC
was O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
groups O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
protocol O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
EPM O-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Nicotine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
itself O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
EPM O-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
pentylenetetrazole B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
anxiogenic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
apparent O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
decreases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
open O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
arm O-MISC B-ANAT-MISC
time O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
entry O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Nicotine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
blocked O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
pentylenetetrazole B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
anxiety B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
drug O-MISC O-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
combinations O-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
locomotor O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
results O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
antagonistic O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
nicotine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
anxiety B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
instead O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
specific O-MISC I-CHED-MISC
anxiolytic O-MISC I-DISO-MISC
effect O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
extend O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
current O-MISC B-CHED-MISC
findings O-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
interaction O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
nicotine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Long O-MISC B-CONC-MISC
term O-MISC I-CONC-MISC
hormone O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
perimenopausal O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
postmenopausal O-MISC I-ACTI-MISC
women O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Hormone O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
HT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
controlling O-MISC B-OCCU-MISC
menopausal B-DISO-MISC I-DISO-MISC
symptoms I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
prevention O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
osteoporosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
dementia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
women O-MISC I-PHEN-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
supporting O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
indications O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
largely O-MISC B-ACTI-MISC
observational O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
assess O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
HT O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
venous B-DISO-MISC I-ACTI-MISC
thromboembolism I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
transient B-DISO-MISC I-ACTI-MISC
ischaemic I-DISO-MISC B-ANAT-MISC
attacks I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
endometrial B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
gallbladder B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
cognitive O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
dementia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
fractures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
quality O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
life O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

SEARCH O-MISC B-ACTI-MISC
STRATEGY O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
searched O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
databases O-MISC B-CHED-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
November O-MISC B-ACTI-MISC
2004 O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Cochrane O-MISC B-CHED-MISC
Menstrual O-MISC I-CHED-MISC
Disorders O-MISC I-CHED-MISC
and O-MISC I-CHED-MISC
Subfertility O-MISC I-CHED-MISC
Group O-MISC I-CHED-MISC
Trials O-MISC I-CHED-MISC
Register O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
Cochrane O-MISC B-CHED-MISC
Central O-MISC I-CHED-MISC
Register O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
Controlled O-MISC I-CHED-MISC
Trials O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
CENTRAL O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
MEDLINE O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
EMBASE O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
Biological O-MISC B-CHED-MISC
Abstracts O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Relevant O-MISC B-ACTI-MISC
non O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
indexed O-MISC I-GEOG-MISC
journals O-MISC I-GEOG-MISC
and O-MISC B-ACTI-MISC
conference O-MISC B-CHED-MISC
abstracts O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
searched O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

SELECTION O-MISC B-CHED-MISC
CRITERIA O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
Randomised O-MISC B-CONC-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
trials O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
HT O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
oestrogens B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
progestogens B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
perimenopausal O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
postmenopausal O-MISC I-ACTI-MISC
women O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

DATA O-MISC B-CHED-MISC
COLLECTION O-MISC I-CHED-MISC
AND O-MISC B-ACTI-MISC
ANALYSIS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Fifteen O-MISC B-ACTI-MISC
RCTs O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Trials O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
quality O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
review O-MISC I-ANAT-MISC
authors O-MISC I-ANAT-MISC
extracted O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
independently O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

They O-MISC B-ACTI-MISC
calculated O-MISC B-DEVI-MISC
risk O-MISC B-CHED-MISC
ratios O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
dichotomous O-MISC B-CHED-MISC
outcomes O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
weighted O-MISC B-CHED-MISC
mean O-MISC I-CHED-MISC
differences O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
continuous O-MISC B-CHED-MISC
outcomes O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC I-ACTI-MISC
heterogeneity O-MISC B-ANAT-MISC
precluded O-MISC B-ACTI-MISC
meta O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
outcomes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

MAIN O-MISC B-CHED-MISC
RESULTS O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
All O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
results O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
biggest O-MISC B-ACTI-MISC
trials O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
women O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
combined O-MISC B-ACTI-MISC
continuous O-MISC B-CHED-MISC
HT O-MISC I-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
venous B-DISO-MISC I-ACTI-MISC
thromboembolism I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
coronary O-MISC B-DEVI-MISC
event O-MISC I-DEVI-MISC
( O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
' O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
gallbladder B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
oestrogen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
HT O-MISC O-MISC
also O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
gallbladder B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Overall O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
benefits O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HT O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fractures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
colon B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
use O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
women O-MISC I-ANAT-MISC
over O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
taking O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
combined O-MISC B-ACTI-MISC
HT O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dementia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
use O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
combined O-MISC B-CHED-MISC
continuous O-MISC B-CONC-MISC
HT O-MISC I-CONC-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
venous B-DISO-MISC I-ACTI-MISC
thromboembolism I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

No O-MISC I-ACTI-MISC
trials O-MISC B-CONC-MISC
focussed O-MISC B-ACTI-MISC
specifically O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
younger O-MISC I-ANAT-MISC
women O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
trial O-MISC B-CONC-MISC
analysed O-MISC B-CONC-MISC
subgroups O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
2839 O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
50 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
combined O-MISC B-CHED-MISC
continuous O-MISC B-CHED-MISC
HT O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
1637 O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
oestrogen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
only O-MISC B-CHED-MISC
HT O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
sized O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
reported O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
venous B-DISO-MISC I-ACTI-MISC
thromboembolism I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
combined O-MISC B-CHED-MISC
continuous O-MISC B-CHED-MISC
HT O-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
absolute O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
remained O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

AUTHORS O-MISC B-CHED-MISC
' O-MISC I-CHED-MISC
CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
HT O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
indicated O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
routine O-MISC B-CONC-MISC
management O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
HT O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
menopausal O-MISC I-DISO-MISC
symptom O-MISC I-ACTI-MISC
control O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
though O-MISC B-ACTI-MISC
short O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
use O-MISC B-CHED-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
younger O-MISC I-ANAT-MISC
women O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Drug B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
induced I-DISO-MISC B-ANAT-MISC
liver I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
461 O-MISC B-ACTI-MISC
incidences O-MISC B-CHED-MISC
submitted O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Spanish O-MISC B-CHED-MISC
registry O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
& O-MISC B-ACTI-MISC
AIMS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Progress O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
understanding O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
susceptibility O-MISC O-MISC
factors O-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
drug B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
induced I-DISO-MISC B-ANAT-MISC
liver I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DILI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
outcome O-MISC B-CHED-MISC
predictability O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
hampered O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
systematic O-MISC B-CHED-MISC
programs O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
detect O-MISC I-ACTI-MISC
bona O-MISC B-CHED-MISC
fide O-MISC I-CHED-MISC
cases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
cooperative O-MISC B-PHYS-MISC
network O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
created O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
1994 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Spain O-MISC B-ORGA-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
suspicions O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
DILI B-DISO-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prospective O-MISC B-ACTI-MISC
structured O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
form O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
liver B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hepatocellular O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
cholestatic B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mixed O-MISC B-CHED-MISC
laboratory O-MISC I-CHED-MISC
criteria O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
histologic O-MISC B-CHED-MISC
criteria O-MISC B-CHED-MISC
when O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
causality O-MISC B-CHED-MISC
assessment O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
centrally O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Since O-MISC B-ACTI-MISC
April O-MISC B-ACTI-MISC
1994 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
August O-MISC B-ACTI-MISC
2004 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
461 O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
570 O-MISC B-ACTI-MISC
submitted O-MISC B-CHED-MISC
cases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
involving O-MISC B-ACTI-MISC
505 O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
deemed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
DILI B-DISO-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
antiinfective O-MISC O-MISC
group O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
incriminated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
amoxicillin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
clavulanate I-CHED-MISC B-DISO-MISC
accounting O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
whole O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hepatocellular O-MISC I-GENE-MISC
pattern O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
damage O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
inversely O-MISC B-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
worst O-MISC B-ACTI-MISC
outcome O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
Cox O-MISC B-CHED-MISC
regression O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
034 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Indeed O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
group O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
jaundice B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
presentation O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
corresponding O-MISC B-ACTI-MISC
figure O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
nonjaundiced O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
04 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Factors O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fulminant B-DISO-MISC B-CHED-MISC
hepatic I-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
sex O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
151 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
hepatocellular O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
009 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
plasma O-MISC I-GENE-MISC
bilirubin B-CHED-MISC O-MISC
value O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
09 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
hepatocellular O-MISC I-ACTI-MISC
jaundice B-DISO-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
chance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
progressing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
transplantation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Amoxicillin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
clavulanate I-CHED-MISC B-DISO-MISC
stands O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
drug O-MISC O-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
DILI B-DISO-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Morphological O-MISC B-CHED-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
ribose I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
adriamycin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
evoked O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
ribose I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
adriamycin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myocardiopathy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Adriamycin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
evoked O-MISC B-CHED-MISC
fully O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
ribose I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
influence O-MISC B-ACTI-MISC
ADR B-CHED-MISC O-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
evidences O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
vancomycin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
protection O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
erdosteine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aims O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
examine O-MISC B-ACTI-MISC
vancomycin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
promotes O-MISC B-DEVI-MISC
production O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
reactive O-MISC O-MISC
oxygen B-CHED-MISC B-DISO-MISC
species O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ROS O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
erdosteine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
expectorant O-MISC O-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
antioxidant O-MISC I-DISO-MISC
properties O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
against O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
renal B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
plus O-MISC B-CHED-MISC
erdosteine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

VCM B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
administrated O-MISC B-ACTI-MISC
intraperitoneally O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
200mgkg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
twice O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Erdosteine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
orally O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

VCM B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
control O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
significantly O-MISC B-CHED-MISC
increased O-MISC B-CHED-MISC
renal O-MISC I-GENE-MISC
malondialdehyde B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
MDA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
urinary O-MISC I-GENE-MISC
N O-MISC O-MISC
- O-MISC B-DISO-MISC
acetyl O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
beta O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
d O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
glucosaminidase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NAG O-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marker O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
tubular I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
excretion O-MISC I-DISO-MISC
but O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
superoxide B-CHED-MISC O-MISC
dismutase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
SOD O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
catalase O-MISC O-MISC
( O-MISC B-ACTI-MISC
CAT O-MISC O-MISC
) O-MISC B-ACTI-MISC
activities O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Erdosteine B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
injections O-MISC B-CONC-MISC
caused O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
renal O-MISC I-GENE-MISC
MDA B-CHED-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
urinary O-MISC B-CHED-MISC
NAG O-MISC O-MISC
excretion O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
SOD O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
CAT O-MISC I-DISO-MISC
activity O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Erdosteine B-CHED-MISC O-MISC
showed O-MISC B-ACTI-MISC
histopathological O-MISC B-CHED-MISC
protection O-MISC I-ACTI-MISC
against O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
dilatation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
tubular O-MISC I-GENE-MISC
lumens O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
extensive O-MISC B-ACTI-MISC
epithelial O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
vacuolization O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
atrophy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
desquamation B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
erdosteine B-CHED-MISC O-MISC
groups O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Erdosteine B-CHED-MISC O-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
extent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
tubular O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
oxidative O-MISC I-GENE-MISC
tubular O-MISC B-GEOG-MISC
damage O-MISC I-ACTI-MISC
plays O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
modulation O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
erdosteine B-CHED-MISC O-MISC
reduces O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
VCM B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
kidney B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
both O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
histological O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Gemfibrozil B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
lovastatin B-CHED-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
hyperlipoproteinemias B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
aim O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
retrospective O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
observational O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-ACTI-MISC
safety O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
label O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
gemfibrozil B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
lovastatin B-CHED-MISC I-CONC-MISC
treatment O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
mixed O-MISC B-ANAT-MISC
hyperlipidemia B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
atherosclerotic B-DISO-MISC I-ACTI-MISC
vascular I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
ideal O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
targets O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
reached O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
low O-MISC O-MISC
- O-MISC B-DISO-MISC
density O-MISC B-DISO-MISC
lipoprotein O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
LDL O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
cholesterol B-CHED-MISC B-DISO-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
130 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
high O-MISC O-MISC
- O-MISC B-DISO-MISC
density O-MISC B-DISO-MISC
lipoprotein O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
HDL O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
cholesterol B-CHED-MISC B-DISO-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
total O-MISC O-MISC
cholesterol B-CHED-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
HDL O-MISC O-MISC
cholesterol B-CHED-MISC B-DISO-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
diet O-MISC B-GENE-MISC
plus O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
drug O-MISC O-MISC
, O-MISC B-ACTI-MISC
gemfibrozil B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
lovastatin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
primarily O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
visits O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
scheduled O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
every O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
visits O-MISC B-CONC-MISC
per O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
741 O-MISC B-ACTI-MISC
batteries O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
function O-MISC I-CONC-MISC
tests O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
714 O-MISC B-ACTI-MISC
creatine B-CHED-MISC O-MISC
phosphokinase O-MISC B-DISO-MISC
levels O-MISC B-CHED-MISC
measured O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
446 O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
function O-MISC I-CONC-MISC
tests O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gamma O-MISC O-MISC
glutamyl O-MISC B-DISO-MISC
transferase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
equal O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
upper O-MISC B-CHED-MISC
normal O-MISC I-CHED-MISC
limit O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
714 O-MISC B-ACTI-MISC
creatine B-CHED-MISC O-MISC
phosphokinase O-MISC I-DISO-MISC
levels O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
equal O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
upper O-MISC B-CHED-MISC
normal O-MISC I-CHED-MISC
limit O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
total O-MISC O-MISC
cholesterol B-CHED-MISC O-MISC
decreased O-MISC B-CHED-MISC
22 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
255 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
decreased O-MISC B-CHED-MISC
35 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
236 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
154 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
LDL O-MISC O-MISC
cholesterol B-CHED-MISC B-DISO-MISC
decreased O-MISC B-CHED-MISC
26 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
176 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
131 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
cholesterol B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
HDL O-MISC O-MISC
cholesterol B-CHED-MISC B-DISO-MISC
ratio O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
24 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
equal O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Myositis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
attributable O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
combination O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
symptomatic O-MISC B-CHED-MISC
enough O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
discontinue O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
concurrent O-MISC B-CHED-MISC
high O-MISC B-ACTI-MISC
creatine B-CHED-MISC O-MISC
phosphokinase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
769 O-MISC B-ACTI-MISC
U O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
liter O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
myoglobinuria B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
ABSTRACT O-MISC B-ACTI-MISC
TRUNCATED O-MISC B-ACTI-MISC
AT O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
WORDS O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC

Does O-MISC B-ACTI-MISC
domperidone B-CHED-MISC O-MISC
potentiate O-MISC B-CHED-MISC
mirtazapine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
restless B-DISO-MISC I-ACTI-MISC
legs I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
? O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
now O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
central O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dopaminergic O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
restless B-DISO-MISC I-ACTI-MISC
legs I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
RLS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
example O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
RLS B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
dramatically O-MISC B-ACTI-MISC
improved O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
agonists O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
central O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
D2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonists O-MISC B-DISO-MISC
can O-MISC B-ACTI-MISC
induce O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
aggravate O-MISC B-ACTI-MISC
RLS B-DISO-MISC I-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
regarding O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
domperidone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
dopamine B-CHED-MISC O-MISC
D2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC O-MISC
, O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
aggravate O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
RLS B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Mirtazapine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
noradrenergic O-MISC O-MISC
and O-MISC B-DISO-MISC
specific O-MISC B-DISO-MISC
serotonergic O-MISC B-DISO-MISC
antidepressant O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NaSSA O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
RLS B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
publications O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
report O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
depressed O-MISC I-ACTI-MISC
patient O-MISC I-ANAT-MISC
comorbid O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
postprandial B-DISO-MISC I-ACTI-MISC
dyspepsia I-DISO-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
RLS B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
mirtazapine B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
added O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
domperidone B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
started O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
RLS B-DISO-MISC I-ACTI-MISC
only O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
mirtazapine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
RLS B-DISO-MISC I-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
resolved O-MISC I-ACTI-MISC
completely O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
mirtazapine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Such O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
temporal O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mirtazapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
RLS B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
support O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
potentiating O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
domperione B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
mirtazapine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
RLS B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
physicians O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
mirtazapine B-CHED-MISC O-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
RLS B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
concomitant O-MISC B-CHED-MISC
dopamine B-CHED-MISC O-MISC
D2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonists O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Antiandrogenic O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
can O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
arterial I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

AIM O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
change O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lipid O-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
antiandrogen O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
prostate B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

MATERIALS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
the O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
cholesterols B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
C B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
triglycerides B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
TG B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
lipoproteins O-MISC O-MISC
( O-MISC B-ACTI-MISC
LP O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
apolipoproteins O-MISC O-MISC
( O-MISC B-DISO-MISC
Apo O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
B O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
100 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
A O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
A O-MISC O-MISC
- O-MISC B-DISO-MISC
II O-MISC B-DISO-MISC
pro O-MISC B-ACTI-MISC
fi O-MISC B-ACTI-MISC
les O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
60 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
prostate B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
stage O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
T1cN0M0 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Gleason O-MISC I-ACTI-MISC
score O-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
cyproterone B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CPA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
surgical O-MISC B-CONC-MISC
management O-MISC I-CONC-MISC
or O-MISC B-ACTI-MISC
radiation O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Significant O-MISC B-ACTI-MISC
decreases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HDL O-MISC O-MISC
- O-MISC B-DISO-MISC
C O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
Apo O-MISC O-MISC
A O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Apo O-MISC O-MISC
A O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
II O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
levels O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
VLDL O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
CPA B-CHED-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
CPA B-CHED-MISC B-CONC-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
out O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Ischaemic O-MISC I-ACTI-MISC
coronary B-DISO-MISC B-ANAT-MISC
arteriosclerosis I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
CPA B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
HDL O-MISC O-MISC
cholesterol B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
Apo O-MISC O-MISC
A O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Apo O-MISC O-MISC
A O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
II O-MISC B-DISO-MISC
pro O-MISC B-ACTI-MISC
fi O-MISC B-ACTI-MISC
les O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
hyperglyceridemic B-DISO-MISC I-ACTI-MISC
effect I-DISO-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
estrogen B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
Fluorouracil I-CHED-MISC B-DISO-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
alpha B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluoro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
beta I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
alanine I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Cardiotoxicity B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
occurring O-MISC B-DEVI-MISC
during O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
malignancies B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
herein O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
level O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
alpha B-CHED-MISC I-CONC-MISC
- I-CHED-MISC I-CONC-MISC
fluoro I-CHED-MISC I-CONC-MISC
- I-CHED-MISC I-CONC-MISC
beta I-CHED-MISC I-CONC-MISC
- I-CHED-MISC I-CONC-MISC
alanine I-CHED-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
FBAL B-CHED-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
unresectable O-MISC I-DISO-MISC
colon B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
metastases O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
lung O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
referred O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
us O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
affiliated O-MISC B-GENE-MISC
hospital O-MISC I-GEOG-MISC
; O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
infusion O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
1000 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
precordial B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
with O-MISC B-ANAT-MISC
right B-DISO-MISC B-ANAT-MISC
bundle I-DISO-MISC B-ANAT-MISC
branch I-DISO-MISC B-ANAT-MISC
block I-DISO-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
concomitantly O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
FBAL B-CHED-MISC O-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
1955 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
precordial B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
electrocardiographic O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
disappeared O-MISC B-ACTI-MISC
spontaneously O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
precordial B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
abandoned O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Instead O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
S O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
derivative O-MISC O-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
twice O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
instituted O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
S O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
strong O-MISC B-ACTI-MISC
inhibitory O-MISC B-DEVI-MISC
effect O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
dihydropyrimidine B-CHED-MISC O-MISC
dehydrogenase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
catalyzes O-MISC B-OCCU-MISC
the O-MISC B-ACTI-MISC
degradative O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
into O-MISC B-ACTI-MISC
FBAL B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
FBAL B-CHED-MISC O-MISC
concentration O-MISC B-CHED-MISC
subsequently O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
352 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
value O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
S O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Thereafter O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
cardiac B-DISO-MISC B-ANAT-MISC
symptoms I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
achieved O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
response O-MISC B-ANAT-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
S O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
experience O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
literature O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
FBAL B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

S O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
safely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Hepatocellular B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Fanconi B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
anemia I-DISO-MISC B-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
androgen B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
corticosteroid B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
boy O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
Fanconi B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
anemia I-DISO-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
androgens B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
corticosteroids B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
transfusions O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-CHED-MISC
weeks O-MISC I-CHED-MISC
before O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
he O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
readmitted O-MISC B-CONC-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aplastic O-MISC I-ACTI-MISC
crisis O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
septicemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
abnormalities O-MISC I-ACTI-MISC
in O-MISC B-ANAT-MISC
liver O-MISC B-ANAT-MISC
function O-MISC B-UnknownType-MISC
and O-MISC B-ACTI-MISC
died O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC B-CHED-MISC
bronchopneumonia I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
autopsy O-MISC B-CONC-MISC
peliosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
multiple O-MISC B-ACTI-MISC
hepatic B-DISO-MISC I-ACTI-MISC
tumors I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
histologically O-MISC B-CHED-MISC
proved O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
well O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
differentiated O-MISC I-CHED-MISC
hepatocellular B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
contributes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
observations O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
metastasizing O-MISC B-ANAT-MISC
hepatic B-DISO-MISC I-ACTI-MISC
neoplasms I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
peliosis B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
androgen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
corticosteroid B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
Fanconi B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
anemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
influence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
between O-MISC B-ACTI-MISC
monoHER B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protection O-MISC I-ACTI-MISC
against O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Despite O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anthracyclin O-MISC O-MISC
doxorubicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
continues O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
chemotherapeutic O-MISC O-MISC
agent O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

DOX B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
presumably O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
formation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
free O-MISC O-MISC
radicals O-MISC B-DISO-MISC
by O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Reactive O-MISC O-MISC
oxygen B-CHED-MISC B-DISO-MISC
species O-MISC B-DISO-MISC
particularly O-MISC B-ACTI-MISC
affect O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
myocytes O-MISC B-GEOG-MISC
because O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
seem O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
poor O-MISC B-ACTI-MISC
antioxidant O-MISC O-MISC
defense O-MISC I-DISO-MISC
system O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
semisynthetic O-MISC O-MISC
flavonoid B-CHED-MISC B-DISO-MISC
monohydroxyethylrutoside B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
monoHER B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
cardioprotection O-MISC I-ACTI-MISC
against O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
through O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
radical O-MISC I-DISO-MISC
scavenging O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
iron B-CHED-MISC O-MISC
chelating O-MISC B-DISO-MISC
properties O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
short O-MISC B-ACTI-MISC
final O-MISC B-ACTI-MISC
half O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
life O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
monoHER B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
expected O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
between O-MISC B-ACTI-MISC
monoHER B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
might O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
influence O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardioprotective O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
monoHER B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
aim O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-CHED-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
this O-MISC B-ACTI-MISC
possible O-MISC I-ACTI-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Six O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
BALB O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
c O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
preceded O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
monoHER B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
interval O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
120 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
treatment O-MISC B-CHED-MISC
period O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
sacrificed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Their O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
tissues O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
processed O-MISC B-OCCU-MISC
for O-MISC B-ACTI-MISC
light O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
cardiomyocyte B-DISO-MISC I-GENE-MISC
damage I-DISO-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Billingham O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Cancer B-DISO-MISC B-ACTI-MISC
Treat O-MISC B-ACTI-MISC
Rep O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
865 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
872 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1978 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Microscopic O-MISC B-CONC-MISC
evaluation O-MISC I-CONC-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
significant O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
comparison O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
damaged O-MISC B-CHED-MISC
cardiomyocytes O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ratio O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
aberrant O-MISC B-CHED-MISC
cardiomyocytes O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
preceded O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
monoHER B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
ranged O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
019 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
protective O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
by O-MISC B-ACTI-MISC
adding O-MISC B-ACTI-MISC
monoHER B-CHED-MISC O-MISC
before O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
cardiomyocytes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
protective O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
depend O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
between O-MISC B-ACTI-MISC
monoHER B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
345 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
outpatient O-MISC I-ANAT-MISC
clinical O-MISC B-CHED-MISC
setting O-MISC I-CHED-MISC
monoHER B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
shortly O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CONC-MISC
evaluation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
bepridil B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
flutter I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Bepridil B-CHED-MISC O-MISC
hydrochloride I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Bpd B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
attracted O-MISC B-ACTI-MISC
attention O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
drug O-MISC O-MISC
for O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AF B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
flutter I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AFL B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
torsade B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
Tdp B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
Bpd B-CHED-MISC O-MISC
requiring O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Bpd B-CHED-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
459 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
361 O-MISC B-ACTI-MISC
males O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
63 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
old O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
comprising O-MISC B-ACTI-MISC
378 O-MISC B-ACTI-MISC
AF B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
AFL B-DISO-MISC I-ACTI-MISC
cases O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Mean O-MISC I-DISO-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
ejection O-MISC I-LIVB-MISC
fraction O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
atrial O-MISC I-GENE-MISC
dimension O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
LAD O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
66 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
QT B-DISO-MISC B-CONC-MISC
prolongation I-DISO-MISC B-CHED-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
beats O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
dizziness B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
general O-MISC I-ACTI-MISC
fatigue B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
each O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
QT B-DISO-MISC B-CONC-MISC
prolongation I-DISO-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
Tdp B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
triggering O-MISC I-DISO-MISC
factors O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
Tdp B-DISO-MISC O-MISC
were O-MISC B-ACTI-MISC
hypokalemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
sudden O-MISC I-ACTI-MISC
decrease O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
differences O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC I-DISO-MISC
backgrounds O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
Tdp B-DISO-MISC I-ACTI-MISC
other O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
LAD O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
larger O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
older O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Tdp B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Careful O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
potassium B-CHED-MISC I-CONC-MISC
concentration O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ECG O-MISC B-CONC-MISC
should O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
done O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
Bpd B-CHED-MISC B-CONC-MISC
administration O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Enhanced O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
transgenic O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
low O-MISC I-ACTI-MISC
brain O-MISC I-GENE-MISC
angiotensinogen O-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
permanent O-MISC B-CHED-MISC
deficiency O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
renin O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
angiotensin B-CHED-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
RAS O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
sensitivity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
baroreflex O-MISC I-DISO-MISC
control O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
we O-MISC B-ACTI-MISC
aimed O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
studying O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
involvement O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
RAS O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
reactivity O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
adrenoceptor O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
beta O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
AR O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
agonist O-MISC B-DISO-MISC
isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Iso B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Transgenic O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
low O-MISC I-ACTI-MISC
brain O-MISC I-GENE-MISC
angiotensinogen O-MISC O-MISC
( O-MISC B-ACTI-MISC
TGR O-MISC O-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
hearts O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
Iso B-CHED-MISC O-MISC
induced O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
LV O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
maximal O-MISC B-CHED-MISC
contraction O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
dP O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dt O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
max O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
TGR O-MISC I-ANAT-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Sprague O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Dawley O-MISC I-PHEN-MISC
( O-MISC I-PHEN-MISC
SD O-MISC I-PHEN-MISC
) O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

LV B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
Iso B-CHED-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
TGR O-MISC I-ANAT-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
SD O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
LV O-MISC I-GENE-MISC
wt O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
body O-MISC B-ACTI-MISC
wt O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
004 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
004 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
LV B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
TGR O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
more O-MISC B-ACTI-MISC
pronounced O-MISC B-ACTI-MISC
downregulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
AR O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
upregulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
LV O-MISC O-MISC
beta O-MISC B-LIVB-MISC
- O-MISC B-DISO-MISC
AR O-MISC B-DISO-MISC
kinase O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
1 O-MISC I-PROC-MISC
mRNA O-MISC O-MISC
levels O-MISC B-CHED-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
SD O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
HR O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
AR O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
metoprolol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
conscious O-MISC I-ACTI-MISC
rats O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
TGR O-MISC I-ANAT-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
SD O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
parasympathetic O-MISC I-GENE-MISC
blockade O-MISC O-MISC
by O-MISC B-ACTI-MISC
atropine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
HR O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
strains O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
TGR O-MISC O-MISC
are O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
AR O-MISC B-DISO-MISC
agonist O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
inotropic I-DISO-MISC B-ANAT-MISC
response O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
hypertrophy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
chronically O-MISC B-CHED-MISC
low O-MISC B-CHED-MISC
sympathetic O-MISC I-GENE-MISC
outflow O-MISC B-GEOG-MISC
directed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
long B-DISO-MISC I-ACTI-MISC
QT I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
injection O-MISC I-ACTI-MISC
drug O-MISC I-ANAT-MISC
users O-MISC I-PHEN-MISC
receiving O-MISC B-CHED-MISC
methadone B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
hospitalized O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Drug O-MISC O-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
long B-DISO-MISC B-ANAT-MISC
QT I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
drug O-MISC B-ANAT-MISC
reaction O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Methadone B-CHED-MISC O-MISC
prolongs O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
QT O-MISC I-DISO-MISC
interval O-MISC I-LIVB-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
manner O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inpatient O-MISC I-ANAT-MISC
setting O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
QT B-DISO-MISC B-CONC-MISC
interval I-DISO-MISC B-CHED-MISC
prolongation I-DISO-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
dependence O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
importance O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cofactors O-MISC O-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
drug O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
drug O-MISC I-LIVB-MISC
interactions O-MISC I-LIVB-MISC
remain O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
systematic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
comparing O-MISC B-DEVI-MISC
active O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
former O-MISC B-CHED-MISC
intravenous O-MISC B-CHED-MISC
drug O-MISC O-MISC
users O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
among O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
hospitalized O-MISC I-PHEN-MISC
over O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
period O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tertiary O-MISC B-GENE-MISC
care O-MISC I-GEOG-MISC
hospital O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
167 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-CHED-MISC
methadone B-CHED-MISC O-MISC
fulfilled O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inclusion O-MISC B-CHED-MISC
criteria O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
injection O-MISC O-MISC
drug O-MISC B-DISO-MISC
users O-MISC I-ANAT-MISC
not O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
demographic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
biological O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
pharmacological O-MISC B-CHED-MISC
variables O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
QT B-DISO-MISC B-CONC-MISC
prolongation I-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Among O-MISC B-ACTI-MISC
167 O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
maintenance O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
QTc O-MISC B-CHED-MISC
prolongation O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
longer O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
group O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

QTc O-MISC I-ACTI-MISC
length O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
weakly O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
methadone B-CHED-MISC O-MISC
daily O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
Spearman O-MISC B-CHED-MISC
rank O-MISC I-CHED-MISC
correlation O-MISC I-CHED-MISC
coefficient O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Multivariate O-MISC B-CHED-MISC
regression O-MISC I-CHED-MISC
analysis O-MISC I-CHED-MISC
allowed O-MISC B-ACTI-MISC
attribution O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
QTc O-MISC O-MISC
variability O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
cytochrome O-MISC O-MISC
P O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
450 O-MISC B-DISO-MISC
3A4 O-MISC B-DISO-MISC
drug O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
drug O-MISC I-LIVB-MISC
interactions O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
hypokalemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
altered O-MISC I-DISO-MISC
liver O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
QT B-DISO-MISC B-CHED-MISC
interval I-DISO-MISC I-CHED-MISC
prolongation I-DISO-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
maintenance O-MISC B-DEVI-MISC
patients O-MISC I-ANAT-MISC
hospitalized O-MISC I-PHEN-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tertiary O-MISC B-GENE-MISC
care O-MISC I-GEOG-MISC
center O-MISC I-GEOG-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
finding O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Methadone B-CHED-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cytochrome O-MISC O-MISC
P O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
450 O-MISC B-DISO-MISC
3A4 O-MISC B-DISO-MISC
inhibitors O-MISC O-MISC
, O-MISC B-ACTI-MISC
potassium B-CHED-MISC B-OCCU-MISC
level O-MISC I-OCCU-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
liver O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
QT B-DISO-MISC I-DISO-MISC
prolongation I-DISO-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Long B-DISO-MISC I-ACTI-MISC
QT I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
can O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Mechanisms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
nitric B-CHED-MISC I-ACTI-MISC
oxide I-CHED-MISC B-ANAT-MISC
( O-MISC B-ANAT-MISC
NO B-CHED-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
deficiency O-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
focus O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
venous O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Loss O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
endothelial O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
- O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
nitric B-CHED-MISC O-MISC
oxide I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NO B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hallmark O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
arterial B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Experimental O-MISC I-ACTI-MISC
hypertension B-DISO-MISC B-ANAT-MISC
created O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
removal O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
NO B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
involves O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
addition O-MISC I-CHED-MISC
to O-MISC I-CHED-MISC
decreased O-MISC B-CHED-MISC
arterial O-MISC I-GENE-MISC
vasodilator O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
include O-MISC B-ACTI-MISC
augmented O-MISC B-CHED-MISC
endothelin O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ET O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
release O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
sympathetic O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
activity O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
tissue O-MISC I-GENE-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
hypothesized O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
venous O-MISC I-DISO-MISC
smooth O-MISC I-LIVB-MISC
muscle O-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
venomotor O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
tone O-MISC I-LIVB-MISC
plays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Nomega B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
nitro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
L I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
arginine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
LNNA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
through O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
the O-MISC B-ACTI-MISC
NO B-CHED-MISC O-MISC
synthase O-MISC B-DISO-MISC
inhibitor O-MISC O-MISC
LNNA B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
drinking O-MISC B-GENE-MISC
water O-MISC I-GEOG-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Mean O-MISC I-DISO-MISC
arterial O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
conscious O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
119 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
194 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
LNNA B-CHED-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Carotid O-MISC I-GENE-MISC
arteries O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
vena O-MISC I-GENE-MISC
cava O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
removed O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
measurement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
isometric O-MISC I-DISO-MISC
contraction O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Maximal O-MISC B-CHED-MISC
contraction O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
norepinephrine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
modestly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
arteries O-MISC I-GENE-MISC
from O-MISC B-ACTI-MISC
LNNA B-CHED-MISC I-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
contraction O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
ET O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Maximum O-MISC B-ACTI-MISC
contraction O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
vena O-MISC I-ANAT-MISC
cava O-MISC I-PHEN-MISC
to O-MISC B-ACTI-MISC
norepinephrine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
ET O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Mean O-MISC B-CHED-MISC
circulatory O-MISC I-CHED-MISC
filling O-MISC I-CHED-MISC
pressure O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
measure O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
venomotor O-MISC I-DISO-MISC
tone O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
elevated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
LNNA B-CHED-MISC I-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
LNNA B-CHED-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
superoxide B-CHED-MISC O-MISC
scavenger O-MISC O-MISC
tempol B-CHED-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
IV O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
change O-MISC B-ACTI-MISC
arterial O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
but O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
LNNA B-CHED-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Similarly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ganglionic O-MISC I-GENE-MISC
blockade O-MISC B-UnknownType-MISC
with O-MISC B-ACTI-MISC
hexamethonium B-CHED-MISC O-MISC
caused O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
greater O-MISC I-CHED-MISC
fall O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
LNNA B-CHED-MISC I-ANAT-MISC
hypertensive B-DISO-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Carotid O-MISC I-GENE-MISC
arteries O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
vena O-MISC I-GENE-MISC
cava O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sympathetic O-MISC I-GENE-MISC
ganglia O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
LNNA B-CHED-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
basal O-MISC B-CHED-MISC
levels O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
superoxide B-CHED-MISC I-CONC-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
NO B-CHED-MISC I-ACTI-MISC
deficiency O-MISC B-ANAT-MISC
increases O-MISC B-CHED-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
sympathetic O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
arterial O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
venous O-MISC I-GENE-MISC
vessels O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
impact O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
veins O-MISC I-GENE-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
make O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
contribution O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Association O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
DRD2 O-MISC B-LIVB-MISC
polymorphisms O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
chlorpromazine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
extrapyramidal B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
schizophrenic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

AIM O-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
Extrapyramidal B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
EPS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
commonly O-MISC B-CHED-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
antipsychotic O-MISC O-MISC
drugs O-MISC B-DISO-MISC
that O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
affinity O-MISC B-OCCU-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
D2 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
research O-MISC B-PHEN-MISC
groups O-MISC B-UnknownType-MISC
have O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genetic O-MISC B-OCCU-MISC
variations O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DRD2 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
therapeutic O-MISC I-DISO-MISC
response O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
variations O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
receptor O-MISC O-MISC
in O-MISC B-ACTI-MISC
modulating O-MISC B-CHED-MISC
receptor O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
evaluate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
DRD2 O-MISC O-MISC
plays O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
chlorpromazine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
EPS B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
schizophrenic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
seven O-MISC B-ACTI-MISC
SNP O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
single O-MISC B-LIVB-MISC
nucleotide O-MISC I-PROC-MISC
polymorphism O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-LIVB-MISC
141Cins O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
del O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
TaqIB O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
TaqID O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
Ser311Cys O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
rs6275 O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
rs6277 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
TaqIA O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DRD2 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
146 O-MISC B-ACTI-MISC
schizophrenic B-DISO-MISC I-ACTI-MISC
inpatients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
EPS B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
87 O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
EPS B-DISO-MISC I-ACTI-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Simpson O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
Angus O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
chlorpromazine B-CHED-MISC O-MISC
after O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
alleles O-MISC B-LIVB-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
loci O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-CHED-MISC
by O-MISC I-CHED-MISC
PCR O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
polymerase O-MISC B-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Polymorphisms O-MISC B-LIVB-MISC
TaqID O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
Ser311Cys O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
rs6277 O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
polymorphic O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
recruited O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-CHED-MISC
statistical O-MISC I-CHED-MISC
significance O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
allele O-MISC B-LIVB-MISC
distribution O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
- O-MISC B-LIVB-MISC
141Cins O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
del O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
TaqIB O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
rs6275 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
TaqIA O-MISC B-LIVB-MISC
or O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
haplotypes O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
constituted O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
TaqIB O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
rs6275 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
TaqIA O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
linkage O-MISC B-CHED-MISC
disequilibrium O-MISC I-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
lend O-MISC B-ACTI-MISC
strong O-MISC B-ACTI-MISC
support O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
view O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genetic O-MISC B-OCCU-MISC
variation O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DRD2 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
plays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
individually O-MISC B-ACTI-MISC
variable O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
chlorpromazine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
results O-MISC I-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
DRD2 O-MISC O-MISC
and O-MISC B-ACTI-MISC
EPS B-DISO-MISC O-MISC
in O-MISC B-ACTI-MISC
Caucasians O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Physical O-MISC B-CONC-MISC
training O-MISC I-CONC-MISC
decreases O-MISC B-CHED-MISC
susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Regular O-MISC B-PHEN-MISC
motor O-MISC B-UnknownType-MISC
activity O-MISC B-UnknownType-MISC
has O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
benefits O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
mental O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
physical O-MISC I-ACTI-MISC
condition O-MISC B-ANAT-MISC
but O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
implications O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
still O-MISC B-ACTI-MISC
controversial O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
elucidate O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
problem O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
physical O-MISC B-DEVI-MISC
activity O-MISC I-DEVI-MISC
on O-MISC B-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
subsequent O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Male O-MISC B-CHED-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
subjected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
repeated O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
sessions O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
treadmill O-MISC B-GENE-MISC
and O-MISC B-ACTI-MISC
swimming O-MISC B-GENE-MISC
pool O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

Thereafter O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
injections O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
trained O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
trained O-MISC I-PHEN-MISC
control O-MISC I-PHEN-MISC
groups O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
latency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
motor O-MISC B-ANAT-MISC
sign O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intensity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
when O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
occurred O-MISC B-DEVI-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
period O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
when O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
ended O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
parameters O-MISC B-CHED-MISC
showed O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
changes O-MISC B-CHED-MISC
suggesting O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
regular O-MISC B-CHED-MISC
physical O-MISC B-DEVI-MISC
exercises O-MISC I-DEVI-MISC
decrease O-MISC B-CHED-MISC
susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
subsequently O-MISC B-CHED-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
ameliorate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
experimentally O-MISC B-CHED-MISC
induced O-MISC B-CHED-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Tonic O-MISC B-CONC-MISC
dopaminergic O-MISC I-CONC-MISC
stimulation O-MISC I-CONC-MISC
impairs B-DISO-MISC B-CHED-MISC
associative I-DISO-MISC I-DISO-MISC
learning I-DISO-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Endogenous O-MISC B-CHED-MISC
dopamine B-CHED-MISC O-MISC
plays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
central O-MISC B-ACTI-MISC
role O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
salience O-MISC I-DISO-MISC
coding O-MISC I-LIVB-MISC
during O-MISC B-ACTI-MISC
associative O-MISC I-DISO-MISC
learning O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
precursor O-MISC B-DISO-MISC
levodopa B-CHED-MISC O-MISC
enhances O-MISC B-DEVI-MISC
learning O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
increases O-MISC B-CHED-MISC
both O-MISC B-ACTI-MISC
phasic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
tonic O-MISC I-DISO-MISC
dopaminergic O-MISC I-LIVB-MISC
neurotransmission O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
critical O-MISC B-CHED-MISC
mechanism O-MISC B-CHED-MISC
mediating O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
enhancement O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
learning O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
unresolved O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
probed O-MISC B-ACTI-MISC
how O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
tonic O-MISC B-CHED-MISC
dopaminergic O-MISC I-DISO-MISC
stimulation O-MISC I-LIVB-MISC
affects O-MISC B-ACTI-MISC
associative O-MISC I-DISO-MISC
learning O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Forty O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
trained O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
vocabulary O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
concrete O-MISC B-CHED-MISC
nouns O-MISC I-CHED-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
consecutive O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
days O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
design O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Subjects O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tonically O-MISC B-CHED-MISC
stimulating O-MISC B-OCCU-MISC
dopamine B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
agonist O-MISC O-MISC
pergolide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
120 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
day O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
agonist O-MISC B-DISO-MISC
significantly O-MISC B-CHED-MISC
impaired B-DISO-MISC B-CHED-MISC
novel I-DISO-MISC B-CHED-MISC
word I-DISO-MISC I-DISO-MISC
learning I-DISO-MISC I-LIVB-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
learning O-MISC I-ACTI-MISC
decrement O-MISC B-ANAT-MISC
persisted O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
training O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Subjects O-MISC B-CONC-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
pergolide B-CHED-MISC O-MISC
also O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
restricted O-MISC B-CHED-MISC
emotional O-MISC I-DISO-MISC
responses O-MISC I-DISO-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PLACEBO O-MISC B-CONC-MISC
group O-MISC B-UnknownType-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
extent O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
' O-MISC B-ACTI-MISC
flattened O-MISC B-CHED-MISC
' O-MISC B-ACTI-MISC
affect O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
pergolide B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
degree O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
learning O-MISC I-DISO-MISC
inhibition O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
tonic O-MISC I-DISO-MISC
occupation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
receptors O-MISC B-DISO-MISC
impairs O-MISC B-CHED-MISC
learning O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
competition O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
phasic O-MISC B-CHED-MISC
dopamine B-CHED-MISC O-MISC
signals O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
phasic O-MISC I-DISO-MISC
signaling O-MISC I-LIVB-MISC
seems O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
critical O-MISC B-CHED-MISC
mechanism O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
enhances O-MISC B-DEVI-MISC
associative O-MISC I-DISO-MISC
learning O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Minocycline B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
fulfilling O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
criteria O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
polyarteritis B-DISO-MISC I-ACTI-MISC
nodosa I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
minocycline B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
palmoplantar B-DISO-MISC I-ACTI-MISC
pustulosis I-DISO-MISC B-ANAT-MISC
developed O-MISC B-ACTI-MISC
fever B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
myalgias B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
polyneuropathy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
testicular B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
elevated O-MISC O-MISC
C O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
reactive O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CRP O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
myeloperoxidase O-MISC O-MISC
- O-MISC B-DISO-MISC
nor O-MISC B-ACTI-MISC
proteinase O-MISC O-MISC
- O-MISC B-DISO-MISC
3 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
antineutrophil O-MISC B-DISO-MISC
cytoplasmic O-MISC B-DISO-MISC
antibody O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
manifestations O-MISC I-ACTI-MISC
met O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
American O-MISC B-PHYS-MISC
College O-MISC I-PHYS-MISC
of O-MISC I-PHYS-MISC
Rheumatology O-MISC I-PHYS-MISC
1990 O-MISC B-ACTI-MISC
criteria O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
classification O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
polyarteritis B-DISO-MISC I-ACTI-MISC
nodosa I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Stopping O-MISC B-DEVI-MISC
minocycline B-CHED-MISC O-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
amelioration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
normalization O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
CRP O-MISC B-OCCU-MISC
level O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
minocycline B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
satisfying O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
criteria O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Differential O-MISC B-CONC-MISC
diagnosis O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
disease O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
invaluable O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
classical O-MISC I-ACTI-MISC
polyarteritis B-DISO-MISC B-ANAT-MISC
nodosa I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Intramuscular O-MISC B-CHED-MISC
hepatitis B-DISO-MISC O-MISC
B I-DISO-MISC B-DISO-MISC
immune O-MISC B-DISO-MISC
globulin O-MISC B-DISO-MISC
combined O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
prevention O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ACTI-MISC
B I-DISO-MISC B-ANAT-MISC
recurrence O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Combined O-MISC B-CHED-MISC
hepatitis B-DISO-MISC O-MISC
B I-DISO-MISC B-DISO-MISC
immune O-MISC O-MISC
globulin O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
HBIg O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
prophylaxis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recurrence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ACTI-MISC
B I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
has O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
improved O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
survival O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HBsAg B-CHED-MISC B-OCCU-MISC
positive O-MISC I-OCCU-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
undertaken O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
outcomes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ANAT-MISC
B I-DISO-MISC I-PHEN-MISC
virus O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
HBV O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
chart O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
organ O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
database O-MISC B-CHED-MISC
identified O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
transplanted O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
benign O-MISC B-CHED-MISC
HBV O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
cirrhotic B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
between O-MISC B-ACTI-MISC
June O-MISC B-ACTI-MISC
2002 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
December O-MISC B-ACTI-MISC
2004 O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
survived O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

HBIg O-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
intravenously O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
intramuscularly O-MISC B-CHED-MISC
thereafter O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
At O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
recurrence O-MISC B-OCCU-MISC
rate O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
patient O-MISC I-ANAT-MISC
survival O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
88 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
82 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
oral O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
transplantation O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
enabled O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
HBV O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
DNA O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
HBeAg B-CHED-MISC B-OCCU-MISC
positive O-MISC I-OCCU-MISC
patients O-MISC I-ANAT-MISC
respectively O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
convert O-MISC B-OCCU-MISC
to O-MISC I-OCCU-MISC
be O-MISC I-OCCU-MISC
negative O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

Intramuscular O-MISC B-CHED-MISC
HBIg O-MISC O-MISC
was O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Lamivudine B-CHED-MISC O-MISC
combined O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
intramuscular O-MISC B-CHED-MISC
HBIg O-MISC O-MISC
can O-MISC B-ACTI-MISC
effectively O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
allograft O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recurrence O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
HBV O-MISC I-ANAT-MISC
after O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Anticonvulsant O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
eslicarbazepine B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
BIA B-CHED-MISC B-LIVB-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
093 I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
microperfusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
picrotoxin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
freely O-MISC B-ACTI-MISC
moving O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Eslicarbazepine B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
BIA B-CHED-MISC O-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
093 I-CHED-MISC B-DISO-MISC
, O-MISC B-DISO-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
10 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
acetoxy I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
10 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
11 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dihydro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
5H I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dibenzo I-CHED-MISC B-DISO-MISC
/ I-CHED-MISC B-DISO-MISC
b I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
f I-CHED-MISC B-DISO-MISC
/ I-CHED-MISC B-ACTI-MISC
azepine I-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
carboxamide I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
antiepileptic O-MISC O-MISC
drug O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
now O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Phase O-MISC B-CHED-MISC
III O-MISC I-CHED-MISC
clinical O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
designed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
improving O-MISC B-CHED-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
comparison O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
structurally O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
carbamazepine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CBZ B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
oxcarbazepine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
OXC B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
eslicarbazepine B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
whole O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
model O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
elicited O-MISC B-CHED-MISC
repeatedly O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
without O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
threshold O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
patterns O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
threshold O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
picrotoxin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
duration O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
2h O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
picrotoxin B-CHED-MISC O-MISC
microperfusion O-MISC B-CONC-MISC
prevented O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Lower O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
suppress O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-CHED-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
10mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
reductions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
duration O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8s O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
number O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

No O-MISC I-ACTI-MISC
adverse O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
eslicarbazepine B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
/ O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
patterns O-MISC B-CHED-MISC
studied O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
sleep O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
wakefulness O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
studied O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
prolonged O-MISC B-CHED-MISC
intake O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
slimming O-MISC B-OBJC-MISC
pills O-MISC B-DISO-MISC
containing O-MISC B-ACTI-MISC
anthraquinones B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Chinese B-CHED-MISC B-ORGA-MISC
herbal I-CHED-MISC O-MISC
medicine O-MISC O-MISC
preparations O-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
available O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
regarded O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
public O-MISC B-PHYS-MISC
as O-MISC B-ACTI-MISC
natural O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
safe O-MISC B-CHED-MISC
remedies O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
medical O-MISC I-ACTI-MISC
conditions O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Nephropathy B-DISO-MISC I-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
Chinese B-CHED-MISC I-ANAT-MISC
herbs I-CHED-MISC I-PHEN-MISC
has O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
involving O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aristolochic B-CHED-MISC O-MISC
acids I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
prolonged O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
proprietary O-MISC B-ACTI-MISC
Chinese B-CHED-MISC B-ORGA-MISC
herbal I-CHED-MISC O-MISC
slimming O-MISC O-MISC
pill O-MISC B-DISO-MISC
that O-MISC B-ACTI-MISC
contained O-MISC B-ACTI-MISC
anthraquinone B-CHED-MISC O-MISC
derivatives O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
extracted O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
Rhizoma O-MISC I-ANAT-MISC
Rhei O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
rhubarb O-MISC I-ANAT-MISC
) O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
aggravated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
concomitant O-MISC B-CHED-MISC
intake O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
steroidal O-MISC B-DISO-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drug O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
diclofenac B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Renal O-MISC I-GENE-MISC
pathology O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hypocellular O-MISC I-ACTI-MISC
interstitial O-MISC B-ANAT-MISC
fibrosis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Spontaneous O-MISC B-CHED-MISC
renal O-MISC I-DISO-MISC
recovery O-MISC I-LIVB-MISC
occurred O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
cessation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
slimming O-MISC B-OBJC-MISC
pills O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
mild O-MISC B-CHED-MISC
interstitial O-MISC I-ACTI-MISC
fibrosis B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
tubular O-MISC I-ACTI-MISC
atrophy B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
still O-MISC B-ACTI-MISC
evident O-MISC B-ACTI-MISC
histologically O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
later O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
causal O-MISC B-ACTI-MISC
relationship O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
anthraquinone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
containing O-MISC B-ACTI-MISC
herbal O-MISC O-MISC
agent O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
remains O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
proven O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
phytotherapy O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
interstitial O-MISC I-ACTI-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
unexplained O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Chloroacetaldehyde B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sulfhydryl B-CHED-MISC O-MISC
reagent O-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
critical O-MISC B-CHED-MISC
thiol B-CHED-MISC O-MISC
groups O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
ifosfamide B-CHED-MISC O-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Chloroacetaldehyde B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CAA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
metabolite O-MISC O-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alkylating O-MISC O-MISC
agent O-MISC B-DISO-MISC
ifosfamide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
IFO B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
putatively O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
anti O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
tumor B-DISO-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
IFO B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Depletion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sulfhydryl B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
SH B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
cell O-MISC B-CONC-MISC
culture O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
animal O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
work O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CAA B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
proximal O-MISC I-GENE-MISC
tubule O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
primary O-MISC B-CONC-MISC
culture O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
hRPTEC O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Toxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
CAA B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
protein O-MISC O-MISC
content O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
cell O-MISC B-CONC-MISC
number O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
LDH O-MISC B-CONC-MISC
release O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
trypan B-CHED-MISC B-CONC-MISC
blue I-CHED-MISC I-CONC-MISC
exclusion O-MISC I-CONC-MISC
assay O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
caspase O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
3 O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Free O-MISC B-CHED-MISC
thiols B-CHED-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
method O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
Ellman O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

CAA B-CHED-MISC O-MISC
reduced O-MISC B-CHED-MISC
hRPTEC O-MISC I-GENE-MISC
cell O-MISC I-CONC-MISC
number O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
protein O-MISC O-MISC
, O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
loss O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
free O-MISC B-ACTI-MISC
intracellular O-MISC B-CHED-MISC
thiols B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
markers O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

CAA B-CHED-MISC O-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
acrolein B-CHED-MISC O-MISC
inhibited O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
cysteine B-CHED-MISC O-MISC
proteases O-MISC B-DISO-MISC
caspase O-MISC O-MISC
- O-MISC B-DISO-MISC
3 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
caspase O-MISC O-MISC
- O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
cathepsin O-MISC O-MISC
B O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Caspase O-MISC O-MISC
activation O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
inhibited O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
CAA B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
stained O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
fluorescent O-MISC O-MISC
dyes O-MISC B-DISO-MISC
targeting O-MISC B-CHED-MISC
lysosomes O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
CAA B-CHED-MISC O-MISC
induced O-MISC I-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
lysosomal O-MISC I-GENE-MISC
size O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
lysosomal O-MISC I-ACTI-MISC
leakage O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
CAA B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
cysteine B-CHED-MISC I-DISO-MISC
protease O-MISC I-LIVB-MISC
activities O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
thiols B-CHED-MISC O-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
reproduced O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cell O-MISC I-GENE-MISC
lysate O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Acidification O-MISC O-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
slowed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reaction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CAA B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
thiol B-CHED-MISC O-MISC
donors O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
attenuate O-MISC B-ACTI-MISC
effects O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CAA B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
markers O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
thiol B-CHED-MISC O-MISC
depletion O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
cysteine B-CHED-MISC O-MISC
protease O-MISC B-DISO-MISC
inhibition O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
living O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
CAA B-CHED-MISC O-MISC
directly O-MISC B-ACTI-MISC
reacts O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
cellular O-MISC O-MISC
protein O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
thiols B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
mediating O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
hRPTEC O-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
acidification O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
urinary O-MISC B-CONC-MISC
acidification O-MISC I-CONC-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
option O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
IFO B-CHED-MISC I-ACTI-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Stereological O-MISC B-CHED-MISC
methods O-MISC I-CHED-MISC
reveal O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
robust O-MISC B-CHED-MISC
size O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
stability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ectopic O-MISC B-CHED-MISC
hilar O-MISC I-GENE-MISC
granule O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
after O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Following O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
dentate O-MISC I-GENE-MISC
granule O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
neurogenesis O-MISC I-DISO-MISC
increases O-MISC B-CHED-MISC
greatly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
ectopically O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hilar O-MISC I-GENE-MISC
region O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
formation O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ectopic O-MISC B-CHED-MISC
hilar O-MISC I-GENE-MISC
granule O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
could O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
ultimately O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
has O-MISC B-ACTI-MISC
never O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
quantified O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
so O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
unclear O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
substantial O-MISC B-CHED-MISC
enough O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
strong O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
epileptogenesis O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
quantify O-MISC B-CHED-MISC
this O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ectopic O-MISC B-CHED-MISC
hilar O-MISC I-GENE-MISC
granule O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
estimated O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
unbiased O-MISC B-CONC-MISC
stereology O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hilar O-MISC I-GENE-MISC
neurons O-MISC I-GENE-MISC
immunoreactive O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
Prox O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
granule O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-DISO-MISC
marker O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
optical O-MISC B-CONC-MISC
fractionator O-MISC I-CONC-MISC
method O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
size O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hilar O-MISC I-GENE-MISC
ectopic O-MISC B-CHED-MISC
granule O-MISC B-GEOG-MISC
cell O-MISC I-GENE-MISC
population O-MISC B-GEOG-MISC
after O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
substantial O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
stable O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Interestingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
size O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
population O-MISC I-CHED-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
behavioral O-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
ectopic O-MISC B-CHED-MISC
granule O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hilus O-MISC I-GENE-MISC
have O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
behavioral O-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hilar O-MISC I-GENE-MISC
ectopic O-MISC B-CHED-MISC
granule O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
population O-MISC B-GEOG-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
vary O-MISC B-ACTI-MISC
systematically O-MISC B-CHED-MISC
across O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
septotemporal O-MISC I-GENE-MISC
axis O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
volume O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hilus O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
provide O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
insight O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ectopic O-MISC B-CHED-MISC
hilar O-MISC I-GENE-MISC
granule O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
temporal B-DISO-MISC I-ACTI-MISC
lobe I-DISO-MISC B-ANAT-MISC
epilepsy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
label O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
galantamine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
autistic B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Post O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
mortem O-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
abnormalities O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cholinergic O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
autism B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
galantamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acetylcholinesterase O-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
nicotinic O-MISC O-MISC
receptor O-MISC B-DISO-MISC
modulator O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
interfering O-MISC B-ACTI-MISC
behaviors O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
autism B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Thirteen O-MISC B-ACTI-MISC
medication O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
free O-MISC B-CHED-MISC
children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
autism B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
participated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
label O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
galantamine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
rated O-MISC B-ACTI-MISC
monthly O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
parents O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Aberrant O-MISC B-CHED-MISC
Behavior O-MISC I-CHED-MISC
Checklist O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
ABC O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Conners O-MISC B-CHED-MISC
' O-MISC I-CHED-MISC
Parent O-MISC I-CHED-MISC
Rating O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
Revised O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
physician O-MISC I-ANAT-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Children O-MISC B-CHED-MISC
' O-MISC I-CHED-MISC
s O-MISC I-CHED-MISC
Psychiatric O-MISC I-CHED-MISC
Rating O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Clinical O-MISC B-CHED-MISC
Global O-MISC I-CHED-MISC
Impressions O-MISC I-CHED-MISC
scale O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
Patients O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
reduction O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
parent O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
rated O-MISC B-ACTI-MISC
irritability B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
social O-MISC I-ACTI-MISC
withdrawal O-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ABC O-MISC B-OBJC-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
improvements O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
emotional O-MISC I-ACTI-MISC
lability O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
inattention O-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Conners O-MISC B-CHED-MISC
' O-MISC I-CHED-MISC
Parent O-MISC I-CHED-MISC
Rating O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
Revised O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Similarly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
clinician O-MISC I-ANAT-MISC
ratings O-MISC B-DEVI-MISC
showed O-MISC B-ACTI-MISC
reductions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anger O-MISC B-CHED-MISC
subscale O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Children O-MISC B-CHED-MISC
' O-MISC I-CHED-MISC
s O-MISC I-CHED-MISC
Psychiatric O-MISC I-CHED-MISC
Rating O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Eight O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
rated O-MISC B-DEVI-MISC
as O-MISC B-ACTI-MISC
responders O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
scores O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Clinical O-MISC B-CHED-MISC
Global O-MISC I-CHED-MISC
Impressions O-MISC I-CHED-MISC
scale O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Overall O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
galantamine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
apart O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
headaches B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
trial O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
galantamine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
appeared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
beneficial O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
interfering O-MISC B-ACTI-MISC
behaviors O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
autism B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
aggression B-DISO-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
behavioral B-DISO-MISC I-ACTI-MISC
dyscontrol I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
inattention B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
controlled O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
are O-MISC B-ACTI-MISC
warranted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Randomized O-MISC B-CONC-MISC
comparison O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
versus O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
episode O-MISC I-CHED-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
month O-MISC B-ACTI-MISC
outcomes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
compared O-MISC B-DEVI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
month O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
outcomes O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
versus O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
episode O-MISC I-CHED-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
spectrum O-MISC I-ACTI-MISC
disorders O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHOD O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
One O-MISC B-ACTI-MISC
hundred O-MISC B-ACTI-MISC
twelve O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
; O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
= O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
[ O-MISC B-ACTI-MISC
SD O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
episode O-MISC I-CHED-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
schizophreniform B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
schizoaffective B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
randomly O-MISC B-CONC-MISC
assigned O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Response O-MISC B-CHED-MISC
rates O-MISC I-CHED-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
differ O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
responding O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
subjects O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
group O-MISC B-PHEN-MISC
( O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
ratings O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
meeting O-MISC B-ACTI-MISC
response O-MISC B-ACTI-MISC
criteria O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Negative O-MISC I-ACTI-MISC
symptom O-MISC I-ACTI-MISC
outcomes O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
measures O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
parkinsonism B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
akathisia B-DISO-MISC I-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
differ O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
medications O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Extrapyramidal B-DISO-MISC I-ACTI-MISC
symptom I-DISO-MISC B-ANAT-MISC
severity O-MISC B-CHED-MISC
scores O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Significantly O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
weight B-DISO-MISC I-ACTI-MISC
gain I-DISO-MISC B-ANAT-MISC
occurred O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
than O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
weight O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
relative O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
weight O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Body O-MISC I-DISO-MISC
mass O-MISC I-LIVB-MISC
index O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Clinical O-MISC I-ACTI-MISC
outcomes O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
equal O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
stable O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Olanzapine B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
advantage O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
motor O-MISC I-ACTI-MISC
side O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
medications O-MISC O-MISC
caused O-MISC B-ACTI-MISC
substantial O-MISC B-ACTI-MISC
rapid O-MISC B-ACTI-MISC
weight B-DISO-MISC I-ACTI-MISC
gain I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
weight B-DISO-MISC I-ACTI-MISC
gain I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
olanzapine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Early O-MISC B-ACTI-MISC
paracentral O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
field I-DISO-MISC B-ANAT-MISC
loss I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
hydroxychloroquine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
review O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
natural O-MISC B-PROC-MISC
history O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
ocular O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
systemic O-MISC I-ACTI-MISC
adverse O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
hydroxychloroquine B-CHED-MISC O-MISC
sulfate I-CHED-MISC B-DISO-MISC
who O-MISC B-ACTI-MISC
attended O-MISC B-CHED-MISC
an O-MISC B-ACTI-MISC
ophthalmic O-MISC B-CONC-MISC
screening O-MISC I-CONC-MISC
program O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Retrospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Records O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
262 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
hydroxychloroquine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
screened O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Department O-MISC B-PHYS-MISC
of O-MISC I-PHYS-MISC
Ophthalmology O-MISC I-PHYS-MISC
were O-MISC B-ACTI-MISC
reviewed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
262 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
stopped O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
experienced O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Systemic O-MISC I-ACTI-MISC
adverse O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ocular O-MISC I-GENE-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Thirty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
field I-DISO-MISC B-ANAT-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
attributed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hydroxychloroquine B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
and O-MISC B-ANAT-MISC
liver O-MISC B-CONC-MISC
function O-MISC B-ANAT-MISC
test O-MISC B-ANAT-MISC
results O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
used O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
protocol O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
visual O-MISC I-DISO-MISC
acuity O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
color O-MISC I-DISO-MISC
vision O-MISC I-CONC-MISC
assessment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
funduscopy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Humphrey O-MISC B-CONC-MISC
10 O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
2 O-MISC I-CONC-MISC
visual O-MISC I-CONC-MISC
field O-MISC I-CONC-MISC
testing O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
shows O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
visual B-DISO-MISC B-CHED-MISC
field I-DISO-MISC I-CHED-MISC
defects I-DISO-MISC B-CHED-MISC
appeared O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
corresponding O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
clinical O-MISC B-CHED-MISC
parameters O-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
defects O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
reproducible O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
test O-MISC B-CHED-MISC
parameters O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
reliable O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
hydroxychloroquine B-CHED-MISC O-MISC
can O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
reaction O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
retina O-MISC I-GENE-MISC
despite O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Screening O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
Humphrey O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
visual O-MISC B-CONC-MISC
field O-MISC I-CONC-MISC
assessment O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
recommended O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
yearly O-MISC B-CHED-MISC
thereafter O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Peri O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
operative O-MISC I-CHED-MISC
atrioventricular B-DISO-MISC I-ACTI-MISC
block I-DISO-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
epirubicin B-CHED-MISC I-CONC-MISC
and O-MISC I-CONC-MISC
paclitaxel B-CHED-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
mastectomy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
immediate O-MISC B-CHED-MISC
latissimus O-MISC I-GENE-MISC
dorsi O-MISC B-GEOG-MISC
flap O-MISC B-CONC-MISC
reconstruction O-MISC I-CONC-MISC
having O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
carcinoma B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
the I-DISO-MISC B-ANAT-MISC
breast I-DISO-MISC B-ANAT-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
previously O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
preceding O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
she O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
neo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
adjuvant O-MISC I-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
epirubicin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
Taxol B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
apparently O-MISC B-ACTI-MISC
uncomplicated O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
maintained O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
remarkably O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
physical O-MISC B-DEVI-MISC
activity O-MISC I-DEVI-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
bradycardic B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
operative O-MISC I-CHED-MISC
assessment O-MISC B-CONC-MISC
but O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Second O-MISC I-ACTI-MISC
degree O-MISC B-ANAT-MISC
Mobitz O-MISC B-ANAT-MISC
type O-MISC B-ANAT-MISC
II O-MISC B-ANAT-MISC
atrioventricular B-DISO-MISC B-ANAT-MISC
block I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
electrocardiogram O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
temporary O-MISC B-CHED-MISC
transvenous O-MISC B-CONC-MISC
ventricular O-MISC I-CONC-MISC
pacing O-MISC I-CONC-MISC
instituted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
peri O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
operative O-MISC I-CHED-MISC
period O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
discuss O-MISC B-ACTI-MISC
how O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
based O-MISC I-CHED-MISC
guidelines O-MISC B-CHED-MISC
would O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
helpful O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
how O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
can O-MISC B-ACTI-MISC
exhibit O-MISC B-ACTI-MISC
substantial O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
should O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
operative O-MISC I-CHED-MISC
electrocardiogram O-MISC I-ACTI-MISC
even O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
asymptomatic O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Risks O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
benefits O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
COX B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
inhibitors I-CHED-MISC B-DISO-MISC
vs O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
: O-MISC B-ACTI-MISC
does O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
cardiovascular O-MISC I-ACTI-MISC
risk O-MISC B-ANAT-MISC
exceed O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
gastrointestinal O-MISC B-CHED-MISC
benefit O-MISC B-CHED-MISC
? O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
cohort O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
myocardial I-DISO-MISC B-ANAT-MISC
infarction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AMI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
COX B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
inhibitors I-CHED-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
offset O-MISC B-CHED-MISC
their O-MISC B-ACTI-MISC
gastrointestinal O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
GI O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
benefit O-MISC B-CHED-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
NS O-MISC O-MISC
) O-MISC B-ACTI-MISC
non B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
steroidal I-CHED-MISC B-DISO-MISC
anti I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
inflammatory I-CHED-MISC B-DISO-MISC
drugs I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
compare O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risks O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hospitalization O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
AMI B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
GI B-DISO-MISC I-ACTI-MISC
bleeding I-DISO-MISC I-ACTI-MISC
among O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
using O-MISC B-ACTI-MISC
COX B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
inhibitors I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
NS O-MISC O-MISC
- O-MISC B-DISO-MISC
NSAIDs O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
cohort O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
using O-MISC B-ACTI-MISC
administrative O-MISC B-CHED-MISC
data O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
age O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
filled O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prescription O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
NSAID O-MISC O-MISC
or O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
during O-MISC B-ACTI-MISC
1999 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2002 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Outcomes O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
using O-MISC B-ACTI-MISC
Cox O-MISC B-CHED-MISC
regression O-MISC I-CHED-MISC
models O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-ACTI-MISC
exposures O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Person O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
years O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
exposure O-MISC I-CHED-MISC
among O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
users O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
761 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
671 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
rofecoxib B-CHED-MISC O-MISC
65 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
860 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
celecoxib B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
495 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
NS O-MISC O-MISC
- O-MISC B-DISO-MISC
NSAIDs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
users O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
671 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
rofecoxib B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
875 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
celecoxib B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
832 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
NS O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
and O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
048 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
users O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adjusted O-MISC B-ACTI-MISC
hazard O-MISC B-CHED-MISC
ratios O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hospitalization O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
AMI B-DISO-MISC O-MISC
/ O-MISC B-ACTI-MISC
GI O-MISC B-CHED-MISC
vs O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
aspirin B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
rofecoxib B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
celecoxib B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
93 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
83 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
naproxen B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
93 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
diclofenac B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
99 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
74 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
users O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
rofecoxib B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
73 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
celecoxib B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
diclofenac B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
69 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
naproxen B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
35 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
97 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
88 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Among O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
users O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
naproxen B-CHED-MISC O-MISC
seemed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
carry O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
highest O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
AMI B-DISO-MISC O-MISC
/ O-MISC B-ACTI-MISC
GI B-DISO-MISC O-MISC
bleeding I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
AMI B-DISO-MISC O-MISC
/ O-MISC B-ACTI-MISC
GI O-MISC O-MISC
toxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
celecoxib B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
seemed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
better O-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
rofecoxib B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
NS O-MISC O-MISC
- O-MISC B-DISO-MISC
NSAIDs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
celecoxib B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
naproxen B-CHED-MISC O-MISC
seemed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
least O-MISC B-CHED-MISC
toxic O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Quinine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
severe B-DISO-MISC B-CHED-MISC
malaria I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
reported O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
severe B-DISO-MISC B-CHED-MISC
malaria I-DISO-MISC I-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
jaundice B-DISO-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
presented O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
premature B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
contraction I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
getting O-MISC B-ACTI-MISC
quinine B-CHED-MISC B-CONC-MISC
infusion O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
reported O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
old O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC I-CONC-MISC
hospital O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
high O-MISC I-ACTI-MISC
fever B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
chill B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
jaundice B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
fully O-MISC B-ACTI-MISC
conscious O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
120 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
pulse O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
100 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
minute O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
regular O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
laboratory O-MISC B-CONC-MISC
examination O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
Plasmodium O-MISC I-ANAT-MISC
falciparum O-MISC I-PHEN-MISC
( O-MISC I-OCCU-MISC
+ O-MISC I-OCCU-MISC
+ O-MISC I-OCCU-MISC
+ O-MISC I-OCCU-MISC
+ O-MISC I-OCCU-MISC
) O-MISC I-OCCU-MISC
, O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
bilirubin B-CHED-MISC O-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
conjugated O-MISC B-CHED-MISC
bilirubin B-CHED-MISC O-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
unconjugated O-MISC B-CHED-MISC
bilirubin B-CHED-MISC O-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
89 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
potassium B-CHED-MISC O-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
meq O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
Patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
severe B-DISO-MISC B-ACTI-MISC
malaria I-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
jaundice B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
got O-MISC B-CONC-MISC
quinine B-CHED-MISC I-CONC-MISC
infusion O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
dextrose B-CHED-MISC O-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
hour O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
day O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
vomitus B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
diarrhea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
tinnitus B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
loss B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
hearing I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
quinine B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
felt O-MISC B-ACTI-MISC
palpitation B-DISO-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
electrocardiography O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
ECG O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
recording O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
premature B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
contraction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PVC B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
minute O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
trigemini O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
constant O-MISC I-ACTI-MISC
type O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
sinoatrial B-DISO-MISC B-ANAT-MISC
block I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
U O-MISC B-ANAT-MISC
wave O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
lidocaine B-CHED-MISC O-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
intravenously O-MISC B-CHED-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
1500 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
dextrose B-CHED-MISC O-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hour O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
potassium B-CHED-MISC O-MISC
aspartate I-CHED-MISC B-DISO-MISC
tablet O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Quinine B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
changed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
sulfate O-MISC O-MISC
quinine B-CHED-MISC B-DISO-MISC
tablets O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
felt O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PVC B-DISO-MISC O-MISC
reduced O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
minute O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
ECG O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
potassium B-CHED-MISC B-CONC-MISC
level O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
meq O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
discharged O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
7th O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
good O-MISC B-ACTI-MISC
condition O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Quinine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
quinidine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
chincona O-MISC O-MISC
alkaloid O-MISC O-MISC
that O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
anti O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
arrhythmic B-DISO-MISC B-ANAT-MISC
property O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
pro O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
arrhythmic B-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
arrhythmias B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
multiple O-MISC I-ACTI-MISC
PVC B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
parenteral O-MISC O-MISC
quinine B-CHED-MISC B-DISO-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
done O-MISC B-ACTI-MISC
carefully O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
good O-MISC B-ACTI-MISC
observation O-MISC B-CHED-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
pro O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
arrhythmic B-DISO-MISC I-CHED-MISC
effect O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
electrolyte B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
hypokalemia B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
occurs O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
diarrhea B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
malaria B-DISO-MISC I-ACTI-MISC
cases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Penicillamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
lichenoid B-DISO-MISC I-ACTI-MISC
dermatitis I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
utility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
zinc B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
presentation O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
SPECT O-MISC B-CONC-MISC
abnormalities O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Wilson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal O-MISC I-ACTI-MISC
recessive O-MISC B-ANAT-MISC
disorder O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
copper B-CHED-MISC I-DISO-MISC
metabolism O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
consequent O-MISC B-ACTI-MISC
copper B-CHED-MISC O-MISC
accumulation O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
tissues O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
consequent O-MISC B-ACTI-MISC
hepatic B-DISO-MISC I-ACTI-MISC
, I-DISO-MISC B-ACTI-MISC
neurologic I-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
psychiatric I-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
presenting O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
levels O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
state O-MISC I-ACTI-MISC
anxiety B-DISO-MISC B-ANAT-MISC
without O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
99mTc O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
ECD O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
SPECT O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
cortical O-MISC I-ACTI-MISC
hypoperfusion O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
frontal O-MISC I-GENE-MISC
lobes O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
frontal O-MISC B-GEOG-MISC
lobe O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
penicillamine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
interrupted O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lichenoid B-DISO-MISC I-ACTI-MISC
dermatitis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
zinc B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
permitted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
continue O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
successful O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
zinc B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
represented O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
patient O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
penicillamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
appeared O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
zinc B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
allowed O-MISC B-ACTI-MISC
us O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
avoid O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
potentially O-MISC B-CHED-MISC
toxic O-MISC I-CHED-MISC
chelating O-MISC O-MISC
drugs O-MISC O-MISC
; O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
observation O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
line O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
growing O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Since O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
penicillamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
do O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
seem O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
skin B-DISO-MISC I-ACTI-MISC
lesion I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
conceivable O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
genetic O-MISC B-CHED-MISC
factor O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
drug O-MISC I-DISO-MISC
response O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
clarification O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
particular O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
differentiate O-MISC B-CHED-MISC
specific O-MISC B-CHED-MISC
therapies O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
phenotypes O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
dramatic O-MISC B-ACTI-MISC
drop B-DISO-MISC I-ACTI-MISC
in I-DISO-MISC B-ANAT-MISC
blood I-DISO-MISC B-ANAT-MISC
pressure I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
prehospital O-MISC I-GENE-MISC
GTN B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
sixties O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
awoke O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
afternoon O-MISC B-CHED-MISC
sleep O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
self O-MISC I-DISO-MISC
medicate O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
observations O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
limits O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
oxygen B-CHED-MISC B-CONC-MISC
via O-MISC I-CONC-MISC
a O-MISC I-CONC-MISC
face O-MISC I-CONC-MISC
mask O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
glyceryl B-CHED-MISC O-MISC
trinitrate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GTN B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Several O-MISC B-CHED-MISC
minutes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
GTN B-CHED-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
experienced O-MISC I-DISO-MISC
a O-MISC B-ACTI-MISC
sudden O-MISC B-CHED-MISC
drop B-DISO-MISC B-CHED-MISC
in I-DISO-MISC B-ACTI-MISC
blood I-DISO-MISC I-DISO-MISC
pressure I-DISO-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
rectified O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
atropine B-CHED-MISC O-MISC
sulphate I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fluid O-MISC B-CONC-MISC
challenge O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
deterioration O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
condition O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
transport O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
hospital O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
case O-MISC B-CHED-MISC
like O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prehospital O-MISC I-GENE-MISC
scientific O-MISC B-CHED-MISC
literature O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Bezold O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
Jarish O-MISC B-ANAT-MISC
reflex O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
stimulation O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ventricular O-MISC I-GENE-MISC
walls O-MISC B-GEOG-MISC
which O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
turn O-MISC B-ACTI-MISC
decreases O-MISC B-CHED-MISC
sympathetic O-MISC I-DISO-MISC
outflow O-MISC I-LIVB-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vasomotor O-MISC I-GENE-MISC
centre O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Prehospital O-MISC I-ANAT-MISC
care O-MISC I-PHEN-MISC
providers O-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
managing O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
syncopal B-DISO-MISC B-CHED-MISC
episode I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
fails O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
recover O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reasonable O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
frame O-MISC I-CHED-MISC
should O-MISC B-ACTI-MISC
consider O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Bezold O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
Jarisch O-MISC I-CHED-MISC
reflex O-MISC I-CHED-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
manage O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
accordingly O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC I-ACTI-MISC
lesion O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
rostral O-MISC I-GENE-MISC
ventrolateral O-MISC B-GEOG-MISC
medulla O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
spontaneously O-MISC I-ANAT-MISC
hypertensive B-DISO-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
selective O-MISC B-ACTI-MISC
neuronal O-MISC I-GENE-MISC
lesion O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
rostral O-MISC I-GENE-MISC
ventrolateral O-MISC B-GEOG-MISC
medulla O-MISC B-GEOG-MISC
on O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
neurogenic O-MISC I-DISO-MISC
tone O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
conscious O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
unrestrained O-MISC B-ACTI-MISC
spontaneously O-MISC I-ANAT-MISC
hypertensive B-DISO-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
lesions O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
placed O-MISC B-ACTI-MISC
via O-MISC B-ACTI-MISC
bilateral O-MISC B-CONC-MISC
microinjections O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
nmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
nl O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
methyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
D I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
aspartic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
restimulation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
area O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
methyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
D I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
aspartic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
15 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
postlesion O-MISC B-CONC-MISC
failed O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
response O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
postlesion O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
resting O-MISC I-ACTI-MISC
mean O-MISC B-ANAT-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
lesioned O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
173 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Fifteen O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
later O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lesioned O-MISC I-ACTI-MISC
group O-MISC B-CHED-MISC
still O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
values O-MISC B-CHED-MISC
significantly O-MISC B-CHED-MISC
lower O-MISC I-CHED-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
group O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
167 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

No O-MISC I-ACTI-MISC
significant O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
differences O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
lesioned O-MISC I-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ganglionic O-MISC O-MISC
blocker O-MISC B-DISO-MISC
trimethaphan B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
reductions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
lesioned O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
trimethaphan B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
accompanied O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
lesioned O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
beats O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
minute O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
beats O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
minute O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
postlesion O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
rostral O-MISC B-CHED-MISC
ventrolateral O-MISC I-GENE-MISC
medulla O-MISC B-GEOG-MISC
neurons O-MISC I-GENE-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
play O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
role O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
maintaining O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
conscious O-MISC I-DISO-MISC
spontaneously O-MISC I-ANAT-MISC
hypertensive B-DISO-MISC I-ACTI-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Spinal O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
suprabulbar O-MISC I-GENE-MISC
structures O-MISC B-GEOG-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gradual O-MISC B-ACTI-MISC
recovery O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lesioned O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Acute B-DISO-MISC I-ACTI-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
vasospasm I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
multiagent O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
including O-MISC B-ACTI-MISC
PEG B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
asparaginase I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
intrathecal O-MISC B-CHED-MISC
cytarabine B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
lymphoblastic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC I-ANAT-MISC
girl O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unusual O-MISC B-CHED-MISC
reaction O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
chemotherapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
precursor O-MISC I-GENE-MISC
B O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
acute B-DISO-MISC I-ACTI-MISC
lymphoblastic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ALL B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
evidenced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
behavioral O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
aphasia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
incontinence B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
hallucinations I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
right O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
sided O-MISC B-ANAT-MISC
weakness B-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
diffuse O-MISC I-ACTI-MISC
cerebral B-DISO-MISC B-ANAT-MISC
vasospasm I-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
angiography O-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
intrathecal O-MISC I-GENE-MISC
cytarabine B-CHED-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Vincristine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
polyethylene B-CHED-MISC O-MISC
glycol I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
asparaginase I-CHED-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
episode O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
induction O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Neurologic O-MISC B-CHED-MISC
status O-MISC B-ANAT-MISC
returned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
event O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
angiography O-MISC I-CONC-MISC
findings O-MISC B-ACTI-MISC
returned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Comparison O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
valsartan B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
hydrochlorothiazide B-CHED-MISC O-MISC
combination O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
320 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
monotherapy O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
combination O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
hypertensive B-DISO-MISC I-ACTI-MISC
adults O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
One O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
attain O-MISC B-ACTI-MISC
adequate O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
BP O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
control O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
multidrug O-MISC B-CONC-MISC
regimens O-MISC I-CONC-MISC
are O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Given O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lifelong O-MISC B-ACTI-MISC
nature O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
need O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
tolerability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
anti O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
hypertensive B-DISO-MISC I-CONC-MISC
therapies O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
investigated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
tolerability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
valsartan B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
VAL B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
hydrochlorothiazide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
monotherapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
combinations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
essential B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
multicenter O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
controlled O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
parallel O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
group O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
essential B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
mean O-MISC I-DISO-MISC
sitting O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
BP O-MISC I-LIVB-MISC
[ O-MISC B-ACTI-MISC
MSDBP O-MISC B-CHED-MISC
] O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
110 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
randomized O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
VAL B-CHED-MISC B-CONC-MISC
160 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
320 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
VAL B-CHED-MISC B-CONC-MISC
/ O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
160 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
320 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
320 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
. O-MISC B-ACTI-MISC

Mean O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
MSDBP O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
sitting O-MISC B-ANAT-MISC
systolic O-MISC B-ANAT-MISC
BP O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MSSBP O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
core O-MISC B-CHED-MISC
study O-MISC I-CONC-MISC
end O-MISC B-CHED-MISC
point O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

VAL B-CHED-MISC O-MISC
/ O-MISC B-DISO-MISC
HCTZ B-CHED-MISC B-DISO-MISC
320 O-MISC B-DISO-MISC
/ O-MISC B-DISO-MISC
12 O-MISC O-MISC
. O-MISC B-DISO-MISC
5 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
320 O-MISC O-MISC
/ O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
label O-MISC I-CONC-MISC
extension O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Response O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
MSDBP O-MISC B-CHED-MISC
< O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Control O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
MSDBP O-MISC B-CHED-MISC
< O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC O-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Tolerability O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
monitoring O-MISC B-CONC-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
randomization O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
visits O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
regular O-MISC B-ACTI-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
hematology O-MISC B-PROC-MISC
and O-MISC B-ACTI-MISC
blood O-MISC B-CONC-MISC
chemistry O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
1346 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
core O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
734 O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
612 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
924 O-MISC B-ACTI-MISC
white O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
291 O-MISC B-ACTI-MISC
black O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
Asian O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
108 O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
weight O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
92 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
active O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
significantly O-MISC B-CHED-MISC
reduced O-MISC I-CHED-MISC
MSSBP O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
MSDBP O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
core O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
monotherapy O-MISC B-CONC-MISC
significantly O-MISC B-ACTI-MISC
contributing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
VAL B-CHED-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Each O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
reductions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
MSSBP O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
MSDBP O-MISC B-CHED-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
monotherapies O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
MSSBP O-MISC B-CHED-MISC
/ O-MISC I-CHED-MISC
MSDBP O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
VAL B-CHED-MISC O-MISC
/ O-MISC B-DISO-MISC
HCTZ B-CHED-MISC O-MISC
320 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
MSSBP O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
VAL B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
320 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
VAL B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
160 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
002 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Rates O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
BP O-MISC I-DISO-MISC
control O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
combination O-MISC B-CONC-MISC
treatment O-MISC B-CONC-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
monotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypokalemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
VAL B-CHED-MISC B-CONC-MISC
/ O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
combinations O-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
monotherapies O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
core O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mild O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
severity O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
tolerability O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
VAL B-CHED-MISC B-CONC-MISC
/ O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
combinations O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
maintained O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
extension O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
797 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
therapies O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
VAL B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
significantly O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
BP O-MISC I-DISO-MISC
reductions O-MISC B-CONC-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
monotherapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
less O-MISC B-ACTI-MISC
hypokalemia B-DISO-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
HCTZ B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Succimer B-CHED-MISC O-MISC
chelation O-MISC B-DISO-MISC
improves O-MISC I-ACTI-MISC
learning O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
attention O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
arousal O-MISC I-DISO-MISC
regulation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
lead B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
exposed O-MISC B-ANAT-MISC
rats O-MISC I-PHEN-MISC
but O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
lasting O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lead B-CHED-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
There O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
growing O-MISC B-ACTI-MISC
pressure O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
clinicians O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
prescribe O-MISC B-CONC-MISC
chelation O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
slightly O-MISC B-ACTI-MISC
elevated O-MISC I-ACTI-MISC
blood O-MISC B-ANAT-MISC
lead B-CHED-MISC B-ANAT-MISC
levels O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
have O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
chelation O-MISC B-CONC-MISC
improves O-MISC B-ACTI-MISC
cognitive O-MISC B-CHED-MISC
outcomes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
children O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
agents O-MISC O-MISC
have O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
brain O-MISC I-DISO-MISC
development O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
designed O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
answer O-MISC B-CHED-MISC
these O-MISC B-ACTI-MISC
questions O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rodent O-MISC I-ACTI-MISC
model O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
childhood O-MISC I-CHED-MISC
Pb B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
succimer B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
chelating O-MISC O-MISC
agent O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
Pb B-DISO-MISC O-MISC
poisoning I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
produced O-MISC B-ACTI-MISC
lasting O-MISC B-ACTI-MISC
impairments B-DISO-MISC B-CHED-MISC
in I-DISO-MISC B-ACTI-MISC
learning I-DISO-MISC I-DISO-MISC
, I-DISO-MISC B-ACTI-MISC
attention I-DISO-MISC I-DISO-MISC
, I-DISO-MISC B-ACTI-MISC
inhibitory I-DISO-MISC B-DEVI-MISC
control I-DISO-MISC I-LIVB-MISC
, I-DISO-MISC B-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
arousal I-DISO-MISC I-DISO-MISC
regulation I-DISO-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
paralleling O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
areas O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
dysfunction O-MISC B-CHED-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
children O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Succimer B-CHED-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
significantly O-MISC B-ACTI-MISC
improved O-MISC B-ACTI-MISC
learning O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
attention O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
arousal O-MISC I-DISO-MISC
regulation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
varied O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
function O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
level O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
deficit O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
succimer B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
not O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
Pb B-CHED-MISC O-MISC
produced O-MISC B-ACTI-MISC
lasting O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
pervasive O-MISC B-CHED-MISC
cognitive B-DISO-MISC B-CHED-MISC
and I-DISO-MISC B-ACTI-MISC
affective I-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
comparable O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
magnitude O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
regimen O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
These O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
chelating O-MISC O-MISC
agent O-MISC B-DISO-MISC
can O-MISC B-ACTI-MISC
alleviate O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
succimer B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
protocol O-MISC I-CONC-MISC
that O-MISC B-ACTI-MISC
improves O-MISC B-ACTI-MISC
cognitive O-MISC B-CHED-MISC
outcomes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC I-ANAT-MISC
children O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
succimer B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
strongly O-MISC I-ACTI-MISC
discouraged O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
do O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
tissue O-MISC I-GENE-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Pb B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
heavy O-MISC O-MISC
metals O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Caffeine B-CHED-MISC B-CONC-MISC
challenge O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
attacks I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
aim O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
observe O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
major B-DISO-MISC I-ACTI-MISC
depression I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
attacks I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MDP B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
Diagnostic O-MISC B-CHED-MISC
and O-MISC I-CHED-MISC
Statistical O-MISC I-CHED-MISC
Manual O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
Mental B-DISO-MISC I-CHED-MISC
Disorders I-DISO-MISC I-CHED-MISC
, O-MISC I-CHED-MISC
Fourth O-MISC I-CHED-MISC
Edition O-MISC I-CHED-MISC
criteria O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
respond O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
similar O-MISC B-CHED-MISC
way O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
attacks I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
caffeine B-CHED-MISC I-CONC-MISC
challenge O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
selected O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
MDP B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
major B-DISO-MISC B-CHED-MISC
depression I-DISO-MISC I-ACTI-MISC
without O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
attacks I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
volunteers O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
psychotropic O-MISC O-MISC
drug O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
double O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
experiment O-MISC I-CONC-MISC
performed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
occasions O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
apart O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
480 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
free O-MISC B-DISO-MISC
( O-MISC B-PHEN-MISC
placebo O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
solution O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
coffee O-MISC O-MISC
form O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
anxiety B-DISO-MISC B-CHED-MISC
scales O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
applied O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
test O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
MDP B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
MD B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
attack I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
480 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
caffeine B-CHED-MISC B-CONC-MISC
challenge O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
chi O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
MDP B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
than O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
MD B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
volunteers O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

No O-MISC I-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
attack I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
free O-MISC B-DISO-MISC
solution O-MISC B-GENE-MISC
intake O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
MD B-DISO-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
response O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
test O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
way O-MISC I-CHED-MISC
analysis O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
variance O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
interaction O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
Greenhouse O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
Geisser O-MISC I-CHED-MISC
correction O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
F O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
762 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
026 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
attacks I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
matter O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
PD B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
MDP B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
hyperreactivity O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
caffeine B-CHED-MISC I-CONC-MISC
challenge O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Mitral O-MISC B-CONC-MISC
annuloplasty O-MISC I-CONC-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
ventricular O-MISC B-CONC-MISC
restoration O-MISC I-CONC-MISC
method O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
failing B-DISO-MISC I-ACTI-MISC
left I-DISO-MISC B-ANAT-MISC
ventricle I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pilot O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
AIM O-MISC B-ACTI-MISC
OF O-MISC B-ACTI-MISC
THE O-MISC B-ACTI-MISC
STUDY O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Undersized O-MISC B-CONC-MISC
mitral O-MISC I-CONC-MISC
annuloplasty O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
MAP O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
dilated B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
functional O-MISC I-ACTI-MISC
mitral B-DISO-MISC B-ANAT-MISC
regurgitation I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MR B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
since O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
addressing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MR B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MAP O-MISC B-CONC-MISC
may O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
reshape O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dilated O-MISC I-ACTI-MISC
left O-MISC I-GENE-MISC
ventricular O-MISC B-GEOG-MISC
( O-MISC B-GEOG-MISC
LV O-MISC B-GEOG-MISC
) O-MISC B-GEOG-MISC
base O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
benefits O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
reshaping O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
MR B-DISO-MISC I-DISO-MISC
remain O-MISC B-ACTI-MISC
incompletely O-MISC B-ACTI-MISC
understood O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
aim O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
benefits O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
canine O-MISC I-ANAT-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
heart B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Six O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
underwent O-MISC B-ACTI-MISC
MAP O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prosthetic O-MISC B-OBJC-MISC
band O-MISC I-OBJC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
posterior O-MISC I-GENE-MISC
mitral O-MISC B-GEOG-MISC
annulus O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
mattress O-MISC B-OBJC-MISC
sutures O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
sutures O-MISC B-OBJC-MISC
were O-MISC B-ACTI-MISC
passed O-MISC B-ACTI-MISC
individually O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
tourniquets O-MISC B-OBJC-MISC
and O-MISC B-ACTI-MISC
exteriorized O-MISC B-ACTI-MISC
untied O-MISC B-CHED-MISC
via O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
atriotomy O-MISC B-PROC-MISC
. O-MISC B-ACTI-MISC

Sonomicrometry O-MISC B-CONC-MISC
crystals O-MISC O-MISC
were O-MISC B-ACTI-MISC
implanted O-MISC B-CONC-MISC
around O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mitral O-MISC I-GENE-MISC
annulus O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
ventricle O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
measure O-MISC B-ACTI-MISC
geometry O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
regional O-MISC B-CHED-MISC
function O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC I-ACTI-MISC
heart B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
volume O-MISC B-CHED-MISC
loading O-MISC B-DEVI-MISC
after O-MISC B-ACTI-MISC
weaning O-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
cardiopulmonary O-MISC B-CONC-MISC
bypass O-MISC I-CONC-MISC
; O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MR B-DISO-MISC B-OCCU-MISC
was O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
echocardiography O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

MAP O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
accomplished O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
cinching O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
tourniquets O-MISC B-OBJC-MISC
. O-MISC B-ACTI-MISC

Data O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
acquired O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
heart B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
MAP O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
MAP O-MISC I-ACTI-MISC
decreased O-MISC B-CHED-MISC
mitral O-MISC I-GENE-MISC
annular O-MISC B-CHED-MISC
dimensions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
commissure O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
commissure O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
septal O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
lateral O-MISC I-CHED-MISC
directions O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Concomitantly O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
diameter O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LV O-MISC I-GENE-MISC
base O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
sphericity O-MISC I-LIVB-MISC
decreased O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
063 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
67 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
016 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Decreases O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
evident O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
end O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0480 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Tau O-MISC O-MISC
( O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
ms O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
fractional O-MISC I-ACTI-MISC
shortening O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LV O-MISC I-GENE-MISC
base O-MISC B-GEOG-MISC
increased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
045 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
MAP O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Emax O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
acquired O-MISC B-ACTI-MISC
suggest O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
MAP O-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
benefits O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
LV O-MISC B-CHED-MISC
dimension O-MISC I-CHED-MISC
/ O-MISC B-ACTI-MISC
function O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
heart B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MR B-DISO-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
investigations O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
warranted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
heart B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Piperacillin B-CHED-MISC O-MISC
/ I-CHED-MISC B-DISO-MISC
tazobactam I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
rapidly O-MISC B-CHED-MISC
reversed O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
high O-MISC B-CONC-MISC
flux O-MISC I-CONC-MISC
hemodialysis O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
peritoneal O-MISC I-GENE-MISC
dialysis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Despite O-MISC B-ACTI-MISC
popular O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
piperacillin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dire O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
piperacillin B-CHED-MISC O-MISC
still O-MISC B-ACTI-MISC
goes O-MISC B-ACTI-MISC
unrecognized O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
delay O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
appropriate O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
end B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
stage I-DISO-MISC B-ANAT-MISC
renal I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
receiving O-MISC B-ACTI-MISC
continuous O-MISC B-CONC-MISC
ambulatory O-MISC I-CONC-MISC
peritoneal O-MISC I-CONC-MISC
dialysis O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
CAPD O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
slurred O-MISC I-ACTI-MISC
speech O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
tremor B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
bizarre O-MISC I-ACTI-MISC
behavior O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
mental O-MISC I-ACTI-MISC
confusion B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
episodes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
generalized O-MISC B-CHED-MISC
tonic B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
clonic I-DISO-MISC B-ANAT-MISC
seizure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
GTCS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
piperacillin B-CHED-MISC O-MISC
/ I-CHED-MISC B-DISO-MISC
tazobactam I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
bronchiectasis B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
secondary B-DISO-MISC I-ACTI-MISC
infection I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
laboratory O-MISC B-CHED-MISC
data O-MISC I-CHED-MISC
revealed O-MISC B-CHED-MISC
normal O-MISC B-ACTI-MISC
plasma O-MISC O-MISC
electrolyte O-MISC O-MISC
and O-MISC B-ACTI-MISC
ammonia B-CHED-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
but O-MISC B-ACTI-MISC
leukocytosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Neurologic O-MISC B-CONC-MISC
examinations O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
dysarthria B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
bilateral O-MISC B-CHED-MISC
Babinski O-MISC I-ACTI-MISC
sign O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Computed O-MISC B-CONC-MISC
tomography O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
electroencephalogram O-MISC B-OCCU-MISC
were O-MISC B-ACTI-MISC
unremarkable O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Despite O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
antiepileptic O-MISC O-MISC
agents O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
GTCS B-DISO-MISC O-MISC
episode O-MISC B-ACTI-MISC
recurred O-MISC B-OCCU-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sixth O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
piperacillin B-CHED-MISC O-MISC
/ I-CHED-MISC B-DISO-MISC
tazobactam I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Brain O-MISC I-GENE-MISC
magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
infarction B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
organic B-DISO-MISC B-CHED-MISC
brain I-DISO-MISC I-ACTI-MISC
lesions I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
flux O-MISC I-CONC-MISC
hemodialysis O-MISC I-CONC-MISC
rapidly O-MISC B-ACTI-MISC
reversed O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
neurologic O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
within O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Piperacillin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
uremic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
unexplained O-MISC B-ACTI-MISC
neurological O-MISC I-ACTI-MISC
manifestations O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CAPD O-MISC O-MISC
is O-MISC B-ACTI-MISC
inefficient O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
removing O-MISC B-CONC-MISC
piperacillin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
hemodialysis O-MISC B-CONC-MISC
can O-MISC B-ACTI-MISC
rapidly O-MISC B-ACTI-MISC
terminate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
piperacillin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Frequency O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
transient O-MISC B-CHED-MISC
ipsilateral O-MISC B-CHED-MISC
vocal B-DISO-MISC I-ACTI-MISC
cord I-DISO-MISC B-ANAT-MISC
paralysis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
carotid O-MISC B-CONC-MISC
endarterectomy O-MISC I-CONC-MISC
under O-MISC B-ACTI-MISC
local O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Especially O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
improvements O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
neurologic O-MISC B-CONC-MISC
monitoring O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
carotid O-MISC I-GENE-MISC
endarterectomy O-MISC B-CONC-MISC
done O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
local O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
has O-MISC B-ACTI-MISC
become O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
technique O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
choice O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
centers O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

Temporary O-MISC B-CHED-MISC
ipsilateral O-MISC B-CHED-MISC
vocal B-DISO-MISC I-ACTI-MISC
nerve I-DISO-MISC B-ANAT-MISC
palsies I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
local O-MISC B-CONC-MISC
anesthetics O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Such O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
situations O-MISC B-ACTI-MISC
where O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
existing O-MISC I-CHED-MISC
contralateral O-MISC B-CHED-MISC
paralysis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
local O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
vocal O-MISC I-DISO-MISC
cord O-MISC B-ANAT-MISC
function O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
understand O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
consequences O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
included O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
carotid O-MISC B-CONC-MISC
endarterectomy O-MISC I-CONC-MISC
under O-MISC B-ACTI-MISC
local O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Vocal O-MISC I-DISO-MISC
cord O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
before O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
during O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-CHED-MISC
surgery O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
postoperative O-MISC B-CHED-MISC
day O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
flexible O-MISC B-CONC-MISC
laryngoscopy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Anesthesia O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
injecting O-MISC B-CHED-MISC
20 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mixture O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
long O-MISC O-MISC
- O-MISC B-DISO-MISC
acting O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ropivacaine B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
short O-MISC O-MISC
- O-MISC B-DISO-MISC
acting O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
prilocaine B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
anesthetic O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
vocal O-MISC I-DISO-MISC
cord O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
preoperatively O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Twelve O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
intraoperative O-MISC B-CHED-MISC
ipsilateral O-MISC B-CHED-MISC
vocal B-DISO-MISC I-ACTI-MISC
cord I-DISO-MISC B-ANAT-MISC
paralysis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
resolved O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
operating O-MISC B-CONC-MISC
time O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
volume O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
anesthetic O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
temporary O-MISC B-CHED-MISC
vocal B-DISO-MISC I-ACTI-MISC
cord I-DISO-MISC B-ANAT-MISC
paralysis I-DISO-MISC B-ANAT-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Local O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
temporary O-MISC B-CHED-MISC
ipsilateral O-MISC B-CHED-MISC
vocal B-DISO-MISC I-ACTI-MISC
cord I-DISO-MISC B-ANAT-MISC
paralysis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
half O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
existing O-MISC I-CHED-MISC
paralysis B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relevant O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
preoperative O-MISC B-CHED-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
vocal O-MISC I-DISO-MISC
cord O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
before O-MISC B-ACTI-MISC
carotid O-MISC B-CONC-MISC
endarterectomy O-MISC I-CONC-MISC
under O-MISC B-ACTI-MISC
local O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
avoid O-MISC B-ACTI-MISC
intraoperative O-MISC B-CHED-MISC
bilateral O-MISC B-CHED-MISC
paralysis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
preoperative O-MISC B-CHED-MISC
contralateral O-MISC B-CHED-MISC
vocal B-DISO-MISC I-ACTI-MISC
cord I-DISO-MISC B-ANAT-MISC
paralysis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
under O-MISC B-ACTI-MISC
general O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Impaired B-DISO-MISC B-CHED-MISC
fear I-DISO-MISC I-DISO-MISC
recognition I-DISO-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
regular O-MISC B-ACTI-MISC
recreational O-MISC B-DEVI-MISC
cocaine B-CHED-MISC O-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

INTRODUCTION O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
ability O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
read O-MISC B-CONC-MISC
facial O-MISC I-DISO-MISC
expressions O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
essential O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
human O-MISC I-ANAT-MISC
social O-MISC I-ACTI-MISC
interaction O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
conduct O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
investigation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
facial O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
recognition O-MISC I-LIVB-MISC
performance O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
recreational O-MISC B-DEVI-MISC
cocaine B-CHED-MISC O-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

MATERIALS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Three O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
comprised O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
naive O-MISC I-ANAT-MISC
participants O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
CN O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
occasional O-MISC B-CHED-MISC
cocaine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
OC O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
regular O-MISC B-CHED-MISC
recreational O-MISC O-MISC
cocaine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
RC O-MISC O-MISC
) O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
emotional O-MISC I-DISO-MISC
facial O-MISC I-LIVB-MISC
expression O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
EFE O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
task O-MISC B-ACTI-MISC
consisting O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
face O-MISC I-GENE-MISC
expressing O-MISC I-DISO-MISC
six O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
emotions O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
happiness O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
surprise O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
sadness O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
anger O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
fear O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
disgust O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Mean O-MISC B-CHED-MISC
percent O-MISC B-CHED-MISC
accuracy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
latencies O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
correct O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
across O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
presentations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
emotion O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
derived O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Participants O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
Eyes O-MISC B-CONC-MISC
task O-MISC I-CONC-MISC
" O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
their O-MISC B-ACTI-MISC
ability O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
recognize O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
complex O-MISC B-CHED-MISC
emotional O-MISC I-DISO-MISC
states O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Symptom O-MISC B-CHED-MISC
CheckList O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
90 O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
Revised O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
measure O-MISC B-CHED-MISC
psychopathology O-MISC B-PROC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
differences O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
psychopathology O-MISC B-PROC-MISC
or O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
eyes O-MISC B-CONC-MISC
task O-MISC I-CONC-MISC
" O-MISC B-ACTI-MISC
performance O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RC O-MISC I-ACTI-MISC
group O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
otherwise O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
illicit O-MISC I-ACTI-MISC
substance O-MISC B-ANAT-MISC
use O-MISC B-ANAT-MISC
histories O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
OC O-MISC I-ACTI-MISC
group O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
exhibited O-MISC B-ACTI-MISC
impaired B-DISO-MISC B-CHED-MISC
fear I-DISO-MISC I-DISO-MISC
recognition I-DISO-MISC I-DISO-MISC
accuracy O-MISC B-CHED-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
OC O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
CN O-MISC I-ACTI-MISC
groups O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
RC O-MISC B-CONC-MISC
group O-MISC I-ANAT-MISC
also O-MISC B-ACTI-MISC
correctly O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
anger O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
fear O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
happiness O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
surprise O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
slowly O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
CN O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
OC O-MISC I-ACTI-MISC
participants O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
OC O-MISC I-ACTI-MISC
group O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
slower O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
CN O-MISC B-CHED-MISC
when O-MISC B-ACTI-MISC
correctly O-MISC B-ACTI-MISC
identifying O-MISC B-ACTI-MISC
disgust O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
deficit B-DISO-MISC B-CHED-MISC
in I-DISO-MISC B-ACTI-MISC
fear I-DISO-MISC I-DISO-MISC
recognition I-DISO-MISC I-DISO-MISC
accuracy O-MISC B-CHED-MISC
manifested O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RC O-MISC B-CONC-MISC
group O-MISC I-ANAT-MISC
cannot O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
explained O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subacute O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
within O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
group O-MISC B-PHEN-MISC
were O-MISC B-ACTI-MISC
similarly O-MISC B-ACTI-MISC
impaired O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Possible O-MISC B-ACTI-MISC
parallels O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
RC O-MISC B-CONC-MISC
users O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
psychopaths B-DISO-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
respect O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
impaired B-DISO-MISC B-CHED-MISC
fear I-DISO-MISC I-DISO-MISC
recognition I-DISO-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
amygdala B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
etiology O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Damage B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
substantia I-DISO-MISC I-GENE-MISC
nigra I-DISO-MISC B-GEOG-MISC
pars I-DISO-MISC B-GEOG-MISC
reticulata I-DISO-MISC B-GEOG-MISC
during O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
immunohistochemical O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
astrocytes O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
protein O-MISC I-CONC-MISC
extravasation O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
substantia O-MISC I-GENE-MISC
nigra O-MISC B-GEOG-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gating O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
controlling O-MISC B-OCCU-MISC
the O-MISC B-ACTI-MISC
spread O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
epileptic B-DISO-MISC I-ACTI-MISC
seizure I-DISO-MISC B-ANAT-MISC
activity O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Additionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
models O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
prolonged B-DISO-MISC B-CHED-MISC
status I-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
the O-MISC B-ACTI-MISC
pars O-MISC I-GENE-MISC
reticulata O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
substantia O-MISC I-GENE-MISC
nigra O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
SNR O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
suffers O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
massive O-MISC B-CHED-MISC
lesion O-MISC I-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
arise O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
massive O-MISC B-CHED-MISC
metabolic B-DISO-MISC I-ACTI-MISC
derangement I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
hyperexcitation O-MISC I-DISO-MISC
developing O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activated O-MISC B-DEVI-MISC
SNR O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
systemic O-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
neuropathology O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
SNR O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
immunohistochemical O-MISC B-CONC-MISC
techniques O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
emphasis O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
course O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
astrocytes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
surviving O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
perfusion O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
fixed O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
brains O-MISC I-GENE-MISC
processed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
immunohistochemical O-MISC B-CONC-MISC
staining O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
SNR O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Nissl O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
staining O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
antibodies O-MISC O-MISC
against O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neuron O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
binding O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
parvalbumin O-MISC O-MISC
, O-MISC B-ACTI-MISC
served O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
detect O-MISC B-ACTI-MISC
neuronal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
SNR O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Antibodies O-MISC O-MISC
against O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
astroglia O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-CHED-MISC
cytoskeletal O-MISC O-MISC
protein O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
glial O-MISC O-MISC
fibrillary O-MISC B-DISO-MISC
acidic O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GFAP O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
against O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
glial O-MISC O-MISC
calcium B-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
binding O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
S O-MISC O-MISC
- O-MISC B-DISO-MISC
100 O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
status O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
astrocytes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Immunohistochemical O-MISC B-CONC-MISC
staining O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
serum O-MISC O-MISC
- O-MISC B-DISO-MISC
albumin O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
immunoglobulins O-MISC O-MISC
in O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
indicator O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
brain O-MISC B-GEOG-MISC
barrier O-MISC B-GEOG-MISC
disturbances O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
vasogenic B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
formation O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Immunohistochemical O-MISC B-CONC-MISC
staining O-MISC I-CONC-MISC
indicated O-MISC B-ACTI-MISC
loss O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
GFAP O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
staining O-MISC I-CONC-MISC
already O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
oval O-MISC B-CHED-MISC
focus O-MISC B-CHED-MISC
situated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
center O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
SNR O-MISC I-GENE-MISC
while O-MISC B-ACTI-MISC
sparing O-MISC B-ACTI-MISC
medial O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
lateral O-MISC B-CHED-MISC
aspects O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
vacuolation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
S O-MISC O-MISC
- O-MISC B-DISO-MISC
100 O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
staining O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
parvalbumin O-MISC O-MISC
- O-MISC I-CONC-MISC
staining O-MISC I-CONC-MISC
changed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
SNR O-MISC B-GEOG-MISC
indicating O-MISC B-ACTI-MISC
neuronal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Nissl O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
staining O-MISC I-CONC-MISC
visualized O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
neuronal O-MISC I-ACTI-MISC
distortion O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Staining O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
proteins O-MISC O-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patchy O-MISC B-ACTI-MISC
manner O-MISC B-ACTI-MISC
throughout O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
forebrain O-MISC I-GENE-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
vasogenic B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
covered O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lesioned B-DISO-MISC I-ACTI-MISC
SNR I-DISO-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
glial O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
neuronal O-MISC I-GENE-MISC
markers O-MISC I-DISO-MISC
indicated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
massive O-MISC I-ACTI-MISC
lesion O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
center O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
SNR O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
72 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
astrocytes O-MISC I-GENE-MISC
surrounding O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lesion O-MISC I-ACTI-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
size O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
polymorphic O-MISC B-CHED-MISC
phagocytotic O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
invaded O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
damaged O-MISC B-CHED-MISC
area O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
group O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
surviving O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
conventional O-MISC B-ACTI-MISC
paraffin O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
sections O-MISC B-GEOG-MISC
confirmed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neuronal O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
glial O-MISC I-GENE-MISC
damage B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
SNR I-DISO-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Additional O-MISC B-ACTI-MISC
pathology O-MISC B-PROC-MISC
of O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
quality O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
globus O-MISC I-ANAT-MISC
pallidus O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Since O-MISC B-ACTI-MISC
astrocytes O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
damaged O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
parallel O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
SNR O-MISC I-DISO-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
proposed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anatomical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
interrelationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
astrocytes O-MISC I-GENE-MISC
is O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
tight O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
SNR O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
cell O-MISC I-GENE-MISC
elements O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
suffer O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
disturbance O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
neurotransmitter B-DISO-MISC O-MISC
dysfunction I-DISO-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
massive O-MISC I-ACTI-MISC
status B-DISO-MISC B-ANAT-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Neuroprotective O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
melatonin B-CHED-MISC O-MISC
upon O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
offspring O-MISC I-ANAT-MISC
cerebellar O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
BCNU B-CHED-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cortical B-DISO-MISC I-ACTI-MISC
dysplasia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Cortical B-DISO-MISC I-ACTI-MISC
dysplasia I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
malformation O-MISC I-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
defects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
proliferation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
migration O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
maturation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
designed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alterations O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
offspring O-MISC I-ANAT-MISC
rat O-MISC I-ANAT-MISC
cerebellum O-MISC I-GENE-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
maternal O-MISC I-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
carmustine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
1 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
bis I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
chloroethyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
nitrosoure I-CHED-MISC B-DISO-MISC
] O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
exogenous O-MISC B-CHED-MISC
melatonin B-CHED-MISC O-MISC
upon O-MISC B-ACTI-MISC
cerebellar O-MISC I-GENE-MISC
BCNU B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cortical B-DISO-MISC I-ACTI-MISC
dysplasia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
histological O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
biochemical O-MISC B-CONC-MISC
analyses O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Pregnant O-MISC B-ACTI-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
assigned O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
- O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
melatonin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
plus O-MISC B-ACTI-MISC
melatonin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
BCNU B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
embryonic O-MISC I-GENE-MISC
day O-MISC B-CHED-MISC
15 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
melatonin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
until O-MISC B-ACTI-MISC
delivery O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Immuno O-MISC B-CONC-MISC
/ O-MISC I-CONC-MISC
histochemistry O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
electron O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
offspring O-MISC I-ANAT-MISC
cerebellum O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
malondialdehyde B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
superoxide B-CHED-MISC O-MISC
dismutase O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Histopathologically O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebella O-MISC I-GENE-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
early O-MISC B-CHED-MISC
embryonic O-MISC I-DISO-MISC
development O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
cortical B-DISO-MISC I-ACTI-MISC
dysplasia I-DISO-MISC B-ANAT-MISC
group O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
TUNEL O-MISC B-CONC-MISC
positive O-MISC I-ACTI-MISC
cells O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
nestin O-MISC I-GENE-MISC
positive O-MISC I-ACTI-MISC
cells O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
immunoreactivity O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
glial O-MISC O-MISC
fibrillary O-MISC B-DISO-MISC
acidic O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
synaptophysin O-MISC O-MISC
and O-MISC B-ACTI-MISC
transforming O-MISC O-MISC
growth O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
beta1 O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
delayed O-MISC I-DISO-MISC
maturation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
melatonin B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
reversed O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Malondialdehyde B-CHED-MISC O-MISC
level O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
melatonin B-CHED-MISC O-MISC
decreased O-MISC B-CHED-MISC
malondialdehyde B-CHED-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
BCNU B-CHED-MISC I-ACTI-MISC
group O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
significant O-MISC B-ANAT-MISC
differences O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
superoxide B-CHED-MISC O-MISC
dismutase O-MISC B-DISO-MISC
levels O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
BCNU B-CHED-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
pregnancy O-MISC I-DISO-MISC
leads O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
delayed O-MISC B-CHED-MISC
maturation O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
offspring O-MISC I-ANAT-MISC
cerebellum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
melatonin B-CHED-MISC O-MISC
protects O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebellum O-MISC I-GENE-MISC
against O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
BCNU B-CHED-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Reduced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
given O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
hydroxypropyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
methacrylamide I-CHED-MISC B-DISO-MISC
conjugates O-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
experimental O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
model O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
general O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
toxicity B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
late O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
free O-MISC B-CHED-MISC
drug O-MISC O-MISC
or O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
hydroxypropyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
methacrylamide I-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
HPMA B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
copolymer O-MISC B-DISO-MISC
conjugates O-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
HPMA B-CHED-MISC O-MISC
copolymers O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
covalently O-MISC I-DISO-MISC
bound O-MISC I-LIVB-MISC
via O-MISC B-ACTI-MISC
peptide O-MISC I-DISO-MISC
linkages O-MISC I-LIVB-MISC
that O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
biodegradable O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
Gly O-MISC O-MISC
- O-MISC B-DISO-MISC
Gly O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
degradable O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
lysosomal O-MISC O-MISC
proteinases O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Gly B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
Phe I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
Leu I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
Gly I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
biodegradable O-MISC O-MISC
conjugate O-MISC O-MISC
containing O-MISC B-ACTI-MISC
galactosamine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
residue O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
targeted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
free O-MISC O-MISC
and O-MISC B-ACTI-MISC
polymer O-MISC O-MISC
- O-MISC B-DISO-MISC
bound O-MISC B-DISO-MISC
DOX B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transient O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maximal O-MISC B-CHED-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
polymer O-MISC O-MISC
- O-MISC B-ACTI-MISC
bound O-MISC B-DEVI-MISC
DOX B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
lower O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
free O-MISC O-MISC
DOX B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mixture O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unmodified O-MISC B-CHED-MISC
parent O-MISC B-CHED-MISC
HPMA B-CHED-MISC O-MISC
copolymer O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
free O-MISC O-MISC
DOX B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Throughout O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
deaths O-MISC I-DISO-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
only O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
either O-MISC B-ACTI-MISC
free O-MISC O-MISC
DOX B-CHED-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mixture O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
HPMA B-CHED-MISC O-MISC
copolymer O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
free O-MISC O-MISC
DOX B-CHED-MISC B-DISO-MISC
; O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
histological O-MISC B-CONC-MISC
investigations O-MISC I-CONC-MISC
revealed O-MISC B-CHED-MISC
marked O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
that O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
DOX B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Sequential O-MISC B-CHED-MISC
measurements O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
surviving O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
either O-MISC B-ACTI-MISC
free O-MISC O-MISC
DOX B-CHED-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mixture O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
HPMA B-CHED-MISC O-MISC
copolymer O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
free O-MISC O-MISC
DOX B-CHED-MISC B-DISO-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
approximately O-MISC B-CHED-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
function O-MISC B-CHED-MISC
beginning O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
4th O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
approximately O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
matched O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HPMA B-CHED-MISC O-MISC
copolymer O-MISC B-DISO-MISC
conjugates O-MISC B-DISO-MISC
containing O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
exhibited O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
change O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
throughout O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
histological O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
HPMA B-CHED-MISC O-MISC
copolymer O-MISC B-DISO-MISC
conjugates O-MISC O-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
killed O-MISC B-DEVI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
end O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
beginning O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
ABSTRACT O-MISC B-ACTI-MISC
TRUNCATED O-MISC B-ACTI-MISC
AT O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
WORDS O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC

Corneal B-DISO-MISC I-ACTI-MISC
ulcers I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
aerosolized O-MISC B-GENE-MISC
crack B-CHED-MISC B-OCCU-MISC
cocaine I-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
corneal B-DISO-MISC I-ACTI-MISC
ulcers I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
drug B-DISO-MISC I-ACTI-MISC
abuse I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
ulcers B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
these O-MISC I-CONC-MISC
patients O-MISC I-CONC-MISC
are O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
reviewed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Review O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
corneal B-DISO-MISC I-ACTI-MISC
ulcers I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
drug B-DISO-MISC I-ACTI-MISC
abuse I-DISO-MISC B-ANAT-MISC
seen O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
institution O-MISC B-PHYS-MISC
from O-MISC B-ACTI-MISC
July O-MISC B-ACTI-MISC
2006 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
December O-MISC B-ACTI-MISC
2006 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
corneal B-DISO-MISC I-ACTI-MISC
ulcers I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
crack B-CHED-MISC O-MISC
cocaine I-CHED-MISC B-DISO-MISC
use O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
reviewed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
corneal B-DISO-MISC I-ACTI-MISC
ulcers I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
cultured O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC I-CONC-MISC
the O-MISC I-CONC-MISC
hospital O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
intensive O-MISC B-CONC-MISC
topical O-MISC I-CONC-MISC
antibiotic O-MISC I-CONC-MISC
treatment O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Each O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
comprehensive O-MISC B-CONC-MISC
health O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
medical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
substance B-DISO-MISC B-CONC-MISC
abuse I-DISO-MISC I-CONC-MISC
consultations O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Streptococcal O-MISC I-ANAT-MISC
organisms O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
Capnocytophaga O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
Brevibacterium O-MISC I-ANAT-MISC
casei O-MISC I-PHEN-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
infections B-DISO-MISC I-ACTI-MISC
responded O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
antibiotic O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
needed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lateral O-MISC B-CONC-MISC
tarsorrhaphy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
epithelial B-DISO-MISC I-ACTI-MISC
defects I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Aerosolized O-MISC B-OCCU-MISC
crack B-CHED-MISC I-OCCU-MISC
cocaine I-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
corneal B-DISO-MISC I-ACTI-MISC
ulcers I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Drug B-DISO-MISC I-ACTI-MISC
abuse I-DISO-MISC B-ANAT-MISC
provides O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
challenges O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Not O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
infections B-DISO-MISC I-ACTI-MISC
but O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
poor O-MISC I-ACTI-MISC
health O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
noncompliance O-MISC I-ACTI-MISC
need O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
addressed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Comprehensive O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
may O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
the O-MISC B-ACTI-MISC
opportunity O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
discontinue O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
substance B-DISO-MISC I-ACTI-MISC
abuse I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
improve O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
health O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
future O-MISC B-CHED-MISC
corneal O-MISC I-ACTI-MISC
complications O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Topical O-MISC B-CONC-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
025 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
post B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
herpetic I-DISO-MISC B-ANAT-MISC
neuralgia I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
predictors O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
course O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
course O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
action O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
predictors O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
topical O-MISC O-MISC
capsaicin B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
post B-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
herpetic I-DISO-MISC B-ANAT-MISC
neuralgia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PHN B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
24 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
025 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
cream O-MISC O-MISC
for O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
rated O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
visual O-MISC B-CONC-MISC
analogue O-MISC I-CONC-MISC
scale O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
VAS O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
verbal O-MISC B-CHED-MISC
outcome O-MISC I-CHED-MISC
scale O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
investigation O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
onset O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Nineteen O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
substantially O-MISC I-ACTI-MISC
improved O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
trial O-MISC B-CONC-MISC
; O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
discontinued O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
intolerable O-MISC I-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
burning O-MISC I-ACTI-MISC
sensations O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
mastitis B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
benefit O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
decrease O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
VAS O-MISC B-CONC-MISC
ratings O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
application O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
responders O-MISC I-ANAT-MISC
72 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
still O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
; O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
continued O-MISC B-ACTI-MISC
application O-MISC B-CHED-MISC
irregularly O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
localization O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PHN B-DISO-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
trigeminal O-MISC B-CHED-MISC
involvement O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
excluded O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
sensory B-DISO-MISC I-ACTI-MISC
disturbance I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
character O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC I-DISO-MISC
response O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
course O-MISC I-CHED-MISC
or O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
burning O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

If O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
controlled O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
results O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
open O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
non O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
randomized O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
might O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
analgesic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
PHN B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
interference O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
neuropeptide O-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
morphological O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
perhaps O-MISC B-ACTI-MISC
degeneration O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nociceptive O-MISC I-GENE-MISC
afferents O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Myo B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
inositol I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
phosphate I-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
MIP B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
synthase O-MISC B-DISO-MISC
inhibition O-MISC I-DISO-MISC
: O-MISC B-ACTI-MISC
in O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
vivo O-MISC I-CONC-MISC
study O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Lithium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
valproate B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prototypic O-MISC B-ACTI-MISC
mood O-MISC O-MISC
stabilizers O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
diverse O-MISC B-CHED-MISC
structures O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
targets O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
influence O-MISC B-CHED-MISC
inositol B-CHED-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Lithium B-CHED-MISC O-MISC
inhibits O-MISC B-DEVI-MISC
IMPase O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
valproate B-CHED-MISC O-MISC
inhibits O-MISC B-DEVI-MISC
MIP B-CHED-MISC O-MISC
synthase O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
shows O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
MIP B-CHED-MISC O-MISC
synthase O-MISC B-DISO-MISC
inhibition O-MISC B-DEVI-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
replicate O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
augment O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inositol B-CHED-MISC O-MISC
sensitive O-MISC B-ANAT-MISC
pilocarpine B-CHED-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
seizures B-DISO-MISC I-ACTI-MISC
model O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
stem O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
contribution O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
de O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
novo O-MISC I-CHED-MISC
synthesis O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
cellular O-MISC I-DISO-MISC
inositol B-CHED-MISC O-MISC
supply O-MISC I-LIVB-MISC
or O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
de O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
novo O-MISC I-CHED-MISC
synthesis O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
itself O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Non O-MISC O-MISC
- O-MISC B-DISO-MISC
steroidal O-MISC B-DISO-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
acute O-MISC I-ACTI-MISC
interstitial B-DISO-MISC B-ANAT-MISC
nephritis I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
granular O-MISC B-CHED-MISC
tubular O-MISC I-GENE-MISC
basement O-MISC B-GEOG-MISC
membrane O-MISC B-GEOG-MISC
deposits O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Acute B-DISO-MISC I-ACTI-MISC
tubulo I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
interstitial I-DISO-MISC B-ANAT-MISC
nephritis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ATIN B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
resulting O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
insults O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
immune O-MISC I-GENE-MISC
complex O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
tubulo B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
interstitial I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
steroidal O-MISC B-DISO-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
far O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
frequent O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Overall O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
entity O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ATIN B-DISO-MISC I-ACTI-MISC
remains O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
diagnosed O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
resolve O-MISC B-ACTI-MISC
spontaneously O-MISC B-CHED-MISC
if O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medication O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
stopped O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
boy O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
aortic O-MISC B-CONC-MISC
valve O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
put O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
following O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
took O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
fever B-DISO-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
nearly O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
presentation O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emergency O-MISC B-GENE-MISC
department O-MISC I-GEOG-MISC
feeling O-MISC B-ACTI-MISC
quite O-MISC B-ACTI-MISC
ill O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
blood B-CHED-MISC O-MISC
urea I-CHED-MISC B-DISO-MISC
nitrogen I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
BUN B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
147 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
creatinine B-CHED-MISC O-MISC
of O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
potassium B-CHED-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
mEq O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
l O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Dialysis O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
immediately O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
kidney O-MISC B-CONC-MISC
biopsy O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
inflammatory O-MISC I-ACTI-MISC
infiltrate O-MISC B-ANAT-MISC
consistent O-MISC B-ACTI-MISC
with O-MISC I-CHED-MISC
ATIN B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tubular O-MISC I-GENE-MISC
basement O-MISC B-GEOG-MISC
membrane O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
TBM O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
intense O-MISC B-CHED-MISC
granular O-MISC B-CHED-MISC
deposits O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
polyclonal O-MISC O-MISC
IgG O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
C3 O-MISC O-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
dialysis O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
successfully O-MISC B-CHED-MISC
with O-MISC I-CONC-MISC
steroids B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

His O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
recovery O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
disappearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
proteinuria B-DISO-MISC I-ACTI-MISC
took O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
ATIN B-DISO-MISC O-MISC
, O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
deposits O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
granular O-MISC I-GENE-MISC
immune O-MISC B-GEOG-MISC
complex O-MISC B-GEOG-MISC
present O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
TBM O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
glomeruli O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Rifampicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
segmental O-MISC B-CHED-MISC
necrotizing O-MISC I-ACTI-MISC
glomerulonephritis B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
staphylococcal B-DISO-MISC I-ACTI-MISC
endocarditis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Segmental O-MISC I-ACTI-MISC
necrotising O-MISC B-ANAT-MISC
glomerulonephritis B-DISO-MISC I-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
rifampicin B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
tuberculosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Changing O-MISC B-CHED-MISC
epidemiology O-MISC B-PROC-MISC
of O-MISC B-ACTI-MISC
infections B-DISO-MISC I-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
infective B-DISO-MISC I-ACTI-MISC
endocarditis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
IE B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
rifampicin B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
Staphylococcal B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Staphylococcal B-DISO-MISC I-ACTI-MISC
IE I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
secondary O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
segmental O-MISC B-CHED-MISC
necrotising O-MISC I-ACTI-MISC
glomerulonephritis B-DISO-MISC I-ACTI-MISC
while O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
rifampicin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
the O-MISC I-CHED-MISC
literature O-MISC I-CHED-MISC
regarding O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
rifampicin B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
YMDD O-MISC B-LIVB-MISC
motif O-MISC B-LIVB-MISC
mutants O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
Iranian O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
B I-DISO-MISC B-ANAT-MISC
virus I-DISO-MISC B-ANAT-MISC
infection I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Lamivudine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
B I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Recent O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
YMDD O-MISC I-ANAT-MISC
motif O-MISC B-LIVB-MISC
mutants O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
resistant O-MISC B-CHED-MISC
hepatitis B-DISO-MISC I-ANAT-MISC
B I-DISO-MISC I-PHEN-MISC
virus O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
natural O-MISC B-CHED-MISC
genome O-MISC B-LIVB-MISC
variability O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
B I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
we O-MISC B-ACTI-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
YMDD O-MISC B-LIVB-MISC
motif O-MISC B-LIVB-MISC
mutants O-MISC O-MISC
in O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
B I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
Iran O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

PATIENTS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
B I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
lamivudine B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Serum O-MISC I-GENE-MISC
samples O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
polymerase O-MISC B-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
- O-MISC B-ACTI-MISC
restriction O-MISC B-CONC-MISC
fragment O-MISC I-CONC-MISC
length O-MISC I-CONC-MISC
polymorphism O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PCR O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
RFLP O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
detection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
YMDD O-MISC B-LIVB-MISC
motif O-MISC I-PROC-MISC
mutants O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
liver O-MISC B-ACTI-MISC
enzymes O-MISC O-MISC
, O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
HCV O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
HBeAg B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
HBe O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
enrolled O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
73 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Mean O-MISC I-DISO-MISC
ALT O-MISC O-MISC
and O-MISC B-ACTI-MISC
AST O-MISC B-CONC-MISC
levels O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
124 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
73 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
103 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
IU O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
l O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

HBeAg B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
anti O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
HBe O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Anti O-MISC O-MISC
- O-MISC B-DISO-MISC
HCV O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

YMDD O-MISC I-ANAT-MISC
motif O-MISC B-ACTI-MISC
mutants O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
detected O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
despite O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
enzyme O-MISC B-CONC-MISC
levels O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
HBeAg B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
HBe O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
natural O-MISC B-CHED-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
YMDD O-MISC B-LIVB-MISC
motif O-MISC B-LIVB-MISC
mutants O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
B I-DISO-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mutants O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
detected O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Iranian O-MISC I-ANAT-MISC
lamivudine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
B I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Branch O-MISC I-ACTI-MISC
retinal B-DISO-MISC B-ANAT-MISC
vein I-DISO-MISC B-ANAT-MISC
occlusion I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
branch O-MISC I-ACTI-MISC
retinal B-DISO-MISC B-ANAT-MISC
vein I-DISO-MISC B-ANAT-MISC
occlusion I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
fluoxetine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
secondary O-MISC I-ACTI-MISC
hypertension B-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
infrequent O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
selective O-MISC B-CONC-MISC
serotonin B-CHED-MISC I-CONC-MISC
reuptake O-MISC I-CONC-MISC
inhibitor O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
ophthalmologists O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
aware O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
agents O-MISC O-MISC
can O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
because O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
class O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
is O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
differential O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
bupivacaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
prostaglandin B-CHED-MISC I-DISO-MISC
E2 I-CHED-MISC I-LIVB-MISC
release O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
cyclooxygenase O-MISC O-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
pain B-DISO-MISC I-ACTI-MISC
model O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-CHED-MISC
addition O-MISC I-CHED-MISC
to O-MISC I-CHED-MISC
blocking O-MISC B-CHED-MISC
nociceptive O-MISC I-GENE-MISC
input O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
surgical O-MISC I-GENE-MISC
sites O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
long O-MISC O-MISC
- O-MISC B-DISO-MISC
acting O-MISC B-DISO-MISC
local O-MISC B-DISO-MISC
anesthetics O-MISC B-DISO-MISC
might O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
modulate O-MISC B-CHED-MISC
inflammation B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proinflammatory O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
local O-MISC B-ACTI-MISC
prostaglandin B-CHED-MISC I-DISO-MISC
E2 I-CHED-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
PGE2 B-CHED-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
production O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
cyclooxygenase O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
COX O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
that O-MISC B-ACTI-MISC
increases O-MISC B-ACTI-MISC
postoperative B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
subjects O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Subjects O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
114 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
undergoing O-MISC B-ACTI-MISC
extraction O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
impacted O-MISC I-GENE-MISC
third O-MISC B-GEOG-MISC
molars O-MISC B-GEOG-MISC
received O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
before O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
rofecoxib B-CHED-MISC O-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
orally O-MISC B-CHED-MISC
90 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC B-CONC-MISC
mucosal O-MISC I-CONC-MISC
biopsies O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
before O-MISC B-CHED-MISC
surgery O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
extraction O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
microdialysis O-MISC B-CONC-MISC
probe O-MISC B-OBJC-MISC
was O-MISC B-ACTI-MISC
placed O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
surgical O-MISC B-CHED-MISC
site O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
PGE2 B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
thromboxane B-CHED-MISC O-MISC
B2 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TXB2 B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
measurements O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
rofecoxib B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
reported O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
less O-MISC I-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
visual O-MISC B-CONC-MISC
analog O-MISC I-CONC-MISC
scale O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
treatment O-MISC B-PHEN-MISC
groups O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
group O-MISC B-CHED-MISC
reported O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
more O-MISC I-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
PGE2 B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
groups O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
COX O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
2 O-MISC I-PROC-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Thromboxane B-CHED-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
were O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
significantly O-MISC B-ANAT-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
seen O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
attributable O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
COX O-MISC O-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
COX O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
stimulates O-MISC I-DISO-MISC
COX O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
2 O-MISC I-PROC-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
after O-MISC B-ACTI-MISC
tissue B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
higher O-MISC B-CHED-MISC
PGE2 B-CHED-MISC O-MISC
production O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
local O-MISC B-CHED-MISC
anesthetic O-MISC I-CHED-MISC
effect O-MISC I-CHED-MISC
dissipates O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

p75NTR O-MISC O-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
urinary O-MISC I-GENE-MISC
bladder O-MISC B-GEOG-MISC
sensory O-MISC I-GENE-MISC
neurons O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
spinal O-MISC I-GENE-MISC
cord O-MISC B-GEOG-MISC
with O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
nerve O-MISC O-MISC
growth O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NGF O-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
contributing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
voiding O-MISC I-ACTI-MISC
frequency O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
altered O-MISC B-CHED-MISC
sensation O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urinary O-MISC I-GENE-MISC
bladder O-MISC B-GEOG-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Previous O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
have O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
regulation O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
tyrosine B-CHED-MISC O-MISC
kinase O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Trks O-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
micturition O-MISC I-DISO-MISC
reflexes O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
urinary B-DISO-MISC I-ACTI-MISC
bladder I-DISO-MISC B-ANAT-MISC
inflammation I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
examine O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
regulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
receptor O-MISC O-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
bind O-MISC I-DISO-MISC
NGF O-MISC O-MISC
, O-MISC B-ACTI-MISC
p75 O-MISC O-MISC
( O-MISC B-ACTI-MISC
NTR O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
durations O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bladder B-DISO-MISC I-ACTI-MISC
inflammation I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CYP B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
increased O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
p75 O-MISC O-MISC
( O-MISC B-ACTI-MISC
NTR O-MISC O-MISC
) O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
superficial O-MISC I-GENE-MISC
lateral O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
medial O-MISC I-GENE-MISC
dorsal O-MISC B-GEOG-MISC
horn O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
L1 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
L2 O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
L6 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
S1 O-MISC B-GEOG-MISC
spinal O-MISC B-GEOG-MISC
segments O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
p75 O-MISC O-MISC
( O-MISC B-ACTI-MISC
NTR O-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
immunoreactive O-MISC I-GENE-MISC
( O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
IR O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lumbosacral O-MISC I-GENE-MISC
dorsal O-MISC I-GENE-MISC
root O-MISC B-GEOG-MISC
ganglia O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
DRG O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
intermediate O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Quantitative O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
real O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
time O-MISC I-CONC-MISC
polymerase O-MISC I-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
also O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
p75 O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
NTR O-MISC O-MISC
) O-MISC B-ACTI-MISC
mRNA O-MISC O-MISC
in O-MISC B-ACTI-MISC
DRG O-MISC B-ORGA-MISC
with O-MISC B-ACTI-MISC
intermediate O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
CYP B-CHED-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Retrograde O-MISC B-ACTI-MISC
dye O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
tracing O-MISC I-CONC-MISC
techniques O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
Fastblue O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
presumptive O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
afferent O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lumbosacral O-MISC I-GENE-MISC
DRG O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
afferent O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
DRG O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
p75 O-MISC O-MISC
( O-MISC B-DISO-MISC
NTR O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
IR O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
cystitis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
p75 O-MISC O-MISC
( O-MISC B-DISO-MISC
NTR O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
IR O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
DRG O-MISC I-GENE-MISC
cell O-MISC I-GENE-MISC
bodies O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
pericellular O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
encircling O-MISC I-GENE-MISC
DRG O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
p75 O-MISC O-MISC
( O-MISC B-DISO-MISC
NTR O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
IR O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
DRG O-MISC I-GENE-MISC
also O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Confocal O-MISC B-CONC-MISC
analyses O-MISC I-CONC-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
pericellular O-MISC O-MISC
p75 O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
NTR O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
IR O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
colocalized O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
glial O-MISC I-GENE-MISC
marker O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
glial O-MISC O-MISC
fibrillary O-MISC B-DISO-MISC
acidic O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GFAP O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
p75 O-MISC O-MISC
( O-MISC B-ACTI-MISC
NTR O-MISC O-MISC
) O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
micturition O-MISC I-DISO-MISC
reflexes O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
constitutively O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
modified O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
bladder B-DISO-MISC I-ACTI-MISC
inflammation I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
significance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
p75 O-MISC O-MISC
( O-MISC B-ACTI-MISC
NTR O-MISC O-MISC
) O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
micturition O-MISC I-DISO-MISC
reflexes O-MISC I-LIVB-MISC
remains O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Azathioprine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
suicidal O-MISC I-ACTI-MISC
erythrocyte O-MISC I-GENE-MISC
death O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Azathioprine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
immunosuppressive O-MISC O-MISC
drug O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
azathioprine B-CHED-MISC O-MISC
include O-MISC B-DEVI-MISC
anemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
attributed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
bone O-MISC I-GENE-MISC
marrow O-MISC B-GEOG-MISC
suppression O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Alternatively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
anemia B-DISO-MISC I-ACTI-MISC
could O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
accelerated O-MISC B-CHED-MISC
suicidal O-MISC I-ACTI-MISC
erythrocyte O-MISC I-GENE-MISC
death O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
eryptosis O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
exposure O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
phosphatidylserine B-CHED-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PS B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
erythrocyte O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
cell O-MISC I-ACTI-MISC
shrinkage O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
present O-MISC I-ACTI-MISC
experiments O-MISC B-CONC-MISC
explored O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
azathioprine B-CHED-MISC O-MISC
influences O-MISC B-CHED-MISC
eryptosis O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

According O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
annexin O-MISC O-MISC
V O-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
erythrocytes O-MISC I-GENE-MISC
from O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
indeed O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PS B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
azathioprine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cytosolic O-MISC I-GENE-MISC
Ca2 B-CHED-MISC I-DISO-MISC
+ O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
Fluo3 B-CHED-MISC O-MISC
fluorescence O-MISC B-OCCU-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
volume O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
forward O-MISC B-OCCU-MISC
scatter O-MISC B-OCCU-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
PS B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
annexin O-MISC O-MISC
V O-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
FACS O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
erythrocytes O-MISC I-GENE-MISC
from O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
volunteers O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
azathioprine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
increased O-MISC B-CHED-MISC
cytosolic O-MISC I-GENE-MISC
Ca2 B-CHED-MISC I-DISO-MISC
+ O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
annexin O-MISC O-MISC
V O-MISC B-DISO-MISC
binding O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
forward O-MISC B-CHED-MISC
scatter O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
azathioprine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
annexin O-MISC O-MISC
V O-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
forward O-MISC I-DISO-MISC
scatter O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
blunted O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nominal O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
extracellular O-MISC I-GENE-MISC
Ca2 B-CHED-MISC O-MISC
+ O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Azathioprine B-CHED-MISC O-MISC
triggers O-MISC B-CHED-MISC
suicidal O-MISC I-ACTI-MISC
erythrocyte O-MISC I-GENE-MISC
death O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
presumably O-MISC B-ACTI-MISC
contributing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
azathioprine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
anemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Levetiracetam B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
adjunct O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
phenobarbital B-CHED-MISC I-GENE-MISC
treatment O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
epilepsy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
assess O-MISC B-ACTI-MISC
pharmacokinetics O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
tolerability O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
levetiracetam B-CHED-MISC O-MISC
administered O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
adjunct O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
phenobarbital B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
poorly O-MISC B-CHED-MISC
controlled O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
epilepsy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
Open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
label O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
noncomparative O-MISC B-CONC-MISC
clinical O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

ANIMALS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
suspected O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
epilepsy I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
poorly O-MISC B-CHED-MISC
controlled O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
phenobarbital B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
unacceptable O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
when O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
phenobarbital B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

PROCEDURES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Cats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
levetiracetam B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
lb O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
PO O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
q O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
minimum O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
levetiracetam B-CHED-MISC O-MISC
concentrations O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
before O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
after O-MISC B-CHED-MISC
drug O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
minimum O-MISC B-CHED-MISC
serum O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
elimination O-MISC B-CHED-MISC
half O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
life O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Seizure B-DISO-MISC I-ACTI-MISC
frequencies O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-CHED-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levetiracetam B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Median O-MISC B-CHED-MISC
maximum O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
levetiracetam B-CHED-MISC O-MISC
concentration O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
minimum O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
levetiracetam B-CHED-MISC O-MISC
concentration O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
elimination O-MISC B-CHED-MISC
half O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
life O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-CHED-MISC
seizure B-DISO-MISC I-ACTI-MISC
frequency O-MISC B-CHED-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
levetiracetam B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
mo O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
than O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
seizure B-DISO-MISC I-ACTI-MISC
frequency O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levetiracetam B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
mo O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
having O-MISC B-ACTI-MISC
responded O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
levetiracetam B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
ie O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
transient O-MISC I-DISO-MISC
lethargy B-DISO-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
inappetence B-DISO-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
CLINICAL O-MISC B-ACTI-MISC
RELEVANCE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Results O-MISC B-CHED-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
levetiracetam B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
useful O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
adjunct O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
phenobarbital B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
epilepsy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Serotonin B-CHED-MISC O-MISC
reuptake O-MISC B-DISO-MISC
inhibitors O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
paranoia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ventral O-MISC I-GENE-MISC
basal O-MISC B-GEOG-MISC
ganglia O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Antidepressants O-MISC O-MISC
have O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
paranoid B-DISO-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
psychiatric O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
paranoid B-DISO-MISC I-ACTI-MISC
exacerbation O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serotonin B-CHED-MISC O-MISC
reuptake O-MISC B-DISO-MISC
inhibitors O-MISC B-DISO-MISC
fluoxetine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
amitriptyline B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Elements O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
included O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
paranoid B-DISO-MISC I-ACTI-MISC
symptomatology O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
concomitant O-MISC B-CHED-MISC
occurrence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
depressive B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
psychotic I-DISO-MISC I-ACTI-MISC
symptoms I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Complicated O-MISC B-CHED-MISC
depressive B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
atypicality O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
symptomatology O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
chronicity O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
psychosis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
bipolarity O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
secondary O-MISC B-CHED-MISC
onset O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
psychosis B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
particular O-MISC B-ACTI-MISC
vulnerability O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
paranoid B-DISO-MISC I-ACTI-MISC
exacerbations O-MISC B-ANAT-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
serotonin B-CHED-MISC O-MISC
reuptake O-MISC B-DISO-MISC
inhibitors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pharmacology O-MISC B-PROC-MISC
and O-MISC B-ACTI-MISC
neurobiology O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
paranoia B-DISO-MISC I-ACTI-MISC
remain O-MISC B-ACTI-MISC
cryptic O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
5HT3 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
dopamine B-CHED-MISC I-DISO-MISC
release O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
noradrenergic O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
downregulation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
GABAB O-MISC O-MISC
receptor O-MISC B-DISO-MISC
upregulation O-MISC I-DISO-MISC
acting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vicinity O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ventral O-MISC I-GENE-MISC
basal O-MISC B-GEOG-MISC
ganglia O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
lateral O-MISC I-GENE-MISC
orbitofrontal O-MISC B-GEOG-MISC
or O-MISC B-ACTI-MISC
anterior O-MISC I-GENE-MISC
cingulate O-MISC B-GEOG-MISC
circuits O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
might O-MISC B-ACTI-MISC
apply O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
phenomenon O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
call O-MISC B-ACTI-MISC
attention O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
paranoid B-DISO-MISC I-ACTI-MISC
exacerbations O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
serotonin B-CHED-MISC O-MISC
reuptake O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
select O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
raise O-MISC B-ACTI-MISC
neurobiological O-MISC B-CHED-MISC
considerations O-MISC B-ANAT-MISC
regarding O-MISC B-ACTI-MISC
paranoia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC I-ACTI-MISC
comparison O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
cardiorespiratory O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
during O-MISC B-ACTI-MISC
unilateral O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
conventional O-MISC B-CONC-MISC
spinal O-MISC I-CONC-MISC
anaesthesia O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Spinal O-MISC B-CONC-MISC
anaesthesia O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
employed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
practice O-MISC I-CONC-MISC
but O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
main O-MISC B-ACTI-MISC
drawback O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
post O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
spinal O-MISC B-ANAT-MISC
block O-MISC B-ANAT-MISC
hypotension B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Efforts O-MISC B-ACTI-MISC
must O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
continue O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
made O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
obviate O-MISC B-CHED-MISC
this O-MISC B-ACTI-MISC
setback O-MISC B-ACTI-MISC
OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
respiratory O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
unilateral O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
conventional O-MISC B-CONC-MISC
spinal O-MISC B-CONC-MISC
anaesthesia O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
With O-MISC B-ACTI-MISC
ethical O-MISC B-CHED-MISC
approval O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
74 O-MISC B-ACTI-MISC
American O-MISC B-PHYS-MISC
Society O-MISC I-PHYS-MISC
of O-MISC I-PHYS-MISC
Anesthesiologists O-MISC I-PHYS-MISC
( O-MISC B-ACTI-MISC
ASA O-MISC B-PHYS-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
physical O-MISC I-ACTI-MISC
status O-MISC B-ANAT-MISC
class O-MISC B-ANAT-MISC
1 O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
2 O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
scheduled O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
elective O-MISC B-CHED-MISC
unilateral O-MISC B-CHED-MISC
lower O-MISC B-CONC-MISC
limb O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
allocated O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
lateral O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
conventional O-MISC B-CONC-MISC
spinal O-MISC I-CONC-MISC
anaesthesia O-MISC I-CONC-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lateral O-MISC B-CHED-MISC
position O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
operative O-MISC B-CONC-MISC
side O-MISC I-CONC-MISC
down O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
recived O-MISC B-CONC-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2mls O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
hyperbaric O-MISC O-MISC
bupivacaine B-CHED-MISC B-DISO-MISC
through O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
25 O-MISC B-OBJC-MISC
- O-MISC I-OBJC-MISC
gauge O-MISC I-OBJC-MISC
spinal O-MISC I-OBJC-MISC
needle O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unilateral O-MISC B-CHED-MISC
group O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
maintained O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lateral O-MISC B-CHED-MISC
position O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
spinal O-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
while O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
conventional O-MISC B-CHED-MISC
group O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
turned O-MISC B-ACTI-MISC
supine O-MISC B-CHED-MISC
immediately O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
respiratory O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
oxygen B-CHED-MISC I-DISO-MISC
saturation O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
monitored O-MISC B-CONC-MISC
over O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
hour O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
Three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unilateral O-MISC B-CHED-MISC
group O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
conventional O-MISC B-CHED-MISC
group O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
71 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
conventional O-MISC B-CHED-MISC
group O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unilateral O-MISC B-CHED-MISC
group O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
treat O-MISC B-CONC-MISC
hypotension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
conventional O-MISC B-CHED-MISC
group O-MISC I-CHED-MISC
had O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
greater O-MISC B-CHED-MISC
fall O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressures O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
003 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
004 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
respiratory O-MISC B-ANAT-MISC
rate O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
oxygen B-CHED-MISC I-DISO-MISC
saturations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Compared O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
conventional O-MISC B-CHED-MISC
spinal O-MISC B-CONC-MISC
anaesthesia O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
unilateral O-MISC B-CHED-MISC
spinal O-MISC B-CONC-MISC
anaesthesia O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
fewer O-MISC B-ACTI-MISC
cardiovascular O-MISC I-ACTI-MISC
perturbations O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Also O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
spinal O-MISC I-ACTI-MISC
block O-MISC B-ANAT-MISC
instituted O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
neither O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
respiratory O-MISC I-DISO-MISC
rate O-MISC B-CHED-MISC
nor O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
arterial O-MISC I-GENE-MISC
oxygen B-CHED-MISC I-LIVB-MISC
saturation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Spectrum O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
generic O-MISC B-ACTI-MISC
HAART O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
southern O-MISC B-ORGA-MISC
Indian O-MISC I-ORGA-MISC
HIV B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
infected I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
clinically O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
fixed O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
generic O-MISC O-MISC
highly O-MISC B-CONC-MISC
active O-MISC I-CONC-MISC
antiretroviral O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
HAART O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
infected I-DISO-MISC B-ANAT-MISC
individuals O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
South O-MISC B-ORGA-MISC
India O-MISC I-ORGA-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
experiences O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
3154 O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
infected I-DISO-MISC B-ANAT-MISC
individuals O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
minimum O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
generic O-MISC B-CHED-MISC
HAART O-MISC B-CONC-MISC
between O-MISC B-ACTI-MISC
February O-MISC B-ACTI-MISC
1996 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
December O-MISC B-ACTI-MISC
2006 O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tertiary O-MISC B-GENE-MISC
HIV O-MISC I-GEOG-MISC
care O-MISC I-GEOG-MISC
referral O-MISC I-GEOG-MISC
center O-MISC I-GEOG-MISC
in O-MISC B-ACTI-MISC
South O-MISC B-ORGA-MISC
India O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
regimens O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
3TC B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
d4T B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
nevirapine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
NVP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
zidovudine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
AZT B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
3TC B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
NVP B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3TC B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
d4T B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
efavirenz B-CHED-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
EFV B-CHED-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
AZT B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
3TC B-CHED-MISC O-MISC
+ O-MISC B-ACTI-MISC
EFV B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
CD4 O-MISC I-GENE-MISC
at O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
event O-MISC B-DEVI-MISC
were O-MISC B-ACTI-MISC
rash B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
CD4 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
285 O-MISC B-ACTI-MISC
cells O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
microL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
348 O-MISC B-ACTI-MISC
cells O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
microL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinically O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
anemia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
hemoglobin O-MISC O-MISC
< O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
CD4 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
165 O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
/ O-MISC B-ACTI-MISC
microL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
jaundice B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
alanine B-CHED-MISC O-MISC
aminotransferase O-MISC B-DISO-MISC
> O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
upper O-MISC B-ACTI-MISC
limits O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
CD4 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
260 O-MISC B-ACTI-MISC
cells O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
microL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Women O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
experience O-MISC B-ACTI-MISC
lactic B-DISO-MISC I-ACTI-MISC
acidosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
experience O-MISC B-ACTI-MISC
immune B-DISO-MISC I-ACTI-MISC
reconstitution I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
NVP B-CHED-MISC B-CONC-MISC
therapy O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
developing O-MISC B-ACTI-MISC
rash B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
d4T B-CHED-MISC B-CONC-MISC
therapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Anemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ACTI-MISC
often O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
initiating O-MISC B-ACTI-MISC
generic O-MISC B-CHED-MISC
HAART O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Frequent O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
monitoring O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
toxicities B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
warranted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
developing O-MISC B-CHED-MISC
countries O-MISC I-CHED-MISC
where O-MISC B-ACTI-MISC
generic O-MISC B-CHED-MISC
HAART O-MISC O-MISC
is O-MISC B-ACTI-MISC
increasingly O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Thalidomide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
sensory B-DISO-MISC B-CHED-MISC
neurotoxicity I-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
neurophysiological O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Recent O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
confirmed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sensory B-DISO-MISC I-ACTI-MISC
axonal I-DISO-MISC B-ANAT-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
different O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
' O-MISC I-CONC-MISC
s O-MISC I-CONC-MISC
aims O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
measure O-MISC B-CHED-MISC
variations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
sural O-MISC I-DISO-MISC
nerve O-MISC I-LIVB-MISC
sensory O-MISC I-LIVB-MISC
action O-MISC I-LIVB-MISC
potential O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
SAP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
amplitude O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
cutaneous B-DISO-MISC B-ANAT-MISC
lupus I-DISO-MISC B-ANAT-MISC
erythematosus I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CLE B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
thalidomide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC B-CHED-MISC
potential O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recovery O-MISC I-DISO-MISC
capacity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sensory O-MISC I-GENE-MISC
fibres O-MISC B-GEOG-MISC
after O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

PATIENTS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Clinical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
electrophysiological O-MISC B-CONC-MISC
data O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
CLE B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
analysed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Sural O-MISC I-GENE-MISC
nerve O-MISC B-GEOG-MISC
SAP O-MISC B-CONC-MISC
amplitude O-MISC B-CONC-MISC
reduction O-MISC B-CONC-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
criteria O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
discontinuing O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
During O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
sural O-MISC I-GENE-MISC
nerve O-MISC B-GEOG-MISC
SAP O-MISC I-DISO-MISC
amplitude O-MISC B-CHED-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
values O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
SAP O-MISC I-DISO-MISC
amplitude O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
complained O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
paresthesias B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
leg O-MISC I-ACTI-MISC
cramps B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
treatment O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
sural O-MISC I-GENE-MISC
SAP O-MISC O-MISC
amplitude O-MISC B-ACTI-MISC
recovered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
detection O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
sural O-MISC I-GENE-MISC
nerve O-MISC B-GEOG-MISC
SAP O-MISC B-CONC-MISC
amplitude O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
cumulative O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
threshold O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC O-MISC
dosage O-MISC I-CHED-MISC
is O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Sural O-MISC I-GENE-MISC
nerve O-MISC B-GEOG-MISC
SAP O-MISC B-CONC-MISC
amplitude O-MISC I-CONC-MISC
reduction O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reliable O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
marker O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
degeneration O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
recovery O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
sensory O-MISC I-GENE-MISC
fibres O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
electrophysiological O-MISC B-CONC-MISC
parameter O-MISC I-ACTI-MISC
provides O-MISC B-ACTI-MISC
information O-MISC B-CHED-MISC
about O-MISC B-ACTI-MISC
subclinical O-MISC B-CHED-MISC
neurotoxic B-DISO-MISC I-DISO-MISC
potential O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
but O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
helpful O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
predicting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sensory O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
encephalitis B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
loiasis B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
diethylcarbamazine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
encephalitis B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
diethylcarbamazine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DEC B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Congolese O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Loa O-MISC I-ACTI-MISC
loa O-MISC B-ANAT-MISC
filariasis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
outcome O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
sequelae O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
notable O-MISC B-ACTI-MISC
fact O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
hospitalized O-MISC I-PHEN-MISC
before O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
began O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
strict O-MISC B-ACTI-MISC
therapeutic O-MISC B-CONC-MISC
precautions O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
DEC B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
gradual O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
increases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
allergic O-MISC B-DISO-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
uncommon O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
highly O-MISC B-CHED-MISC
endemic O-MISC I-ACTI-MISC
regions O-MISC B-PHEN-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
occurs O-MISC B-CHED-MISC
primarily O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
exclusively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
presenting O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
microfilarial O-MISC I-GENE-MISC
load O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
encephalitis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
microfilaremia B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
evident O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pathophysiological O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
light O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
comments O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
subject O-MISC B-ACTI-MISC
published O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Amiodarone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
mass I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
unique O-MISC B-CHED-MISC
membranous B-DISO-MISC I-ACTI-MISC
glomerulonephritis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
valvular B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
Diagnostic O-MISC I-ACTI-MISC
pitfall O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
findings O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Amiodarone B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
arrhythmic B-DISO-MISC B-DISO-MISC
drug O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
life O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Reported O-MISC B-ACTI-MISC
herein O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autopsy O-MISC B-CONC-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
valvular B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lung B-DISO-MISC I-ACTI-MISC
mass I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
cm O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
diameter O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
proteinuria B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
lung B-DISO-MISC I-ACTI-MISC
mass I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
lung B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
positron O-MISC B-CONC-MISC
emission O-MISC I-CONC-MISC
tomography O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
histologically O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
lesion O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
composed O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lymphoplasmacytic O-MISC I-ACTI-MISC
infiltrates O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
alveolar O-MISC I-GENE-MISC
walls O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
intra O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
alveolar O-MISC I-CHED-MISC
accumulation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
foamy O-MISC I-GENE-MISC
macrophages O-MISC B-GEOG-MISC
containing O-MISC B-ACTI-MISC
characteristic O-MISC B-CHED-MISC
myelinoid O-MISC I-GENE-MISC
bodies O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
lesion O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lung O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
had O-MISC B-ACTI-MISC
unevenly O-MISC B-ACTI-MISC
distributed O-MISC B-ACTI-MISC
hemosiderin B-DISO-MISC O-MISC
deposition O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
abnormally O-MISC I-ACTI-MISC
tortuous O-MISC I-ACTI-MISC
capillaries O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mass O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
heavily O-MISC B-ACTI-MISC
hemosiderotic B-DISO-MISC I-GENE-MISC
lung O-MISC I-GENE-MISC
portions O-MISC B-GEOG-MISC
outside O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mass O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidneys O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
glomeruli O-MISC I-GENE-MISC
had O-MISC B-ACTI-MISC
membrane O-MISC I-GENE-MISC
spikes O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
prominent O-MISC B-CHED-MISC
swelling O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
podocytes O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
subepithelial O-MISC I-GENE-MISC
deposits O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
sometimes O-MISC B-ACTI-MISC
large O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
hump O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
like O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Autoimmune B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
viral B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
malignant O-MISC I-ACTI-MISC
neoplasms B-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
diseases O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
relationship O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
membranous B-DISO-MISC I-ACTI-MISC
glomerulonephritis I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
highlights O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
differential O-MISC B-CONC-MISC
diagnosis O-MISC I-CONC-MISC
between O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
lesion I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
neoplasm B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
difficult O-MISC B-CHED-MISC
radiologically O-MISC B-PROC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
membranous B-DISO-MISC I-ACTI-MISC
glomerulonephritis I-DISO-MISC B-ANAT-MISC
might O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
initial O-MISC B-ACTI-MISC
sulphonylurea B-CHED-MISC I-ANAT-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
type B-DISO-MISC I-ACTI-MISC
2 I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
matched O-MISC B-CONC-MISC
case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

AIMS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
sought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CAD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
initial O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
type B-DISO-MISC I-ACTI-MISC
2 I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
sulphonylureas B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
type B-DISO-MISC I-ACTI-MISC
2 I-DISO-MISC B-ANAT-MISC
diabetic I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-CHED-MISC
CAD B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
retrospectively O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
risk O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
CAD B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
UKPDS O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
engine O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
match O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CAD B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
152 O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hazard O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
CAD B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
initial O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
004 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
glibenclamide B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
099 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
glipizide B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
unchanged O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hazard O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
385 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
glimepiride B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
192 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
gliclazide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
09 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Initiating O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
type B-DISO-MISC I-ACTI-MISC
2 I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
glibenclamide B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
glipizide B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CAD B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
comparison O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
gliclazide B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
glimepiride B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

If O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
important O-MISC B-CHED-MISC
because O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
Indian O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
receive O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cheaper O-MISC I-ACTI-MISC
older O-MISC B-ACTI-MISC
sulphonylureas B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
guidelines O-MISC B-CHED-MISC
do O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
distinguish O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
individual O-MISC B-CHED-MISC
agents O-MISC O-MISC
. O-MISC B-ACTI-MISC

Reduced O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
adriamycin B-CHED-MISC O-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
spontaneously O-MISC I-ACTI-MISC
hypertensive B-DISO-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
treated O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
losartan B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
antihypertensive O-MISC O-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
angiotensin B-CHED-MISC O-MISC
II I-CHED-MISC B-DISO-MISC
type O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
blocker O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
losartan B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
slowing O-MISC B-ACTI-MISC
down O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
progression O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
spontaneously O-MISC B-CHED-MISC
hypertensive B-DISO-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
SHR O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
adriamycin B-CHED-MISC I-ACTI-MISC
( O-MISC B-ANAT-MISC
ADR B-CHED-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Six O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
month O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
old O-MISC I-CHED-MISC
female O-MISC I-DISO-MISC
SHR O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
selected O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
SH O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
SH O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
vehicle O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

Groups O-MISC I-ANAT-MISC
ADR B-CHED-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ADR B-CHED-MISC B-CHED-MISC
+ O-MISC B-ACTI-MISC
LOS B-CHED-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ADR B-CHED-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ADR B-CHED-MISC B-CHED-MISC
+ O-MISC B-ACTI-MISC
LOS B-CHED-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
ADR B-CHED-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
b O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
w O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
twice O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
interval O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Group O-MISC B-CHED-MISC
ADR B-CHED-MISC B-CHED-MISC
+ O-MISC B-ACTI-MISC
LOS B-CHED-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
losartan B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
b O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
w O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
gavages O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
ADR B-CHED-MISC B-CHED-MISC
+ O-MISC B-ACTI-MISC
LOS B-CHED-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ADR B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
killed O-MISC B-DEVI-MISC
after O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Haemodynamic O-MISC I-DISO-MISC
measurements O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
anaesthetized O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
samples O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
biochemical O-MISC B-CONC-MISC
analysis O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
kidney O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
processed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
morphological O-MISC B-CHED-MISC
studies O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Short O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
losartan B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
besides O-MISC B-ACTI-MISC
antihypertensive O-MISC O-MISC
effect O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
glomerular O-MISC B-CONC-MISC
filtration O-MISC I-CONC-MISC
rate O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
ameliorated O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
proteinuria B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Prolonged O-MISC B-CHED-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
losartan B-CHED-MISC O-MISC
showed O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
reduction O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
reduced O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
tubular O-MISC I-ACTI-MISC
atrophy B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
interstitial B-DISO-MISC I-ACTI-MISC
fibrosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
thus O-MISC B-ACTI-MISC
preventing O-MISC B-ACTI-MISC
heavy O-MISC I-ACTI-MISC
proteinuria B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Losartan B-CHED-MISC O-MISC
reduced O-MISC B-CHED-MISC
uraemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
urea B-CHED-MISC I-DISO-MISC
clearance O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
advanced O-MISC B-ACTI-MISC
ADR B-CHED-MISC I-ACTI-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
SHR O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Histological O-MISC B-CHED-MISC
examination O-MISC B-UnknownType-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
losartan B-CHED-MISC O-MISC
could O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
tubular O-MISC I-ACTI-MISC
atrophy B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
interstitial O-MISC I-ACTI-MISC
infiltration O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
fibrosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
ADR B-CHED-MISC I-ACTI-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Losartan B-CHED-MISC O-MISC
reduces O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
ADR B-CHED-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
focal B-DISO-MISC I-ACTI-MISC
segmental I-DISO-MISC B-ANAT-MISC
glomerulosclerosis I-DISO-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
end B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
stage I-DISO-MISC B-ANAT-MISC
renal I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
SHR O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
risks O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
aprotinin O-MISC O-MISC
and O-MISC B-ACTI-MISC
tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
one O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
year O-MISC I-CONC-MISC
follow O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
1188 O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
aim O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
postoperative O-MISC I-ACTI-MISC
complications O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
aprotinin O-MISC O-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unselected O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
cohort O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Perioperative O-MISC B-CHED-MISC
data O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
cardiac O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
prospectively O-MISC B-ACTI-MISC
collected O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
September O-MISC B-ACTI-MISC
2005 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
June O-MISC B-ACTI-MISC
2006 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
university O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
affiliated O-MISC I-GEOG-MISC
clinic O-MISC I-GEOG-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
1188 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mo O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
596 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
aprotinin O-MISC O-MISC
( O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
A O-MISC B-UnknownType-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
next O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mo O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
592 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
T O-MISC B-UnknownType-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Except O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
antifibrinolytic O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anesthetic O-MISC O-MISC
and O-MISC B-ACTI-MISC
surgical O-MISC B-CONC-MISC
protocols O-MISC I-CONC-MISC
remained O-MISC B-ACTI-MISC
unchanged O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
intraoperative O-MISC B-CHED-MISC
variables O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
comparable O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
groups O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Postoperatively O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
T O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-CONC-MISC
valve O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CONC-MISC
risk O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
subgroups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
003 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
035 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Persistent O-MISC B-ACTI-MISC
atrial O-MISC B-ANAT-MISC
fibrillation O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
020 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
002 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
T O-MISC B-UnknownType-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-CONC-MISC
valve O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
subgroup O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
contrary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
coronary O-MISC B-CONC-MISC
artery O-MISC I-CONC-MISC
bypass O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
myocardial B-DISO-MISC B-ANAT-MISC
infarctions I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
A O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
027 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
036 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
yr O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
after O-MISC B-ACTI-MISC
aprotinin O-MISC O-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CONC-MISC
risk O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
group O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
034 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Both O-MISC B-ACTI-MISC
antifibrinolytic O-MISC O-MISC
drugs O-MISC B-DISO-MISC
bear O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
outcome O-MISC B-ANAT-MISC
depending O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
aprotinin O-MISC O-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
avoided O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
coronary O-MISC B-CONC-MISC
artery O-MISC I-CONC-MISC
bypass O-MISC I-CONC-MISC
graft O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
high O-MISC I-ACTI-MISC
risk O-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
recommended O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
valve O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Delirium B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
woman O-MISC I-ANAT-MISC
possibly O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
misoprostol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Misoprostol B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
gastrointestinal O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
gynecologic O-MISC I-ACTI-MISC
problems O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
headache B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mental O-MISC I-ACTI-MISC
status O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
89 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
term O-MISC I-GEOG-MISC
care O-MISC I-GEOG-MISC
facility O-MISC I-GEOG-MISC
became O-MISC B-ACTI-MISC
confused O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
misoprostol B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
change O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mental O-MISC I-ACTI-MISC
status O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Her O-MISC B-ACTI-MISC
delirium B-DISO-MISC I-ACTI-MISC
significantly O-MISC B-CHED-MISC
improved O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
misoprostol B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
mental O-MISC I-DISO-MISC
status O-MISC I-LIVB-MISC
returned O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
normal O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
changed O-MISC B-CHED-MISC
significantly O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
delirium B-DISO-MISC I-DISO-MISC
experienced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
possibly O-MISC B-ACTI-MISC
resulted O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
misoprostol B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
biological O-MISC B-CHED-MISC
properties O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
optical O-MISC B-OCCU-MISC
isomers O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
arrhythmias I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
optical O-MISC B-OCCU-MISC
isomers O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
beta O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
blocking O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
antiarrhythmic O-MISC I-DISO-MISC
activities O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
blocking O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
positive O-MISC B-ACTI-MISC
inotropic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
chronotropic O-MISC B-CHED-MISC
responses O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
isoprenaline B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
( O-MISC O-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
propranolol B-CHED-MISC B-DISO-MISC
had O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
hundredth O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potency O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
( O-MISC O-MISC
- O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
propranolol B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
levels O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
( O-MISC O-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
propranolol B-CHED-MISC B-DISO-MISC
which O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
isoprenaline B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
prolongation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PR O-MISC B-CONC-MISC
interval O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
electrocardiogram O-MISC I-ACTI-MISC
. O-MISC B-ANAT-MISC
3 O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
metabolic O-MISC I-DISO-MISC
responses O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
isoprenaline B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
circulating O-MISC B-CHED-MISC
glucose B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
lactate B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
free O-MISC I-ACTI-MISC
fatty B-CHED-MISC B-ANAT-MISC
acids I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
blocked O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
( O-MISC O-MISC
- O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
propranolol B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

( O-MISC O-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
Propranolol B-CHED-MISC B-DISO-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
fatty B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
mobilization O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
reduced O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
increments O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
lactate B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
glucose B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
isomers O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
possessed O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
depressant O-MISC O-MISC
potency O-MISC B-OCCU-MISC
on O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
atrial O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
taken O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
guinea O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
pigs O-MISC I-PHEN-MISC
. O-MISC I-PHEN-MISC
5 O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
isomers O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
exhibited O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
local O-MISC B-CHED-MISC
anaesthetic O-MISC O-MISC
potencies O-MISC B-OCCU-MISC
on O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
frog O-MISC I-GENE-MISC
nerve O-MISC I-CONC-MISC
preparation O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
approximately O-MISC B-CHED-MISC
three O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
procaine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
racemic O-MISC B-GENE-MISC
compound O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
less O-MISC B-CHED-MISC
potent O-MISC B-OCCU-MISC
than O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
isomer O-MISC O-MISC
. O-MISC B-DISO-MISC
6 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
isomers O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
capable O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
preventing O-MISC B-ACTI-MISC
adrenaline B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
arrhythmias I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
anaesthetized O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
halothane B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
( O-MISC O-MISC
- O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
propranolol B-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
09 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
( O-MISC O-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
propranolol B-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
level O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
( O-MISC O-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
propranolol B-CHED-MISC B-DISO-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
prolongation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PR O-MISC B-CONC-MISC
interval O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
electrocardiogram O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Blockade O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
arrhythmias B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
isomers O-MISC B-PHEN-MISC
was O-MISC B-ACTI-MISC
surmountable O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
adrenaline B-CHED-MISC O-MISC
. O-MISC B-DISO-MISC
7 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
isomers O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
capable O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
reversing O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
ouabain B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
anaesthetized O-MISC O-MISC
cats O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
( O-MISC O-MISC
- O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
propranolol B-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
smaller O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
( O-MISC O-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
propranolol B-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
species O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
much O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
blockade O-MISC B-DISO-MISC
. O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
implications O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Topotecan B-CHED-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
radiotherapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
unresectable O-MISC I-DISO-MISC
glioblastoma B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
2 O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Improving O-MISC B-ACTI-MISC
glioblastoma B-DISO-MISC I-ACTI-MISC
multiforme I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
GBM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
radio O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
remains O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
challenge O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Topotecan B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
attractive O-MISC B-ACTI-MISC
option O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
exhibits O-MISC B-ACTI-MISC
growth O-MISC I-DISO-MISC
inhibition O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
glioma B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
penetration O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
assessed O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
radiotherapy O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
Gy O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
fractions O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
topotecan B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
histologically O-MISC B-CHED-MISC
proven O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
GBM B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
hematological O-MISC B-ANAT-MISC
toxicities B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
grade O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
hematological O-MISC I-ACTI-MISC
toxicities B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
mainly O-MISC B-ACTI-MISC
lymphopenia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Partial O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
stabilization O-MISC B-CHED-MISC
rates O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
time O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
progression O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
year O-MISC I-CHED-MISC
overall O-MISC B-CHED-MISC
survival O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
OS O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
OS O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Topotecan B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
radiotherapy O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
stabilization O-MISC B-CONC-MISC
concerned O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
benefits O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
terms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
survival O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
unresectable O-MISC B-CHED-MISC
GBM B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
lithium B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hyperparathyroidism B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
paper O-MISC B-ACTI-MISC
reviews O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
lithium B-CHED-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
calcium B-CHED-MISC I-CONC-MISC
level O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
parathyroid O-MISC I-GENE-MISC
glands O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
options O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
recurrent O-MISC B-PHEN-MISC
hypercalcemia B-DISO-MISC B-UnknownType-MISC
to O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
understand O-MISC I-DISO-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
process O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Primary B-DISO-MISC I-ACTI-MISC
hyperparathyroidism I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
potentially O-MISC B-ACTI-MISC
life O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
lithium B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Careful O-MISC B-ACTI-MISC
patient O-MISC B-CONC-MISC
selection O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
long O-MISC B-CONC-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
follow O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
can O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
morbidity O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

PRACTICAL O-MISC B-CHED-MISC
IMPLICATIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
As O-MISC B-ACTI-MISC
much O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
become O-MISC B-ACTI-MISC
hypercalcemic B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
routinely O-MISC B-ACTI-MISC
monitoring O-MISC B-CONC-MISC
serum O-MISC B-CONC-MISC
calcium B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
healthcare O-MISC I-ANAT-MISC
providers O-MISC I-PHEN-MISC
can O-MISC B-ACTI-MISC
improve O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
quality O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
life O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Comparison O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
laryngeal O-MISC B-OBJC-MISC
mask O-MISC I-OBJC-MISC
with O-MISC B-ACTI-MISC
endotracheal O-MISC B-OBJC-MISC
tube O-MISC I-OBJC-MISC
for O-MISC B-ACTI-MISC
anesthesia O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
endoscopic O-MISC B-CONC-MISC
sinus O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
compare O-MISC B-DEVI-MISC
surgical O-MISC B-CONC-MISC
conditions O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
amount O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
intraoperative O-MISC B-CHED-MISC
bleeding B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
intraoperative O-MISC B-CHED-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
functional O-MISC B-CONC-MISC
endoscopic O-MISC I-CONC-MISC
sinus O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
FESS O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
flexible O-MISC B-OBJC-MISC
reinforced O-MISC I-OBJC-MISC
laryngeal O-MISC I-OBJC-MISC
mask O-MISC I-OBJC-MISC
airway O-MISC I-OBJC-MISC
( O-MISC B-ACTI-MISC
FRLMA O-MISC B-OBJC-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
endotracheal O-MISC B-OBJC-MISC
tube O-MISC I-OBJC-MISC
( O-MISC B-ACTI-MISC
ETT O-MISC B-OBJC-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
maintaining O-MISC B-ACTI-MISC
controlled O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
anesthesia O-MISC I-CONC-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
remifentanil B-CHED-MISC B-DISO-MISC
total O-MISC I-CONC-MISC
i O-MISC I-CONC-MISC
. O-MISC I-CONC-MISC
v O-MISC I-CONC-MISC
. O-MISC I-CONC-MISC
anesthesia O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
TIVA O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Sixty O-MISC B-ACTI-MISC
normotensive O-MISC I-ACTI-MISC
American O-MISC B-PHYS-MISC
Society O-MISC I-PHYS-MISC
of O-MISC I-PHYS-MISC
Anesthesiologists O-MISC I-PHYS-MISC
I O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
II O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
FESS O-MISC B-CONC-MISC
under O-MISC B-ACTI-MISC
controlled O-MISC B-CHED-MISC
hypotension B-DISO-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
remifentanil B-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
TIVA O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
assigned O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
I O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
FRLMA O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
II O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
ETT O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hemorrhage B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
visibility O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
operative O-MISC B-CHED-MISC
field O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
point O-MISC B-ACTI-MISC
scale O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Controlled O-MISC I-ACTI-MISC
hypotension B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
achieved O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
shorter O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
laryngeal O-MISC B-CONC-MISC
mask O-MISC I-CONC-MISC
using O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
rates O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
remifentanil B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
total O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
remifentanil B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
summary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
airway O-MISC B-CONC-MISC
management O-MISC I-CONC-MISC
using O-MISC B-ACTI-MISC
FRLMA O-MISC O-MISC
during O-MISC B-ACTI-MISC
controlled O-MISC B-CHED-MISC
hypotension B-DISO-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
provided O-MISC B-ACTI-MISC
better O-MISC B-CHED-MISC
surgical O-MISC B-CHED-MISC
conditions O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
terms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
quality O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
operative O-MISC B-CHED-MISC
field O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
blood O-MISC I-ACTI-MISC
loss O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
allowed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
convenient O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
remifentanil B-CHED-MISC O-MISC
during O-MISC B-ACTI-MISC
TIVA O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
FESS O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Nonalcoholic B-DISO-MISC I-ACTI-MISC
fatty I-DISO-MISC B-ANAT-MISC
liver I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
valproate B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Valproic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
VPA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
types O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nonalcoholic B-DISO-MISC I-ACTI-MISC
fatty I-DISO-MISC B-ANAT-MISC
liver I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
NAFLD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
arising O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
child O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
obesity B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
VPA B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Laboratory O-MISC B-CHED-MISC
data O-MISC I-CHED-MISC
revealed O-MISC B-ACTI-MISC
hyperinsulinemia B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
insulin B-DISO-MISC I-ACTI-MISC
resistance I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
withdrawal O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
VPA B-CHED-MISC B-CONC-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
weight B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
mass O-MISC I-LIVB-MISC
index O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
normalization O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
endocrine O-MISC B-CHED-MISC
parameters O-MISC I-CHED-MISC
; O-MISC B-ACTI-MISC
moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ultrasound O-MISC B-CONC-MISC
measurements O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
normalization O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
obesity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
hyperinsulinemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
insulin B-DISO-MISC I-ACTI-MISC
resistance I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
VPA B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
NAFLD B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
reversible O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
VPA B-CHED-MISC O-MISC
withdrawal O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Carbimazole B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
ANCA B-DISO-MISC O-MISC
positive I-DISO-MISC I-ACTI-MISC
vasculitis I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Anti B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
thyroid I-CHED-MISC B-DISO-MISC
drugs I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
carbimazole B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
propylthiouracil B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
PTU B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
commonly O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyperthyroidism B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
antithyroid B-CHED-MISC O-MISC
medications I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Antineutrophil B-DISO-MISC O-MISC
cytoplasmic I-DISO-MISC B-DISO-MISC
antibody I-DISO-MISC B-DISO-MISC
( I-DISO-MISC B-ACTI-MISC
ANCA I-DISO-MISC O-MISC
) I-DISO-MISC B-ACTI-MISC
- I-DISO-MISC B-ACTI-MISC
- I-DISO-MISC B-ACTI-MISC
associated I-DISO-MISC B-ACTI-MISC
vasculitis I-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
potentially O-MISC B-ACTI-MISC
life O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
adverse O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
antithyroidmedications B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Graves B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
ANCA O-MISC O-MISC
positive O-MISC B-DISO-MISC
carbimazole B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
episode O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
characterized O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
vasculitic B-DISO-MISC I-ACTI-MISC
skin B-DISO-MISC B-ANAT-MISC
rash I-DISO-MISC B-ANAT-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
large O-MISC I-ACTI-MISC
joint O-MISC B-ANAT-MISC
arthritis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
pyrexia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
parotiditis B-DISO-MISC I-ACTI-MISC
but O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
renal O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
pulmonary O-MISC I-GENE-MISC
involvement O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
referred O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
us O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
neurological O-MISC B-CHED-MISC
evaluation O-MISC B-CONC-MISC
because O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
difficulty O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
getting O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
squatting O-MISC B-CHED-MISC
position O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
suspected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
myositis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Carbimazole B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
methimazole B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
ANCA O-MISC O-MISC
positive O-MISC I-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
than O-MISC B-ACTI-MISC
PUT O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
ANCA O-MISC O-MISC
positive O-MISC B-DISO-MISC
carbimazole B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
case O-MISC B-ACTI-MISC
reported O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
India O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

Aspirin B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-CONC-MISC
prevention O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
cardiovascular O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
update O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
U O-MISC B-ORGA-MISC
. O-MISC I-ORGA-MISC
S O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

Preventive O-MISC B-PHYS-MISC
Services O-MISC I-PHYS-MISC
Task O-MISC I-PHYS-MISC
Force O-MISC I-PHYS-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Coronary B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
cerebrovascular B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
causes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
United O-MISC B-ORGA-MISC
States O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
2002 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
U O-MISC B-ORGA-MISC
. O-MISC I-ORGA-MISC
S O-MISC I-ORGA-MISC
. O-MISC I-ORGA-MISC

Preventive O-MISC B-PHYS-MISC
Services O-MISC I-PHYS-MISC
Task O-MISC I-PHYS-MISC
Force O-MISC I-PHYS-MISC
( O-MISC B-ACTI-MISC
USPSTF O-MISC B-PHYS-MISC
) O-MISC B-ACTI-MISC
strongly O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
clinicians O-MISC I-ANAT-MISC
discuss O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
benefits O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
harms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-CONC-MISC
prevention O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarctions I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
strokes B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

DATA O-MISC B-ACTI-MISC
SOURCES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
MEDLINE O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
Cochrane O-MISC B-CHED-MISC
Library O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
search O-MISC B-ACTI-MISC
dates O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
January O-MISC B-ACTI-MISC
2001 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
August O-MISC B-ACTI-MISC
2008 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
systematic O-MISC B-CHED-MISC
reviews O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
reference O-MISC B-CHED-MISC
lists O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
retrieved O-MISC B-CHED-MISC
articles O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
suggestions O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
experts O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

STUDY O-MISC B-CHED-MISC
SELECTION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
English O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
language O-MISC I-CHED-MISC
randomized O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
controlled O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
RCTs O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
; O-MISC B-ACTI-MISC
meta O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
analyses O-MISC I-CONC-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
systematic O-MISC B-CHED-MISC
reviews O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
versus O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-CONC-MISC
prevention O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CVD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
selected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
answer O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
questions O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Does O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
decrease O-MISC B-CHED-MISC
coronary O-MISC I-ACTI-MISC
heart O-MISC B-ANAT-MISC
events O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
strokes B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
coronary O-MISC I-ACTI-MISC
heart O-MISC B-ANAT-MISC
events O-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
mortality O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
CVD B-DISO-MISC I-ACTI-MISC
? O-MISC B-ACTI-MISC

Does O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
increase O-MISC B-CHED-MISC
gastrointestinal B-DISO-MISC I-ACTI-MISC
bleeding I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
strokes I-DISO-MISC B-ANAT-MISC
? O-MISC B-ACTI-MISC

DATA O-MISC B-ACTI-MISC
EXTRACTION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
All O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
reviewed O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
abstracted O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
rated O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
quality O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
predefined O-MISC B-ACTI-MISC
USPSTF O-MISC B-PHYS-MISC
criteria O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

DATA O-MISC B-ACTI-MISC
SYNTHESIS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
New O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
good O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
quality O-MISC I-CHED-MISC
RCT O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
good O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
quality O-MISC I-CHED-MISC
meta O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
fair O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
quality O-MISC I-CHED-MISC
subanalyses O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
RCTs O-MISC B-CONC-MISC
demonstrates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
reduces O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CVD B-DISO-MISC I-ACTI-MISC
events O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
CVD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Men O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
experienced O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarctions I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
experienced O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
ischemic O-MISC I-ACTI-MISC
strokes B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Aspirin B-CHED-MISC O-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
seem O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
CVD B-DISO-MISC I-ACTI-MISC
mortality O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
or O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
primary O-MISC B-CONC-MISC
prevention O-MISC I-CONC-MISC
increases O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
major O-MISC I-ACTI-MISC
bleeding B-DISO-MISC B-ANAT-MISC
events O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
primarily O-MISC B-ACTI-MISC
gastrointestinal B-DISO-MISC I-ACTI-MISC
bleeding I-DISO-MISC B-ANAT-MISC
events O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Men O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
strokes I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
RCT O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
meta O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
strokes I-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

LIMITATIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
New O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-CONC-MISC
prevention O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
CVD B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
limited O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RCTs O-MISC B-CONC-MISC
varied O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
estimation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
appropriate O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
primary O-MISC B-CONC-MISC
prevention O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Several O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RCTs O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
health O-MISC I-ANAT-MISC
professionals O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
potentially O-MISC B-ACTI-MISC
limits O-MISC B-ACTI-MISC
generalizability O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Aspirin B-CHED-MISC O-MISC
reduces O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
strokes B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Aspirin B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
increases O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
bleeding B-DISO-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Reducing O-MISC B-CHED-MISC
harm O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
anticoagulation O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
practical O-MISC I-ACTI-MISC
considerations O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
heparin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
thrombocytopenia B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Argatroban B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hepatically O-MISC I-GENE-MISC
metabolized O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
thrombin O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
prophylaxis O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
heparin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
thrombocytopenia B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HIT B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
at O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC I-ACTI-MISC
undergoing O-MISC B-ACTI-MISC
percutaneous O-MISC B-CONC-MISC
coronary O-MISC I-CONC-MISC
intervention O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PCI O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
objective O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
summarize O-MISC B-ACTI-MISC
practical O-MISC I-ACTI-MISC
considerations O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
HIT B-DISO-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
US O-MISC B-PHYS-MISC
FDA O-MISC B-PHYS-MISC
- O-MISC B-ACTI-MISC
recommended O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
HIT B-DISO-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hepatic B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
paediatric O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
adjusted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
achieve O-MISC B-ACTI-MISC
activated O-MISC B-CONC-MISC
partial O-MISC I-CONC-MISC
thromboplastin O-MISC I-CONC-MISC
times O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
aPTTs O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
seconds O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Contemporary O-MISC B-CHED-MISC
experiences O-MISC I-DISO-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
are O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
conditions O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
hepatic O-MISC I-ACTI-MISC
hypoperfusion O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
unnecessary O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
age O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
race O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
ethnicity O-MISC I-PHEN-MISC
or O-MISC B-ACTI-MISC
obesity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Argatroban B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
typically O-MISC B-ACTI-MISC
supports O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
aPTTs O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
FDA O-MISC B-PHYS-MISC
- O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
PCI O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
350 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
bolus O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
adjusted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
achieve O-MISC B-ACTI-MISC
activated O-MISC B-CHED-MISC
clotting O-MISC I-CHED-MISC
times O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
ACTs O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
450 O-MISC B-ACTI-MISC
sec O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
PCI O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
hepatically O-MISC I-ACTI-MISC
impaired O-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
adjustment O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
unnecessary O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
age O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
race O-MISC I-ACTI-MISC
/ O-MISC B-ANAT-MISC
ethnicity O-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
obesity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
lesser O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
adequate O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
concurrent O-MISC B-CHED-MISC
glycoprotein O-MISC O-MISC
IIb O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
IIIa O-MISC O-MISC
inhibition O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Argatroban B-CHED-MISC O-MISC
prolongs O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
International O-MISC B-CHED-MISC
Normalized O-MISC I-CHED-MISC
Ratio O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
published O-MISC B-CHED-MISC
approaches O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
monitoring O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
transition O-MISC B-OCCU-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
followed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Major O-MISC B-ACTI-MISC
bleeding B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
non O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
interventional O-MISC I-CHED-MISC
setting O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
periprocedurally O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Argatroban B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
specific O-MISC B-CHED-MISC
antidote O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
excessive O-MISC B-CHED-MISC
anticoagulation O-MISC B-CONC-MISC
occurs O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
stopped O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Improved O-MISC I-ACTI-MISC
familiarity O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
healthcare O-MISC I-ANAT-MISC
professionals O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
HIT B-DISO-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
special O-MISC I-ANAT-MISC
populations O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
PCI O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
facilitate O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
harm O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
HIT B-DISO-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
thromboses O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
medication O-MISC B-CHED-MISC
errors O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Rhabdomyolysis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
brain O-MISC I-ACTI-MISC
ischemic B-DISO-MISC B-ANAT-MISC
stroke I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
heroin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
under O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
maintenance O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
There O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
heroin B-DISO-MISC I-ACTI-MISC
abuse I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
life O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Methadone B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
aggravate O-MISC B-CHED-MISC
this O-MISC B-ACTI-MISC
problem O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHOD O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
case O-MISC B-CHED-MISC
description O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
cerebral O-MISC I-ACTI-MISC
ischemic B-DISO-MISC B-ANAT-MISC
stroke I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
heroin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
heroin B-CHED-MISC O-MISC
since O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
20 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
daily O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
unconsciousness B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
home O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
sent O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
hospital O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ER O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
opiate O-MISC B-OCCU-MISC
level O-MISC I-OCCU-MISC
was O-MISC B-ACTI-MISC
4497 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ICU O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
respiratory B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
transfer O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
internal O-MISC B-GENE-MISC
ward O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
aphasia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
weakness B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
limbs O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
MRI O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
ischemic I-DISO-MISC B-ANAT-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Those O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
methadone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
heroin B-CHED-MISC O-MISC
simultaneously O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
stroke I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
under O-MISC B-ACTI-MISC
methadone B-CHED-MISC B-CONC-MISC
maintenance O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
warned O-MISC B-ACTI-MISC
regarding O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Hypotheses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heroin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
heroin B-CHED-MISC O-MISC
abusers O-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-CHED-MISC
vulnerability O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
6 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
hydroxydopamine I-CHED-MISC B-DISO-MISC
lesion O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
lacking O-MISC B-ACTI-MISC
CB1 O-MISC O-MISC
cannabinoid O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Motor O-MISC I-ACTI-MISC
impairment O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
neuronal O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
proenkephalin B-CHED-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
PENK B-CHED-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
caudate O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
putamen O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
CPu O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
6 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
OHDA I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
lesioned O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
DOPA I-CHED-MISC B-DISO-MISC
+ I-CHED-MISC B-ACTI-MISC
benserazide I-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
CB1 O-MISC B-LIVB-MISC
KO O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
lesion O-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
6 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
OHDA I-CHED-MISC B-DISO-MISC
produced O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
motor O-MISC B-OCCU-MISC
deterioration O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
CB1 O-MISC I-ACTI-MISC
KO O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
accompanied O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
loss O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
DA B-CHED-MISC I-GENE-MISC
neurons O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
PENK B-CHED-MISC O-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CPu O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Oxidative O-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
nitrosative O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
neuroinflammatory O-MISC B-CHED-MISC
parameters O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
estimated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CPu O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
cingulate O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
Cg O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CB1 O-MISC B-LIVB-MISC
KO O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
exhibited O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
MDA B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
iNOS O-MISC O-MISC
protein O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CPu O-MISC O-MISC
and O-MISC B-ACTI-MISC
Cg O-MISC O-MISC
compared O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
DOPA I-CHED-MISC B-DISO-MISC
+ I-CHED-MISC B-ACTI-MISC
benserazide I-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
CB1 O-MISC I-ANAT-MISC
KO O-MISC I-ANAT-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cannabinoid O-MISC O-MISC
CB1 O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
increased O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
motor O-MISC I-ACTI-MISC
impairment O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
DA B-CHED-MISC I-ACTI-MISC
lesion O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
DOPA I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
activation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
CB1 O-MISC B-LIVB-MISC
receptors O-MISC I-PROC-MISC
offers O-MISC B-ACTI-MISC
neuroprotection O-MISC I-DISO-MISC
against O-MISC B-ACTI-MISC
dopaminergic O-MISC I-ACTI-MISC
lesion O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
DOPA I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Hepatocellular O-MISC I-GENE-MISC
oxidant O-MISC O-MISC
stress O-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
intestinal O-MISC I-ACTI-MISC
ischemia B-DISO-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
reperfusion B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Reperfusion O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
intestine O-MISC I-GENE-MISC
results O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
liver B-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
hepatocellular O-MISC I-GENE-MISC
enzyme O-MISC O-MISC
release O-MISC B-CHED-MISC
into O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
bile O-MISC I-DISO-MISC
flow O-MISC I-LIVB-MISC
rate O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
neutrophil O-MISC B-OCCU-MISC
sequestration O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pathophysiology O-MISC B-CHED-MISC
underlying O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
hepatic B-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
undertaken O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
oxidants O-MISC O-MISC
are O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
hepatic B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
relative O-MISC B-ACTI-MISC
value O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
indirect O-MISC B-CHED-MISC
methods O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
assessing O-MISC B-ACTI-MISC
oxidant O-MISC O-MISC
exposure O-MISC B-CHED-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
subjected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
standardized O-MISC B-CHED-MISC
intestinal O-MISC I-ACTI-MISC
ischemia B-DISO-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
reperfusion B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Hepatic O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
assayed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
lipid O-MISC I-DISO-MISC
peroxidation O-MISC I-LIVB-MISC
products O-MISC B-GENE-MISC
and O-MISC B-ACTI-MISC
oxidized B-CHED-MISC I-DISO-MISC
and I-CHED-MISC B-ACTI-MISC
reduced I-CHED-MISC B-OCCU-MISC
glutathione I-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
total O-MISC B-ACTI-MISC
glutathione B-CHED-MISC O-MISC
following O-MISC B-ACTI-MISC
intestinal O-MISC I-ACTI-MISC
ischemia B-DISO-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
reperfusion B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Oxidized B-CHED-MISC O-MISC
glutathione I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GSSG B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
significantly O-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
reperfusion O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
products O-MISC O-MISC
of O-MISC B-ACTI-MISC
lipid O-MISC I-DISO-MISC
peroxidation O-MISC I-LIVB-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
this O-MISC B-ACTI-MISC
injury O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
GSSG B-CHED-MISC O-MISC
within O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
during O-MISC B-ACTI-MISC
intestinal O-MISC I-ACTI-MISC
reperfusion O-MISC B-ANAT-MISC
suggests O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hepatocytes O-MISC I-GENE-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
oxidant O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
products O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lipid O-MISC I-DISO-MISC
peroxidation O-MISC I-LIVB-MISC
suggests O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
oxidant O-MISC O-MISC
stress O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
insufficient O-MISC B-CHED-MISC
magnitude O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
irreversible O-MISC B-ACTI-MISC
injury O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
hepatocyte O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
membranes O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
also O-MISC B-ACTI-MISC
suggest O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
measurement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tissue O-MISC I-GENE-MISC
GSSG B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
indicator O-MISC O-MISC
of O-MISC B-ACTI-MISC
oxidant O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
than O-MISC B-ACTI-MISC
measurement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
products O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lipid O-MISC I-DISO-MISC
peroxidation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Animal O-MISC I-ANAT-MISC
model O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
mania B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
ouabain B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
Evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
submitochondrial O-MISC I-GENE-MISC
particles O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-GENE-MISC
brain O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
intracerebroventricular O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
ICV O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ouabain B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Na B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
/ O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
ATPase O-MISC B-DISO-MISC
inhibitor O-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
mimic O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
bipolar B-DISO-MISC I-ACTI-MISC
mania I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Herein O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ICV O-MISC B-CHED-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ouabain B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
achieve O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
ouabain B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
immediately O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
ICV O-MISC B-CONC-MISC
administration O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
concentrations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
M O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
locomotion O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
open O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
field O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Additionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
thiobarbituric B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
reactive O-MISC B-DISO-MISC
substances O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TBARSs O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
superoxide B-CHED-MISC O-MISC
production O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
submitochondrial O-MISC I-GENE-MISC
particles O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prefrontal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
striatum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
amygdala O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
findings O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
ouabain B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
M O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperlocomotion B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
remained O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
ICV O-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
spontaneous O-MISC I-DISO-MISC
locomotion O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
increased O-MISC B-ACTI-MISC
TBARS O-MISC O-MISC
levels O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
superoxide B-CHED-MISC O-MISC
generation O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
submitochondrial O-MISC I-GENE-MISC
particles O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prefrontal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
striatum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
amygdala O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ouabain B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
mania B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ANAT-MISC
behavior O-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
animal O-MISC I-ACTI-MISC
model O-MISC I-PHEN-MISC
to O-MISC B-ACTI-MISC
test O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
involvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Intraoperative O-MISC B-CONC-MISC
dialysis O-MISC I-CONC-MISC
during O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
citrate B-CHED-MISC O-MISC
dialysate O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
acutely O-MISC I-ACTI-MISC
ill O-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
fulminant B-DISO-MISC B-CHED-MISC
liver I-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
carries O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
intraoperative O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
immediate O-MISC B-ACTI-MISC
postoperative O-MISC B-CHED-MISC
risks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
concomitant O-MISC B-CHED-MISC
acute B-DISO-MISC I-ACTI-MISC
kidney I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AKI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
intraoperative O-MISC B-CONC-MISC
dialysis O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
sometimes O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
allow O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transplant O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
proceed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
derangements O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
procoagulant O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
anticoagulant O-MISC I-DISO-MISC
pathways O-MISC I-LIVB-MISC
during O-MISC B-ACTI-MISC
fulminant B-DISO-MISC B-CHED-MISC
liver I-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
can O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
difficulties O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
anticoagulation O-MISC B-CONC-MISC
during O-MISC B-ACTI-MISC
dialysis O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
continued O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
operating O-MISC B-GENE-MISC
room O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

Systemic O-MISC B-CHED-MISC
anticoagulation O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
unsafe O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
regional O-MISC B-CHED-MISC
citrate B-CHED-MISC I-DISO-MISC
anticoagulation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
functional O-MISC I-GENE-MISC
liver O-MISC B-GEOG-MISC
carries O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
citrate B-CHED-MISC I-ACTI-MISC
toxicity B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Citrate B-CHED-MISC O-MISC
dialysate O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
dialysate O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
citric B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
anticoagulation O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
cannot O-MISC B-ACTI-MISC
tolerate O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
regional O-MISC B-CHED-MISC
citrate B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
fulminant B-DISO-MISC B-CHED-MISC
liver I-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
AKI B-DISO-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
intraoperative O-MISC B-CHED-MISC
dialytic O-MISC B-CONC-MISC
support O-MISC I-CONC-MISC
during O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
anticoagulated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
citrate B-CHED-MISC O-MISC
dialysate O-MISC I-CONC-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
entire O-MISC B-ACTI-MISC
procedure O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
tolerated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
procedure O-MISC B-CONC-MISC
well O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
signs O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
citrate B-CHED-MISC O-MISC
toxicity B-DISO-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
maintained O-MISC B-ACTI-MISC
adequate O-MISC B-CHED-MISC
anticoagulation O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
patency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dialysis O-MISC B-PHEN-MISC
circuit O-MISC B-UnknownType-MISC
. O-MISC B-ACTI-MISC

Citrate B-CHED-MISC B-CONC-MISC
dialysate O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
intradialytic O-MISC B-CONC-MISC
support O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
fulminant B-DISO-MISC B-ACTI-MISC
liver I-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Delirium B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
toxic O-MISC B-CHED-MISC
flecainide B-CHED-MISC O-MISC
plasma O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pharmacokinetic O-MISC I-DISO-MISC
drug O-MISC I-LIVB-MISC
interaction O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
paroxetine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
delirium B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
pharmacokinetic O-MISC I-DISO-MISC
drug O-MISC I-LIVB-MISC
interaction O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
paroxetine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CASE O-MISC B-CHED-MISC
SUMMARY O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
69 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
white O-MISC I-ACTI-MISC
female O-MISC I-DISO-MISC
presented O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emergency O-MISC B-GENE-MISC
department O-MISC I-GEOG-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
confusion B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
paranoia B-DISO-MISC I-ACTI-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
past O-MISC B-CHED-MISC
several O-MISC I-ACTI-MISC
days O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
carvedilol B-CHED-MISC O-MISC
12 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
twice O-MISC B-CHED-MISC
daily O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
folic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
levothyroxine B-CHED-MISC O-MISC
100 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
pantoprazole B-CHED-MISC O-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
paroxetine B-CHED-MISC O-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
twice O-MISC B-CHED-MISC
daily O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Flecainide B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
started O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Laboratory O-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
findings O-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
notable O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
plasma O-MISC B-CHED-MISC
concentration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
1360 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
reference O-MISC B-ACTI-MISC
range O-MISC I-CHED-MISC
200 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1000 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
drug O-MISC I-DISO-MISC
interaction O-MISC I-LIVB-MISC
between O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
paroxetine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Paroxetine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
twice O-MISC B-CHED-MISC
daily O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Her O-MISC B-ACTI-MISC
delirium B-DISO-MISC I-ACTI-MISC
resolved O-MISC I-ACTI-MISC
3 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

DISCUSSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Flecainide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pharmacologically O-MISC B-CHED-MISC
similar O-MISC B-ACTI-MISC
agents O-MISC O-MISC
that O-MISC B-ACTI-MISC
interact O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
channels O-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
delirium B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
susceptible O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
MEDLINE O-MISC B-CHED-MISC
search O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1966 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
January O-MISC B-ACTI-MISC
2009 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
revealed O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
pharmacokinetic O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
interaction O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
CYP2D6 O-MISC O-MISC
substrate O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
paroxetine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
CYP2D6 O-MISC O-MISC
inhibitor O-MISC O-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
reports O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
delirium B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

According O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Naranjo O-MISC B-CHED-MISC
probability O-MISC I-CHED-MISC
scale O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
probable O-MISC B-CHED-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
delirium B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Horn O-MISC B-CHED-MISC
Drug O-MISC I-CHED-MISC
Interaction O-MISC I-CHED-MISC
Probability O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
indicates O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
pharmacokinetic O-MISC I-DISO-MISC
drug O-MISC I-LIVB-MISC
interaction O-MISC I-LIVB-MISC
between O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
paroxetine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Supratherapeutic O-MISC O-MISC
flecainide B-CHED-MISC O-MISC
plasma O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
may O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
delirium B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
paroxetine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
potent O-MISC B-ACTI-MISC
CYP2D6 O-MISC O-MISC
inhibitors O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
flecainide B-CHED-MISC O-MISC
plasma O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
monitored O-MISC B-ACTI-MISC
closely O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
commencement O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CYP2D6 O-MISC O-MISC
inhibitors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
everolimus B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
RAD001 B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
advanced O-MISC B-CHED-MISC
NSCLC B-DISO-MISC I-ACTI-MISC
previously O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
chemotherapy O-MISC B-CONC-MISC
alone O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
EGFR O-MISC O-MISC
inhibitors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Treatment O-MISC B-CONC-MISC
options O-MISC I-CONC-MISC
are O-MISC B-ACTI-MISC
scarce O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
pretreated O-MISC B-ACTI-MISC
advanced O-MISC B-ACTI-MISC
non B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
small I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
lung I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
NSCLC B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

RAD001 B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
oral O-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mammalian O-MISC O-MISC
target O-MISC B-DISO-MISC
of O-MISC B-DISO-MISC
rapamycin B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
mTOR O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
I O-MISC I-CONC-MISC
efficacy O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
NSCLC B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Stage O-MISC B-CHED-MISC
IIIb O-MISC I-CHED-MISC
or O-MISC B-ACTI-MISC
IV O-MISC B-CHED-MISC
NSCLC B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
regimens O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
platinum B-CHED-MISC O-MISC
based O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
stratum O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
epidermal O-MISC O-MISC
growth O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
tyrosine B-CHED-MISC B-DISO-MISC
kinase O-MISC B-DISO-MISC
inhibitors O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
stratum O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
RAD001 B-CHED-MISC O-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
until O-MISC B-ACTI-MISC
progression O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
unacceptable O-MISC B-ACTI-MISC
toxicity B-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Primary O-MISC B-ACTI-MISC
objective O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
response O-MISC I-CHED-MISC
rate O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
ORR O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Analyses O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
markers O-MISC I-DISO-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
mTOR O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
archival O-MISC I-ACTI-MISC
tumor B-DISO-MISC B-ANAT-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
subgroup O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
immunohistochemistry O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
IHC O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
direct O-MISC B-CONC-MISC
mutation O-MISC I-CONC-MISC
sequencing O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Eighty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
stratum O-MISC I-GENE-MISC
1 O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
stratum O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

ORR O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
stratum O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
stratum O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Overall O-MISC B-ACTI-MISC
disease O-MISC B-CONC-MISC
control O-MISC I-CONC-MISC
rate O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-ACTI-MISC
progression O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
free O-MISC I-CHED-MISC
survivals O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
PFSs O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
stratum O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
stratum O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Common O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
grade O-MISC B-CHED-MISC
3 O-MISC B-ACTI-MISC
events O-MISC B-DEVI-MISC
were O-MISC B-ACTI-MISC
fatigue B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
dyspnea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
stomatitis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
anemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Pneumonitis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mainly O-MISC B-ACTI-MISC
grade O-MISC I-ACTI-MISC
1 O-MISC B-ANAT-MISC
/ O-MISC B-ACTI-MISC
2 O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
occurred O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Cox O-MISC B-CHED-MISC
regression O-MISC I-CHED-MISC
analysis O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
IHC O-MISC B-CHED-MISC
scores O-MISC B-CHED-MISC
found O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
phospho O-MISC O-MISC
AKT O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
pAKT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
independent O-MISC B-CHED-MISC
predictor O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
worse O-MISC I-ACTI-MISC
PFS O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
RAD001 B-CHED-MISC O-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
modest O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
activity O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
pretreated O-MISC B-ACTI-MISC
NSCLC B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
RAD001 B-CHED-MISC O-MISC
plus O-MISC B-ACTI-MISC
standard O-MISC B-CONC-MISC
therapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
metastatic O-MISC I-ACTI-MISC
NSCLC B-DISO-MISC B-ANAT-MISC
continues O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Posttransplant O-MISC I-ACTI-MISC
anemia B-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
sirolimus B-CHED-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Posttransplant O-MISC I-ACTI-MISC
anemia B-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
problem O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
hinder O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
' O-MISC B-ACTI-MISC
quality O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
life O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
occurs O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
immediate O-MISC B-ACTI-MISC
posttransplant O-MISC B-CHED-MISC
period O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
posttransplant O-MISC I-ACTI-MISC
anemia B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Sirolimus B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mammalian O-MISC I-ANAT-MISC
target O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
rapamycin B-CHED-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
playing O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
special O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
posttransplant O-MISC I-ACTI-MISC
anemia B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
considers O-MISC B-ACTI-MISC
anemia B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
sirolimus B-CHED-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
presentation O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Coronary O-MISC B-CONC-MISC
computerized O-MISC I-CONC-MISC
tomography O-MISC I-CONC-MISC
angiography O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
rapid O-MISC B-ACTI-MISC
discharge O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
risk O-MISC I-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
presenting O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
emergency O-MISC B-GENE-MISC
departments O-MISC I-GEOG-MISC
( O-MISC B-ACTI-MISC
EDs O-MISC B-GENE-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
at O-MISC B-CHED-MISC
least O-MISC I-CHED-MISC
12 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
rule O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
coronary I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
" O-MISC B-ACTI-MISC
protocol O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
noninvasive O-MISC B-CONC-MISC
testing O-MISC B-CONC-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
discharge O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
coronary O-MISC I-GENE-MISC
computerized O-MISC B-CONC-MISC
tomography O-MISC I-CONC-MISC
angiography O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
CTA O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
identifying O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
safely O-MISC B-ACTI-MISC
discharged O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
unclear O-MISC I-ACTI-MISC
whether O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
coronary O-MISC I-GENE-MISC
CTA O-MISC B-CONC-MISC
strategy O-MISC B-CONC-MISC
would O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
efficacious O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
vasospasm I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
account O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ischemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
coronary O-MISC I-GENE-MISC
CTA O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ANAT-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
could O-MISC B-ACTI-MISC
identify O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
subset O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
discharge O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
prospectively O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
coronary O-MISC I-GENE-MISC
CTA O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
risk O-MISC I-CHED-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ED O-MISC B-GENE-MISC
with O-MISC B-ACTI-MISC
cocaineassociated O-MISC I-ACTI-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
self O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
reported O-MISC I-CONC-MISC
or O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
urine O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Consecutive O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
immediate O-MISC B-CHED-MISC
coronary O-MISC B-CONC-MISC
CTA O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ED O-MISC B-GENE-MISC
( O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
serial O-MISC B-ACTI-MISC
markers O-MISC B-OBJC-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
coronary O-MISC B-CONC-MISC
CTA O-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
brief O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
period O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
serial O-MISC B-ACTI-MISC
cardiac O-MISC B-OBJC-MISC
marker O-MISC I-OBJC-MISC
measurements O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
coronary O-MISC I-GENE-MISC
CTA O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
maximal O-MISC B-ACTI-MISC
stenosis B-DISO-MISC B-CHED-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
discharged O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
main O-MISC B-CHED-MISC
outcome O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
cardiovascular O-MISC I-ACTI-MISC
death O-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
yrs O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
black O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
66 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Seventy O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
nonspecific O-MISC B-CHED-MISC
ECG O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
TIMI O-MISC B-CHED-MISC
score O-MISC B-CHED-MISC
< O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
received O-MISC B-CHED-MISC
coronary O-MISC I-GENE-MISC
CTA O-MISC B-CONC-MISC
immediately O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ED O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
discharged O-MISC B-CONC-MISC
following O-MISC B-ACTI-MISC
CTA O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Thirty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
coronary O-MISC I-GENE-MISC
CTA O-MISC B-CONC-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
brief O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
period O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
discharged O-MISC B-CONC-MISC
home O-MISC I-CONC-MISC
following O-MISC B-ACTI-MISC
CTA O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
stenosis I-DISO-MISC B-ANAT-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
period O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
died O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cardiovascular O-MISC I-ACTI-MISC
event O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
sustained O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
nonfatal O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Although O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
myocardial B-DISO-MISC B-ANAT-MISC
ischemia I-DISO-MISC B-ANAT-MISC
can O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
coronary O-MISC I-ACTI-MISC
vasoconstriction O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
associated O-MISC B-ANAT-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
ischemic B-DISO-MISC B-ANAT-MISC
ECG O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
TIMI O-MISC I-ACTI-MISC
risk O-MISC B-CHED-MISC
score O-MISC B-CHED-MISC
< O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
safely O-MISC B-ACTI-MISC
discharged O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ED O-MISC B-GENE-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
coronary O-MISC I-GENE-MISC
CTA O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Bilateral O-MISC B-CHED-MISC
haemorrhagic B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
globus I-DISO-MISC I-ANAT-MISC
pallidus I-DISO-MISC I-PHEN-MISC
after O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
alcohol B-CHED-MISC I-ACTI-MISC
intoxication O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Cocaine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
haemorrhagic I-DISO-MISC B-CHED-MISC
stroke I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
bilateral O-MISC I-ACTI-MISC
ischemia B-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
globus I-DISO-MISC I-GENE-MISC
pallidus I-DISO-MISC B-GEOG-MISC
after O-MISC B-ACTI-MISC
excessive O-MISC B-CHED-MISC
alcohol B-CHED-MISC B-PHEN-MISC
and O-MISC B-ACTI-MISC
intranasal O-MISC B-CHED-MISC
cocaine B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
globus B-DISO-MISC I-ANAT-MISC
pallidus I-DISO-MISC I-PHEN-MISC
infarctions I-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
heroin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Bilateral O-MISC B-CHED-MISC
basal B-DISO-MISC I-ACTI-MISC
ganglia I-DISO-MISC B-ANAT-MISC
infarcts I-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
concurrent O-MISC B-CHED-MISC
heroin B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
never O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
transient O-MISC I-ACTI-MISC
cardiac B-DISO-MISC B-ANAT-MISC
arrhythmia I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
respiratory B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
ethanol B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
causes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
hypoperfusion I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Late O-MISC I-ACTI-MISC
fulminant O-MISC B-ANAT-MISC
posterior B-DISO-MISC B-ANAT-MISC
reversible I-DISO-MISC B-ANAT-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Posterior B-DISO-MISC I-ACTI-MISC
leukoencephalopathy I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
calcineurin O-MISC O-MISC
- O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
immunosuppressive O-MISC O-MISC
agents O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
primarily O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
kidney O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pathophysiologic O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
disorder O-MISC I-ACTI-MISC
remain O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CASE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
center O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
alcoholic B-DISO-MISC I-ACTI-MISC
cirrhosis I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fulminant O-MISC B-ACTI-MISC
course O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
posterior B-DISO-MISC I-ACTI-MISC
leukoencephalopathy I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
posterior B-DISO-MISC I-ACTI-MISC
reversible I-DISO-MISC B-ANAT-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
developed O-MISC B-ACTI-MISC
110 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
transplant O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
initially O-MISC B-ACTI-MISC
uneventful O-MISC B-ACTI-MISC
course O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transplant O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
rapidly O-MISC B-ACTI-MISC
fell O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
deep O-MISC I-ACTI-MISC
coma O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Cerebral O-MISC B-CONC-MISC
MRI O-MISC I-CONC-MISC
scan O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
signs O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
enhancement O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pontine O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
posterior O-MISC I-GENE-MISC
regions O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Switching O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
immunosuppressive O-MISC B-CONC-MISC
regimen O-MISC I-CONC-MISC
from O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
improve O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
situation O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
termination O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
calcineurin O-MISC O-MISC
inhibitor O-MISC B-CHED-MISC
resulted O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
resolution O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Posterior B-DISO-MISC I-ACTI-MISC
reversible I-DISO-MISC B-ANAT-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
recommend O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
cessation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
calcineurin O-MISC O-MISC
inhibitor O-MISC O-MISC
rather O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
reduction O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Prolonged O-MISC B-CHED-MISC
hypothermia B-DISO-MISC B-CONC-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
bridge O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
recovery O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
intracranial B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
fulminant B-DISO-MISC B-CHED-MISC
hepatic I-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
evidence O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
options O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
complicating O-MISC B-CHED-MISC
fulminant B-DISO-MISC B-CHED-MISC
hepatic I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
FHF B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
discuss O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
applications O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
hypothermia B-DISO-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

METHOD O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
based O-MISC I-CONC-MISC
observations O-MISC I-CONC-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
medical O-MISC B-GENE-MISC
intensive O-MISC I-GEOG-MISC
care O-MISC I-GEOG-MISC
unit O-MISC I-GEOG-MISC
( O-MISC B-ACTI-MISC
MICU O-MISC B-GENE-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tertiary O-MISC B-GENE-MISC
care O-MISC I-GEOG-MISC
facility O-MISC I-GEOG-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
FHF B-DISO-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
resultant O-MISC B-CHED-MISC
cerebral B-DISO-MISC B-ANAT-MISC
edema I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MICU O-MISC B-CONC-MISC
after O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
unresponsive O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
presumed O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
ingested O-MISC B-OCCU-MISC
over O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
period O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
depressed O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
mental O-MISC I-ACTI-MISC
status O-MISC B-ANAT-MISC
lasting O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Initial O-MISC B-ACTI-MISC
evaluation O-MISC B-CONC-MISC
confirmed O-MISC B-ACTI-MISC
FHF B-DISO-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
hyperosmolar O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
hyperventilation B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
sedation O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
chemical O-MISC B-OCCU-MISC
paralysis B-DISO-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

Her O-MISC B-ACTI-MISC
intracranial O-MISC I-ACTI-MISC
pressure O-MISC B-ANAT-MISC
remained O-MISC B-ACTI-MISC
elevated O-MISC B-ANAT-MISC
despite O-MISC B-ACTI-MISC
maximal O-MISC B-CHED-MISC
medical O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
therapeutic O-MISC B-CONC-MISC
hypothermia B-DISO-MISC I-CONC-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
continued O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
re O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
warming O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
resolution O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
intracranial B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
discharge O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
recovery O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
neurological O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
hepatic O-MISC I-DISO-MISC
functions O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
FHF B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
from O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
overdose B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
therapeutic O-MISC B-CONC-MISC
hypothermia B-DISO-MISC I-CONC-MISC
could O-MISC B-ACTI-MISC
potentially O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
life O-MISC B-CHED-MISC
saving O-MISC I-CHED-MISC
therapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
bridge O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
neurological O-MISC B-CHED-MISC
recovery O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
hypothermia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
condition O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
warranted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Binasal B-DISO-MISC I-GENE-MISC
visual I-DISO-MISC I-ACTI-MISC
field I-DISO-MISC B-ANAT-MISC
defects I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
vigabatrin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
investigated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
defects I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
antiepileptic O-MISC O-MISC
drug O-MISC B-DISO-MISC
vigabatrin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
VGB B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
hundred O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
people O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
grouped O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
antiepileptic O-MISC O-MISC
drug O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
current O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
previous O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
VGB B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Groups O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
matched O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
respect O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
gender O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
frequency O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
underwent O-MISC B-ACTI-MISC
objective O-MISC B-CHED-MISC
assessment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
electrophysiological O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
wide O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
field O-MISC I-CONC-MISC
multifocal O-MISC I-CONC-MISC
electroretinography O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
conventional O-MISC B-CHED-MISC
visual O-MISC B-CONC-MISC
field O-MISC I-CONC-MISC
testing O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
static O-MISC B-CONC-MISC
perimetry O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Bilateral O-MISC B-CHED-MISC
visual O-MISC I-ACTI-MISC
field O-MISC B-ANAT-MISC
constriction O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
currently O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
VGB B-CHED-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
took O-MISC B-ACTI-MISC
VGB B-CHED-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
VGB B-CHED-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Assessment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
retinal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
revealed O-MISC B-CHED-MISC
abnormal O-MISC I-ACTI-MISC
responses O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
VGB B-CHED-MISC I-ANAT-MISC
users O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
VGB B-CHED-MISC I-ANAT-MISC
users O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
VGB B-CHED-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Bilateral B-DISO-MISC B-CHED-MISC
visual I-DISO-MISC I-DISO-MISC
field I-DISO-MISC I-LIVB-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
population O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
irrespective O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Assessment O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
conventional O-MISC B-CHED-MISC
static O-MISC B-CONC-MISC
perimetry O-MISC I-CONC-MISC
may O-MISC B-ACTI-MISC
neither O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
sufficiently O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
nor O-MISC B-ACTI-MISC
specific O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
reliably O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
retinal B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
VGB B-CHED-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Smoking O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
crack B-CHED-MISC O-MISC
cocaine I-CHED-MISC B-DISO-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
infection I-DISO-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
people O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
injection O-MISC O-MISC
drugs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Little O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
smoking O-MISC B-DEVI-MISC
crack B-CHED-MISC O-MISC
cocaine I-CHED-MISC B-DISO-MISC
has O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
infection I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Given O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
use O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
crack B-CHED-MISC O-MISC
cocaine I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
sought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
examine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
illicit O-MISC O-MISC
drug O-MISC B-DISO-MISC
has O-MISC B-ACTI-MISC
become O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
infection I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
people O-MISC I-ANAT-MISC
participating O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Vancouver O-MISC B-CHED-MISC
Injection O-MISC I-CHED-MISC
Drug O-MISC I-CHED-MISC
Users O-MISC I-CHED-MISC
Study O-MISC I-CHED-MISC
who O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
injecting O-MISC O-MISC
illicit O-MISC O-MISC
drugs O-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
once O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
month O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
enrolment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
lived O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
Vancouver O-MISC B-ORGA-MISC
area O-MISC I-ORGA-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
HIV O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
negative O-MISC I-OCCU-MISC
at O-MISC B-ACTI-MISC
enrolment O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
completed O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
visit O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
seroconversion I-DISO-MISC B-OCCU-MISC
among O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
smokers O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
crack B-CHED-MISC B-ANAT-MISC
cocaine I-CHED-MISC B-ANAT-MISC
changed O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
Cox O-MISC B-CHED-MISC
proportional O-MISC I-CHED-MISC
hazards O-MISC I-CHED-MISC
regression O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
into O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
periods O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
May O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1996 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
Nov O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1999 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
period O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Dec O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1999 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
Nov O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2002 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Dec O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2002 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
Dec O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2005 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
period O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Overall O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1048 O-MISC B-ACTI-MISC
eligible O-MISC B-ACTI-MISC
injection O-MISC O-MISC
drug O-MISC I-ANAT-MISC
users O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
137 O-MISC B-ACTI-MISC
acquired O-MISC B-CHED-MISC
HIV B-DISO-MISC I-ACTI-MISC
infection I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
proportion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
smoking O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
crack B-CHED-MISC O-MISC
cocaine I-CHED-MISC B-DISO-MISC
increased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
adjusting O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
confounders O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
seroconversion I-DISO-MISC B-OCCU-MISC
among O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
smokers O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
crack B-CHED-MISC O-MISC
cocaine I-CHED-MISC B-ANAT-MISC
increased O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
1 O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
hazard O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
[ O-MISC B-ACTI-MISC
HR O-MISC B-CHED-MISC
] O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
[ O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
] O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
2 O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
HR O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
3 O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
HR O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
74 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
06 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

INTERPRETATION O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Smoking O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
crack B-CHED-MISC O-MISC
cocaine I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
independent O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ANAT-MISC
seroconversion I-DISO-MISC B-OCCU-MISC
among O-MISC B-ACTI-MISC
people O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
injection O-MISC I-ACTI-MISC
drug O-MISC I-ANAT-MISC
users O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
finding O-MISC B-ACTI-MISC
points O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urgent O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
public O-MISC B-CONC-MISC
health O-MISC I-CONC-MISC
initiatives O-MISC I-CONC-MISC
targeted O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
people O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
smoke O-MISC B-DEVI-MISC
crack B-CHED-MISC O-MISC
cocaine I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Fluoxetine B-CHED-MISC O-MISC
improves O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
memory B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
chemotherapy O-MISC O-MISC
agent O-MISC B-DISO-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Cancer B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
systemic O-MISC B-CONC-MISC
adjuvant O-MISC I-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
experiencing O-MISC B-ACTI-MISC
deteriorations O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
cognition O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
chemotherapeutic O-MISC O-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
readily O-MISC B-ACTI-MISC
crosses O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
brain O-MISC B-GEOG-MISC
barrier O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
so O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
brain O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
particular O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
anti O-MISC O-MISC
mitotic O-MISC B-DISO-MISC
drug O-MISC B-DISO-MISC
could O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
cell O-MISC I-DISO-MISC
proliferation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neurogenic O-MISC I-GENE-MISC
regions O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
brain O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
reports O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
dependent O-MISC B-ACTI-MISC
neurogenesis O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
cognition O-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SSRI B-CHED-MISC O-MISC
antidepressant O-MISC B-DISO-MISC
Fluoxetine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
investigation O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
behavioural O-MISC B-DEVI-MISC
effects O-MISC I-DEVI-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
Fluoxetine B-CHED-MISC O-MISC
either O-MISC B-ACTI-MISC
separately O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
Lister O-MISC I-ANAT-MISC
hooded O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Behavioural O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
context O-MISC B-CONC-MISC
dependent O-MISC I-CONC-MISC
conditioned O-MISC I-CONC-MISC
emotional O-MISC I-CONC-MISC
response O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
CER O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
freezing O-MISC I-ACTI-MISC
time O-MISC B-CHED-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
separate O-MISC B-ACTI-MISC
group O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
dependent O-MISC B-ACTI-MISC
spatial O-MISC B-CONC-MISC
working O-MISC I-CONC-MISC
memory O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
object O-MISC B-CONC-MISC
location O-MISC I-CONC-MISC
recognition O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
OLR O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
only O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
showed O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
deficits O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
ability O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
carry O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
OLR O-MISC B-DEVI-MISC
task O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
co O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
Fluoxetine B-CHED-MISC O-MISC
improved O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
performance O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

5 B-CHED-MISC B-CONC-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
chemotherapy O-MISC B-CONC-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
proliferating O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sub O-MISC I-GENE-MISC
granular O-MISC B-GEOG-MISC
zone O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dentate O-MISC I-GENE-MISC
gyrus O-MISC B-GEOG-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
eliminated O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
Fluoxetine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
co O-MISC B-CONC-MISC
administered O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Fluoxetine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
own O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
proliferating O-MISC B-CHED-MISC
cell O-MISC B-CONC-MISC
number O-MISC I-CONC-MISC
or O-MISC B-ACTI-MISC
behaviour O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
can O-MISC B-ACTI-MISC
negatively O-MISC I-ACTI-MISC
affect O-MISC I-DISO-MISC
both O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
proliferation O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
dependent O-MISC B-ACTI-MISC
working O-MISC I-DISO-MISC
memory O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
deficits O-MISC B-CHED-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
reversed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
simultaneous O-MISC B-CHED-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
antidepressant O-MISC O-MISC
Fluoxetine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Liver O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-CHED-MISC
ablation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
integrin O-MISC O-MISC
- O-MISC B-DISO-MISC
linked O-MISC B-DISO-MISC
kinase O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
results O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
cell O-MISC I-DISO-MISC
proliferation O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
hepatomegaly B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
phenobarbital B-CHED-MISC I-GENE-MISC
administration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
disruption O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
extracellular O-MISC I-GENE-MISC
matrix O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
ECM O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
integrin O-MISC I-DISO-MISC
signaling O-MISC I-LIVB-MISC
via O-MISC B-ACTI-MISC
elimination O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
integrin O-MISC O-MISC
- O-MISC B-DISO-MISC
linked O-MISC B-DISO-MISC
kinase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ILK O-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hepatocytes O-MISC I-GENE-MISC
interferes O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
signals O-MISC B-OCCU-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
termination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
liver O-MISC I-DISO-MISC
regeneration O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
investigates O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ILK O-MISC O-MISC
in O-MISC B-ACTI-MISC
liver O-MISC I-ACTI-MISC
enlargement O-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
phenobarbital B-CHED-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
PB B-CHED-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Wild O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
type O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ILK O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
liver O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
/ O-MISC I-PHEN-MISC
- O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
PB B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
drinking O-MISC B-GENE-MISC
water O-MISC I-GEOG-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Livers O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
harvested O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
PB B-CHED-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hepatocyte O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-CHED-MISC
ILK O-MISC O-MISC
/ O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
: O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
ratio O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
double O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
5 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
enlarged O-MISC B-CHED-MISC
three O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
expected O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
seems O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
leveled O-MISC B-ACTI-MISC
off O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
slightly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
proliferating O-MISC B-CHED-MISC
cell O-MISC B-GEOG-MISC
nuclear O-MISC B-GEOG-MISC
antigen O-MISC B-GEOG-MISC
- O-MISC B-ACTI-MISC
positive O-MISC B-GEOG-MISC
cells O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ILK O-MISC O-MISC
/ O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
WT O-MISC B-LIVB-MISC
after O-MISC B-ACTI-MISC
PB B-CHED-MISC I-ACTI-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proliferative O-MISC I-ACTI-MISC
response O-MISC I-DISO-MISC
had O-MISC B-ACTI-MISC
come O-MISC B-ACTI-MISC
back O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
5 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hepatocytes O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ILK O-MISC B-LIVB-MISC
/ O-MISC I-PROC-MISC
liver O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
/ O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
mice O-MISC I-ANAT-MISC
continued O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
proliferate O-MISC B-CHED-MISC
up O-MISC B-ACTI-MISC
until O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

ILK O-MISC O-MISC
/ O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
also O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
key O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hepatocyte O-MISC I-DISO-MISC
proliferation O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
points O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
PB B-CHED-MISC B-CONC-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
summary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ECM O-MISC O-MISC
proteins O-MISC B-DISO-MISC
communicate O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
signaling O-MISC I-DISO-MISC
machinery O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
dividing O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
via O-MISC B-ACTI-MISC
ILK O-MISC O-MISC
to O-MISC B-ACTI-MISC
regulate O-MISC B-ACTI-MISC
hepatocyte O-MISC I-DISO-MISC
proliferation O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
termination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proliferative O-MISC B-CHED-MISC
response O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ILK O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hepatocytes O-MISC I-GENE-MISC
imparts O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
proliferative O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
not O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
stimuli O-MISC B-OCCU-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
liver O-MISC I-DISO-MISC
regeneration O-MISC I-LIVB-MISC
but O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
xenobiotic O-MISC O-MISC
chemical O-MISC O-MISC
mitogens O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
PB B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Decreased O-MISC B-CHED-MISC
Expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
Na B-CHED-MISC O-MISC
/ O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
ATPase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
NHE3 O-MISC O-MISC
, O-MISC B-ACTI-MISC
NBC1 O-MISC O-MISC
, O-MISC B-ACTI-MISC
AQP1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
OAT O-MISC O-MISC
in O-MISC B-ACTI-MISC
Gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
Nephropathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
altered O-MISC B-CHED-MISC
regulation O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
tubular O-MISC O-MISC
transporters O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Sprague O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Dawley O-MISC I-PHEN-MISC
male O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
~ O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
subcutaneously O-MISC I-ACTI-MISC
injected O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
tubular O-MISC O-MISC
transporters O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
immunoblotting O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
immunohistochemistry O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mRNA O-MISC O-MISC
and O-MISC B-ACTI-MISC
protein O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
OAT O-MISC O-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
exhibited O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
creatinine B-CHED-MISC O-MISC
clearance O-MISC I-DISO-MISC
along O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
plasma O-MISC B-CONC-MISC
creatinine B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Accordingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fractional O-MISC I-DISO-MISC
excretion O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
increased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Urine O-MISC I-DISO-MISC
volume O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
urine O-MISC I-DISO-MISC
osmolality O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
free O-MISC B-OCCU-MISC
water O-MISC I-OCCU-MISC
reabsorption O-MISC I-OCCU-MISC
were O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Immunoblotting O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
immunohistochemistry O-MISC B-CONC-MISC
revealed O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
Na B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
/ O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
ATPase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
NHE3 O-MISC O-MISC
, O-MISC B-ACTI-MISC
NBC1 O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
AQP1 O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
OAT1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
OAT3 O-MISC O-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
causally O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
Na B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
/ O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
ATPase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
NHE3 O-MISC O-MISC
, O-MISC B-ACTI-MISC
NBC1 O-MISC O-MISC
, O-MISC B-ACTI-MISC
AQP1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
OAT O-MISC O-MISC
. O-MISC B-ACTI-MISC

Acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
methotrexate B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ileostomy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

High O-MISC O-MISC
- O-MISC B-DISO-MISC
dose O-MISC B-DISO-MISC
methotrexate B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
HD O-MISC O-MISC
- O-MISC B-DISO-MISC
MTX B-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
Burkitt B-DISO-MISC I-ACTI-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
hepatic B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
renal I-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
when O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
clearance O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
delayed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
HD O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MTX B-CHED-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ileostomy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
boy O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
living O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
congenital O-MISC I-ACTI-MISC
biliary B-DISO-MISC B-ANAT-MISC
atresia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
833 O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transplantation O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
PTLD B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
post B-DISO-MISC B-CHED-MISC
- I-DISO-MISC I-CHED-MISC
transplantation I-DISO-MISC I-CHED-MISC
lymphoproliferative I-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
Burkitt B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
type I-DISO-MISC B-ANAT-MISC
malignant I-DISO-MISC B-ANAT-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
induction O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
suffered O-MISC B-ACTI-MISC
ileal O-MISC I-ACTI-MISC
perforation O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
ileostomy O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Subsequent O-MISC B-ACTI-MISC
HD O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MTX B-CHED-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
caused O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
hemodialysis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
supposed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
intravascular O-MISC I-ACTI-MISC
hypovolemia B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
substantial O-MISC B-ACTI-MISC
drainage O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ileostoma O-MISC I-ACTI-MISC
caused O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
prerenal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
recovery O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
safely O-MISC B-ACTI-MISC
treat O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
HD O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MTX B-CHED-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
by O-MISC B-ACTI-MISC
controlling O-MISC B-ACTI-MISC
drainage O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
ileostoma O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
total O-MISC B-CONC-MISC
parenteral O-MISC I-CONC-MISC
nutrition O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Longitudinal O-MISC B-CHED-MISC
association O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
alcohol B-CHED-MISC B-DEVI-MISC
use O-MISC I-DEVI-MISC
with O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC I-ACTI-MISC
progression O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
psychological O-MISC I-DISO-MISC
health O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
HIV O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
alcohol B-CHED-MISC B-DEVI-MISC
consumption O-MISC I-DEVI-MISC
and O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC I-ACTI-MISC
progression O-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
HIV O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
included O-MISC B-CHED-MISC
871 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
HIV O-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
recruited O-MISC B-DEVI-MISC
from O-MISC B-ACTI-MISC
1993 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1995 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
US O-MISC B-ORGA-MISC
cities O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
physical O-MISC B-CONC-MISC
examination O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
medical O-MISC B-CONC-MISC
record O-MISC I-CONC-MISC
extraction O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
venipuncture O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
CD4 O-MISC B-CONC-MISC
+ O-MISC I-CONC-MISC
T O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
cell O-MISC I-CONC-MISC
counts O-MISC I-CONC-MISC
determination O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
measurement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
self O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
report O-MISC I-CHED-MISC
Center O-MISC B-PHYS-MISC
for O-MISC I-PHYS-MISC
Epidemiological O-MISC I-PHYS-MISC
Studies O-MISC I-PHYS-MISC
- O-MISC B-ACTI-MISC
Depression B-DISO-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
alcohol B-CHED-MISC B-DEVI-MISC
use O-MISC I-DEVI-MISC
assessment O-MISC I-DEVI-MISC
at O-MISC B-ACTI-MISC
enrollment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
semiannually O-MISC B-CHED-MISC
until O-MISC B-ACTI-MISC
March O-MISC B-ACTI-MISC
2000 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Multilevel O-MISC B-CHED-MISC
random O-MISC B-CHED-MISC
coefficient O-MISC I-CHED-MISC
ordinal O-MISC I-CHED-MISC
models O-MISC I-CHED-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
multilevel O-MISC B-CHED-MISC
models O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
joint O-MISC I-ACTI-MISC
responses O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
level O-MISC B-DEVI-MISC
of O-MISC I-DEVI-MISC
alcohol B-CHED-MISC I-DEVI-MISC
use O-MISC I-DEVI-MISC
and O-MISC B-ACTI-MISC
CD4 O-MISC I-GENE-MISC
+ O-MISC B-GEOG-MISC
T O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
counts O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
stratified O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
antiretroviral O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
ART O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
alcohol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
CD4 O-MISC I-GENE-MISC
+ O-MISC B-GEOG-MISC
T O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
reach O-MISC B-ACTI-MISC
statistical O-MISC B-CHED-MISC
significance O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
alcohol B-CHED-MISC B-DEVI-MISC
consumption O-MISC I-DEVI-MISC
and O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Depression B-DISO-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
negative O-MISC I-ACTI-MISC
effect O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
CD4 O-MISC I-GENE-MISC
+ O-MISC B-GEOG-MISC
T O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
cell O-MISC I-CONC-MISC
counts O-MISC I-CONC-MISC
over O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
regardless O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ART O-MISC B-CONC-MISC
use O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
alcohol B-CHED-MISC B-DEVI-MISC
consumption O-MISC I-DEVI-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
depression B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
HIV B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC I-ACTI-MISC
progression O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
have O-MISC B-ACTI-MISC
implications O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
provision O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
alcohol B-CHED-MISC B-DEVI-MISC
use O-MISC I-DEVI-MISC
interventions O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
psychological O-MISC B-CHED-MISC
resources O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
improve O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
health O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
HIV O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Chemokine O-MISC O-MISC
CCL2 O-MISC O-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
receptor O-MISC O-MISC
CCR2 O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
following O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Neuroinflammation B-DISO-MISC I-ACTI-MISC
occurs O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
epileptogenesis O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CCR2 O-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
chemokine O-MISC O-MISC
receptor O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
CCL2 O-MISC O-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
interaction O-MISC I-DISO-MISC
mediates O-MISC B-ACTI-MISC
monocyte O-MISC I-GENE-MISC
infiltration O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neuroinflammatory B-DISO-MISC I-DISO-MISC
cascade O-MISC I-LIVB-MISC
triggered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
brain O-MISC I-ACTI-MISC
pathologies O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
work O-MISC B-ACTI-MISC
CCR2 O-MISC O-MISC
and O-MISC B-ACTI-MISC
CCL2 O-MISC O-MISC
expression O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
examined O-MISC B-CONC-MISC
following O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SE B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
SE B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
instead O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
SE B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
CCR2 O-MISC O-MISC
staining O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
glial O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
using O-MISC B-ACTI-MISC
imunohistochemical O-MISC B-CONC-MISC
analyses O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CCR2 O-MISC I-GENE-MISC
positive O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
stereology O-MISC B-OBJC-MISC
probes O-MISC I-OBJC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

CCL2 O-MISC O-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
molecular O-MISC B-CONC-MISC
assay O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Increased O-MISC B-CHED-MISC
CCR2 O-MISC O-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
after O-MISC B-ACTI-MISC
SE B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Seizures B-DISO-MISC I-ACTI-MISC
also O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
alterations O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cell O-MISC B-CHED-MISC
types O-MISC I-CHED-MISC
expressing O-MISC I-DISO-MISC
CCR2 O-MISC O-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-CHED-MISC
numbers O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
that O-MISC B-ACTI-MISC
expressed O-MISC I-DISO-MISC
CCR2 O-MISC O-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
SE B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Microglial O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
closely O-MISC B-ACTI-MISC
apposed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CCR2 O-MISC O-MISC
- O-MISC B-ACTI-MISC
labeled O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
SE B-DISO-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
experienced O-MISC I-DISO-MISC
SE B-DISO-MISC I-ACTI-MISC
exhibited O-MISC B-ACTI-MISC
CCR2 O-MISC O-MISC
- O-MISC B-ACTI-MISC
labeling O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
hypertrophied B-DISO-MISC I-ACTI-MISC
astrocytes O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
CA1 O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
dentate O-MISC I-GENE-MISC
gyrus O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
CCR2 O-MISC O-MISC
+ O-MISC B-DISO-MISC
astroctytes O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Examination O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
CCL2 O-MISC B-LIVB-MISC
expression O-MISC I-DISO-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
following O-MISC B-ACTI-MISC
SE B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
CCR2 O-MISC O-MISC
and O-MISC B-ACTI-MISC
CCL2 O-MISC O-MISC
are O-MISC B-ACTI-MISC
up O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
regulated O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
after O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
SE B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Seizures B-DISO-MISC I-ACTI-MISC
also O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
CCR2 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
astrocytes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
might O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
detrimental O-MISC B-ACTI-MISC
neuroplasticity O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
neuroinflammatory B-DISO-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Metallothionein B-CHED-MISC O-MISC
induction O-MISC B-CHED-MISC
reduces O-MISC B-CHED-MISC
caspase O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
3 O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
TNFalpha O-MISC O-MISC
levels O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
preservation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cognitive O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
hippocampal O-MISC I-GENE-MISC
neurons O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
carmustine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Hippocampal O-MISC I-GENE-MISC
integrity O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
essential O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
cognitive O-MISC I-DISO-MISC
functions O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
hand O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
metallothionein B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
MT B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
ZnSO B-CHED-MISC O-MISC
( I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
role O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
neuroprotection O-MISC I-DISO-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
aimed O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
explore O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MT B-CHED-MISC I-GENE-MISC
induction O-MISC I-DISO-MISC
on O-MISC B-ACTI-MISC
carmustine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hippocampal O-MISC I-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
Wistar O-MISC I-ANAT-MISC
albino O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
group O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
injected O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
saline O-MISC B-GENE-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
solvent O-MISC O-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
administered O-MISC B-CHED-MISC
ZnSO B-CHED-MISC O-MISC
( I-CHED-MISC B-ACTI-MISC
4 I-CHED-MISC B-ACTI-MISC
) I-CHED-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
microl O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
saline O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
once O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
solvent O-MISC O-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Third O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
received O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
once O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
normal O-MISC B-GENE-MISC
saline O-MISC I-GEOG-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Fourth O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ZnSO B-CHED-MISC O-MISC
( I-CHED-MISC B-ACTI-MISC
4 I-CHED-MISC B-ACTI-MISC
) I-CHED-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
micromol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
microl O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
saline O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
once O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
deterioration B-DISO-MISC B-OCCU-MISC
of I-DISO-MISC B-ACTI-MISC
learning I-DISO-MISC I-DISO-MISC
and I-DISO-MISC B-ACTI-MISC
short I-DISO-MISC B-CHED-MISC
- I-DISO-MISC I-CHED-MISC
term I-DISO-MISC I-CHED-MISC
memory I-DISO-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
STM O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
radial O-MISC B-GENE-MISC
arm O-MISC I-GEOG-MISC
water O-MISC I-GEOG-MISC
maze O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
accompanied O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
hippocampal O-MISC I-GENE-MISC
glutathione B-CHED-MISC O-MISC
reductase O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
GR O-MISC O-MISC
) O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
glutathione B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
GSH B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
content O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Also O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
increased O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
tumor B-DISO-MISC O-MISC
necrosis B-DISO-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
alpha O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TNFalpha O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
MT B-CHED-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
malondialdehyde B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
MDA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
contents O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
caspase O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
3 O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
histological O-MISC I-DISO-MISC
alterations O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

ZnSO B-CHED-MISC O-MISC
( I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
pretreatment O-MISC B-DEVI-MISC
counteracted O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
GR O-MISC O-MISC
and O-MISC B-ACTI-MISC
depletion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
GSH B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MDA B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
TNFalpha O-MISC O-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
caspase O-MISC O-MISC
- O-MISC B-DISO-MISC
3 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
histological O-MISC B-ACTI-MISC
features O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
improved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
ZnSO B-CHED-MISC O-MISC
( I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
+ O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
MT B-CHED-MISC O-MISC
induction O-MISC B-CHED-MISC
halts O-MISC B-ACTI-MISC
BCNU B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hippocampal O-MISC I-GENE-MISC
toxicity B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
GR O-MISC O-MISC
inhibition O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
GSH B-CHED-MISC O-MISC
depletion O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
counteracted O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
TNFalpha O-MISC O-MISC
, O-MISC B-ACTI-MISC
MDA B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
caspase O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
3 O-MISC I-LIVB-MISC
activity O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
preservation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cognition O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Fatal O-MISC B-CHED-MISC
carbamazepine B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
fulminant B-DISO-MISC I-ACTI-MISC
eosinophilic I-DISO-MISC B-ANAT-MISC
( O-MISC B-ANAT-MISC
hypersensitivity B-DISO-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
myocarditis B-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
emphasis O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
anatomical O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
histological O-MISC I-DISO-MISC
characteristics O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
genetics O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
drug B-DISO-MISC I-ACTI-MISC
hypersensitivity I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
differential O-MISC B-CONC-MISC
diagnosis O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
carbamazepine B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
haemopoietic O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
frequently O-MISC B-CHED-MISC
fatal O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
exceptionally O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
carbamazepine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
necrotizing O-MISC I-ACTI-MISC
eosinophilic O-MISC B-ANAT-MISC
( O-MISC B-ANAT-MISC
hypersensitivity B-DISO-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
myocarditis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypersensitivity B-DISO-MISC I-ACTI-MISC
myocarditis B-DISO-MISC B-ANAT-MISC
secondary O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
carbamazepine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC I-ACTI-MISC
hypersensitivity B-DISO-MISC B-ANAT-MISC
myocarditis B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
suspected O-MISC B-ACTI-MISC
clinically O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
made O-MISC B-ACTI-MISC
post O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
mortem O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Histology O-MISC B-PROC-MISC
revealed O-MISC B-CHED-MISC
diffuse O-MISC B-CHED-MISC
infiltration O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardium O-MISC I-GENE-MISC
by O-MISC B-ACTI-MISC
eosinophils O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
lymphocytes O-MISC I-GENE-MISC
with O-MISC B-ACTI-MISC
myocyte O-MISC I-ACTI-MISC
damage O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinically O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cardiogenic B-DISO-MISC I-ACTI-MISC
shock I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
carbamazepine B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
myocarditis B-DISO-MISC I-ACTI-MISC
reported O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
English O-MISC B-CHED-MISC
literature O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Neuropsychiatric O-MISC I-DISO-MISC
behaviors O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MPTP B-CHED-MISC I-ACTI-MISC
marmoset O-MISC I-GENE-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Neuropsychiatric O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
increasingly O-MISC B-ACTI-MISC
recognised O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
problem O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
' O-MISC B-ACTI-MISC
sensitisation O-MISC I-ACTI-MISC
' O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
repeated O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
effect O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
state O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
MPTP B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
lesioned O-MISC I-ACTI-MISC
marmoset O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
neuropsychiatric B-DISO-MISC I-ACTI-MISC
symptoms I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
compare O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
course O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
motor O-MISC I-GENE-MISC
fluctuations O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
neuropsychiatric B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ACTI-MISC
like I-DISO-MISC B-ACTI-MISC
behaviors I-DISO-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
symptoms O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Marmosets O-MISC B-GENE-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
1 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
methyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
phenyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
6 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
tetrahydropyridine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
stable O-MISC B-CHED-MISC
parkinsonism B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Levodopa B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
benserazide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
o O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

b O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
parkinsonian B-DISO-MISC I-ACTI-MISC
disability I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
motor O-MISC I-ACTI-MISC
fluctuations O-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
neuropsychiatric B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
like I-DISO-MISC B-ANAT-MISC
behaviors I-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
Day O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
Days O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
using O-MISC B-ACTI-MISC
post O-MISC B-CONC-MISC
hoc O-MISC I-CONC-MISC
DVD O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
trained O-MISC B-ACTI-MISC
rater O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
blind O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
day O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
neuropsychiatric B-DISO-MISC B-CHED-MISC
- I-DISO-MISC I-CHED-MISC
like I-DISO-MISC I-CHED-MISC
behavior I-DISO-MISC I-CHED-MISC
rating O-MISC I-CHED-MISC
scale O-MISC I-CHED-MISC
demonstrated O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
interrater O-MISC B-ACTI-MISC
reliability O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
trained O-MISC B-CONC-MISC
raters O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
differing O-MISC B-ACTI-MISC
professional O-MISC B-PROC-MISC
backgrounds O-MISC I-UnknownType-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
anticipated O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
exhibited O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
motor O-MISC I-ACTI-MISC
fluctuations O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
wearing O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
off O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
neuropsychiatric B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
like I-DISO-MISC B-ANAT-MISC
behaviors I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
Day O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
correlate O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
neuropsychiatric B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
interaction O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
state O-MISC B-ANAT-MISC
than O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
consequence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
sensitisation O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
repeated O-MISC B-ACTI-MISC
dopaminergic O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Contrast B-CHED-MISC O-MISC
medium I-CHED-MISC B-DISO-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
artery O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
coronary O-MISC B-CONC-MISC
angioplasty O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Renal B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
iodinated O-MISC O-MISC
contrast B-CHED-MISC B-DISO-MISC
medium I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CM B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
can O-MISC B-ACTI-MISC
minimize O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
benefit O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
interventional O-MISC B-CONC-MISC
procedure O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
angioplasty O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PTRA O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
compare O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
nephrotoxic B-DISO-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
CM B-CHED-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
PTRA O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
submitted O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
percutaneous O-MISC B-CONC-MISC
coronary O-MISC I-CONC-MISC
intervention O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PCI O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

MATERIAL O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
successfully O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC I-CONC-MISC
PTRA O-MISC O-MISC
( O-MISC B-ACTI-MISC
PTRA O-MISC O-MISC
group O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
70 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
basal O-MISC O-MISC
creatinine B-CHED-MISC B-DISO-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
79 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
successful O-MISC B-CHED-MISC
PCI O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
PCI O-MISC B-CONC-MISC
group O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
matched O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
basal O-MISC O-MISC
creatinine B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
gender O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
postprocedural O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
creatinine B-CHED-MISC I-CONC-MISC
was O-MISC I-CONC-MISC
measured O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
Postprocedural O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
level O-MISC B-ANAT-MISC
decreased O-MISC B-CHED-MISC
nonsignificantly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PTRA O-MISC B-CONC-MISC
group O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
NS O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
significantly O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PCI O-MISC B-CONC-MISC
group O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Changes O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
intervention O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PTRA O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
PCI O-MISC B-CONC-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
014 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
profile O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
volume O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CM B-CHED-MISC I-GENE-MISC
administered O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
preliminary O-MISC B-CHED-MISC
study O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
submitted O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
PTRA O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
CM B-CHED-MISC B-CONC-MISC
administration O-MISC B-CONC-MISC
than O-MISC B-ACTI-MISC
PCI O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effectiveness O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PTRA O-MISC O-MISC
on O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
seems O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
barely O-MISC B-ACTI-MISC
influenced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
CM B-CHED-MISC I-GENE-MISC
toxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Diphenhydramine B-CHED-MISC O-MISC
prevents O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
haemodynamic O-MISC I-DISO-MISC
changes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cimetidine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
ICU O-MISC B-GENE-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Cimetidine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
histamine B-CHED-MISC O-MISC
2 O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
H2 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
antagonist O-MISC O-MISC
, O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
arterial O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
vasodilatation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
critically O-MISC I-ACTI-MISC
ill O-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
cimetidine B-CHED-MISC O-MISC
acts O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
histamine B-CHED-MISC O-MISC
agonist O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
histamine B-CHED-MISC O-MISC
1 O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
H1 O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
diphenhydramine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
haemodynamic O-MISC I-DISO-MISC
changes O-MISC I-LIVB-MISC
observed O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
cimetidine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
ICU O-MISC B-GENE-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Each O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
separate O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
random O-MISC B-ACTI-MISC
fashion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
cimetidine B-CHED-MISC O-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
iv O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
diphenhydramine B-CHED-MISC O-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
iv O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
cimetidine B-CHED-MISC O-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
iv O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
non O-MISC B-DEVI-MISC
- O-MISC I-PHEN-MISC
pretreatment O-MISC I-PHEN-MISC
group O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MAP O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
107 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
cimetidine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Also O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
systemic O-MISC I-ACTI-MISC
vascular O-MISC B-ANAT-MISC
resistance O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SVR O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
minute O-MISC B-CHED-MISC
observation O-MISC B-CONC-MISC
period O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
group O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
little O-MISC B-ACTI-MISC
haemodynamic O-MISC I-DISO-MISC
change O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
H1 O-MISC O-MISC
antagonist O-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
preventing O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
iv O-MISC I-ANAT-MISC
cimetidine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
since O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vasodilating O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
cimetidine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
H1 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Medical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
psychiatric O-MISC B-CHED-MISC
outcomes O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
transplanted O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hepatotoxicity B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ALF B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
UK O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
often O-MISC B-ACTI-MISC
consume O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
with O-MISC B-ACTI-MISC
suicidal O-MISC I-ACTI-MISC
intent O-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
background O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
substance O-MISC I-ACTI-MISC
dependence O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

AIMS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pretransplant O-MISC I-ACTI-MISC
illness O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
psychiatric O-MISC B-CHED-MISC
co O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
morbidity O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
medical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
psychosocial O-MISC B-CHED-MISC
outcomes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
undergone O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
emergently O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
1999 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2004 O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
matched O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
emergent O-MISC B-CHED-MISC
LT O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
elective O-MISC B-CHED-MISC
LT O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CLD B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
illness O-MISC I-ACTI-MISC
reflected O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
Acute O-MISC B-CHED-MISC
Physiology O-MISC I-CHED-MISC
and O-MISC I-CHED-MISC
Chronic O-MISC I-CHED-MISC
Health O-MISC I-CHED-MISC
Evaluation O-MISC I-CHED-MISC
II O-MISC I-CHED-MISC
scores O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
requirement O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
organ O-MISC B-CONC-MISC
support O-MISC I-CONC-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
formal O-MISC B-ACTI-MISC
psychiatric O-MISC I-ACTI-MISC
diagnosis O-MISC B-ANAT-MISC
before O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
acetaminophen B-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
CLD B-DISO-MISC I-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previous O-MISC B-CHED-MISC
suicide O-MISC I-ACTI-MISC
attempt O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rejection O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
graft O-MISC I-ACTI-MISC
failure O-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
survival O-MISC B-DEVI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
1 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
87 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
75 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
88 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
78 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
CLD B-DISO-MISC I-ACTI-MISC
93 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
82 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
log O-MISC B-ACTI-MISC
rank O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
reattempted O-MISC B-CHED-MISC
suicide O-MISC I-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
died O-MISC I-DISO-MISC
8 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
post O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Despite O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
prevalence O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
psychiatric O-MISC I-ACTI-MISC
disturbance O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
outcomes O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
transplanted O-MISC B-CONC-MISC
emergently O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
comparable O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
transplanted O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
acetaminophen B-CHED-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ALF B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
electively O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
CLD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Multidisciplinary O-MISC B-CONC-MISC
approaches O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
psychiatric O-MISC B-CONC-MISC
follow O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
may O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
transplant O-MISC I-CHED-MISC
suicide O-MISC I-ACTI-MISC
rates O-MISC B-CHED-MISC
seen O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
rates O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
graft O-MISC I-ACTI-MISC
loss O-MISC B-ANAT-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
compliance O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Antithrombotic O-MISC I-ACTI-MISC
drug O-MISC B-ANAT-MISC
use O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
microbleeds I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
intracerebral B-DISO-MISC I-ACTI-MISC
hemorrhage I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
systematic O-MISC B-CHED-MISC
review O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
published O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
unpublished O-MISC B-CHED-MISC
studies O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Cerebral B-DISO-MISC I-GENE-MISC
microbleeds I-DISO-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
MB B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
intracerebral B-DISO-MISC I-ACTI-MISC
hemorrhage I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
unclear O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
contraindication O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
antithrombotic O-MISC O-MISC
drugs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Insights O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
gained O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pooling O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
MB B-DISO-MISC I-ACTI-MISC
frequency O-MISC B-CHED-MISC
stratified O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
antithrombotic O-MISC I-ACTI-MISC
use O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
cohorts O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
stroke I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
IS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
transient B-DISO-MISC I-ACTI-MISC
ischemic I-DISO-MISC B-ANAT-MISC
attack I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
TIA B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
systematic O-MISC B-CHED-MISC
review O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
published O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
unpublished O-MISC B-CHED-MISC
data O-MISC I-CHED-MISC
from O-MISC B-ACTI-MISC
cohorts O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
TIA B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
compare O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
MB B-DISO-MISC B-OBJC-MISC
in O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
antithrombotic O-MISC I-ACTI-MISC
users O-MISC B-ANAT-MISC
vs O-MISC B-ACTI-MISC
nonantithrombotic O-MISC I-ANAT-MISC
users O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
antithrombotic O-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
vs O-MISC B-ACTI-MISC
nonusers O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
IS B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
TIA B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
vs O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
events O-MISC B-DEVI-MISC
stratified O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
antithrombotic O-MISC O-MISC
use O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
published O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
unpublished O-MISC B-CHED-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
data O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
antithrombotic O-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
MB B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pooled O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
1460 O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
3817 O-MISC B-ACTI-MISC
IS B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
TIA B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
MB B-DISO-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
vs O-MISC B-ACTI-MISC
IS B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
TIA B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
groups O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
excess O-MISC B-CHED-MISC
increased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
; O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
nonantithrombotic O-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
antiplatelet O-MISC O-MISC
users O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
users O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
excess O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
MB B-DISO-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
users O-MISC B-DISO-MISC
vs O-MISC B-ACTI-MISC
nonusers O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
users O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
IS B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
TIA B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
smaller O-MISC B-ACTI-MISC
excess O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
MB B-DISO-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
antiplatelet O-MISC I-ANAT-MISC
users O-MISC I-PHEN-MISC
vs O-MISC B-ACTI-MISC
nonusers O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
findings O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
antiplatelet O-MISC I-ANAT-MISC
users O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
IS B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
TIA B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
pooled O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
data O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
768 O-MISC B-ACTI-MISC
antithrombotic O-MISC O-MISC
users O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
MB B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
substantially O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
excess O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MB B-DISO-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
users O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ICH B-DISO-MISC I-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
suggests O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
MB B-DISO-MISC B-CONC-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
ICH B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Limited O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
data O-MISC B-CHED-MISC
corroborate O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
larger O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
are O-MISC B-ACTI-MISC
urgently O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Studies O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
synergy O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
sodium B-CHED-MISC O-MISC
channel O-MISC B-DISO-MISC
blocker O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
CNSB002 B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
models O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
inflammatory O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
neuropathic B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
antihyperalgesic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
CNSB002 B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
channel O-MISC B-DISO-MISC
blocker O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
antioxidant O-MISC I-DISO-MISC
properties O-MISC B-CHED-MISC
given O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combinations O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
models O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
inflammatory O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
neuropathic B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Dose O-MISC B-CHED-MISC
response O-MISC I-CHED-MISC
curves O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
nonsedating O-MISC I-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
CNSB002 B-CHED-MISC O-MISC
given O-MISC B-ACTI-MISC
intraperitoneally O-MISC B-CHED-MISC
alone O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combinations O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
constructed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
antihyperalgesic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
using O-MISC B-ACTI-MISC
paw O-MISC I-GENE-MISC
withdrawal O-MISC B-DEVI-MISC
from O-MISC B-ACTI-MISC
noxious O-MISC B-OCCU-MISC
heat O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
pain B-DISO-MISC I-ACTI-MISC
models O-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
carrageenan B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
paw O-MISC I-GENE-MISC
inflammation B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
diabetic B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
nonsedating O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
CNSB002 B-CHED-MISC O-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
CNSB002 B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
calculated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
50 O-MISC B-CHED-MISC
% O-MISC I-CHED-MISC
reversal O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
hyperalgesia B-DISO-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
ED50 O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
83 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
carrageenan B-CHED-MISC O-MISC
model O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
neuropathy B-DISO-MISC I-ACTI-MISC
model O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
CNSB002 B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
SEM O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
values O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
nonsedating O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ED50 O-MISC B-CHED-MISC
values O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
when O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
CNSB002 B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maximum O-MISC B-ACTI-MISC
nonsedating O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
carrageenan B-CHED-MISC O-MISC
model O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neuropathy B-DISO-MISC I-ACTI-MISC
model O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
SEM O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
antinociception O-MISC I-DISO-MISC
after O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
co O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
CNSB002 B-CHED-MISC O-MISC
from O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
114 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
reversal O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyperalgesia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inflammatory O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
neuropathic B-DISO-MISC B-CHED-MISC
models O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
way O-MISC B-ACTI-MISC
analysis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
variance O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
drug O-MISC O-MISC
given O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
maximum O-MISC B-ACTI-MISC
antihyperalgesic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
achievable O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
nonsedating O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
significantly O-MISC B-CHED-MISC
when O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
is O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
CNSB002 B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Heparin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
practical O-MISC B-CHED-MISC
review O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Heparin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
thrombocytopenia B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HIT B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
remains O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
despite O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
potentially O-MISC B-CHED-MISC
devastating O-MISC B-ACTI-MISC
outcomes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
begins O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
stimulates O-MISC B-OCCU-MISC
the O-MISC B-ACTI-MISC
formation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
platelet O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
4 O-MISC B-DISO-MISC
antibodies O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
turn O-MISC B-ACTI-MISC
triggers O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
release O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
procoagulant O-MISC O-MISC
platelet O-MISC I-GENE-MISC
particles O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Thrombosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
follow O-MISC B-ACTI-MISC
comprise O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
hallmark O-MISC B-CHED-MISC
traits O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
former O-MISC B-CHED-MISC
largely O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
vascular O-MISC I-ACTI-MISC
complications O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC I-ACTI-MISC
varies O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
subgroups O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
surgical O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
medical O-MISC I-ANAT-MISC
populations O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

HIT B-DISO-MISC B-CONC-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
acknowledged O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
intense O-MISC B-CHED-MISC
predilection O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
whenever O-MISC B-ACTI-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
occurs O-MISC B-DEVI-MISC
after O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Early O-MISC B-PHEN-MISC
recognition O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
incorporates O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
serologic O-MISC B-CHED-MISC
clues O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
paramount O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
timely O-MISC B-ACTI-MISC
institution O-MISC B-PHYS-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
delay O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
catastrophic O-MISC B-CHED-MISC
outcomes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC B-CONC-MISC
mandates O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
immediate O-MISC B-CHED-MISC
cessation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
institution O-MISC B-PHYS-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
antithrombotic O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
commonly O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct B-CHED-MISC O-MISC
thrombin I-CHED-MISC B-DISO-MISC
inhibitor I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Current O-MISC B-ACTI-MISC
" O-MISC B-CONC-MISC
diagnostic O-MISC B-CONC-MISC
" O-MISC I-CONC-MISC
tests O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
primarily O-MISC B-ACTI-MISC
include O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
antigenic O-MISC O-MISC
assays O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
confirmatory O-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
diagnostic O-MISC B-CHED-MISC
role O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Special O-MISC B-ACTI-MISC
attention O-MISC B-ACTI-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
paid O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cardiac O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
heparin B-CHED-MISC O-MISC
multiple O-MISC B-CHED-MISC
times O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Direct B-CHED-MISC B-ACTI-MISC
thrombin I-CHED-MISC O-MISC
inhibitors I-CHED-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
appropriate O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
alternatives O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
undergo O-MISC B-ACTI-MISC
percutaneous O-MISC B-CONC-MISC
coronary O-MISC I-CONC-MISC
intervention O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
remains O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
medications O-MISC O-MISC
today O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
HIT B-DISO-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
close O-MISC B-ACTI-MISC
vigilance O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
platelet O-MISC B-CONC-MISC
counts O-MISC I-CONC-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
practiced O-MISC B-ACTI-MISC
whenever O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Abductor O-MISC I-ACTI-MISC
paralysis B-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
botox B-CHED-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
adductor B-DISO-MISC I-ACTI-MISC
spasmodic I-DISO-MISC B-ANAT-MISC
dysphonia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-CONC-MISC
/ O-MISC B-ACTI-MISC
HYPOTHESIS O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
Botulinum O-MISC O-MISC
toxin O-MISC B-DISO-MISC
( O-MISC O-MISC
Botox B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
injections O-MISC O-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
thyroarytenoid O-MISC I-GENE-MISC
muscles O-MISC B-GEOG-MISC
are O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
standard O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
care O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
adductor B-DISO-MISC I-ACTI-MISC
spasmodic I-DISO-MISC B-ANAT-MISC
dysphonia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ADSD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Reported O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
include O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
breathiness O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
throat B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
difficulty O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
swallowing O-MISC I-DISO-MISC
liquids O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
multiple O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bilateral O-MISC I-ACTI-MISC
abductor O-MISC B-ANAT-MISC
paralysis B-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
Botox B-CHED-MISC O-MISC
injections O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
ADSD B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
previously O-MISC B-ACTI-MISC
unreported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

STUDY O-MISC B-ACTI-MISC
DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Retrospective O-MISC B-CONC-MISC
case O-MISC B-CONC-MISC
series O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Patients O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
Botox B-CHED-MISC O-MISC
injections O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
spasmodic B-DISO-MISC I-ACTI-MISC
dysphonia I-DISO-MISC B-ANAT-MISC
between O-MISC B-ACTI-MISC
January O-MISC B-ACTI-MISC
2000 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
October O-MISC B-ACTI-MISC
2009 O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ADSD B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
received O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
bilateral O-MISC I-ACTI-MISC
abductor O-MISC B-ANAT-MISC
paralysis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
paralytic O-MISC B-CHED-MISC
Botox B-CHED-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
prior O-MISC B-CHED-MISC
Botox B-CHED-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
course O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
paralysis B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
From O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
database O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
452 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-CHED-MISC
Botox B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
352 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
ADSD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
352 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
suffered O-MISC B-ACTI-MISC
bilateral O-MISC I-ACTI-MISC
abductor O-MISC B-ANAT-MISC
paralysis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
suffered O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
twice O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
females O-MISC I-DISO-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
abductor O-MISC I-ACTI-MISC
paralysis B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
continued O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
paralysis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Seven O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
recovered O-MISC I-LIVB-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
brief O-MISC B-ACTI-MISC
period O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
activity O-MISC I-ACTI-MISC
restrictions O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tracheotomy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
abductor O-MISC I-ACTI-MISC
paralysis B-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
Botox B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
ADSD B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Bilateral O-MISC I-ACTI-MISC
abductor O-MISC B-ANAT-MISC
paralysis B-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
Botox B-CHED-MISC O-MISC
injections O-MISC O-MISC
for O-MISC B-ACTI-MISC
ADSD B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
difficulty O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
breathing O-MISC I-DISO-MISC
upon O-MISC B-ACTI-MISC
exertion O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
paralysis B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
diffusion O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
Botox B-CHED-MISC O-MISC
around O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
muscular O-MISC I-GENE-MISC
process O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
arytenoid O-MISC O-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
posterior O-MISC I-GENE-MISC
cricoarytenoid O-MISC B-GEOG-MISC
muscles O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
paralysis B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
temporary O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
watchful O-MISC B-ACTI-MISC
waiting O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
restriction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recommended O-MISC B-ACTI-MISC
management O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Mitochondrial B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
contributes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
Prevention O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
targeted O-MISC B-CHED-MISC
antioxidant O-MISC O-MISC
MitoQ B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
goal O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-DEVI-MISC
mitochondrial O-MISC B-PHEN-MISC
function O-MISC B-UnknownType-MISC
and O-MISC B-ACTI-MISC
ROS O-MISC O-MISC
production O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
model O-MISC I-OBJC-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
hypothesized O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
cocaine B-DISO-MISC I-ACTI-MISC
abuse I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
mitochondrial O-MISC B-PHEN-MISC
function O-MISC B-UnknownType-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
turn O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
left B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Seven O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
oxygen B-CHED-MISC I-DISO-MISC
consumption O-MISC I-LIVB-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
fibers O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
specifically O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
complex O-MISC O-MISC
I O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
complex O-MISC O-MISC
III O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

ROS O-MISC O-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
specifically O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
interfibrillar O-MISC I-GENE-MISC
mitochondria O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
parallel O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
ATP B-CHED-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
difference O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
subsarcolemmal O-MISC I-GENE-MISC
mitochondria O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
uncoupling O-MISC I-DISO-MISC
effect O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
oxidative O-MISC I-DISO-MISC
phosphorylation O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
detectable O-MISC I-DISO-MISC
after O-MISC B-ACTI-MISC
short O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
cocaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-GENE-MISC
abnormalities I-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
late O-MISC B-ACTI-MISC
rather O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
event O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
response O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
cocaine B-CHED-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

MitoQ B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mitochondrial O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
targeted O-MISC B-CHED-MISC
antioxidant O-MISC O-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
completely O-MISC B-CHED-MISC
prevent O-MISC B-CHED-MISC
these O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-ACTI-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
characterized O-MISC B-DEVI-MISC
here O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
diastolic B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
studied O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
conductance O-MISC B-OBJC-MISC
catheter O-MISC I-OBJC-MISC
to O-MISC B-ACTI-MISC
obtain O-MISC B-ACTI-MISC
pressure O-MISC B-OCCU-MISC
- O-MISC B-ACTI-MISC
volume O-MISC B-CHED-MISC
data O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Taken O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
extend O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-ACTI-MISC
defect I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Trimethoprim B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
immune O-MISC I-ACTI-MISC
hemolytic B-DISO-MISC B-ANAT-MISC
anemia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pediatric O-MISC B-CHED-MISC
oncology O-MISC B-PROC-MISC
patient O-MISC I-ANAT-MISC
presenting O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
hemolytic O-MISC B-ANAT-MISC
transfusion O-MISC B-ANAT-MISC
reaction O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
leukemia I-DISO-MISC B-ANAT-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
anemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
red O-MISC B-CONC-MISC
cell O-MISC I-CONC-MISC
transfusion O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
hemoglobinuria B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Transfusion O-MISC B-CONC-MISC
reaction O-MISC B-CHED-MISC
workup O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
immune O-MISC I-ACTI-MISC
hemolytic B-DISO-MISC B-ANAT-MISC
anemia I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
positive O-MISC B-CONC-MISC
direct O-MISC I-CONC-MISC
antiglobulin O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
eluate O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
microspherocytes O-MISC I-GENE-MISC
on O-MISC B-ACTI-MISC
smear O-MISC B-CONC-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
transfusion O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Drug O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
indirect O-MISC B-CONC-MISC
antiglobulin O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
strongly O-MISC I-ACTI-MISC
positive O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
trimethoprim B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
trimethoprim B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
sulfamethoxazole I-CHED-MISC B-DISO-MISC
but O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
sulfamethoxazole B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-DISO-MISC
recovered O-MISC I-LIVB-MISC
after O-MISC B-ACTI-MISC
discontinuing O-MISC B-CONC-MISC
the O-MISC I-CONC-MISC
drug O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
recurrence O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Other O-MISC B-ACTI-MISC
causes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
anemia B-DISO-MISC I-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
worse O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
expected O-MISC B-ACTI-MISC
anemia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
hemolysis B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
transfusion O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transfusion O-MISC B-CONC-MISC
reaction O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Verapamil B-CHED-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
loss O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
prolactin O-MISC I-DISO-MISC
response O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
anatomic O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
stalk O-MISC I-GENE-MISC
effect O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

AIM O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
Verapamil B-CHED-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tool O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
differential O-MISC B-CONC-MISC
diagnosis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
conflicting O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Macroprolactinemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
never O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
re O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
investigate O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
diagnostic O-MISC I-ACTI-MISC
value O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
screened O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
macroprolactinemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Prolactin O-MISC O-MISC
responses O-MISC I-OCCU-MISC
to O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
age O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
descriptive O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
matched O-MISC B-CONC-MISC
case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Verapamil B-CHED-MISC O-MISC
80 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
o O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
8th O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
16th O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
immunometric O-MISC B-CONC-MISC
chemiluminescence O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Verapamil B-CHED-MISC I-GENE-MISC
responsiveness O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
peak O-MISC B-ACTI-MISC
percent O-MISC B-CHED-MISC
change O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
basal O-MISC B-CONC-MISC
prolactin O-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PRL O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Verapamil B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
PRL O-MISC O-MISC
levels O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
controls O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
N O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
: O-MISC B-ACTI-MISC
183 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
macroprolactinoma B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
N O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
: O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
microprolactinoma B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
N O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
: O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
macroprolactinemia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
N O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
: O-MISC B-ACTI-MISC
126 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
pseudoprolactinoma B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
N O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
: O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
N O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
: O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

ROC O-MISC B-CHED-MISC
curve O-MISC I-CHED-MISC
analysis O-MISC B-CONC-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
unresponsiveness O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
defined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
< O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
discriminated O-MISC B-ACTI-MISC
anatomical O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
stalk O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
sensitivity O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
74 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
specificity O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
73 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
AUC O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
855 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
04 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
768 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
942 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
pseudoprolactinoma B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
risperidone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Verapamil B-CHED-MISC O-MISC
responsiveness O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reliable O-MISC B-ACTI-MISC
finding O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
differential O-MISC B-CONC-MISC
diagnosis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
unresponsiveness O-MISC I-ACTI-MISC
discriminates O-MISC B-CHED-MISC
stalk O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
anatomically O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
functionally O-MISC B-CHED-MISC
inhibited O-MISC I-CHED-MISC
dopaminergic O-MISC I-GENE-MISC
tonus O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
causes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
varying O-MISC B-ACTI-MISC
degrees O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
responsiveness O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Blockade O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
endothelial O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
mesenchymal O-MISC I-LIVB-MISC
transition O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Smad3 O-MISC O-MISC
inhibitor O-MISC O-MISC
delays O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
development O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
diabetic B-DISO-MISC I-ACTI-MISC
nephropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
multicenter O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
controlled O-MISC B-CONC-MISC
trial O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
blockade O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renin O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
angiotensin B-CHED-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
type B-DISO-MISC I-ACTI-MISC
1 I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
normoalbuminuria O-MISC I-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
retard O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
( O-MISC I-CHED-MISC
s O-MISC I-CHED-MISC
) O-MISC I-CHED-MISC
are O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
diabetic B-DISO-MISC I-ACTI-MISC
nephropathy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
diabetic B-DISO-MISC I-ACTI-MISC
nephropathy I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
endothelial O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
mesenchymal O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
transition O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
EndoMT O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
contributes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-ACTI-MISC
interstitial O-MISC B-ANAT-MISC
fibrosis B-DISO-MISC B-ANAT-MISC
independently O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
microalbuminuria O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
diabetes B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
hypothesized O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
blocking O-MISC B-CHED-MISC
EndoMT O-MISC B-CONC-MISC
reduces O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-CONC-MISC
development O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
diabetic B-DISO-MISC I-ACTI-MISC
nephropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

RESEARCH O-MISC B-ACTI-MISC
DESIGN O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
EndoMT O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
pancreatic O-MISC I-GENE-MISC
microvascular O-MISC B-GEOG-MISC
endothelial O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
line O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
MMEC O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
advanced O-MISC B-ACTI-MISC
glycation O-MISC O-MISC
end O-MISC B-DISO-MISC
products O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
AGEs O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
endothelial O-MISC I-GENE-MISC
lineage O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
traceble O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
line O-MISC B-GEOG-MISC
Tie2 O-MISC B-LIVB-MISC
- O-MISC B-GEOG-MISC
Cre O-MISC B-GEOG-MISC
; O-MISC B-ACTI-MISC
Loxp O-MISC O-MISC
- O-MISC B-DISO-MISC
EGFP O-MISC B-DISO-MISC
by O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
AGEs O-MISC O-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
nonglycated O-MISC O-MISC
mouse O-MISC B-DISO-MISC
albumin O-MISC B-DISO-MISC
serving O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Phosphorylated O-MISC O-MISC
Smad3 O-MISC O-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
immunoprecipitation O-MISC B-CONC-MISC
/ O-MISC B-ACTI-MISC
Western O-MISC B-CONC-MISC
blotting O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
confocal O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Blocking O-MISC B-CHED-MISC
studies O-MISC B-CONC-MISC
using O-MISC B-ACTI-MISC
receptor O-MISC O-MISC
for O-MISC B-ACTI-MISC
AGE O-MISC O-MISC
siRNA O-MISC O-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
inhibitor O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Smad3 O-MISC O-MISC
( O-MISC B-ACTI-MISC
SIS3 O-MISC O-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
MMECs O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
diabetic B-DISO-MISC I-ACTI-MISC
nephropathy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Tie2 O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
Cre O-MISC I-PROC-MISC
; O-MISC B-ACTI-MISC
Loxp O-MISC B-LIVB-MISC
- O-MISC I-PHEN-MISC
EGFP O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Confocal O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
real O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
time O-MISC I-CONC-MISC
PCR O-MISC I-CONC-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
AGEs O-MISC O-MISC
induced O-MISC B-CHED-MISC
EndoMT O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
MMECs O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Tie2 O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
Cre O-MISC I-PROC-MISC
; O-MISC B-ACTI-MISC
Loxp O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
EGFP O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Immunoprecipitation O-MISC B-CONC-MISC
/ O-MISC B-ACTI-MISC
Western O-MISC B-CONC-MISC
blotting O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
Smad3 O-MISC O-MISC
was O-MISC B-ACTI-MISC
activated O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
AGEs O-MISC O-MISC
but O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
inhibited O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
SIS3 O-MISC O-MISC
in O-MISC B-ACTI-MISC
MMECs O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
STZ B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
diabetic B-DISO-MISC I-ACTI-MISC
nephropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Confocal O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
real O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
time O-MISC I-CONC-MISC
PCR O-MISC I-CONC-MISC
further O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
SIS3 O-MISC B-LIVB-MISC
abrogated O-MISC B-ACTI-MISC
EndoMT O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
renal O-MISC I-ACTI-MISC
fibrosis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
retarded O-MISC B-CHED-MISC
progression O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
EndoMT O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
pathway O-MISC B-CHED-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
early O-MISC B-CONC-MISC
development O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
diabetic B-DISO-MISC I-ACTI-MISC
nephropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Blockade O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
EndoMT O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
SIS3 O-MISC B-LIVB-MISC
may O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
strategy O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
retard O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
diabetic B-DISO-MISC I-ACTI-MISC
nephropathy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
complications I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Cytostatic O-MISC O-MISC
and O-MISC B-ACTI-MISC
anti O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
angiogenic O-MISC B-ANAT-MISC
effects O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
temsirolimus B-CHED-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
mantle B-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Mantle B-DISO-MISC I-ACTI-MISC
cell I-DISO-MISC B-ANAT-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MCL B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
aggressive O-MISC B-CHED-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
B B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
non I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
Hodgkin I-DISO-MISC B-ANAT-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
become O-MISC B-ACTI-MISC
progressively O-MISC B-CHED-MISC
refractory O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
conventional O-MISC B-CHED-MISC
chemotherapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
prognosis O-MISC I-ACTI-MISC
is O-MISC B-ANAT-MISC
poor O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
remission O-MISC I-ACTI-MISC
rate O-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
refractory O-MISC B-CHED-MISC
MCL B-DISO-MISC O-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
temsirolimus B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mTOR O-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC
Here O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
opportunity O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
refractory O-MISC B-CHED-MISC
MCL B-DISO-MISC O-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
regression O-MISC B-ANAT-MISC
two O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
temsirolimus B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
progression O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
free O-MISC B-CHED-MISC
survival O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
lymph O-MISC B-CONC-MISC
node O-MISC I-CONC-MISC
biopsies O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
before O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
temsirolimus B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Comparison O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
biopsies O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
temsirolimus B-CHED-MISC O-MISC
inhibited O-MISC B-DEVI-MISC
tumor B-DISO-MISC I-DISO-MISC
cell O-MISC I-LIVB-MISC
proliferation O-MISC I-LIVB-MISC
through O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
arrest O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
any O-MISC B-ACTI-MISC
change O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
apoptotic O-MISC B-CHED-MISC
tumor B-DISO-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Apart O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
cytostatic O-MISC I-DISO-MISC
effect O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
temsirolimus B-CHED-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
antiangiogenic O-MISC I-DISO-MISC
effect O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
microvessel O-MISC I-GENE-MISC
density O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
VEGF O-MISC O-MISC
expression O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
numerous O-MISC B-ACTI-MISC
patchy O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
fibrotic O-MISC B-CHED-MISC
areas O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
compatible O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
post O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
necrotic B-DISO-MISC I-LIVB-MISC
tissue O-MISC B-CONC-MISC
repair O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
found O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
month O-MISC B-ACTI-MISC
temsirolimus B-CHED-MISC I-ACTI-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
temsirolimus B-CHED-MISC I-ANAT-MISC
reduced O-MISC B-CHED-MISC
tumor B-DISO-MISC I-ACTI-MISC
burden O-MISC B-CHED-MISC
through O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
cytostatic O-MISC O-MISC
and O-MISC B-ACTI-MISC
anti O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
angiogenic O-MISC I-LIVB-MISC
effects O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
dual O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
temsirolimus B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
could O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
efficiency O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
refractory O-MISC B-CHED-MISC
MCL B-DISO-MISC O-MISC
resistant O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
conventional O-MISC B-CHED-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
rifampicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
patient O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
bacteriologically O-MISC I-ACTI-MISC
proven O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
tuberculosis I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
the O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
regimens O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
antituberculosis O-MISC O-MISC
drugs O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
nearly O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Rifampicin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
thrice O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
drug O-MISC O-MISC
regimen O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
he O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
untoward O-MISC I-ACTI-MISC
side O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
like O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
fever B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
chills O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
rigors O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
episode O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
renal O-MISC B-ANAT-MISC
failure O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
stage O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
made O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
full O-MISC B-CHED-MISC
recovery O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Syncope B-DISO-MISC I-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combined O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
angiotensin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
converting O-MISC B-DISO-MISC
enzyme O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
spironolactone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
coronary O-MISC B-CONC-MISC
artery O-MISC I-CONC-MISC
bypass O-MISC I-CONC-MISC
grafting O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
transferred O-MISC B-CONC-MISC
to O-MISC I-CONC-MISC
the O-MISC B-ACTI-MISC
emergency O-MISC B-GENE-MISC
room O-MISC I-GEOG-MISC
with O-MISC B-ACTI-MISC
loss B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
consciousness I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
caused O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
concentration O-MISC B-PHEN-MISC
of O-MISC B-ANAT-MISC
serum O-MISC B-UnknownType-MISC
potassium B-CHED-MISC B-UnknownType-MISC
was O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
normal O-MISC I-ACTI-MISC
sinus O-MISC B-ANAT-MISC
rhythm O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
restored O-MISC B-CONC-MISC
after O-MISC B-ACTI-MISC
correction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
potassium B-CHED-MISC I-CONC-MISC
level O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
considered O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
several O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
spiranolactone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
aldosterone B-CHED-MISC O-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
intake O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ramipril B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
ACE O-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
good O-MISC B-ACTI-MISC
example O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
electrolyte O-MISC O-MISC
imbalance O-MISC I-ACTI-MISC
causing O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
life O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
cardiac O-MISC B-ANAT-MISC
events O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Clinicians O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
alert O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
using O-MISC B-ACTI-MISC
ACE O-MISC O-MISC
/ O-MISC B-ACTI-MISC
ARB O-MISC O-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
potassium B-CHED-MISC O-MISC
sparing O-MISC B-DISO-MISC
agents O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
mild O-MISC I-ACTI-MISC
renal B-DISO-MISC B-ANAT-MISC
disturbance I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Diffuse O-MISC B-CHED-MISC
skeletal O-MISC I-ACTI-MISC
pain B-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
alendronate B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Osteoporosis B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
bone O-MISC I-DISO-MISC
resorption O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
excess O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bone O-MISC I-DISO-MISC
formation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
bisphosphonates B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
inhibit O-MISC B-DEVI-MISC
bone O-MISC I-DISO-MISC
resorption O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Alendronate B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
biphosphonate B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
prevention O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
osteoporosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
postmenopausal O-MISC I-ACTI-MISC
women O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
prominently O-MISC B-CHED-MISC
gastrointestinal O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Musculoskeletal B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
out O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
patient O-MISC I-GEOG-MISC
clinic O-MISC I-GEOG-MISC
with O-MISC B-ACTI-MISC
diffuse O-MISC I-ACTI-MISC
skeletal O-MISC B-ANAT-MISC
pain B-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
alendronate B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
osteoporosis B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
bisphosphonate B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
should O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
ascribing O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
complaint O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
osteoporosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Cerebrospinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
penetration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
daptomycin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
Staphylococcus O-MISC I-ACTI-MISC
aureus O-MISC B-ANAT-MISC
meningitis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
methicillin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
sensitive O-MISC B-ANAT-MISC
Staphylococcus O-MISC B-ANAT-MISC
aureus O-MISC B-ANAT-MISC
( O-MISC B-ANAT-MISC
MSSA O-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
bacteremia B-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
suspected O-MISC B-ACTI-MISC
MSSA O-MISC I-ANAT-MISC
meningitis B-DISO-MISC I-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
daptomycin B-CHED-MISC O-MISC
assessed O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
concurrent O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
cerebrospinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
CSF O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
concentrations O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CASE O-MISC B-CHED-MISC
SUMMARY O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
presented O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emergency O-MISC B-GENE-MISC
department O-MISC I-GEOG-MISC
with O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
weakness B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
presumed O-MISC B-ACTI-MISC
health O-MISC B-CONC-MISC
- O-MISC B-ANAT-MISC
care O-MISC I-CONC-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
pneumonia B-DISO-MISC B-ANAT-MISC
shown O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
chest O-MISC B-CONC-MISC
radiograph O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
empirically O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
vancomycin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
levofloxacin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
piperacillin B-CHED-MISC O-MISC
/ O-MISC B-DISO-MISC
tazobactam B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Blood O-MISC B-CONC-MISC
cultures O-MISC I-CONC-MISC
revealed O-MISC B-ACTI-MISC
S O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
aureus O-MISC I-PHEN-MISC
susceptible O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
oxacillin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Empiric O-MISC B-CHED-MISC
antibiotic O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
narrowed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
nafcillin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
serum O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
Glasgow O-MISC B-CHED-MISC
Coma O-MISC I-CHED-MISC
Score O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
normal O-MISC I-ACTI-MISC
findings O-MISC B-ANAT-MISC
shown O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
computed O-MISC B-CONC-MISC
tomography O-MISC I-CONC-MISC
scan O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
head O-MISC I-GENE-MISC
72 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
episode O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
arrest I-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
experienced O-MISC B-ACTI-MISC
relapsing O-MISC B-OCCU-MISC
MSSA O-MISC I-ACTI-MISC
bacteremia B-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
9 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
increasing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
suspicion O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
central O-MISC I-ACTI-MISC
nervous O-MISC B-ANAT-MISC
system O-MISC B-ANAT-MISC
( O-MISC B-ANAT-MISC
CNS O-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
infection B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Nafcillin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
daptomycin B-CHED-MISC O-MISC
9 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
suspected O-MISC B-ACTI-MISC
meningitis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
continued O-MISC B-ACTI-MISC
until O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ACTI-MISC
' O-MISC B-ANAT-MISC
s O-MISC B-ANAT-MISC
death O-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Daptomycin B-CHED-MISC O-MISC
serum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
CSF O-MISC I-GENE-MISC
trough O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
ug O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
ug O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Lumbar O-MISC B-CONC-MISC
puncture O-MISC I-CONC-MISC
results O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
inconclusive O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
blood O-MISC B-CONC-MISC
cultures O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
MSSA O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Creatine B-CHED-MISC O-MISC
kinase O-MISC B-DISO-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
daptomycin B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
reassessed O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

DISCUSSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Daptomycin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
secondary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
nafcillin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
interstitial B-DISO-MISC B-ANAT-MISC
nephritis I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
relapsing O-MISC B-ACTI-MISC
bacteremia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
resultant O-MISC B-OCCU-MISC
penetration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
reports O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
inflamed O-MISC I-ACTI-MISC
meninges O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
High O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
daptomycin B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
option O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
MSSA O-MISC I-ANAT-MISC
bacteremia B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
CNS O-MISC I-GENE-MISC
source O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
failed O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
cannot O-MISC B-ACTI-MISC
tolerate O-MISC B-ACTI-MISC
standard O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
evaluation O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
meningitis B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
warranted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nitric B-CHED-MISC O-MISC
oxide I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
lindane B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Lindane B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
organochloride O-MISC O-MISC
pesticide O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
scabicide O-MISC O-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
evokes O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
mainly O-MISC B-ACTI-MISC
trough O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blockage O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Nitric B-CHED-MISC O-MISC
oxide I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NO B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
gaseous O-MISC O-MISC
neurotransmitter O-MISC O-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
contradictor O-MISC B-CHED-MISC
role O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
epileptogenesis O-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
opposite O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
arginine I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
precursor O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
NO B-CHED-MISC B-OCCU-MISC
syntheses O-MISC I-OCCU-MISC
( O-MISC B-ACTI-MISC
NOS O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NAME I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NOS O-MISC O-MISC
inhibitor O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
models O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
NO B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
characteristics O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lindane B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
Wistar O-MISC I-ANAT-MISC
albino O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
arginine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
800 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1000 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
manner O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
convulsion B-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
shortened O-MISC B-ACTI-MISC
latency O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
convulsion B-DISO-MISC I-ACTI-MISC
elicited O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
lindane B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
contrary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NAME I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
700 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
900 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
convulsion B-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
latency O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
convulsion B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
convulsive B-DISO-MISC I-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lindane B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

EEG O-MISC B-CONC-MISC
analyses O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ictal O-MISC I-ACTI-MISC
periods O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
l B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
arginine I-CHED-MISC B-DISO-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
lindane B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
pretreated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
NAME I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
support O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
NO B-CHED-MISC O-MISC
plays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
endogenous O-MISC B-CHED-MISC
convulsant O-MISC O-MISC
in O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
model O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
lindane B-CHED-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Severe O-MISC B-CHED-MISC
polyneuropathy B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
motor O-MISC I-ACTI-MISC
loss O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
intrathecal O-MISC B-CHED-MISC
thiotepa B-CHED-MISC B-CONC-MISC
combination O-MISC B-CONC-MISC
chemotherapy O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
description O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
delayed O-MISC I-ACTI-MISC
neurologic B-DISO-MISC B-ANAT-MISC
toxicity I-DISO-MISC B-ANAT-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
intrathecal O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
IT O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
including O-MISC B-ACTI-MISC
thiotepa B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
TSPA B-CHED-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
axonal B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
motor O-MISC I-GENE-MISC
predominance O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lower O-MISC I-GENE-MISC
extremities O-MISC B-GEOG-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
IT O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Neurologic B-DISO-MISC I-ACTI-MISC
toxicities I-DISO-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
IT O-MISC O-MISC
- O-MISC B-DISO-MISC
methotrexate B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
IT O-MISC O-MISC
- O-MISC B-DISO-MISC
cytosine B-CHED-MISC B-DISO-MISC
arabinoside I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
IT O-MISC O-MISC
- O-MISC B-DISO-MISC
TSPA B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
axonal B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
agents O-MISC O-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
described O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
spite O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fact O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
TSPA B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
IT O-MISC O-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
MTX B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
ara B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
C I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
radiotherapy O-MISC B-CONC-MISC
could O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
unexpected O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
indicates O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
toxicology O-MISC B-PROC-MISC
research O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
IT O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
TSPA B-CHED-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cromakalim B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pinacidil B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
large O-MISC B-CHED-MISC
epicardial O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
small O-MISC B-CHED-MISC
coronary O-MISC I-GENE-MISC
arteries O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
conscious O-MISC I-ANAT-MISC
dogs O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
bolus O-MISC O-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cromakalim B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
pinacidil B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
large O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
circumflex O-MISC I-GENE-MISC
artery O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
small O-MISC B-CHED-MISC
coronary O-MISC I-GENE-MISC
arteries O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
hemodynamics O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
chronically O-MISC B-CHED-MISC
instrumented O-MISC B-CHED-MISC
conscious O-MISC I-ANAT-MISC
dogs O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nitroglycerin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Nitroglycerin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
selectively O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
circumflex O-MISC I-GENE-MISC
artery O-MISC B-GEOG-MISC
diameter O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CxAD O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
without O-MISC B-CHED-MISC
simultaneously O-MISC B-CHED-MISC
affecting O-MISC B-CHED-MISC
any O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
hemodynamic O-MISC I-DISO-MISC
parameter O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cromakalim B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pinacidil B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
nitroglycerin B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
higher O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
simultaneously O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependently O-MISC B-CHED-MISC
increased O-MISC B-CHED-MISC
CxAD O-MISC O-MISC
, O-MISC B-ACTI-MISC
coronary O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
flow O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
coronary O-MISC I-ACTI-MISC
vascular O-MISC B-ANAT-MISC
resistance O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
aortic O-MISC I-ACTI-MISC
pressure O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Cromakalim B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
approximately O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
potent O-MISC B-OCCU-MISC
than O-MISC B-ACTI-MISC
pinacidil B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
increasing O-MISC B-ACTI-MISC
CxAD O-MISC O-MISC
. O-MISC B-ACTI-MISC

Vasodilation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
small O-MISC B-CHED-MISC
coronary O-MISC I-GENE-MISC
vessels O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
cromakalim B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pinacidil B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-CHED-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
combined O-MISC B-CHED-MISC
beta B-CHED-MISC O-MISC
adrenergic I-CHED-MISC B-DISO-MISC
and I-CHED-MISC B-DISO-MISC
muscarinic I-CHED-MISC B-DISO-MISC
receptors I-CHED-MISC B-DISO-MISC
blockade I-CHED-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
abolished O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
circumflex O-MISC I-DISO-MISC
artery O-MISC I-LIVB-MISC
blood O-MISC I-LIVB-MISC
flow O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
maintained O-MISC B-CHED-MISC
constant O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
CxAD O-MISC O-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
cromakalim B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
pinacidil B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nitroglycerin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
nitroglycerin B-CHED-MISC O-MISC
preferentially O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
flow O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
independently O-MISC B-ACTI-MISC
dilates O-MISC I-ACTI-MISC
large O-MISC B-ACTI-MISC
coronary O-MISC I-GENE-MISC
arteries O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
cromakalim B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pinacidil B-CHED-MISC O-MISC
dilate O-MISC I-ACTI-MISC
both O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
small O-MISC B-CHED-MISC
coronary O-MISC I-GENE-MISC
arteries O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-CHED-MISC
dependent O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
simultaneous O-MISC B-CHED-MISC
beta O-MISC O-MISC
adrenoceptors O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
rise O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
myocardial O-MISC I-DISO-MISC
metabolic O-MISC I-DISO-MISC
demand O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Finally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
vasodilation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
flow O-MISC I-DISO-MISC
dependency O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cromakalim B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
pinacidil B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
CxAD O-MISC O-MISC
. O-MISC B-ACTI-MISC

Mefenamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
females O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
hypothyroidism B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
mefenamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
oliguric O-MISC B-ANAT-MISC
renal B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
occurring O-MISC B-ACTI-MISC
simultaneously O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
females O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
maturation O-MISC I-DISO-MISC
arrest O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myeloid O-MISC I-GENE-MISC
series O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
hypothyroid B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
clear O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
predisposing O-MISC B-CHED-MISC
factor O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
would O-MISC B-ACTI-MISC
seem O-MISC B-ACTI-MISC
prudent O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
mefenamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
hypothyroid B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
until O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothyroidism B-DISO-MISC I-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
corrected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Etiology O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypercalcemia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
hemodialysis O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
calcium B-CHED-MISC B-CONC-MISC
carbonate I-CHED-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Fourteen O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
dialysis O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
became O-MISC B-ACTI-MISC
hypercalcemic B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
switching O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
carbonate I-CHED-MISC B-DISO-MISC
as O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
principal O-MISC O-MISC
phosphate B-CHED-MISC B-DISO-MISC
binder O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypercalcemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
indirect O-MISC B-CHED-MISC
parameters O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
intestinal O-MISC I-GENE-MISC
calcium B-CHED-MISC I-DISO-MISC
reabsorption O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
bone O-MISC I-GENE-MISC
turnover O-MISC I-DISO-MISC
rate O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
eucalcemic O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
matched O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
length O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
dialysis O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
etiology O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-CHED-MISC
addition O-MISC I-CHED-MISC
to O-MISC I-CHED-MISC
experiencing O-MISC B-ACTI-MISC
hypercalcemic B-DISO-MISC I-ACTI-MISC
episodes O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
peak O-MISC B-CHED-MISC
calcium B-CHED-MISC O-MISC
values O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
mmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypercalcemic B-DISO-MISC I-ACTI-MISC
group O-MISC B-CHED-MISC
exhibited O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
calcium B-CHED-MISC O-MISC
concentration O-MISC B-CHED-MISC
obtained O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
switch O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
value O-MISC B-CHED-MISC
obtained O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
switch O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
mmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
006 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
eucalcemic O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
exhibited O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
calcium B-CHED-MISC O-MISC
values O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
period O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
mmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CaCO3 B-CHED-MISC O-MISC
dosage O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
dietary O-MISC B-GENE-MISC
calcium B-CHED-MISC O-MISC
intake O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
circulating O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
vitamin B-CHED-MISC O-MISC
D I-CHED-MISC B-DISO-MISC
metabolites O-MISC O-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Physical O-MISC B-DEVI-MISC
activity O-MISC I-DEVI-MISC
index O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
predialysis O-MISC B-CHED-MISC
serum O-MISC B-CONC-MISC
bicarbonate B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
also O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
difference O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
parameters O-MISC I-ACTI-MISC
reflecting O-MISC B-ACTI-MISC
bone O-MISC I-GENE-MISC
turnover O-MISC I-DISO-MISC
rates O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
ABSTRACT O-MISC B-ACTI-MISC
TRUNCATED O-MISC B-ACTI-MISC
AT O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
WORDS O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC

Late O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
onset O-MISC B-ANAT-MISC
scleroderma B-DISO-MISC B-ANAT-MISC
renal I-DISO-MISC B-ANAT-MISC
crisis I-DISO-MISC B-ANAT-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
prednisolone B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Scleroderma B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
crisis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SRC B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
systemic B-DISO-MISC I-ACTI-MISC
sclerosis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SSc B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
enough O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
require O-MISC B-ACTI-MISC
temporary O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
permanent O-MISC B-CHED-MISC
renal O-MISC B-CONC-MISC
replacement O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Moderate O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
corticosteroid B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-CHED-MISC
risk O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
SRC B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reports O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
thrombotic B-DISO-MISC I-ACTI-MISC
microangiopathy I-DISO-MISC B-ANAT-MISC
precipitated O-MISC B-CHED-MISC
by O-MISC I-CHED-MISC
cyclosporine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
SSc B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
article O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
SRC B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
corticosteroids B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
work O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
call O-MISC B-ACTI-MISC
attention O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
SSc B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Methyldopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
presenting O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
near O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
syncope B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Methyldopa B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
antihypertensive O-MISC O-MISC
medication O-MISC B-DISO-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
available O-MISC B-CHED-MISC
generically O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
trade O-MISC B-CHED-MISC
name O-MISC I-CHED-MISC
Aldomet B-CHED-MISC O-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
population O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
infrequently O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Methyldopa B-CHED-MISC O-MISC
causes O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autoimmune B-DISO-MISC I-ACTI-MISC
hemolytic I-DISO-MISC B-ANAT-MISC
anemia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
percentage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
take O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
methyldopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
boy O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emergency B-DISO-MISC B-GENE-MISC
department I-DISO-MISC I-GEOG-MISC
with O-MISC B-ACTI-MISC
near O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
syncope B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
boy O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
intravenous O-MISC B-CHED-MISC
methyldopa B-CHED-MISC O-MISC
during O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
trauma B-DISO-MISC I-ACTI-MISC
admission O-MISC B-CONC-MISC
seven O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
presentation O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Evaluation O-MISC B-CONC-MISC
revealed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hemoglobin O-MISC O-MISC
of O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
grams O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
Coombs O-MISC B-CONC-MISC
' O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
polyspecific O-MISC B-CHED-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
human O-MISC B-DISO-MISC
globulin O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
monospecific O-MISC O-MISC
IgG O-MISC B-DISO-MISC
reagents O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
warm O-MISC B-OCCU-MISC
reacting O-MISC I-OCCU-MISC
autoantibody O-MISC O-MISC
. O-MISC B-ACTI-MISC

Transfusion O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
corticosteroid B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complete O-MISC B-CHED-MISC
recovery O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Emergency O-MISC I-ANAT-MISC
physicians O-MISC I-PHEN-MISC
treating O-MISC B-CHED-MISC
children O-MISC I-ANAT-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
syndrome O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
diagnose O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
treat O-MISC B-CONC-MISC
it O-MISC B-ACTI-MISC
correctly O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
brief O-MISC B-ACTI-MISC
review O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
autoimmune O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
anemias I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
provided O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
factors O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
psychosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
Malaysia O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
objective O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lifetime O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
psychosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
dependence O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
psychiatric O-MISC B-CHED-MISC
co O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
morbidity O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
psychosis B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cross O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
sectional O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
conducted O-MISC B-ACTI-MISC
concurrently O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
teaching O-MISC B-GENE-MISC
hospital O-MISC I-GEOG-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
drug O-MISC B-GENE-MISC
rehabilitation O-MISC I-PHYS-MISC
center O-MISC I-PHYS-MISC
in O-MISC B-ACTI-MISC
Malaysia O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
DSM O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
IV O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
interviewed O-MISC B-DEVI-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Mini O-MISC B-CONC-MISC
International O-MISC I-CHED-MISC
Neuropsychiatric O-MISC I-CONC-MISC
Interview O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
M O-MISC B-CHED-MISC
. O-MISC I-CHED-MISC
I O-MISC I-CHED-MISC
. O-MISC I-CHED-MISC
N O-MISC I-CHED-MISC
. O-MISC I-CHED-MISC
I O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
psychosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
Axis O-MISC I-ACTI-MISC
I O-MISC B-ANAT-MISC
psychiatric B-DISO-MISC B-ANAT-MISC
disorders I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
information O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
sociodemographic O-MISC B-CHED-MISC
background O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
use O-MISC B-ANAT-MISC
history O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
interview O-MISC B-DEVI-MISC
or O-MISC B-ACTI-MISC
medical O-MISC B-CHED-MISC
records O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Of O-MISC B-ACTI-MISC
292 O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
past O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
psychotic B-DISO-MISC I-ACTI-MISC
symptoms I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
having O-MISC B-ACTI-MISC
current O-MISC B-CHED-MISC
psychotic B-DISO-MISC I-ACTI-MISC
symptoms I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Co O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
morbid O-MISC I-CHED-MISC
major O-MISC B-ANAT-MISC
depressive B-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
612 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
708 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
807 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
194 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
706 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
antisocial B-DISO-MISC I-ACTI-MISC
personality I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
619 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
702 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
759 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
heavy O-MISC B-CHED-MISC
methamphetamine B-CHED-MISC B-DISO-MISC
uses O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
lifetime O-MISC B-CHED-MISC
methamphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
psychosis B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
adjusted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Major B-DISO-MISC I-ACTI-MISC
depressive I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
870 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
154 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
142 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
antisocial B-DISO-MISC I-ACTI-MISC
personality I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
299 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
375 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
914 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
current O-MISC B-ACTI-MISC
psychosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC I-ACTI-MISC
risk O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
psychosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
dependence O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
co O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
morbid O-MISC I-CHED-MISC
affective B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
antisocial B-DISO-MISC I-ACTI-MISC
personality I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
heavy O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
dependence O-MISC I-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
screened O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
psychotic B-DISO-MISC I-ACTI-MISC
symptoms I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Cerebellar O-MISC I-GENE-MISC
sensory O-MISC I-DISO-MISC
processing O-MISC I-LIVB-MISC
alterations O-MISC B-CHED-MISC
impact O-MISC B-ACTI-MISC
motor O-MISC I-DISO-MISC
cortical O-MISC I-LIVB-MISC
plasticity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
clues O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
dyskinetic B-DISO-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
plasticity O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
primary O-MISC I-GENE-MISC
motor O-MISC B-GEOG-MISC
cortex O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
M1 O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
levodopa B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
dyskinesias B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
LIDs B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
severely O-MISC B-CHED-MISC
impaired O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
young O-MISC B-CHED-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
that O-MISC B-ACTI-MISC
inhibitory O-MISC B-DEVI-MISC
cerebellar O-MISC I-GENE-MISC
stimulation O-MISC I-CONC-MISC
enhanced O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
sensorimotor O-MISC I-DISO-MISC
plasticity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
M1 O-MISC I-GENE-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
paired O-MISC B-CONC-MISC
associative O-MISC I-CONC-MISC
stimulation O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PAS O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
demonstrates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
deficient O-MISC B-ACTI-MISC
sensorimotor O-MISC I-DISO-MISC
M1 O-MISC I-LIVB-MISC
plasticity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
LIDs B-DISO-MISC I-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
reinstated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
session O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
real O-MISC B-ACTI-MISC
inhibitory O-MISC I-CONC-MISC
cerebellar O-MISC I-CONC-MISC
stimulation O-MISC I-CONC-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
evident O-MISC B-CHED-MISC
only O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sensory O-MISC I-GENE-MISC
component O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
plasticity O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
cerebellar O-MISC I-GENE-MISC
sensory O-MISC I-DISO-MISC
processing O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
resurgence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
M1 O-MISC I-GENE-MISC
plasticity O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
benefit O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
inhibitory O-MISC I-DISO-MISC
cerebellar O-MISC I-LIVB-MISC
stimulation O-MISC I-LIVB-MISC
on O-MISC B-ACTI-MISC
LIDs B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
explore O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
benefit O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
linked O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
restoration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
sensorimotor O-MISC I-DISO-MISC
plasticity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
M1 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
looking O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
LIDs B-DISO-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
PAS O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
plasticity O-MISC I-DISO-MISC
after O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
sessions O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
bilateral O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
real O-MISC B-CONC-MISC
inhibitory O-MISC B-CONC-MISC
cerebellar O-MISC I-CONC-MISC
stimulation O-MISC I-CONC-MISC
or O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
real O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
had O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
antidyskinetic O-MISC B-CHED-MISC
effect O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
paralleled O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
resurgence O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sensorimotor O-MISC I-DISO-MISC
plasticity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
M1 O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
alterations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
cerebellar O-MISC I-GENE-MISC
sensory O-MISC I-DISO-MISC
processing O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
occurring O-MISC B-DEVI-MISC
secondary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
basal O-MISC I-GENE-MISC
ganglia O-MISC B-GEOG-MISC
signals O-MISC B-OCCU-MISC
reaching O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
element O-MISC B-ACTI-MISC
contributing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maladaptive O-MISC B-CHED-MISC
sensorimotor O-MISC I-DISO-MISC
plasticity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
M1 O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emergence O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
abnormal B-DISO-MISC I-ACTI-MISC
involuntary I-DISO-MISC B-ANAT-MISC
movements I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
danazol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
angioedema I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
short O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
safety O-MISC B-OCCU-MISC
( O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
equal O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
danazol B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
established O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
settings O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
information O-MISC B-ACTI-MISC
exists O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
safety O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
danazol B-CHED-MISC O-MISC
by O-MISC B-ACTI-MISC
performing O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
retrospective O-MISC B-CHED-MISC
chart O-MISC B-CONC-MISC
review O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
angioedema I-DISO-MISC B-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
danazol B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
longer O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Virtually O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
experienced O-MISC I-DISO-MISC
one O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Menstrual B-DISO-MISC I-ACTI-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
79 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
weight B-DISO-MISC I-ACTI-MISC
gain I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
muscle B-DISO-MISC I-ACTI-MISC
cramps I-DISO-MISC B-ANAT-MISC
/ O-MISC B-ACTI-MISC
myalgias B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
transaminase O-MISC O-MISC
elevations O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
drug O-MISC O-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
has O-MISC B-ACTI-MISC
died O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
suffered O-MISC I-ACTI-MISC
any O-MISC B-ACTI-MISC
apparent O-MISC B-CHED-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
sequelae O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
attributable O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
despite O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
danazol B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
proven O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
remarkably O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
group O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
function O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
P2X3 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
NK1 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
antagonists O-MISC I-DISO-MISC
on O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
purpose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
explore O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
function O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
P2X3 O-MISC O-MISC
and O-MISC B-ACTI-MISC
NK1 O-MISC O-MISC
receptors O-MISC B-DISO-MISC
antagonists O-MISC O-MISC
on O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Sixty O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
Sprague O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Dawley O-MISC I-PHEN-MISC
( O-MISC I-PHEN-MISC
SD O-MISC I-PHEN-MISC
) O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
intraperitoneally O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
model O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intervention O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
subsequently O-MISC B-ACTI-MISC
perfusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
with O-MISC B-ACTI-MISC
P2X3 O-MISC O-MISC
and O-MISC B-ACTI-MISC
NK1 O-MISC O-MISC
receptors O-MISC B-DISO-MISC
' O-MISC B-DISO-MISC
antagonists O-MISC O-MISC
, O-MISC B-ACTI-MISC
Suramin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
GR B-CHED-MISC O-MISC
82334 I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Spontaneous O-MISC B-ACTI-MISC
pain B-DISO-MISC B-DEVI-MISC
behaviors O-MISC I-DEVI-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Urodynamic O-MISC I-DISO-MISC
parameters O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
bladder O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
volume O-MISC I-LIVB-MISC
curve O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
maximum O-MISC I-DISO-MISC
voiding O-MISC I-LIVB-MISC
pressure O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
MVP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
maximum O-MISC B-CONC-MISC
cystometric O-MISC I-CONC-MISC
capacity O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
MCC O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Pathological O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Immunofluorescence O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
detect O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
P2X3 O-MISC O-MISC
and O-MISC B-ACTI-MISC
NK1 O-MISC I-DISO-MISC
receptors O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Cyclophosphamide B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
pain B-DISO-MISC B-DEVI-MISC
behaviors O-MISC I-DEVI-MISC
scores O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bladder O-MISC I-ACTI-MISC
instability O-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
urine O-MISC B-CONC-MISC
storage O-MISC B-ANAT-MISC
period O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
model O-MISC B-PHEN-MISC
group O-MISC B-UnknownType-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
intervention O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
X O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
619 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
007 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
X O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
755 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

MCC O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
model O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
intervention O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Histological O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
evident O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
model O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
intervention O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
rats O-MISC I-ANAT-MISC
' O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
included O-MISC B-ACTI-MISC
edema B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
vasodilation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
infiltration O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
inflammatory O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
model O-MISC B-CHED-MISC
group O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
P2X3 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
urothelium O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
suburothelium O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
NK1 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
suburothelium O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
intervention O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
P2X3 O-MISC O-MISC
and O-MISC B-ACTI-MISC
NK1 O-MISC O-MISC
receptors O-MISC B-DISO-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
urothelium O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
suburothelium O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Perfusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
with O-MISC B-ACTI-MISC
P2X3 O-MISC O-MISC
and O-MISC B-ACTI-MISC
NK1 O-MISC O-MISC
receptors O-MISC B-DISO-MISC
antagonists O-MISC B-DISO-MISC
ameliorated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Patient O-MISC B-CONC-MISC
tolerance O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
topical O-MISC O-MISC
chlorhexidine B-CHED-MISC B-DISO-MISC
diphosphanilate I-CHED-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
topical O-MISC O-MISC
agent O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
burns B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Effective O-MISC B-ACTI-MISC
topical O-MISC O-MISC
antimicrobial O-MISC B-DISO-MISC
agents O-MISC B-DISO-MISC
decrease O-MISC B-CHED-MISC
infection B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
burn B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Chlorhexidine B-CHED-MISC O-MISC
phosphanilate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CHP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
broad O-MISC O-MISC
- O-MISC B-DISO-MISC
spectrum O-MISC B-DISO-MISC
antimicrobial O-MISC B-DISO-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
topical O-MISC B-CHED-MISC
burn B-DISO-MISC O-MISC
wound O-MISC B-DISO-MISC
dressing O-MISC I-OBJC-MISC
in O-MISC B-ACTI-MISC
cream O-MISC O-MISC
form O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
preliminary O-MISC B-CHED-MISC
clinical O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
reported O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
painful O-MISC I-ACTI-MISC
upon O-MISC B-ACTI-MISC
application O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
compared O-MISC B-DEVI-MISC
various O-MISC B-ACTI-MISC
concentrations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CHP B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tolerable O-MISC B-CHED-MISC
concentration O-MISC B-CHED-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
retention O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
antimicrobial O-MISC O-MISC
efficacy O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
burn B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
burns B-DISO-MISC I-ACTI-MISC
which O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
separately O-MISC B-CHED-MISC
treated O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
pairs O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
successive O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
intervals O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
burn B-DISO-MISC I-ACTI-MISC
site O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC I-CONC-MISC
each O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
CHP B-CHED-MISC B-CHED-MISC
concentrations O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
cent O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
cent O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
vehicle O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
cent O-MISC B-ACTI-MISC
silver B-CHED-MISC O-MISC
sulphadiazine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
AgSD B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
cream O-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
antimicrobial O-MISC O-MISC
agent O-MISC B-DISO-MISC
frequently O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
topical O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
burn B-DISO-MISC I-ACTI-MISC
wounds O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
site O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
AgSD B-CHED-MISC O-MISC
cream O-MISC O-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
relationship O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
CHP B-CHED-MISC B-CHED-MISC
concentration O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
' O-MISC B-ACTI-MISC
ratings O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
analogue O-MISC B-CONC-MISC
scale O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
cent O-MISC B-ACTI-MISC
CHP B-CHED-MISC B-GENE-MISC
cream O-MISC I-GEOG-MISC
was O-MISC B-ACTI-MISC
closest O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
AgSD B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
tolerance O-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
differed O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
AgSD B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ease O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
application O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CHP B-CHED-MISC B-GENE-MISC
creams O-MISC I-GEOG-MISC
was O-MISC B-ACTI-MISC
less O-MISC B-CHED-MISC
satisfactory O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
AgSD B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
formulations O-MISC O-MISC
at O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
below O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
cent O-MISC B-ACTI-MISC
CHP B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
prove O-MISC B-ACTI-MISC
acceptable O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
wound O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vehicle O-MISC B-GENE-MISC
system O-MISC B-CHED-MISC
needs O-MISC B-ACTI-MISC
pharmaceutical O-MISC B-PROC-MISC
improvement O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
render O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
tolerable O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
easier O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC I-ACTI-MISC
hepatitis B-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
clopidogrel B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
literature O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hepatotoxicity B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
hepatitis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recognition O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
drug O-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
difficult O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
clopidogrel B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
hepatitis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
strongly O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
accurate O-MISC B-CHED-MISC
medical O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
biopsy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Reports O-MISC B-CHED-MISC
about O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hepatotoxicity B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
clopidogrel B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
drug O-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
believe O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
physicians O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
carefully O-MISC B-ACTI-MISC
consider O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
hepatic B-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
when O-MISC B-ACTI-MISC
clopidogrel B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Bortezomib B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
salvage O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
relapsed O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
multiple B-DISO-MISC B-ANAT-MISC
myeloma I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
clinical O-MISC I-ACTI-MISC
outcomes O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Bortezomib B-CHED-MISC O-MISC
( O-MISC O-MISC
bort B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
dexamethasone B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
dex B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
relapsed O-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
( O-MISC B-ANAT-MISC
R O-MISC B-ANAT-MISC
/ O-MISC B-ANAT-MISC
R O-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
multiple B-DISO-MISC B-ANAT-MISC
myeloma I-DISO-MISC B-ANAT-MISC
( O-MISC B-ANAT-MISC
MM B-DISO-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
investigated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bort B-CHED-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dex B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
bort B-CHED-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
salvage O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
R O-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
R O-MISC I-ACTI-MISC
MM B-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
prior O-MISC B-CHED-MISC
autologous O-MISC B-CONC-MISC
stem O-MISC I-CONC-MISC
cell O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
or O-MISC B-ACTI-MISC
conventional O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
lines O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Eighty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
immunomodulatory O-MISC O-MISC
drugs O-MISC B-DISO-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
line O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
before O-MISC B-ACTI-MISC
bort B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
dex B-CHED-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bort B-CHED-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dex B-CHED-MISC I-CHED-MISC
cycles O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
maximum O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
cycles O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
intention O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
treat O-MISC I-CONC-MISC
basis O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
achieved O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
partial O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CR O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
achieved O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
good O-MISC B-ACTI-MISC
partial O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-CHED-MISC
durations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
next O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
free O-MISC I-CHED-MISC
interval O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
relevant O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
event O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
occurred O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
78 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
grade O-MISC B-CHED-MISC
II O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
grade O-MISC B-CHED-MISC
III O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
discontinuation O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
follow O-MISC B-CONC-MISC
up O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
time O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
progression O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
free O-MISC I-CHED-MISC
survival O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
PFS O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
survival O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
OS O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Prolonged O-MISC B-CHED-MISC
PFS O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
OS O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
achieving O-MISC B-ACTI-MISC
CR O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
bort B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
dex B-CHED-MISC B-DISO-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
line O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
prior O-MISC B-CHED-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Bort B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
dex B-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
salvage O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
MM B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
relapse O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

Pubertal O-MISC B-CHED-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
Bisphenol B-CHED-MISC O-MISC
A I-CHED-MISC B-DISO-MISC
increases O-MISC B-CHED-MISC
anxiety B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
behavior O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
decreases O-MISC B-CHED-MISC
acetylcholinesterase O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-DISO-MISC
male O-MISC I-LIVB-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
Bisphenol B-CHED-MISC O-MISC
A I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
BPA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
neurodevelopment O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
behaviors O-MISC B-DEVI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
established O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Acetylcholinesterase O-MISC O-MISC
( O-MISC B-ACTI-MISC
AChE O-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
regulatory O-MISC B-CHED-MISC
enzyme O-MISC O-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
behavior O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
investigated O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
phenotypes O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
AChE O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
mice O-MISC I-ANAT-MISC
following O-MISC B-ACTI-MISC
BPA B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
puberty O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
postnatal O-MISC B-CHED-MISC
day O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
PND O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
mice O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
50mg O-MISC B-ACTI-MISC
BPA B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
diet O-MISC B-GENE-MISC
per O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
PND71 O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
behavioral O-MISC B-CONC-MISC
assay O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
elevated O-MISC B-CONC-MISC
plus O-MISC I-CONC-MISC
maze O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
EPM O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
light O-MISC B-CONC-MISC
/ O-MISC I-CONC-MISC
dark O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
AChE O-MISC O-MISC
activity O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prefrontal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
hypothalamus O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
cerebellum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Results O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
behavioral O-MISC B-CONC-MISC
phenotyping O-MISC I-CONC-MISC
indicated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
behavior O-MISC B-DEVI-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
BPA B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

AChE O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
BPA B-CHED-MISC O-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
control O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
difference O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prefrontal O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
hypothalamus O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
cerebellum O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
pubertal O-MISC I-DISO-MISC
BPA B-CHED-MISC O-MISC
exposure O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
behavior O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
decreased O-MISC B-CHED-MISC
AChE O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-DISO-MISC
male O-MISC I-LIVB-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
necessary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
cholinergic O-MISC B-CHED-MISC
signaling O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
PBE O-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
anxiety B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
behaviors O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Biochemical O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Solidago O-MISC I-ANAT-MISC
virgaurea O-MISC B-DISO-MISC
extract O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Cardiovascular B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CVDs B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-CHED-MISC
health O-MISC B-CHED-MISC
problem O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
advanced O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
developing O-MISC B-CHED-MISC
countries O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
world O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
protective O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Solidago O-MISC O-MISC
virgaurea O-MISC B-DISO-MISC
extract O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
subcutaneous O-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
twice O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
interval O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
consecutive O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
serum O-MISC O-MISC
lactate B-CHED-MISC B-ANAT-MISC
dehydrogenase O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
creatine B-CHED-MISC O-MISC
phosphokinase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
alanine B-CHED-MISC O-MISC
transaminase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
aspartate B-CHED-MISC O-MISC
transaminase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
angiotensin B-CHED-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
converting O-MISC I-LIVB-MISC
enzyme O-MISC I-LIVB-MISC
activities O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
total O-MISC O-MISC
cholesterol B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
triglycerides B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
free O-MISC B-OCCU-MISC
serum O-MISC I-OCCU-MISC
fatty B-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
malondialdehyde B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
MDA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nitric B-CHED-MISC O-MISC
oxide I-CHED-MISC B-DISO-MISC
levels O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
glutathione B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
superoxide B-CHED-MISC O-MISC
dismutase O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC I-ANAT-MISC
control O-MISC I-PHEN-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
S O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
virgaurea O-MISC I-PHEN-MISC
extract O-MISC O-MISC
for O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
significantly O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
alterations O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Captopril B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
orally O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inhibitor O-MISC O-MISC
of O-MISC B-ACTI-MISC
angiotensin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
converting O-MISC B-DISO-MISC
enzyme O-MISC B-DISO-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
standard O-MISC B-ACTI-MISC
cardioprotective O-MISC O-MISC
drug O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
positive O-MISC B-CHED-MISC
control O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
S O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
virgaurea O-MISC I-PHEN-MISC
extract O-MISC O-MISC
exerts O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
protective O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
by O-MISC B-ACTI-MISC
decreasing O-MISC B-ACTI-MISC
MDA B-CHED-MISC O-MISC
level O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
antioxidant O-MISC I-DISO-MISC
status O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
emphasizes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beneficial O-MISC B-CHED-MISC
action O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
S O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
virgaurea O-MISC I-PHEN-MISC
extract O-MISC O-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cardioprotective O-MISC O-MISC
agent O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

" O-MISC B-ACTI-MISC
Real O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
world O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
lenalidomide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
relapsed O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
multiple B-DISO-MISC B-ANAT-MISC
myeloma I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
standard O-MISC B-CHED-MISC
clinical O-MISC I-CHED-MISC
practice O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Greek O-MISC B-PHYS-MISC
Myeloma B-DISO-MISC I-PHYS-MISC
Study O-MISC I-PHYS-MISC
Group O-MISC I-PHYS-MISC
. O-MISC B-ACTI-MISC

Lenalidomide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
RD B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
standard O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
care O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
relapsed O-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
multiple B-DISO-MISC B-ANAT-MISC
myeloma I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
RRMM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
published O-MISC B-CHED-MISC
data O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
real O-MISC B-CHED-MISC
world O-MISC I-CHED-MISC
" O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
RW O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
International O-MISC B-CHED-MISC
Society O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
Pharmacoeconomics O-MISC I-CHED-MISC
and O-MISC I-CHED-MISC
Outcomes O-MISC I-CHED-MISC
Research O-MISC I-CHED-MISC
definition O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
212 O-MISC B-ACTI-MISC
RRMM B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
RD B-CHED-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
RW O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Objective O-MISC I-DISO-MISC
response O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
PR O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
partial O-MISC I-DISO-MISC
response O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
complete O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CR O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
response O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
CR O-MISC B-CONC-MISC
when O-MISC B-ACTI-MISC
RD B-CHED-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
2nd O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
2 O-MISC I-CONC-MISC
( O-MISC I-CONC-MISC
nd O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
line O-MISC I-CONC-MISC
treatment O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Quality O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
response O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
independent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
lines O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
therapies O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
thalidomide B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
bortezomib B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-CHED-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
response O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
RD B-CHED-MISC B-CONC-MISC
until O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
reached O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Improvement O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
humoral O-MISC I-DISO-MISC
immunity O-MISC I-LIVB-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
responders O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
achieved O-MISC B-ACTI-MISC
stable O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
myelosuppression B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
needed O-MISC B-ACTI-MISC
hospitalization O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
deep B-DISO-MISC I-ACTI-MISC
vein I-DISO-MISC B-ANAT-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Dose O-MISC B-CHED-MISC
reductions O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
permanent O-MISC B-CHED-MISC
discontinuation O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
discontinuation O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Performance O-MISC I-DISO-MISC
status O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
PS O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
lenalidomide B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
predicted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
discontinuation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Extra O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
medullary O-MISC B-ANAT-MISC
relapses O-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
confirms O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
RD B-CHED-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
RRMM B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RW O-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
durable O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
continue O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
till O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
improves O-MISC I-ACTI-MISC
humoral O-MISC I-DISO-MISC
immunity O-MISC I-LIVB-MISC
even O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
stable O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cytogenetic O-MISC B-CONC-MISC
action O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
ifosfamide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
mesna B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
rabbit O-MISC I-ANAT-MISC
lymphocytes O-MISC I-GENE-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
/ O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
cytogenetic O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Ifosfamide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
IFO B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alkylating O-MISC O-MISC
nitrogen B-CHED-MISC B-DISO-MISC
mustard O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
administrated O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
antineoplasmic O-MISC O-MISC
agent O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
intense O-MISC B-CHED-MISC
urotoxic O-MISC I-ACTI-MISC
action O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
cystitis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
IFO B-CHED-MISC O-MISC
raises O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
requirement O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
co O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sulfanylethanesulfonate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Mesna B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
aiming O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
avoid O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
minimize O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

IFO B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
Mesna B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
administrated O-MISC B-ACTI-MISC
separately O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
rabbit O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
lymphocytes O-MISC I-GENE-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Cytogenetic O-MISC I-DISO-MISC
markers O-MISC I-LIVB-MISC
for O-MISC B-ACTI-MISC
sister O-MISC I-DISO-MISC
chromatid O-MISC I-LIVB-MISC
exchanges O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
SCEs O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
proliferation O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
index O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
PRI O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Mitotic O-MISC I-DISO-MISC
Index O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Mesna B-CHED-MISC B-CHED-MISC
' O-MISC I-CHED-MISC
s O-MISC I-CHED-MISC
action O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
conjunction O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
IFO B-CHED-MISC B-CONC-MISC
reduces O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
SCEs O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
comparison O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SCEs O-MISC I-ACTI-MISC
recordings O-MISC B-CHED-MISC
obtained O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
IFO B-CHED-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
alone O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
concentrations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Mesna B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
alone O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
reductions O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PRI O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
IFO B-CHED-MISC O-MISC
acting O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lymphocytes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Mesna B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
reduces O-MISC B-CHED-MISC
IFO B-CHED-MISC O-MISC
' O-MISC B-DISO-MISC
s O-MISC B-DISO-MISC
genotoxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
concentrations O-MISC B-CHED-MISC
it O-MISC B-ACTI-MISC
acts O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inhibitory O-MISC B-DEVI-MISC
fashion O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cytostatic O-MISC B-OCCU-MISC
action O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
. O-MISC B-ACTI-MISC

Risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
predictors O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
among O-MISC B-ACTI-MISC
multiethnic O-MISC I-ANAT-MISC
Malaysians O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC B-CHED-MISC
pulsatile O-MISC O-MISC
levodopa B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
leads O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
motor O-MISC I-ACTI-MISC
fluctuations O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
predictors O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
among O-MISC B-ACTI-MISC
multiethnic O-MISC B-ACTI-MISC
Malaysian O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cross O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
sectional O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
involving O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
PD B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
uninterrupted O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
instrument O-MISC B-OBJC-MISC
used O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
UPDRS O-MISC B-CHED-MISC
questionnaires O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
predictors O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
multivariate O-MISC B-PHEN-MISC
logistic O-MISC B-UnknownType-MISC
regression O-MISC B-UnknownType-MISC
analysis O-MISC B-UnknownType-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
age O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
65 O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC I-CHED-MISC
8 O-MISC B-ACTI-MISC
. O-MISC I-CHED-MISC
5 O-MISC I-CHED-MISC
years O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
onset O-MISC B-CHED-MISC
age O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
disease O-MISC B-CHED-MISC
duration O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Dyskinesia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
64 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
Malays O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
Indians O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
ethnic O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Eighty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
fluctuations O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
onset O-MISC B-CHED-MISC
age O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
longer O-MISC B-CHED-MISC
duration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
longer O-MISC B-CHED-MISC
disease O-MISC B-CHED-MISC
duration O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
total O-MISC B-ACTI-MISC
daily O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
total O-MISC B-CHED-MISC
UPDRS O-MISC I-CHED-MISC
scores O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
predictors O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
age O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
levodopa B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
predictors O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
levodopa B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
age O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
busulfan B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
pharmacological O-MISC B-CONC-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Busulfan B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC O-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
remains O-MISC B-ACTI-MISC
poorly O-MISC B-ACTI-MISC
characterized O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
123 O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
busulfan B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
combined O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
before O-MISC B-ACTI-MISC
bone O-MISC B-CONC-MISC
marrow O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
malignant O-MISC I-ACTI-MISC
solid O-MISC B-ANAT-MISC
tumors B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
brain B-DISO-MISC I-ACTI-MISC
tumors I-DISO-MISC B-ANAT-MISC
excluded O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Busulfan B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
p O-MISC B-CHED-MISC
. O-MISC I-CHED-MISC
o O-MISC I-CHED-MISC
. O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
consecutively O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
calculation O-MISC B-DEVI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
area O-MISC B-GEOG-MISC
results O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
young O-MISC B-CHED-MISC
children O-MISC I-ANAT-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Ninety O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
anticonvulsive O-MISC B-CONC-MISC
prophylaxis O-MISC I-CONC-MISC
; O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
course O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
account O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
terms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
among O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
under O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
under O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
total O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
clonazepam B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
neurological B-DISO-MISC I-ACTI-MISC
symptoms I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Busulfan B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gas O-MISC B-CONC-MISC
chromatographic O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
mass O-MISC I-CONC-MISC
spectrometry O-MISC I-CONC-MISC
assay O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
cerebrospinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
central B-DISO-MISC I-ACTI-MISC
nervous I-DISO-MISC B-ANAT-MISC
system I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
under O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
clonazepam B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
cerebrospinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
: O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
ratio O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebrospinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
: O-MISC B-ACTI-MISC
plasma O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
previously O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
shows O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
efficiently O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
clonazepam B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
calculated O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
area O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
young O-MISC B-CHED-MISC
children O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
close O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Since O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
pharmacokinetic O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
faster O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
clearance O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
approximate O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
closely O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
systemic O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
obtained O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
usual O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
total O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
inferences O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
terms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
anticancer O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
myeloablative O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
busulfan B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
infants O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
bone O-MISC B-CONC-MISC
marrow O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
reconsidered O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pharmacokinetic O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
unexpected O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
renal O-MISC I-ANAT-MISC
- O-MISC I-CONC-MISC
transplant O-MISC I-CONC-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
proteinuria B-DISO-MISC I-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
everolimus B-CHED-MISC I-ACTI-MISC
: O-MISC B-ANAT-MISC
AL B-DISO-MISC B-ANAT-MISC
amyloidosis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Proteinuria B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
expected O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
transplant O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
mammalian O-MISC I-ANAT-MISC
target O-MISC O-MISC
of O-MISC B-DISO-MISC
rapamycin B-CHED-MISC B-DISO-MISC
inhibitors O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
mTOR O-MISC O-MISC
- O-MISC B-DISO-MISC
i O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
suspicion O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
supported O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
histological O-MISC B-CHED-MISC
evidence O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
potential O-MISC B-ACTI-MISC
alternate O-MISC B-ACTI-MISC
diagnoses O-MISC I-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
rejection O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
interstitial O-MISC I-ACTI-MISC
fibrosis B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
tubular O-MISC I-ACTI-MISC
atrophy B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
recurrent O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
de O-MISC B-CHED-MISC
novo O-MISC I-CHED-MISC
glomerulopathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unexpected O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
amyloidosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
transplant O-MISC I-CONC-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
transplant O-MISC I-CHED-MISC
monoclonal O-MISC I-ACTI-MISC
gammapathy O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
undetermined O-MISC B-ACTI-MISC
significance O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
proteinuria B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
conversion O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
tacrolimus B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
everolimus B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
oral O-MISC O-MISC
galactose B-CHED-MISC B-DISO-MISC
treatment O-MISC B-CONC-MISC
prevents O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
treated O-MISC B-CONC-MISC
intracerebroventricularly O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Basic O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
research O-MISC I-CONC-MISC
has O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
dementia B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
sporadic O-MISC I-ACTI-MISC
Alzheimer B-DISO-MISC B-ANAT-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
sAD O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
dysfunction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
insulin O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
receptor O-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
IR O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
system O-MISC I-LIVB-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
glucose B-CHED-MISC I-DISO-MISC
transport O-MISC I-LIVB-MISC
via O-MISC B-ACTI-MISC
glucose B-CHED-MISC O-MISC
transporter O-MISC B-DISO-MISC
GLUT4 O-MISC O-MISC
and O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
glucose B-CHED-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
source O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
energy O-MISC O-MISC
is O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
galactose I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C O-MISC O-MISC
- O-MISC B-DISO-MISC
4 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
epimer O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
glucose I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
transported O-MISC I-DISO-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
by O-MISC B-ACTI-MISC
insulin O-MISC O-MISC
- O-MISC B-ACTI-MISC
independent O-MISC B-CHED-MISC
GLUT3 O-MISC O-MISC
transporter O-MISC O-MISC
where O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
might O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
metabolized O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
glucose B-CHED-MISC O-MISC
via O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Leloir O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Exclusively O-MISC B-ACTI-MISC
parenteral O-MISC B-CHED-MISC
daily O-MISC B-ACTI-MISC
injections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
galactose B-CHED-MISC O-MISC
induce O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
deterioration I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rodents O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
generate O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
aging O-MISC I-DISO-MISC
model O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
galactose B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
cognitive O-MISC I-DISO-MISC
functions O-MISC I-LIVB-MISC
have O-MISC B-ACTI-MISC
never O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
tested O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
continuous O-MISC B-CHED-MISC
daily O-MISC B-CHED-MISC
oral O-MISC O-MISC
galactose B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
STZ B-CHED-MISC B-LIVB-MISC
- O-MISC I-PHEN-MISC
icv O-MISC I-PROC-MISC
) O-MISC I-PHEN-MISC
rat O-MISC I-ANAT-MISC
model O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
sAD O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
Morris O-MISC B-CONC-MISC
Water O-MISC I-CONC-MISC
Maze O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
Passive O-MISC B-CONC-MISC
Avoidance O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
month O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
oral O-MISC O-MISC
galactose B-CHED-MISC B-DISO-MISC
treatment O-MISC B-CONC-MISC
initiated O-MISC B-ACTI-MISC
immediately O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
icv O-MISC O-MISC
administration O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
successfully O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
development O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
icv O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cognitive B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Beneficial O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oral O-MISC O-MISC
galactose B-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
independent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
age O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
galactose B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
ranging O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Additionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
oral O-MISC O-MISC
galactose B-CHED-MISC B-DISO-MISC
administration O-MISC B-CONC-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
galactose B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
galactose B-CHED-MISC O-MISC
concentration O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebrospinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
than O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
parenteral O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
galactose B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC O-MISC
galactose B-CHED-MISC B-DISO-MISC
exposure O-MISC B-CHED-MISC
might O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
beneficial O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
learning O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
ability O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
worth O-MISC B-ACTI-MISC
investigating O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
glucose B-DISO-MISC I-DISO-MISC
hypometabolism I-DISO-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
AD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
investigation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pattern O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
kidney B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
HIV O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
positive O-MISC I-OCCU-MISC
persons O-MISC I-ANAT-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
tenofovir B-CHED-MISC O-MISC
disoproxil I-CHED-MISC B-DISO-MISC
fumarate I-CHED-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
examination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
large O-MISC B-CHED-MISC
population O-MISC I-CHED-MISC
database O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
MHRA O-MISC B-CHED-MISC
database O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
tenofovir B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
kidney O-MISC I-ACTI-MISC
syndromes O-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
established O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
mechanistic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
randomised O-MISC B-CONC-MISC
clinical O-MISC I-CONC-MISC
trials O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
exact O-MISC B-ACTI-MISC
pattern O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
involvement O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
still O-MISC B-ACTI-MISC
uncertain O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
undertook O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
descriptive O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
Yellow O-MISC B-CHED-MISC
Card O-MISC I-CHED-MISC
records O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
407 O-MISC B-ACTI-MISC
HIV O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
positive O-MISC I-OCCU-MISC
persons O-MISC I-ANAT-MISC
taking O-MISC B-ACTI-MISC
tenofovir B-CHED-MISC O-MISC
disoproxil I-CHED-MISC B-DISO-MISC
fumarate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TDF B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
antiretroviral O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
regimen O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
submitted O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Medicines O-MISC B-PHYS-MISC
and O-MISC I-PHYS-MISC
Healthcare O-MISC I-PHYS-MISC
Products O-MISC I-PHYS-MISC
Regulatory O-MISC I-PHYS-MISC
Agency O-MISC I-PHYS-MISC
( O-MISC B-ACTI-MISC
MHRA O-MISC B-PHYS-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
suspected O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Reports O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
satisfy O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
criteria O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
kidney I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
kidney B-DISO-MISC I-ACTI-MISC
tubular I-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
Fanconi B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
407 O-MISC B-ACTI-MISC
Yellow O-MISC B-CHED-MISC
Card O-MISC I-CHED-MISC
records O-MISC I-CHED-MISC
analysed O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
106 O-MISC B-ACTI-MISC
satisfied O-MISC B-ACTI-MISC
criteria O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
TDF B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
kidney B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
53 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
features O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
kidney B-DISO-MISC I-ACTI-MISC
tubular I-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
features O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
glomerular B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
Fanconi B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
TDF B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
316 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
interquartile O-MISC B-CHED-MISC
range O-MISC I-CHED-MISC
120 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
740 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hospitalisation O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
TDF B-CHED-MISC I-GENE-MISC
kidney O-MISC I-GENE-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
amongst O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
features O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Fanconi B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pattern O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
kidney O-MISC I-ACTI-MISC
syndromes O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
series O-MISC B-ACTI-MISC
mirrors O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
randomised O-MISC B-CONC-MISC
clinical O-MISC I-CONC-MISC
trials O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Cessation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
TDF B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
complete O-MISC B-ACTI-MISC
restoration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
kidney O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
half O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
postoperative B-DISO-MISC I-ACTI-MISC
delirium I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
even O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Postoperative B-DISO-MISC B-CHED-MISC
delirium I-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
postoperative B-DISO-MISC I-ACTI-MISC
delirium I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ICU O-MISC B-GENE-MISC
for O-MISC B-ACTI-MISC
postoperative O-MISC B-CONC-MISC
monitoring O-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
elective O-MISC B-CONC-MISC
major O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
secondary O-MISC B-ACTI-MISC
outcome O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
eventual O-MISC B-ACTI-MISC
independent O-MISC B-CHED-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
demographic O-MISC B-CHED-MISC
data O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
anesthetic O-MISC O-MISC
drugs O-MISC B-DISO-MISC
used O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
An O-MISC B-ACTI-MISC
observational O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
cohort O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
ICU O-MISC B-GENE-MISC
within O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
surgical O-MISC B-CONC-MISC
procedures O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Exclusion O-MISC B-CHED-MISC
criteria O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
preexisting O-MISC B-ACTI-MISC
predisposing O-MISC B-CHED-MISC
factor O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
delirium B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
potentially O-MISC B-ACTI-MISC
confounding O-MISC B-CHED-MISC
neurological B-DISO-MISC I-ACTI-MISC
dysfunctions I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
daily O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
confusion B-DISO-MISC I-ACTI-MISC
assessment O-MISC B-CHED-MISC
method O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ICU O-MISC B-CHED-MISC
scale O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
surgical O-MISC B-CONC-MISC
procedure O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Early O-MISC B-CHED-MISC
postoperative B-DISO-MISC B-CHED-MISC
delirium I-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
through O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
different O-MISC B-CHED-MISC
multiple O-MISC B-CHED-MISC
regression O-MISC I-CHED-MISC
models O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
According O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
confusion O-MISC I-ACTI-MISC
assessment O-MISC B-CHED-MISC
method O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ICU O-MISC B-CHED-MISC
scale O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
early O-MISC I-ACTI-MISC
postoperative B-DISO-MISC B-ANAT-MISC
delirium I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
thiopentone B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
risk O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
delirium B-DISO-MISC I-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
RR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
X2 O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
256 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
df O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
early O-MISC B-CHED-MISC
postoperative B-DISO-MISC I-ACTI-MISC
delirium I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
common O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
major O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Thiopentone B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
independently O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
relative O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
methamphetamine B-CHED-MISC O-MISC
induces O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
lasting O-MISC I-CHED-MISC
depressive B-DISO-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
like O-MISC B-ANAT-MISC
behaviour O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Methamphetamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
METH B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
triggers O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
disruption O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
monoaminergic O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
METH B-CHED-MISC O-MISC
abuse O-MISC I-DISO-MISC
leads O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
emotional O-MISC I-ACTI-MISC
states O-MISC B-ANAT-MISC
including O-MISC B-ACTI-MISC
depressive B-DISO-MISC I-ACTI-MISC
symptoms I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
withdrawal O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
currently O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
toxic O-MISC B-CHED-MISC
dosage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
METH B-CHED-MISC O-MISC
also O-MISC B-ACTI-MISC
causes O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
lasting O-MISC I-CHED-MISC
depressive B-DISO-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
persistent O-MISC B-ACTI-MISC
monoaminergic O-MISC I-ACTI-MISC
deficits O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
now O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
depressive B-DISO-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
like O-MISC B-ANAT-MISC
behaviour O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
periods O-MISC I-CHED-MISC
following O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
METH B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METH B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
alter O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
motor O-MISC I-DISO-MISC
function O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
procedural O-MISC I-DISO-MISC
memory O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
as O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
swimming O-MISC B-DEVI-MISC
speed O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
escape O-MISC B-ACTI-MISC
latency O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
find O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
platform O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cued O-MISC B-CHED-MISC
version O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
water O-MISC B-DEVI-MISC
maze O-MISC I-DEVI-MISC
task O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
METH B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
immobility O-MISC I-ACTI-MISC
time O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tail O-MISC B-CONC-MISC
suspension O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
administration O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
depressive B-DISO-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
like O-MISC B-ANAT-MISC
profile O-MISC B-ANAT-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
METH B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
accompanied O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
depletion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
frontostriatal O-MISC I-GENE-MISC
dopaminergic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
serotonergic O-MISC I-DISO-MISC
neurotransmission O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
indicated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
levels O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
DOPAC B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
HVA B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
tyrosine B-CHED-MISC O-MISC
hydroxylase O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
serotonin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
post O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
parallel O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
neurochemical O-MISC I-GENE-MISC
feature O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
astroglial O-MISC I-ACTI-MISC
dysfunction O-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
unaffected O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cortex O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
striatal O-MISC I-GENE-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
astrocytic O-MISC I-GENE-MISC
protein O-MISC O-MISC
marker O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
glial O-MISC O-MISC
fibrillary O-MISC B-DISO-MISC
acidic O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
transiently O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
METH B-CHED-MISC O-MISC
induces O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
lasting O-MISC I-CHED-MISC
depressive B-DISO-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
like O-MISC B-ANAT-MISC
behaviour O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
disruption O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
frontostriatal O-MISC I-GENE-MISC
dopaminergic O-MISC O-MISC
and O-MISC B-ACTI-MISC
serotonergic O-MISC I-DISO-MISC
homoeostasis O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Linezolid B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
optic B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Many O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
antimicrobials O-MISC O-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
ocular O-MISC I-GENE-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
relevant O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
multidrug O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
where O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
drug O-MISC O-MISC
can O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
ocular O-MISC I-GENE-MISC
adverse O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
loss B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
vision I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
linezolid B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
second O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
line O-MISC I-CONC-MISC
anti O-MISC I-CONC-MISC
- O-MISC B-DISO-MISC
tuberculous O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
including O-MISC B-ACTI-MISC
linezolid B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
ethambutol B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
extensively B-DISO-MISC I-ACTI-MISC
drug I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
resistant I-DISO-MISC B-ANAT-MISC
tuberculosis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
XDR B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
TB I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
us O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
painless O-MISC B-CHED-MISC
progressive O-MISC B-CHED-MISC
loss B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
vision I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
both O-MISC I-GENE-MISC
eyes O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Color O-MISC I-DISO-MISC
vision O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
defective O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
fundus O-MISC B-CONC-MISC
examination O-MISC I-CONC-MISC
revealed O-MISC B-CHED-MISC
optic B-DISO-MISC I-ACTI-MISC
disc I-DISO-MISC B-ANAT-MISC
edema I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
eyes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Ethambutol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
toxic B-DISO-MISC B-CHED-MISC
optic I-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
tablet O-MISC O-MISC
ethambutol B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
withdrawn O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Deterioration B-DISO-MISC B-OCCU-MISC
of I-DISO-MISC B-ACTI-MISC
vision I-DISO-MISC I-DISO-MISC
occurred O-MISC B-ACTI-MISC
despite O-MISC B-ACTI-MISC
withdrawal O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ethambutol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
linezolid B-CHED-MISC O-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
vision O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
emphasizes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
monitoring O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
visual O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
linezolid B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Resuscitation O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
, O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
levobupivacaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
newborn O-MISC I-ANAT-MISC
piglets O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
optimal O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
regimens O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
emulsion O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
neonates O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
local O-MISC I-ACTI-MISC
anaesthetic O-MISC B-ANAT-MISC
systemic O-MISC B-ANAT-MISC
toxicity B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
LAST O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Newborn O-MISC B-CHED-MISC
piglets O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
levobupivacaine B-CHED-MISC O-MISC
until O-MISC B-ACTI-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
collapse I-DISO-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Standard O-MISC B-CHED-MISC
cardiopulmonary O-MISC B-CONC-MISC
resuscitation O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
started O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
electrocardiogram O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
ECG O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
monitored O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
fibrillation B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
QRS O-MISC B-CONC-MISC
prolongation O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Piglets O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
allocated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Intralipid O-MISC O-MISC
( O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Intralipd O-MISC O-MISC
plus O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Resuscitation O-MISC B-CONC-MISC
continued O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
until O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
return O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
spontaneous O-MISC I-DISO-MISC
circulation O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
ROSC O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
accompanied O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
superior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
pressure O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
normal O-MISC I-ACTI-MISC
sinus O-MISC B-ANAT-MISC
rhythm O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
ROSC O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
achieved O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
piglets O-MISC I-ANAT-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
piglets O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Mortality O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
lower O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
groups O-MISC I-ANAT-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ECG O-MISC I-ACTI-MISC
abnormalities O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
zero O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Intralipid O-MISC O-MISC
only O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
plus O-MISC B-DISO-MISC
lipid O-MISC O-MISC
groups O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Lipid O-MISC O-MISC
emulsion O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
equally O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
achieving O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
return O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
spontaneous O-MISC I-ACTI-MISC
circulation O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
LAST O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Epinephrine B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
lipid O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ECG O-MISC I-ACTI-MISC
abnormalities O-MISC B-ANAT-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
emulsion O-MISC B-DISO-MISC
alone O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
thrombocytopenia B-DISO-MISC B-ANAT-MISC
type I-DISO-MISC B-ANAT-MISC
II I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
postoperative O-MISC B-CHED-MISC
recovery O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
platelet O-MISC B-CONC-MISC
count O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
graft O-MISC B-GEOG-MISC
recipients O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
cohort O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Thrombocytopenia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
end B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
stage I-DISO-MISC B-ANAT-MISC
liver I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC I-ACTI-MISC
disorder O-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
mainly O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
portal B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
low O-MISC I-ACTI-MISC
levels O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
thrombopoetin O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
endotoxemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
impact O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
immune O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
mediated O-MISC I-OCCU-MISC
heparin B-CHED-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
thrombocytopenia B-DISO-MISC B-ANAT-MISC
type I-DISO-MISC B-ANAT-MISC
II I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HIT B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
II I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
understood O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
citations O-MISC B-CHED-MISC
reporting O-MISC B-ACTI-MISC
contradictory O-MISC B-CHED-MISC
results O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
perioperative O-MISC B-CHED-MISC
course O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
HIT B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
II I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHOD O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
retrospectively O-MISC B-CONC-MISC
evaluated O-MISC I-CONC-MISC
the O-MISC B-ACTI-MISC
medical O-MISC B-CHED-MISC
records O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
205 O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
adult O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
full O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
size O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
between O-MISC B-ACTI-MISC
January O-MISC B-CHED-MISC
2006 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
December O-MISC B-CHED-MISC
2010 O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
end B-DISO-MISC B-CHED-MISC
- I-DISO-MISC I-CHED-MISC
stage I-DISO-MISC I-CHED-MISC
or I-DISO-MISC B-ACTI-MISC
malignant I-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Preoperative O-MISC B-CHED-MISC
platelet O-MISC B-CONC-MISC
count O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
postoperative O-MISC B-CHED-MISC
course O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
platelets O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
signs O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
II I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
155 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
205 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
before O-MISC B-ACTI-MISC
transplantation O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
influenced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
Model O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
End B-DISO-MISC I-CHED-MISC
- I-DISO-MISC I-CHED-MISC
Stage I-DISO-MISC I-CHED-MISC
Liver I-DISO-MISC I-CHED-MISC
Disease I-DISO-MISC I-CHED-MISC
score O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
liver B-DISO-MISC I-ACTI-MISC
cirrhosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
platelet O-MISC B-CONC-MISC
count O-MISC I-CONC-MISC
exceeded O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
uL O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
193 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
medium O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Regarding O-MISC B-ACTI-MISC
HIT B-DISO-MISC B-CHED-MISC
II I-DISO-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
background O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC B-CHED-MISC
type I-DISO-MISC B-ANAT-MISC
II I-DISO-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
end B-DISO-MISC B-CHED-MISC
- I-DISO-MISC I-CHED-MISC
stage I-DISO-MISC I-CHED-MISC
hepatic I-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HIT B-DISO-MISC O-MISC
type I-DISO-MISC B-DISO-MISC
II I-DISO-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
intravenous O-MISC O-MISC
heparin B-CHED-MISC O-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
avoided O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prophylactic O-MISC B-CONC-MISC
anticoagulation O-MISC I-CONC-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
low O-MISC O-MISC
- O-MISC B-DISO-MISC
molecular O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
weight O-MISC B-DISO-MISC
heparin B-CHED-MISC B-DISO-MISC
after O-MISC B-ACTI-MISC
normalization O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
platelet O-MISC B-CONC-MISC
count O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Takotsubo B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
apical B-DISO-MISC I-ACTI-MISC
ballooning I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
secondary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Zolmitriptan B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Takotsubo B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
TS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
broken B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
ventricle O-MISC B-GEOG-MISC
apical O-MISC B-CONC-MISC
ballooning O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
elevated O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
biomarkers O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
electrocardiographic O-MISC B-CONC-MISC
changes O-MISC B-CHED-MISC
suggestive O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
coronary I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ie O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ST O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
segment O-MISC B-ACTI-MISC
elevation O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
T O-MISC I-ACTI-MISC
wave O-MISC B-ANAT-MISC
inversions O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
pathologic O-MISC B-CHED-MISC
Q O-MISC I-DISO-MISC
waves O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
medical O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
mitral B-DISO-MISC I-ACTI-MISC
valve I-DISO-MISC B-ANAT-MISC
prolapse I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
migraines B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC I-CONC-MISC
the O-MISC I-CONC-MISC
hospital O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
substernal O-MISC I-ACTI-MISC
chest B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
electrocardiogram O-MISC B-CONC-MISC
demonstrated O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
ST O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
segment O-MISC I-CHED-MISC
elevation O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
leads O-MISC O-MISC
II O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
III O-MISC O-MISC
, O-MISC B-ACTI-MISC
aVF O-MISC O-MISC
, O-MISC B-ACTI-MISC
V5 O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
V6 O-MISC O-MISC
and O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
troponin O-MISC O-MISC
I O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Emergent O-MISC B-ACTI-MISC
coronary O-MISC B-CONC-MISC
angiogram O-MISC I-CONC-MISC
revealed O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
coronary O-MISC I-GENE-MISC
arteries O-MISC B-GEOG-MISC
with O-MISC B-ACTI-MISC
moderately O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
ejection O-MISC I-LIVB-MISC
fraction O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
wall O-MISC I-ACTI-MISC
motion O-MISC B-ANAT-MISC
abnormalities O-MISC I-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
TS B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Detailed O-MISC B-ACTI-MISC
history O-MISC B-CHED-MISC
obtained O-MISC B-ACTI-MISC
retrospectively O-MISC B-CHED-MISC
revealed O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
took O-MISC B-ACTI-MISC
zolmitriptan B-CHED-MISC O-MISC
sparingly O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
migraines B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

But O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
event O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
zolmitriptan B-CHED-MISC O-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
daily O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
several O-MISC I-ACTI-MISC
days O-MISC B-ANAT-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
migraine B-DISO-MISC I-ACTI-MISC
headache I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
otherwise O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
quite O-MISC B-ACTI-MISC
active O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
rides O-MISC B-DEVI-MISC
horses O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
does O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
jumping O-MISC B-DEVI-MISC
without O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
limitations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
physical O-MISC B-DEVI-MISC
activity O-MISC I-DEVI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
evidence O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
any O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
stress O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
status B-DISO-MISC B-CHED-MISC
migrainosus I-DISO-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Extensive O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
search O-MISC I-CHED-MISC
revealed O-MISC B-ACTI-MISC
multiple O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
vasospasm I-DISO-MISC B-ANAT-MISC
secondary O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
zolmitriptan B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
TS B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Depression B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
impulsiveness B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
sleep O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
past O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
polydrug O-MISC O-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
3 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
methylenedioxymethamphetamine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MDMA B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RATIONALE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Ecstasy B-CHED-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
3 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
methylenedioxymethamphetamine I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
MDMA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
worldwide O-MISC B-CHED-MISC
recreational O-MISC O-MISC
drug O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
abuse O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Unfortunately O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
human O-MISC B-CONC-MISC
research O-MISC I-CONC-MISC
investigating O-MISC B-CHED-MISC
its O-MISC B-ACTI-MISC
psychological O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
inconsistent O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
aimed O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
largest O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
date O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
sample O-MISC B-CHED-MISC
size O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
5HT O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
behaviors O-MISC B-DEVI-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
compare O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
past O-MISC B-CHED-MISC
users O-MISC I-ANAT-MISC
after O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
abstinence O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
include O-MISC B-ACTI-MISC
robust O-MISC B-CHED-MISC
controls O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
recreational O-MISC O-MISC
substances O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
sample O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
997 O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
recruited O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-UnknownType-MISC
drug O-MISC B-UnknownType-MISC
( O-MISC B-ACTI-MISC
ND O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
alcohol B-CHED-MISC B-PHEN-MISC
/ O-MISC B-ACTI-MISC
nicotine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
AN B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cannabis B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
alcohol B-CHED-MISC B-PHEN-MISC
/ O-MISC B-ACTI-MISC
nicotine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CAN B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC I-PHEN-MISC
ecstasy B-CHED-MISC I-PHEN-MISC
polydrug O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
PD O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
polydrug O-MISC B-ANAT-MISC
groups O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
present O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
MDMA B-CHED-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
past O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
EX O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
MDMA B-CHED-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Participants O-MISC I-ANAT-MISC
completed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
drug O-MISC B-CHED-MISC
history O-MISC I-CHED-MISC
questionnaire O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
Beck O-MISC B-CHED-MISC
Depression B-DISO-MISC I-CHED-MISC
Inventory O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
Barratt O-MISC B-CHED-MISC
Impulsiveness B-DISO-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
Pittsburgh O-MISC B-CHED-MISC
Sleep O-MISC I-CHED-MISC
Quality O-MISC I-CHED-MISC
Index O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Wechsler O-MISC B-CHED-MISC
Memory O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
Revised O-MISC I-CHED-MISC
which O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
provided O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
psychometric O-MISC B-CONC-MISC
measures O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
While O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CAN B-CHED-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
PD O-MISC I-ACTI-MISC
groups O-MISC B-PHEN-MISC
tended O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
record O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
deficits O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
drug O-MISC I-PHEN-MISC
controls O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MDMA B-CHED-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
EX O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
MDMA B-CHED-MISC B-ANAT-MISC
groups O-MISC B-PHEN-MISC
recorded O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
deficits O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
on O-MISC B-ACTI-MISC
ten O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
psychometric O-MISC B-CONC-MISC
measures O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Strikingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
despite O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
abstinence O-MISC B-DEVI-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
past O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
signs O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
recovery O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
past O-MISC B-CHED-MISC
users O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
ten O-MISC B-ACTI-MISC
measures O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
impairment O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
measures O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
just O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
measure O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Given O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
record O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
impaired B-DISO-MISC I-ACTI-MISC
memory I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
clinically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
impulsiveness B-DISO-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sleep B-DISO-MISC I-ACTI-MISC
disturbance I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prognosis O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
generation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
concern O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Association O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
genetic O-MISC B-LIVB-MISC
variants O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
HOMER1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
with O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Levodopa B-CHED-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
symptomatic O-MISC I-ACTI-MISC
therapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
use O-MISC B-CHED-MISC
could O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
adverse O-MISC B-ANAT-MISC
outcomes O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
motor O-MISC I-ACTI-MISC
fluctuations O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
hallucinations I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

HOMER1 O-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
protein O-MISC O-MISC
with O-MISC B-ACTI-MISC
pivotal O-MISC B-ACTI-MISC
function O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
glutamate B-CHED-MISC I-DISO-MISC
transmission O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
investigates O-MISC B-CHED-MISC
whether O-MISC B-ACTI-MISC
polymorphisms O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HOMER1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
promoter O-MISC O-MISC
region O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
complications O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
205 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
Parkinson I-DISO-MISC B-ANAT-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
genotyped O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
rs4704559 O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
rs10942891 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
rs4704560 O-MISC B-LIVB-MISC
by O-MISC B-ACTI-MISC
allelic O-MISC B-LIVB-MISC
discrimination O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
Taqman O-MISC B-CONC-MISC
assays O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
rs4704559 O-MISC B-LIVB-MISC
G O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dyskinesia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
PR O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
615 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
426 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
887 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
009 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
hallucinations I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
515 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
295 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
899 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
020 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
HOMER1 O-MISC B-LIVB-MISC
rs4704559 O-MISC I-PROC-MISC
G O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
protective O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Crocin B-CHED-MISC O-MISC
improves O-MISC I-ACTI-MISC
lipid O-MISC I-DISO-MISC
dysregulation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
subacute O-MISC B-CHED-MISC
diazinon B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
through O-MISC B-ACTI-MISC
ERK1 O-MISC I-DISO-MISC
/ O-MISC I-LIVB-MISC
2 O-MISC I-LIVB-MISC
pathway O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
liver O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

INTRODUCTION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Diazinon B-CHED-MISC O-MISC
Yis O-MISC B-DISO-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
broadly O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
organophosphorus B-CHED-MISC O-MISC
insecticides O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
agriculture O-MISC B-PROC-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
diazinon B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
interfere O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
lipid O-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypolipidemic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
crocin B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
established O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Earlier O-MISC B-CHED-MISC
studies O-MISC B-CONC-MISC
revealed O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Extracellular O-MISC I-DISO-MISC
signal O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
regulated O-MISC I-LIVB-MISC
kinase O-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
ERK O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
pathways O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
low O-MISC O-MISC
- O-MISC B-DISO-MISC
density O-MISC B-DISO-MISC
lipoprotein O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
LDLr O-MISC O-MISC
) O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
regulation O-MISC I-DISO-MISC
of O-MISC I-LIVB-MISC
lipid O-MISC I-LIVB-MISC
metabolism O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
ERK O-MISC O-MISC
and O-MISC B-ACTI-MISC
LDLr O-MISC O-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
subacute O-MISC B-CHED-MISC
diazinon B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
ameliorating O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
crocin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
disturbed O-MISC B-CHED-MISC
cholesterol B-CHED-MISC I-DISO-MISC
homeostasis O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
Rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
divided O-MISC B-CHED-MISC
into O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
Corn O-MISC O-MISC
oil O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
15mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
orally O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
crocin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
25mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
intraperitoneally O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cholesterol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
LDL O-MISC O-MISC
in O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
mRNA O-MISC O-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
LDLr O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
ERK1 O-MISC B-LIVB-MISC
/ O-MISC B-ACTI-MISC
2 O-MISC O-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
protein O-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
activated O-MISC B-DEVI-MISC
forms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ERK1 O-MISC B-LIVB-MISC
/ O-MISC B-ACTI-MISC
2 O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
liver O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
Western O-MISC B-CONC-MISC
blotting O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
quantitative O-MISC B-CONC-MISC
real O-MISC I-CONC-MISC
time O-MISC I-CONC-MISC
polymerase O-MISC I-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
subacute O-MISC B-CHED-MISC
exposure O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
concentrations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cholesterol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
triglyceride B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
LDL O-MISC O-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
decreased O-MISC B-CHED-MISC
ERK1 O-MISC O-MISC
/ O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
phosphorylation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
LDLr O-MISC O-MISC
transcript O-MISC O-MISC
. O-MISC B-ACTI-MISC

Crocin B-CHED-MISC O-MISC
reduced O-MISC B-CHED-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
ERK O-MISC O-MISC
activation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperlipemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
levels O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
LDLr O-MISC B-LIVB-MISC
transcript O-MISC O-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Crocin B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
protective O-MISC O-MISC
agent O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperlipemia B-DISO-MISC I-ACTI-MISC
through O-MISC B-ACTI-MISC
modulating O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ERK O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
LDLr O-MISC O-MISC
expression O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

GEM B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
P O-MISC I-CONC-MISC
chemotherapy O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
active O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
relapsed O-MISC B-CHED-MISC
Hodgkin B-DISO-MISC I-ACTI-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Hodgkin B-DISO-MISC I-ACTI-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HL B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
chemosensitive O-MISC I-ACTI-MISC
malignancy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
relapse O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
chemotherapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
autologous O-MISC B-CONC-MISC
stem O-MISC I-CONC-MISC
cell O-MISC I-CONC-MISC
transplant O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
choice O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
relies O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
adequate O-MISC B-ACTI-MISC
disease O-MISC B-CONC-MISC
control O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
salvage O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Regimens O-MISC B-CONC-MISC
commonly O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
require O-MISC B-ACTI-MISC
inpatient O-MISC I-ANAT-MISC
administration O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
difficult O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
deliver O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
toxicity B-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Gemcitabine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
activity O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
HL B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
overlapping O-MISC B-ACTI-MISC
toxicity B-DISO-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
first O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
line O-MISC I-CONC-MISC
chemotherapeutics O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
delivered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
outpatient O-MISC I-ANAT-MISC
setting O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
retrospective O-MISC B-CHED-MISC
single O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
centre O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
relapsed O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
refractory O-MISC B-CHED-MISC
HL B-DISO-MISC I-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
gemcitabine B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
D O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
D8 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
D15 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
methylprednisolone B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
D1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
D15 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
GEM B-CHED-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Demographic O-MISC B-PROC-MISC
, O-MISC B-ACTI-MISC
survival O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
response O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
data O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Forty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
eligible O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
27 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
hundred O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
cycles O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
GEM B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
P O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
cycles O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
GEM B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
P O-MISC I-CONC-MISC
as O-MISC B-ACTI-MISC
second O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
line O-MISC I-CONC-MISC
treatment O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
third O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
line O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Overall O-MISC B-CHED-MISC
response O-MISC I-CHED-MISC
rate O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
ORR O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
GEM B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
P O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
entire O-MISC B-ACTI-MISC
cohort O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
complete O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CR O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
response O-MISC B-ANAT-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
CR O-MISC B-CONC-MISC
confirmed O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
CR O-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
PET O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
ORR O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
second O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
line O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
grade O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
toxicities B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
haematological O-MISC B-PROC-MISC
: O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
54 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
51 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Median O-MISC B-CONC-MISC
follow O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
start O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
GEM B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
P O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Following O-MISC B-ACTI-MISC
GEM B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
P O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
progression O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
free O-MISC I-CHED-MISC
survival O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
survival O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
74 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Fourteen O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
proceeded O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
autologous O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

GEM B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
P O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
salvage O-MISC B-CONC-MISC
chemotherapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
response O-MISC B-OCCU-MISC
rates O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
successful O-MISC B-ACTI-MISC
transplantation O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
appropriate O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
relapsed O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
refractory O-MISC B-CHED-MISC
HL B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Basal O-MISC B-CHED-MISC
functioning O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothalamic O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
pituitary O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
adrenal O-MISC B-GEOG-MISC
( O-MISC B-GEOG-MISC
HPA O-MISC B-GEOG-MISC
) O-MISC B-GEOG-MISC
axis O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
psychological O-MISC I-ACTI-MISC
distress O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
recreational O-MISC B-DEVI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
polydrug O-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

RATIONALE O-MISC O-MISC
: O-MISC B-ACTI-MISC
Ecstasy B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
MDMA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
psychostimulant O-MISC O-MISC
drug O-MISC B-DISO-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
increasingly O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
psychobiological B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

While O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
neuroendocrine O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
HPA O-MISC O-MISC
functionality O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
recreational O-MISC B-DEVI-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
explore O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
polydrug O-MISC I-ACTI-MISC
use O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
psychological O-MISC I-ACTI-MISC
distress O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
basal O-MISC B-CHED-MISC
functioning O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HPA O-MISC O-MISC
axis O-MISC B-GEOG-MISC
through O-MISC B-ACTI-MISC
assessing O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
secretion O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
cortisol B-CHED-MISC O-MISC
across O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diurnal O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHOD O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Seventy O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
nonusers O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
light O-MISC I-ACTI-MISC
ecstasy B-CHED-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
polydrug O-MISC O-MISC
users O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
heavy O-MISC I-ACTI-MISC
ecstasy B-CHED-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
polydrug O-MISC I-ACTI-MISC
users O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
completed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
substance O-MISC B-DEVI-MISC
use O-MISC I-CHED-MISC
inventory O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
measures O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
psychological O-MISC I-ACTI-MISC
distress O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cortisol B-CHED-MISC O-MISC
sampling O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
awakening O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
post O-MISC B-ACTI-MISC
awakening O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
1400 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1600 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
bedtime O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
also O-MISC B-ACTI-MISC
attended O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
laboratory O-MISC B-GENE-MISC
to O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
multitasking O-MISC B-CHED-MISC
stressor O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Both O-MISC B-ACTI-MISC
user O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
exhibited O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
levels O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
nonusers O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
participants O-MISC I-ANAT-MISC
exhibited O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
cortisol B-CHED-MISC O-MISC
profile O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
though O-MISC B-ACTI-MISC
light O-MISC B-OCCU-MISC
users O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
bed O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
heavy O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
demonstrated O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
upon O-MISC B-ACTI-MISC
awakening O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
polydrug O-MISC O-MISC
users O-MISC I-ANAT-MISC
demonstrated O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
bed O-MISC I-OCCU-MISC
levels O-MISC B-CHED-MISC
compared O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
users O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Significant O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
group O-MISC B-PHEN-MISC
differences O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
afternoon O-MISC B-CHED-MISC
cortisol B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
cortisol B-CHED-MISC O-MISC
secretion O-MISC B-OCCU-MISC
across O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
line O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
recreational O-MISC B-DEVI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
polydrug O-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Dysregulated O-MISC B-CHED-MISC
diurnal O-MISC O-MISC
cortisol B-CHED-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
indicative O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
inappropriate O-MISC B-CHED-MISC
anticipation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
forthcoming O-MISC B-ACTI-MISC
demands O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
hypersecretion O-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
psychological O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
physical O-MISC I-ACTI-MISC
morbidity O-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
heavy O-MISC B-ACTI-MISC
recreational O-MISC B-DEVI-MISC
use O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Ifosfamide B-CHED-MISC O-MISC
related O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
timely O-MISC B-CHED-MISC
EEG O-MISC B-CONC-MISC
evaluation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Ifosfamide B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alkylating O-MISC O-MISC
agent O-MISC B-DISO-MISC
useful O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
wide O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cancers B-DISO-MISC I-ACTI-MISC
including O-MISC B-ACTI-MISC
sarcomas B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
gynecologic B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
testicular I-DISO-MISC I-ACTI-MISC
cancers I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Encephalopathy B-DISO-MISC I-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-CHED-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
IV O-MISC B-DISO-MISC
ifosfamide B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
highlight O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
electroencephalogram O-MISC B-OCCU-MISC
( O-MISC B-ACTI-MISC
EEG O-MISC B-OCCU-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-CONC-MISC
detection O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ifosfamide B-CHED-MISC O-MISC
related O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Retrospective O-MISC B-CONC-MISC
chart O-MISC I-CONC-MISC
review O-MISC I-CONC-MISC
including O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
data O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
recordings O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
done O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
MD O-MISC B-PHYS-MISC
Anderson O-MISC I-PHYS-MISC
Cancer B-DISO-MISC I-PHYS-MISC
Center O-MISC I-PHYS-MISC
between O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
2009 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2012 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
ifosfamide B-CHED-MISC O-MISC
related O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
encephalopathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
All O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
experienced O-MISC I-DISO-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
soon O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
receiving O-MISC B-CHED-MISC
ifosfamide B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
convulsions B-DISO-MISC B-ANAT-MISC
while O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
continuous O-MISC I-ACTI-MISC
non B-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
convulsive I-DISO-MISC B-ANAT-MISC
status I-DISO-MISC B-ANAT-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
NCSE B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
ICU O-MISC B-CONC-MISC
admission O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
intubation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Initial O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
epileptiform O-MISC I-ACTI-MISC
discharges O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
run O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
triphasic O-MISC I-ACTI-MISC
waves O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
degree O-MISC B-ACTI-MISC
diffuse O-MISC I-ACTI-MISC
generalized O-MISC I-ACTI-MISC
slowing O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Mixed O-MISC B-CHED-MISC
pattern O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
sharps O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
triphasic O-MISC I-ACTI-MISC
waves O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Repeat O-MISC B-ACTI-MISC
EEGs O-MISC B-CONC-MISC
within O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
_ O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
symptom O-MISC B-CHED-MISC
onset O-MISC I-CHED-MISC
showed O-MISC B-ACTI-MISC
marked O-MISC B-CHED-MISC
improvement O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
improvement O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ifosfamide B-CHED-MISC O-MISC
related O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
correlates O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
changes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
timely O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
evaluation O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
ifosfamide B-CHED-MISC O-MISC
who O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
features O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Incidence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
contrast B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
hospitalised O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
with O-MISC I-PHEN-MISC
cancer B-DISO-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
contrast B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CIN O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hospitalised O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Ninety O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
excluded O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Blood O-MISC I-GENE-MISC
samples O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
contrast B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
enhanced O-MISC I-CONC-MISC
computed O-MISC I-CONC-MISC
tomography O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
serially O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
thereafter O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CIN O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
Cr B-CHED-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
elevation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Cr B-CHED-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Relationships O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
CIN O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
CIN O-MISC O-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CIN O-MISC I-ACTI-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CIN O-MISC I-ACTI-MISC
more O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
undergone O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
within O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
independent O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
017 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CIN O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
more O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
bevacizumab B-CHED-MISC O-MISC
/ O-MISC B-DISO-MISC
irinotecan B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
021 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
044 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CIN O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
hospitalised O-MISC I-ANAT-MISC
oncological O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CIN O-MISC I-ACTI-MISC
developed O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
frequently O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC I-PHEN-MISC
cancer B-DISO-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
undergone O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Hypertension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bevacizumab B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
irinotecan B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
CIN O-MISC I-ACTI-MISC
development O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

KEY O-MISC B-ACTI-MISC
POINTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Contrast B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CIN O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
concern O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
oncological O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

. O-MISC B-ACTI-MISC
CIN O-MISC B-CONC-MISC
occurs O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

. O-MISC B-ACTI-MISC
Hypertension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
bevacizumab B-CHED-MISC O-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
additional O-MISC B-CHED-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Syndrome B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
inappropriate I-DISO-MISC B-ACTI-MISC
antidiuretic I-DISO-MISC O-MISC
hormone I-DISO-MISC B-DISO-MISC
secretion O-MISC B-OCCU-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
desvenlafaxine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
syndrome B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
inappropriate I-DISO-MISC B-ACTI-MISC
anti I-DISO-MISC O-MISC
- I-DISO-MISC B-DISO-MISC
diuretic I-DISO-MISC B-DISO-MISC
hormone I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
SIADH B-DISO-MISC O-MISC
) O-MISC B-ACTI-MISC
secretion O-MISC I-DISO-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
desvenlafaxine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

CASE O-MISC B-CHED-MISC
SUMMARY O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
hyponatraemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Her O-MISC B-ACTI-MISC
medications O-MISC B-CONC-MISC
included O-MISC B-ACTI-MISC
desvenlafaxine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
included O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
confusion B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
sodium B-CHED-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
120 O-MISC B-ACTI-MISC
mmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
serum O-MISC I-DISO-MISC
osmolality O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
263 O-MISC B-ACTI-MISC
mosmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
urine O-MISC I-DISO-MISC
osmolality O-MISC I-LIVB-MISC
410 O-MISC B-ACTI-MISC
mosmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
urine O-MISC B-CONC-MISC
sodium B-CHED-MISC I-CONC-MISC
63 O-MISC B-ACTI-MISC
mmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
SIADH B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Desvenlafaxine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
ceased O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
fluid O-MISC B-CONC-MISC
restriction O-MISC I-CONC-MISC
implemented O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
increased O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
128 O-MISC B-ACTI-MISC
mmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
fluid O-MISC B-CONC-MISC
restriction O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
relaxed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
inpatient O-MISC I-ANAT-MISC
admission O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
serum O-MISC B-OCCU-MISC
sodium B-CHED-MISC I-OCCU-MISC
ranged O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
134 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
137 O-MISC B-ACTI-MISC
mmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
mirtazapine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

DISCUSSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
SIADH B-DISO-MISC I-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
reported O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
antidepressants O-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
desvenlafaxine B-CHED-MISC O-MISC
might O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
clinically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
hyponatremia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Clinicians O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
antidepressants O-MISC O-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
hyponatremia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
take O-MISC B-ACTI-MISC
appropriate O-MISC B-ACTI-MISC
corrective O-MISC B-CHED-MISC
action O-MISC B-CHED-MISC
where O-MISC B-ACTI-MISC
necessary O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
remains O-MISC B-ACTI-MISC
controversial O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
66 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
injections O-MISC B-CONC-MISC
intraperitoneally O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
assigned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
protocols O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
killed O-MISC B-DEVI-MISC
before O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
acute O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
injections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
/ O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
killed O-MISC B-DEVI-MISC
before O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
M0 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
M1 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
M2 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
M3 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
M4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
chronological O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
used O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
M0 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
moment O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Cardiac O-MISC I-GENE-MISC
total O-MISC B-CONC-MISC
antioxidant O-MISC I-CONC-MISC
performance O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
TAP O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
DNA O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
morphology O-MISC B-CHED-MISC
analyses O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
point O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Single O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
increased O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
disarrangement I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
DNA O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
strand O-MISC I-ACTI-MISC
breaks O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SBs O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
oxidized O-MISC O-MISC
pyrimidines O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
TAP O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
chronological O-MISC B-CONC-MISC
study O-MISC I-CHED-MISC
showed O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effect O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
R O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
99 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
011 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
R O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
00 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
004 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
TAP O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
R O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
049 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
SBs O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
R O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
049 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

DNA O-MISC I-GENE-MISC
SBs O-MISC B-GEOG-MISC
damage O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
negatively O-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
TAP O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
R O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
018 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
R O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
97 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
027 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
oxidative O-MISC B-CHED-MISC
damage O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
acute O-MISC I-ACTI-MISC
cardiotoxicity B-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
only O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-CHED-MISC
resistance O-MISC B-OCCU-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
plausible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
toxicity B-DISO-MISC I-ACTI-MISC
versus O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
toxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Tacrolimus B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
pediatric O-MISC B-CHED-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
center O-MISC B-ACTI-MISC
experience O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
new O-MISC B-PHEN-MISC
- O-MISC B-UnknownType-MISC
onset O-MISC B-UnknownType-MISC
seizures B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
pediatric O-MISC B-CHED-MISC
LT O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
clinical O-MISC I-DISO-MISC
implications O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
prognosis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
laboratory O-MISC B-CHED-MISC
data O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
children O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
January O-MISC B-CHED-MISC
2007 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
December O-MISC B-CHED-MISC
2010 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
center O-MISC B-GENE-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
retrospectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
group O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
seizures B-DISO-MISC I-PHEN-MISC
group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
operative O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
intra O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
operative O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
post O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
operative O-MISC B-ANAT-MISC
data O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
collected O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Seizures B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
exhibited O-MISC B-ACTI-MISC
generalized O-MISC B-CHED-MISC
tonic B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
clonic I-DISO-MISC B-ANAT-MISC
seizures I-DISO-MISC B-ANAT-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
wk O-MISC I-GENE-MISC
after O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Univariate O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
pediatric O-MISC B-CHED-MISC
LT O-MISC B-CONC-MISC
included O-MISC B-ACTI-MISC
gender O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
pediatric O-MISC B-CHED-MISC
end B-DISO-MISC I-CHED-MISC
- I-DISO-MISC I-CHED-MISC
stage I-DISO-MISC I-CHED-MISC
liver I-DISO-MISC I-CHED-MISC
disease I-DISO-MISC I-CHED-MISC
score O-MISC I-CHED-MISC
before O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
Child O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
Pugh O-MISC I-CHED-MISC
score O-MISC I-CHED-MISC
before O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
total O-MISC I-CONC-MISC
bilirubin B-CHED-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
trough O-MISC B-ACTI-MISC
TAC B-CHED-MISC I-GENE-MISC
level O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Multivariate O-MISC B-CHED-MISC
analysis O-MISC I-CHED-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
trough O-MISC B-ACTI-MISC
TAC B-CHED-MISC I-GENE-MISC
level O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
independent O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
experienced O-MISC I-DISO-MISC
seizures B-DISO-MISC I-ACTI-MISC
survived O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
good O-MISC B-ACTI-MISC
graft O-MISC I-DISO-MISC
function O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
remained O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
free O-MISC B-ANAT-MISC
without O-MISC B-CHED-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
epileptic B-DISO-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
over O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
period O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

High O-MISC B-ACTI-MISC
trough O-MISC B-ACTI-MISC
TAC B-CHED-MISC I-GENE-MISC
level O-MISC I-OCCU-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
predominant O-MISC B-ACTI-MISC
factor O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
contributed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
post O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
operative O-MISC B-ANAT-MISC
period O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
pediatric O-MISC B-CHED-MISC
LT O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

High O-MISC B-CHED-MISC
PELD O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
Child O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
Pugh O-MISC I-CHED-MISC
scores O-MISC I-CHED-MISC
before O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
operative O-MISC I-CHED-MISC
serum O-MISC I-GENE-MISC
Tbil O-MISC B-CONC-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
contributory O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
TAC B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
flavonoid B-CHED-MISC O-MISC
apigenin B-CHED-MISC O-MISC
delays O-MISC B-ACTI-MISC
forgetting O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-DISO-MISC
conditioning O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
experiments O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
flavonoid B-CHED-MISC O-MISC
apigenin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
intraperitoneally O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
acquisition O-MISC B-DEVI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
retention O-MISC I-DISO-MISC
performance O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
forgetting O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
step O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
task O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
young O-MISC B-CHED-MISC
male O-MISC I-DISO-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
apigenin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
retention O-MISC B-CONC-MISC
trial O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
apigenin B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
amnesia B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acquisition O-MISC B-DEVI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
apigenin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
step O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dark O-MISC B-CHED-MISC
compartment O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cut O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
off O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
540 O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
retested O-MISC B-CHED-MISC
weekly O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
treated O-MISC B-CHED-MISC
group O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
decline O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
response O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
complete O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acquisition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-DISO-MISC
task O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
end O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
experimental O-MISC B-CONC-MISC
period O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
apigenin B-CHED-MISC O-MISC
still O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
step O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
apigenin B-CHED-MISC O-MISC
delays O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
forgetting O-MISC I-ACTI-MISC
but O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
modulate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
retention O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
fear O-MISC I-DISO-MISC
memory O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
beneficial O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
apigenin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
conditioning O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
do O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
implicate O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
action O-MISC B-DEVI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
muscarinic O-MISC I-GENE-MISC
cholinergic O-MISC I-CHED-MISC
system O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Histamine B-CHED-MISC O-MISC
antagonists O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
tubocurarine I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
surgical O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Hemodynamic O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
histamine B-CHED-MISC O-MISC
release O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
bolus O-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
tubocurarine I-CHED-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

H1 O-MISC O-MISC
- O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
H2 O-MISC O-MISC
- O-MISC B-DISO-MISC
histamine B-CHED-MISC B-DISO-MISC
antagonists O-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
tubocurarine I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
double O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
fashion O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
1 O-MISC I-CHED-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
; O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
2 O-MISC I-CHED-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-DISO-MISC
cimetidine B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
plus O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
; O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
3 O-MISC I-CHED-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
chlorpheniramine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
plus O-MISC B-CHED-MISC
placebo O-MISC O-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
4 O-MISC I-CHED-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-DISO-MISC
cimetidine B-CHED-MISC B-DISO-MISC
plus O-MISC B-ACTI-MISC
chlorpheniramine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Histamine B-CHED-MISC O-MISC
release O-MISC B-CHED-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
highest O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
tubocurarine I-CHED-MISC B-DISO-MISC
dosing O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Group O-MISC B-CHED-MISC
1 O-MISC I-CHED-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
moderate O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
correlation O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
plasma O-MISC B-CONC-MISC
histamine B-CHED-MISC B-DISO-MISC
change O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
systemic O-MISC I-ACTI-MISC
vascular O-MISC B-ANAT-MISC
resistance O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
r O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
present O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
4 O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Prior O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
antagonists O-MISC O-MISC
partially O-MISC B-ACTI-MISC
prevented O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
fall O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
vascular O-MISC I-ACTI-MISC
resistance O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hemodynamic O-MISC I-DISO-MISC
changes O-MISC B-CHED-MISC
associated O-MISC B-ACTI-MISC
with O-MISC I-CHED-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
tubocurarine I-CHED-MISC B-DISO-MISC
dosing O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
partially O-MISC B-ACTI-MISC
explained O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
histamine B-CHED-MISC O-MISC
release O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
H1 O-MISC O-MISC
- O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
H2 O-MISC O-MISC
- O-MISC B-DISO-MISC
antagonists O-MISC O-MISC
provides O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
protection O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Cholecystokinin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
octapeptide I-CHED-MISC B-DISO-MISC
restored O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hippocampal O-MISC I-GENE-MISC
long O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
term O-MISC I-LIVB-MISC
potentiation O-MISC I-LIVB-MISC
impairment O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Cholecystokinin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
octapeptide I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
brain O-MISC O-MISC
- O-MISC B-DISO-MISC
gut O-MISC B-DISO-MISC
peptide O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
exerts O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
wide O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
biological O-MISC I-DISO-MISC
activities O-MISC I-OCCU-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
significantly O-MISC B-ACTI-MISC
alleviated O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
amnesia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
reversed O-MISC B-CHED-MISC
spine O-MISC I-ACTI-MISC
density O-MISC B-ANAT-MISC
decreases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CA1 O-MISC I-GENE-MISC
region O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
long O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
term O-MISC I-LIVB-MISC
potentiation O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
LTP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lateral O-MISC I-GENE-MISC
perforant O-MISC B-GEOG-MISC
path O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
LPP O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
granule O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
synapse O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
dentate O-MISC I-GENE-MISC
gyrus O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
DG O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
saline O-MISC B-GENE-MISC
or O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Population O-MISC I-DISO-MISC
spikes O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
PS O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
evoked O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
stimulation O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LPP O-MISC O-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DG O-MISC I-GENE-MISC
region O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC B-CHED-MISC
morphine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
30mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
significantly O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
hippocampal O-MISC I-GENE-MISC
LTP O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
1ug O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
restored O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
amplitude O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PS O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
microinjection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1ug O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
augmented O-MISC B-CHED-MISC
hippocampal O-MISC I-GENE-MISC
LTP O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
1ml O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CCK2 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC O-MISC
L O-MISC O-MISC
- O-MISC B-DISO-MISC
365 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
260 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10ug O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
reversed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CCK1 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC O-MISC
L O-MISC O-MISC
- O-MISC B-DISO-MISC
364 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
718 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10ug O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
attenuates O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
LTP O-MISC I-DISO-MISC
through O-MISC B-ACTI-MISC
CCK2 O-MISC O-MISC
receptors O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
ameliorative O-MISC B-CHED-MISC
function O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Glial O-MISC I-GENE-MISC
activation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
post O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
synaptic O-MISC I-LIVB-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
key O-MISC B-ACTI-MISC
events O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
Streptozotocin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
ICV O-MISC O-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
glial O-MISC I-GENE-MISC
activation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
post O-MISC I-DISO-MISC
synaptic O-MISC I-LIVB-MISC
toxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
ICV O-MISC I-ANAT-MISC
Streptozotocin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
impaired I-DISO-MISC B-ANAT-MISC
rats O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
explored O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
experiment O-MISC B-CONC-MISC
set O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Memory B-DISO-MISC I-ACTI-MISC
deficit I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Morris O-MISC B-CONC-MISC
water O-MISC I-CONC-MISC
maze O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
ICV O-MISC O-MISC
; O-MISC B-ACTI-MISC
3mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
Kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

STZ B-CHED-MISC I-GENE-MISC
causes O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
GFAP O-MISC O-MISC
, O-MISC B-ACTI-MISC
CD11b O-MISC O-MISC
and O-MISC B-ACTI-MISC
TNF O-MISC O-MISC
- O-MISC B-DISO-MISC
a O-MISC B-DISO-MISC
indicating O-MISC B-ACTI-MISC
glial O-MISC I-ACTI-MISC
activation O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
neuroinflammation B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

STZ B-CHED-MISC O-MISC
also O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ROS O-MISC O-MISC
, O-MISC B-ACTI-MISC
nitrite B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
mitochondrial O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
synaptosomal O-MISC I-GENE-MISC
preparation O-MISC B-DEVI-MISC
illustrating O-MISC B-ACTI-MISC
free O-MISC O-MISC
radical O-MISC B-DISO-MISC
generation O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
excitotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
Caspase O-MISC O-MISC
- O-MISC B-DISO-MISC
3 O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
treated O-MISC B-CHED-MISC
rat O-MISC I-ANAT-MISC
which O-MISC B-ACTI-MISC
specify O-MISC B-ACTI-MISC
apoptotic O-MISC I-DISO-MISC
cell O-MISC I-LIVB-MISC
death O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
cortex O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

STZ B-CHED-MISC I-GENE-MISC
treatment O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
post O-MISC B-ACTI-MISC
synaptic O-MISC I-LIVB-MISC
markers O-MISC I-DISO-MISC
CaMKIIa O-MISC O-MISC
and O-MISC B-ACTI-MISC
PSD O-MISC O-MISC
- O-MISC B-DISO-MISC
95 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
pre O-MISC O-MISC
synaptic O-MISC B-GEOG-MISC
markers O-MISC O-MISC
( O-MISC B-ACTI-MISC
synaptophysin O-MISC O-MISC
and O-MISC B-ACTI-MISC
SNAP O-MISC O-MISC
- O-MISC B-DISO-MISC
25 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
remains O-MISC B-ACTI-MISC
unaltered O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
post O-MISC I-DISO-MISC
synaptic O-MISC I-LIVB-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC I-GENE-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
Memantine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Ibuprofen B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
attenuated O-MISC B-DEVI-MISC
STZ B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
glial O-MISC I-ACTI-MISC
activation O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
apoptotic O-MISC I-DISO-MISC
cell O-MISC I-DISO-MISC
death O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
post O-MISC I-DISO-MISC
synaptic O-MISC I-LIVB-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rat O-MISC I-GENE-MISC
brain O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
experiment O-MISC B-CONC-MISC
set O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
where O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
GFAP O-MISC O-MISC
, O-MISC B-ACTI-MISC
CD11b O-MISC O-MISC
, O-MISC B-ACTI-MISC
TNF O-MISC O-MISC
- O-MISC B-DISO-MISC
a O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
ROS O-MISC O-MISC
and O-MISC B-ACTI-MISC
nitrite B-CHED-MISC B-OCCU-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
hand O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
apoptotic O-MISC I-DISO-MISC
marker O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
synaptic O-MISC B-ACTI-MISC
markers O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
mitochondrial O-MISC I-GENE-MISC
activity O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
levels O-MISC B-CHED-MISC
remained O-MISC B-ACTI-MISC
unaffected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Collective O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
indicates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
neuroinflammatory B-DISO-MISC I-ACTI-MISC
process O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
occurs O-MISC B-DEVI-MISC
earlier O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Present O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
clearly O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
glial O-MISC I-GENE-MISC
activation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
post O-MISC I-DISO-MISC
synaptic O-MISC I-LIVB-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
key O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
STZ B-CHED-MISC I-GENE-MISC
induced O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
neuronal O-MISC I-DISO-MISC
cell O-MISC I-LIVB-MISC
death O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Comparison O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
isotonic O-MISC O-MISC
sodium B-CHED-MISC B-DISO-MISC
chloride I-CHED-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
diltiazem B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
prevention O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
contrast B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

INTRODUCTION O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Contrast B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CIN O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
morbidity O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
compare O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
protective O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
isotonic O-MISC O-MISC
sodium B-CHED-MISC B-DISO-MISC
chloride I-CHED-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
bicarbonate I-CHED-MISC B-DISO-MISC
infusion O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
isotonic O-MISC O-MISC
sodium B-CHED-MISC B-DISO-MISC
chloride I-CHED-MISC B-DISO-MISC
infusion O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
diltiazem B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
channel O-MISC B-DISO-MISC
blocker O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
preventing O-MISC B-ACTI-MISC
CIN O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

MATERIALS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
included O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
30 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
iodinated O-MISC O-MISC
contrast B-CHED-MISC B-DISO-MISC
agent O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
percutaneous O-MISC B-CONC-MISC
coronary O-MISC I-CONC-MISC
angiography O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PCAG O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
creatinine B-CHED-MISC O-MISC
values O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
had O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
isotonic O-MISC O-MISC
sodium B-CHED-MISC B-DISO-MISC
chloride I-CHED-MISC B-DISO-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
solution O-MISC B-GENE-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
dextrose B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
bicarbonate I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
isotonic O-MISC O-MISC
sodium B-CHED-MISC B-DISO-MISC
chloride I-CHED-MISC B-DISO-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
contrast B-CHED-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
received O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
injection O-MISC O-MISC
of O-MISC B-ACTI-MISC
diltiazem B-CHED-MISC O-MISC
the O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
contrast B-CHED-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
' O-MISC B-ACTI-MISC
plasma O-MISC B-CONC-MISC
blood B-CHED-MISC I-CONC-MISC
urea I-CHED-MISC I-CONC-MISC
nitrogen I-CHED-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
BUN B-CHED-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
creatinine B-CHED-MISC B-CONC-MISC
levels O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
seventh O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
intravenous O-MISC O-MISC
contrast B-CHED-MISC B-DISO-MISC
material O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
basal O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
levels O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ARF B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
contrast B-CHED-MISC O-MISC
material O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-CHED-MISC
ARF B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
group O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
group O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
third O-MISC B-CHED-MISC
group O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
difference O-MISC I-CHED-MISC
between O-MISC B-ACTI-MISC
isotonic O-MISC O-MISC
sodium B-CHED-MISC B-DISO-MISC
chloride I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
bicarbonate I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
isotonic O-MISC O-MISC
sodium B-CHED-MISC B-DISO-MISC
chloride I-CHED-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
diltiazem B-CHED-MISC O-MISC
application O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
prevention O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
CIN O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Neurocognitive O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
neuroradiologic O-MISC B-CHED-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
late O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
Pediatric O-MISC B-CHED-MISC
Oncology O-MISC I-CHED-MISC
Group O-MISC I-CHED-MISC
( O-MISC I-CHED-MISC
POG O-MISC I-CHED-MISC
) O-MISC I-CHED-MISC
P9605 O-MISC O-MISC
( O-MISC B-ACTI-MISC
standard O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
P9201 O-MISC O-MISC
( O-MISC B-ACTI-MISC
lesser O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
lymphoblastic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
protocols O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
ACCL0131 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
methotrexate B-CHED-MISC O-MISC
consequence O-MISC B-CHED-MISC
? O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Children O-MISC B-PHYS-MISC
' O-MISC I-PHYS-MISC
s O-MISC I-PHYS-MISC
Oncology O-MISC I-PHYS-MISC
Group O-MISC I-PHYS-MISC
. O-MISC B-ACTI-MISC

Concerns O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
methotrexate B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
MTX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
1990s O-MISC B-ACTI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
modifications O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
intrathecal O-MISC B-CONC-MISC
( O-MISC I-CONC-MISC
IT O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
leucovorin O-MISC O-MISC
rescue O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
MTX B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
lymphoblastic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
neurocognitive O-MISC B-CHED-MISC
outcomes O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
neuroradiologic O-MISC B-CHED-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
leukoencephalopathy B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
intense O-MISC B-CHED-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
CNS O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
directed O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
P9605 O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
CNS O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
directed O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
days O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
intensive O-MISC B-CONC-MISC
consolidation O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
P9201 O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
66 O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
Pediatric O-MISC B-PHYS-MISC
Oncology O-MISC I-PHYS-MISC
Group O-MISC I-PHYS-MISC
institutions O-MISC I-PHYS-MISC
with O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
standard O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
risk O-MISC I-CHED-MISC
" O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
lymphoblastic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
00 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
99 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CNS O-MISC I-ACTI-MISC
leukemia B-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
ACCL0131 O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
P9201 O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
P9605 O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
scans O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
standard O-MISC B-ACTI-MISC
neuropsychological O-MISC B-CONC-MISC
tests O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
end O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Significantly O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
P9605 O-MISC B-LIVB-MISC
patients O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
leukoencephalopathy B-DISO-MISC I-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
P9201 O-MISC B-LIVB-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
49 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
83 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
late O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
end O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Overall O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
scored O-MISC B-CHED-MISC
< O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
Verbal O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
Performance O-MISC B-DEVI-MISC
IQ O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Children O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
had O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
attention B-DISO-MISC I-ACTI-MISC
problems I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
P9605 O-MISC O-MISC
children O-MISC I-ANAT-MISC
scored O-MISC B-CHED-MISC
below O-MISC B-ACTI-MISC
average O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
neurocognitive O-MISC B-CHED-MISC
measures O-MISC I-CONC-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
P9201 O-MISC O-MISC
( O-MISC B-ACTI-MISC
82 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
measures O-MISC B-CHED-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
measures O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
supports O-MISC B-ACTI-MISC
ongoing O-MISC B-ACTI-MISC
concerns O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
intensive O-MISC B-ACTI-MISC
MTX B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
contributor O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
CNS O-MISC I-GENE-MISC
late O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
overdosage O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC I-ANAT-MISC
lady O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
kidney I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
stage O-MISC I-ACTI-MISC
4 O-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
tubulointerstial B-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
center O-MISC B-GENE-MISC
for O-MISC B-ACTI-MISC
severe O-MISC I-ACTI-MISC
anemia B-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
menorrhagia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
deterioration B-DISO-MISC B-OCCU-MISC
of I-DISO-MISC B-ACTI-MISC
renal I-DISO-MISC I-DISO-MISC
function I-DISO-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
infused O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
units O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
packed O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
during O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
session O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
hemodialysis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC O-MISC
TNA B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
g O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
hourly O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
bleeding B-DISO-MISC I-ACTI-MISC
per O-MISC B-ACTI-MISC
vaginum O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sixth O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
TNA B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
episode O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
generalized O-MISC B-CHED-MISC
tonic B-DISO-MISC I-GENE-MISC
clonic I-DISO-MISC I-ACTI-MISC
convulsions I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

TNA B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Investigations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
revealed O-MISC B-CHED-MISC
no O-MISC I-ACTI-MISC
biochemical O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
structural O-MISC B-CHED-MISC
central O-MISC I-ACTI-MISC
nervous B-DISO-MISC B-ANAT-MISC
system I-DISO-MISC B-ANAT-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
provoked O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
require O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
dialytic O-MISC B-CONC-MISC
support O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
episodes O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
convulsion B-DISO-MISC I-ACTI-MISC
till O-MISC B-ACTI-MISC
dis O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
charge O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
precipitating O-MISC B-OCCU-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
believed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
overdose B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
TNA B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
depression I-DISO-MISC B-ANAT-MISC
using O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
formulations O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
emulsions O-MISC B-DISO-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
lethal O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lipid O-MISC O-MISC
content O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
alleviate O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
intralipid O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
medialipid O-MISC O-MISC
emulsions O-MISC O-MISC
on O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
anaesthetised O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
ketamine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
intralipid O-MISC O-MISC
( O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
P O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
medialipid O-MISC O-MISC
( O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
L O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
( O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
C O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Thereafter O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
infused O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
dysrhythmia B-DISO-MISC I-ACTI-MISC
occurrence O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respective O-MISC B-ACTI-MISC
times O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
HR O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
asystole B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
amount O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
consumption O-MISC B-PHEN-MISC
. O-MISC B-ACTI-MISC

Blood O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
tissue O-MISC I-GENE-MISC
samples O-MISC B-GENE-MISC
were O-MISC B-ACTI-MISC
collected O-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
asystole B-DISO-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
dysrhythmia B-DISO-MISC I-ACTI-MISC
occurrence O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
reductions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
HR O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
asystole B-DISO-MISC O-MISC
were O-MISC B-ACTI-MISC
longer O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
P O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
groups O-MISC B-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
bupivacaine B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
given O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
points O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
P O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
Plasma O-MISC I-GENE-MISC
bupivacaine B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
P O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
C O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
Bupivacaine B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
P O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
L O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
C O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
intralipid O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
medialipid O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
delayed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxic B-DISO-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
plasma O-MISC I-GENE-MISC
bupivacaine B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
explore O-MISC B-ACTI-MISC
tissue O-MISC I-GENE-MISC
bupivacaine B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
medialipid O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
adapt O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
results O-MISC B-OCCU-MISC
to O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
practice O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Drug B-DISO-MISC O-MISC
- I-DISO-MISC B-ACTI-MISC
Induced I-DISO-MISC B-CHED-MISC
Acute I-DISO-MISC I-ACTI-MISC
Liver I-DISO-MISC B-ANAT-MISC
Injury I-DISO-MISC B-ANAT-MISC
Within O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
Hours O-MISC B-ACTI-MISC
After O-MISC B-ACTI-MISC
Fluvastatin B-CHED-MISC O-MISC
Therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
statins B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
, O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
drug B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
induced I-DISO-MISC B-ANAT-MISC
liver I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
their O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
man O-MISC I-DISO-MISC
reported O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
liver B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
appeared O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
beginning O-MISC B-CHED-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
fluvastatin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Patient O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
complaints O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
nausea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
anorexia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
upper O-MISC I-ACTI-MISC
abdominal B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

His O-MISC B-ACTI-MISC
laboratory O-MISC B-CHED-MISC
values O-MISC I-CHED-MISC
showed O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
creatine B-CHED-MISC O-MISC
kinase O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
transaminases O-MISC O-MISC
. O-MISC B-ACTI-MISC

Testing O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
autoantibodies O-MISC O-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
biochemistries O-MISC B-PROC-MISC
eventually O-MISC B-ACTI-MISC
normalized O-MISC B-CONC-MISC
within O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
stopping O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fluvastatin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
prescribing O-MISC B-CONC-MISC
statins O-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hepatic B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
account O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Fluconazole B-CHED-MISC O-MISC
associated O-MISC B-ACTI-MISC
agranulocytosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CASE O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
fluconazole B-CHED-MISC O-MISC
associated O-MISC B-ACTI-MISC
agranulocytosis B-DISO-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
recovery O-MISC B-DEVI-MISC
upon O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
began O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
white O-MISC I-GENE-MISC
blood O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
platelets O-MISC I-GENE-MISC
within O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
fluconazole B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
began O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
recover O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
highlights O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
blood B-DISO-MISC I-ACTI-MISC
dyscrasias I-DISO-MISC B-ANAT-MISC
can O-MISC B-ACTI-MISC
occur O-MISC B-DEVI-MISC
unexpectedly O-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
commonly O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
drug O-MISC O-MISC
thought O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
According O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Naranjo O-MISC B-CHED-MISC
' O-MISC I-CHED-MISC
s O-MISC I-CHED-MISC
algorithm O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
likelihood O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
agranulocytosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
fluconazole B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
probable O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
points O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
feel O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
weight O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
strong O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
particular O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
temporal O-MISC B-CHED-MISC
relationship O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bone B-DISO-MISC I-GENE-MISC
marrow I-DISO-MISC B-GEOG-MISC
suppression I-DISO-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fluconazole B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
abatement O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
rapidly O-MISC B-ACTI-MISC
reversed O-MISC B-ACTI-MISC
immediately O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
dimensional O-MISC I-CONC-MISC
speckle O-MISC I-CONC-MISC
tracking O-MISC I-CONC-MISC
echocardiography O-MISC I-CONC-MISC
combined O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
sensitive O-MISC I-CHED-MISC
cardiac O-MISC I-CHED-MISC
troponin O-MISC O-MISC
T O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
early O-MISC B-CONC-MISC
detection O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
prediction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
epirubicine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

AIMS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
whether O-MISC B-ACTI-MISC
alterations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-GENE-MISC
strain I-DISO-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
high O-MISC O-MISC
- O-MISC B-DISO-MISC
sensitive O-MISC B-DISO-MISC
cardiac O-MISC B-DISO-MISC
troponin O-MISC B-DISO-MISC
T O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
cTnT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
predict O-MISC B-ACTI-MISC
future O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
after O-MISC B-ACTI-MISC
epirubicin B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Seventy O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
non B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Hodgkin I-DISO-MISC B-ANAT-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
epirubicin B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Blood O-MISC B-CONC-MISC
collection O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
echocardiography O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
third O-MISC B-CONC-MISC
cycle O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
completion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
echocardiography O-MISC B-CONC-MISC
during O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Global O-MISC B-CHED-MISC
longitudinal O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
GLS O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
circumferential O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
GCS O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
radial O-MISC I-ACTI-MISC
strain O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
GRS O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
speckle O-MISC B-CONC-MISC
tracking O-MISC I-CONC-MISC
echocardiography O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
ejection O-MISC I-LIVB-MISC
fraction O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
analysed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
real O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
time O-MISC I-CONC-MISC
3D O-MISC I-CONC-MISC
echocardiography O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Cardiotoxicity B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LVEF O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
asymptomatic O-MISC I-ACTI-MISC
reduction O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LVEF O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Fourteen O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
67 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

GLS O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
72 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
96 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
GCS O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
93 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
GRS O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
markedly O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cTnT O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0010 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0020 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0073 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0038 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
completion O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
values O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
GLS O-MISC I-ACTI-MISC
[ O-MISC B-ACTI-MISC
sensitivity O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
specificity O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
area O-MISC B-CHED-MISC
under O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
curve O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
AUC O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
815 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
004 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
elevation O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
cTnT O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
sensitivity O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
79 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
specificity O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
64 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
AUC O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
757 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
third O-MISC B-CONC-MISC
cycle O-MISC I-CONC-MISC
of O-MISC I-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
predicted O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
GLS O-MISC I-ACTI-MISC
remained O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
independent O-MISC B-ACTI-MISC
predictor O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
GLS O-MISC I-ACTI-MISC
combined O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
cTnT O-MISC B-CONC-MISC
may O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reliable O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
non O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
invasive O-MISC I-CHED-MISC
method O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
predict O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
anthracycline B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Prevention O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myoclonus B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
superior O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Fentanyl B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
midazolam B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
? O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
Retrospective O-MISC B-CONC-MISC
comparative O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
comparative O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
compare O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
effectiveness O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
midazolam B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
midazolam B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myoclonus B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

MATERIAL O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
anesthesia O-MISC B-CONC-MISC
records O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Depending O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
that O-MISC B-ACTI-MISC
would O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
anesthesia O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
separated O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
no O-MISC B-PHEN-MISC
pretreatment O-MISC B-UnknownType-MISC
( O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
NP O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
ug O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
F O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
midazolam B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
M O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
midazolam B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
015 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
ug O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
FM O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
anesthetic O-MISC B-CONC-MISC
procedure O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
selected O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
injections O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
drugs O-MISC O-MISC
, O-MISC B-ACTI-MISC
anesthesia O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
injected O-MISC B-CONC-MISC
intravenously O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
period O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
seconds O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Myoclonic B-DISO-MISC I-GENE-MISC
movements I-DISO-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
graded O-MISC B-CHED-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
severity O-MISC I-CHED-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Study O-MISC I-ACTI-MISC
results O-MISC B-ANAT-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
myoclonus B-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
NP O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
F O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
M O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
FM O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
F O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
FM O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
midazolam B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
preventing O-MISC B-CONC-MISC
etomidate B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myoclonus B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Convulsant O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
lindane B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
regional O-MISC B-CHED-MISC
brain O-MISC I-GENE-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Lindane B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
hexachlorocyclohexane I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
organochlorine O-MISC O-MISC
insecticide O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Its O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
action O-MISC B-DEVI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
understood O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
proposed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
lindane B-CHED-MISC O-MISC
acts O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
competitive O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminobutyric I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
GABA B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lindane B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
GABAergic O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
dopaminergic O-MISC I-GENE-MISC
systems O-MISC B-GEOG-MISC
by O-MISC B-ACTI-MISC
measuring O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
metabolites O-MISC O-MISC
in O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
areas O-MISC B-GEOG-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
suffered O-MISC B-ACTI-MISC
tonic O-MISC I-ACTI-MISC
convulsions B-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
lindane B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
slightly O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
colliculi O-MISC I-GENE-MISC
without O-MISC B-ACTI-MISC
modifications O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
areas O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mesencephalon O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
metabolite O-MISC O-MISC
DOPAC B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mesencephalon O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
striatum O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Cholestatic B-DISO-MISC B-CHED-MISC
presentation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
yellow O-MISC O-MISC
phosphorus B-CHED-MISC B-DISO-MISC
poisoning B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Yellow O-MISC O-MISC
phosphorus B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
component O-MISC O-MISC
of O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
pesticide O-MISC O-MISC
pastes O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
fireworks O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
hepatotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Poisoning B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
yellow O-MISC O-MISC
phosphorus B-CHED-MISC B-DISO-MISC
classically O-MISC B-ACTI-MISC
manifests O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
yellow O-MISC O-MISC
phosphorus B-CHED-MISC B-DISO-MISC
poisoning B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
florid O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
features O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cholestasis B-DISO-MISC I-ACTI-MISC
highlighting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fact O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
cholestasis B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
rarely O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
presenting O-MISC B-ACTI-MISC
feature O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
yellow O-MISC O-MISC
phosphorus B-CHED-MISC B-DISO-MISC
hepatotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Vasovagal B-DISO-MISC I-ACTI-MISC
syncope I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
severe O-MISC I-ACTI-MISC
bradycardia B-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
intranasal O-MISC B-CHED-MISC
dexmedetomidine B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
pediatric O-MISC B-CHED-MISC
procedural O-MISC B-CONC-MISC
sedation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
syncope B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC I-ANAT-MISC
girl O-MISC I-PHEN-MISC
following O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
intranasal O-MISC B-CHED-MISC
dexmedetomidine B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
sedation O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
voiding O-MISC I-ACTI-MISC
cystourethrogram O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Following O-MISC B-ACTI-MISC
successful O-MISC B-ACTI-MISC
completion O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
VCUG O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
recovery O-MISC I-DISO-MISC
period O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
level O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
consciousness O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
vital O-MISC I-DISO-MISC
signs O-MISC I-LIVB-MISC
returned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
presedation O-MISC B-CONC-MISC
levels O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Upon O-MISC B-ACTI-MISC
leaving O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sedation O-MISC I-ACTI-MISC
area O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
collapsed O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
apparent O-MISC B-CHED-MISC
inciting O-MISC B-ACTI-MISC
event O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
quickly O-MISC B-ACTI-MISC
regained O-MISC B-ACTI-MISC
consciousness O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
injury O-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
abnormality O-MISC B-ANAT-MISC
found O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
persistent O-MISC I-ACTI-MISC
bradycardia B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC I-CONC-MISC
the O-MISC I-CONC-MISC
hospital O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
telemetric O-MISC B-CONC-MISC
observation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
lasted O-MISC B-ACTI-MISC
~ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
workup O-MISC I-CONC-MISC
revealed O-MISC B-CHED-MISC
no O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
abnormality O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Unanticipated O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
unreported O-MISC B-ACTI-MISC
outcomes O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
witnessed O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
expand O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
sedatives O-MISC O-MISC
to O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
routes O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
administration O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Paradoxical O-MISC I-ACTI-MISC
severe O-MISC B-ANAT-MISC
agitation B-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
add O-MISC O-MISC
- O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
doses O-MISC I-CHED-MISC
quetiapine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
schizo B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
affective I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
suffering O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
schizo B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
affective I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
since O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
first O-MISC O-MISC
- O-MISC B-DISO-MISC
generation O-MISC B-DISO-MISC
antipsychotics O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
zuclopenthixol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
lithium B-CHED-MISC O-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
mEq O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
l O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
personality B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
antisocial B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
substance B-DISO-MISC I-ACTI-MISC
abuse I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gradual O-MISC B-ACTI-MISC
introduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
quetiapine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
agitation B-DISO-MISC I-ACTI-MISC
without O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
environmental O-MISC B-CHED-MISC
explanation O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
contrasting O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aggressiveness B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
personality B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
diagnoses O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
manic B-DISO-MISC I-ACTI-MISC
shift O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
akathisia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
dismissed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
withdrawal O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gradual O-MISC B-ACTI-MISC
reintroduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
quetiapine B-CHED-MISC O-MISC
2 O-MISC B-CHED-MISC
weeks O-MISC I-CHED-MISC
later O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
agitation B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
enabled O-MISC B-ACTI-MISC
us O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
attribute O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
agitation B-DISO-MISC I-ACTI-MISC
specifically O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
quetiapine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Antioxidant O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
bovine O-MISC O-MISC
lactoferrin O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Dexamethasone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
Dex B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
enhanced O-MISC B-DEVI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Lactoferrin O-MISC O-MISC
( O-MISC B-ACTI-MISC
LF O-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
iron B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
binding O-MISC B-DISO-MISC
glycoprotein O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
antihypertensive O-MISC O-MISC
properties O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
LF O-MISC O-MISC
on O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
upon O-MISC B-ACTI-MISC
Dex B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Male O-MISC I-DISO-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
Dex B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
u O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
subcutaneously O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
for O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC O-MISC
bovine O-MISC B-DISO-MISC
LF O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
8 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reversal O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prevention O-MISC B-CHED-MISC
study O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
LF O-MISC I-GENE-MISC
treatment O-MISC B-CONC-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
Dex B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
continued O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
test O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Systolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
SBP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
tail O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
cuff O-MISC I-CONC-MISC
method O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Thymus O-MISC I-GENE-MISC
weight O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marker O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
glucocorticoid O-MISC B-OCCU-MISC
activity O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

Plasma O-MISC I-GENE-MISC
hydrogen B-CHED-MISC O-MISC
peroxide I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
H2O2 B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
ferric O-MISC B-CONC-MISC
reducing O-MISC I-CONC-MISC
antioxidant O-MISC I-CONC-MISC
power O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
FRAP O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
value O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Dexamethasone B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
SBP O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
H2O2 B-CHED-MISC O-MISC
level O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
thymus O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weights O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

LF O-MISC I-GENE-MISC
lowered O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
dependently O-MISC B-CHED-MISC
prevented O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
Dex B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

LF O-MISC O-MISC
prevented O-MISC B-ACTI-MISC
body O-MISC I-ACTI-MISC
weight B-DISO-MISC B-ANAT-MISC
loss I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
reduced O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
plasma O-MISC I-GENE-MISC
H2O2 B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
FRAP O-MISC O-MISC
values O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
LF O-MISC O-MISC
strongly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
production O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
ROS O-MISC O-MISC
and O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
antioxidant O-MISC B-OCCU-MISC
capacity O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
Dex B-CHED-MISC O-MISC
- O-MISC B-ANAT-MISC
induced O-MISC I-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
antihypertensive O-MISC I-ACTI-MISC
action O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
LF O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
convulsive B-DISO-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
multivariate O-MISC B-CHED-MISC
analysis O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
529 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
contemporary O-MISC B-CHED-MISC
data O-MISC I-CHED-MISC
regarding O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
undertook O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
prospectively O-MISC B-ACTI-MISC
collected O-MISC B-CHED-MISC
data O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
529 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
cardiopulmonary O-MISC B-CONC-MISC
bypass O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
January O-MISC B-ACTI-MISC
2004 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
December O-MISC B-ACTI-MISC
2010 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
convulsive B-DISO-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transient O-MISC B-CHED-MISC
episode O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
disturbed O-MISC B-ACTI-MISC
brain O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
characterised O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
abnormal B-DISO-MISC I-ACTI-MISC
involuntary I-DISO-MISC I-ACTI-MISC
motor I-DISO-MISC B-ANAT-MISC
movements I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Multivariate O-MISC B-CHED-MISC
regression O-MISC B-CHED-MISC
analysis O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
independent O-MISC B-ACTI-MISC
predictors O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
postoperative O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
postoperative O-MISC B-CHED-MISC
convulsive B-DISO-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Generalised B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
focal I-DISO-MISC I-ACTI-MISC
seizures I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
median O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
IQR O-MISC B-CHED-MISC
[ O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
when O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-DEVI-MISC
was O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
216 O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
h O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
h O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Epileptiform O-MISC I-ACTI-MISC
findings O-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
electroencephalography O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Independent O-MISC B-CHED-MISC
predictors O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
postoperative O-MISC I-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
included O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
sex O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
redo O-MISC B-CONC-MISC
cardiac O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
calcification O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
ascending O-MISC I-GENE-MISC
aorta O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
congestive B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
deep O-MISC I-ACTI-MISC
hypothermic B-DISO-MISC B-ANAT-MISC
circulatory O-MISC B-ANAT-MISC
arrest O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
aortic O-MISC I-ACTI-MISC
cross O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
clamp O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
multivariate O-MISC B-CHED-MISC
regression O-MISC I-CHED-MISC
analysis O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
strong O-MISC B-CHED-MISC
independent O-MISC B-ACTI-MISC
predictor O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
convulsive B-DISO-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
had O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
hospital O-MISC I-CHED-MISC
mortality O-MISC I-CHED-MISC
rates O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
twice O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
length O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
hospital O-MISC I-CHED-MISC
stay O-MISC I-CHED-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
convulsive B-DISO-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Mean O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
IQR O-MISC B-CHED-MISC
[ O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
length O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
stay O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intensive O-MISC B-GENE-MISC
care O-MISC I-GEOG-MISC
unit O-MISC I-GEOG-MISC
was O-MISC B-ACTI-MISC
115 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
228 O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
481 O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
convulsive B-DISO-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
69 O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1080 O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Convulsive B-DISO-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
postoperative B-DISO-MISC B-CHED-MISC
complication I-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
modifiable O-MISC B-CHED-MISC
factor O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
exceeding O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
weighed O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
postoperative O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Dysfunctional B-DISO-MISC B-CHED-MISC
overnight I-DISO-MISC B-CHED-MISC
memory I-DISO-MISC I-DISO-MISC
consolidation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Sleep O-MISC I-DISO-MISC
plays O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-CHED-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
consolidation O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
integration O-MISC I-DISO-MISC
of O-MISC I-LIVB-MISC
memory O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
process O-MISC B-OCCU-MISC
called O-MISC B-ACTI-MISC
overnight O-MISC B-CHED-MISC
memory O-MISC I-DISO-MISC
consolidation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Previous O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
neurocognitive O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
sleep B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
related I-DISO-MISC B-ANAT-MISC
impairments I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
extend O-MISC B-ACTI-MISC
past O-MISC B-ACTI-MISC
research O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
examining O-MISC B-ACTI-MISC
overnight O-MISC B-CHED-MISC
memory O-MISC I-DISO-MISC
consolidation O-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
regular O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
drug O-MISC I-ANAT-MISC
naive O-MISC I-PHEN-MISC
healthy O-MISC I-CHED-MISC
controls O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Memory O-MISC I-DISO-MISC
recall O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
word O-MISC I-DISO-MISC
pairs O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
before O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
period O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sleep O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
interference O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
testing O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
neurocognitive O-MISC B-CHED-MISC
performances O-MISC B-DEVI-MISC
across O-MISC B-ACTI-MISC
tasks O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
learning O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
executive O-MISC I-DISO-MISC
functioning O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
demonstrated O-MISC B-ACTI-MISC
impaired B-DISO-MISC B-CHED-MISC
overnight I-DISO-MISC B-CHED-MISC
memory I-DISO-MISC I-DISO-MISC
consolidation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
finding O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
pronounced O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
associative O-MISC B-CHED-MISC
interference O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Additionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
demonstrated O-MISC B-ACTI-MISC
impairments O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
tasks O-MISC B-ACTI-MISC
recruiting O-MISC B-ACTI-MISC
frontostriatal O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
neural O-MISC B-PHEN-MISC
circuitry O-MISC B-UnknownType-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
domains O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
proactive O-MISC I-DISO-MISC
interference O-MISC I-LIVB-MISC
memory O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
long O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
term O-MISC I-LIVB-MISC
memory O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
encoding O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
working O-MISC I-DISO-MISC
memory O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
complex O-MISC B-CHED-MISC
planning O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
dysfunction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
fronto O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
temporal O-MISC B-GEOG-MISC
circuitry O-MISC B-GEOG-MISC
may O-MISC B-ACTI-MISC
underlie O-MISC B-ACTI-MISC
overnight O-MISC B-CHED-MISC
consolidation O-MISC I-ACTI-MISC
memory B-DISO-MISC I-ACTI-MISC
impairments I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
regular O-MISC B-ACTI-MISC
ecstasy B-CHED-MISC I-ACTI-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Normoammonemic O-MISC I-ACTI-MISC
encephalopathy B-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
solely O-MISC B-ACTI-MISC
valproate B-CHED-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
? O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
subacute O-MISC I-ACTI-MISC
onset O-MISC I-CHED-MISC
progressive O-MISC B-CHED-MISC
confusion B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
aggression B-DISO-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
auditory B-DISO-MISC I-ACTI-MISC
hallucinations I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
delusions B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
preceding O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
admissions O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
transient O-MISC B-CHED-MISC
unilateral O-MISC B-CHED-MISC
hemiparesis B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
facial O-MISC I-ACTI-MISC
droop O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
started O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
valproate B-CHED-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
presumed O-MISC B-ACTI-MISC
hemiplegic B-DISO-MISC I-ACTI-MISC
migraine I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Valproate B-CHED-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
withdrawn O-MISC I-ACTI-MISC
soon O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
cognitive O-MISC I-DISO-MISC
abilities O-MISC I-LIVB-MISC
have O-MISC B-ACTI-MISC
gradually O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
over O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Valproate B-CHED-MISC I-ACTI-MISC
levels O-MISC B-ANAT-MISC
taken O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
withdrawal O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
subtherapeutic O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
normoammonaemic O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

EEG O-MISC B-CONC-MISC
undertaken O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
inpatient O-MISC I-ANAT-MISC
stay O-MISC B-CHED-MISC
showed O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
low O-MISC O-MISC
titre O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
methyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
D I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
aspartate I-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
NMDA B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antibodies O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
aetiologies O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
valproate B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
NMDA B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
encephalitis B-DISO-MISC I-ACTI-MISC
present O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
diagnostic O-MISC B-CHED-MISC
dilemma O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
putative O-MISC B-ACTI-MISC
combinatorial O-MISC B-CHED-MISC
hypothesis O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
explain O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
symptoms O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Cerebellar B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
oculomotor I-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
rapid O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
pethidine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Pethidine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
opioid O-MISC O-MISC
that O-MISC B-ACTI-MISC
gains O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
popularity O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
pain B-DISO-MISC B-CONC-MISC
control O-MISC I-CONC-MISC
through O-MISC B-ACTI-MISC
acting O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
opioid O-MISC O-MISC
- O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
rapid O-MISC B-CONC-MISC
pain B-DISO-MISC B-CONC-MISC
relief O-MISC I-CONC-MISC
sometimes O-MISC B-ACTI-MISC
brings O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
unfavourable O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
largely O-MISC B-ACTI-MISC
limit O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
utility O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Common O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
include O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
impaired B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
liver I-DISO-MISC I-DISO-MISC
function I-DISO-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
pain B-DISO-MISC B-CONC-MISC
control O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
pethidine B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
excitatory O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
CNS O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
through O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC O-MISC
metabolite O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
norpethidine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
irritability B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
attack O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
contrary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
though O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
clinically O-MISC B-CHED-MISC
apparent O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
pethidine B-CHED-MISC O-MISC
potentially O-MISC B-CHED-MISC
causes O-MISC B-ACTI-MISC
inhibitory O-MISC I-DISO-MISC
impacts O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CNS O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
impairs O-MISC B-CHED-MISC
normal O-MISC B-ACTI-MISC
cerebellar O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
oculomotor O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
short O-MISC B-CHED-MISC
term O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
highlight O-MISC B-ACTI-MISC
opioid O-MISC O-MISC
' O-MISC B-DISO-MISC
s O-MISC B-DISO-MISC
inhibitory O-MISC I-ACTI-MISC
side O-MISC B-CHED-MISC
effects O-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebellar O-MISC I-GENE-MISC
structure O-MISC B-GEOG-MISC
that O-MISC B-ACTI-MISC
causes O-MISC B-ACTI-MISC
dysmetria B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
dysarthria B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
smooth O-MISC I-ACTI-MISC
pursuit O-MISC B-ANAT-MISC
gain O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
saccadic O-MISC I-DISO-MISC
velocity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Baboon B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
ketoconazole B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
patient O-MISC I-LIVB-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
maculopapular B-DISO-MISC I-ACTI-MISC
eruption I-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
flexural O-MISC I-GENE-MISC
areas O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
buttocks O-MISC I-GENE-MISC
after O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
ketoconazole B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
baboon B-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
sensitivity O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
topical O-MISC O-MISC
ketoconazole B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
physical O-MISC B-CONC-MISC
examination O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
histopathological O-MISC B-CHED-MISC
findings O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Baboon B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
contact O-MISC O-MISC
allergen O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
maculopapular B-DISO-MISC I-ACTI-MISC
eruption I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
typically O-MISC B-ACTI-MISC
involves O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
flexural O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
gluteal O-MISC I-GENE-MISC
areas O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ketoconazole B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
baboon B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
English O-MISC B-CHED-MISC
literature O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
Case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Sudden B-DISO-MISC I-ACTI-MISC
Cardiac I-DISO-MISC B-ANAT-MISC
Death I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Pilsicainide B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
Induced O-MISC B-CHED-MISC
Torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
Pointes I-DISO-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
received O-MISC B-ACTI-MISC
oral O-MISC O-MISC
pilsicainide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pure O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
channel O-MISC B-DISO-MISC
blocker O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
slow O-MISC I-ACTI-MISC
recovery O-MISC B-ANAT-MISC
kinetics O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
convert O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
paroxysmal O-MISC I-ACTI-MISC
atrial B-DISO-MISC B-ANAT-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sinus O-MISC I-ACTI-MISC
rhythm O-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
sudden B-DISO-MISC I-ACTI-MISC
cardiac I-DISO-MISC B-ANAT-MISC
death I-DISO-MISC B-ANAT-MISC
two O-MISC I-ACTI-MISC
days O-MISC B-ANAT-MISC
later O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Holter O-MISC B-CONC-MISC
electrocardiogram O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
worn O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
chance O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
revealed O-MISC B-ACTI-MISC
torsade B-DISO-MISC B-ACTI-MISC
de I-DISO-MISC B-ACTI-MISC
pointes I-DISO-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
gradually O-MISC B-ACTI-MISC
prolonged O-MISC B-ACTI-MISC
QT O-MISC I-DISO-MISC
intervals O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
drug O-MISC O-MISC
is O-MISC B-ACTI-MISC
rapidly O-MISC B-CHED-MISC
absorbed O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gastrointestinal O-MISC I-GENE-MISC
tract O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
excreted O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
impaired O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pilsicainide B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
plasma O-MISC B-CHED-MISC
concentration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
pilsicainide B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ACTI-MISC
pointes I-DISO-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
octogenarian O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
class O-MISC B-ACTI-MISC
IC O-MISC O-MISC
drugs O-MISC O-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
pilsicainide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
terminate O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
careful O-MISC B-ACTI-MISC
consideration O-MISC B-ACTI-MISC
must O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
giving O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
to O-MISC B-ACTI-MISC
octogenarians O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

All B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
trans I-CHED-MISC B-DISO-MISC
retinoic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
inflammatory O-MISC I-ACTI-MISC
myositis B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
promyelocytic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

All B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
trans I-CHED-MISC B-DISO-MISC
retinoic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ATRA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
component O-MISC O-MISC
of O-MISC B-ACTI-MISC
standard O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
promyelocytic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
APL B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
potentially O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
treatable O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
involving O-MISC B-ACTI-MISC
numerous O-MISC B-CHED-MISC
organ O-MISC I-GENE-MISC
systems O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
skeletal O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
involvement O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
handful O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ATRA B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myositis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
radiology O-MISC B-CHED-MISC
literature O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
boy O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
APL B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
where O-MISC B-ACTI-MISC
recognition O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
imaging O-MISC B-CONC-MISC
findings O-MISC I-OCCU-MISC
played O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
crucial O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
making O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
facilitated O-MISC B-ACTI-MISC
prompt O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Tolerability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lomustine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
describes O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
protocol O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lomustine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CCNU B-CHED-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
CTX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CCNU B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
per O-MISC B-ACTI-MISC
os O-MISC O-MISC
( O-MISC B-ACTI-MISC
PO O-MISC O-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
targeted O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
area O-MISC B-GEOG-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
CTX B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
PO O-MISC O-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
targeted O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
received O-MISC B-CHED-MISC
prophylactic O-MISC B-CHED-MISC
antibiotics O-MISC O-MISC
. O-MISC B-ACTI-MISC

Ninety O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Neutropenia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
principal O-MISC B-CHED-MISC
toxic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
grade O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
CCNU B-CHED-MISC B-CONC-MISC
/ O-MISC B-ACTI-MISC
CTX B-CHED-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
grade O-MISC I-ACTI-MISC
4 O-MISC B-ANAT-MISC
neutropenia B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC I-ACTI-MISC
less O-MISC B-ANAT-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ANAT-MISC
develop O-MISC B-ACTI-MISC
grade O-MISC I-ACTI-MISC
4 O-MISC B-ANAT-MISC
neutropenia B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
dog O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
hematologic O-MISC I-ACTI-MISC
changes O-MISC B-CHED-MISC
suggestive O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hepatotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
renal B-DISO-MISC I-GENE-MISC
toxicity I-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
cystitis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Adverse O-MISC I-ACTI-MISC
gastrointestinal O-MISC B-ANAT-MISC
effects O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
uncommon O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
reported O-MISC B-ACTI-MISC
herein O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CCNU B-CHED-MISC O-MISC
combined O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CTX B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
q O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
wk O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
tolerable O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
bearing O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Nelarabine B-CHED-MISC O-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
concurrent O-MISC B-CHED-MISC
intrathecal O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
Case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
literature O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Severe O-MISC B-ACTI-MISC
nelarabine B-CHED-MISC O-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
concurrent O-MISC B-CONC-MISC
intrathecal O-MISC B-CONC-MISC
( O-MISC I-CONC-MISC
IT O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
Caucasian O-MISC I-ANAT-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
T B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
lymphoblastic I-DISO-MISC B-ANAT-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
relapsed O-MISC I-ACTI-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
originally O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
induction O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autologous O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
relapsed O-MISC I-ACTI-MISC
disease O-MISC I-ACTI-MISC
10 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
leukemic B-DISO-MISC I-ACTI-MISC
involvement O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
re O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
induced O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
nelarabine B-CHED-MISC O-MISC
1500 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
IT O-MISC B-CHED-MISC
cytarabine B-CHED-MISC O-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
CNS O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
prophylaxis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
replacement O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
sequelae O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
lysis I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
TLS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
well O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
entered O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complete O-MISC I-ACTI-MISC
remission O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
recovered O-MISC B-CHED-MISC
her O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
cycle O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
nelarabine B-CHED-MISC O-MISC
without O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
IT O-MISC B-CONC-MISC
prophylaxis O-MISC I-CONC-MISC
one O-MISC B-ACTI-MISC
month O-MISC I-CHED-MISC
later O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
cycle O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
numbness O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
lower O-MISC I-GENE-MISC
extremities O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Predominantly O-MISC B-ACTI-MISC
sensory O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
though O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
motor O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
autonomic O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
started O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
feet O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
ascended O-MISC B-ACTI-MISC
proximally O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mid O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
thoracic O-MISC B-GEOG-MISC
region O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
eventually O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
distal O-MISC B-CHED-MISC
upper O-MISC I-GENE-MISC
extremities O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
MRI O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
spine O-MISC I-GENE-MISC
demonstrated O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
C2 O-MISC I-GENE-MISC
to O-MISC B-ACTI-MISC
C6 O-MISC I-GENE-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
subacute O-MISC B-CHED-MISC
combined O-MISC B-CHED-MISC
degeneration O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Nelarabine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
felt O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Her O-MISC B-ACTI-MISC
neuropathy B-DISO-MISC I-ACTI-MISC
stabilized O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
slight O-MISC B-ACTI-MISC
improvement O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ultimately O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
reduced O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
intensity O-MISC B-ACTI-MISC
allogeneic O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
while O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
complete O-MISC B-CHED-MISC
remission O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
relapsed O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
10 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
currently O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
best O-MISC B-ACTI-MISC
supportive O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
published O-MISC B-CHED-MISC
case O-MISC I-CHED-MISC
report O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
nelarabine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
concurrent O-MISC B-CHED-MISC
IT O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Valproate B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
hyperammonemic B-DISO-MISC I-ACTI-MISC
encephalopathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
transplanted O-MISC I-CONC-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Neurological B-DISO-MISC I-ACTI-MISC
complications I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
constitute O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-CHED-MISC
cause O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
morbidity O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Their O-MISC B-ACTI-MISC
differential O-MISC B-CONC-MISC
diagnosis O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
difficult O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
essential O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
patient O-MISC B-CONC-MISC
' O-MISC I-CONC-MISC
s O-MISC I-CONC-MISC
management O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Valproate B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperammonemic B-DISO-MISC I-ACTI-MISC
encephalopathy B-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
uncommon O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
valproate B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
girl O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
term O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
valproate B-CHED-MISC I-ACTI-MISC
due O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
revealed O-MISC B-ACTI-MISC
impaired B-DISO-MISC I-ACTI-MISC
consciousness I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
hyperammonemia B-DISO-MISC I-ACTI-MISC
12 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
withdraw O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
valproate B-CHED-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
' O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
resolved O-MISC I-ACTI-MISC
within O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinicians O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
awareness O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
valproate B-CHED-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
transplanted O-MISC I-ACTI-MISC
patients O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Necrotising B-DISO-MISC I-ACTI-MISC
fasciitis I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
bortezomib B-CHED-MISC O-MISC
and O-MISC B-DISO-MISC
dexamethasone B-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
containing O-MISC B-ACTI-MISC
regimen O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
patient O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
Waldenstrom B-DISO-MISC I-ACTI-MISC
macroglobulinaemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Bortezomib B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
dexamethasone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
containing O-MISC B-ACTI-MISC
regimens O-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
considered O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
tolerable O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
bacterial B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
B O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
cell O-MISC B-ANAT-MISC
malignancies B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
information O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
concerning O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
regimen O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
Waldenstrom B-DISO-MISC I-ACTI-MISC
macroglobulinaemia I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
suffered O-MISC B-ACTI-MISC
necrotising B-DISO-MISC I-DISO-MISC
fasciitis I-DISO-MISC I-ACTI-MISC
without O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
bortezomib B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
dexamethasone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
rituximab O-MISC O-MISC
. O-MISC B-ACTI-MISC

Despite O-MISC B-ACTI-MISC
immediate O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
antimicrobial O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
succumbed O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Physicians O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
recognise O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
bacterial B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
bortezomib B-CHED-MISC O-MISC
plus O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
dexamethasone B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
believe O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
warrants O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
investigation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
integrated O-MISC B-ACTI-MISC
characterization O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
serological O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
events O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Many O-MISC B-ACTI-MISC
efficacious O-MISC B-CHED-MISC
cancer B-DISO-MISC B-CONC-MISC
treatments O-MISC I-CONC-MISC
cause O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
cardiac O-MISC I-ACTI-MISC
morbidity O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
biomarkers O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
indices O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
damage O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
would O-MISC B-ACTI-MISC
allow O-MISC B-ACTI-MISC
monitoring O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
intervention O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
lacking O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
utilized O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
model O-MISC B-OBJC-MISC
of O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
doxorubicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiomyopathy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
applying O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
approaches O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-CHED-MISC
cardiac O-MISC I-GENE-MISC
magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
MRI O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
comprehensive O-MISC B-CHED-MISC
characterization O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
date O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
timecourse O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
serological O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
events O-MISC B-DEVI-MISC
underlying O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Hannover O-MISC I-ANAT-MISC
Wistar O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
dosed O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
weekly O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
off O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
" O-MISC B-ACTI-MISC
recovery O-MISC B-DEVI-MISC
" O-MISC B-ACTI-MISC
period O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Electron O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardium O-MISC I-GENE-MISC
revealed O-MISC B-CHED-MISC
subcellular B-DISO-MISC I-ACTI-MISC
degeneration I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
mitochondrial O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Histopathological O-MISC B-CHED-MISC
analysis O-MISC B-CONC-MISC
revealed O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
cardiomyocyte B-DISO-MISC I-GENE-MISC
degeneration I-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
hypertrophy B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
cytomegaly O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
extensive O-MISC B-CHED-MISC
vacuolation O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Extensive O-MISC I-ACTI-MISC
replacement O-MISC B-ANAT-MISC
fibrosis B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
quantified O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
Sirius O-MISC B-CONC-MISC
red O-MISC I-CONC-MISC
staining O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
off O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
period O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Functional O-MISC B-CHED-MISC
indices O-MISC I-CHED-MISC
assessed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
MRI O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
ejection O-MISC I-LIVB-MISC
fraction O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
LVEF O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
E O-MISC I-DISO-MISC
/ O-MISC I-CHED-MISC
A O-MISC I-LIVB-MISC
ratio O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
declined O-MISC B-ACTI-MISC
progressively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
reaching O-MISC B-ACTI-MISC
statistical O-MISC B-CHED-MISC
significance O-MISC I-CHED-MISC
after O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
culminating O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
" O-MISC B-ACTI-MISC
LV B-DISO-MISC I-GENE-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Significant O-MISC B-CHED-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
peak O-MISC I-DISO-MISC
myocardial O-MISC I-DISO-MISC
contrast O-MISC I-LIVB-MISC
enhancement O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
serological O-MISC B-CHED-MISC
cardiac O-MISC I-GENE-MISC
troponin O-MISC O-MISC
I O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
cTnI O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
emerged O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
importantly O-MISC B-ACTI-MISC
preceding O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LVEF O-MISC I-DISO-MISC
decline O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Troponin O-MISC O-MISC
I O-MISC B-DISO-MISC
levels O-MISC B-CHED-MISC
positively O-MISC B-ACTI-MISC
correlated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
delayed O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
peak O-MISC B-ACTI-MISC
gadolinium B-CHED-MISC O-MISC
contrast O-MISC B-DISO-MISC
enhancement O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
histopathological O-MISC B-CHED-MISC
grading O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
diastolic B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
summary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
subcellular O-MISC I-GENE-MISC
cardiomyocyte B-DISO-MISC B-ANAT-MISC
degeneration I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
earliest O-MISC B-ACTI-MISC
marker O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
functional O-MISC I-ACTI-MISC
decline O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
histopathological O-MISC B-CHED-MISC
manifestations O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Myocardial O-MISC I-DISO-MISC
contrast O-MISC I-LIVB-MISC
enhancement O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
elevations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
cTnI O-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
indices O-MISC B-CHED-MISC
predated O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
" O-MISC B-ACTI-MISC
LV B-DISO-MISC I-GENE-MISC
dysfunction I-DISO-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
thus O-MISC B-ACTI-MISC
warrant O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
evaluation O-MISC B-CONC-MISC
as O-MISC B-ACTI-MISC
predictive O-MISC B-CHED-MISC
biomarkers O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Intradermal O-MISC B-CHED-MISC
glutamate B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
injections O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
intra O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
interindividual O-MISC B-CHED-MISC
variability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
provoked O-MISC B-ACTI-MISC
hyperalgesia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
allodynia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Intradermal O-MISC B-CHED-MISC
injections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
glutamate B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
attractive O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
experimental O-MISC B-CHED-MISC
pain B-DISO-MISC I-ACTI-MISC
models O-MISC B-ANAT-MISC
because O-MISC B-ACTI-MISC
hyperalgesia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
allodynia B-DISO-MISC I-ACTI-MISC
mimic O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
aspects O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
pain B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
reproducibility O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
models O-MISC B-OBJC-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
male O-MISC I-PHEN-MISC
volunteers O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
24 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
intradermal O-MISC B-CONC-MISC
injections O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
glutamate B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
volar O-MISC I-GENE-MISC
forearm O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Magnitudes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
secondary O-MISC I-ACTI-MISC
pinprick O-MISC B-ANAT-MISC
hyperalgesia B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
brush O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
evoked O-MISC B-ANAT-MISC
allodynia B-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
von O-MISC B-OBJC-MISC
Frey O-MISC I-OBJC-MISC
filaments O-MISC I-OBJC-MISC
( O-MISC B-ACTI-MISC
gauges O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
brush O-MISC O-MISC
strokes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Areas O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
secondary B-DISO-MISC I-ACTI-MISC
hyperalgesia I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
allodynia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
quantified O-MISC B-CHED-MISC
immediately O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
identical O-MISC B-ACTI-MISC
experiments O-MISC B-CONC-MISC
separated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Reproducibility O-MISC B-CHED-MISC
across O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
volunteers O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
inter O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
intra O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
individual O-MISC I-PHEN-MISC
variation O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
using O-MISC B-ACTI-MISC
intraclass O-MISC B-CHED-MISC
correlation O-MISC I-CHED-MISC
coefficient O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
ICC O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
coefficient O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
variation O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
CV O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Secondary O-MISC B-CHED-MISC
pinprick O-MISC I-ACTI-MISC
hyperalgesia B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
visual O-MISC B-CONC-MISC
analogue O-MISC I-CONC-MISC
scale O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
VAS O-MISC B-CONC-MISC
) O-MISC I-LIVB-MISC
response O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
von O-MISC B-OCCU-MISC
Frey O-MISC I-OCCU-MISC
gauges O-MISC I-OCCU-MISC
60 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
glutamate B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
secondary O-MISC B-ACTI-MISC
pinprick O-MISC I-ACTI-MISC
hyperalgesia B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
von O-MISC B-OCCU-MISC
Frey O-MISC I-OCCU-MISC
gauges O-MISC I-OCCU-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Glutamate B-CHED-MISC O-MISC
evoked O-MISC B-CHED-MISC
reproducible O-MISC B-ACTI-MISC
VAS O-MISC I-DISO-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
von O-MISC B-CHED-MISC
Frey O-MISC I-CHED-MISC
gauges O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
ICC O-MISC B-CHED-MISC
> O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
brush O-MISC O-MISC
strokes O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
ICC O-MISC B-CHED-MISC
> O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
83 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Capsaicin B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
reproducible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
secondary B-DISO-MISC I-ACTI-MISC
hyperalgesia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ICC O-MISC B-CHED-MISC
> O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
allodynia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
ICC O-MISC B-CHED-MISC
> O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
71 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Intra O-MISC B-CHED-MISC
- O-MISC I-PHEN-MISC
individual O-MISC I-ANAT-MISC
variability O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
VAS O-MISC I-DISO-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
von O-MISC O-MISC
Frey O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
brush O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
areas O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
secondary B-DISO-MISC I-ACTI-MISC
hyperalgesia I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
allodynia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
glutamate B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
capsaicin B-CHED-MISC O-MISC
yield O-MISC B-ACTI-MISC
reproducible O-MISC B-ACTI-MISC
hyperalgesic B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
allodynic B-DISO-MISC I-DISO-MISC
responses O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
model O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
suited O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
research O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
assessing O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
modulation O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
central O-MISC B-CHED-MISC
phenomena O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

Ocular O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
ER O-MISC I-GENE-MISC
stress O-MISC B-CONC-MISC
reduction O-MISC I-CONC-MISC
rescues O-MISC B-ACTI-MISC
glaucoma B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
murine O-MISC I-ANAT-MISC
glucocorticoid O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
glaucoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
glucocorticoids O-MISC O-MISC
induces O-MISC B-ACTI-MISC
ocular B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

If O-MISC B-ACTI-MISC
untreated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
can O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
secondary O-MISC I-ACTI-MISC
glaucoma B-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
resembles O-MISC B-ACTI-MISC
primary B-DISO-MISC I-ACTI-MISC
open I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
angle I-DISO-MISC B-ANAT-MISC
glaucoma I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
POAG B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
pathology O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
glucocorticoid O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
glaucoma B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
fully O-MISC B-ACTI-MISC
understood O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
appropriate O-MISC B-CHED-MISC
animal O-MISC I-ANAT-MISC
model O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
murine O-MISC I-ANAT-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
glucocorticoid O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
glaucoma B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
exhibits O-MISC B-ACTI-MISC
glaucoma B-DISO-MISC I-ACTI-MISC
features O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
topical O-MISC B-CHED-MISC
ocular O-MISC I-GENE-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
elevation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
intraocular O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
IOP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
structural O-MISC B-ACTI-MISC
loss O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
retinal B-DISO-MISC I-GENE-MISC
ganglion I-DISO-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
axonal B-DISO-MISC I-ACTI-MISC
degeneration I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
resembling O-MISC B-ACTI-MISC
glucocorticoid O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
glaucoma B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ocular B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
chronic O-MISC I-ACTI-MISC
ER O-MISC B-ANAT-MISC
stress O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
trabecular O-MISC I-GENE-MISC
meshwork O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
TM O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
withdrawal O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
reduced O-MISC B-CHED-MISC
elevated O-MISC B-ACTI-MISC
IOP O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
ER O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
model O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Dexamethasone B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
transcriptional O-MISC O-MISC
factor O-MISC B-DISO-MISC
CHOP O-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marker O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
ER O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anterior O-MISC B-CHED-MISC
segment O-MISC I-CHED-MISC
tissues O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Chop O-MISC I-DISO-MISC
deletion O-MISC I-LIVB-MISC
reduced O-MISC B-CHED-MISC
ER O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
tissues O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
prevented O-MISC B-CHED-MISC
dexamethasone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ocular B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ER O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
TM O-MISC I-GENE-MISC
with O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
phenylbutyrate I-CHED-MISC B-DISO-MISC
prevented O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
ocular B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
ER O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
contributes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
glucocorticoid O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ocular B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
suggest O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
reducing O-MISC B-CHED-MISC
ER O-MISC I-GENE-MISC
stress O-MISC I-ACTI-MISC
has O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
therapeutic O-MISC B-CONC-MISC
strategy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
treating O-MISC B-CHED-MISC
glucocorticoid O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
glaucoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ginsenosides B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
opioid O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperalgesia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Opioid O-MISC O-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
hyperalgesia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
OIH B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
nociceptive O-MISC I-ACTI-MISC
sensitization O-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cessation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
opioid O-MISC O-MISC
use O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OIH B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
limit O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
use O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
opioid O-MISC O-MISC
analgesics O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
complicate O-MISC B-CHED-MISC
withdrawal O-MISC B-DEVI-MISC
from O-MISC B-ACTI-MISC
opioid B-DISO-MISC I-ACTI-MISC
addiction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
Re B-CHED-MISC O-MISC
, I-CHED-MISC B-ACTI-MISC
Rg1 I-CHED-MISC O-MISC
, I-CHED-MISC B-ACTI-MISC
and I-CHED-MISC B-ACTI-MISC
Rb1 I-CHED-MISC O-MISC
ginsenosides I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bioactive O-MISC B-GENE-MISC
components O-MISC I-GEOG-MISC
of O-MISC B-ACTI-MISC
ginseng O-MISC O-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
OIH B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

OIH B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
achieved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
after O-MISC B-ACTI-MISC
subcutaneous O-MISC B-CHED-MISC
administration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
consecutive O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
three O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
withdrawal O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
8 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
Re B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
Rg1 B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
Rb1 B-CHED-MISC O-MISC
intragastrically O-MISC B-CHED-MISC
two O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
test O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
subjected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
thermal O-MISC B-CONC-MISC
sensitivity O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acetic B-CHED-MISC B-CONC-MISC
acid I-CHED-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
induced O-MISC I-CONC-MISC
writhing O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Re B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
inhibited O-MISC B-CHED-MISC
OIH B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
thermal O-MISC B-CONC-MISC
sensitivity O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acetic B-CHED-MISC B-CONC-MISC
acid I-CHED-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
induced O-MISC I-CONC-MISC
writhing O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Rg1 B-CHED-MISC O-MISC
and I-CHED-MISC B-ACTI-MISC
Rb1 I-CHED-MISC O-MISC
ginsenosides I-CHED-MISC B-DISO-MISC
failed O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
OIH B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
test O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Rg1 B-CHED-MISC O-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tendency O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
aggravate O-MISC B-ACTI-MISC
OIH B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acetic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
writhing O-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ginsenoside B-CHED-MISC O-MISC
Re I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
Rg1 B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
Rb1 B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
toward O-MISC B-ACTI-MISC
reversal O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
OIH B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
comparison O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
hemodynamic O-MISC I-DISO-MISC
disturbances O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
dexmedetomidine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
sedation O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
neurocritical O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Dexmedetomidine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
commonly O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
sedatives O-MISC O-MISC
in O-MISC B-ACTI-MISC
neurocritical O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
as O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
allow O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
neurologic O-MISC B-CONC-MISC
examinations O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
agents O-MISC O-MISC
are O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
significant O-MISC B-ACTI-MISC
hemodynamic O-MISC I-DISO-MISC
side O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
primary O-MISC B-ACTI-MISC
objective O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
compare O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
hemodynamic O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
neurocritical O-MISC I-ACTI-MISC
care O-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
dexmedetomidine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Multicenter O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
propensity O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
matched O-MISC I-CONC-MISC
cohort O-MISC I-CONC-MISC
study O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

SETTING O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Neurocritical O-MISC B-PHYS-MISC
care O-MISC I-PHYS-MISC
units O-MISC I-PHYS-MISC
at O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
academic O-MISC B-GENE-MISC
medical O-MISC I-GEOG-MISC
centers O-MISC I-GEOG-MISC
with O-MISC B-ACTI-MISC
dedicated O-MISC B-ACTI-MISC
neurocritical O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
teams O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
board O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
certified O-MISC I-PHEN-MISC
neurointensivists O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

PATIENTS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Neurocritical O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
admitted O-MISC B-CONC-MISC
between O-MISC B-ACTI-MISC
July O-MISC B-CHED-MISC
2009 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
September O-MISC B-CHED-MISC
2012 O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
matched O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
propensity O-MISC B-CHED-MISC
scoring O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
characteristics O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

INTERVENTIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Continuous O-MISC B-CHED-MISC
sedation O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
dexmedetomidine B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

MEASUREMENTS O-MISC B-CHED-MISC
AND O-MISC B-ACTI-MISC
MAIN O-MISC B-ACTI-MISC
RESULTS O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
342 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
105 O-MISC B-ACTI-MISC
dexmedetomidine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
237 O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
190 O-MISC B-ACTI-MISC
matched O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
group O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
propensity O-MISC B-CHED-MISC
score O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
outcome O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
composite O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
severe O-MISC I-ACTI-MISC
hypotension B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
< O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
< O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
beats O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
sedative O-MISC B-CONC-MISC
infusion O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

No O-MISC I-ACTI-MISC
difference O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-ACTI-MISC
composite O-MISC B-CHED-MISC
outcome O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unmatched O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
94 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
matched O-MISC B-CHED-MISC
cohorts O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
separately O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
severe O-MISC I-ACTI-MISC
hypotension B-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unmatched O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
matched O-MISC B-CHED-MISC
cohorts O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Severe O-MISC I-ACTI-MISC
hypotension B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
occur O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
neurocritical O-MISC B-CONC-MISC
care O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
dexmedetomidine B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Providers O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
similarly O-MISC B-ACTI-MISC
consider O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
likelihood O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
before O-MISC B-ACTI-MISC
starting O-MISC B-CHED-MISC
either O-MISC B-ACTI-MISC
sedative O-MISC O-MISC
. O-MISC B-ACTI-MISC

Hydroxytyrosol B-CHED-MISC O-MISC
ameliorates O-MISC B-CHED-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
involved O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
processes O-MISC B-OCCU-MISC
including O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
aging O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
potentiate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
therapeutic O-MISC I-DISO-MISC
effect O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Doxorubicin B-CHED-MISC O-MISC
causes O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
mitochondrial B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Herein O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
whether O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
ameliorated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
antioxidant O-MISC I-GENE-MISC
hydroxytyrosol B-CHED-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Thirty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
bearing O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
tumors I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
chemically O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
hydroxytyrosol B-CHED-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
5days O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
plus O-MISC B-CHED-MISC
hydroxytyrosol B-CHED-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Cardiac B-DISO-MISC I-ACTI-MISC
disturbances I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cellular O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
mitochondrial O-MISC I-GENE-MISC
level O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
mitochondrial O-MISC I-GENE-MISC
electron O-MISC B-DISO-MISC
transport O-MISC B-DISO-MISC
chain O-MISC B-DISO-MISC
complexes O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
IV O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
apoptosis O-MISC O-MISC
- O-MISC B-DISO-MISC
inducing O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
markers O-MISC I-DISO-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Hydroxytyrosol B-CHED-MISC O-MISC
improved O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
disturbances I-DISO-MISC B-CHED-MISC
enhanced O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
by O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
reducing O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
percentage O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
mitochondria O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
oxidative O-MISC B-CHED-MISC
damage O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
hydroxytyrosol B-CHED-MISC I-GENE-MISC
improve O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
mitochondrial O-MISC I-GENE-MISC
electron O-MISC I-DISO-MISC
transport O-MISC I-LIVB-MISC
chain O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
demonstrates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
hydroxytyrosol B-CHED-MISC I-GENE-MISC
protect O-MISC I-ACTI-MISC
rat O-MISC I-ANAT-MISC
heart B-DISO-MISC I-GENE-MISC
damage I-DISO-MISC I-ACTI-MISC
provoked O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
decreasing O-MISC I-ACTI-MISC
oxidative O-MISC B-CHED-MISC
damage O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
mitochondrial O-MISC I-ACTI-MISC
alterations O-MISC B-UnknownType-MISC
. O-MISC B-ACTI-MISC

Amiodarone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
myxoedema B-DISO-MISC I-ACTI-MISC
coma I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC I-ANAT-MISC
man O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
hypothermia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
respiratory B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Thyroid O-MISC O-MISC
- O-MISC B-DISO-MISC
stimulating O-MISC B-DISO-MISC
hormone O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
168 O-MISC B-ACTI-MISC
uIU O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
nl O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
uIU O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
free O-MISC O-MISC
thyroxine B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
FT4 O-MISC O-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
nl O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
fluids O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
vasopressor O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
stress O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
steroids B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
intubated O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intensive O-MISC B-GENE-MISC
care O-MISC I-GEOG-MISC
unit O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
ug O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
levothyroxine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
ug O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
daily O-MISC B-CHED-MISC
thereafter O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Haemodynamic O-MISC I-DISO-MISC
improvement O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
along O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
complete O-MISC B-CHED-MISC
recovery O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
mental O-MISC I-ACTI-MISC
status O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Twelve O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
FT4 O-MISC O-MISC
was O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
96 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
maintained O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
levothyroxine B-CHED-MISC O-MISC
175 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
POorally O-MISC O-MISC
daily O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
thyroid O-MISC B-CONC-MISC
ultrasound O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
diffuse O-MISC B-CHED-MISC
heterogeneity O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hour O-MISC B-CHED-MISC
excretion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
iodine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
3657 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
mcg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
756 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
mcg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myxoedema B-DISO-MISC I-ACTI-MISC
coma I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
report O-MISC B-ACTI-MISC
patient O-MISC I-ACTI-MISC
death O-MISC B-ANAT-MISC
despite O-MISC B-ACTI-MISC
supportive O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
thyroid O-MISC B-CONC-MISC
hormone O-MISC I-CONC-MISC
replacement O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
represents O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
thoroughly O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amiodarone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myxoedema B-DISO-MISC I-ACTI-MISC
coma I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
subclinical O-MISC I-ACTI-MISC
thyroid B-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
catheter O-MISC B-OBJC-MISC
- O-MISC B-ACTI-MISC
directed O-MISC B-ACTI-MISC
thrombolysis B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
alteplase O-MISC O-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
oncology O-MISC I-ANAT-MISC
patient O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
heparin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
thrombocytopenia B-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
oncology O-MISC I-ANAT-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
heparin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
thrombocytopenia B-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
HITT B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
argatroban B-CHED-MISC B-CONC-MISC
plus O-MISC I-CONC-MISC
catheter O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
directed O-MISC I-CONC-MISC
thrombolysis B-DISO-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
CDT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
alteplase O-MISC O-MISC
is O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

SUMMARY O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
63 O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
year O-MISC I-PHEN-MISC
- O-MISC I-PHEN-MISC
old O-MISC I-PHEN-MISC
Caucasian O-MISC I-ANAT-MISC
man O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
renal O-MISC I-ACTI-MISC
amyloidosis B-DISO-MISC B-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
peripheral O-MISC B-CONC-MISC
blood O-MISC I-CONC-MISC
stem O-MISC I-CONC-MISC
cell O-MISC I-CONC-MISC
collection O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autologous O-MISC B-CONC-MISC
stem O-MISC I-CONC-MISC
cell O-MISC I-CONC-MISC
transplant O-MISC I-CONC-MISC
developed O-MISC B-ACTI-MISC
extensive O-MISC B-CHED-MISC
bilateral O-MISC B-CHED-MISC
upper B-DISO-MISC I-GENE-MISC
- I-DISO-MISC B-GEOG-MISC
extremity I-DISO-MISC B-GEOG-MISC
deep I-DISO-MISC I-ACTI-MISC
venous I-DISO-MISC B-ANAT-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DVT B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-DISO-MISC
embolism I-DISO-MISC I-LIVB-MISC
secondary O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
heparin B-CHED-MISC O-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
managed O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
general O-MISC B-CONC-MISC
medical O-MISC I-CONC-MISC
floor O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
one O-MISC B-CHED-MISC
week O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
transferred O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intensive O-MISC B-GENE-MISC
care O-MISC I-GEOG-MISC
unit O-MISC I-GEOG-MISC
with O-MISC B-ACTI-MISC
cardiopulmonary O-MISC I-GENE-MISC
compromise O-MISC I-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
superior B-DISO-MISC I-ACTI-MISC
vena I-DISO-MISC B-ANAT-MISC
cava I-DISO-MISC B-ANAT-MISC
( I-DISO-MISC B-ANAT-MISC
SVC I-DISO-MISC B-ANAT-MISC
) I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
percutaneous O-MISC B-CONC-MISC
mechanical O-MISC I-CONC-MISC
thrombectomy O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
CDT O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
alteplase O-MISC O-MISC
were O-MISC B-ACTI-MISC
attempted O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
procedure O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
aborted O-MISC B-CHED-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
epistaxis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
epistaxis B-DISO-MISC I-ACTI-MISC
resolved O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
next O-MISC B-CHED-MISC
day O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
restarted O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
percutaneous O-MISC B-CONC-MISC
mechanical O-MISC I-CONC-MISC
thrombectomy O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
revascularization O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SVC O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
veins O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Postthrombectomy O-MISC B-CONC-MISC
continuous O-MISC B-ACTI-MISC
CDT O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
alteplase O-MISC O-MISC
was O-MISC B-ACTI-MISC
commenced O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
withheld O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
patency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SVC O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
veins O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
achieved O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Alteplase O-MISC O-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
reinitiated O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
argatroban B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
ultimately O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
transitioned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
anticoagulation O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
recovered O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
experienced O-MISC B-ACTI-MISC
permanent O-MISC B-CHED-MISC
vision B-DISO-MISC I-DISO-MISC
and I-DISO-MISC B-ACTI-MISC
hearing I-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
end B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
stage I-DISO-MISC B-ANAT-MISC
renal I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
63 O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
year O-MISC I-PHEN-MISC
- O-MISC I-PHEN-MISC
old O-MISC I-PHEN-MISC
man O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
renal O-MISC I-ACTI-MISC
amyloidosis B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
SVC B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
secondary O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
HITT B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
successfully O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
argatroban B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
CDT O-MISC O-MISC
with O-MISC B-ACTI-MISC
alteplase O-MISC O-MISC
. O-MISC B-ACTI-MISC

Effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dehydroepiandrosterone B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
models O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
examine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
dehydroepiandrosterone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DHEA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
models O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Seventy O-MISC B-ACTI-MISC
Swiss O-MISC I-ANAT-MISC
albino O-MISC I-PHEN-MISC
female O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
free O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
DHEA B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
DHEA B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
intraperitoneally O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
ip O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Amphetamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
ip O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyper B-DISO-MISC I-DISO-MISC
locomotion O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
subcutaneously O-MISC I-ACTI-MISC
[ O-MISC B-ACTI-MISC
sc O-MISC B-CHED-MISC
] O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
climbing O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
sc O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
catalepsy B-DISO-MISC B-CONC-MISC
tests O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
models O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Animal O-MISC B-GENE-MISC
Experiment O-MISC I-GEOG-MISC
Laboratories O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
Department O-MISC B-PHYS-MISC
of O-MISC I-PHYS-MISC
Pharmacology O-MISC I-PHYS-MISC
, O-MISC B-ACTI-MISC
Medical O-MISC B-GENE-MISC
School O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
Eskisehir O-MISC B-GENE-MISC
Osmangazi O-MISC I-GEOG-MISC
University O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
Eskisehir O-MISC B-PHEN-MISC
, O-MISC B-ACTI-MISC
Turkey O-MISC B-ORGA-MISC
between O-MISC B-ACTI-MISC
March O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
May O-MISC B-ACTI-MISC
2012 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Statistical O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
Kruskal O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
Wallis O-MISC I-CHED-MISC
test O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
hyper B-DISO-MISC B-CHED-MISC
locomotion O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
way O-MISC I-CHED-MISC
ANOVA O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
climbing O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC B-CONC-MISC
tests O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
locomotion O-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
movements O-MISC I-DISO-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
free O-MISC B-CHED-MISC
group O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
DHEA B-CHED-MISC O-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
all O-MISC B-ACTI-MISC
movements O-MISC I-DISO-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
locomotion O-MISC I-DISO-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
difference O-MISC I-CHED-MISC
between O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
catalepsy B-DISO-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
difference O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
terms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
total O-MISC B-CHED-MISC
climbing O-MISC I-ACTI-MISC
time O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
climbing O-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
DHEA B-CHED-MISC O-MISC
reduced O-MISC B-ACTI-MISC
locomotor O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
climbing O-MISC I-ACTI-MISC
behavior O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
DHEA B-CHED-MISC O-MISC
displays O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
neuroleptic O-MISC O-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
schizophrenia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Availability O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
induced O-MISC I-GENE-MISC
pluripotent O-MISC B-GEOG-MISC
stem O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
- O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
cardiomyocytes O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
assessment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
drug O-MISC O-MISC
potential O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
QT B-DISO-MISC B-CONC-MISC
prolongation I-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Field O-MISC I-DISO-MISC
potential O-MISC I-LIVB-MISC
duration O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
FPD O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
- O-MISC B-GEOG-MISC
induced O-MISC I-GENE-MISC
pluripotent O-MISC B-GEOG-MISC
stem O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
- O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
cardiomyocytes O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
hiPS O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
CMs O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
express O-MISC B-ACTI-MISC
QT O-MISC I-DISO-MISC
interval O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
electrocardiogram O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
tool O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
predict O-MISC B-CHED-MISC
K B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
channel O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
channel O-MISC B-DISO-MISC
blocker O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
QT O-MISC I-DISO-MISC
interval O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
showing O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
technique O-MISC B-CHED-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
predict O-MISC B-ACTI-MISC
multichannel O-MISC B-CHED-MISC
blocker O-MISC I-CHED-MISC
potential O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
QT B-DISO-MISC I-DISO-MISC
prolongation I-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
FPD O-MISC B-OCCU-MISC
from O-MISC B-ACTI-MISC
MEA O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
Multielectrode O-MISC B-OBJC-MISC
array O-MISC I-OBJC-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hiPS O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
CMs O-MISC B-GEOG-MISC
can O-MISC B-ACTI-MISC
detect O-MISC I-ACTI-MISC
QT B-DISO-MISC I-DISO-MISC
prolongation I-DISO-MISC I-LIVB-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
multichannel O-MISC B-OBJC-MISC
blockers O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

hiPS O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
CMs O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
seeded O-MISC B-CONC-MISC
onto O-MISC B-ACTI-MISC
MEA O-MISC O-MISC
and O-MISC B-ACTI-MISC
FPD O-MISC B-OCCU-MISC
was O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
2min O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
10min O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
30min O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vehicle O-MISC O-MISC
and O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
drug O-MISC O-MISC
concentration O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

IKr O-MISC O-MISC
and O-MISC B-ACTI-MISC
IKs O-MISC O-MISC
blockers O-MISC O-MISC
concentration O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependently O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
corrected O-MISC B-CHED-MISC
FPD O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
FPDc O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
channel O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
concentration O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependently O-MISC B-ACTI-MISC
shortened O-MISC B-CHED-MISC
FPDc O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Also O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
multichannel O-MISC O-MISC
blockers O-MISC B-DISO-MISC
Amiodarone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
Paroxetine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
Terfenadine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
Citalopram B-CHED-MISC O-MISC
prolonged O-MISC B-CHED-MISC
FPDc O-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
dependent O-MISC B-CHED-MISC
manner O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Finally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
IKr O-MISC O-MISC
blockers O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
Terfenadine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
Citalopram B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
Torsade B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
Pointes I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
TdP B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
practice O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
afterdepolarization O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
EAD O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

hiPS O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
CMs O-MISC B-GEOG-MISC
using O-MISC B-ACTI-MISC
MEA O-MISC B-OBJC-MISC
system O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
FPDc O-MISC B-OCCU-MISC
can O-MISC B-ACTI-MISC
predict O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
drug O-MISC O-MISC
candidates O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
QT O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
shows O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
assay O-MISC B-CONC-MISC
can O-MISC B-ACTI-MISC
help O-MISC B-ACTI-MISC
detect O-MISC I-ACTI-MISC
EAD O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
with O-MISC B-ACTI-MISC
TdP B-DISO-MISC O-MISC
potential O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Dermal O-MISC B-CHED-MISC
developmental O-MISC B-CHED-MISC
toxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
N O-MISC O-MISC
- O-MISC B-DISO-MISC
phenylimide O-MISC B-DISO-MISC
herbicides O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
53482 I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
23121 I-CHED-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
N O-MISC O-MISC
- O-MISC B-DISO-MISC
phenylimide O-MISC B-DISO-MISC
herbicides O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
embryolethality B-DISO-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
teratogenicity B-DISO-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
mainly O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
septal I-DISO-MISC B-ANAT-MISC
defects I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
wavy O-MISC I-GENE-MISC
ribs O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
growth B-DISO-MISC I-ACTI-MISC
retardation I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
conventional O-MISC B-ACTI-MISC
oral O-MISC I-GENE-MISC
developmental O-MISC B-CONC-MISC
toxicity B-DISO-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
objective O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
whether O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
compounds O-MISC O-MISC
induce O-MISC B-CHED-MISC
developmental O-MISC I-ACTI-MISC
toxicity B-DISO-MISC B-ANAT-MISC
via O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dermal O-MISC I-GENE-MISC
route O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
relevant O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
occupational O-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
hence O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
addressing O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
health O-MISC B-CHED-MISC
risks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
53482 I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
dermally O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
organogenesis O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
23121 I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
800 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maximum O-MISC B-ACTI-MISC
applicable O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
level O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Fetuses O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Cesarean O-MISC B-CONC-MISC
section O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
external O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
visceral O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
skeletal O-MISC I-GENE-MISC
alterations O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Dermal O-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
53482 I-CHED-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
patterns O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
developmental O-MISC B-CHED-MISC
toxicity B-DISO-MISC I-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
oral O-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Toxicity B-DISO-MISC I-ACTI-MISC
included O-MISC B-ACTI-MISC
embryolethality B-DISO-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
teratogenicity B-DISO-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
growth B-DISO-MISC I-ACTI-MISC
retardation I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Dermal O-MISC B-PHEN-MISC
administration O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
23121 I-CHED-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
800 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
embryonic B-DISO-MISC I-ACTI-MISC
death I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
septal I-DISO-MISC B-ANAT-MISC
defect I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
retarded O-MISC B-CHED-MISC
fetal O-MISC I-DISO-MISC
growth O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
23121 I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
S B-CHED-MISC B-LIVB-MISC
- I-CHED-MISC I-PROC-MISC
53482 I-CHED-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
S B-CHED-MISC B-LIVB-MISC
- I-CHED-MISC I-PROC-MISC
23121 I-CHED-MISC I-PROC-MISC
were O-MISC B-ACTI-MISC
teratogenic B-DISO-MISC I-DISO-MISC
when O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
dermally O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
pregnant O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
as O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
compounds O-MISC O-MISC
administered O-MISC B-CONC-MISC
orally O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
investigation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
relevancy O-MISC B-CHED-MISC
become O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Rates O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Renal B-DISO-MISC I-ACTI-MISC
Toxicity I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Cancer B-DISO-MISC I-ACTI-MISC
Patients O-MISC I-ANAT-MISC
Receiving O-MISC B-ACTI-MISC
Cisplatin B-CHED-MISC O-MISC
With O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
Without O-MISC B-CHED-MISC
Mannitol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Cisplatin B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
antineoplastic O-MISC O-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
limiting O-MISC I-CHED-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
strategies O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-CONC-MISC
this O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mannitol B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nephroprotectant O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
hydration O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
rates O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
agent O-MISC B-DISO-MISC
cisplatin B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
mannitol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
center O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
quasi O-MISC B-ACTI-MISC
experiment O-MISC B-ACTI-MISC
created O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
national O-MISC B-CHED-MISC
mannitol B-CHED-MISC O-MISC
shortage O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Data O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
collected O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
cancer B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
single O-MISC O-MISC
- O-MISC B-DISO-MISC
agent O-MISC B-DISO-MISC
cisplatin B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
outpatient O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
January O-MISC B-ACTI-MISC
2011 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
September O-MISC B-ACTI-MISC
2012 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
outcome O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
kidney I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AKI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
143 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
single O-MISC O-MISC
- O-MISC B-DISO-MISC
agent O-MISC B-DISO-MISC
cisplatin B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
97 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
head B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ANAT-MISC
neck I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
malignancy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
mannitol B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
[ O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
] O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
646 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
008 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
944 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
048 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
also O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
likelihood O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
494 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
149 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
258 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
OR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
219 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
228 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
439 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
017 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
When O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
quantities O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
mannitol B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
preferentially O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
high O-MISC I-ACTI-MISC
risk O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
schedule O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
every O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
greatest O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
would O-MISC B-ACTI-MISC
benefit O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mannitol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Metformin B-CHED-MISC O-MISC
protects O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
learning B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
memory I-DISO-MISC I-ACTI-MISC
impairments I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
oxidative O-MISC B-CHED-MISC
damage O-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pentylenetetrazole B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
kindling O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
comorbidity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
greatly O-MISC B-ACTI-MISC
diminishes O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
quality O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
life O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
therapeutic O-MISC B-CONC-MISC
interventions O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
untoward O-MISC I-ACTI-MISC
cognitive O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
urgent O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
kinds O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
agents O-MISC O-MISC
targeting O-MISC B-CHED-MISC
both O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
cognition B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
play O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-CHED-MISC
role O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
epileptogenesis O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
antioxidants O-MISC O-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
putative O-MISC B-ACTI-MISC
antiepileptic O-MISC O-MISC
potential O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Metformin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
commonly O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
antidiabetic O-MISC O-MISC
oral O-MISC B-DISO-MISC
drug O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
antioxidant O-MISC I-DISO-MISC
properties O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
designed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
ameliorative O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
metformin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
markers O-MISC I-DISO-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
pentylenetetrazole B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
kindling O-MISC I-ANAT-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Male O-MISC I-DISO-MISC
C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
subconvulsive O-MISC I-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pentylenetetrazole B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
injections O-MISC O-MISC
. O-MISC B-ACTI-MISC

Metformin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
intraperitoneally O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
200mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
along O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
alternate O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
day O-MISC I-CHED-MISC
PTZ B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
suppressed O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
kindling O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
ameliorated O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
brain O-MISC I-GENE-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
agent O-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
protective O-MISC B-ACTI-MISC
medicine O-MISC O-MISC
against O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

P53 O-MISC O-MISC
inhibition O-MISC I-DISO-MISC
exacerbates O-MISC B-ACTI-MISC
late O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
stage O-MISC B-ACTI-MISC
anthracycline B-CHED-MISC O-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

AIMS O-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
Doxorubicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
cancer B-DISO-MISC B-DISO-MISC
therapeutic O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
both O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
late O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
stage O-MISC I-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Children O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
heart B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
impact O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
p53 O-MISC O-MISC
inhibition O-MISC B-DEVI-MISC
on O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
late O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
stage O-MISC I-CHED-MISC
DOX B-CHED-MISC O-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
juvenile O-MISC B-CHED-MISC
model O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Two O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
MHC O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
CB7 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
express O-MISC B-ACTI-MISC
dominant O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
interfering O-MISC B-ACTI-MISC
p53 O-MISC O-MISC
in O-MISC B-ACTI-MISC
cardiomyocytes O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
transgenic O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
NON O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
TXG O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
littermates O-MISC B-GENE-MISC
received O-MISC B-ACTI-MISC
weekly O-MISC B-CHED-MISC
DOX B-CHED-MISC O-MISC
injections O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
stage O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
MHC O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
CB7 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
exhibited O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
cardiac O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
levels O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
apoptosis O-MISC I-DISO-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
NON O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
TXG O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Surprisingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
late O-MISC B-CHED-MISC
stage O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
MHC O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
CB7 O-MISC I-PROC-MISC
exhibited O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
progressive O-MISC B-ACTI-MISC
decrease O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
rates O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
apoptosis O-MISC I-DISO-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
NON O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
TXG O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

p53 O-MISC O-MISC
inhibition O-MISC B-DEVI-MISC
blocked O-MISC B-CHED-MISC
transient O-MISC B-CHED-MISC
DOX B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
STAT3 O-MISC O-MISC
activation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
MHC O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
CB7 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
enhanced O-MISC B-ACTI-MISC
induction O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DNA O-MISC I-DISO-MISC
repair O-MISC I-LIVB-MISC
proteins O-MISC O-MISC
Ku70 O-MISC O-MISC
and O-MISC B-ACTI-MISC
Ku80 O-MISC O-MISC
. O-MISC B-ACTI-MISC

Mice O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
restricted O-MISC B-CHED-MISC
deletion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
STAT3 O-MISC B-LIVB-MISC
exhibited O-MISC B-ACTI-MISC
worse O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
apoptosis O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Ku70 O-MISC O-MISC
and O-MISC B-ACTI-MISC
Ku80 O-MISC O-MISC
in O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
DOX B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
stage O-MISC B-CHED-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
support O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
model O-MISC B-CHED-MISC
wherein O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
p53 O-MISC O-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-ACTI-MISC
cardioprotective O-MISC I-DISO-MISC
pathway O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
via O-MISC B-ACTI-MISC
STAT3 O-MISC O-MISC
activation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
mitigates O-MISC B-OCCU-MISC
DOX B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC I-ACTI-MISC
myocardial O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
drug O-MISC B-OBJC-MISC
delivery O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
explanation O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
how O-MISC B-ACTI-MISC
p53 O-MISC O-MISC
inhibition O-MISC B-DEVI-MISC
can O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cardioprotection O-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
paradoxically O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
enhanced O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
long O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cessation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Metronidazole B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
uncommon O-MISC B-CHED-MISC
scenario O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Metronidazole B-CHED-MISC O-MISC
can O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
neurological O-MISC I-ACTI-MISC
complications O-MISC B-ANAT-MISC
although O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
scenario O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
where O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
features O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
metronidazole B-CHED-MISC O-MISC
intake O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
MRI O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
showed O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
signal O-MISC B-OCCU-MISC
intensity O-MISC I-OCCU-MISC
involving O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
dentate O-MISC I-GENE-MISC
nuclei O-MISC I-GENE-MISC
of O-MISC B-GEOG-MISC
cerebellum O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
splenium O-MISC I-GENE-MISC
of O-MISC B-GEOG-MISC
corpus O-MISC B-GEOG-MISC
callosum O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
metronidazole B-CHED-MISC O-MISC
toxicity B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
made O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MRI O-MISC B-CONC-MISC
findings O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
supported O-MISC B-ACTI-MISC
clinically O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Aconitine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
Ca2 B-CHED-MISC O-MISC
+ O-MISC B-DISO-MISC
overload O-MISC B-ANAT-MISC
causes O-MISC B-ACTI-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
triggers O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
through O-MISC B-ACTI-MISC
p38 O-MISC O-MISC
MAPK O-MISC B-DISO-MISC
signaling O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Aconitine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
bioactive O-MISC B-GENE-MISC
diterpenoid O-MISC I-GEOG-MISC
alkaloid O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
content O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
herbal O-MISC I-ANAT-MISC
aconitum O-MISC I-PHEN-MISC
plants O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Emerging O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
indicates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
voltage O-MISC I-DISO-MISC
- O-MISC B-DISO-MISC
dependent O-MISC B-DISO-MISC
Na B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
have O-MISC B-ACTI-MISC
pivotal O-MISC B-ACTI-MISC
roles O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
aconitine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
reports O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
aconitine B-CHED-MISC O-MISC
poisoning B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
explored O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
importance O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
Ca B-CHED-MISC I-DISO-MISC
( O-MISC I-LIVB-MISC
2 O-MISC I-LIVB-MISC
+ O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
signaling O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
aconitine B-CHED-MISC O-MISC
poisoning B-DISO-MISC I-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
overload O-MISC I-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
accelerated O-MISC B-CHED-MISC
beating O-MISC I-ACTI-MISC
rhythm O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
adult O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
ventricular O-MISC I-GENE-MISC
myocytes O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
caused O-MISC B-CHED-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
conscious O-MISC I-DISO-MISC
freely O-MISC B-ACTI-MISC
moving O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
aconitine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
cytotoxicity B-DISO-MISC B-CONC-MISC
assay O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
neonatal O-MISC I-ANAT-MISC
rat O-MISC I-ANAT-MISC
ventricular O-MISC I-GENE-MISC
myocytes O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
NRVMs O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
lactate B-CHED-MISC O-MISC
dehydrogenase O-MISC B-DISO-MISC
level O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
culture O-MISC O-MISC
medium O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
NRVMs O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
activities O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
cardiac O-MISC B-GEOG-MISC
enzymes O-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
aconitine B-CHED-MISC O-MISC
resulted O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
NRVMs O-MISC I-GENE-MISC
viability O-MISC I-DISO-MISC
dose O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependently O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
confirm O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pro O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
apoptotic O-MISC I-CHED-MISC
effects O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
flow O-MISC B-CONC-MISC
cytometric O-MISC I-CONC-MISC
detection O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
histology O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
transmission O-MISC B-CONC-MISC
electron O-MISC I-CONC-MISC
microscopy O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
terminal O-MISC B-CONC-MISC
deoxynucleotidyl O-MISC I-CONC-MISC
transferase O-MISC I-CONC-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
dUTP B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
biotin B-CHED-MISC I-CONC-MISC
nick O-MISC I-CONC-MISC
end O-MISC I-CONC-MISC
labeling O-MISC I-CONC-MISC
assay O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
aconitine B-CHED-MISC O-MISC
stimulated O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
time O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependently O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
expression O-MISC B-CONC-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
handling O-MISC O-MISC
proteins O-MISC O-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
aconitine B-CHED-MISC O-MISC
promoted O-MISC B-DEVI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
overload O-MISC I-ACTI-MISC
through O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
regulation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
handling O-MISC O-MISC
proteins O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
expression O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
apoptosis O-MISC O-MISC
- O-MISC B-DISO-MISC
related O-MISC B-DISO-MISC
proteins O-MISC B-DISO-MISC
revealed O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
pro O-MISC O-MISC
- O-MISC B-DISO-MISC
apoptotic O-MISC B-DISO-MISC
protein O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
upregulated O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
apoptotic O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
BCL O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
expression O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
downregulated O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
phosphorylation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
MAPK O-MISC O-MISC
family O-MISC B-DISO-MISC
members O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
P O-MISC O-MISC
- O-MISC B-DISO-MISC
P38 O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
P38 O-MISC O-MISC
ratio O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
tissues O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Hence O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
aconitine B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
aggravates O-MISC B-ACTI-MISC
Ca B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
overload O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
causes O-MISC B-ACTI-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
finally O-MISC B-ACTI-MISC
promotes O-MISC B-ACTI-MISC
apoptotic O-MISC I-DISO-MISC
development O-MISC I-LIVB-MISC
via O-MISC B-ACTI-MISC
phosphorylation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
P38 O-MISC O-MISC
mitogen O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
activated O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
kinase O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
suppresses O-MISC B-CHED-MISC
toll O-MISC O-MISC
- O-MISC B-DISO-MISC
like O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
4 O-MISC B-DISO-MISC
signaling O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
attenuates O-MISC B-DEVI-MISC
left B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC B-CHED-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
protective O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
in O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
suppression O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
inflammatory O-MISC I-ACTI-MISC
responses O-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
activation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
AMP B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
activated O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
kinase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
AMPK O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
toll O-MISC O-MISC
- O-MISC B-DISO-MISC
like O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
4 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TLR4 O-MISC O-MISC
) O-MISC B-ACTI-MISC
activities O-MISC B-DEVI-MISC
following O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
relation O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
AMPK O-MISC O-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Male O-MISC B-CHED-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
assigned O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
normal O-MISC I-ANAT-MISC
control O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
isoproterenol B-CHED-MISC O-MISC
after O-MISC B-ACTI-MISC
chronic O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
100mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
twice O-MISC B-CHED-MISC
daily O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
100mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
injected O-MISC B-CONC-MISC
subcutaneously O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
13th O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
14th O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
acute B-DISO-MISC I-ACTI-MISC
myocardial I-DISO-MISC B-ANAT-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Isoproterenol B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
systolic O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
myocardial O-MISC I-DISO-MISC
contractility O-MISC I-LIVB-MISC
indexed O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
LVdp O-MISC B-OCCU-MISC
/ O-MISC B-ACTI-MISC
dtmax O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
LVdp O-MISC B-CONC-MISC
/ O-MISC B-ACTI-MISC
dtmin O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
left B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
lower O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
25 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Metfromin O-MISC O-MISC
markedly O-MISC B-ACTI-MISC
lowered O-MISC B-CHED-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
elevation O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
TLR4 O-MISC B-LIVB-MISC
mRNA O-MISC O-MISC
, O-MISC B-ACTI-MISC
myeloid O-MISC O-MISC
differentiation O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
88 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MyD88 O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
tumor B-DISO-MISC O-MISC
necrosis B-DISO-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
alpha O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TNF O-MISC O-MISC
- O-MISC B-DISO-MISC
a O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
interleukin O-MISC O-MISC
6 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
IL O-MISC O-MISC
- O-MISC B-DISO-MISC
6 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
tissues O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Similar O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
levels O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
TNF O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
a O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
IL O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
6 O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
100mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Phosphorylated O-MISC O-MISC
AMPKa O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
p O-MISC O-MISC
- O-MISC B-DISO-MISC
AMPK O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardium O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
25mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
slightly O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
50mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
100mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC B-CHED-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
treatment O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
metformin B-CHED-MISC O-MISC
reduces O-MISC B-CHED-MISC
post O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
myocardial B-DISO-MISC B-ANAT-MISC
infarction I-DISO-MISC B-ANAT-MISC
cardiac O-MISC I-ACTI-MISC
dysfunction O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
suppresses O-MISC B-CHED-MISC
inflammatory O-MISC I-ACTI-MISC
responses O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
TLR4 O-MISC O-MISC
activities O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
target O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
protect O-MISC I-ACTI-MISC
infarcted O-MISC I-ACTI-MISC
myocardium O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Unusual O-MISC I-ACTI-MISC
complications O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
antithyroid O-MISC B-CONC-MISC
drug O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
reports O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
literature O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
propylthiouracil B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
hepatitis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
methimazole B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
hepatocellular B-DISO-MISC I-ACTI-MISC
necrosis I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
propylthiouracil B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
lupus B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
like I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
antithyroid O-MISC O-MISC
drug O-MISC B-DISO-MISC
side O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
reviewed O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
thyroidectomy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
radioiodine O-MISC O-MISC
compared O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
antithyroid O-MISC O-MISC
drugs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
circumstances O-MISC B-CHED-MISC
131I O-MISC O-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
choice O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
hyperthyroidism B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
tetrabenazine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
tiapride B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Huntington B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
terminal O-MISC B-CHED-MISC
stage O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
recurrent O-MISC I-ACTI-MISC
breast B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
herein O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initiation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
tiapride B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
tetrabenazine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
Huntington B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
tiapride B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
tetrabenazine B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
advanced O-MISC I-ACTI-MISC
breast B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
when O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
tetrabenazine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
tiapride B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Tetrabenazine B-CHED-MISC O-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
very O-MISC B-ACTI-MISC
carefully O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
neuroleptic B-CHED-MISC O-MISC
drugs I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
worsening O-MISC I-ACTI-MISC
general O-MISC I-ACTI-MISC
condition O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
metoprolol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
terbinafine B-CHED-MISC O-MISC
combination O-MISC B-CHED-MISC
induced O-MISC B-CHED-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sinus B-DISO-MISC I-ACTI-MISC
bradycardia I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
metoprolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
terbinafine B-CHED-MISC O-MISC
drug O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
drug O-MISC I-LIVB-MISC
interaction O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
63 O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
Caucasian O-MISC I-ANAT-MISC
man O-MISC I-DISO-MISC
on O-MISC B-ACTI-MISC
metoprolol B-CHED-MISC O-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
stable O-MISC B-CHED-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
a O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
course O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
oral O-MISC O-MISC
terbinafine B-CHED-MISC B-DISO-MISC
250 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
onychomycosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
49th O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
terbinafine B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
brought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emergency O-MISC B-GENE-MISC
room O-MISC I-GEOG-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
global O-MISC B-CHED-MISC
health O-MISC I-CHED-MISC
status O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
confusion B-DISO-MISC I-ACTI-MISC
and O-MISC B-ANAT-MISC
falls O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
electrocardiogram O-MISC B-CONC-MISC
revealed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
beats O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
sinus B-DISO-MISC I-ACTI-MISC
bradycardia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
score O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Naranjo O-MISC B-CHED-MISC
adverse B-DISO-MISC I-CHED-MISC
drug I-DISO-MISC I-CHED-MISC
reaction I-DISO-MISC I-CHED-MISC
probability O-MISC B-CHED-MISC
scale O-MISC I-CHED-MISC
indicates O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
probable O-MISC I-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
sinus B-DISO-MISC I-ACTI-MISC
bradycardia I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC I-DISO-MISC
interaction O-MISC I-LIVB-MISC
between O-MISC B-ACTI-MISC
metoprolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
terbinafine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
ameliorated O-MISC I-ACTI-MISC
first O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
metoprolol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
subsequently O-MISC B-ACTI-MISC
changed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
bisoprolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
remained O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
inhibiting O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
cytochrome O-MISC O-MISC
P450 O-MISC B-DISO-MISC
2D6 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
terbinafine B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
metoprolol B-CHED-MISC O-MISC
' O-MISC B-DISO-MISC
s O-MISC B-DISO-MISC
clearance O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
metoprolol B-CHED-MISC O-MISC
accumulation O-MISC I-ACTI-MISC
which O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
clinically O-MISC B-ACTI-MISC
significant O-MISC B-ANAT-MISC
sinus B-DISO-MISC I-ACTI-MISC
bradycardia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Optochiasmatic O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
ethambutol B-CHED-MISC O-MISC
overtreatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Ethambutol B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
optic B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
rarely O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
axonal O-MISC I-ACTI-MISC
polyneuropathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
characterize O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
neurophysiological O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
neuroimaging O-MISC B-CONC-MISC
findings O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
72 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
paresthesias B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
supratherapeutic O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
ethambutol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
demonstrates O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
vulnerability O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anterior O-MISC I-GENE-MISC
visual O-MISC B-GEOG-MISC
pathways O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
peripheral O-MISC I-GENE-MISC
nerves O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
ethambutol B-CHED-MISC O-MISC
toxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Testosterone B-CHED-MISC O-MISC
ameliorates O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

AIM O-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
testosterone B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Adult O-MISC I-DISO-MISC
male O-MISC I-LIVB-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
intracerebroventricularly O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
icv O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
infused O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
750 O-MISC B-ACTI-MISC
ug O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
task O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Castration O-MISC B-CONC-MISC
surgery O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
task O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
operation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Testosterone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
sc O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
androgen B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
flutamide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ip O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
estrogen B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
tamoxifen B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ip O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
aromatase O-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
letrozole B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
ip O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
castration O-MISC B-CONC-MISC
markedly O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
both O-MISC B-ACTI-MISC
STL1 O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
short O-MISC I-DISO-MISC
memory O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
STL2 O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
long O-MISC I-DISO-MISC
memory O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
tests O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Testosterone B-CHED-MISC O-MISC
replacement O-MISC I-CONC-MISC
almost O-MISC B-ACTI-MISC
restored O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
STL1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
STL2 O-MISC O-MISC
in O-MISC B-ACTI-MISC
castrated O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
STL1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
STL2 O-MISC O-MISC
in O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
flutamide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
letrozole B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
tamoxifen B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
impaired B-DISO-MISC B-CHED-MISC
the I-DISO-MISC B-ACTI-MISC
memory I-DISO-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
testosterone B-CHED-MISC O-MISC
replacement O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
improving O-MISC B-CHED-MISC
STZ B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
castration O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Testosterone B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
ameliorates O-MISC B-ACTI-MISC
STZ B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
castration O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
memory B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Behavioral O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
neurochemical O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
pretreated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
garcinielliptone B-CHED-MISC O-MISC
FC I-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Garcinielliptone B-CHED-MISC O-MISC
FC I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GFC B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
isolated O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
hexanic O-MISC O-MISC
fraction O-MISC B-DISO-MISC
seed O-MISC B-DISO-MISC
extract O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
species O-MISC B-CHED-MISC
Platonia O-MISC I-ANAT-MISC
insignis O-MISC I-PHEN-MISC
Mart O-MISC I-PHEN-MISC
. O-MISC I-PHEN-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
folk O-MISC B-PROC-MISC
medicine O-MISC I-UnknownType-MISC
to O-MISC B-ACTI-MISC
treat O-MISC B-CONC-MISC
skin B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
seed O-MISC I-ACTI-MISC
decoction O-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
treat O-MISC B-CONC-MISC
diarrheas B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
inflammatory B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
research O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
GFC B-CHED-MISC I-GENE-MISC
effects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
rodents O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
GFC B-CHED-MISC O-MISC
effects O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
parameters O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
amino B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
r B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminobutyric I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
glutamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
aspartate B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
glutathione B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
acetylcholinesterase O-MISC I-DISO-MISC
( O-MISC I-LIVB-MISC
AChE O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
hippocampus O-MISC I-GENE-MISC
after O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

GFC B-CHED-MISC O-MISC
produced O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
latency O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
25mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
50mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
99 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
seized O-MISC I-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
content O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
hippocampus O-MISC I-GENE-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
GFC75 O-MISC O-MISC
plus O-MISC B-DISO-MISC
P400 O-MISC O-MISC
showed O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
seized O-MISC I-DISO-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
aspartate B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
glutamine B-CHED-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
glutamate B-CHED-MISC B-CONC-MISC
levels O-MISC I-CONC-MISC
detected O-MISC I-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
hippocampus O-MISC I-GENE-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
GFC75 O-MISC O-MISC
plus O-MISC B-DISO-MISC
P400 O-MISC B-DISO-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
seized O-MISC I-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Hippocampus O-MISC I-GENE-MISC
mice O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
GFC75 O-MISC O-MISC
plus O-MISC B-ACTI-MISC
P400 O-MISC O-MISC
showed O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
AChE O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
63 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
seized O-MISC B-DEVI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
GFC B-CHED-MISC O-MISC
can O-MISC B-ACTI-MISC
exert O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
installation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
latency O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
GFC B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
epileptogenesis O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
promote O-MISC B-DEVI-MISC
anticonvulsant O-MISC I-DISO-MISC
actions O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
model O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
modulating O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
glutamate B-CHED-MISC O-MISC
contents O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
AChE O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
seized O-MISC I-ANAT-MISC
mice O-MISC I-ANAT-MISC
hippocampus O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
compound O-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
neuronal O-MISC I-DISO-MISC
protection O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
anticonvulsant O-MISC O-MISC
agent O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Standard O-MISC B-CHED-MISC
operating O-MISC I-CHED-MISC
procedures O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
antibiotic O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
kidney I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
non O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
interventional O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
observational O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

INTRODUCTION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Acute B-DISO-MISC I-ACTI-MISC
kidney I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AKI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
occurs O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hospitalized O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
66 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Intensive O-MISC B-GENE-MISC
Care O-MISC I-GEOG-MISC
Unit O-MISC I-GEOG-MISC
( O-MISC B-ACTI-MISC
ICU O-MISC B-GENE-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
increases O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
hospital O-MISC B-GENE-MISC
length O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
stay O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
costs O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
association O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
adherence O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
guidelines O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
standard O-MISC B-CHED-MISC
operating O-MISC I-CHED-MISC
procedures O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
SOP O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
potentially O-MISC B-CHED-MISC
nephrotoxic B-DISO-MISC B-CHED-MISC
antibiotics O-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
AKI B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prospective O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
non O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
interventional O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
observational O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Data O-MISC B-CONC-MISC
collection O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
170 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
ICUs O-MISC B-GENE-MISC
at O-MISC B-ACTI-MISC
Charite O-MISC B-PHYS-MISC
- O-MISC I-PHYS-MISC
Universitaetsmedizin O-MISC I-PHYS-MISC
Berlin O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
675 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
163 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
vancomycin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
tobramycin B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ICU O-MISC B-GENE-MISC
for O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
adherence O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
SOP O-MISC O-MISC
> O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC I-ANAT-MISC
adherence O-MISC I-PHEN-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
HAG O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
adherence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
low O-MISC I-ANAT-MISC
adherence O-MISC I-PHEN-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
LAG O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

AKI B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
RIFLE O-MISC B-CONC-MISC
criteria O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Adherence O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
SOPs O-MISC O-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
expert O-MISC I-CONC-MISC
audit O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
AKI B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
exact O-MISC B-ACTI-MISC
Chi2 O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
test O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
multivariate O-MISC B-PHEN-MISC
logistic O-MISC B-UnknownType-MISC
regression O-MISC B-UnknownType-MISC
analysis O-MISC B-UnknownType-MISC
( O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
sided O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
LAG O-MISC I-ACTI-MISC
consisted O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
88 O-MISC B-ACTI-MISC
HAG O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

AKI B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-DEVI-MISC
significantly O-MISC B-CHED-MISC
more O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
LAG O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
HAG O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
035 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Basic O-MISC B-CHED-MISC
characteristics O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
comparable O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
except O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
soft O-MISC I-ACTI-MISC
tissue O-MISC B-ANAT-MISC
infections B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
LAG O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Multivariate O-MISC B-CHED-MISC
analysis O-MISC I-CHED-MISC
revealed O-MISC B-CHED-MISC
an O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
LAG O-MISC O-MISC
to O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
AKI B-DISO-MISC I-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
HAG O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
195 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
124 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
039 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Low O-MISC B-CHED-MISC
adherence O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
SOPs O-MISC O-MISC
for O-MISC B-ACTI-MISC
potentially O-MISC B-CHED-MISC
nephrotoxic B-DISO-MISC B-CHED-MISC
antibiotics O-MISC O-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
AKI B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

TRIAL O-MISC B-ACTI-MISC
REGISTRATION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Current O-MISC B-CONC-MISC
Controlled O-MISC I-CONC-MISC
Trials O-MISC I-CONC-MISC
ISRCTN54598675 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Registered O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
August O-MISC B-ACTI-MISC
2007 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Rhabdomyolysis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ANAT-MISC
C I-DISO-MISC I-PHEN-MISC
virus I-DISO-MISC I-PHEN-MISC
infected I-DISO-MISC I-ACTI-MISC
patient O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
telaprevir B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
simvastatin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
hepatitis B-DISO-MISC B-ANAT-MISC
C I-DISO-MISC B-ANAT-MISC
virus I-DISO-MISC B-ANAT-MISC
infection I-DISO-MISC B-ANAT-MISC
received O-MISC B-ACTI-MISC
triple O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
ribavirin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
pegylated B-CHED-MISC O-MISC
interferon I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
telaprevir B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
also O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
simvastatin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
month O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
starting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
antiviral O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
to O-MISC I-CONC-MISC
the O-MISC I-CONC-MISC
hospital O-MISC I-CONC-MISC
because O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
admission O-MISC B-ACTI-MISC
simvastatin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
antiviral O-MISC O-MISC
drugs O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
because O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
drug O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
drug O-MISC I-LIVB-MISC
interaction O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
creatine B-CHED-MISC O-MISC
kinase O-MISC B-DISO-MISC
peaked O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
246 O-MISC B-ACTI-MISC
IU O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
intravenous O-MISC B-CHED-MISC
normal O-MISC B-GENE-MISC
saline O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
remained O-MISC B-ACTI-MISC
unaffected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Fourteen O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
hospitalization O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
creatine B-CHED-MISC O-MISC
kinase O-MISC B-DISO-MISC
level O-MISC B-CHED-MISC
had O-MISC B-ACTI-MISC
returned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
230 O-MISC B-ACTI-MISC
IU O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC I-CONC-MISC
discharged O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Telaprevir B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
probable O-MISC B-CHED-MISC
causative O-MISC I-ACTI-MISC
agent O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
interaction O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
simvastatin B-CHED-MISC O-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Drug O-MISC B-CHED-MISC
Interaction O-MISC I-CHED-MISC
Probability O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
interaction O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
CYP3A4 O-MISC O-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
simvastatin B-CHED-MISC O-MISC
clearance O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Simvastatin B-CHED-MISC O-MISC
plasma O-MISC B-CHED-MISC
concentration O-MISC I-CHED-MISC
increased O-MISC B-CHED-MISC
30 O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
statin B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
muscle B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
statin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
illustrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
telaprevir B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
statins B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
susceptible O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
relevant O-MISC B-CHED-MISC
drug O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
drug O-MISC I-LIVB-MISC
interactions O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Combination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bortezomib B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
VTD O-MISC O-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
consolidation O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
autologous O-MISC B-CONC-MISC
stem O-MISC I-CONC-MISC
cell O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
symptomatic O-MISC B-CHED-MISC
multiple B-DISO-MISC I-ACTI-MISC
myeloma I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Consolidation O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
multiple B-DISO-MISC I-ACTI-MISC
myeloma I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
adopted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
improve O-MISC I-ACTI-MISC
treatment O-MISC I-DISO-MISC
response O-MISC I-LIVB-MISC
following O-MISC B-ACTI-MISC
autologous O-MISC B-CONC-MISC
stem O-MISC I-CONC-MISC
cell O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
retrospectively O-MISC B-CONC-MISC
analyzed O-MISC I-CONC-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
combination O-MISC B-CONC-MISC
regimen O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
bortezomib B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
thalidomide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
VTD O-MISC O-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
consolidation O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
newly O-MISC B-CHED-MISC
diagnosed O-MISC I-CHED-MISC
MM B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

VTD O-MISC I-ACTI-MISC
consisted O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bortezomib B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dexamethasone B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
cycle O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
oral O-MISC O-MISC
thalidomide B-CHED-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Grade O-MISC I-ACTI-MISC
3 O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
4 O-MISC B-ANAT-MISC
neutropenia B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
drug O-MISC B-OCCU-MISC
dose O-MISC I-OCCU-MISC
reduction O-MISC B-CHED-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cytopenia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-CHED-MISC
required O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
63 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
grade O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Very O-MISC I-ACTI-MISC
good O-MISC B-ANAT-MISC
partial O-MISC B-ANAT-MISC
response O-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
VGPR O-MISC B-OCCU-MISC
) O-MISC B-ACTI-MISC
rates O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
consolidation O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
79 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
probability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
improving O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
VGPR O-MISC O-MISC
before O-MISC B-ACTI-MISC
consolidation O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
VGPR O-MISC B-OCCU-MISC
after O-MISC B-ACTI-MISC
consolidation O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
041 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
VTD O-MISC B-CONC-MISC
regimen O-MISC I-CONC-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
consolidation O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MM O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Conversion O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
sirolimus B-CHED-MISC I-GENE-MISC
ameliorates O-MISC B-CHED-MISC
cyclosporine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
focus O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
protein O-MISC I-DISO-MISC
renal O-MISC I-LIVB-MISC
expression O-MISC I-LIVB-MISC
biomarkers O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Protocols O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
conversion O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
cyclosporin B-CHED-MISC O-MISC
A I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CsA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
sirolimus B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
SRL B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
immunotherapy O-MISC B-CONC-MISC
after O-MISC B-ACTI-MISC
transplantation O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
CsA B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
molecular O-MISC I-DISO-MISC
mechanisms O-MISC I-LIVB-MISC
underlying O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
protocols O-MISC B-CHED-MISC
remain O-MISC B-ACTI-MISC
nuclear O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
molecular O-MISC I-DISO-MISC
pathways O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
putative O-MISC I-DISO-MISC
biomarkers O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
CsA B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SRL B-CHED-MISC O-MISC
conversion O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
model O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
CsA B-CHED-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
SRL B-CHED-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
conversion O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
CsA B-CHED-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
SRL B-CHED-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Classical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
emergent O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
urinary O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
protein O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
markers O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Renal B-DISO-MISC I-GENE-MISC
lesions I-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hematoxylin B-CHED-MISC B-CONC-MISC
and O-MISC I-CONC-MISC
eosin B-CHED-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
periodic O-MISC B-CONC-MISC
acid O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
Schiff O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Masson O-MISC B-CONC-MISC
' O-MISC I-CONC-MISC
s O-MISC I-CONC-MISC
trichrome O-MISC I-CONC-MISC
stains O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

SRL B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
proteinuria B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
NGAL O-MISC O-MISC
( O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
urinary O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
markers O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Short O-MISC B-ACTI-MISC
CsA B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
presented O-MISC B-ACTI-MISC
slight O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
absent O-MISC B-ACTI-MISC
kidney B-DISO-MISC I-ACTI-MISC
lesions I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
TGF O-MISC O-MISC
- O-MISC B-DISO-MISC
b O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
NF O-MISC O-MISC
- O-MISC B-DISO-MISC
kb O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
mTOR O-MISC O-MISC
, O-MISC B-ACTI-MISC
PCNA O-MISC O-MISC
, O-MISC B-ACTI-MISC
TP53 O-MISC O-MISC
, O-MISC B-ACTI-MISC
KIM O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
CTGF O-MISC O-MISC
as O-MISC B-ACTI-MISC
relevant O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
protein O-MISC O-MISC
changes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Prolonged O-MISC B-CHED-MISC
CsA B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
aggravated O-MISC B-CHED-MISC
renal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
clear O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
traditional O-MISC I-DISO-MISC
markers O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
serums O-MISC I-GENE-MISC
TGF O-MISC O-MISC
- O-MISC B-DISO-MISC
b O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
IL O-MISC O-MISC
- O-MISC B-DISO-MISC
7 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
TBARs O-MISC O-MISC
clearance O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
TGF O-MISC O-MISC
- O-MISC B-DISO-MISC
b O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
mTOR O-MISC O-MISC
. O-MISC B-ACTI-MISC

Conversion O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
SRL B-CHED-MISC O-MISC
prevented O-MISC B-ACTI-MISC
CsA B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
renal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
evolution O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
absent O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
mild O-MISC B-ACTI-MISC
grade O-MISC B-ACTI-MISC
lesions O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
NGAL O-MISC O-MISC
( O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
versus O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
seems O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
feasible O-MISC B-ACTI-MISC
biomarker O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
CsA B-CHED-MISC O-MISC
replacement O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
SRL B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Kinin O-MISC O-MISC
B2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
deletion O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
blockage O-MISC B-CHED-MISC
ameliorates O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Cisplatin B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
adopted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
chemotherapies O-MISC B-CONC-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
drug O-MISC O-MISC
can O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
acute B-DISO-MISC I-ACTI-MISC
kidney I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
ability O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
negatively O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
augment O-MISC B-CHED-MISC
serum O-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
of O-MISC I-OCCU-MISC
creatinine B-CHED-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
urea B-CHED-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
tubular I-DISO-MISC B-ANAT-MISC
necrosis I-DISO-MISC B-ANAT-MISC
score O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
up O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
regulate O-MISC I-LIVB-MISC
cytokines O-MISC O-MISC
( O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
IL O-MISC O-MISC
- O-MISC B-DISO-MISC
1b O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
TNF O-MISC O-MISC
- O-MISC B-DISO-MISC
a O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
kinin O-MISC O-MISC
B2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
inflammation B-DISO-MISC I-ACTI-MISC
process O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
regulation O-MISC B-OCCU-MISC
of O-MISC I-LIVB-MISC
cytokine O-MISC O-MISC
expression O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
deletion O-MISC I-DISO-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
improvement O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diabetic B-DISO-MISC I-ACTI-MISC
nephropathy I-DISO-MISC B-ANAT-MISC
status O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
examine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kinin O-MISC O-MISC
B2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
acute B-DISO-MISC I-ACTI-MISC
kidney I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
kinin O-MISC O-MISC
B2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
knockout O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
challenged O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Additionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
a O-MISC B-ACTI-MISC
B2 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
after O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

B2 O-MISC O-MISC
receptor O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
deficient O-MISC B-CHED-MISC
mice O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
drug O-MISC O-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
weight B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
preservation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
kidney O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
down O-MISC I-DISO-MISC
regulation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
inflammatory O-MISC B-CHED-MISC
cytokines O-MISC O-MISC
and O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
acute B-DISO-MISC B-CHED-MISC
tubular I-DISO-MISC I-ACTI-MISC
necrosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kinin O-MISC O-MISC
B2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC O-MISC
effectively O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
levels O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
serum O-MISC B-ANAT-MISC
creatinine B-CHED-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
blood O-MISC B-CONC-MISC
urea B-CHED-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kinin O-MISC O-MISC
B2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
acute B-DISO-MISC I-ACTI-MISC
kidney I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
mediating O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
necrotic B-DISO-MISC I-DISO-MISC
process O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
inflammatory O-MISC B-CHED-MISC
cytokines O-MISC O-MISC
, O-MISC B-ACTI-MISC
thus O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
declined O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
highlight O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kinin O-MISC O-MISC
B2 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC O-MISC
treatment O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
amelioration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Safety O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fluocinolone B-CHED-MISC O-MISC
acetonide I-CHED-MISC B-DISO-MISC
intravitreal O-MISC B-CHED-MISC
implant O-MISC B-OBJC-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
birdshot B-DISO-MISC I-ACTI-MISC
retinochoroidopathy I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
outcomes O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fluocinolone B-CHED-MISC O-MISC
acetonide I-CHED-MISC B-DISO-MISC
intravitreal O-MISC B-CONC-MISC
implant O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
birdshot B-DISO-MISC I-ACTI-MISC
retinochoroidopathy I-DISO-MISC I-ACTI-MISC
whose O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
intolerant O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
conventional O-MISC B-ACTI-MISC
immunomodulatory O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
retrospective O-MISC B-CONC-MISC
case O-MISC I-CONC-MISC
series O-MISC I-CONC-MISC
involving O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
birdshot B-DISO-MISC I-ACTI-MISC
retinochoroidopathy I-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
eyes O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Eleven O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
eyes O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
fluocinolone B-CHED-MISC O-MISC
acetonide I-CHED-MISC B-DISO-MISC
implant O-MISC B-OBJC-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-OCCU-MISC
outcomes O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
interest O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
fluocinolone B-CHED-MISC O-MISC
acetonide I-CHED-MISC B-DISO-MISC
implant O-MISC B-OBJC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
beyond O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Disease O-MISC I-ACTI-MISC
activity O-MISC B-DEVI-MISC
markers O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
signs O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
ocular O-MISC I-ACTI-MISC
inflammation B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
retinal B-DISO-MISC I-ACTI-MISC
vasculitis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
Swedish O-MISC B-CHED-MISC
interactive O-MISC I-CHED-MISC
threshold O-MISC I-CHED-MISC
algorithm O-MISC I-CHED-MISC
- O-MISC B-ACTI-MISC
short O-MISC B-CHED-MISC
wavelength O-MISC B-CHED-MISC
automated O-MISC B-CHED-MISC
perimetry O-MISC I-CONC-MISC
Humphrey O-MISC B-ACTI-MISC
visual O-MISC B-CONC-MISC
field O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
electroretinographic O-MISC B-CONC-MISC
parameters O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
optical O-MISC B-CONC-MISC
coherence O-MISC I-CONC-MISC
tomography O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Data O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cataract B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
raised B-DISO-MISC I-ACTI-MISC
intraocular I-DISO-MISC I-DISO-MISC
pressure I-DISO-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
collected O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
eyes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Intraocular O-MISC I-ACTI-MISC
inflammation B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
beyond O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
implant O-MISC B-OBJC-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Active O-MISC B-CHED-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

More O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
61 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
67 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
central O-MISC I-ACTI-MISC
retinal O-MISC B-ANAT-MISC
thickness O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cystoid B-DISO-MISC I-ACTI-MISC
macular I-DISO-MISC B-ANAT-MISC
edema I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
postimplant O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
immunomodulatory O-MISC O-MISC
agents O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
percentage O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
postimplant O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
included O-MISC B-ACTI-MISC
increased B-DISO-MISC I-ACTI-MISC
intraocular I-DISO-MISC B-ANAT-MISC
pressure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cataract B-DISO-MISC I-ACTI-MISC
formation O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
fluocinolone B-CHED-MISC O-MISC
acetonide I-CHED-MISC B-DISO-MISC
implant O-MISC B-OBJC-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
helps O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
inflammation B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
otherwise O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
refractory O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
birdshot B-DISO-MISC I-ACTI-MISC
retinochoroidopathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
significant O-MISC B-CHED-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
cataract B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
ocular B-DISO-MISC I-ACTI-MISC
hypertension I-DISO-MISC B-ANAT-MISC
requiring O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Optimal O-MISC B-CHED-MISC
precurarizing O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rocuronium B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
fasciculation B-DISO-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
myalgia B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Succinylcholine B-CHED-MISC O-MISC
commonly O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
muscle B-DISO-MISC I-GENE-MISC
fasciculation I-DISO-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
myalgia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
identified O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
optimal O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rocuronium B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
fasciculation B-DISO-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
myalgia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rocuronium B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
speed O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blinded O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
randomly O-MISC B-CHED-MISC
allocated O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
each O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
04 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
06 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
rocuronium B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
precurarizing O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Neuromuscular O-MISC B-CONC-MISC
monitoring O-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
precurarizing O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adductor O-MISC I-GENE-MISC
pollicis O-MISC B-GEOG-MISC
muscle O-MISC B-GEOG-MISC
using O-MISC B-ACTI-MISC
acceleromyography O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
train O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
of O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
four O-MISC I-CONC-MISC
stimulation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ulnar O-MISC I-GENE-MISC
nerve O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
precurarization O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fasciculations B-DISO-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
myalgia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
at O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
visible O-MISC B-CHED-MISC
muscle B-DISO-MISC I-GENE-MISC
fasciculation I-DISO-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
less O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
amount O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
precurarizing O-MISC B-CONC-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rocuronium B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
myalgia B-DISO-MISC I-ACTI-MISC
tend O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
amount O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
precurarizing O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rocuronium B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significance O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
072 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
longer O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
increasing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
amount O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
precurarizing O-MISC B-CONC-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rocuronium B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Precurarization O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
04 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
rocuronium B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
optimal O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
considering O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
fasciculation B-DISO-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
myalgia B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
acceptable O-MISC B-CHED-MISC
onset O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
precurarization O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PKC O-MISC O-MISC
- O-MISC B-DISO-MISC
alpha O-MISC B-DISO-MISC
attenuates O-MISC B-DEVI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephrogenic B-DISO-MISC I-ACTI-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Lithium B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
antipsychotic O-MISC O-MISC
, O-MISC B-ACTI-MISC
induces O-MISC B-ACTI-MISC
nephrogenic B-DISO-MISC I-ACTI-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
NDI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
capacity O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
concentrate O-MISC B-DEVI-MISC
urine O-MISC I-GENE-MISC
is O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
acutely O-MISC B-ACTI-MISC
disrupting O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
cAMP B-CHED-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
chronically O-MISC B-CHED-MISC
reducing O-MISC I-CHED-MISC
urea B-CHED-MISC O-MISC
transporter O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
UT O-MISC O-MISC
- O-MISC B-DISO-MISC
A1 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
water O-MISC O-MISC
channel O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
AQP2 O-MISC O-MISC
) O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inner O-MISC B-CHED-MISC
medulla O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Targeting O-MISC B-CHED-MISC
an O-MISC B-ACTI-MISC
alternative O-MISC B-ACTI-MISC
signaling O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
PKC O-MISC O-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
signaling O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
method O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treating O-MISC B-CHED-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
polyuria B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

PKC O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
alpha O-MISC I-PROC-MISC
null O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
PKCa O-MISC B-LIVB-MISC
KO O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
strain O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
matched O-MISC I-PHEN-MISC
wild O-MISC I-PHEN-MISC
type O-MISC I-PHEN-MISC
( O-MISC I-PHEN-MISC
WT O-MISC I-PHEN-MISC
) O-MISC I-PHEN-MISC
controls O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
had O-MISC B-ACTI-MISC
increased O-MISC I-ACTI-MISC
urine O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
lowered O-MISC I-ACTI-MISC
urine O-MISC B-ANAT-MISC
osmolality O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
whereas O-MISC B-ACTI-MISC
PKCa O-MISC O-MISC
KO O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
had O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
urine O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
or O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Western O-MISC B-CONC-MISC
blot O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
AQP2 O-MISC O-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
medullary O-MISC I-GENE-MISC
tissues O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
lowered O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
AQP2 O-MISC O-MISC
was O-MISC B-ACTI-MISC
unchanged O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
PKCa O-MISC B-LIVB-MISC
KO O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Similar O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
UT O-MISC O-MISC
- O-MISC B-DISO-MISC
A1 O-MISC B-DISO-MISC
expression O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
WT O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
had O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
urine O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
whereas O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
PKCa O-MISC O-MISC
KO O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
output O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

AQP2 O-MISC O-MISC
and O-MISC B-ACTI-MISC
UT O-MISC O-MISC
- O-MISC B-DISO-MISC
A1 O-MISC B-DISO-MISC
expression O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
lowered O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
WT O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
whereas O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
PKCa O-MISC I-ANAT-MISC
KO O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
AQP2 O-MISC O-MISC
was O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
UT O-MISC O-MISC
- O-MISC B-DISO-MISC
A1 O-MISC B-DISO-MISC
expression O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
unaffected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Urinary O-MISC I-GENE-MISC
sodium B-CHED-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
potassium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
fed O-MISC B-DEVI-MISC
WT O-MISC I-ANAT-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
fed O-MISC B-DEVI-MISC
PKCa O-MISC O-MISC
KO O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
ablation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
PKCa O-MISC O-MISC
preserves O-MISC B-ACTI-MISC
AQP2 O-MISC O-MISC
and O-MISC B-ACTI-MISC
UT O-MISC O-MISC
- O-MISC B-DISO-MISC
A1 O-MISC B-DISO-MISC
protein O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
localization O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
NDI B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
prevents O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
polyuria B-DISO-MISC I-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Is O-MISC B-ACTI-MISC
Dysguesia B-DISO-MISC I-ACTI-MISC
Going O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Rare O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Common O-MISC B-CHED-MISC
Side O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
Amlodipine B-CHED-MISC O-MISC
? O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
side O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
amlodipine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
dysguesia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
produced O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
female O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
essential O-MISC I-ACTI-MISC
hypertension B-DISO-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
amlodipine B-CHED-MISC O-MISC
developed O-MISC B-ACTI-MISC
loss B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
taste I-DISO-MISC B-ANAT-MISC
sensation I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Condition O-MISC I-ACTI-MISC
moderately O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
stoppage O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
for O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
amlodipine B-CHED-MISC O-MISC
can O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
dysguesia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
presentation O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
relevant O-MISC B-CHED-MISC
literature O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
amlodipine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
dysguesia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Rhabdomyolysis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
simvastatin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
increment O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
clarithromycin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Clarithromycin B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
documented O-MISC B-ACTI-MISC
cytochrome O-MISC O-MISC
P450 O-MISC B-DISO-MISC
3A4 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CYP3A4 O-MISC O-MISC
) O-MISC B-ACTI-MISC
inhibitor O-MISC O-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
interaction O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
simvastatin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
particular O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
interest O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
only O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
clarithromycin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
raised O-MISC B-CHED-MISC
cardiac O-MISC I-DISO-MISC
biomarkers O-MISC I-DISO-MISC
without O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
obvious O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
issues O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
phenomenon O-MISC B-OCCU-MISC
that O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
linked O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
previously O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
date O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
structure O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
function O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
muscle O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Clinicians O-MISC I-ANAT-MISC
need O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
prescribing O-MISC B-CONC-MISC
concomitant O-MISC B-CHED-MISC
medications O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
myopathy B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
inhibit O-MISC I-DISO-MISC
the O-MISC B-ACTI-MISC
CYP3A4 O-MISC O-MISC
enzyme O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
troponin O-MISC O-MISC
elevation O-MISC B-CHED-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
statin B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
rhabdomyolysis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
warrant O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Characterization O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
BCHE O-MISC B-LIVB-MISC
" O-MISC I-PROC-MISC
silent O-MISC I-PROC-MISC
" O-MISC I-PROC-MISC
allele O-MISC I-PROC-MISC
: O-MISC I-LIVB-MISC
point O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC I-PROC-MISC
. O-MISC I-PROC-MISC
Val204Asp O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
causes O-MISC B-ACTI-MISC
loss O-MISC B-CHED-MISC
of O-MISC B-ANAT-MISC
activity O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
apnea B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Butyrylcholinesterase B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
apnea B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
muscle O-MISC O-MISC
relaxants O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
mivacurium B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BCHE O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
neuromuscular O-MISC I-ACTI-MISC
block O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
discovery O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
BCHE O-MISC O-MISC
variant O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
c O-MISC O-MISC
. O-MISC B-DISO-MISC
695T O-MISC B-DISO-MISC
> O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
, O-MISC B-DISO-MISC
p O-MISC B-DISO-MISC
. O-MISC B-DISO-MISC
Val204Asp O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Inhibition O-MISC I-DISO-MISC
studies O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
kinetic O-MISC B-OCCU-MISC
analysis O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
molecular O-MISC I-DISO-MISC
dynamics O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
undertaken O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
understand O-MISC B-ACTI-MISC
how O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
disrupts O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
catalytic O-MISC B-CHED-MISC
triad O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
determines O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
silent O-MISC B-CHED-MISC
" O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Low O-MISC B-CHED-MISC
activity O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
plasma O-MISC I-GENE-MISC
butyrylcholinesterase O-MISC O-MISC
with O-MISC B-ACTI-MISC
butyrylthiocholine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
BTC B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
benzoylcholine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
values O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dibucaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
fluoride B-CHED-MISC O-MISC
numbers O-MISC B-DISO-MISC
fit O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
atypical O-MISC I-DISO-MISC
silent O-MISC I-LIVB-MISC
genotype O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Electrophoretic O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
BChE O-MISC O-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proband O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
mother O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
amount O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
tetrameric O-MISC O-MISC
enzyme O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
minor O-MISC B-CHED-MISC
fast O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
moving O-MISC I-LIVB-MISC
BChE O-MISC O-MISC
components O-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
monomer O-MISC O-MISC
, O-MISC B-ACTI-MISC
dimer O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
monomer O-MISC O-MISC
- O-MISC B-DISO-MISC
albumin O-MISC B-DISO-MISC
conjugate O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
missing O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Kinetic O-MISC B-OCCU-MISC
analysis O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
p O-MISC O-MISC
. O-MISC B-DISO-MISC
Val204Asp O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
p O-MISC O-MISC
. O-MISC B-DISO-MISC
Asp70Gly O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
p O-MISC B-DISO-MISC
. O-MISC B-DISO-MISC
Ala539Thr O-MISC B-DISO-MISC
BChE O-MISC B-DISO-MISC
displays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pure O-MISC B-ACTI-MISC
Michaelian O-MISC B-OCCU-MISC
behavior O-MISC I-OCCU-MISC
with O-MISC B-ACTI-MISC
BTC B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
substrate O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
catalytic O-MISC B-OCCU-MISC
parameters O-MISC B-CHED-MISC
Km O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
265 O-MISC B-ACTI-MISC
uM O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
BTC B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
atypical O-MISC B-ACTI-MISC
enzyme O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
Vmax O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
consistent O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
against O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Molecular O-MISC B-DEVI-MISC
dynamic O-MISC I-DEVI-MISC
( O-MISC I-DEVI-MISC
MD O-MISC I-DEVI-MISC
) O-MISC I-DEVI-MISC
simulations O-MISC I-DEVI-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
p O-MISC B-LIVB-MISC
. O-MISC I-PROC-MISC
Val204Asp O-MISC I-PROC-MISC
is O-MISC B-ACTI-MISC
disruption O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hydrogen B-CHED-MISC B-OCCU-MISC
bonding O-MISC I-OCCU-MISC
between O-MISC B-ACTI-MISC
Gln223 O-MISC O-MISC
and O-MISC B-ACTI-MISC
Glu441 O-MISC O-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
Ser198 O-MISC O-MISC
and O-MISC B-ACTI-MISC
His438 O-MISC O-MISC
to O-MISC B-ACTI-MISC
move O-MISC B-ACTI-MISC
away O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
disruption O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
catalytic O-MISC B-CHED-MISC
triad O-MISC I-CHED-MISC
functionality O-MISC I-CHED-MISC
regardless O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
substrate O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

MD O-MISC B-CONC-MISC
also O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
enzyme O-MISC O-MISC
volume O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
denaturation O-MISC I-CHED-MISC
state O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
fits O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
p O-MISC O-MISC
. O-MISC B-DISO-MISC
Ala204Asp O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
p O-MISC O-MISC
. O-MISC B-DISO-MISC
Asp70Gly O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
p O-MISC B-DISO-MISC
. O-MISC B-DISO-MISC
Ala539Thr O-MISC B-DISO-MISC
tetrameric O-MISC B-DISO-MISC
enzyme O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
non O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
detectable O-MISC I-LIVB-MISC
fast O-MISC B-CHED-MISC
moving O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
bands O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
electrophoresis O-MISC B-CONC-MISC
gels O-MISC O-MISC
. O-MISC B-ACTI-MISC

Delayed O-MISC I-ACTI-MISC
anemia B-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
injectable O-MISC O-MISC
artesunate B-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Democratic O-MISC B-ORGA-MISC
Republic O-MISC I-ORGA-MISC
of O-MISC I-ORGA-MISC
the O-MISC I-ORGA-MISC
Congo O-MISC I-ORGA-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
manageable O-MISC B-ACTI-MISC
issue O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
delayed O-MISC I-ACTI-MISC
hemolytic B-DISO-MISC B-ANAT-MISC
anemia I-DISO-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
injectable O-MISC O-MISC
artesunate B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
World O-MISC B-PHYS-MISC
Health O-MISC I-PHYS-MISC
Organization O-MISC I-PHYS-MISC
( O-MISC B-ACTI-MISC
WHO O-MISC B-PHYS-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
first O-MISC O-MISC
- O-MISC B-DISO-MISC
line O-MISC I-CONC-MISC
drug O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
malaria B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
350 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
215 O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
61 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
age O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
135 O-MISC B-ACTI-MISC
[ O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
] O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
age O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
followed O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
injectable O-MISC O-MISC
artesunate B-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
malaria B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
hospitals O-MISC B-GENE-MISC
and O-MISC B-ACTI-MISC
health O-MISC B-GENE-MISC
centers O-MISC I-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Democratic O-MISC B-ORGA-MISC
Republic O-MISC I-ORGA-MISC
of O-MISC I-ORGA-MISC
the O-MISC I-ORGA-MISC
Congo O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

Complete O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hemoglobin O-MISC B-CONC-MISC
( O-MISC I-CONC-MISC
Hb O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
measurements O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
201 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Hb O-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
between O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
period O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
Hb O-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
decreased O-MISC B-CHED-MISC
below O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dL O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
visit O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
delayed O-MISC I-ACTI-MISC
anemia B-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
clinically O-MISC B-ACTI-MISC
manageable O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
resolved O-MISC I-ACTI-MISC
within O-MISC B-ACTI-MISC
one O-MISC B-CHED-MISC
month O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Regulation O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
signal O-MISC O-MISC
transducer O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
activator O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
transcription O-MISC I-DISO-MISC
3 O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
apoptotic O-MISC I-DISO-MISC
pathways O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
betaine B-CHED-MISC O-MISC
attenuates O-MISC B-DEVI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
acute O-MISC I-ACTI-MISC
myocardial B-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
designed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
cardioprotective O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
betaine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
myocardial B-DISO-MISC B-ANAT-MISC
ischemia I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
experimentally O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
focusing O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
regulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
signal O-MISC O-MISC
transducer O-MISC B-DISO-MISC
and O-MISC B-DISO-MISC
activator O-MISC B-DISO-MISC
of O-MISC B-DISO-MISC
transcription O-MISC B-DISO-MISC
3 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
STAT3 O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
apoptotic O-MISC I-DISO-MISC
pathways O-MISC I-LIVB-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
mechanism O-MISC B-CHED-MISC
underlying O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Male O-MISC I-DISO-MISC
Sprague O-MISC I-ANAT-MISC
Dawley O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC I-CONC-MISC
betaine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
orally O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC I-ACTI-MISC
myocardial B-DISO-MISC B-ANAT-MISC
ischemic I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
subcutaneous O-MISC B-CHED-MISC
injection O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
consecutive O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Serum O-MISC I-GENE-MISC
cardiac O-MISC B-GEOG-MISC
marker O-MISC I-DISO-MISC
enzyme O-MISC O-MISC
, O-MISC B-ACTI-MISC
histopathological O-MISC B-CHED-MISC
variables O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
protein O-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
betaine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
marker O-MISC I-LIVB-MISC
enzyme O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
left O-MISC I-ACTI-MISC
ventricular B-DISO-MISC B-ANAT-MISC
remodeling I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Western O-MISC B-CONC-MISC
blot O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
phosphorylation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
STAT3 O-MISC O-MISC
was O-MISC B-ACTI-MISC
maintained O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
betaine B-CHED-MISC O-MISC
treatment O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
myocardium O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
betaine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
ventricular O-MISC B-CHED-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
Bcl O-MISC O-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Bax O-MISC O-MISC
, O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ratio O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Bcl O-MISC O-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
Bax O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
protective O-MISC B-CHED-MISC
role O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
betaine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
confirmed O-MISC B-CHED-MISC
by O-MISC I-CHED-MISC
histopathological O-MISC B-CHED-MISC
examination O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
summary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
betaine B-CHED-MISC O-MISC
pretreatment O-MISC B-DEVI-MISC
attenuated O-MISC B-DEVI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
myocardial B-DISO-MISC B-ANAT-MISC
ischemia I-DISO-MISC B-ANAT-MISC
via O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
regulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
STAT3 O-MISC O-MISC
and O-MISC B-ACTI-MISC
apoptotic O-MISC I-DISO-MISC
pathways O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Quetiapine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
bipolar B-DISO-MISC B-CHED-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hepatocellular B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Quetiapine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dibenzothiazepine O-MISC O-MISC
derivative O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
clozapine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
highest O-MISC I-ACTI-MISC
risk O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
blood B-DISO-MISC I-ACTI-MISC
dyscrasias I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
reports O-MISC I-CHED-MISC
about O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
quetiapine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
seldom O-MISC B-CHED-MISC
discussed O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hepatocellular B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
quetiapine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CASE O-MISC B-CHED-MISC
REPORT O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
Taiwanese O-MISC I-ANAT-MISC
widow O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
hepatocellular B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
60 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
leucopenia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
quetiapine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
quetiapine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
white O-MISC B-CONC-MISC
blood O-MISC B-ANAT-MISC
cell O-MISC I-CONC-MISC
count O-MISC I-CONC-MISC
returned O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
normal O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Although O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-CHED-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
quetiapine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
physicians O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
cautious O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
presentation O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Hepatic B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
concomitant O-MISC B-CHED-MISC
fever B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
diagnostic O-MISC I-DISO-MISC
marker O-MISC I-LIVB-MISC
for O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
reaction O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
quetiapine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Lateral O-MISC I-ACTI-MISC
antebrachial O-MISC B-ANAT-MISC
cutaneous O-MISC B-ANAT-MISC
neuropathy B-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
steroid B-CHED-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
lateral O-MISC I-GENE-MISC
epicondyle O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lateral O-MISC I-ACTI-MISC
antebrachial O-MISC B-ANAT-MISC
cutaneous O-MISC B-ANAT-MISC
neuropathy B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
LACNP O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
steroid B-CHED-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lateral O-MISC I-GENE-MISC
epicondyle O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
treat O-MISC B-CONC-MISC
lateral B-DISO-MISC I-ACTI-MISC
epicondylitis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

MATERIAL O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHOD O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
sensation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
paresthesia B-DISO-MISC I-ACTI-MISC
over O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
right O-MISC I-GENE-MISC
lateral O-MISC B-GEOG-MISC
forearm O-MISC B-GEOG-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
paresthesia B-DISO-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
steroid B-CHED-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
right O-MISC I-GENE-MISC
lateral O-MISC B-GEOG-MISC
epicondyle O-MISC B-GEOG-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Her O-MISC B-ACTI-MISC
sensation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
light O-MISC I-DISO-MISC
touch O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
diminished O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lateral O-MISC I-GENE-MISC
side O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
right O-MISC I-GENE-MISC
forearm O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
wrist O-MISC I-GENE-MISC
area O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
sensory O-MISC I-DISO-MISC
action O-MISC I-LIVB-MISC
potential O-MISC I-LIVB-MISC
amplitude O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
right O-MISC I-GENE-MISC
lateral O-MISC B-GEOG-MISC
antebrachial O-MISC B-GEOG-MISC
cutaneous O-MISC B-GEOG-MISC
nerve O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
LACN O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
uV O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
uV O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amplitude O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
sides O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
reduction O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
right O-MISC I-GENE-MISC
LACNP O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
mainly O-MISC B-ACTI-MISC
axonal O-MISC I-GENE-MISC
involvement O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
manifestation O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
electrodiagnostic O-MISC I-ACTI-MISC
findings O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Her O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
improved O-MISC I-ACTI-MISC
through O-MISC B-ACTI-MISC
physical O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
but O-MISC B-ACTI-MISC
persisted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
degree O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
describes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
LACNP O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
steroid B-CHED-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lateral B-DISO-MISC I-ACTI-MISC
epicondylitis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
electrodiagnostic O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nerve O-MISC B-CONC-MISC
conduction O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LACN O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
helpful O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
diagnose O-MISC I-ACTI-MISC
right O-MISC I-GENE-MISC
LACNP O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
find O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
passage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LACN O-MISC I-GENE-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lateral O-MISC I-GENE-MISC
epicondyle O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Curcumin B-CHED-MISC O-MISC
prevents O-MISC B-ACTI-MISC
maleate B-CHED-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
relation O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hemodynamic O-MISC I-DISO-MISC
alterations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
mitochondrial O-MISC I-GENE-MISC
oxygen B-CHED-MISC I-DISO-MISC
consumption O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
respiratory O-MISC O-MISC
complex O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
protective O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dietary O-MISC B-GENE-MISC
antioxidant O-MISC O-MISC
curcumin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
120 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
Kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
against O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
maleate B-CHED-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Tubular O-MISC I-ACTI-MISC
proteinuria B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
injection O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
maleate B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Maleate B-CHED-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC I-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
included O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-ACTI-MISC
vascular O-MISC B-ANAT-MISC
resistance O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urinary O-MISC B-CHED-MISC
excretion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
total O-MISC O-MISC
protein O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
glucose B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
neutrophil O-MISC O-MISC
gelatinase O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
associated O-MISC B-DISO-MISC
lipocalin O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NGAL O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
N O-MISC O-MISC
- O-MISC B-DISO-MISC
acetyl O-MISC B-DISO-MISC
b O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
D O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
glucosaminidase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NAG O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
upregulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
kidney B-DISO-MISC O-MISC
injury I-DISO-MISC B-DISO-MISC
molecule O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
KIM O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
flow O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
claudin O-MISC O-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
expression O-MISC I-DISO-MISC
besides O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
apoptosis O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
tubular O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
on O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-CHED-MISC
by O-MISC I-CHED-MISC
measuring O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
oxidation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
lipids O-MISC O-MISC
and O-MISC B-ACTI-MISC
proteins O-MISC O-MISC
and O-MISC B-ACTI-MISC
diminution O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
Nrf2 O-MISC O-MISC
levels O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Studies O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
epithelial O-MISC I-GENE-MISC
LLC O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
PK1 O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mitochondria O-MISC I-GENE-MISC
isolated O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
kidneys O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
groups O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Maleate B-CHED-MISC I-DISO-MISC
induced O-MISC B-CHED-MISC
cell O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
reactive O-MISC O-MISC
oxygen B-CHED-MISC B-DISO-MISC
species O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ROS O-MISC O-MISC
) O-MISC B-ACTI-MISC
production O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
LLC O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
PK1 O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
culture O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
maleate B-CHED-MISC I-DISO-MISC
treatment O-MISC B-CONC-MISC
reduced O-MISC B-CHED-MISC
oxygen B-CHED-MISC I-DISO-MISC
consumption O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
ADP B-CHED-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
stimulated O-MISC B-OCCU-MISC
mitochondria O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
diminished O-MISC B-CHED-MISC
respiratory O-MISC B-CHED-MISC
control O-MISC I-CHED-MISC
index O-MISC I-CHED-MISC
when O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
malate B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
glutamate B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
substrate O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
activities O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
complex O-MISC O-MISC
I O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
aconitase O-MISC O-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
diminished O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
above O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
alterations O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
curcumin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
curcumin B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
able O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
attenuate O-MISC B-DEVI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
maleate B-CHED-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
cell O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
protection O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prevention O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oxidative O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
preservation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
mitochondrial O-MISC I-GENE-MISC
oxygen B-CHED-MISC I-DISO-MISC
consumption O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
respiratory O-MISC I-GENE-MISC
complex O-MISC B-GEOG-MISC
I O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
protection O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prevention O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ROS O-MISC O-MISC
production O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

Anticonvulsant O-MISC I-ACTI-MISC
actions O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
pilocarpine B-CHED-MISC B-DISO-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
noncompetitive O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
methyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
D I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
aspartate I-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
NMDA B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
tested O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
using O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
models O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
coadministration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

First O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
produced O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
anticonvulsant O-MISC I-ACTI-MISC
action O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
model O-MISC B-OBJC-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
pilocarpine B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
control O-MISC I-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
models O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Second O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
pilocarpine B-CHED-MISC B-DISO-MISC
model O-MISC B-OBJC-MISC
only O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
periods O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
observation O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
demonstration O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
experiments O-MISC B-CONC-MISC
that O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
requires O-MISC B-ACTI-MISC
agonist O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
opening O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
channel O-MISC B-CHED-MISC
sites O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
NMDA B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Third O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
easy O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
block O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
by O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
anticonvulsants O-MISC O-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
difficult O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
terminate O-MISC B-ACTI-MISC
ongoing O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
block O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
lethality O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
30 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
gradually O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
electrical O-MISC I-ACTI-MISC
and O-MISC B-ANAT-MISC
behavioral O-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
activity O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
greatly O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
survival O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
activation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
NMDA B-CHED-MISC O-MISC
receptors O-MISC B-DISO-MISC
plays O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-CHED-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
status B-DISO-MISC B-CHED-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
brain B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
pilocarpine B-CHED-MISC B-DISO-MISC
model O-MISC B-OBJC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
supported O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
nonconvulsive O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
NMDA B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
synergistic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Continuous O-MISC B-CONC-MISC
infusion O-MISC I-CONC-MISC
tobramycin B-CHED-MISC I-CONC-MISC
combined O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
carbenicillin B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
infections B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cure O-MISC B-CHED-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
infections B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
adversely O-MISC I-ACTI-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mm3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
particular O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mm3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
poor O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
antibiotics O-MISC O-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
overcome O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
tobramycin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
continuous O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
combined O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
intermittent O-MISC B-CHED-MISC
carbenicillin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Tobramycin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
carbenicillin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
gm O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
125 O-MISC B-ACTI-MISC
infectious O-MISC I-ACTI-MISC
episodes O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
116 O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
patients O-MISC I-PHEN-MISC
receiving O-MISC B-ACTI-MISC
myelosuppressive O-MISC B-CONC-MISC
chemotherapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
cure O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Pneumonia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-CHED-MISC
infection B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
61 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
episodes O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
cured O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Gram O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
negative O-MISC I-PHEN-MISC
bacilli O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
causative O-MISC I-ACTI-MISC
organisms O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
69 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
infections B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
cured O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
pathogen O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
Klebsiella O-MISC I-ANAT-MISC
pneumoniae B-DISO-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
Escherichia O-MISC I-ANAT-MISC
coli O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
Pseudomonas O-MISC I-ANAT-MISC
aeruginosa O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
accounted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
74 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
gram B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
negative I-DISO-MISC B-ANAT-MISC
bacillary I-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Response O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
influenced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
neutrophil O-MISC B-CONC-MISC
count O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
cure O-MISC B-CHED-MISC
rate O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
episodes O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
severe O-MISC B-CHED-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
failure O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neutrophil O-MISC B-CONC-MISC
count O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
adversely O-MISC B-CHED-MISC
affected O-MISC I-CHED-MISC
response O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Azotemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
recognized O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
episodes O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Major O-MISC B-ACTI-MISC
azotemia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
serum O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
BUN O-MISC I-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dl O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Azotemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
tobramycin B-CHED-MISC I-CONC-MISC
concentration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
antibiotic O-MISC B-CONC-MISC
regimen O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
efficacy O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
acceptable O-MISC B-CHED-MISC
renal B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
solid O-MISC I-ACTI-MISC
tumours B-DISO-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
pesticide O-MISC B-PHEN-MISC
applicators O-MISC B-UnknownType-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
organophosphate B-CHED-MISC O-MISC
insecticide O-MISC B-DISO-MISC
diazinon B-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Agricultural O-MISC B-CONC-MISC
Health O-MISC I-CONC-MISC
Study O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
updated O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Diazinon B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
organophosphate B-CHED-MISC O-MISC
insecticide O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
genotoxic O-MISC I-ACTI-MISC
properties O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
lung B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Agricultural O-MISC B-CONC-MISC
Health O-MISC I-CONC-MISC
Study O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
AHS O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
cohort O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
epidemiological O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
cancer B-DISO-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
updated O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
information O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
solid O-MISC I-ACTI-MISC
tumour B-DISO-MISC B-ANAT-MISC
risk O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
AHS O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Male O-MISC I-DISO-MISC
pesticide O-MISC O-MISC
applicators O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
Iowa O-MISC B-ORGA-MISC
and O-MISC B-ACTI-MISC
North O-MISC B-ORGA-MISC
Carolina O-MISC I-ORGA-MISC
reported O-MISC B-ACTI-MISC
lifetime O-MISC B-CHED-MISC
diazinon B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
enrolment O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
1993 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1997 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
1998 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
2010 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
North O-MISC B-ORGA-MISC
Carolina O-MISC I-ORGA-MISC
) O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
2011 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
Iowa O-MISC B-ORGA-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
applicators O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
usage O-MISC B-CHED-MISC
information O-MISC B-CHED-MISC
sufficient O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
exposure O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
response O-MISC B-OCCU-MISC
patterns O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
Poisson O-MISC B-CHED-MISC
regression O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
estimate O-MISC B-CHED-MISC
adjusted O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
ratios O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
RRs O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-GENE-MISC
sites O-MISC B-GEOG-MISC
with O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
cases O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
lifetime O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
LT O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
days O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
intensity O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
weighted O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
IW O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
lifetime O-MISC B-CHED-MISC
exposure O-MISC B-CHED-MISC
days O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
accounting O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
impacting O-MISC B-CHED-MISC
exposure O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
lung B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
risks O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
N O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
283 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
applicators O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
greatest O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
LT O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
RR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
Ptrend O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
IW O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
RR O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
04 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
Ptrend O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
08 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Kidney B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
N O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
94 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
risks O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
significantly O-MISC B-ANAT-MISC
elevated O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
RRLT O-MISC B-CONC-MISC
days O-MISC B-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
Ptrend O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
09 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
RRIW O-MISC B-CHED-MISC
days O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
64 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
92 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
Ptrend O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
risks O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
aggressive O-MISC I-ACTI-MISC
prostate B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
N O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
656 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
updated O-MISC B-ACTI-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
diazinon B-CHED-MISC O-MISC
provides O-MISC B-ACTI-MISC
additional O-MISC B-CHED-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
lung B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
risk O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Newly O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
links O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
kidney B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
associations O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
aggressive O-MISC I-ACTI-MISC
prostate B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
require O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
evaluation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Associations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Ozone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
PM2 O-MISC B-GENE-MISC
. O-MISC I-GEOG-MISC
5 O-MISC I-GEOG-MISC
Concentrations O-MISC B-CHED-MISC
With O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
Disease I-DISO-MISC B-ANAT-MISC
Among O-MISC B-ACTI-MISC
Participants O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Agricultural O-MISC B-CONC-MISC
Health O-MISC I-CONC-MISC
Study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
describes O-MISC B-ACTI-MISC
associations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ozone B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
fine O-MISC B-ACTI-MISC
particulate B-CHED-MISC B-GENE-MISC
matter I-CHED-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
observed O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
farmers O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
North O-MISC B-ORGA-MISC
Carolina O-MISC I-ORGA-MISC
and O-MISC B-ACTI-MISC
Iowa O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
logistic O-MISC B-CONC-MISC
regression O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
associations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
pollutants O-MISC O-MISC
with O-MISC B-ACTI-MISC
self O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
reported O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
doctor O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
diagnosed O-MISC B-ANAT-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Daily O-MISC B-CHED-MISC
predicted O-MISC B-CHED-MISC
pollutant O-MISC O-MISC
concentrations O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
derive O-MISC B-ACTI-MISC
surrogates O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
exposure O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
link O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
participants O-MISC I-ANAT-MISC
' O-MISC B-ACTI-MISC
geocoded O-MISC B-CHED-MISC
addresses O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
associations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
ozone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
fine O-MISC B-ACTI-MISC
particulate B-CHED-MISC O-MISC
matter I-CHED-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
93 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
93 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
North O-MISC B-ORGA-MISC
Carolina O-MISC I-ORGA-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Iowa O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
plausibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ambient O-MISC B-CHED-MISC
concentrations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
pollutants O-MISC O-MISC
on O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
risk O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
supported O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
data O-MISC B-CHED-MISC
demonstrating O-MISC B-ACTI-MISC
damage O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
dopaminergic O-MISC I-GENE-MISC
neurons O-MISC B-GEOG-MISC
at O-MISC B-ACTI-MISC
relevant O-MISC B-CHED-MISC
concentrations O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Additional O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
address O-MISC B-ACTI-MISC
uncertainties O-MISC I-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
confounding O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
examine O-MISC B-ACTI-MISC
temporal O-MISC B-CHED-MISC
aspects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
associations O-MISC B-CHED-MISC
we O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Low O-MISC B-CHED-MISC
functional O-MISC B-ACTI-MISC
programming O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
AT2R O-MISC O-MISC
mediates O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
developmental O-MISC B-CHED-MISC
origin O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
offspring O-MISC I-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
prenatal O-MISC I-ANAT-MISC
caffeine B-CHED-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

UNASSIGNED O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Our O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
indicated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
prenatal O-MISC B-CHED-MISC
caffeine B-CHED-MISC I-ACTI-MISC
exposure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PCE O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
intrauterine B-DISO-MISC I-ACTI-MISC
growth I-DISO-MISC B-ANAT-MISC
retardation I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
IUGR B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
offspring O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Recent O-MISC B-ACTI-MISC
research O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
IUGR B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
PCE O-MISC O-MISC
could O-MISC B-ACTI-MISC
induce O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
remain O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
offspring O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
PCE O-MISC O-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
intrauterine O-MISC B-CHED-MISC
programming O-MISC I-DISO-MISC
mechanisms O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
IUGR B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
established O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
PCE O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
male O-MISC I-GENE-MISC
fetuses O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
offspring O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
postnatal O-MISC B-CHED-MISC
week O-MISC B-CHED-MISC
24 O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
euthanized O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
offspring O-MISC I-ANAT-MISC
kidneys O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PCE O-MISC I-ACTI-MISC
group O-MISC B-CHED-MISC
exhibited O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
interstitial B-DISO-MISC I-ACTI-MISC
fibrosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
accompanied O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
levels O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
serum O-MISC I-CONC-MISC
creatinine B-CHED-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
urine O-MISC B-CONC-MISC
protein O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Renal O-MISC B-LIVB-MISC
angiotensin B-CHED-MISC I-PROC-MISC
II I-CHED-MISC I-PROC-MISC
receptor O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
2 O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
AT2R O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
offspring O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
PCE O-MISC O-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renal O-MISC O-MISC
angiotensin B-CHED-MISC B-DISO-MISC
II I-CHED-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
type O-MISC B-DISO-MISC
1a O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
AT1aR O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
AT2R O-MISC O-MISC
expression O-MISC I-DISO-MISC
ratio O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
fetal O-MISC I-GENE-MISC
kidneys O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PCE O-MISC I-ACTI-MISC
group O-MISC B-CHED-MISC
displayed O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
enlarged O-MISC B-CHED-MISC
Bowman O-MISC I-GENE-MISC
' O-MISC B-GEOG-MISC
s O-MISC B-GEOG-MISC
space O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
shrunken O-MISC B-ACTI-MISC
glomerular O-MISC I-GENE-MISC
tuft O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
accompanied O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
cortex O-MISC I-GENE-MISC
width O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nephrogenic O-MISC B-CHED-MISC
zone O-MISC I-CHED-MISC
/ O-MISC B-ACTI-MISC
cortical O-MISC I-GENE-MISC
zone O-MISC B-GEOG-MISC
ratio O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Observation O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
electronic O-MISC B-OBJC-MISC
microscope O-MISC I-OBJC-MISC
revealed O-MISC B-ACTI-MISC
structural O-MISC B-CHED-MISC
damage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
podocytes O-MISC I-GENE-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
expression O-MISC B-CHED-MISC
level O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
podocyte O-MISC I-GENE-MISC
marker O-MISC B-LIVB-MISC
genes O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
nephrin O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
podocin O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
q O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
PCR O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
AT2R O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
protein O-MISC I-DISO-MISC
expressions O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
fetal O-MISC I-GENE-MISC
kidneys O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
inhibited O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
PCE O-MISC O-MISC
, O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
repression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
glial O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
line O-MISC B-GEOG-MISC
- O-MISC I-LIVB-MISC
derived O-MISC I-LIVB-MISC
neurotrophic O-MISC I-LIVB-MISC
factor O-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
GDNF O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
/ O-MISC I-LIVB-MISC
tyrosine B-CHED-MISC I-LIVB-MISC
kinase O-MISC I-LIVB-MISC
receptor O-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
c O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
Ret O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
signaling O-MISC I-LIVB-MISC
pathway O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
PCE O-MISC I-ACTI-MISC
could O-MISC B-ACTI-MISC
induce O-MISC B-ACTI-MISC
dysplasia B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
fetal I-DISO-MISC I-GENE-MISC
kidneys I-DISO-MISC B-GEOG-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
offspring O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
functional O-MISC B-CHED-MISC
programming O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
AT2R O-MISC O-MISC
might O-MISC B-ACTI-MISC
mediate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
developmental O-MISC B-CHED-MISC
origin O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

1 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
Butadiene I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
CML B-DISO-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
translocation O-MISC I-DISO-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
reality O-MISC B-CONC-MISC
check O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

UNASSIGNED O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Epidemiological O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
1 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
butadiene I-CHED-MISC B-DISO-MISC
have O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
exposures O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
chronic B-DISO-MISC I-ACTI-MISC
myeloid I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CML B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CML B-DISO-MISC I-ACTI-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
documented O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
ionizing O-MISC B-OCCU-MISC
radiation O-MISC I-OCCU-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
reports O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
associations O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
chemical O-MISC I-ACTI-MISC
exposures O-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
questioned O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Ionizing O-MISC B-OCCU-MISC
radiation O-MISC I-OCCU-MISC
is O-MISC B-ACTI-MISC
capable O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
inducing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
requisite O-MISC B-ACTI-MISC
CML B-DISO-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
t O-MISC I-DISO-MISC
( O-MISC I-LIVB-MISC
9 O-MISC I-LIVB-MISC
: O-MISC I-LIVB-MISC
22 O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
translocation O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
Philadelphia B-DISO-MISC I-GENE-MISC
chromosome I-DISO-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
appropriate O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
but O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
thus O-MISC B-ACTI-MISC
far O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
chemicals O-MISC O-MISC
have O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
capacity O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
proposed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
1 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
butadiene I-CHED-MISC B-DISO-MISC
metabolites O-MISC B-DISO-MISC
be O-MISC B-ACTI-MISC
so O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reality O-MISC B-ACTI-MISC
check O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epidemiological O-MISC B-CHED-MISC
reports O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
conduct O-MISC B-ACTI-MISC
reliable O-MISC B-ACTI-MISC
testing O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
regard O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
essential O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
control O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
induction O-MISC B-CONC-MISC
be O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
ionizing O-MISC B-OCCU-MISC
radiation O-MISC I-OCCU-MISC
to O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Results O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
agent O-MISC O-MISC
does O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
fact O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
pathogenic O-MISC B-CHED-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
translocations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
myeloid O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
line O-MISC B-GEOG-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
does O-MISC B-ACTI-MISC
so O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
frequencies O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Conditions O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
will O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
1 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
butadiene I-CHED-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Cancer B-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
metolachlor B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Agricultural O-MISC B-CONC-MISC
Health O-MISC I-CONC-MISC
Study O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
An O-MISC B-ACTI-MISC
update O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

UNASSIGNED O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Metolachlor B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
herbicide O-MISC O-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Group O-MISC O-MISC
C O-MISC B-DISO-MISC
carcinogen O-MISC O-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
U O-MISC B-ORGA-MISC
. O-MISC I-ORGA-MISC
S O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

Environmental O-MISC B-PHYS-MISC
Protection O-MISC I-PHYS-MISC
Agency O-MISC I-PHYS-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
liver B-DISO-MISC I-ACTI-MISC
neoplasms I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Epidemiologic O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
health O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
metolachlor B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Agricultural O-MISC B-CONC-MISC
Health O-MISC I-CONC-MISC
Study O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
AHS O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
cohort O-MISC B-CHED-MISC
study O-MISC I-CONC-MISC
including O-MISC B-ACTI-MISC
licensed O-MISC B-CHED-MISC
private O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
commercial O-MISC B-PROC-MISC
pesticide O-MISC O-MISC
applicators O-MISC I-PHEN-MISC
in O-MISC B-ACTI-MISC
Iowa O-MISC B-ORGA-MISC
and O-MISC B-ACTI-MISC
North O-MISC B-ORGA-MISC
Carolina O-MISC I-ORGA-MISC
enrolled O-MISC B-CONC-MISC
1993 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1997 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
cancer B-DISO-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
through O-MISC B-ACTI-MISC
2010 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
2011 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
NC O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
IA O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
616 O-MISC B-ACTI-MISC
applicators O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
53 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
ever O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
metolachlor B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
Poisson O-MISC B-CHED-MISC
regression O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
relations O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
metrics O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
metolachlor B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
lifetime O-MISC B-CHED-MISC
days O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
intensity O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
weighted O-MISC I-CHED-MISC
lifetime O-MISC B-CHED-MISC
days O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
incidence O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
saw O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
metolachlor B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
cancers B-DISO-MISC I-ACTI-MISC
combined O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
701 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
lag O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
site O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
specific O-MISC I-CHED-MISC
cancers B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
liver B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
analyses O-MISC B-CONC-MISC
restricted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
exposed O-MISC I-ANAT-MISC
workers O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
elevations O-MISC B-CHED-MISC
observed O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
categories O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
trends O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
lifetime O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
intensity O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
weighted O-MISC I-CHED-MISC
lifetime O-MISC I-CHED-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
metolachor B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unexposed O-MISC I-ANAT-MISC
reference O-MISC I-PHEN-MISC
group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
pattern O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
follicular B-DISO-MISC I-GENE-MISC
cell I-DISO-MISC I-ACTI-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
subtypes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
earlier O-MISC B-ACTI-MISC
suggestion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
lung B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
risk O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
metolachlor B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
cohort O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
update O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
suggestion O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
metolachlor B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
liver B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
pesticide O-MISC B-PHEN-MISC
applicators O-MISC B-UnknownType-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
finding O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
echoes O-MISC B-ACTI-MISC
observation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
liver B-DISO-MISC I-ACTI-MISC
neoplasms I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
studies O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
liver B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
follicular O-MISC I-ACTI-MISC
cell O-MISC B-ANAT-MISC
lymphoma B-DISO-MISC B-ANAT-MISC
warrant O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
differentiate O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
metolachlor B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Mechanisms O-MISC B-ACTI-MISC
Underlying O-MISC B-ACTI-MISC
Latent O-MISC I-ACTI-MISC
Disease O-MISC B-ANAT-MISC
Risk O-MISC B-CHED-MISC
Associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
Early O-MISC B-CHED-MISC
- O-MISC B-ANAT-MISC
Life O-MISC B-CHED-MISC
Arsenic B-CHED-MISC I-ACTI-MISC
Exposure O-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
Current O-MISC B-CHED-MISC
Research O-MISC B-CONC-MISC
Trends O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
Scientific O-MISC B-CHED-MISC
Gaps O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Millions O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
worldwide O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
living O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rural O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
developing O-MISC B-CHED-MISC
areas O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
harmful O-MISC B-CHED-MISC
levels O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
inorganic B-CHED-MISC O-MISC
arsenic I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
iAs B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
drinking O-MISC B-GENE-MISC
water O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

Inorganic B-CHED-MISC O-MISC
As I-CHED-MISC B-DISO-MISC
exposure O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
key O-MISC B-ACTI-MISC
developmental O-MISC B-CHED-MISC
periods O-MISC I-CHED-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
health O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
including O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
evident O-MISC B-CHED-MISC
in O-MISC B-CHED-MISC
adulthood O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
considerable O-MISC B-ACTI-MISC
interest O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
identifying O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
molecular O-MISC I-DISO-MISC
mechanisms O-MISC I-LIVB-MISC
that O-MISC B-ACTI-MISC
relate O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
life O-MISC B-ACTI-MISC
iAs B-CHED-MISC O-MISC
exposure O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
latent O-MISC I-ACTI-MISC
diseases O-MISC B-UnknownType-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

OBJECTIVES O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
work O-MISC B-ACTI-MISC
summarizes O-MISC B-ACTI-MISC
research O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
molecular O-MISC I-DISO-MISC
mechanisms O-MISC I-LIVB-MISC
that O-MISC B-ACTI-MISC
underlie O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
development O-MISC B-CHED-MISC
in O-MISC B-CHED-MISC
adulthood O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
early O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
life O-MISC B-ACTI-MISC
iAs B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

DISCUSSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Epigenetic O-MISC I-DISO-MISC
reprogramming O-MISC I-LIVB-MISC
that O-MISC B-ACTI-MISC
imparts O-MISC B-ACTI-MISC
functional O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-GENE-MISC
stem O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
immunomodulation O-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
plausible O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
mechanisms O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
life O-MISC B-ACTI-MISC
iAs B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
elicits O-MISC B-ACTI-MISC
latent O-MISC B-CHED-MISC
carcinogenic O-MISC I-ACTI-MISC
effects O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Evidence O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
mounting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
relates O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
life O-MISC B-ACTI-MISC
iAs B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
development O-MISC B-CHED-MISC
later O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
life O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Future O-MISC B-ACTI-MISC
research O-MISC B-CONC-MISC
should O-MISC B-ACTI-MISC
include O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
studies O-MISC I-PHEN-MISC
that O-MISC B-ACTI-MISC
address O-MISC B-ACTI-MISC
mechanistic O-MISC B-CHED-MISC
hypotheses O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
populations O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
integrate O-MISC B-ACTI-MISC
early O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
life O-MISC B-ANAT-MISC
exposure O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
alterations O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
latent O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
outcomes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Nifedipine B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
autonomic B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
old O-MISC B-ACTI-MISC
diabetic B-DISO-MISC I-ACTI-MISC
male O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
peripheral B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
autonomic I-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
flutter I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
ventricular O-MISC B-CHED-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
slowed O-MISC B-ACTI-MISC
down O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
divided O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
paced O-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
inconsistent O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
established O-MISC B-ACTI-MISC
finding O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
induces O-MISC B-CHED-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
normally O-MISC B-ACTI-MISC
innervated O-MISC I-DISO-MISC
hearts O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
deprived O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
compensatory O-MISC I-DISO-MISC
sympathetic O-MISC I-LIVB-MISC
drive O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
intoxication O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effectiveness O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
pretreatment O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
preventing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
model O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
intraperitoneal O-MISC B-CONC-MISC
( O-MISC I-CONC-MISC
i O-MISC I-CONC-MISC
. O-MISC I-CONC-MISC
p O-MISC I-CONC-MISC
. O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
injection O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
75 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
death O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
70 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
82 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
death O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Haloperidol B-CHED-MISC O-MISC
failed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
at O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
tested O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Haloperidol B-CHED-MISC O-MISC
decreased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
seizures B-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
highest O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lowering O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ANAT-MISC
reach O-MISC B-ACTI-MISC
statistical O-MISC B-CHED-MISC
significance O-MISC I-CHED-MISC
at O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
protective O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
central O-MISC O-MISC
dopamine B-CHED-MISC B-DISO-MISC
blocker O-MISC B-DISO-MISC
haloperidol B-CHED-MISC O-MISC
against O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
amphetamine B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
without O-MISC B-ACTI-MISC
reducing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
demonstrated O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
ability O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
seizures B-DISO-MISC I-ACTI-MISC
without O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
reducing O-MISC B-CHED-MISC
mortality O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Autoradiographic O-MISC B-CHED-MISC
evidence O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
estrogen B-CHED-MISC O-MISC
binding O-MISC O-MISC
sites O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
nuclei O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
diethylstilbesterol B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
hamster O-MISC I-ACTI-MISC
renal B-DISO-MISC B-ANAT-MISC
carcinomas I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Estrogen B-CHED-MISC O-MISC
binding O-MISC B-DISO-MISC
sites O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
autoradiography O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
transplantable O-MISC O-MISC
and O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
diethylstilbesterol B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
renal B-DISO-MISC I-ACTI-MISC
carcinomas I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
hamsters O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Radiolabelling O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
injection O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
3H O-MISC O-MISC
- O-MISC B-DISO-MISC
17 O-MISC B-DISO-MISC
beta O-MISC B-DISO-MISC
estradiol B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nuclei O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
; O-MISC B-ACTI-MISC
stereologic O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
revealed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
silver B-CHED-MISC O-MISC
grains O-MISC B-DISO-MISC
over O-MISC B-ACTI-MISC
nuclei O-MISC I-GENE-MISC
than O-MISC B-ACTI-MISC
cytoplasm O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Despite O-MISC B-ACTI-MISC
rapid O-MISC B-ACTI-MISC
tubular O-MISC I-GENE-MISC
excretion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
estradiol B-CHED-MISC O-MISC
which O-MISC B-ACTI-MISC
peaked O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
cells O-MISC B-GEOG-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
bind O-MISC I-DISO-MISC
the O-MISC B-ACTI-MISC
ligand O-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
published O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
documenting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
preferential O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
binding O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
estrogen B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
nuclei O-MISC I-GENE-MISC
of O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
estrogen B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
hamster O-MISC I-ACTI-MISC
renal B-DISO-MISC B-ANAT-MISC
carcinomas I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Bradycardia B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
biperiden B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
patient O-MISC I-LIVB-MISC
suffering O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
postzosteric B-DISO-MISC I-ACTI-MISC
trigeminal B-DISO-MISC B-ANAT-MISC
neuralgia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
intravenous O-MISC O-MISC
application O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-DISO-MISC
mg O-MISC B-DISO-MISC
biperiden B-CHED-MISC O-MISC
lactate I-CHED-MISC B-DISO-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
lasting O-MISC B-ACTI-MISC
paradoxical O-MISC I-ACTI-MISC
reaction O-MISC B-ANAT-MISC
characterized O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
considerable O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
dysarthria B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dysphagia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
back O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
orciprenaline B-CHED-MISC O-MISC
under O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
monitoring O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
intensive O-MISC B-GENE-MISC
care O-MISC I-GEOG-MISC
unit O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

Bradycardia B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
biperiden B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
attributed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
speed O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
related O-MISC I-CHED-MISC
dual O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
atropine B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
like O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
muscarine B-CHED-MISC O-MISC
receptors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Deliberate O-MISC I-ACTI-MISC
hypotension B-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
labetalol B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
halothane B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
enflurane B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
isoflurane B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
middle O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
ear O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
feasibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
labetalol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
adrenergic O-MISC B-DISO-MISC
blocking O-MISC B-DISO-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hypotensive B-DISO-MISC O-MISC
agent O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
inhalation O-MISC O-MISC
anaesthetics O-MISC O-MISC
( O-MISC B-ACTI-MISC
halothane B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
enflurane B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
isoflurane B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
middle O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
ear O-MISC I-CONC-MISC
surgery O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
86 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
mmHg O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
kPa O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
halothane B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
H B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
79 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
53 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
kPa O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
129 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
enflurane B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
E B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
kPa O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
135 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
isoflurane B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
I B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
H B-CHED-MISC I-CHED-MISC
concentration O-MISC I-CHED-MISC
during O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inspiratory O-MISC O-MISC
gas O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
vol O-MISC B-CHED-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
E B-CHED-MISC I-CHED-MISC
concentration O-MISC I-CHED-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
vol O-MISC B-CHED-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
I B-CHED-MISC I-CHED-MISC
concentration O-MISC I-CHED-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
vol O-MISC B-CHED-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
tubocurarine I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
initial O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
labetalol B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
lowering O-MISC I-ACTI-MISC
blood O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
stable O-MISC B-CHED-MISC
without O-MISC B-ACTI-MISC
tachy B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
or I-DISO-MISC B-ACTI-MISC
bradycardia I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
operating O-MISC B-CONC-MISC
conditions O-MISC I-CHED-MISC
regarding O-MISC B-ACTI-MISC
bleeding B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
manner O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
differ O-MISC B-ANAT-MISC
significantly O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
concentration O-MISC B-ANAT-MISC
rose O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
values O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
returned O-MISC B-ACTI-MISC
postoperatively O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initial O-MISC B-CHED-MISC
level O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
except O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
isoflurane B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
rebound O-MISC B-OCCU-MISC
phenomenon O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
or O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
labetalol B-CHED-MISC O-MISC
induces O-MISC B-CHED-MISC
easily O-MISC B-ACTI-MISC
adjustable O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
without O-MISC B-ACTI-MISC
compensatory O-MISC B-CHED-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
rebound O-MISC B-OCCU-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Convulsion B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
intravenous O-MISC B-CONC-MISC
fluorescein B-CHED-MISC I-CONC-MISC
angiography O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Tonic B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
clonic I-DISO-MISC B-ANAT-MISC
seizures I-DISO-MISC B-ANAT-MISC
followed O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
fluorescein B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
fundus O-MISC B-CONC-MISC
angiography O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Despite O-MISC B-ACTI-MISC
precautions O-MISC B-PHEN-MISC
this O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
reaction O-MISC B-ANAT-MISC
recurred O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
re O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
exposure O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
intravenous O-MISC O-MISC
fluorescein B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Pharmacology O-MISC B-PROC-MISC
of O-MISC B-ACTI-MISC
ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
prodrug O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disodium B-CHED-MISC O-MISC
phosphate I-CHED-MISC B-DISO-MISC
ester I-CHED-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
3 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
hydroxymethyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
diphenylhydantoin I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prodrug O-MISC O-MISC
of O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
advantageous O-MISC B-ACTI-MISC
physicochemical O-MISC B-CHED-MISC
properties O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
rapidly O-MISC B-ACTI-MISC
converted O-MISC B-ACTI-MISC
enzymatically O-MISC O-MISC
to O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
have O-MISC B-ACTI-MISC
equivalent O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
against O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
maximal O-MISC B-CONC-MISC
electroshock O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
MES O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
following O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ED50 O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
have O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
antiarrhythmic O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
against O-MISC B-ACTI-MISC
ouabain B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
dogs O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
total O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
necessary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
convert O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
normal O-MISC I-ACTI-MISC
sinus O-MISC B-ANAT-MISC
rhythm O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
displayed O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
antiarrhythmic O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
against O-MISC B-ACTI-MISC
strophanthidin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
arrhythmias B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
guinea O-MISC I-ANAT-MISC
pig O-MISC I-PHEN-MISC
right O-MISC I-GENE-MISC
atria O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
dogs O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
infused O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
equimolar O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
treatments O-MISC B-CONC-MISC
produced O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
reductions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
contractile O-MISC I-DISO-MISC
force O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
LVdP O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
dt O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
occurred O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
levels O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC B-CHED-MISC
toxicity B-DISO-MISC B-CHED-MISC
studies O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
rabbits O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
routes O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
administration O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
toxic O-MISC I-ACTI-MISC
signs O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
agents O-MISC O-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
approximately O-MISC B-CHED-MISC
equivalent O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Importantly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
local O-MISC I-ACTI-MISC
irritation O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
ACC B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9653 I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
markedly O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
sodium I-CHED-MISC B-DISO-MISC
following O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
m O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
ABSTRACT O-MISC B-ACTI-MISC
TRUNCATED O-MISC B-ACTI-MISC
AT O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
WORDS O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC

Tachyphylaxis O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
airway O-MISC I-DISO-MISC
responses O-MISC I-LIVB-MISC
during O-MISC B-CHED-MISC
prolonged O-MISC B-CHED-MISC
therapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
inhaled O-MISC I-DISO-MISC
salbutamol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
asthmatics B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

High O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
inhaled O-MISC I-DISO-MISC
salbutamol B-CHED-MISC O-MISC
produce O-MISC B-ACTI-MISC
substantial O-MISC B-ACTI-MISC
improvements O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
airway O-MISC I-DISO-MISC
response O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
asthma B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
systemic O-MISC B-CHED-MISC
beta O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
adrenoceptor O-MISC I-LIVB-MISC
responses O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
whether O-MISC B-ACTI-MISC
tachyphylaxis O-MISC I-ACTI-MISC
occurs O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
inhaled O-MISC I-DISO-MISC
salbutamol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Twelve O-MISC B-ACTI-MISC
asthmatic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
FEV1 O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
predicted O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
requiring O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
occasional O-MISC B-ACTI-MISC
inhaled O-MISC O-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
agonists O-MISC B-DISO-MISC
as O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
sole O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
inhaled O-MISC O-MISC
salbutamol B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
HDS O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
daily O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
inhaled O-MISC O-MISC
salbutamol B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
LDS O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
800 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
daily O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
( O-MISC B-ACTI-MISC
PI O-MISC O-MISC
) O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
metered O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
inhaler O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
crossover O-MISC I-CONC-MISC
design O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
run O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
in O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
washout O-MISC B-CHED-MISC
periods O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
inhaled O-MISC I-DISO-MISC
beta O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
agonists O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
withheld O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ipratropium B-CHED-MISC O-MISC
bromide I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
substituted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
rescue O-MISC B-DEVI-MISC
purposes O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
end O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
response O-MISC I-CHED-MISC
curve O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
DRC O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
airway O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
FEV1 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
FEF25 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
75 O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
chronotropic O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
HR O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
tremor B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
K B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
Glu B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
step O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
had O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
effect O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
values O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
increases O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
FEV1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
FEF25 O-MISC O-MISC
- O-MISC B-DISO-MISC
75 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
HDS O-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
displace O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DRC O-MISC O-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
right O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

DRC O-MISC I-GENE-MISC
for O-MISC B-ACTI-MISC
HR O-MISC O-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
K B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Glu B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
HDS O-MISC O-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
PI O-MISC O-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
HDS O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
LDS O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
HR O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Glu B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Frequency O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
subjective O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
HDS O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
tremor B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
palpitations B-DISO-MISC B-OCCU-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
ABSTRACT O-MISC B-ACTI-MISC
TRUNCATED O-MISC B-ACTI-MISC
AT O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
WORDS O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC

Phenytoin B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
fatal O-MISC B-CHED-MISC
hepatic B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
61 O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
developed O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
hepatic B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
multisystem O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
pattern O-MISC B-CHED-MISC
precedes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
manifestations O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
hepatic B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hematologic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
pathologic O-MISC B-CHED-MISC
features O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mixed O-MISC I-GENE-MISC
hepatocellular B-DISO-MISC I-GENE-MISC
damage I-DISO-MISC B-CHED-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
drug B-DISO-MISC I-ACTI-MISC
hypersensitivity I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
who O-MISC B-ACTI-MISC
presents O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
viral O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
like O-MISC B-ANAT-MISC
illness O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
early O-MISC B-CONC-MISC
recognition O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
are O-MISC B-ACTI-MISC
mandatory O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lethal O-MISC I-ACTI-MISC
pertussis B-CHED-MISC B-ANAT-MISC
vaccine I-CHED-MISC O-MISC
reaction O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
histamine B-CHED-MISC O-MISC
H1 O-MISC B-DISO-MISC
antagonists O-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
pertussis B-DISO-MISC I-ACTI-MISC
immunization O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Without O-MISC B-CHED-MISC
treatment O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
73 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
92 O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
died O-MISC I-DISO-MISC
after O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
bovine O-MISC O-MISC
serum O-MISC B-DISO-MISC
albumin O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
BSA O-MISC O-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pertussis B-DISO-MISC I-ACTI-MISC
immunization O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cyproheptadine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
mianserin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
chlorpheniramine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
105 O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
died O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
BSA O-MISC O-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Blockade O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
histamine B-CHED-MISC O-MISC
H1 O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
mortality O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
pertussis B-DISO-MISC I-ACTI-MISC
immunization O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Support O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
adrenaline B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
hypertension B-DISO-MISC B-ANAT-MISC
hypothesis O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
hour O-MISC B-CHED-MISC
pressor O-MISC O-MISC
effect O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
adrenaline B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
crossover O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
6 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
infusions O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
adrenaline B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
458 O-MISC B-ACTI-MISC
pmol O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
noradrenaline B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
911 O-MISC B-ACTI-MISC
pmol O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
dextrose B-CHED-MISC O-MISC
solution O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
ten O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
volunteers O-MISC I-PHEN-MISC
in O-MISC B-ACTI-MISC
random O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
apart O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
means O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
intra O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
arterial O-MISC I-CONC-MISC
ambulatory O-MISC I-CONC-MISC
monitoring O-MISC I-CONC-MISC
the O-MISC B-ACTI-MISC
haemodynamic O-MISC I-DISO-MISC
effects O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
followed O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
infusions O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
stopped O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Adrenaline B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
noradrenaline B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
delayed O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
protracted O-MISC B-CHED-MISC
pressor O-MISC B-CONC-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
postinfusion O-MISC B-CHED-MISC
period O-MISC I-CHED-MISC
systolic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
arterial O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
SEM O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
dextrose B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
ANOVA O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
" O-MISC B-PHEN-MISC
stress O-MISC B-UnknownType-MISC
" O-MISC B-UnknownType-MISC
levels O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
adrenaline B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
230 O-MISC B-ACTI-MISC
pg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
delayed O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
protracted O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
strong O-MISC B-ACTI-MISC
support O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adrenaline B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
hypertension B-DISO-MISC B-ANAT-MISC
hypothesis O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
alkylxanthines B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Adenosine B-CHED-MISC O-MISC
antagonists O-MISC B-DISO-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
benefit O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
ischaemic B-DISO-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
nephrotoxic B-DISO-MISC B-CHED-MISC
models O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ARF B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
three O-MISC B-ACTI-MISC
alkylxanthines B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
potencies O-MISC B-OCCU-MISC
as O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
antagonists O-MISC B-DISO-MISC
8 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
phenyltheophylline I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
theophylline B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
enprofylline B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
developing O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
injections O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
plasma O-MISC B-CONC-MISC
urea B-CHED-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
creatinine B-CHED-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
analysis O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
[ O-MISC O-MISC
3H O-MISC B-DISO-MISC
] O-MISC B-DISO-MISC
inulin O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
[ O-MISC O-MISC
14C O-MISC B-DISO-MISC
] O-MISC B-DISO-MISC
p B-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
aminohippuric I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
clearances O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
morphological O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
degree O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
necrosis B-DISO-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
indices O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
treatments O-MISC I-CONC-MISC
produced O-MISC B-ACTI-MISC
improvements O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
measurements O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
largely O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
beneficial O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
exerted O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
vehicle O-MISC O-MISC
( O-MISC B-ACTI-MISC
polyethylene B-CHED-MISC O-MISC
glycol I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
NaOH B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
consistent O-MISC B-ACTI-MISC
protective O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
noted O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alkylxanthines B-CHED-MISC O-MISC
tested O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
indicates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
plays O-MISC B-ACTI-MISC
little O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
pathophysiological O-MISC B-CHED-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ARF B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Adverse O-MISC I-ACTI-MISC
ocular O-MISC B-ANAT-MISC
reactions O-MISC B-ANAT-MISC
possibly O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
isotretinoin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
261 O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
ocular O-MISC B-ANAT-MISC
reactions O-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
237 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
isotretinoin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
commonly O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
drug O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
cystic O-MISC I-ACTI-MISC
acne B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Blepharoconjunctivitis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
subjective O-MISC I-ACTI-MISC
complaints O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
dry B-DISO-MISC I-ACTI-MISC
eyes I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
blurred B-DISO-MISC I-ACTI-MISC
vision I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
contact O-MISC I-ACTI-MISC
lens O-MISC B-ANAT-MISC
intolerance O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
photodermatitis B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
reversible O-MISC B-CHED-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

More O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
ocular O-MISC I-GENE-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
include O-MISC B-DEVI-MISC
papilledema B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
pseudotumor B-DISO-MISC I-ACTI-MISC
cerebri I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
white O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
gray O-MISC I-ACTI-MISC
subepithelial O-MISC B-ANAT-MISC
corneal B-DISO-MISC B-ANAT-MISC
opacities I-DISO-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
reversible O-MISC B-CHED-MISC
if O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
is O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Reported O-MISC B-CONC-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
dark O-MISC B-OCCU-MISC
adaptation O-MISC I-OCCU-MISC
are O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
investigation O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Isotretinoin B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
contraindicated O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
pregnancy O-MISC I-DISO-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
maternal O-MISC I-ACTI-MISC
use O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
microphthalmos B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
orbital O-MISC I-ACTI-MISC
hypertelorism B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
optic B-DISO-MISC I-ACTI-MISC
nerve I-DISO-MISC B-ANAT-MISC
hypoplasia I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Procaterol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
terbutaline B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
bronchial B-DISO-MISC I-ACTI-MISC
asthma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
cross O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
over O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Procaterol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
adrenoceptor O-MISC B-DISO-MISC
stimulant O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
cross O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
over O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
bronchial B-DISO-MISC I-ACTI-MISC
asthma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC O-MISC
procaterol B-CHED-MISC B-DISO-MISC
50 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
b O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
procaterol B-CHED-MISC O-MISC
100 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
b O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
terbutaline B-CHED-MISC O-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
treatment O-MISC B-CHED-MISC
periods O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
terbutaline B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
anti O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
asthmatic B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
tremorgenic B-DISO-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
procaterol B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Procaterol B-CHED-MISC O-MISC
appeared O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
tested O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
twice O-MISC B-CHED-MISC
daily O-MISC B-CHED-MISC
regimen O-MISC B-CONC-MISC
would O-MISC B-ACTI-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
suitable O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
drug O-MISC O-MISC
. O-MISC B-ACTI-MISC

Subacute O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
B O-MISC O-MISC
24 O-MISC B-DISO-MISC
/ O-MISC B-DISO-MISC
76 O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
heart B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
blocker O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
B O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC O-MISC
- O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
, O-MISC B-DISO-MISC
4 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
dichlorophenoxy O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
3 O-MISC B-DISO-MISC
[ O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
3 O-MISC B-DISO-MISC
, O-MISC B-DISO-MISC
4 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
dimethoxyphenyl O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
ethanolamino O-MISC B-DISO-MISC
] O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
prop O-MISC O-MISC
an O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
ol O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
beta O-MISC I-DISO-MISC
1 O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
adrenoceptor O-MISC I-LIVB-MISC
blocking O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
beta O-MISC O-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
adrenoceptor O-MISC B-DISO-MISC
stimulating O-MISC B-OCCU-MISC
properties O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
model O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
heart B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
neither O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
nor O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
attempt O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
suppress O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
influenced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypertrophy B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
reproducible O-MISC B-ACTI-MISC
extent O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
suppress O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
ornithine B-CHED-MISC I-DISO-MISC
decarboxylase O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
hypertrophied B-DISO-MISC I-ACTI-MISC
hearts I-DISO-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-ACTI-MISC
mass O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
nor O-MISC B-ACTI-MISC
B O-MISC O-MISC
24 O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
76 O-MISC O-MISC
could O-MISC B-ACTI-MISC
stop O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
characteristic O-MISC B-ACTI-MISC
myosin O-MISC O-MISC
isoenzyme O-MISC O-MISC
pattern O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypertrophied B-DISO-MISC I-ACTI-MISC
rat O-MISC I-ANAT-MISC
heart O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
investigations O-MISC B-CHED-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
propranolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
B O-MISC O-MISC
24 O-MISC B-DISO-MISC
/ O-MISC B-ACTI-MISC
76 O-MISC O-MISC
have O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potency O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
from O-MISC B-ACTI-MISC
producing O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-CHED-MISC
anxiogenic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
ratings O-MISC I-DEVI-MISC
, O-MISC B-ACTI-MISC
somatic O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
plasma O-MISC B-CONC-MISC
levels O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
3 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
methoxy I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
hydroxyphenethyleneglycol I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MHPG B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cortisol B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
meeting O-MISC B-ACTI-MISC
DSM O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
III O-MISC I-CHED-MISC
criteria O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
agoraphobia B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
attacks I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Caffeine B-CHED-MISC O-MISC
produced O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
increases O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
subject O-MISC I-ANAT-MISC
- O-MISC I-CHED-MISC
rated O-MISC I-PHEN-MISC
anxiety B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
nervousness O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
fear O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
palpitations B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
restlessness B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
tremors B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
caffeine B-CHED-MISC B-CONC-MISC
levels O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Seventy O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
percent O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
reported O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
experienced O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
attacks I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Caffeine B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
alter O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
MHPG B-CHED-MISC B-CONC-MISC
levels O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
or O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Caffeine B-CHED-MISC O-MISC
increased O-MISC I-ACTI-MISC
plasma O-MISC B-OCCU-MISC
cortisol B-CHED-MISC I-OCCU-MISC
levels O-MISC I-CONC-MISC
equally O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
groups O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
panic B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
abnormalities B-DISO-MISC I-ACTI-MISC
in I-DISO-MISC B-ACTI-MISC
neuronal I-DISO-MISC I-GENE-MISC
systems I-DISO-MISC B-GEOG-MISC
involving O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
anxiety B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
benefit O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
avoiding O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
containing O-MISC B-ACTI-MISC
foods O-MISC B-GENE-MISC
and O-MISC B-ACTI-MISC
beverages O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

Comparison O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oxitropium B-CHED-MISC O-MISC
bromide I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
slow O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
release O-MISC B-ANAT-MISC
theophylline B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
nocturnal O-MISC I-ACTI-MISC
asthma B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
inhaled O-MISC I-DISO-MISC
antimuscarinic O-MISC O-MISC
drug O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
oxitropium B-CHED-MISC O-MISC
bromide I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
slow O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
release O-MISC B-ACTI-MISC
theophylline B-CHED-MISC O-MISC
preparation O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
nocturnal O-MISC I-ACTI-MISC
asthma B-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
double O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
samples O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
oxitropium B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
t O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
theophylline B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
b O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Morning O-MISC B-CONC-MISC
dipping O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fall O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
peak O-MISC B-CHED-MISC
flow O-MISC B-OCCU-MISC
overnight O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
reduced O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
periods O-MISC B-CHED-MISC
when O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
active O-MISC O-MISC
drug O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
taken O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
difference O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
noticed O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
significant O-MISC B-ANAT-MISC
difference O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
noticed O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
results O-MISC B-OCCU-MISC
obtained O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
active O-MISC O-MISC
drug O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oxitropium B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
subject O-MISC I-ANAT-MISC
reported O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
oxitropium B-CHED-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
reporting O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
tremors B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
theophylline B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Oxitropium B-CHED-MISC O-MISC
proves O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
valuable O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
theophylline B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
nocturnal O-MISC I-ACTI-MISC
asthma B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
since O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
equally O-MISC B-CHED-MISC
potent O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
safer O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
require O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
titration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Penicillin B-CHED-MISC O-MISC
anaphylaxis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
penicillin B-CHED-MISC O-MISC
anaphylaxis B-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
terminology O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
manifestations O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
prevention O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
anaphylaxis B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
reviewed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Emergency O-MISC I-ANAT-MISC
physicians O-MISC I-PHEN-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
penicillin B-CHED-MISC O-MISC
anaphylaxis B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-CONC-MISC
its O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
prescribing O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
antibiotic O-MISC O-MISC
judiciously O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
knowledgeably O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
offer O-MISC B-ACTI-MISC
optimal O-MISC B-CHED-MISC
medical O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
once O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
life O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
reaction O-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
begun O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Reversible O-MISC B-ACTI-MISC
valproic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dementia B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Reversible O-MISC B-ACTI-MISC
valproic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dementia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
insidious O-MISC B-CHED-MISC
progressive O-MISC B-CHED-MISC
decline O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
global O-MISC B-CHED-MISC
cognitive O-MISC I-DISO-MISC
abilities O-MISC I-LIVB-MISC
documented O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
serial O-MISC B-ACTI-MISC
neuropsychological O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Repeat O-MISC B-ACTI-MISC
neuropsychological O-MISC B-CONC-MISC
testing O-MISC I-CONC-MISC
7 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
revealed O-MISC B-ACTI-MISC
dramatic O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
IQ O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
naming O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
tasks O-MISC B-DEVI-MISC
commensurate O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
recovery O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
intellectual O-MISC I-DISO-MISC
capacity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Possible O-MISC B-ACTI-MISC
pathophysiological O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
operative O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
include O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-CHED-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
CNS O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
valproic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
; O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
paradoxical O-MISC B-CHED-MISC
epileptogenic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
secondary O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
indirect O-MISC B-CHED-MISC
CNS O-MISC I-GENE-MISC
toxic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
mediated O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
valproic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperammonemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Reversal O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
amnesia B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC I-LIVB-MISC
training O-MISC I-LIVB-MISC
naloxone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
experiments O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
modulating O-MISC B-CHED-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
naloxone B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
retention B-DISO-MISC I-ACTI-MISC
deficit I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
paradigm O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Scopolamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
methyl B-CHED-MISC O-MISC
scopolamine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
an O-MISC B-ACTI-MISC
amnesia B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
latency O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
parameters O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Naloxone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
attenuated O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
retention B-DISO-MISC I-ACTI-MISC
deficit I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
peak O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
naloxone B-CHED-MISC O-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
antagonized O-MISC O-MISC
with O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
demonstrating O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
opioid O-MISC O-MISC
specificity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
naloxone B-CHED-MISC O-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Post O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
training O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
naloxone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
split O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
also O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
amnesia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Control O-MISC I-ANAT-MISC
experiments O-MISC B-CONC-MISC
indicated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
neither O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
sensitivity O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
training O-MISC I-CHED-MISC
naloxone B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
nor O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
aversive O-MISC B-CHED-MISC
state O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
training O-MISC I-CHED-MISC
naloxone B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
naloxone B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
retention B-DISO-MISC I-DISO-MISC
deficit I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
extend O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
implicating O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cholinergic O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
opioid O-MISC O-MISC
interaction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
processes O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
interaction O-MISC B-CHED-MISC
involving O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
septo O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
hippocampal O-MISC B-GEOG-MISC
cholinergic O-MISC B-CHED-MISC
pathway O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Electron O-MISC B-CONC-MISC
microscopic O-MISC I-CONC-MISC
investigations O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
lesions B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
urinary I-DISO-MISC I-GENE-MISC
bladder I-DISO-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
prevention O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
mesna B-CHED-MISC B-OBJC-MISC
. O-MISC B-ACTI-MISC

Fully O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cystitis B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
nearly O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
detachment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urothelium O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
submucosal O-MISC I-ACTI-MISC
edema B-DISO-MISC B-ANAT-MISC
owing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
damage O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
microvascular O-MISC I-GENE-MISC
bed O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
focal O-MISC I-ACTI-MISC
muscle O-MISC B-ANAT-MISC
necroses B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
initial O-MISC B-CHED-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
attack O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
metabolites O-MISC O-MISC
seems O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
fragmentation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
luminal B-CHED-MISC I-GENE-MISC
membrane O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
damages O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
cellular O-MISC I-DISO-MISC
barrier O-MISC B-ANAT-MISC
against O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypertonic O-MISC I-ACTI-MISC
urine O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Subsequent O-MISC B-ACTI-MISC
breaks O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lateral O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
membranes O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
superficial O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
membranes O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intermediate O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
basal O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
intercellular O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
intracellular O-MISC B-CHED-MISC
edema B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
disintegration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
desmosomes O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
hemidesmosomes O-MISC O-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
degeneration O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
detachment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epithelial O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
with O-MISC B-ACTI-MISC
exposure O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
splitting O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basal O-MISC I-GENE-MISC
membrane O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
morphological O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
endothelial O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
become O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
pronounced O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
later O-MISC B-CHED-MISC
stages O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
experiment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
involvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
vessels O-MISC B-GEOG-MISC
regardless O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
diameter O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
location O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
extent O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
damage O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
damage O-MISC B-CHED-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
preceded O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mediator O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
permeability O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
morphological O-MISC B-CHED-MISC
correlate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
formation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
gaps O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
interendothelial O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
connections O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
venules O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
effectively O-MISC B-ACTI-MISC
prevented O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
mesna B-CHED-MISC B-OBJC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
sign O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
involvement O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
granules O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
presumed O-MISC B-ACTI-MISC
lysosomal O-MISC I-GENE-MISC
function O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
superficial O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
intragastric O-MISC B-CHED-MISC
pressure O-MISC B-OCCU-MISC
during O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
muscle B-DISO-MISC I-GENE-MISC
fasciculations I-DISO-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
alfentanil B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Changes O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
intragastric O-MISC B-CHED-MISC
pressure O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
yr O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
pretreated O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
physiological O-MISC B-GENE-MISC
saline O-MISC I-GEOG-MISC
or O-MISC B-ACTI-MISC
alfentanil B-CHED-MISC O-MISC
50 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Anaesthesia O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
thiopentone B-CHED-MISC O-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
intensity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
muscle B-DISO-MISC I-GENE-MISC
fasciculations I-DISO-MISC I-DISO-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
greater O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alfentanil B-CHED-MISC O-MISC
group O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
intragastric O-MISC B-CHED-MISC
pressure O-MISC B-OCCU-MISC
during O-MISC B-ACTI-MISC
muscle B-DISO-MISC I-GENE-MISC
fasciculations I-DISO-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
SEM O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
cm O-MISC B-ACTI-MISC
H2O B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alfentanil B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
SEM O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
cm O-MISC B-ACTI-MISC
H2O B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
intragastric O-MISC B-CHED-MISC
pressure O-MISC B-OCCU-MISC
was O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intensity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
muscle B-DISO-MISC I-GENE-MISC
fasciculations I-DISO-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
regression O-MISC B-CHED-MISC
line O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
y O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
78x O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
r O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
78 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
intragastric O-MISC B-CHED-MISC
pressure O-MISC B-OCCU-MISC
increases O-MISC B-CHED-MISC
significantly O-MISC B-ACTI-MISC
during O-MISC B-CHED-MISC
muscle B-DISO-MISC I-GENE-MISC
fasciculations I-DISO-MISC I-DISO-MISC
caused O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
healthy O-MISC I-ACTI-MISC
children O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Alfentanil B-CHED-MISC O-MISC
50 O-MISC B-DISO-MISC
micrograms O-MISC B-DISO-MISC
kg O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
effectively O-MISC B-CHED-MISC
inhibits O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
intensity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
muscle B-DISO-MISC I-GENE-MISC
fasciculations I-DISO-MISC I-DISO-MISC
; O-MISC B-ACTI-MISC
moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
intragastric O-MISC B-OCCU-MISC
pressure O-MISC I-OCCU-MISC
remains O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC B-CHED-MISC
insulin O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
normalizes O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
resistance O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiotoxic B-DISO-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC O-MISC
diabetic B-DISO-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
morphometric O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
myocardial O-MISC I-ACTI-MISC
fibrosis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
insulin O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
earlier O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
protective O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC I-ACTI-MISC
diabetes B-DISO-MISC B-ANAT-MISC
against O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiotoxic B-DISO-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
ISO B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Thirty O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
135 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
crystalline O-MISC O-MISC
insulin O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
ISO B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
subcutaneously O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
ISO B-CHED-MISC O-MISC
induced O-MISC B-ACTI-MISC
fibrosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardium O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
morphometrically O-MISC B-CONC-MISC
analyzed O-MISC I-CONC-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
later O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
highly O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
correlation O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
r O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
83 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
006 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
slope O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fall O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
blood O-MISC O-MISC
glucose B-CHED-MISC B-DISO-MISC
after O-MISC B-ACTI-MISC
insulin O-MISC O-MISC
treatment O-MISC B-CHED-MISC
appeared O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
myocardial O-MISC I-GENE-MISC
content O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
catecholamines B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
diabetic B-DISO-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
norepinephrine B-CHED-MISC O-MISC
content O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
while O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
remained O-MISC B-ACTI-MISC
unchanged O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
enhanced O-MISC B-ACTI-MISC
sympathetic O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
activity O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
consequent O-MISC B-ACTI-MISC
down O-MISC I-DISO-MISC
regulation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardial O-MISC I-GENE-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
adrenergic O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
could O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
explain O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
catecholamine B-CHED-MISC O-MISC
resistance O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
rapid O-MISC B-CHED-MISC
reversion O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
insulin O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
excludes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
streptozotocin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
itself O-MISC B-ACTI-MISC
causes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ISO B-CHED-MISC O-MISC
resistance O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
points O-MISC B-ACTI-MISC
towards O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
insulin O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
myocardial O-MISC I-GENE-MISC
catecholamine B-CHED-MISC O-MISC
sensitivity O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
diabetic B-DISO-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
phenomenon O-MISC B-OCCU-MISC
described O-MISC B-ACTI-MISC
might O-MISC B-ACTI-MISC
elucidate O-MISC B-ACTI-MISC
pathogenetic O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
behind O-MISC B-ACTI-MISC
toxic O-MISC B-CHED-MISC
myocardial O-MISC I-ACTI-MISC
cell O-MISC B-ANAT-MISC
degeneration O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
relevance O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
cardiovascular O-MISC I-ACTI-MISC
complications O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
diabetic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Differential O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
steroidal O-MISC B-DISO-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
muscarinic O-MISC O-MISC
cholinergic O-MISC B-DISO-MISC
agonist O-MISC B-DISO-MISC
pilocarpine B-CHED-MISC O-MISC
induces O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
widespread O-MISC B-CHED-MISC
damage O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
forebrain O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
designed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
steroidal O-MISC B-DISO-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
salicylate I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
phenylbutazone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
mefenamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Pretreatment O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
salicylate I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
ED50 O-MISC B-PHEN-MISC
103 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
174 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
phenylbutazone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
converted O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
convulsant O-MISC B-ANAT-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
convulsant O-MISC O-MISC
one O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Indomethacin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
failed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
modulate O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Mefenamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
protected O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
brain B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
380 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
steroidal O-MISC B-DISO-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drugs O-MISC B-DISO-MISC
differentially O-MISC B-ACTI-MISC
modulate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
threshold O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Acute B-DISO-MISC B-CHED-MISC
neurologic I-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
etoposide B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
malignant B-DISO-MISC I-ACTI-MISC
glioma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Etoposide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
VP B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
16 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
213 I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
solid O-MISC I-ACTI-MISC
tumors B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
hematologic B-DISO-MISC I-ACTI-MISC
malignancies I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
conjunction O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
autologous O-MISC B-CONC-MISC
bone O-MISC I-CONC-MISC
marrow O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
agent O-MISC O-MISC
has O-MISC B-ACTI-MISC
activity O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
treatment O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
resistant O-MISC B-CHED-MISC
cancers B-DISO-MISC I-ACTI-MISC
including O-MISC B-ACTI-MISC
malignant B-DISO-MISC I-ACTI-MISC
glioma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
recurrent O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
resistant O-MISC B-CHED-MISC
glioma B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
sudden O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
neurologic B-DISO-MISC I-ACTI-MISC
deterioration I-DISO-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
median O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
etoposide B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Significant O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
manifestations O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
confusion B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
papilledema B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
somnolence B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
exacerbation O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
motor B-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sharp O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
abnormalities O-MISC I-ACTI-MISC
resolved O-MISC I-ACTI-MISC
rapidly O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
initiation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
intravenous O-MISC B-CONC-MISC
dexamethasone B-CHED-MISC I-CONC-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
computerized O-MISC B-CONC-MISC
tomographic O-MISC I-CONC-MISC
( O-MISC I-CONC-MISC
CT O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
brain O-MISC I-CONC-MISC
scans O-MISC I-CONC-MISC
demonstrated O-MISC B-ACTI-MISC
stability O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
tumor B-DISO-MISC B-CHED-MISC
size O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
peritumor O-MISC I-ACTI-MISC
edema B-DISO-MISC B-ANAT-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
pretransplant O-MISC B-CONC-MISC
scans O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
represent O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
new O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
etoposide B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
malignant B-DISO-MISC I-ACTI-MISC
glioma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Progressive O-MISC B-CHED-MISC
bile B-DISO-MISC I-ACTI-MISC
duct I-DISO-MISC B-ANAT-MISC
injury I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
thiabendazole B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
yr O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
developed O-MISC B-ACTI-MISC
jaundice B-DISO-MISC I-ACTI-MISC
2 O-MISC B-ACTI-MISC
wk O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
thiabendazole B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Cholestasis B-DISO-MISC I-ACTI-MISC
persisted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
yr O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
biopsy O-MISC B-GEOG-MISC
specimens O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hepatectomy O-MISC B-CONC-MISC
specimen O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
remarkable O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
complete O-MISC B-CHED-MISC
disappearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
interlobular O-MISC I-GENE-MISC
bile O-MISC B-GEOG-MISC
ducts O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Prominent O-MISC B-ACTI-MISC
fibrosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hepatocellular O-MISC I-DISO-MISC
regeneration O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lobular O-MISC I-GENE-MISC
architecture O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
preserved O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
represents O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
example O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
idiosyncratic O-MISC I-ACTI-MISC
" O-MISC B-ACTI-MISC
drug B-DISO-MISC O-MISC
- I-DISO-MISC B-ACTI-MISC
induced I-DISO-MISC B-CHED-MISC
liver I-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
primary O-MISC B-CHED-MISC
target O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
injury O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bile O-MISC I-GENE-MISC
duct O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
autoimmune O-MISC I-ACTI-MISC
pathogenesis O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bile B-DISO-MISC I-GENE-MISC
duct I-DISO-MISC B-GEOG-MISC
destruction I-DISO-MISC B-DEVI-MISC
is O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Differential O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
1 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dihydropyridine I-CHED-MISC B-DISO-MISC
calcium B-CHED-MISC B-DISO-MISC
channel I-CHED-MISC B-DISO-MISC
blockers I-CHED-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
implications O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Increasing O-MISC B-ACTI-MISC
recognition O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
importance O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
stimulated O-MISC B-ACTI-MISC
research O-MISC B-CONC-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
channel I-CHED-MISC B-DISO-MISC
blocking I-CHED-MISC B-DISO-MISC
agents I-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiovascular B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
favorable O-MISC B-CHED-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
tolerability O-MISC B-CONC-MISC
profiles O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
agents O-MISC O-MISC
make O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
attractive O-MISC B-CHED-MISC
therapeutic O-MISC B-CHED-MISC
modalities O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CHED-MISC
applications O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
channel I-CHED-MISC B-DISO-MISC
blockers I-CHED-MISC B-DISO-MISC
parallel O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
tissue O-MISC I-GENE-MISC
selectivity O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
diltiazem B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
roughly O-MISC B-ACTI-MISC
equipotent O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
actions O-MISC B-DEVI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
vascular O-MISC I-GENE-MISC
smooth O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dihydropyridine B-CHED-MISC O-MISC
calcium B-CHED-MISC B-DISO-MISC
channel I-CHED-MISC B-DISO-MISC
blockers I-CHED-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
potent O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
vasodilator O-MISC O-MISC
agents O-MISC B-DISO-MISC
that O-MISC B-ACTI-MISC
exert O-MISC B-ACTI-MISC
minimal O-MISC B-ACTI-MISC
electrophysiologic O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
on O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
nodal O-MISC B-GEOG-MISC
or O-MISC B-ACTI-MISC
conduction O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
dihydropyridine B-CHED-MISC O-MISC
available O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
United O-MISC B-ORGA-MISC
States O-MISC I-ORGA-MISC
, O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
controls O-MISC B-CHED-MISC
angina B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
minimal O-MISC B-ACTI-MISC
depression O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Additional O-MISC B-ACTI-MISC
members O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
group O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
channel I-CHED-MISC B-DISO-MISC
blockers I-CHED-MISC B-DISO-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
indications O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
offer O-MISC B-ACTI-MISC
advantages O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
current O-MISC B-CHED-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Once O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
twice O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
dosage O-MISC B-CHED-MISC
possible O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
nitrendipine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
nisoldipine B-CHED-MISC O-MISC
offers O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
convenient O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
schedule O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
encourages O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
compliance O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
therapy O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
coronary O-MISC I-DISO-MISC
vasodilating O-MISC I-LIVB-MISC
properties O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nisoldipine B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
investigation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
agent O-MISC O-MISC
for O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
angina B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Selectivity O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebrovascular O-MISC I-GENE-MISC
bed O-MISC B-GEOG-MISC
makes O-MISC B-ACTI-MISC
nimodipine B-CHED-MISC O-MISC
potentially O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
subarachnoid B-DISO-MISC I-ACTI-MISC
hemorrhage I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
migraine B-DISO-MISC I-ACTI-MISC
headache I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
dementia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
general O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dihydropyridine B-CHED-MISC O-MISC
calcium B-CHED-MISC B-DISO-MISC
channel I-CHED-MISC B-DISO-MISC
blockers I-CHED-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
headache B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
facial O-MISC I-ACTI-MISC
flushing B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
palpitations B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
edema B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
anorexia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dizziness B-DISO-MISC I-ACTI-MISC
being O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
enhancement O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aminonucleoside B-CHED-MISC O-MISC
nephrosis B-DISO-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
co O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
protamine O-MISC O-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
model O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
focal B-DISO-MISC I-ACTI-MISC
segmental I-DISO-MISC B-ANAT-MISC
glomerular I-DISO-MISC B-ANAT-MISC
sclerosis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
FSGS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
combined O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
puromycin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminonucleoside I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
AMNS B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
protamine B-CHED-MISC O-MISC
sulfate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
PS B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Male O-MISC I-DISO-MISC
Sprague O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Dawley O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
uninephrectomized O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
injections O-MISC O-MISC
of O-MISC B-ACTI-MISC
subcutaneous O-MISC B-CHED-MISC
AMNS B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
body O-MISC B-ACTI-MISC
wt O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
PS B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
separated O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
body O-MISC B-ACTI-MISC
wt O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
series O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
injections O-MISC O-MISC
were O-MISC B-ACTI-MISC
repeated O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
intervals O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
sacrificed O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
24 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

They O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
nephrotic B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
finally O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
course O-MISC I-CHED-MISC
curve O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
creatinine B-CHED-MISC O-MISC
clearance O-MISC I-DISO-MISC
dropped O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
difference O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
AMNS B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
PS B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
injected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Their O-MISC B-ACTI-MISC
glomeruli O-MISC I-GENE-MISC
showed O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
FSGS B-DISO-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ultrastructural O-MISC I-GENE-MISC
studies O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initial O-MISC B-CHED-MISC
stage O-MISC I-CHED-MISC
revealed O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
particles O-MISC O-MISC
of O-MISC B-ACTI-MISC
perfused O-MISC B-CHED-MISC
ruthenium B-CHED-MISC O-MISC
red O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lamina O-MISC I-ANAT-MISC
rara O-MISC I-PHEN-MISC
externa O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
epithelial O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
cytoplasm O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
PS B-CHED-MISC O-MISC
enhances O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
AMNS B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
glomerulus O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
readily O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
FSGS B-DISO-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
resulting O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
end B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
stage I-DISO-MISC B-ANAT-MISC
renal I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Theophylline B-CHED-MISC O-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
pregnant O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
investigation O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
theophylline B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
advanced O-MISC I-ACTI-MISC
pregnancy O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Sprague O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Dawley O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
that O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
pregnant O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
nonpregnant O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
strain O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
infusions O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
aminophylline B-CHED-MISC O-MISC
until O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
maximal O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
which O-MISC B-ACTI-MISC
occurred O-MISC B-DEVI-MISC
after O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Theophylline B-CHED-MISC O-MISC
concentrations O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
endpoint O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
total O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
CSF O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
free O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
concentrations O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
slightly O-MISC B-ACTI-MISC
different O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
pregnant O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Theophylline B-CHED-MISC O-MISC
serum O-MISC B-DISO-MISC
protein O-MISC I-DISO-MISC
binding O-MISC I-LIVB-MISC
determined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
equilibrium O-MISC B-CONC-MISC
dialysis O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
pregnant O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Fetal O-MISC B-CONC-MISC
serum O-MISC I-CONC-MISC
concentrations O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mother O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
maternal O-MISC I-ACTI-MISC
brain O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
CSF O-MISC B-CONC-MISC
concentrations O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
correlated O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
former O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
advanced O-MISC I-ACTI-MISC
pregnancy O-MISC I-DISO-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
negligible O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC O-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
theophylline B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Hyperkalemia B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
naproxen B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
reversed O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
fludrocortisone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
rheumatoid B-DISO-MISC I-ACTI-MISC
arthritis I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
mefenamic B-CHED-MISC I-ACTI-MISC
acid I-CHED-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
inappropriate O-MISC B-ACTI-MISC
hypoaldosteronism B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
naproxen B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
major O-MISC B-CHED-MISC
decline O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
preexisting O-MISC I-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
predisposed O-MISC B-CHED-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
type B-DISO-MISC I-ACTI-MISC
IV I-DISO-MISC B-ANAT-MISC
renal I-DISO-MISC B-ANAT-MISC
tubular I-DISO-MISC B-ANAT-MISC
acidosis I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
prostaglandin B-CHED-MISC O-MISC
synthetase O-MISC B-DISO-MISC
inhibitors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
unable O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
discontinue O-MISC B-ACTI-MISC
nonsteroidal O-MISC O-MISC
anti O-MISC I-CONC-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
drug O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
fludrocortisone B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
added O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
correcting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
allowing O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
continued O-MISC B-ACTI-MISC
safely O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hypotension B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
manifestation O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Cardiac O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
advanced O-MISC B-CHED-MISC
colorectal B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
while O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
cisplatin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CDDP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
severe O-MISC B-CHED-MISC
left B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
required O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
discontinuation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Cardiac O-MISC I-ACTI-MISC
enzymes O-MISC B-ANAT-MISC
remained O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
despite O-MISC B-ACTI-MISC
transient O-MISC B-ACTI-MISC
electrocardiographic O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
EKG O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
changes O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
presentation O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
evaluation O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
hemodynamic O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
echocardiographic O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
scintigraphic O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
suggest O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
manifestations O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
FU I-CHED-MISC B-DISO-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
influenced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
CDDP B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
pathophysiologic O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Fatal O-MISC B-CHED-MISC
aplastic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
carbamazepine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
aplastic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
carbamazepine B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
epileptic B-DISO-MISC I-ACTI-MISC
woman O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Despite O-MISC B-ACTI-MISC
concerns O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
bone B-DISO-MISC I-ACTI-MISC
marrow I-DISO-MISC B-ANAT-MISC
toxicity I-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
carbamazepine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fourth O-MISC B-ACTI-MISC
documented O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
published O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Carbamazepine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
drug O-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
physicians O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
aware O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
exceedingly O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
potentially O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
better O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
laboratory O-MISC B-CONC-MISC
monitoring O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Participation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
bulbospinal O-MISC I-GENE-MISC
serotonergic O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-GENE-MISC
brain O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
microinjection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
microliter O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
region O-MISC I-GENE-MISC
adjacent O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ventrolateral O-MISC I-GENE-MISC
surface O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medulla O-MISC I-GENE-MISC
oblongata O-MISC B-GEOG-MISC
on O-MISC B-ACTI-MISC
cardiovascular O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
urethane B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Intramedullary O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
vehicle O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
decrease O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
antagonized O-MISC O-MISC
by O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
spinal O-MISC B-CONC-MISC
transection O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
bilateral O-MISC B-CHED-MISC
vagotomy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
hand O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
antagonized O-MISC O-MISC
by O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
bilateral O-MISC B-CHED-MISC
vagotomy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
spinal O-MISC B-CONC-MISC
transection O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
destruction O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
spinal O-MISC I-GENE-MISC
5 B-CHED-MISC B-GEOG-MISC
- I-CHED-MISC B-GEOG-MISC
HT I-CHED-MISC B-GEOG-MISC
nerves O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
bilateral O-MISC B-CHED-MISC
spinal O-MISC B-CHED-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
7 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dihydroxytryptamine I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
magnitude O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vasodepressor O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bradycardiac B-DISO-MISC I-GENE-MISC
responses O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
microinjected O-MISC B-CONC-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
area O-MISC B-ACTI-MISC
near O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ventrolateral O-MISC B-CHED-MISC
surface O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medulla O-MISC I-GENE-MISC
oblongata O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
bulbospinal O-MISC I-GENE-MISC
serotonergic O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
brought O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
sympathetic O-MISC I-GENE-MISC
efferent O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
vagal O-MISC I-GENE-MISC
efferent O-MISC B-CHED-MISC
activity O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Hypertension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
neuroblastoma B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
imipramine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Hypertension B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
finding O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
neuroblastoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Imipramine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
severe O-MISC I-ACTI-MISC
hypertension B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
190 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
160 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
girl O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
neuroblastoma B-DISO-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
Imipramine B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
behavior B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
tumor B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
recurring O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
hypertensive B-DISO-MISC I-ACTI-MISC
episode O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Since O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
elevation O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
initial O-MISC B-CHED-MISC
diagnosis O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Imipramine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
florid O-MISC B-ACTI-MISC
relapse O-MISC B-OCCU-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
believe O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
drug O-MISC O-MISC
rather O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
underlying O-MISC B-PHEN-MISC
disease O-MISC B-UnknownType-MISC
alone O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
reaction O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
believed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
vasoactive O-MISC O-MISC
catecholamines B-CHED-MISC B-DISO-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
interference O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
physiologic O-MISC B-CHED-MISC
inactivation O-MISC I-CHED-MISC
by O-MISC B-ACTI-MISC
Imipramine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

From O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
experience O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
urge O-MISC B-ACTI-MISC
extreme O-MISC B-ACTI-MISC
caution O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
tricyclic O-MISC O-MISC
antidepressants O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
active O-MISC B-CHED-MISC
neuroblastoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Rechallenge O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
oral B-DISO-MISC I-ACTI-MISC
candidiasis I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
hoarseness B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
beclomethasone B-CHED-MISC O-MISC
dipropionate I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
158 O-MISC B-ACTI-MISC
asthmatic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
placed O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
inhaled O-MISC I-DISO-MISC
beclomethasone B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
hoarseness B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
oral O-MISC I-ACTI-MISC
thrush B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
subsided O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
rechallenged O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
inhaled O-MISC B-CHED-MISC
beclomethasone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
hoarseness B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
Candidiasis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC I-ACTI-MISC
thrush B-DISO-MISC B-ANAT-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
recur O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hoarseness B-DISO-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
recurrence O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
restarted O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
inhaled O-MISC I-DISO-MISC
beclomethasone B-CHED-MISC O-MISC
when O-MISC B-ACTI-MISC
clinically O-MISC B-CHED-MISC
indicated O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
recurrence O-MISC B-CHED-MISC
rate O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
hoarseness B-DISO-MISC I-ACTI-MISC
should O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
re O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
challenged O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Concomitant O-MISC B-CHED-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
oral O-MISC O-MISC
prednisone B-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
topical O-MISC O-MISC
beclomethasone B-CHED-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
hoarseness B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
candidiasis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Cyclophosphamide B-CHED-MISC O-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
undergo O-MISC B-ACTI-MISC
bone O-MISC B-CONC-MISC
marrow O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
are O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
immunosuppressed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
weight O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
definitive O-MISC B-CHED-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
have O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Since O-MISC B-ACTI-MISC
chemotherapeutic O-MISC O-MISC
agent O-MISC B-DISO-MISC
toxicity B-DISO-MISC I-ACTI-MISC
generally O-MISC B-ACTI-MISC
correlates O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
per O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
area O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
retrospectively O-MISC B-CHED-MISC
calculated O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
transplanted O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
institution O-MISC B-PHYS-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
per O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
area O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Eighty O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
preparation O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
marrow O-MISC B-CONC-MISC
grafting O-MISC I-CONC-MISC
underwent O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
transplants O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
aplastic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
Wiskott B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Aldrich I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
severe B-DISO-MISC I-ACTI-MISC
combined I-DISO-MISC B-ANAT-MISC
immunodeficiency I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Fourteen O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
and O-MISC B-ANAT-MISC
signs O-MISC B-ANAT-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
CYA B-CHED-MISC O-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
within O-MISC B-ACTI-MISC
ten O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
died O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
congestive B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
per O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
area O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
daily O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
1 O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
equal O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
Group O-MISC B-CHED-MISC
2 O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Cardiotoxicity B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
thought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
2 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
025 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Congestive B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
contributed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
1 O-MISC B-UnknownType-MISC
v O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
Group O-MISC B-PHEN-MISC
2 O-MISC B-UnknownType-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
difference O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
engraftment O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
evaluable O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
correlates O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
dosage O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
calculated O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
area O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
aplastic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
immunodeficiencies B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
effectively O-MISC B-ACTI-MISC
prepared O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
bone O-MISC B-CONC-MISC
marrow O-MISC I-CONC-MISC
grafting O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
whose O-MISC B-ACTI-MISC
CYA B-CHED-MISC O-MISC
dosage O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
calculated O-MISC B-CONC-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
weight O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
reaffirms O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
principle O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
toxicity B-DISO-MISC B-ANAT-MISC
correlates O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
per O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
area O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Studies O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
aminoglycoside B-CHED-MISC O-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
epidemiology O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
aminoglycoside B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
fully O-MISC B-ACTI-MISC
understood O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Experimental O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
human O-MISC I-PHEN-MISC
volunteers O-MISC I-PHEN-MISC
indicate O-MISC B-ACTI-MISC
aminoglycosides B-CHED-MISC O-MISC
cause O-MISC B-ACTI-MISC
proximal O-MISC B-CHED-MISC
tubular O-MISC I-GENE-MISC
damage O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
rarely O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
ever O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
glomerular B-DISO-MISC I-ACTI-MISC
or I-DISO-MISC B-ACTI-MISC
tubular I-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
aminoglycosides B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
seriously O-MISC I-ACTI-MISC
ill O-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relative O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
ranges O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
attributable O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
is O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
plasma O-MISC B-CONC-MISC
aminoglycoside B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
liver B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
advanced O-MISC I-DISO-MISC
age O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
initial O-MISC B-ACTI-MISC
estimated O-MISC B-CHED-MISC
creatinine B-CHED-MISC O-MISC
clearance O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
gender O-MISC I-LIVB-MISC
all O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Other O-MISC B-ACTI-MISC
causes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
shock B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
additive O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Predictive O-MISC B-CHED-MISC
models O-MISC I-OBJC-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
analyses O-MISC B-CONC-MISC
that O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
identifying O-MISC B-CONC-MISC
patients O-MISC I-CONC-MISC
at O-MISC B-ACTI-MISC
high O-MISC I-ACTI-MISC
risk O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
models O-MISC B-OBJC-MISC
may O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
insights O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathophysiology O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
aminoglycoside B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Central O-MISC B-CHED-MISC
action O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
narcotic O-MISC O-MISC
analgesics O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Part O-MISC B-ACTI-MISC
IV O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Noradrenergic O-MISC O-MISC
influences O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
analgesics O-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
clonidine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
naphazoline B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
xylometazoline B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
analgesia O-MISC B-CONC-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
codeine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pentazocine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
cataleptic B-DISO-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
codine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
biochemical O-MISC B-CONC-MISC
assays O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
analgesics O-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
concentration O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
turnover O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
noradrenaline B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
NA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
stimulating O-MISC B-OCCU-MISC
central O-MISC O-MISC
NA B-CHED-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
failed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
analgesic O-MISC O-MISC
ED50 O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
antinociceptive O-MISC O-MISC
agents O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Codeine B-CHED-MISC O-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
naphazoline B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
xylometazoline B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
concentration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
NA B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
changed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
codeine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
slightly O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
it O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Pentazocine B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependently O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
NA B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
rate O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NA B-CHED-MISC O-MISC
turnover O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
analgesics O-MISC O-MISC
except O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disappearance O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NA B-CHED-MISC O-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
diminished O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
light O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
non O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
uniform O-MISC I-CHED-MISC
data O-MISC I-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
NA B-CHED-MISC O-MISC
plays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
function O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
monoamines B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
behavioural O-MISC B-DEVI-MISC
activity O-MISC I-DEVI-MISC
of O-MISC B-ACTI-MISC
potent O-MISC B-ACTI-MISC
analgesics O-MISC O-MISC
. O-MISC B-ACTI-MISC

Flurothyl B-CHED-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
thresholds O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
neonatally O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
monosodium B-CHED-MISC O-MISC
glutamate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MSG B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
experimental O-MISC B-ACTI-MISC
parameters O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
flurothyl B-CHED-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
testing O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Monosodium B-CHED-MISC O-MISC
glutamate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MSG B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
neonatal O-MISC I-ANAT-MISC
rodents O-MISC I-ANAT-MISC
produces O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
numerous O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
behavioral O-MISC I-ACTI-MISC
deficits O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
undertaken O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
neonatal O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
MSG B-CHED-MISC B-CONC-MISC
produced O-MISC B-ACTI-MISC
permanent O-MISC B-CHED-MISC
alterations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
since O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
investigations O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
inconclusive O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
flurothyl B-CHED-MISC I-ACTI-MISC
ether B-CHED-MISC B-ANAT-MISC
seizure B-DISO-MISC B-ANAT-MISC
screening O-MISC B-CONC-MISC
technique O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
mice O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
neonatal O-MISC B-CHED-MISC
injections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
MSG B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

MSG B-CHED-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
reductions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
whole O-MISC I-GENE-MISC
brain O-MISC I-GENE-MISC
weight O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
alter O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
threshold O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
naloxone B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
challenge O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
ineffective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
altering O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
thresholds O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
control O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
MSG B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Flurothyl B-CHED-MISC O-MISC
ether B-CHED-MISC B-DISO-MISC
produced O-MISC B-ACTI-MISC
hypothermia B-DISO-MISC I-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
flurothyl B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypothermia B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
induction O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
unclear O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Flurothyl B-CHED-MISC B-CONC-MISC
seizure B-DISO-MISC I-CONC-MISC
testing O-MISC I-CONC-MISC
proved O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rapid O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
reliable O-MISC B-ACTI-MISC
technique O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
seizure B-DISO-MISC I-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Susceptibility O-MISC I-ACTI-MISC
to O-MISC B-ANAT-MISC
seizures B-DISO-MISC B-ANAT-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
after O-MISC B-ACTI-MISC
microinjection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
isoniazid B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
vinyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
GABA I-CHED-MISC B-DISO-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
substantia O-MISC I-GENE-MISC
nigra O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
intraperitoneally O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
reproduces O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neuropathological O-MISC I-ACTI-MISC
sequelae O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
temporal B-DISO-MISC I-ACTI-MISC
lobe I-DISO-MISC B-ANAT-MISC
epilepsy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
provides O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relevant O-MISC B-CHED-MISC
animal O-MISC I-ANAT-MISC
model O-MISC I-PHEN-MISC
for O-MISC B-ACTI-MISC
studying O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
buildup O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
convulsive B-DISO-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
pathways O-MISC B-CHED-MISC
operative O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
generalization O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
propagation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
forebrain O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
manipulating O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activity O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminobutyric I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
synaptic O-MISC I-DISO-MISC
inhibition O-MISC I-LIVB-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
substantia O-MISC I-GENE-MISC
nigra O-MISC B-GEOG-MISC
on O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
pretreated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
microinjections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
isoniazid B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inhibitor O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
synthesizing O-MISC B-ACTI-MISC
enzyme O-MISC O-MISC
, O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
glutamic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
decarboxylase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
substantia O-MISC I-GENE-MISC
nigra O-MISC B-GEOG-MISC
pars O-MISC B-GEOG-MISC
reticulata O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
SNR O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
bilaterally O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
convulsant O-MISC B-ANAT-MISC
doses O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
motor O-MISC I-ACTI-MISC
limbic O-MISC B-ANAT-MISC
seizures B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Electroencephalographic O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
monitoring O-MISC B-CONC-MISC
revealed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
profound O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
threshold O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
convulsions B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Morphological O-MISC B-CHED-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
frontal O-MISC I-GENE-MISC
forebrain O-MISC B-GEOG-MISC
sections O-MISC B-GEOG-MISC
with O-MISC B-ACTI-MISC
light O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
revealed O-MISC B-CHED-MISC
seizure B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
damage O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
formation O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
thalamus O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
amygdala O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
olfactory O-MISC I-GENE-MISC
cortex O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
substantia O-MISC I-GENE-MISC
nigra O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
neocortex O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
typically O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
exceeding O-MISC B-ACTI-MISC
350 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Bilateral O-MISC B-CHED-MISC
intrastriatal O-MISC B-CONC-MISC
injections O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
isoniazid B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
augment O-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Application O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
irreversible O-MISC O-MISC
inhibitor O-MISC O-MISC
of O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
transaminase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
vinyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
GABA I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
L I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
amino I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
hex I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
enoic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SNR O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
bilaterally O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
suppressed O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
electrographic O-MISC I-ACTI-MISC
and O-MISC B-ANAT-MISC
behavioral O-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
380 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
sufficient O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
protect O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
brain B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Microinjections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
vinyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
GABA I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dorsal O-MISC I-GENE-MISC
striatum O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
bilaterally O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
failed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
380 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
threshold O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
subjected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
regulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
GABA B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
synaptic O-MISC I-DISO-MISC
inhibition O-MISC I-LIVB-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
substantia O-MISC I-GENE-MISC
nigra O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Human O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
canine O-MISC I-ANAT-MISC
ventricular O-MISC O-MISC
vasoactive O-MISC B-DISO-MISC
intestinal O-MISC B-DISO-MISC
polypeptide O-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Vasoactive O-MISC O-MISC
intestinal O-MISC B-DISO-MISC
polypeptide O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
VIP O-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
systemic O-MISC O-MISC
and O-MISC B-ACTI-MISC
coronary O-MISC O-MISC
vasodilator O-MISC O-MISC
that O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
inotropic O-MISC B-CHED-MISC
properties O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Myocardial O-MISC I-GENE-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VIP O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
assayed O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
canine O-MISC I-ANAT-MISC
models O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cobalt B-CHED-MISC O-MISC
cardiomyopathy B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
VIP O-MISC O-MISC
( O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
radioimmunoassay O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
pg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
protein O-MISC O-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SD O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
pg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
protein O-MISC O-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
heart B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
VIP O-MISC O-MISC
decreased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
pg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
protein O-MISC O-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
VIP O-MISC B-CONC-MISC
content O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
ventricular O-MISC B-GEOG-MISC
muscle O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
resected O-MISC B-ACTI-MISC
failing O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
heart O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
papillary O-MISC I-GENE-MISC
muscles O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
rheumatic B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
myxomatous B-DISO-MISC I-ACTI-MISC
degeneration I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
mitral O-MISC B-OBJC-MISC
valve O-MISC I-OBJC-MISC
prostheses O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
lowest O-MISC B-ACTI-MISC
myocardial O-MISC I-GENE-MISC
VIP O-MISC O-MISC
concentration O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transplant O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
receiving O-MISC B-CHED-MISC
mitral O-MISC B-OBJC-MISC
prostheses O-MISC I-OBJC-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
pg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
protein O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
transplantation O-MISC B-CONC-MISC
had O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
average O-MISC B-CHED-MISC
ejection O-MISC I-ACTI-MISC
fraction O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
VIP O-MISC B-CONC-MISC
level O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
pg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
protein O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
without O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
ejection O-MISC I-DISO-MISC
fraction O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
62 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
VIP O-MISC B-CONC-MISC
concentration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
pg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
protein O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transplant O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Myocardial O-MISC I-GENE-MISC
catecholamines B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
weak O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
r O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tissue O-MISC I-GENE-MISC
concentrations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VIP O-MISC O-MISC
and O-MISC B-ACTI-MISC
norepinephrine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
ABSTRACT O-MISC B-ACTI-MISC
TRUNCATED O-MISC B-ACTI-MISC
AT O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
WORDS O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC

Non O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
invasive O-MISC I-CHED-MISC
detection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
electrocardiographic O-MISC B-CONC-MISC
mapping O-MISC I-CONC-MISC
after O-MISC B-ACTI-MISC
dipyridamole B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Electrocardiographic O-MISC B-CHED-MISC
changes O-MISC I-CHED-MISC
after O-MISC B-ACTI-MISC
dipyridamole B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
568 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
submaximal O-MISC B-CHED-MISC
treadmill O-MISC B-DEVI-MISC
exercise O-MISC I-DEVI-MISC
by O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
body O-MISC B-CONC-MISC
surface O-MISC I-CONC-MISC
mapping O-MISC B-CONC-MISC
technique O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
MI B-DISO-MISC B-ANAT-MISC
group O-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
anterior B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ANT B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
MI I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
inferior B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
INF B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
MI I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Eighty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
unipolar O-MISC I-ACTI-MISC
electrocardiograms O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
ECGs O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
distributed O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
entire O-MISC I-GENE-MISC
thoracic O-MISC B-GEOG-MISC
surface O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
simultaneously O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
dipyridamole B-CHED-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
ST O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
segment O-MISC B-ANAT-MISC
depression B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
mV O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
MI B-DISO-MISC B-ANAT-MISC
group O-MISC B-PHEN-MISC
, O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ANT B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
MI I-DISO-MISC B-ANAT-MISC
group O-MISC B-PHEN-MISC
, O-MISC B-ACTI-MISC
63 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
INF B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC I-CHED-MISC
MI I-DISO-MISC I-CHED-MISC
group O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
61 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Exercise O-MISC B-DEVI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
ST O-MISC I-ACTI-MISC
depression B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC I-CHED-MISC
MI B-DISO-MISC B-ANAT-MISC
group O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ANT B-DISO-MISC B-CHED-MISC
- I-DISO-MISC I-CHED-MISC
MI I-DISO-MISC I-CHED-MISC
group O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
INF B-DISO-MISC B-CHED-MISC
- I-DISO-MISC I-CHED-MISC
MI I-DISO-MISC I-CHED-MISC
group O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
61 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
individual O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
obvious O-MISC B-ACTI-MISC
differences O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
distribution O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ST O-MISC I-ACTI-MISC
depression B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
tests O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
pressure O-MISC B-OCCU-MISC
rate O-MISC B-CHED-MISC
product O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
dipyridamole B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
less O-MISC I-CHED-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treadmill O-MISC B-GENE-MISC
exercise O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dipyridamole B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
ischemia I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inhomogenous O-MISC B-CHED-MISC
distribution O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
myocardial O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
flow O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dipyridamole B-CHED-MISC B-CONC-MISC
ECG O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
ECG O-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
assessment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Bradycardia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
intravenous O-MISC B-CHED-MISC
methylprednisolone B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
rheumatoid B-DISO-MISC I-ACTI-MISC
arthritis I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
high O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
dose O-MISC I-CONC-MISC
methylprednisolone B-CHED-MISC I-CONC-MISC
( O-MISC I-CONC-MISC
MP B-CHED-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
days O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decline O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
pulse O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
pronounced O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
the O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
complaints O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
substernal O-MISC I-ACTI-MISC
pressure O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Reversal O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Electrocardiographic O-MISC B-CONC-MISC
registrations O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
sinus B-DISO-MISC I-ACTI-MISC
bradycardia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
significant O-MISC B-ANAT-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
plasma O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
electrolytes O-MISC O-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Careful O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
MP B-CHED-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

High O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
MP B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
contraindicated O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
heart B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
downbeat B-DISO-MISC I-ACTI-MISC
nystagmus I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
oscillopsia B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
carbamazepine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Downbeat B-DISO-MISC I-ACTI-MISC
nystagmus I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
structural O-MISC B-CHED-MISC
lesions O-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
craniocervical O-MISC I-GENE-MISC
junction O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
occasionally O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
manifestation O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
metabolic O-MISC B-CHED-MISC
imbalance O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
drug O-MISC I-ACTI-MISC
intoxication O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
eye O-MISC I-DISO-MISC
movements O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
reversible O-MISC B-CHED-MISC
downbeat B-DISO-MISC I-ACTI-MISC
nystagmus I-DISO-MISC B-ANAT-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
carbamazepine B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
nystagmus B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
resolved O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
reduction O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
carbamazepine B-CHED-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Neuroradiologic O-MISC B-CONC-MISC
investigations O-MISC I-CONC-MISC
including O-MISC B-ACTI-MISC
magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
scans O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
evidence O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
intracranial O-MISC I-ACTI-MISC
abnormality O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
downbeat B-DISO-MISC I-ACTI-MISC
nystagmus I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
taking O-MISC B-ACTI-MISC
anticonvulsant O-MISC O-MISC
medications O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
consideration O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
investigation O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
undertaken O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Improvement O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
denopamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
TA B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
064 I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pentobarbital B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dog O-MISC I-ANAT-MISC
heart O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
lung O-MISC B-GEOG-MISC
preparation O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
denopamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
orally O-MISC B-CHED-MISC
active O-MISC B-CHED-MISC
beta O-MISC O-MISC
1 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
adrenoceptor O-MISC B-DISO-MISC
agonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
improving O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
dog O-MISC I-ANAT-MISC
heart O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
lung O-MISC B-CONC-MISC
preparations O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Cardiac O-MISC I-DISO-MISC
functions O-MISC I-LIVB-MISC
depressed O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pentobarbital B-CHED-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
118 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SD O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
of O-MISC B-ANAT-MISC
rise O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
left O-MISC B-ANAT-MISC
ventricular O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
LV O-MISC B-CHED-MISC
dP O-MISC I-CHED-MISC
/ O-MISC I-CHED-MISC
dt O-MISC I-CHED-MISC
max O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
respective O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
denopamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
manner O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
denopamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
restoration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
performance O-MISC B-DEVI-MISC
was O-MISC B-ACTI-MISC
attained O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
slight O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

No O-MISC I-ACTI-MISC
arrhythmias B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
denopamine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
warrant O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
trials O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
denopamine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Clonazepam B-CHED-MISC O-MISC
monotherapy O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
childhood O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Sixty O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
month O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
types O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
infantile B-DISO-MISC I-ACTI-MISC
spasms I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
clonazepam B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Disappearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
normalization O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
EEG O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
disappearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Seizures B-DISO-MISC I-ACTI-MISC
disappeared O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
71 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
89 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Improvement O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
EEG O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
noticed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
diffuse O-MISC B-CHED-MISC
paroxysms O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
67 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
focal O-MISC B-CHED-MISC
paroxysms O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
excellent O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
effective O-MISC B-ACTI-MISC
dosages O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
086 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
021 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
infants O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
057 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
022 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
schoolchildren O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
drowsiness B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
ataxia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Postmarketing O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
timolol B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
hydrochlorothiazide B-CHED-MISC B-DISO-MISC
antihypertensive O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
postmarketing O-MISC B-CONC-MISC
surveillance O-MISC I-CONC-MISC
study O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fixed O-MISC B-CONC-MISC
- O-MISC B-DISO-MISC
ratio O-MISC B-DISO-MISC
combination O-MISC B-DISO-MISC
containing O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
timolol B-CHED-MISC O-MISC
maleate I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hydrochlorothiazide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
twice O-MISC B-ACTI-MISC
daily O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
month O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hypertensive B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Data O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
037 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
collected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
455 O-MISC B-ACTI-MISC
participating O-MISC B-CHED-MISC
physicians O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Mean O-MISC B-CHED-MISC
systolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
decreased O-MISC B-ANAT-MISC
25 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
diastolic O-MISC B-ANAT-MISC
blood O-MISC B-ANAT-MISC
pressure O-MISC I-LIVB-MISC
declined O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
one O-MISC B-CHED-MISC
month O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
timolol B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
hydrochlorothiazide B-CHED-MISC I-CONC-MISC
therapy O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
comparisons O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
race O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
appeared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
antihypertensive O-MISC O-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
was O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Overall O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
453 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
experienced O-MISC I-DISO-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
658 O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
fatigue B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
dizziness B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
weakness B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
590 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC I-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Salicylate B-CHED-MISC I-ACTI-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Gunn O-MISC I-ANAT-MISC
rat O-MISC I-PHEN-MISC
: O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
prostaglandins B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
role O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
prostaglandins B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
analgesic O-MISC I-ACTI-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Gunn O-MISC I-ANAT-MISC
strain O-MISC I-PHEN-MISC
of O-MISC I-PHEN-MISC
rat O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
Gunn O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
have O-MISC B-ACTI-MISC
unconjugated O-MISC B-CHED-MISC
hyperbilirubinemia B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
glucuronyl B-CHED-MISC O-MISC
transferase O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
bilirubin B-CHED-MISC O-MISC
deposition O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
medulla O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
papilla O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
susceptible O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
papillary B-DISO-MISC I-ACTI-MISC
necrosis I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
analgesic O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
jj O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
phenotypically O-MISC I-DISO-MISC
normal O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
jJ O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
jj O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
jJ O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
treated O-MISC B-CHED-MISC
either O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
treated O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
one O-MISC B-CHED-MISC
week O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
slices O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
cortex O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
outer O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
inner O-MISC B-CHED-MISC
medulla O-MISC I-GENE-MISC
from O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
incubated O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
buffer O-MISC O-MISC
and O-MISC B-ACTI-MISC
prostaglandin B-CHED-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
radioimmunoassay O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
examined O-MISC B-CONC-MISC
histologically O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
corticomedullary O-MISC I-GENE-MISC
gradient O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
prostaglandin B-CHED-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

PGE2 B-CHED-MISC O-MISC
synthesis O-MISC B-DEVI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
outer O-MISC I-GENE-MISC
medulla O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
cortex O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
inner O-MISC B-CHED-MISC
medulla O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
jj O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
prot O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
jJ O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Aspirin B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
reduced O-MISC B-CHED-MISC
PGE2 B-CHED-MISC O-MISC
synthesis O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
regions O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
outer O-MISC B-ACTI-MISC
medullary O-MISC I-GENE-MISC
PGE2 B-CHED-MISC O-MISC
remained O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
jj O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
jJ O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

PGF2 B-CHED-MISC O-MISC
alpha I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
outer O-MISC B-ACTI-MISC
medulla O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
jj O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
prostaglandin B-CHED-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
accompanied O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
jj O-MISC I-ANAT-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
jJ O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
as O-MISC B-ACTI-MISC
evidenced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hematuria B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
serum O-MISC I-ACTI-MISC
creatinine B-CHED-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
outer O-MISC I-GENE-MISC
medullary O-MISC B-GEOG-MISC
histopathologic O-MISC B-CHED-MISC
lesions O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
005 O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
sham O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
jj O-MISC I-ANAT-MISC
or O-MISC B-ACTI-MISC
aspirin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
jJ O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
prostaglandin B-CHED-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
contributes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
maintenance O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
morphological O-MISC B-CHED-MISC
integrity O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
prostaglandin B-CHED-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
may O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
pathological B-DISO-MISC B-CHED-MISC
renal I-DISO-MISC I-GENE-MISC
medullary I-DISO-MISC B-ANAT-MISC
lesions I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
deterioration B-DISO-MISC B-OCCU-MISC
of I-DISO-MISC B-ACTI-MISC
renal I-DISO-MISC I-DISO-MISC
function I-DISO-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Prophylactic O-MISC B-CHED-MISC
lidocaine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
phase O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
hundred O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
seen O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
symptoms O-MISC I-ACTI-MISC
entered O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
randomized O-MISC B-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
vs O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
hour O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
204 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
myocardial B-DISO-MISC B-ANAT-MISC
infarction I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Lidocaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
intramuscularly O-MISC B-CHED-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
intravenously O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
warning O-MISC B-CHED-MISC
arrhythmias B-DISO-MISC I-ACTI-MISC
between O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
lidocaine B-CHED-MISC O-MISC
level O-MISC B-CHED-MISC
10 O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
higher O-MISC I-CHED-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
infarction B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
lidocaine B-CHED-MISC O-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
blocking O-MISC B-DISO-MISC
agents O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
not O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
beta O-MISC O-MISC
blocking O-MISC B-DISO-MISC
agents O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
1 O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
hour O-MISC I-CHED-MISC
study O-MISC B-CONC-MISC
period O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
central O-MISC I-ACTI-MISC
nervous O-MISC B-ANAT-MISC
system O-MISC B-GEOG-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
greater O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
group O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
lidocaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
died O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
asystole B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
cannot O-MISC B-ACTI-MISC
advocate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
prophylactically O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
hours O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cholinergic O-MISC B-CHED-MISC
role O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Experiments O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
tested O-MISC B-CHED-MISC
previous O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
activation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
cholinergic O-MISC I-GENE-MISC
systems O-MISC B-GEOG-MISC
promotes O-MISC B-DEVI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
cholinergic O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
need O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
intact O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
full O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
neuroleptic B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Large O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cholinomimetic O-MISC O-MISC
, O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
induce O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
when O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
cholinergic O-MISC O-MISC
receptors O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
blocked O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Low O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pronounced O-MISC B-ACTI-MISC
enhancement O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dopaminergic O-MISC O-MISC
blocker O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
muscarinic O-MISC O-MISC
receptor O-MISC B-DISO-MISC
blocker O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
atropine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
disrupted O-MISC B-CHED-MISC
haloperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Intracranial O-MISC I-GENE-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acetylcholine B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
synthesis O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
hemicholinium B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
neuroleptics B-CHED-MISC O-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
actually O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
intrinsic O-MISC B-CHED-MISC
central O-MISC I-CHED-MISC
cholinergic O-MISC I-CHED-MISC
systems O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Alternatively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
activation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
cholinergic O-MISC B-GEOG-MISC
systems O-MISC B-GEOG-MISC
could O-MISC B-ACTI-MISC
promote O-MISC B-DEVI-MISC
catalepsy B-DISO-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
suppression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
dopaminergic O-MISC I-GENE-MISC
systems O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Cardiovascular B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
hypersensitivity B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
pentobarbital I-CHED-MISC B-DISO-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
chronic O-MISC B-OCCU-MISC
barium B-CHED-MISC I-OCCU-MISC
chloride I-CHED-MISC I-OCCU-MISC
ingestion O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

Barium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
supplemented O-MISC B-ACTI-MISC
Long O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Evans O-MISC I-PHEN-MISC
hooded O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
persistent O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
evident O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
month O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
barium B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
mineral O-MISC O-MISC
fortified O-MISC B-DISO-MISC
water O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
myocardial O-MISC I-ACTI-MISC
excitability O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
contractility O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
characteristics O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
revealed O-MISC B-CHED-MISC
other O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
barium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
disturbances B-DISO-MISC B-CHED-MISC
within I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
cardiovascular I-DISO-MISC I-GENE-MISC
system I-DISO-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
distinctive O-MISC B-ACTI-MISC
aspect O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
barium B-CHED-MISC B-CONC-MISC
effect O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
hypersensitivity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
sodium B-CHED-MISC I-GENE-MISC
pentobarbital I-CHED-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Under O-MISC B-ACTI-MISC
barbiturate B-CHED-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
virtually O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardial O-MISC I-DISO-MISC
contractile O-MISC I-LIVB-MISC
indices O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
depressed O-MISC B-CHED-MISC
significantly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
barium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
relative O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
corresponding O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
fed O-MISC B-DEVI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
ketamine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
xylazine B-CHED-MISC O-MISC
anesthesia O-MISC B-CONC-MISC
revealed O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
actions O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
pentobarbital I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
barium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
linked O-MISC B-ACTI-MISC
specifically O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
anesthetic O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
representative O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
generalized O-MISC B-ACTI-MISC
anesthetic O-MISC I-ACTI-MISC
response O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Other O-MISC B-ACTI-MISC
myocardial O-MISC I-GENE-MISC
pathophysiologic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
metabolic O-MISC I-DISO-MISC
changes O-MISC B-CHED-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
barium B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
manifest O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
irrespective O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anesthetic O-MISC O-MISC
employed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
contractile O-MISC I-ACTI-MISC
element O-MISC B-ANAT-MISC
shortening O-MISC B-ANAT-MISC
velocity O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
fibers O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
slower O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
barium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
relative O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
irrespective O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anesthetic O-MISC B-CONC-MISC
regimen O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Similarly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
disturbances O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
myocardial O-MISC I-DISO-MISC
energy O-MISC I-LIVB-MISC
metabolism O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
barium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
contractile O-MISC I-CHED-MISC
element O-MISC I-CHED-MISC
shortening O-MISC B-CHED-MISC
velocity O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
excitability O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
conduction O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
depressed O-MISC I-ACTI-MISC
preferentially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
atrioventricular O-MISC I-GENE-MISC
nodal O-MISC B-GEOG-MISC
region O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
from O-MISC B-ACTI-MISC
barium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Overall O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
altered O-MISC B-CHED-MISC
cardiac O-MISC I-ACTI-MISC
contractility O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
excitability O-MISC I-ACTI-MISC
characteristics O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardial O-MISC I-GENE-MISC
metabolic B-DISO-MISC B-CHED-MISC
disturbances I-DISO-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypersensitivity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
pentobarbital I-CHED-MISC B-DISO-MISC
suggest O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
existence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
heretofore O-MISC O-MISC
undescribed O-MISC B-ACTI-MISC
cardiomyopathic B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
barium B-CHED-MISC B-ANAT-MISC
exposure O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
findings O-MISC B-ACTI-MISC
represent O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
indication O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
life O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
long O-MISC I-OCCU-MISC
barium B-CHED-MISC I-OCCU-MISC
ingestion O-MISC I-OCCU-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mammalian O-MISC I-ANAT-MISC
cardiovascular O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Propranolol B-CHED-MISC O-MISC
antagonism O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
phenylpropanolamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Phenylpropanolamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
PPA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
overdose B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
intracerebral B-DISO-MISC I-ACTI-MISC
hemorrhage I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
PPA B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Subjects O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
either O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
mouth O-MISC I-GENE-MISC
for O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
PPA B-CHED-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rapid O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
infusion O-MISC I-CHED-MISC
after O-MISC B-ACTI-MISC
PPA B-CHED-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

PPA B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
increased O-MISC I-ACTI-MISC
blood O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
systolic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
pretreatment O-MISC B-DEVI-MISC
antagonized O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
systolic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Intravenous O-MISC B-CHED-MISC
propranolol B-CHED-MISC O-MISC
after O-MISC B-ACTI-MISC
PPA B-CHED-MISC B-CONC-MISC
also O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
echocardiography O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
PPA B-CHED-MISC B-CONC-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
stroke B-DISO-MISC I-ACTI-MISC
volume O-MISC B-ANAT-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ejection O-MISC I-ACTI-MISC
fraction O-MISC B-ANAT-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
64 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
output O-MISC B-ANAT-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Intravenous O-MISC B-CHED-MISC
propranolol B-CHED-MISC O-MISC
reversed O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
effects O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Systemic O-MISC B-CHED-MISC
vascular O-MISC I-ACTI-MISC
resistance O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
PPA B-CHED-MISC O-MISC
28 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
1710 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2190 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
700 O-MISC B-ACTI-MISC
dyne O-MISC B-ACTI-MISC
X O-MISC B-ACTI-MISC
sec O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
cm5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
22 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2660 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1200 O-MISC B-ACTI-MISC
dyne O-MISC B-ACTI-MISC
X O-MISC B-ACTI-MISC
sec O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
cm5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
PPA B-CHED-MISC O-MISC
increases O-MISC B-CHED-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
systemic O-MISC I-ACTI-MISC
vascular O-MISC B-ANAT-MISC
resistance O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
antagonizes O-MISC B-DEVI-MISC
this O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
reversing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
PPA B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

That O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
antagonizes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PPA B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
interaction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
enhances O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
norepinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
PPA B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
beta O-MISC I-DISO-MISC
2 O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
than O-MISC B-ACTI-MISC
does O-MISC B-ACTI-MISC
norepinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Mesangial O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
glomerular B-DISO-MISC I-ACTI-MISC
sclerosis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
aminonucleoside B-CHED-MISC I-ACTI-MISC
nephrosis B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
mesangial B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
glomerular B-DISO-MISC I-ACTI-MISC
sclerosis I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
puromycin B-CHED-MISC O-MISC
aminonucleoside I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
model O-MISC B-OBJC-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
Wistar O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
received O-MISC B-ACTI-MISC
repeated O-MISC B-ACTI-MISC
subcutaneous O-MISC B-CHED-MISC
PAN B-CHED-MISC O-MISC
injections O-MISC I-CHED-MISC
; O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
only O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
PAN B-CHED-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
severely O-MISC B-ACTI-MISC
proteinuric B-DISO-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
190 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hr O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
colloidal O-MISC O-MISC
carbon B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CC O-MISC O-MISC
) O-MISC B-ACTI-MISC
intravenously O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
glomerular B-DISO-MISC I-ACTI-MISC
sclerosis I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
glomeruli O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
PAN B-CHED-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
glomeruli O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Glomeruli O-MISC O-MISC
of O-MISC B-ACTI-MISC
PAN B-CHED-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
contained O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
CC O-MISC I-GENE-MISC
than O-MISC B-ACTI-MISC
glomeruli O-MISC O-MISC
of O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Glomeruli O-MISC O-MISC
with O-MISC B-ACTI-MISC
sclerosis B-DISO-MISC I-ACTI-MISC
contained O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
CC O-MISC I-GENE-MISC
than O-MISC B-ACTI-MISC
non O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
sclerotic O-MISC B-GEOG-MISC
glomeruli O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
kidneys O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

CC O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
preferentially O-MISC B-ACTI-MISC
localized O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sclerotic O-MISC I-GENE-MISC
areas O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
glomeruli O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Since O-MISC B-ACTI-MISC
mesangial O-MISC I-GENE-MISC
CC O-MISC I-GENE-MISC
clearance O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mesangium O-MISC I-GENE-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
change O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
PAN B-CHED-MISC I-ACTI-MISC
treatment O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
preferential O-MISC B-ACTI-MISC
CC O-MISC I-GENE-MISC
localization O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lesions O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
CC O-MISC I-GENE-MISC
uptake O-MISC I-DISO-MISC
shortly O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
apparent O-MISC B-ACTI-MISC
vulnerable O-MISC B-CHED-MISC
areas O-MISC B-CHED-MISC
where O-MISC B-ACTI-MISC
sclerosis B-DISO-MISC I-ACTI-MISC
will O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
subsequently O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Cluster O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
random O-MISC B-CONC-MISC
distribution O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lesions O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAN B-CHED-MISC I-GENE-MISC
glomeruli O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
concordance O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
random O-MISC B-CHED-MISC
localization O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
mesangial O-MISC I-GENE-MISC
areas O-MISC B-GEOG-MISC
with O-MISC B-ACTI-MISC
dysfunction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
model O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
remnant O-MISC I-GENE-MISC
kidney O-MISC B-GEOG-MISC
model O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
PAN B-CHED-MISC I-ACTI-MISC
nephrosis B-DISO-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
glomerular B-DISO-MISC I-ACTI-MISC
sclerosis I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
mesangial O-MISC I-ACTI-MISC
overloading O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC

Relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
nicotine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
nicotinic O-MISC O-MISC
receptors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
controversy O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
existed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
concerning O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
physiological O-MISC B-CHED-MISC
relevance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nicotinic O-MISC O-MISC
receptor O-MISC B-DISO-MISC
measured O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
bungarotoxin O-MISC B-DISO-MISC
binding O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Using O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
derived O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
classical O-MISC B-ACTI-MISC
F2 O-MISC O-MISC
and O-MISC B-ACTI-MISC
backcross O-MISC B-ACTI-MISC
genetic O-MISC B-CONC-MISC
design O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
nicotine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
bungarotoxin O-MISC B-DISO-MISC
nicotinic O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
concentration O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Mice O-MISC I-ANAT-MISC
sensitive O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
convulsant O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
nicotine B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
bungarotoxin O-MISC B-DISO-MISC
binding O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
than O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
insensitive O-MISC I-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
binding O-MISC O-MISC
sites O-MISC B-DISO-MISC
from O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
sensitive O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
resistant O-MISC B-CHED-MISC
mice O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
equally O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
dithiothreitol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
trypsin O-MISC O-MISC
or O-MISC B-ACTI-MISC
heat O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
appears O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
difference O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
sensitive O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
insensitive O-MISC I-ACTI-MISC
animals O-MISC I-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
difference O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
hippocampal O-MISC I-GENE-MISC
nicotinic O-MISC O-MISC
receptor O-MISC B-DISO-MISC
concentration O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
bungarotoxin O-MISC B-DISO-MISC
binding O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
p B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminophenol I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bis B-CHED-MISC O-MISC
( I-CHED-MISC B-DISO-MISC
p I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
nitrophenyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
phosphate I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
acetaminophen B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
p B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminophenol I-CHED-MISC B-DISO-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
metabolism O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
Fischer O-MISC I-ANAT-MISC
344 O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Acetaminophen B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
proximal O-MISC B-CHED-MISC
tubular B-DISO-MISC I-GENE-MISC
necrosis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Fischer O-MISC I-ANAT-MISC
344 O-MISC I-PHEN-MISC
( O-MISC I-PHEN-MISC
F344 O-MISC I-PHEN-MISC
) O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminophenol I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
PAP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
potent O-MISC B-ACTI-MISC
nephrotoxicant O-MISC O-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
metabolite O-MISC O-MISC
of O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
F344 O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
PAP B-CHED-MISC O-MISC
formation O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
requisite O-MISC B-ACTI-MISC
step O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bis B-CHED-MISC O-MISC
( I-CHED-MISC B-DISO-MISC
p I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
nitrophenyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
phosphate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
BNPP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acylamidase O-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
PAP B-CHED-MISC O-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
metabolism O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

BNPP B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
mM O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
deacetylation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
covalent O-MISC I-DISO-MISC
binding O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
F344 O-MISC I-GENE-MISC
renal O-MISC B-GEOG-MISC
cortical O-MISC B-GEOG-MISC
homogenates O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
manner O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Pretreatment O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
BNPP B-CHED-MISC B-CHED-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
PAP B-CHED-MISC O-MISC
administration O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
900 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
PAP B-CHED-MISC O-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
disposition O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
acetylated O-MISC I-DISO-MISC
metabolites O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cortical O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Rather O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
BNPP B-CHED-MISC B-CHED-MISC
pretreatment O-MISC B-DEVI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
fraction O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
excreted O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
PAP B-CHED-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
64 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
750 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
900 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

BNPP B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
alter O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
excretion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
non O-MISC O-MISC
- O-MISC B-DISO-MISC
deacetylated O-MISC B-DISO-MISC
metabolites O-MISC B-DISO-MISC
nor O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
BNPP B-CHED-MISC O-MISC
alter O-MISC B-ACTI-MISC
excretion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
PAP B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
metabolites O-MISC O-MISC
after O-MISC B-ACTI-MISC
PAP B-CHED-MISC O-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BNPP B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
deacetylation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
PAP B-CHED-MISC O-MISC
formation O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
accounts O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
APAP B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC I-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
tubular I-DISO-MISC B-ANAT-MISC
necrosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Morphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
newborn O-MISC I-ANAT-MISC
infants O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
neonates O-MISC I-ANAT-MISC
suffered O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
morphine B-CHED-MISC O-MISC
sulfate I-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
post O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
operative O-MISC I-CONC-MISC
analgesia O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

They O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
morphine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
hr O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
hr O-MISC B-ACTI-MISC
larger O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
neonates O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
hr O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Plasma O-MISC I-GENE-MISC
concentrations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
neonates O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
excessive O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Other O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
reasons O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
ruled O-MISC I-ACTI-MISC
out O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
stopped O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
few O-MISC B-CHED-MISC
hours O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
cessation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
morphine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
reoccur O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
operative O-MISC I-CHED-MISC
intravenous O-MISC B-CHED-MISC
morphine B-CHED-MISC O-MISC
should O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
exceed O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
neonates O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Indomethacin B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
volume O-MISC B-CHED-MISC
depleted O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
IDM B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
volume O-MISC B-CHED-MISC
depleted O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
plasma O-MISC I-DISO-MISC
renin O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
PRA O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
fell O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
repleted O-MISC I-CONC-MISC
animals O-MISC I-ANAT-MISC
indomethacin B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
change O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
BP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
plasma O-MISC I-DISO-MISC
renin O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
by O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
prostaglandin B-CHED-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
may O-MISC B-ACTI-MISC
diminish O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
maintaining O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
stimulated O-MISC B-OCCU-MISC
renin O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
angiotensin B-CHED-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
volume O-MISC B-CHED-MISC
depletion O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
antiarrhythmic O-MISC B-OCCU-MISC
activity O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
N O-MISC O-MISC
- O-MISC B-DISO-MISC
substituted O-MISC B-DISO-MISC
piperazine B-CHED-MISC B-DISO-MISC
derivative O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
trans B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
amino I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
hydroxy I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
tetrahydroanaphthalene I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
antiarrhythmic O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
compound O-MISC O-MISC
N B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
trans I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
hydroxy I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
tetrahydro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
naphthyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
N I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
oxo I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
phenyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
2 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
methylpropyl I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
piperazine I-CHED-MISC B-DISO-MISC
hydrochloride I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
referred O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
P11 B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
anaesthesized O-MISC B-CONC-MISC
cats O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
Wistar O-MISC I-ANAT-MISC
albino O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
anaesthesized O-MISC B-ACTI-MISC
rabbits O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
types O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
BaCl2 B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
chloroform B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
adrenaline B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
strophantine B-CHED-MISC O-MISC
G I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
aconitine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
compound O-MISC O-MISC
P11 B-CHED-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
introduced O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
intravenously O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
orally O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
compound O-MISC B-CHED-MISC
manifests O-MISC B-ACTI-MISC
antiarrhythmic O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
models O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
used O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
greatest O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
chloroform B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
adrenaline B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
cent O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
BaCl2 B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
cent O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
beta O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
adrenoblocking O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
membrane O-MISC I-GENE-MISC
- O-MISC I-CHED-MISC
stabilizing O-MISC I-CHED-MISC
action O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
compound O-MISC O-MISC
. O-MISC B-ACTI-MISC

Recurrent O-MISC B-ACTI-MISC
subarachnoid B-DISO-MISC I-ACTI-MISC
hemorrhage I-DISO-MISC B-ANAT-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
aminocaproic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
therapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
artery I-DISO-MISC B-ANAT-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Epsilon B-CHED-MISC O-MISC
aminocaproic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
EACA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
rebleeding O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
subarachnoid B-DISO-MISC I-ACTI-MISC
hemorrhage I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SAH B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
agent O-MISC O-MISC
does O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rebleeding O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
reports O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
thrombotic B-DISO-MISC I-ACTI-MISC
complications O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
EACA B-CHED-MISC I-ACTI-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
have O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
deterioration O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
intracranial B-DISO-MISC I-ACTI-MISC
vascular I-DISO-MISC B-ANAT-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
SAH B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
arteriolar O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
capillary O-MISC I-ACTI-MISC
fibrin O-MISC B-ANAT-MISC
thrombi B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
fibrinolytic O-MISC I-ACTI-MISC
syndromes O-MISC B-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
EACA B-CHED-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
thromboembolic B-DISO-MISC I-ACTI-MISC
phenomena I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Since O-MISC B-ACTI-MISC
intravascular O-MISC B-CHED-MISC
fibrin O-MISC I-ACTI-MISC
thrombi B-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
fibrinolytic O-MISC I-ACTI-MISC
disorders O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
EACA B-CHED-MISC I-ACTI-MISC
should O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
fibrin O-MISC I-ACTI-MISC
thrombi B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
disseminated B-DISO-MISC B-CHED-MISC
intravascular I-DISO-MISC I-DISO-MISC
coagulation I-DISO-MISC I-LIVB-MISC
or O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
consumption B-DISO-MISC I-ACTI-MISC
coagulopathies I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
This O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
describes O-MISC B-ACTI-MISC
subtotal O-MISC I-ACTI-MISC
infarction B-DISO-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
a I-DISO-MISC B-ACTI-MISC
normal I-DISO-MISC B-ACTI-MISC
renal I-DISO-MISC I-GENE-MISC
artery I-DISO-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
occlusion O-MISC I-ACTI-MISC
occurred O-MISC B-DEVI-MISC
after O-MISC B-ACTI-MISC
EACA B-CHED-MISC I-GENE-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
SAH B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
histopathological O-MISC B-CHED-MISC
documentation O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
recurrent O-MISC B-CHED-MISC
SAH B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
corresponding O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
event O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
marked O-MISC I-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
abrupt O-MISC B-CHED-MISC
neurological O-MISC I-ACTI-MISC
deterioration O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Effect O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
vincristine B-CHED-MISC O-MISC
sulfate I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
Pseudomonas B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
monkeys O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
rhesus O-MISC I-ANAT-MISC
monkeys O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
challenge O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
Pseudomonas O-MISC I-ANAT-MISC
aeruginosa O-MISC I-PHEN-MISC
organisms O-MISC I-ANAT-MISC
caused O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
illness O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
' O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
recovery O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
monkeys O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
blood O-MISC B-CONC-MISC
cultures O-MISC I-CONC-MISC
became O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
3 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
challenge O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Leukocytosis B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
monkeys O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Intravenous O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
intratracheal O-MISC B-CHED-MISC
inoculation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
vincristine B-CHED-MISC O-MISC
sulfate I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
leukopenia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Intravenous O-MISC B-CONC-MISC
inoculation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
pyocin O-MISC O-MISC
type O-MISC I-PHEN-MISC
6 O-MISC I-PHEN-MISC
Pseudomonas O-MISC I-ANAT-MISC
organisms O-MISC I-PHEN-MISC
in O-MISC B-ACTI-MISC
monkeys O-MISC I-ANAT-MISC
given O-MISC B-ACTI-MISC
vincristine B-CHED-MISC O-MISC
sulfate I-CHED-MISC B-DISO-MISC
4 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
infection B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
monkeys O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
Pseudomonas O-MISC I-ANAT-MISC
alone O-MISC B-ACTI-MISC
died O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
antimetabolite O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
leukopenia B-DISO-MISC I-ACTI-MISC
predisposes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
Pseudomonas O-MISC I-ACTI-MISC
sepsis B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
monkeys O-MISC I-ANAT-MISC
may O-MISC B-ACTI-MISC
serve O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
biological O-MISC B-OBJC-MISC
model O-MISC I-OBJC-MISC
for O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
comparative O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
antimicrobial O-MISC O-MISC
agents O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Modification O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
of O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypoglycaemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypoglycaemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
blockade O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
fourteen O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
men O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Eight O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
insulin O-MISC O-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
original O-MISC B-ACTI-MISC
insulin O-MISC O-MISC
- O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
group O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
insulin O-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
insulin O-MISC O-MISC
- O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
period O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hypoglycaemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
rate O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fall O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
insulin O-MISC B-DISO-MISC
group O-MISC B-DISO-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
fall O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
rate O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Typical O-MISC B-ACTI-MISC
S O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
T O-MISC I-LIVB-MISC
/ O-MISC I-LIVB-MISC
T O-MISC I-LIVB-MISC
changes O-MISC B-CHED-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
insulin O-MISC O-MISC
- O-MISC B-DISO-MISC
group O-MISC B-DISO-MISC
but O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
insulin O-MISC B-DISO-MISC
group O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Hypertension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
diabetics B-DISO-MISC I-ACTI-MISC
prone O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hypoglycaemia B-DISO-MISC I-ACTI-MISC
attacks O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
because O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
may O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sharp O-MISC I-ACTI-MISC
rise O-MISC B-ANAT-MISC
in O-MISC B-ANAT-MISC
blood O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
pressure O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
propranolol B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
pregnancy O-MISC I-DISO-MISC
: O-MISC B-ACTI-MISC
maternal O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
fetal O-MISC B-CHED-MISC
outcome O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Propranolol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
adrenergic O-MISC B-DISO-MISC
blocking O-MISC B-DISO-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-CHED-MISC
position O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
practice O-MISC B-PROC-MISC
of O-MISC B-ACTI-MISC
medicine O-MISC B-PROC-MISC
. O-MISC B-ACTI-MISC

Its O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
pregnancy O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
open O-MISC B-ACTI-MISC
question O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
detrimental O-MISC B-CHED-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fetus O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
neonate O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Ten O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
pregnancies O-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
where O-MISC B-ACTI-MISC
chronic O-MISC O-MISC
propranolol B-CHED-MISC B-DISO-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
administered O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
serial O-MISC B-ACTI-MISC
pregnancies O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Maternal O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
fetal O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
neonatal O-MISC B-CHED-MISC
complications O-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
attempt O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
made O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
differentiate O-MISC B-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
maternal O-MISC I-ACTI-MISC
disease O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
hypoglycemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
hyperbilirubinemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
polycythemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
neonatal B-DISO-MISC I-ANAT-MISC
apnea I-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
invariable O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cannot O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
correlated O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
propranolol B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Growth B-DISO-MISC I-ACTI-MISC
retardation I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Central O-MISC I-DISO-MISC
excitatory O-MISC I-LIVB-MISC
actions O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
flurazepam B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Toxic O-MISC B-CHED-MISC
actions O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
flurazepam B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
FZP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

High O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
caused O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
apparent O-MISC B-ACTI-MISC
central O-MISC B-ACTI-MISC
excitation O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
clearly O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
clonic O-MISC I-ACTI-MISC
convulsions B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
superimposed O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
general O-MISC I-ACTI-MISC
depression B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Following O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lethal O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
convulsions B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Comparing O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
relative O-MISC B-CHED-MISC
sensitivity O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
central O-MISC I-ACTI-MISC
depression B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
excitation O-MISC B-DEVI-MISC
revealed O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
loss B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
consciousness I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
most O-MISC B-ACTI-MISC
clearly O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
central O-MISC B-ACTI-MISC
excitatory O-MISC I-DISO-MISC
actions O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Signs O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
FZP B-CHED-MISC O-MISC
toxocity B-DISO-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
cats O-MISC I-ANAT-MISC
included O-MISC B-ACTI-MISC
excessive O-MISC B-CHED-MISC
salivation B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
extreme O-MISC B-ACTI-MISC
apprehensive O-MISC I-ACTI-MISC
behavior O-MISC I-DEVI-MISC
, O-MISC B-ACTI-MISC
retching O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
muscle B-DISO-MISC I-ACTI-MISC
tremors I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
interaction O-MISC I-DISO-MISC
between O-MISC B-ACTI-MISC
FZP B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pentylenetetrazol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
PTZ B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pretreating O-MISC B-DEVI-MISC
mice O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
FZP B-CHED-MISC O-MISC
before O-MISC B-ACTI-MISC
PTZ B-CHED-MISC O-MISC
challenge O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
function O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
FZP B-CHED-MISC O-MISC
first O-MISC B-ACTI-MISC
protected O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
again O-MISC B-ACTI-MISC
emerged O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
FZP B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
lower O-MISC B-DEVI-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
would O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
relevant O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
FZP B-CHED-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
situations O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
neural O-MISC I-ACTI-MISC
excitability O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
sedative O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
hypnotic O-MISC B-ANAT-MISC
drug O-MISC B-CONC-MISC
withdrawal O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
orthostatic I-DISO-MISC B-ANAT-MISC
hypotension I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
orthostatic I-DISO-MISC B-ANAT-MISC
hypotension I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
physiologic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
autonomic O-MISC I-ACTI-MISC
dysfunction O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

They O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
exhibited O-MISC B-ACTI-MISC
markedly O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
catecholamines B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
plasma O-MISC I-DISO-MISC
renin O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
recumbent O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
upright O-MISC B-CHED-MISC
positions O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
hypersensitivity B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
infused O-MISC B-CHED-MISC
norepinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
propanolol B-CHED-MISC O-MISC
administered O-MISC I-CONC-MISC
intravenously O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
supine O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
upright O-MISC I-ACTI-MISC
blood O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
rises O-MISC B-CHED-MISC
ranging O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
mmHg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC B-CONC-MISC
oral O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
160 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressures O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
increases O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mmg O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
had O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
withdrawn O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
otherwise O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
continued O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
persistence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
effect O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
degree O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Hemodynamic O-MISC B-CONC-MISC
measurements O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
demonstrated O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
peripheral O-MISC I-DISO-MISC
resistance O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
essentially O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
following O-MISC B-ACTI-MISC
propranolol B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
drug O-MISC O-MISC
in O-MISC B-ACTI-MISC
selected O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
orthostatic I-DISO-MISC B-ANAT-MISC
hypotension I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Total O-MISC B-ACTI-MISC
intravenous O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

III O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Some O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
investigation O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
undertaken O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
required O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
maintain O-MISC B-ACTI-MISC
sleep O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
undergoing O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
under O-MISC B-ACTI-MISC
regional O-MISC B-CONC-MISC
local O-MISC I-CONC-MISC
anesthesia O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Premedication O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
atropine B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sleep O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
maintained O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
intermittent O-MISC B-CHED-MISC
intravenous O-MISC B-CHED-MISC
injections O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
whenever O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
would O-MISC B-ACTI-MISC
open O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
eyes O-MISC I-GENE-MISC
on O-MISC B-ACTI-MISC
request O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
17 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
microgram O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
maintain O-MISC B-DEVI-MISC
sleep O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
great O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
variation O-MISC B-CHED-MISC
occurred O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
requiring O-MISC B-ACTI-MISC
less O-MISC B-CHED-MISC
drug O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
investigation O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
intensity O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
myoclonia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
technique O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
abandoned O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
unlikely O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
will O-MISC B-ACTI-MISC
prove O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypnotic O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
choice O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
totally O-MISC B-ACTI-MISC
intravenous O-MISC B-CONC-MISC
anesthetic O-MISC I-CONC-MISC
technique O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
myoclonia B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
administration O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
uncontrollable O-MISC B-CHED-MISC
muscle O-MISC I-DISO-MISC
movements O-MISC I-LIVB-MISC
persisted O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
complete O-MISC I-ACTI-MISC
recovery O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
consciousness O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Evidence O-MISC B-CHED-MISC
for O-MISC I-CHED-MISC
cardiac O-MISC O-MISC
beta O-MISC O-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
adrenoceptors O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
single O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
atenolol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
cardioselective O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
nonselective O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
on O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
experiments O-MISC B-CONC-MISC
involving O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
normal O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Maximal O-MISC B-CHED-MISC
exercise O-MISC B-DEVI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
187 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
SEM O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
to O-MISC B-ACTI-MISC
146 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
bpm O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
atenolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
138 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
bpm O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-CHED-MISC
before O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-CHED-MISC
atropine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
04 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
IV O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Isoproterenol B-CHED-MISC O-MISC
sensitivity O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
bpm O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
CD25 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
after O-MISC B-CHED-MISC
placebo O-MISC O-MISC
to O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
atenolol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
difference O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
atropine B-CHED-MISC O-MISC
the O-MISC B-ACTI-MISC
CD25 O-MISC O-MISC
was O-MISC B-ACTI-MISC
unchanged O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
atenolol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
remained O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
atenolol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
change O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
sensitivity O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
apparent O-MISC B-CHED-MISC
Ka O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
unchanged O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
atropine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
consistent O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
results O-MISC B-ACTI-MISC
largely O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
beta O-MISC O-MISC
1 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
activation O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
blocked O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
cardioselective O-MISC O-MISC
and O-MISC B-ACTI-MISC
nonselective O-MISC O-MISC
drugs O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
activates O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
beta O-MISC O-MISC
1 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
beta O-MISC O-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
so O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
cardioselective O-MISC O-MISC
blockade O-MISC B-DISO-MISC
there O-MISC B-ACTI-MISC
remains O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
beta O-MISC O-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
component O-MISC B-DISO-MISC
that O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
blocked O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nonselective O-MISC O-MISC
drug O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

While O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
beta O-MISC O-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
receptors O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
heart O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
physiologic O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
pathologic O-MISC B-CHED-MISC
roles O-MISC I-CHED-MISC
remain O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hormones O-MISC O-MISC
and O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
paper O-MISC B-ACTI-MISC
reports O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
menopausal O-MISC I-DISO-MISC
women O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
hormonal O-MISC B-CONC-MISC
replacement O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
surgical O-MISC I-ACTI-MISC
menopause O-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
hypothesized O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
progestins B-CHED-MISC O-MISC
could O-MISC B-ACTI-MISC
equilibrate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
estrogenic O-MISC I-DISO-MISC
stimulation O-MISC I-LIVB-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mammary O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
endometrial O-MISC I-GENE-MISC
target O-MISC B-CHED-MISC
tissues O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
hormonal O-MISC B-CONC-MISC
replacement O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
schedule O-MISC I-CONC-MISC
consisted O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
conjugated B-CHED-MISC B-CHED-MISC
estrogens I-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Premarin B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
Medroxyprogesterone B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
month O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
treatment O-MISC B-CHED-MISC
period O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
period O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
attention O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
paid O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
breast O-MISC I-ACTI-MISC
modifications O-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
evidenced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
symptomatology O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
physical O-MISC B-CONC-MISC
examination O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
plate O-MISC B-CONC-MISC
thermography O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Mastodynia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
physical O-MISC B-CONC-MISC
examination O-MISC I-CONC-MISC
revealed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
light O-MISC B-ACTI-MISC
increase O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
breast O-MISC I-ACTI-MISC
firmness O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
moderate O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
breast O-MISC I-ACTI-MISC
nodularity O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Themography O-MISC B-PROC-MISC
confirmed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
existence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
excessive O-MISC B-CHED-MISC
breast O-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
complained O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
mastodynia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
complained O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
mastodynia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Normalization O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
halving O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
estrogen B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
hormonal O-MISC B-CONC-MISC
replacement O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
safely O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
if O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
criteria O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
satisfied O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
preliminary O-MISC B-CHED-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
cytologic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mammographic O-MISC I-ANAT-MISC
perspective O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
cyclic O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
schedule O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
progestative O-MISC B-CHED-MISC
phase O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
periodic O-MISC B-CHED-MISC
complete O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
accurate O-MISC B-ACTI-MISC
thermographic O-MISC B-CONC-MISC
evaluation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
breast O-MISC I-GENE-MISC
target O-MISC B-GEOG-MISC
tissues O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Early O-MISC B-CHED-MISC
infections B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
transplant O-MISC I-ANAT-MISC
recipients O-MISC I-PHEN-MISC
on O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Eighty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
seventeen O-MISC B-ACTI-MISC
heart O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
infection B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Seventeen O-MISC B-ACTI-MISC
renal O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
received O-MISC B-ACTI-MISC
azathioprine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Aza B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
prednisone B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
immunosuppression O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
prednisone B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
others O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
prednisone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
Aza B-CHED-MISC O-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
infections B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
nonviral O-MISC I-ACTI-MISC
infections B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
randomized O-MISC B-CONC-MISC
cyclosporine B-CHED-MISC O-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Heart O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
infections B-DISO-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
renal O-MISC I-GENE-MISC
patients O-MISC I-ANAT-MISC
but O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
infections B-DISO-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Aza B-CHED-MISC I-ANAT-MISC
renal O-MISC B-GEOG-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
infectious O-MISC I-ACTI-MISC
deaths O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
renal O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
patients O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
Aza B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
infection B-DISO-MISC I-ACTI-MISC
played O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
deaths O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
deaths O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Renal O-MISC I-GENE-MISC
patients O-MISC I-ANAT-MISC
on O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fewest O-MISC B-ACTI-MISC
bacteremias B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
site O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
infection B-DISO-MISC I-ACTI-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
preponderance O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
abdominal B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
liver O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
intrathoracic O-MISC B-CHED-MISC
infections B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
urinary B-DISO-MISC I-ACTI-MISC
tract I-DISO-MISC B-ANAT-MISC
infections I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Pulmonary O-MISC I-ACTI-MISC
infections B-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
renal O-MISC I-GENE-MISC
patients O-MISC I-ANAT-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Aza B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Aza B-CHED-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
staphylococcal B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
than O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
transplant O-MISC B-CONC-MISC
groups O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
fungal B-DISO-MISC B-ANAT-MISC
infections I-DISO-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
liver O-MISC B-CONC-MISC
transplant O-MISC I-CONC-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Cytomegalovirus O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
CMV O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
shedding O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
serological O-MISC B-CHED-MISC
rises O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
antibody O-MISC O-MISC
titer O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
78 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Aza B-CHED-MISC O-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
CMV B-DISO-MISC I-ACTI-MISC
infection I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Serological O-MISC B-CHED-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
Epstein B-DISO-MISC I-ACTI-MISC
Barr I-DISO-MISC B-ANAT-MISC
Virus I-DISO-MISC B-ANAT-MISC
infection I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
patients O-MISC I-ANAT-MISC
studied O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Structure O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
activity O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
relationships O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
antagonism O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
picrotoxin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
cholecystokinin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
fragments O-MISC O-MISC
and O-MISC B-ACTI-MISC
analogues O-MISC O-MISC
of O-MISC B-ACTI-MISC
cholecystokinin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Intraperitoneal O-MISC B-CHED-MISC
administration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
cholecystokinin B-CHED-MISC O-MISC
octapeptide I-CHED-MISC B-DISO-MISC
sulphate O-MISC B-DISO-MISC
ester O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
SE O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nonsulphated O-MISC O-MISC
cholecystokinin B-CHED-MISC B-DISO-MISC
octapeptide I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
NS O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
latency O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
picrotoxin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Experiments O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
N O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
C O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
terminal O-MISC I-PROC-MISC
fragments O-MISC I-PROC-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C O-MISC O-MISC
- O-MISC B-DISO-MISC
terminal O-MISC B-DISO-MISC
tetrapeptide O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CCK O-MISC O-MISC
- O-MISC B-DISO-MISC
5 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
active O-MISC B-CHED-MISC
centre O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CCK O-MISC O-MISC
octapeptide O-MISC B-DISO-MISC
molecule O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
analogues O-MISC O-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
SE O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
NS O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
range O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mumol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
caerulein B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
range O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
mumol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
bell O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
shaped O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
curves O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
greatest O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
inhibition O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
NS O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
peptide O-MISC O-MISC
CCK O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
5 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
had O-MISC B-ACTI-MISC
weak O-MISC B-CHED-MISC
anticonvulsant O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
comparison O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
octapeptides O-MISC O-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mumol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
larger O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reference O-MISC O-MISC
drug O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
totally O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
picrotoxin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
peptides O-MISC O-MISC
tested O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Experiments O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
analogues O-MISC O-MISC
and O-MISC B-ACTI-MISC
derivatives O-MISC O-MISC
of O-MISC B-ACTI-MISC
CCK O-MISC O-MISC
- O-MISC B-DISO-MISC
5 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effectiveness O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
alanyl O-MISC B-DISO-MISC
derivatives O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
CCK O-MISC O-MISC
- O-MISC B-DISO-MISC
5 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
enhanced O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
equipotent O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
SE O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CCK O-MISC O-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
analogues O-MISC O-MISC
, O-MISC B-ACTI-MISC
Ser O-MISC O-MISC
( O-MISC B-DISO-MISC
SO3H O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
7 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
Ac O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
CCK O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
SE O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Thr O-MISC O-MISC
( O-MISC B-DISO-MISC
SO3H O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
7 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
Ac O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
CCK O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
SE O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Hyp O-MISC O-MISC
( O-MISC B-DISO-MISC
SO3H O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
Ac O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
CCK O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
8 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
SE O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
slightly O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
active O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
CCK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
8 I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
SE O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Vasopressin B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
contributor O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
vasopressin B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
agent O-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypertensive B-DISO-MISC I-ACTI-MISC
process O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Vasopressin B-CHED-MISC O-MISC
plays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
DOCA B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
salt O-MISC B-DISO-MISC
hypertension B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
since O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
elevation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
substantial O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
insipidus I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
DOCA B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
salt O-MISC O-MISC
treatment O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
DDAVP B-CHED-MISC O-MISC
which O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
antidiuretic O-MISC I-DISO-MISC
action O-MISC I-LIVB-MISC
but O-MISC B-ACTI-MISC
minimal O-MISC B-CHED-MISC
vasopressor O-MISC O-MISC
effect O-MISC B-CHED-MISC
failed O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
observed O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
AVP O-MISC O-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
action O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
vasopressin B-CHED-MISC O-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
important O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
since O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
pressor O-MISC O-MISC
responsiveness O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hormone O-MISC O-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initial O-MISC B-CHED-MISC
stage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-CHED-MISC
secretion O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
vasopressin B-CHED-MISC O-MISC
from O-MISC B-ACTI-MISC
neurohypophysis O-MISC I-ACTI-MISC
also O-MISC B-ACTI-MISC
promotes O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
function O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hormone O-MISC O-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pathogenetic O-MISC I-ACTI-MISC
factor O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
unproportional O-MISC B-CHED-MISC
release O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
vasopressin B-CHED-MISC O-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
plasma O-MISC I-DISO-MISC
osmolality O-MISC I-LIVB-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
adjusting O-MISC B-CHED-MISC
control O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
angiotensin B-CHED-MISC O-MISC
II O-MISC B-DISO-MISC
forming O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
receptor O-MISC B-CHED-MISC
binding O-MISC I-CHED-MISC
capacity O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
sodium B-CHED-MISC I-DISO-MISC
balance O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
vasopressin B-CHED-MISC O-MISC
remains O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
essential O-MISC I-ACTI-MISC
hypertension B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Toxic B-DISO-MISC I-ACTI-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
disulfiram B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
alcoholic O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
reversible O-MISC B-ACTI-MISC
toxic B-DISO-MISC I-ACTI-MISC
liver I-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
alcoholic O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
disulfiram B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
causative O-MISC B-CHED-MISC
relationship O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
proven O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
challenge O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Atrial B-DISO-MISC I-ACTI-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
involving O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
F O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
344 O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
ingesting O-MISC B-OCCU-MISC
quinacrine B-CHED-MISC O-MISC
hydrochloride I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Quinacrine B-CHED-MISC O-MISC
hydrochloride I-CHED-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
toxic O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
F O-MISC I-ACTI-MISC
- O-MISC I-PHEN-MISC
344 O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Rats O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
500 O-MISC B-ACTI-MISC
ppm O-MISC B-ACTI-MISC
quinacrine B-CHED-MISC O-MISC
hydrochloride I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diet O-MISC B-GENE-MISC
all O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
left O-MISC I-ACTI-MISC
atrial B-DISO-MISC B-ANAT-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
lesion O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
dilatation O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
focal O-MISC I-ACTI-MISC
myocardial B-DISO-MISC B-ANAT-MISC
degeneration I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Rats O-MISC I-ANAT-MISC
died O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
acute O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
congestion O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
the O-MISC B-ACTI-MISC
lungs O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
organs O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Seventy O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
given O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
ppm O-MISC B-ACTI-MISC
quinacrine B-CHED-MISC O-MISC
hydrochloride I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
ppm O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
nitrite I-CHED-MISC B-DISO-MISC
simultaneously O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diet O-MISC B-GENE-MISC
had O-MISC B-ACTI-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
atria O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
untreated O-MISC B-CHED-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
laboratory O-MISC B-GENE-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
atrial B-DISO-MISC I-ACTI-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Sodium B-CHED-MISC O-MISC
nitrite I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
quinacrine B-CHED-MISC O-MISC
hydrochloride I-CHED-MISC B-DISO-MISC
appeared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
additional O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Alternating B-DISO-MISC B-ACTI-MISC
sinus I-DISO-MISC I-ACTI-MISC
rhythm I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
intermittent O-MISC B-CHED-MISC
sinoatrial B-DISO-MISC I-ACTI-MISC
block I-DISO-MISC B-ANAT-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Alternating B-DISO-MISC B-ACTI-MISC
sinus I-DISO-MISC I-ACTI-MISC
rhythm I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
intermittent O-MISC I-ACTI-MISC
sinoatrial B-DISO-MISC B-ANAT-MISC
( I-DISO-MISC B-ANAT-MISC
S I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
A I-DISO-MISC B-ANAT-MISC
) I-DISO-MISC B-ANAT-MISC
block I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
angina B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
daily O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
electrocardiogram O-MISC I-ACTI-MISC
showed O-MISC B-ACTI-MISC
alternation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
short O-MISC B-CHED-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
intervals O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
occasional O-MISC I-ACTI-MISC
pauses O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
pauses O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
preceded O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
short O-MISC B-ACTI-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
intervals O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
intervals O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
92 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
representing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
sinus O-MISC I-GENE-MISC
cycle O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Following O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
sinus O-MISC B-CONC-MISC
cycles O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
alternating B-DISO-MISC B-CHED-MISC
rhythm I-DISO-MISC I-ACTI-MISC
started O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
longer O-MISC B-ACTI-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
interval O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
intervals O-MISC I-CHED-MISC
ranged O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
04 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
short O-MISC B-CHED-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
intervals O-MISC I-CHED-MISC
between O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pauses O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
equal O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
equal O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
short O-MISC B-ACTI-MISC
plus O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
long O-MISC B-ACTI-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
interval O-MISC I-CHED-MISC
or O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
twice O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
sinus O-MISC B-CONC-MISC
cycle O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
recording O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
short O-MISC B-CHED-MISC
period O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
regular O-MISC B-CHED-MISC
sinus O-MISC I-ACTI-MISC
rhythm O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
intermittent O-MISC B-CHED-MISC
2 O-MISC I-DISO-MISC
/ O-MISC I-LIVB-MISC
1 O-MISC I-LIVB-MISC
S B-DISO-MISC I-LIVB-MISC
- I-DISO-MISC I-LIVB-MISC
A I-DISO-MISC I-LIVB-MISC
block I-DISO-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
short O-MISC B-ACTI-MISC
period O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
sinus O-MISC I-ACTI-MISC
rhythm O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
interrupted O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
sudden O-MISC B-CHED-MISC
prolongation O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
interval O-MISC I-CHED-MISC
starting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alternative O-MISC I-DISO-MISC
rhythm O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
shape O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
waves O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
R O-MISC I-CHED-MISC
intervals O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

S O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
A O-MISC I-CHED-MISC
conduction O-MISC I-CHED-MISC
through O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
pathways O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
block O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
having O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
longer O-MISC B-CHED-MISC
conduction O-MISC B-CHED-MISC
time O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
occasional O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
block O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
proposed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
explanation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alternating O-MISC B-ACTI-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
interval O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
electrocardiographic O-MISC B-CHED-MISC
features O-MISC I-CHED-MISC
seen O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Atropine B-CHED-MISC O-MISC
1 O-MISC B-DISO-MISC
mg O-MISC B-DISO-MISC
given O-MISC B-CHED-MISC
intravenously O-MISC B-CHED-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
shortening O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
P O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
P O-MISC I-CHED-MISC
intervals O-MISC B-CHED-MISC
without O-MISC B-ACTI-MISC
changing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rhythm O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
rhythm O-MISC I-ACTI-MISC
disappeared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
withdrawal O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
was O-MISC B-ACTI-MISC
restarted O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
S B-DISO-MISC O-MISC
- I-DISO-MISC B-DISO-MISC
A I-DISO-MISC B-DISO-MISC
block I-DISO-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
accepted O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
being O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
conduction B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Antitumor O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
IgM O-MISC I-ACTI-MISC
solid O-MISC B-ANAT-MISC
immunocytoma B-DISO-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
bearing O-MISC B-ACTI-MISC
LOU O-MISC I-ACTI-MISC
/ O-MISC B-ANAT-MISC
M O-MISC B-ANAT-MISC
/ O-MISC B-ACTI-MISC
WSL O-MISC I-ANAT-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Antitumor O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
LOU O-MISC I-GENE-MISC
/ O-MISC B-ACTI-MISC
M O-MISC I-GENE-MISC
/ O-MISC B-ACTI-MISC
WSL O-MISC I-ACTI-MISC
inbred O-MISC I-ANAT-MISC
rats O-MISC I-PHEN-MISC
each O-MISC B-ACTI-MISC
bearing O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transplantable O-MISC B-CHED-MISC
solid O-MISC I-ACTI-MISC
IgM O-MISC B-ANAT-MISC
immunocytoma B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
diameter O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
iv O-MISC B-CHED-MISC
injections O-MISC O-MISC
of O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
consecutive O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
weekly O-MISC B-CHED-MISC
injection O-MISC O-MISC
for O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
range O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
015 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
body O-MISC B-CHED-MISC
wt O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Tumor B-DISO-MISC I-ACTI-MISC
regression O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Complete O-MISC B-ACTI-MISC
disappearance O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Histologic O-MISC B-CHED-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
scored O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
grade O-MISC B-CHED-MISC
III O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Light O-MISC B-CONC-MISC
microscopic O-MISC I-CONC-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
renal B-DISO-MISC I-GENE-MISC
damage I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
above O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
albuminuria B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
serum O-MISC B-OCCU-MISC
albumin O-MISC I-OCCU-MISC
levels O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC B-OCCU-MISC
albumin O-MISC I-OCCU-MISC
level O-MISC I-OCCU-MISC
decreased O-MISC I-OCCU-MISC
from O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
liter O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Ascites B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hydrothorax B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
simultaneously O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
experiments O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
tumor B-DISO-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
bearing O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
antitumor O-MISC I-ACTI-MISC
activity O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
simultaneously O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
LOU O-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
M O-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
WSL O-MISC I-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Albuminuria B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
extremely O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
serum O-MISC B-OCCU-MISC
albumin O-MISC I-OCCU-MISC
levels O-MISC I-OCCU-MISC
, O-MISC B-ACTI-MISC
so O-MISC B-ACTI-MISC
ascites B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hydrothorax B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
necessarily O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
consequence O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
cardiomyopathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Intraoperative O-MISC B-CHED-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
timolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
eye O-MISC B-DISO-MISC
drops O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
69 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
yr O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
concurrently O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
pilocarpine B-CHED-MISC O-MISC
nitrate I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
timolol B-CHED-MISC O-MISC
maleate I-CHED-MISC B-DISO-MISC
eye O-MISC O-MISC
drops O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
became O-MISC B-ACTI-MISC
hypotensive B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
halothane B-CHED-MISC B-CONC-MISC
anaesthesia O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
timolol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
subsequently O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
collection O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Timolol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
detected O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sample O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
removed O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
plasma O-MISC B-CHED-MISC
concentration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
timolol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
partial O-MISC B-CHED-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
adrenoceptor O-MISC B-DISO-MISC
blockade O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
postulated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
action O-MISC B-DEVI-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
during O-MISC B-ACTI-MISC
halothane B-CHED-MISC B-CONC-MISC
anaesthesia O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
resultant O-MISC B-CHED-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Pilocarpine B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
contributory O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Succinylcholine B-CHED-MISC I-ACTI-MISC
apnoea B-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
attempted O-MISC B-ACTI-MISC
reversal O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
anticholinesterases O-MISC O-MISC
. O-MISC B-ACTI-MISC

Anticholinesterases O-MISC O-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
attempt O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
antagonize O-MISC B-CONC-MISC
prolonged O-MISC B-CHED-MISC
neuromuscular B-DISO-MISC I-ACTI-MISC
blockade I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
later O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
atypical O-MISC B-CHED-MISC
plasma O-MISC I-GENE-MISC
cholinesterase O-MISC O-MISC
. O-MISC B-ACTI-MISC

Edrophonium B-CHED-MISC O-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
74 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
train O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
of O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
four O-MISC I-CONC-MISC
stimulation O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
characteristic O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
block O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
antagonism O-MISC I-DISO-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Repeated O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
edrophonium B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
neostigmine B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
antagonize O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
augment O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
block O-MISC O-MISC
. O-MISC B-ACTI-MISC

Spontaneous O-MISC I-DISO-MISC
respiration O-MISC I-LIVB-MISC
recommenced O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
anticholinesterases O-MISC O-MISC
are O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
partially O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
restoring O-MISC B-CONC-MISC
neuromuscular O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
succinylcholine B-CHED-MISC O-MISC
apnoea B-DISO-MISC B-DISO-MISC
despite O-MISC B-ACTI-MISC
muscle O-MISC I-ACTI-MISC
twitch O-MISC B-ANAT-MISC
activity O-MISC B-ANAT-MISC
typical O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
block O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
[ B-CHED-MISC O-MISC
omega I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
I I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
131 I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
heptadecanoic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
myocardial O-MISC B-CONC-MISC
scintigraphy O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
echocardiography O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
serial O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
dynamic O-MISC B-CONC-MISC
myocardial O-MISC I-CONC-MISC
scintigraphy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
[ B-CHED-MISC O-MISC
omega I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
I I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
131 I-CHED-MISC B-DISO-MISC
] I-CHED-MISC B-DISO-MISC
heptadecanoic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
I B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
131 I-CHED-MISC B-DISO-MISC
HA I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
global O-MISC B-CHED-MISC
left O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
ventricular O-MISC I-LIVB-MISC
function O-MISC I-LIVB-MISC
determined O-MISC B-ACTI-MISC
echocardiographically O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
mongrel O-MISC I-ANAT-MISC
dogs O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Total O-MISC B-CHED-MISC
extractable O-MISC O-MISC
myocardial O-MISC O-MISC
lipid O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
postmortem O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
dogs O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
dogs O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
fall O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
global O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
doxorubicin B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myocardial O-MISC I-DISO-MISC
t1 O-MISC B-CHED-MISC
/ O-MISC I-LIVB-MISC
2 O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
131 I-CHED-MISC B-DISO-MISC
HA I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
cumulative O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
significant O-MISC B-ANAT-MISC
alteration O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
extractable O-MISC B-ACTI-MISC
myocardial O-MISC I-GENE-MISC
lipids O-MISC O-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
dogs O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
doxorubicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alteration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
myocardial O-MISC B-CONC-MISC
dynamic O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
I B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
131 I-CHED-MISC B-DISO-MISC
HA I-CHED-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initiating O-MISC B-ACTI-MISC
factor O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Hemodynamics O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
myocardial O-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
under O-MISC B-ACTI-MISC
deliberate O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
experimental O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Coronary O-MISC I-ACTI-MISC
blood O-MISC B-ANAT-MISC
flow O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
work O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
metabolism O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
under O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
nitroprusside I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
SNP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
trimetaphan B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
TMP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
deliberate O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
pressure O-MISC I-DISO-MISC
decrease O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
baseline O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Regarding O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
on O-MISC B-ACTI-MISC
coronary O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
flow O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
aortic O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
coronary O-MISC I-GENE-MISC
sinus O-MISC B-GEOG-MISC
metabolic O-MISC B-CHED-MISC
data O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
pH O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
pO2 O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
pCO2 O-MISC B-OCCU-MISC
) O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
confirm O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
nitroprusside B-CHED-MISC I-ACTI-MISC
hypotension B-DISO-MISC B-ANAT-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
safely O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
blood O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
decrease O-MISC B-ANAT-MISC
from O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
trimetaphan B-CHED-MISC O-MISC
hypotension B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
blood O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
decrease O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Cardiac O-MISC I-ACTI-MISC
work O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
reduced O-MISC I-CHED-MISC
during O-MISC B-ACTI-MISC
SNP B-CHED-MISC B-LIVB-MISC
hypotension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Myocardial O-MISC I-GENE-MISC
O2 B-CHED-MISC O-MISC
consumption O-MISC B-UnknownType-MISC
and O-MISC B-ACTI-MISC
O2 B-CHED-MISC O-MISC
availability O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
directly O-MISC B-CHED-MISC
dependent O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
coronary O-MISC B-CONC-MISC
perfusion O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Careful O-MISC B-ACTI-MISC
invasive O-MISC B-CHED-MISC
monitoring O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
the O-MISC I-CONC-MISC
blood O-MISC I-CONC-MISC
pressure O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
gases O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ECG O-MISC B-CONC-MISC
ST O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
T O-MISC I-CONC-MISC
segment O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
mandatory O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Evidence O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
noradrenergic O-MISC B-CHED-MISC
involvement O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
locomotor O-MISC I-DISO-MISC
stimulant O-MISC O-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Male O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
noradrenaline B-CHED-MISC O-MISC
neurotoxin O-MISC B-DISO-MISC
DSP4 B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
injection O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
amphetamine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mumol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
amphetamine I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mumol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
DSP4 B-CHED-MISC O-MISC
pretreatment O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
rearings O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
stereotypies B-DISO-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
blocked O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
DSP4 B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
hyperactivity B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
DSP4 B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
blocked O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
noradrenaline B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
uptake O-MISC I-DISO-MISC
blocking O-MISC O-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
desipramine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
prevents O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC B-CHED-MISC
action O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
DSP4 B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
results O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
involvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
noradrenergic O-MISC B-GEOG-MISC
neurones O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
locomotor O-MISC O-MISC
stimulant O-MISC B-DISO-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
amphetamine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Accelerated B-DISO-MISC B-CHED-MISC
junctional I-DISO-MISC I-ACTI-MISC
rhythms I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
verapamil B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
atrioventricular O-MISC I-ACTI-MISC
( O-MISC B-ANAT-MISC
AV O-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
dissociation O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
accelerated B-DISO-MISC B-CHED-MISC
junctional I-DISO-MISC I-ACTI-MISC
rhythms I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-CHED-MISC
oral O-MISC B-CHED-MISC
verapamil B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Accelerated B-DISO-MISC I-ACTI-MISC
junctional I-DISO-MISC B-ANAT-MISC
rhythms I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
AV O-MISC I-ACTI-MISC
dissociation O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
supraventricular B-DISO-MISC I-ACTI-MISC
tachyarrhythmias I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
AV O-MISC I-ACTI-MISC
nodal O-MISC B-ANAT-MISC
reentry O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Verapamil B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
asymptomatic O-MISC I-ACTI-MISC
increase O-MISC I-ACTI-MISC
in O-MISC B-ANAT-MISC
activity O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
junctional O-MISC B-OBJC-MISC
pacemakers O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
syndromes O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
neither O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
junctional O-MISC I-ACTI-MISC
rhythms O-MISC B-ANAT-MISC
nor O-MISC B-ACTI-MISC
suppressed O-MISC B-CHED-MISC
their O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
escape O-MISC I-DISO-MISC
rhythms O-MISC I-DISO-MISC
under O-MISC B-ACTI-MISC
physiologically O-MISC B-CHED-MISC
appropriate O-MISC B-ACTI-MISC
circumstances O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Interstrain O-MISC B-CHED-MISC
variation O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
toxic O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
among O-MISC B-ACTI-MISC
inbred O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC B-CHED-MISC
toxic O-MISC B-CHED-MISC
dosage O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
behavioral O-MISC B-DEVI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
males O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
inbred O-MISC I-ANAT-MISC
mouse O-MISC I-PHEN-MISC
strains O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
A O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
J O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
BALB O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
cJ O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
CBA O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
J O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
C3H O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
HeJ O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6J O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
DBA O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
2J O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
SWR O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
J O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

C57BL O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
6J O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
chosen O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
prototypic O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
strain O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
responses O-MISC I-DEVI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
broad O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
caffeine B-CHED-MISC B-CONC-MISC
doses O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
phenotypic O-MISC I-DISO-MISC
characteristics O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
- O-MISC I-LIVB-MISC
locomotor O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
righting O-MISC B-ACTI-MISC
ability O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
clonic B-DISO-MISC I-ACTI-MISC
seizure I-DISO-MISC B-ANAT-MISC
induction O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
stress O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
lethality O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
without O-MISC B-ACTI-MISC
external O-MISC I-ACTI-MISC
stress O-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
scored O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
doses O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
naive O-MISC I-DISO-MISC
animals O-MISC I-PHEN-MISC
under O-MISC B-ACTI-MISC
empirically O-MISC B-ACTI-MISC
optimized O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
rigidly O-MISC B-CHED-MISC
constant O-MISC I-CHED-MISC
experimental O-MISC I-CHED-MISC
conditions O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Mice O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
point O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
single O-MISC B-ACTI-MISC
IP O-MISC B-GENE-MISC
injections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fixed O-MISC B-ACTI-MISC
volume O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
physiological O-MISC B-CHED-MISC
saline O-MISC B-GENE-MISC
carrier O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
caffeine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
ranging O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
125 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Loss O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
righting O-MISC B-ACTI-MISC
ability O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
scored O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
dosing O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
intervals O-MISC B-CHED-MISC
thereafter O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
clonic B-DISO-MISC I-ACTI-MISC
seizures I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
scored O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
onset O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
proceeded O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
tonic B-DISO-MISC I-ACTI-MISC
seizures I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
death O-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
surviving O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
immediately O-MISC B-ACTI-MISC
stressed O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
swim O-MISC B-CONC-MISC
test O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
25 O-MISC B-CHED-MISC
degrees O-MISC I-CHED-MISC
C O-MISC B-ACTI-MISC
water O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
producing O-MISC B-ACTI-MISC
tonic B-DISO-MISC I-ACTI-MISC
seizures I-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
scored O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
locomotor O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
caffeine B-CHED-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
criterion O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
criteria O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
differences O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
toxic O-MISC B-CHED-MISC
caffeine B-CHED-MISC O-MISC
doses O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
strains O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
behavioral O-MISC B-DEVI-MISC
toxicity B-DISO-MISC I-DEVI-MISC
testing O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
alkylxanthines B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
mouse O-MISC I-ANAT-MISC
strain O-MISC I-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
misleading O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
toxic O-MISC B-CHED-MISC
responses O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
class O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
compounds O-MISC O-MISC
are O-MISC B-ACTI-MISC
genetically O-MISC B-CHED-MISC
influenced O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mammals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cis B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
platinum I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
adriamycin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
hexamethylmelamine B-CHED-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cisplatinum B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CPDD B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
adriamycin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
hexamethylmelamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
HMM B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
daily O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Each O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
repeated O-MISC B-ACTI-MISC
monthly O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

2 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
stage O-MISC I-ACTI-MISC
II O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
stage O-MISC I-ACTI-MISC
III O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
stage O-MISC B-CONC-MISC
IV O-MISC I-LIVB-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

14 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC I-CONC-MISC
chemotherapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
radiation O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
radiation O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
before O-MISC B-ACTI-MISC
CPDD B-CHED-MISC B-CONC-MISC
combination O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

31 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
objective O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
lasting O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
complete O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Hematologic B-DISO-MISC B-CHED-MISC
toxicity I-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
moderate O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
reversible O-MISC B-CHED-MISC
anemia B-DISO-MISC I-ACTI-MISC
developing O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
71 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Gastrointestinal O-MISC I-GENE-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
from O-MISC B-ACTI-MISC
CPDD B-CHED-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
universal O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

HMM B-CHED-MISC O-MISC
gastrointestinal B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
necessitated O-MISC B-ACTI-MISC
discontinuation O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
the O-MISC I-CONC-MISC
drug O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Severe O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
but O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
reversible O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
deaths O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Nontraumatic O-MISC I-ACTI-MISC
dissecting B-DISO-MISC B-ANAT-MISC
aneurysm I-DISO-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basilar O-MISC I-GENE-MISC
artery O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nontraumatic O-MISC I-ACTI-MISC
dissecting B-DISO-MISC B-ANAT-MISC
aneurysm I-DISO-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basilar O-MISC I-GENE-MISC
artery O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
smoke O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
oral B-CHED-MISC O-MISC
contraceptives I-CHED-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
young O-MISC B-CHED-MISC
female O-MISC I-DISO-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
locked B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
in I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
method O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
measurement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tremor B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
comparison O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
tocolytic O-MISC B-CHED-MISC
beta O-MISC O-MISC
- O-MISC I-GEOG-MISC
mimetics O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
method O-MISC B-CHED-MISC
permitting O-MISC B-ACTI-MISC
measurement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
finger O-MISC I-ACTI-MISC
tremor B-DISO-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
displacement O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
curve O-MISC I-CHED-MISC
is O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
test O-MISC B-ACTI-MISC
system O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
simple O-MISC B-ACTI-MISC
amplitude O-MISC B-CHED-MISC
calibration O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
coordinates O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inversion O-MISC B-CHED-MISC
points O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
displacement O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
curves O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
transferred O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
graphical O-MISC B-CHED-MISC
input O-MISC B-GENE-MISC
equipment O-MISC B-GENE-MISC
to O-MISC B-ACTI-MISC
punched O-MISC B-OBJC-MISC
tape O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
means O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
computer O-MISC B-GENE-MISC
program O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
periods O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
amplitudes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tremor B-DISO-MISC I-ACTI-MISC
oscillations O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
event O-MISC B-DEVI-MISC
frequency O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
class O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
periods O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
amplitudes O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
actions O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
fenoterol B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
hydrobromide I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
ritodrin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HCl I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
given O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
by O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
infusion O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
crossover O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
method O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
both O-MISC B-ACTI-MISC
substances O-MISC B-GENE-MISC
raised O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
tremor B-DISO-MISC I-ACTI-MISC
amplitude O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
level O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
class O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amplitudes O-MISC B-CHED-MISC
shortened O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
ms O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mean O-MISC B-CHED-MISC
periods O-MISC B-CHED-MISC
calculated O-MISC B-DEVI-MISC
from O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
oscillations O-MISC I-DISO-MISC
together O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
change O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
end O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
fenoterol B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
hydrobromide I-CHED-MISC B-DISO-MISC
infusion O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
tremor B-DISO-MISC I-ACTI-MISC
amplitudes O-MISC B-CHED-MISC
decreased O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
faster O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
ritodrin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HCl I-CHED-MISC B-DISO-MISC
infusion O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Propylthiouracil B-CHED-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hepatic B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
propylthiouracil B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
liver B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
case O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
type O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
damage O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
proven O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
rechallenge O-MISC B-CONC-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
presents O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
histologic O-MISC I-ACTI-MISC
picture O-MISC B-ANAT-MISC
resembling O-MISC B-ACTI-MISC
chronic B-DISO-MISC I-ACTI-MISC
active I-DISO-MISC B-ANAT-MISC
hepatitis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
remission O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Studies O-MISC B-CONC-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bradycardia B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
bepridil B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Bepridil B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
active O-MISC O-MISC
compound O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
prophylactic O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
anginal B-DISO-MISC I-ACTI-MISC
attacks I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
persistent O-MISC I-ACTI-MISC
bradycardia B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
anti O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
tachycardial B-DISO-MISC B-ANAT-MISC
effect O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
perfusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
bepridil B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
life O-MISC O-MISC
- O-MISC B-DISO-MISC
support O-MISC B-DISO-MISC
medium O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
isolated O-MISC B-ACTI-MISC
sino O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
atrial O-MISC B-GEOG-MISC
tissue O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
rabbit O-MISC I-ANAT-MISC
heart O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
action O-MISC I-DISO-MISC
potential O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
AP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
spike O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
KCl B-CHED-MISC B-OBJC-MISC
microelectrodes O-MISC I-OBJC-MISC
) O-MISC B-ACTI-MISC
starting O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
X O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
M O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
concentrations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
X O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
M O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereupon O-MISC B-ACTI-MISC
blockade O-MISC O-MISC
of O-MISC B-ACTI-MISC
sinus O-MISC I-GENE-MISC
activity O-MISC B-GEOG-MISC
set O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Bepridil B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
X O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
M O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
concomitant O-MISC B-CHED-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
AP O-MISC I-ACTI-MISC
amplitude O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
falling O-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
71 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
mV O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
mV O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
systolic O-MISC I-CHED-MISC
depolarization O-MISC I-CHED-MISC
velocity O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
phase O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
fell O-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
V O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
V O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
diastolic O-MISC I-CHED-MISC
depolarization O-MISC I-CHED-MISC
velocity O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
phase O-MISC B-CHED-MISC
4 O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
fell O-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mV O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mV O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-CHED-MISC
vivo O-MISC I-CONC-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
bepridil B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
anaesthetized O-MISC I-ANAT-MISC
dogs O-MISC I-PHEN-MISC
which O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
undergone O-MISC B-ACTI-MISC
ablation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
extrinsic O-MISC I-ACTI-MISC
cardiac O-MISC I-GENE-MISC
afferent O-MISC B-CHED-MISC
nerve O-MISC B-GEOG-MISC
supply O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
bilateral O-MISC B-CHED-MISC
medullo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
adrenalectomy O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
which O-MISC B-ACTI-MISC
fell O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
98 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
beats O-MISC B-CHED-MISC
/ O-MISC I-CHED-MISC
min O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
beats O-MISC B-CHED-MISC
/ O-MISC I-CHED-MISC
min O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
bepridil B-CHED-MISC O-MISC
reduces O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
acting O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sinus O-MISC I-GENE-MISC
node O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
flattening O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phase O-MISC B-OCCU-MISC
0 O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
phase O-MISC B-OCCU-MISC
4 O-MISC B-ANAT-MISC
slope O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
longer O-MISC B-ACTI-MISC
AP O-MISC I-ACTI-MISC
duration O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
constants O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
slow O-MISC B-CHED-MISC
inward O-MISC B-ANAT-MISC
ionic O-MISC I-DISO-MISC
currents O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
already O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
elsewhere O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
time O-MISC B-CHED-MISC
constant O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
deactivation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
outward O-MISC I-DISO-MISC
potassium B-CHED-MISC I-LIVB-MISC
current O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
Ip O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hepatitis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
tubular I-DISO-MISC B-ANAT-MISC
acidosis I-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
anesthesia O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
methoxyflurane B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
69 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC I-DISO-MISC
operated O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
cholecystitis I-DISO-MISC B-ANAT-MISC
under O-MISC B-ACTI-MISC
methoxyflurane B-CHED-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
developed O-MISC B-ACTI-MISC
postoperatively O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
hepatic B-DISO-MISC I-ACTI-MISC
insufficiency I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-GENE-MISC
tubular I-DISO-MISC B-GEOG-MISC
acidosis I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Massive O-MISC I-ACTI-MISC
bleeding B-DISO-MISC B-ANAT-MISC
appeared O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
surgery O-MISC B-CONC-MISC
which O-MISC B-ACTI-MISC
lasted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Postoperative O-MISC B-CHED-MISC
evolution O-MISC B-CHED-MISC
under O-MISC B-ACTI-MISC
supportive O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
favourable O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Complete O-MISC I-ACTI-MISC
recovery O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
repeated O-MISC B-CHED-MISC
controls O-MISC I-ANAT-MISC
performed O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
period O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
surgery O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Pituitary O-MISC I-GENE-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
luteinizing O-MISC O-MISC
hormone O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
releasing O-MISC B-DISO-MISC
hormone O-MISC B-DISO-MISC
during O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
hour O-MISC B-ACTI-MISC
infusion O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
prolactin O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
luteinizing O-MISC B-OCCU-MISC
hormone O-MISC I-OCCU-MISC
( O-MISC I-OCCU-MISC
LH O-MISC I-OCCU-MISC
) O-MISC I-OCCU-MISC
levels O-MISC I-OCCU-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
subjects O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
starting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
infusions O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pituitary O-MISC I-GENE-MISC
responses O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
LH O-MISC O-MISC
- O-MISC B-DISO-MISC
releasing O-MISC B-DISO-MISC
hormone O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
LH O-MISC O-MISC
- O-MISC B-DISO-MISC
RH O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Control O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
received O-MISC B-CHED-MISC
infusions O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
NaCl B-CHED-MISC O-MISC
solution O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
infusions O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
abolished O-MISC B-ACTI-MISC
pituitary O-MISC I-GENE-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
LH O-MISC O-MISC
- O-MISC B-ACTI-MISC
RH O-MISC O-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Antirifampicin O-MISC O-MISC
antibodies O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
rifampicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
thrombopenia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
hemolysis B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reintroduction O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
rifampicin B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
manifestations O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
total O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
taken O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
antirifampicin O-MISC O-MISC
antibodies O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Antibodies O-MISC O-MISC
suggested O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
IgM O-MISC O-MISC
class O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hematological B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pattern O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
tubular I-DISO-MISC B-ANAT-MISC
necrosis I-DISO-MISC B-ANAT-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
biopsied O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
indistinguishable O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ischemic O-MISC I-ACTI-MISC
origin O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
raised O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
vascular O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
damage O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
triggering O-MISC B-CHED-MISC
immunoallergic O-MISC O-MISC
mechanism O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Cardiovascular O-MISC I-GENE-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
adenosine B-CHED-MISC O-MISC
triphosphate I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
nitroprusside I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
denervated O-MISC B-CHED-MISC
hearts O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Adenosine B-CHED-MISC O-MISC
triphosphate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ATP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
nitroprusside I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
SNP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
control O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
anesthesia O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

SNP B-CHED-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
authorized O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
use O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
USA O-MISC B-ORGA-MISC
and O-MISC B-ACTI-MISC
UK O-MISC B-ORGA-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ATP B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
clinically O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
countries O-MISC B-ORGA-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
Japan O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
how O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
act O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
systems O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
whose O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
denervated O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
procedure O-MISC B-CONC-MISC
we O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
devised O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

ATP B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
SNP B-CHED-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Before O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
during O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-CHED-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
major O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
parameters O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Hypotension B-DISO-MISC I-ACTI-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
ATP B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
accompanied O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
decreases O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
pulmonary O-MISC B-ANAT-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
central O-MISC I-DISO-MISC
venous O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
end O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
total O-MISC I-ACTI-MISC
peripheral O-MISC B-ANAT-MISC
resistance O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
pressure O-MISC I-CHED-MISC
product O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
total O-MISC I-ACTI-MISC
body O-MISC B-ANAT-MISC
oxygen B-CHED-MISC B-ANAT-MISC
consumption O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
variables O-MISC B-ACTI-MISC
returned O-MISC B-CHED-MISC
normal O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
ATP B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
stopped O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
did O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
SNP B-CHED-MISC B-LIVB-MISC
similar O-MISC B-ACTI-MISC
decreases O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
pulmonary O-MISC B-ANAT-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
central O-MISC I-DISO-MISC
venous O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
end O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
total O-MISC I-ACTI-MISC
peripheral O-MISC B-ANAT-MISC
resistance O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
pressure O-MISC I-CHED-MISC
product O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
oxygen B-CHED-MISC O-MISC
content O-MISC I-CONC-MISC
difference O-MISC I-LIVB-MISC
between O-MISC B-ACTI-MISC
arterial O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
mixed O-MISC I-GENE-MISC
venous O-MISC B-GEOG-MISC
blood O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Recoveries O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
end O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
SNP B-CHED-MISC B-LIVB-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
stopped O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
ATP B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
SNP B-CHED-MISC O-MISC
should O-MISC B-ACTI-MISC
act O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pacemaker O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Comparative O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
Endografine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
diatrizoate B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Vasurix B-CHED-MISC O-MISC
polyvidone I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
acetrizoate B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Dimer B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
X I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
iocarmate B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Hexabrix B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
ioxaglate B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hysterosalpingography O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
hysterosalpingography O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
Dimer B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
X I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
Hexabrix B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
Vasurix B-CHED-MISC O-MISC
polyvidone I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Endografine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
142 O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
tested O-MISC B-ACTI-MISC
media O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
replies O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
postal O-MISC B-CHED-MISC
questionnaires O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Dimer B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
X I-CHED-MISC B-DISO-MISC
group O-MISC B-CHED-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
dizziness B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Endografine B-CHED-MISC B-CHED-MISC
group O-MISC I-CHED-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
abdominal B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
differences O-MISC B-CHED-MISC
occur O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
age O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
under O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hexabrix B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
Vasurix B-CHED-MISC O-MISC
polyvidone I-CHED-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
contrast B-CHED-MISC O-MISC
media I-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
hysterosalpingography O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
perhaps O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
toxicity B-DISO-MISC B-CHED-MISC
Hexabrix B-CHED-MISC O-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
preferred O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Post O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC I-ACTI-MISC
pains B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
Nigerian O-MISC B-ORGA-MISC
surgical O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Contrary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
earlier O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
Coxon O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
scoline B-CHED-MISC O-MISC
pain B-DISO-MISC I-ACTI-MISC
occurs O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
African O-MISC I-ANAT-MISC
negroes O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Its O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prospective O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
involving O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
Nigerian O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
out O-MISC I-ANAT-MISC
- O-MISC B-ANAT-MISC
patients O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
in O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
patients O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

About O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
out O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
patients O-MISC I-PHEN-MISC
developed O-MISC B-ACTI-MISC
scoline B-CHED-MISC O-MISC
pain B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
in O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
patients O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
abolition O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
muscle O-MISC I-GENE-MISC
fasciculations B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
075mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Fazadinium B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
scoline B-CHED-MISC O-MISC
pain B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
induction O-MISC O-MISC
agent O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Althesin B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
Thiopentone B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
nor O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
salt O-MISC B-DEVI-MISC
preparation O-MISC I-DEVI-MISC
of O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
used O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
chloride B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
bromide B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
scoline B-CHED-MISC O-MISC
pain B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Invasive O-MISC I-ACTI-MISC
carcinoma B-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
renal I-DISO-MISC I-GENE-MISC
pelvis I-DISO-MISC B-GEOG-MISC
following O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
nonmalignant O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
right O-MISC I-ACTI-MISC
hydroureteronephrosis B-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
ureterovesical O-MISC I-ACTI-MISC
junction O-MISC B-ANAT-MISC
obstruction O-MISC B-ANAT-MISC
had O-MISC B-ACTI-MISC
gross O-MISC B-ACTI-MISC
hematuria B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
wtih O-MISC O-MISC
cyclophosphamide B-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
vasculitis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
right O-MISC B-CONC-MISC
nephroureterectomy O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
bleeding B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pathology O-MISC B-GENE-MISC
specimen O-MISC B-CHED-MISC
contained O-MISC B-ACTI-MISC
clinically O-MISC B-ACTI-MISC
occult O-MISC I-ACTI-MISC
invasive O-MISC I-ACTI-MISC
carcinoma B-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
renal I-DISO-MISC I-GENE-MISC
pelvis I-DISO-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ability O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
cystitis I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
cytologic O-MISC B-ANAT-MISC
abnormalities O-MISC B-ANAT-MISC
indistinguishable O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
high O-MISC I-ACTI-MISC
grade O-MISC B-ANAT-MISC
carcinoma B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
widely O-MISC B-ACTI-MISC
appreciated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
carcinoma B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
urinary I-DISO-MISC I-GENE-MISC
tract I-DISO-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
carcinomas B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
the I-DISO-MISC B-ANAT-MISC
urinary I-DISO-MISC B-ANAT-MISC
bladder I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
carcinoma B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
the I-DISO-MISC B-ANAT-MISC
prostate I-DISO-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC I-ACTI-MISC
case O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
carcinoma B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
the I-DISO-MISC B-ANAT-MISC
renal I-DISO-MISC B-ANAT-MISC
pelvis I-DISO-MISC B-ANAT-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
cyclophosphamide B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
urinary B-DISO-MISC I-ACTI-MISC
tract I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
reported O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
nonmalignant O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
association O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
preexisting O-MISC B-CHED-MISC
hydroureteronephrosis B-DISO-MISC I-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
stasis O-MISC I-ACTI-MISC
prolonged O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
intensified O-MISC B-CHED-MISC
exposure O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
upper O-MISC I-GENE-MISC
urinary O-MISC B-GEOG-MISC
tract O-MISC B-GEOG-MISC
epithelium O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
candidates O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
cyclophosphamide B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
routinely O-MISC B-CHED-MISC
evaluated O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
obstructive B-DISO-MISC I-ACTI-MISC
uropathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Medial O-MISC B-CHED-MISC
changes O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
arterial O-MISC I-ACTI-MISC
spasm B-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
norepinephrine I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
media O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
arteries O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
diameter O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
contain O-MISC B-ACTI-MISC
intracellular O-MISC B-CHED-MISC
vacuoles O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
ultrastructurally O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
herniations O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
smooth O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
into O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
intense O-MISC B-CHED-MISC
vasoconstriction O-MISC I-ACTI-MISC
would O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
vacuoles O-MISC I-GENE-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
media O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
saphenous O-MISC I-GENE-MISC
artery O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
distal O-MISC I-GENE-MISC
branch O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
vasoconstriction O-MISC I-DISO-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
norepinephrine I-CHED-MISC B-DISO-MISC
produced O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
cell O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
to O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
cell O-MISC B-ANAT-MISC
hernias B-DISO-MISC B-ANAT-MISC
within O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

At O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
their O-MISC B-ACTI-MISC
number O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
original O-MISC B-ACTI-MISC
number O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vessel O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
restored O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Triple O-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
over O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
more O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
media O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
smooth O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
are O-MISC B-ACTI-MISC
susceptible O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
damage O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
course O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
specific O-MISC B-CHED-MISC
function O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
data O-MISC I-CHED-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
relation O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
medial O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
instances O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
arterial O-MISC I-ACTI-MISC
spasm B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Endothelial O-MISC I-GENE-MISC
changes O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
model O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
described O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
paper O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Bilateral O-MISC I-ACTI-MISC
retinal B-DISO-MISC B-ANAT-MISC
artery I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
choriocapillaris I-DISO-MISC I-GENE-MISC
occlusion I-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
long O-MISC O-MISC
- O-MISC B-DISO-MISC
acting O-MISC B-DISO-MISC
corticosteroid B-CHED-MISC B-DISO-MISC
suspensions O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
: O-MISC B-ACTI-MISC
I O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
documented O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bilateral O-MISC I-ACTI-MISC
retinal B-DISO-MISC B-ANAT-MISC
artery I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
choriocapillaris I-DISO-MISC I-GENE-MISC
occlusions I-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
blindness B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
head O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
neck O-MISC I-GENE-MISC
soft O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
tissue O-MISC B-GEOG-MISC
injection O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
methylprednisolone B-CHED-MISC O-MISC
acetate I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
penicillin B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
had O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
unilateral O-MISC B-CHED-MISC
injection O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
observations O-MISC B-CONC-MISC
included O-MISC B-ACTI-MISC
hazy O-MISC I-ACTI-MISC
sensorium O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
superior O-MISC I-ACTI-MISC
gaze O-MISC B-ANAT-MISC
palsy B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
pupillary B-DISO-MISC I-ACTI-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
conjunctival O-MISC I-ACTI-MISC
hemorrhages B-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
edema B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
changes O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
visual B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
constricted O-MISC B-CHED-MISC
visual O-MISC B-CHED-MISC
fields O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
optic O-MISC I-ACTI-MISC
nerve O-MISC B-ANAT-MISC
pallor O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
vascular O-MISC I-ACTI-MISC
attenuation O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
chorioretinal B-DISO-MISC I-ACTI-MISC
atrophy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
reviewed O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
causes O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Abnormalities O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pupil O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
visual O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
evoked O-MISC I-LIVB-MISC
potential O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
quinine B-CHED-MISC I-ACTI-MISC
amblyopia B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Total O-MISC B-ACTI-MISC
blindness B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transient O-MISC I-DISO-MISC
tonic B-DISO-MISC I-DISO-MISC
pupillary I-DISO-MISC I-LIVB-MISC
response O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
denervation O-MISC I-ACTI-MISC
supersensitivity O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
visual O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
evoked O-MISC I-LIVB-MISC
potentials O-MISC I-LIVB-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
quinine B-CHED-MISC O-MISC
sulfate I-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
leg B-DISO-MISC I-ACTI-MISC
cramps I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
recovered O-MISC B-CHED-MISC
normal O-MISC B-ACTI-MISC
visual O-MISC I-DISO-MISC
acuity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
transient O-MISC I-DISO-MISC
tonic B-DISO-MISC I-LIVB-MISC
pupillary I-DISO-MISC I-LIVB-MISC
response O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
denervation O-MISC I-ACTI-MISC
supersensitivity O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
visual O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
evoked O-MISC I-LIVB-MISC
potentials O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
quinine B-CHED-MISC O-MISC
toxicity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Suxamethonium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
jaw B-DISO-MISC I-ACTI-MISC
stiffness I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
myalgia B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
atypical O-MISC O-MISC
cholinesterase O-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
boy O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
halothane B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
nitrous B-CHED-MISC O-MISC
oxide I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
oxygen B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
pancuronium B-CHED-MISC O-MISC
0 O-MISC B-DISO-MISC
. O-MISC B-DISO-MISC
4 O-MISC B-DISO-MISC
mg O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
100 O-MISC B-DISO-MISC
mg O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
induction O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
anaesthesia O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
response O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
jaw B-DISO-MISC I-ACTI-MISC
stiffness I-DISO-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
lasted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anaesthesia O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
terminated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
apnoea B-DISO-MISC I-ACTI-MISC
ensued O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
suffered O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
severe O-MISC B-ANAT-MISC
myalgia B-DISO-MISC B-ANAT-MISC
lasting O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
week O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
atypical O-MISC B-CHED-MISC
plasma O-MISC I-GENE-MISC
cholinesterase O-MISC O-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dibucaine B-CHED-MISC O-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
homozygocity O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
verified O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
shows O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
prolonged B-DISO-MISC B-CHED-MISC
jaw I-DISO-MISC I-GENE-MISC
rigidity I-DISO-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
myalgia B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
suxamethonium B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
atypical O-MISC B-CHED-MISC
cholinesterase O-MISC O-MISC
despite O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
pancuronium B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Indomethacin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
gouty B-DISO-MISC I-ACTI-MISC
arthritis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
life O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
hyperkalemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
insufficiency I-DISO-MISC B-ANAT-MISC
developed O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
gouty B-DISO-MISC B-ANAT-MISC
arthritis I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
prostaglandin B-CHED-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
consequent O-MISC B-ACTI-MISC
hyporeninemic B-DISO-MISC I-ACTI-MISC
hypoaidosteronism I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Careful O-MISC B-ACTI-MISC
attention O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
potassium B-CHED-MISC B-CONC-MISC
balance O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
nonsteroidal O-MISC O-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
agents O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
mellitus I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
preexisting O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
will O-MISC B-ACTI-MISC
help O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
potentially O-MISC B-CHED-MISC
serious O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Etomidate B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
foreshortened O-MISC B-CONC-MISC
clinical O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
evaluation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
outpatient O-MISC I-ANAT-MISC
cystoscopy O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
embarked O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Unpremedicated O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
fentanyl B-CHED-MISC O-MISC
1 O-MISC B-ACTI-MISC
microgram O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
etomidate B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Anaesthesia O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
maintained O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
intermittent O-MISC B-CHED-MISC
etomidate B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
interviewed O-MISC B-DEVI-MISC
personally O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
questionnaire O-MISC B-CHED-MISC
three O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
later O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
trial O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
discontinued O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unacceptable O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Venous O-MISC I-ACTI-MISC
pain B-DISO-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
redness O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
swelling B-DISO-MISC I-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
injection O-MISC I-GENE-MISC
site O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
lasting O-MISC B-ACTI-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
anaesthesia O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Skeletal O-MISC I-DISO-MISC
movements O-MISC I-LIVB-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
experienced O-MISC B-ACTI-MISC
respiratory B-DISO-MISC I-ACTI-MISC
upset I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
sufficiently O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
necessitate O-MISC B-ACTI-MISC
abandoning O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
technique O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Nausea B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
disturbing O-MISC B-ACTI-MISC
emergence O-MISC I-ACTI-MISC
psychoses B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
improved O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
motor B-DISO-MISC I-ACTI-MISC
disability I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
responsive O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acute O-MISC B-ACTI-MISC
challenge O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mixed O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
agonist O-MISC O-MISC
, O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
twice O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
without O-MISC B-ACTI-MISC
modification O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
parkinsonian B-DISO-MISC I-ACTI-MISC
motor B-DISO-MISC B-ANAT-MISC
disability I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
predominantly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lower O-MISC I-GENE-MISC
limbs O-MISC B-GEOG-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
disappearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dystonic B-DISO-MISC I-ACTI-MISC
dyskinesias I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
end O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
upper O-MISC I-GENE-MISC
limbs O-MISC B-GEOG-MISC
during O-MISC B-ACTI-MISC
choreic B-DISO-MISC I-ACTI-MISC
mid I-DISO-MISC B-CHED-MISC
- I-DISO-MISC I-CHED-MISC
dose I-DISO-MISC I-CHED-MISC
dyskinesias I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
brain O-MISC I-GENE-MISC
serotoninergic O-MISC I-DISO-MISC
transmission O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
levodopa B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
agonist O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
without O-MISC B-ACTI-MISC
aggravating O-MISC B-ACTI-MISC
parkinsonian B-DISO-MISC I-ACTI-MISC
motor B-DISO-MISC B-ANAT-MISC
disability I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
population O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
based O-MISC I-CONC-MISC
follow O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
trimethoprim B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
sulfamethoxazole I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
trimethoprim B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cephalexin B-CHED-MISC O-MISC
for O-MISC B-ACTI-MISC
uncommon O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
drug B-DISO-MISC I-ACTI-MISC
toxicity I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conducted O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
232 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
390 O-MISC B-ACTI-MISC
people O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
trimethoprim B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
sulfamethoxazole I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TMP B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
SMZ I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
266 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
951 O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
trimethoprim B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
196 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
397 O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
cephalexin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
estimate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
liver B-DISO-MISC I-ACTI-MISC
, I-DISO-MISC B-ACTI-MISC
blood I-DISO-MISC I-ACTI-MISC
, I-DISO-MISC B-ACTI-MISC
skin I-DISO-MISC I-ACTI-MISC
, I-DISO-MISC B-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
renal I-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
referral O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
hospitalization O-MISC B-CONC-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
information O-MISC B-CHED-MISC
recorded O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
office O-MISC B-GENE-MISC
computers O-MISC I-GEOG-MISC
by O-MISC B-ACTI-MISC
selected O-MISC B-ACTI-MISC
general O-MISC I-ANAT-MISC
practitioners O-MISC I-PHEN-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
United O-MISC B-ORGA-MISC
Kingdom O-MISC I-ORGA-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
records O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
risk O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
clinically O-MISC B-CHED-MISC
important O-MISC B-ACTI-MISC
idiopathic O-MISC I-ACTI-MISC
liver B-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
persons O-MISC I-ANAT-MISC
prescribed O-MISC B-CONC-MISC
TMP B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
SMZ I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
trimethoprim B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
risk O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
prescribed O-MISC B-CONC-MISC
cephalexin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
somewhat O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
experienced O-MISC I-DISO-MISC
blood O-MISC I-ACTI-MISC
disorders O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
TMP B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
SMZ I-CHED-MISC B-DISO-MISC
; O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
erythema B-DISO-MISC I-ACTI-MISC
multiforme I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
Stevens B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Johnson I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
exposed O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
TMP B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
SMZ I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
toxic B-DISO-MISC B-CHED-MISC
epidermal I-DISO-MISC B-CONC-MISC
necrolysis I-DISO-MISC I-CONC-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
took O-MISC B-ACTI-MISC
cephalexin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Finally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
parenchymal O-MISC B-ANAT-MISC
renal B-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
study O-MISC O-MISC
drug O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
diseases O-MISC I-ACTI-MISC
studied O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
agents O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
compares O-MISC B-DEVI-MISC
reasonably O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
antibiotics O-MISC O-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CONC-MISC
safety O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

STUDY O-MISC B-ACTI-MISC
OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
setting O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ANAT-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
retrospective O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
multicenter O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

SETTING O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
university O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
university O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
affiliated O-MISC I-GEOG-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
community O-MISC B-PHYS-MISC
hospitals O-MISC I-GEOG-MISC
during O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
period O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
117 O-MISC B-ACTI-MISC
cumulative O-MISC B-CHED-MISC
hospital O-MISC B-GENE-MISC
- O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

PARTICIPANTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
MI B-DISO-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emergency O-MISC B-GENE-MISC
department O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Of O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
setting O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
MI B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
died O-MISC I-DISO-MISC
; O-MISC B-ACTI-MISC
exhibited O-MISC B-ACTI-MISC
bradydysrhythmias B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
; O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
experienced O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Despite O-MISC B-ACTI-MISC
theoretical O-MISC B-CHED-MISC
concerns O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
enhance O-MISC B-DEVI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
toxicity B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lidocaine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
MI B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
cardiovascular B-DISO-MISC I-GENE-MISC
or I-DISO-MISC B-ACTI-MISC
central I-DISO-MISC I-GENE-MISC
nervous I-DISO-MISC B-GEOG-MISC
system I-DISO-MISC B-GEOG-MISC
toxicity I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Experimental O-MISC B-CHED-MISC
progressive O-MISC B-CHED-MISC
muscular B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
anabolizing O-MISC O-MISC
agents O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
still O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC B-ACTI-MISC
way O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
discovering O-MISC B-DEVI-MISC
an O-MISC B-ACTI-MISC
unequivocal O-MISC B-ACTI-MISC
pathogenetic O-MISC I-ACTI-MISC
interpretation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
muscular B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Noteworthy O-MISC B-ACTI-MISC
efforts O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
made O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
experimental O-MISC B-CONC-MISC
field O-MISC I-CONC-MISC
; O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
recessive O-MISC I-ACTI-MISC
autosomic O-MISC B-ANAT-MISC
form O-MISC B-ANAT-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
seems O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
bear O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
closest O-MISC B-ACTI-MISC
resemblance O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
form O-MISC I-PHEN-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genetic O-MISC B-CHED-MISC
point O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
view O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Myopathy B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
vitamin B-CHED-MISC O-MISC
E I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
myopathy B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
viruses O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
much O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
anatomically O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
pathologically O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
form O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myodystrophy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
giving O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
diet O-MISC B-GENE-MISC
lacking O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
vitamin B-CHED-MISC O-MISC
E I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pharmacological O-MISC B-CHED-MISC
characteristics O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
vitamin B-CHED-MISC O-MISC
E I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
degenerative O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
brought O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
deficiency O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
muscles O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
illustrated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
thus O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
histological O-MISC B-CHED-MISC
characteristics O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
myopathic B-DISO-MISC I-ACTI-MISC
rat O-MISC I-ANAT-MISC
muscle O-MISC I-GENE-MISC
induced O-MISC B-CHED-MISC
experimentally O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
extraordinarily O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
myopathy B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
biopsies O-MISC B-CONC-MISC
performed O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Orthopaedic O-MISC B-PHYS-MISC
Traumatological O-MISC I-PHYS-MISC
Centre O-MISC I-PHYS-MISC
, O-MISC B-ACTI-MISC
Florence O-MISC B-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
encouraging O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
authoratative O-MISC B-PHYS-MISC
departments O-MISC I-PHYS-MISC
in O-MISC B-ACTI-MISC
myopathic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
anabolizing O-MISC O-MISC
steroids B-CHED-MISC B-DISO-MISC
have O-MISC B-ACTI-MISC
encouraged O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
beneficial O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
anabolizing O-MISC O-MISC
agent O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Dianabol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
CIBA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
rendered O-MISC B-ACTI-MISC
myopathic B-DISO-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
diet O-MISC B-GENE-MISC
deficient O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
vitamin B-CHED-MISC O-MISC
E I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
way O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
appreciable O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
forty O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
per O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
anabolizing O-MISC O-MISC
agent O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
histological O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
regenerative O-MISC I-DISO-MISC
" O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
muscle O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
maintained O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
myopathic B-DISO-MISC B-CHED-MISC
characteristics O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
that O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
the O-MISC B-ACTI-MISC
anabolizing O-MISC O-MISC
agent O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
conclude O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
affirming O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
undoubted O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anabolizing O-MISC O-MISC
steroids B-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
myopathic B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
reservations O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transfer O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
field O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
where O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
dosage O-MISC I-CHED-MISC
cannot O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
continuously O-MISC B-CHED-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
on O-MISC B-ACTI-MISC
virility O-MISC I-DISO-MISC
; O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tissue O-MISC I-ACTI-MISC
injury O-MISC B-ANAT-MISC
too O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
occurs O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
irreversible O-MISC B-ACTI-MISC
stage O-MISC B-ACTI-MISC
vis O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
vis O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
regeneration O-MISC I-DISO-MISC
" O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
muscle O-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
finally O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dystrophic O-MISC B-CHED-MISC
injurious O-MISC O-MISC
agent O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
certainly O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
vitamin B-CHED-MISC O-MISC
E I-CHED-MISC B-DISO-MISC
but O-MISC B-ACTI-MISC
something O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Paclitaxel B-CHED-MISC B-CONC-MISC
3 O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
hour O-MISC I-CONC-MISC
infusion O-MISC I-CONC-MISC
given O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
combined O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
carboplatin B-CHED-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
preliminary O-MISC B-CHED-MISC
results O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
escalation O-MISC I-CHED-MISC
trials O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Paclitaxel B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Taxol B-CHED-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
Bristol O-MISC B-PHYS-MISC
- O-MISC I-PHYS-MISC
Myers O-MISC I-PHYS-MISC
Squibb O-MISC I-PHYS-MISC
Company O-MISC I-PHYS-MISC
, O-MISC B-ACTI-MISC
Princeton O-MISC B-ORGA-MISC
, O-MISC B-ACTI-MISC
NJ O-MISC B-ORGA-MISC
) O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
3 O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
hour O-MISC I-CHED-MISC
infusion O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
combined O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
carboplatin B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
I O-MISC I-CONC-MISC
/ O-MISC I-CONC-MISC
II O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
directed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
non B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
small I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
lung I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Carboplatin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fixed O-MISC B-CHED-MISC
target O-MISC B-CHED-MISC
area O-MISC I-CHED-MISC
under O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
curve O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Calvert O-MISC B-CHED-MISC
formula O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
escalated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
cohorts O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
dose O-MISC B-CONC-MISC
level O-MISC I-CONC-MISC
I O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
175 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
225 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
225 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
expanded O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
since O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
highest O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
achieved O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
modification O-MISC I-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nonhematologic O-MISC I-ACTI-MISC
toxicities B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
arthralgia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
sensory B-DISO-MISC I-ACTI-MISC
neuropathy I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Therapeutic O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
dose O-MISC B-CONC-MISC
levels O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
objective O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
complete O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
regressions O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Toxicities B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cohort O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
I O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
identical O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Carboplatin B-CHED-MISC B-CONC-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
add O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hematologic B-DISO-MISC I-ACTI-MISC
toxicities I-DISO-MISC B-ANAT-MISC
observed O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC B-CONC-MISC
/ O-MISC I-CONC-MISC
carboplatin B-CHED-MISC I-CONC-MISC
combination O-MISC I-CONC-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
dosed O-MISC B-CHED-MISC
every O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
effect O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
misoprostol B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
renal B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
compensated O-MISC B-CHED-MISC
cirrhosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Misoprostol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
acutely O-MISC B-ACTI-MISC
counteract O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
compensated O-MISC B-CHED-MISC
cirrhotic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prophylactic O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
misoprostol B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Parameters O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
hemodynamics O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
tubular O-MISC B-CONC-MISC
sodium B-CHED-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
water O-MISC O-MISC
handling O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
clearance O-MISC B-CHED-MISC
techniques O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
well O-MISC B-CHED-MISC
compensated O-MISC I-CHED-MISC
cirrhotic B-DISO-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
combination O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
misoprostol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
able O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
totally O-MISC B-ACTI-MISC
abolish O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
deleterious O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
800 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
worsening O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
hemodynamics O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
sodium B-CHED-MISC I-ACTI-MISC
retention O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
maximal O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hour O-MISC B-CHED-MISC
immediately O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
medications O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
slowly O-MISC B-ACTI-MISC
returned O-MISC B-ACTI-MISC
toward O-MISC B-ACTI-MISC
base O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
line O-MISC B-GEOG-MISC
levels O-MISC B-CHED-MISC
thereafter O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
protective O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
misoprostol B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
until O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
apparent O-MISC B-ACTI-MISC
ability O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
misoprostol B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
indomethacin B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
frequent O-MISC B-CHED-MISC
dosing O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
would O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
prudent O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
avoid O-MISC B-ACTI-MISC
nonsteroidal O-MISC O-MISC
anti O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
inflammatory O-MISC B-DISO-MISC
therapy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cirrhosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
angio B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
oedema I-DISO-MISC B-ANAT-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
long O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
term O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
angiotensin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
converting I-CHED-MISC B-DISO-MISC
enzyme I-CHED-MISC B-DISO-MISC
inhibitor I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
to O-MISC B-ANAT-MISC
drugs O-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
urticaria B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
angio B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
oedema I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Angiotensin B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
converting I-CHED-MISC B-DISO-MISC
enzyme I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
ACE I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
inhibitors I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
treat O-MISC B-CONC-MISC
hypertension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
congestive B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
introduced O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Europe O-MISC B-ORGA-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
middle O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
eighties O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
has O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
progressively O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Soon O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
introduction O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ACE B-CHED-MISC O-MISC
inhibitors I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
bouts O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
angio B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
oedema I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
wish O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
draw O-MISC B-ACTI-MISC
attention O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
reactions O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
ACE B-CHED-MISC O-MISC
inhibitors I-CHED-MISC B-DISO-MISC
after O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
use O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
existing O-MISC I-CHED-MISC
angio B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ACTI-MISC
oedema I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Myoclonus B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
lorazepam B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
very O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
low O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
birth O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
weight O-MISC B-ANAT-MISC
infants O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Lorazepam B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
frequency O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sedative O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
newborn O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
young O-MISC B-CHED-MISC
infant O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Concern O-MISC B-CHED-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
raised O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
regard O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
lorazepam B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
age O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
very O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
low O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
birth O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
weight O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
VLBW O-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
infants O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
young O-MISC B-CHED-MISC
infants O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
birth O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
< O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
experienced O-MISC B-ACTI-MISC
myoclonus B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
administration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
lorazepam B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
( O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
vehicle O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Injectable O-MISC B-CHED-MISC
lorazepam B-CHED-MISC O-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
caution O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
VLBW O-MISC I-ACTI-MISC
infants O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Transvenous O-MISC B-CONC-MISC
right O-MISC I-CONC-MISC
ventricular O-MISC I-CONC-MISC
pacing O-MISC I-CONC-MISC
during O-MISC B-ACTI-MISC
cardiopulmonary O-MISC B-CONC-MISC
resuscitation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
pediatric O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
cardiomyopathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiopulmonary O-MISC B-CONC-MISC
resuscitation O-MISC I-CONC-MISC
efforts O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
circulatory B-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
from O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
viral O-MISC B-ANAT-MISC
myocarditis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
carbamazepine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
eosinophilic B-DISO-MISC B-ANAT-MISC
myocarditis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
hemosiderosis O-MISC B-ANAT-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
cardiogenic B-DISO-MISC B-ANAT-MISC
shock I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
continuously O-MISC B-ACTI-MISC
monitored O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
central O-MISC B-OBJC-MISC
venous O-MISC I-OBJC-MISC
and O-MISC B-ACTI-MISC
arterial O-MISC B-OBJC-MISC
catheters O-MISC I-OBJC-MISC
in O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
routine O-MISC B-CHED-MISC
noninvasive O-MISC B-CONC-MISC
monitoring O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
introducer O-MISC B-OBJC-MISC
sheath O-MISC I-OBJC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pacemaker O-MISC B-OBJC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sterile O-MISC B-OBJC-MISC
pacing O-MISC I-OBJC-MISC
wires O-MISC I-OBJC-MISC
were O-MISC B-ACTI-MISC
made O-MISC B-ACTI-MISC
readily O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
arise O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
terminate O-MISC B-ACTI-MISC
resistant O-MISC B-CHED-MISC
cardiac O-MISC I-ACTI-MISC
dysrhythmias B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
cardiocirculatory O-MISC I-ACTI-MISC
arrest O-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
extreme O-MISC I-ACTI-MISC
hypotension B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
dysrhythmias B-DISO-MISC I-ACTI-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pediatric O-MISC B-GENE-MISC
intensive O-MISC I-GEOG-MISC
care O-MISC I-GEOG-MISC
unit O-MISC I-GEOG-MISC
( O-MISC B-ACTI-MISC
PICU O-MISC B-GENE-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Right O-MISC B-OBJC-MISC
ventricular O-MISC I-OBJC-MISC
pacemaker O-MISC I-OBJC-MISC
wires O-MISC I-OBJC-MISC
were O-MISC B-ACTI-MISC
inserted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
during O-MISC B-CHED-MISC
cardiopulmonary O-MISC B-CONC-MISC
resuscitation O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
CPR O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
pacing O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
temporary O-MISC B-CHED-MISC
captured O-MISC B-ACTI-MISC
rhythm O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
restoration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
cardiac O-MISC I-DISO-MISC
output O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
event O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
arrest I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
death O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
pacing O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
used O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
converted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
normal O-MISC I-ACTI-MISC
sinus O-MISC B-ANAT-MISC
rhythm O-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
electrical O-MISC B-CONC-MISC
defibrillation O-MISC I-CONC-MISC
within O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
initiating O-MISC B-CHED-MISC
CPR O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
pacing O-MISC I-CONC-MISC
during O-MISC B-ACTI-MISC
resuscitative O-MISC B-CONC-MISC
efforts O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
pediatric O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
suffering O-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
myocardial B-DISO-MISC B-ANAT-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
value O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
itself O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
temporary O-MISC B-CHED-MISC
hemodynamic O-MISC I-DISO-MISC
stability O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
achieved O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
procedure O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
needed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
institute O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
modalities O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
granisetron B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
selective O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
hydroxytryptamine I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
3 O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prevention O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
cisplatin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

PURPOSE O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
assess O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
antiemetic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-CONC-MISC
profile O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
granisetron B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Kytril B-CHED-MISC O-MISC
; O-MISC B-ACTI-MISC
SmithKline O-MISC B-PHYS-MISC
Beecham O-MISC I-PHYS-MISC
Pharmaceuticals O-MISC I-PHYS-MISC
, O-MISC B-ACTI-MISC
Philadelphia O-MISC B-ORGA-MISC
, O-MISC B-ACTI-MISC
PA O-MISC B-ORGA-MISC
) O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
( O-MISC I-CHED-MISC
IV O-MISC I-CHED-MISC
) O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
prophylaxis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
nausea B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

PATIENTS O-MISC B-CHED-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
One O-MISC B-ACTI-MISC
hundred O-MISC B-ACTI-MISC
eighty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
naive O-MISC I-DISO-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
cisplatin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
120 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
randomized O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
granisetron B-CHED-MISC O-MISC
doses O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
chemotherapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inpatient O-MISC I-ANAT-MISC
basis O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
vital O-MISC I-DISO-MISC
signs O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
retching O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
appetite O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Safety O-MISC B-CONC-MISC
analyses O-MISC I-CONC-MISC
included O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
experiences O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
laboratory O-MISC B-GENE-MISC
parameter O-MISC B-CHED-MISC
changes O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
: O-MISC B-ACTI-MISC
After O-MISC B-ACTI-MISC
granisetron B-CHED-MISC O-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC I-ACTI-MISC
response O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
retching O-MISC B-CONC-MISC
episodes O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
antiemetic O-MISC O-MISC
rescue O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complete O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
vomiting B-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
retching O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
antiemetic O-MISC B-CONC-MISC
rescue O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
longer O-MISC I-CHED-MISC
time O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
episode O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0015 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
additional O-MISC B-ACTI-MISC
antiemetic O-MISC O-MISC
medication O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
dosing O-MISC B-CHED-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
granisetron B-CHED-MISC O-MISC
dose O-MISC B-CHED-MISC
increased O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
appetite O-MISC I-DISO-MISC
return O-MISC I-LIVB-MISC
increased O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
040 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Headache B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
frequently O-MISC B-CHED-MISC
reported O-MISC B-CONC-MISC
adverse O-MISC I-ACTI-MISC
event O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
granisetron B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
controlling O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
cisplatin B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
totally O-MISC B-ACTI-MISC
prevented O-MISC I-ACTI-MISC
vomiting B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
statistically O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
differences O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
/ O-MISC I-CHED-MISC
kg O-MISC I-CHED-MISC
dose O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
/ O-MISC I-CHED-MISC
kg O-MISC I-CHED-MISC
doses O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Granisetron B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
tolerated O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Adverse O-MISC B-CHED-MISC
interaction O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
interaction O-MISC B-ANAT-MISC
between O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
atrioventricular B-DISO-MISC I-ACTI-MISC
( I-DISO-MISC B-ANAT-MISC
AV I-DISO-MISC B-ANAT-MISC
) I-DISO-MISC B-ANAT-MISC
block I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CASE O-MISC B-CHED-MISC
SUMMARIES O-MISC I-CHED-MISC
: O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hyperaldosteronism B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
480 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
spironolactone B-CHED-MISC O-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
minimal O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
bid O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
AV B-DISO-MISC I-ACTI-MISC
block I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
resolved O-MISC I-ACTI-MISC
upon O-MISC B-ACTI-MISC
cessation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
medications O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
extended O-MISC O-MISC
- O-MISC B-DISO-MISC
release O-MISC B-DISO-MISC
verapamil B-CHED-MISC O-MISC
240 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
bid O-MISC B-CHED-MISC
she O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
AV B-DISO-MISC I-ACTI-MISC
block I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
resolved O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
stopped O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

DISCUSSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
An O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
interaction O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
discuss O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
might O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
such O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
interaction O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Clinicians O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
acquainted O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
interaction O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
commonly O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
antihypertensive O-MISC O-MISC
drugs O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Caution O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
combining O-MISC B-ACTI-MISC
clonidine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
verapamil B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
do O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
sinus O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
AV O-MISC I-ACTI-MISC
node O-MISC B-ANAT-MISC
dysfunction O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
may O-MISC B-ACTI-MISC
act O-MISC B-ACTI-MISC
synergistically O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
AV O-MISC I-GENE-MISC
node O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
circulation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Pharmacological O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
dihydrothienopyridine B-CHED-MISC O-MISC
calcium I-CHED-MISC B-DISO-MISC
antagonist O-MISC O-MISC
, O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
312 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
d I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

5th O-MISC B-ACTI-MISC
communication O-MISC B-DEVI-MISC
: O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
effects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
312 I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
312 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
d I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
312 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
L O-MISC O-MISC
- O-MISC B-DISO-MISC
type O-MISC B-DISO-MISC
calcium B-CHED-MISC B-DISO-MISC
channel O-MISC B-DISO-MISC
antagonists O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
audiogenic B-DISO-MISC B-CHED-MISC
tonic I-DISO-MISC I-ACTI-MISC
convulsions I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
DBA O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
2 O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
ED50 O-MISC B-PHEN-MISC
values O-MISC B-UnknownType-MISC
were O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
o O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
o O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
flunarizine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
o O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
moderate O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
312 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
d I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clonic O-MISC I-GENE-MISC
convulsions B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pentylenetetrazole B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
bemegride B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
convulsions B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
N B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
methyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
D I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
aspartate I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
picrotoxin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
electroshock O-MISC O-MISC
in O-MISC B-ACTI-MISC
Slc O-MISC B-LIVB-MISC
: O-MISC I-PHEN-MISC
ddY O-MISC I-PROC-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

S B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
312 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
d I-CHED-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
types O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
epilepsy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Transmural O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
sumatriptan B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
sumatriptan B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
tightness O-MISC I-ACTI-MISC
in O-MISC B-ANAT-MISC
the O-MISC B-ANAT-MISC
chest O-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
myocardial B-DISO-MISC B-ANAT-MISC
infarction I-DISO-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
sumatriptan B-CHED-MISC O-MISC
6 O-MISC B-ACTI-MISC
mg O-MISC B-DISO-MISC
subcutaneously O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
cluster B-DISO-MISC I-ACTI-MISC
headache I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
ischaemic B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
Prinzmetal B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
angina I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
recovered O-MISC B-CHED-MISC
without O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Flumazenil B-CHED-MISC O-MISC
induces O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
mixed O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
intoxications O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

STUDY O-MISC B-CONC-MISC
HYPOTHESIS O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
benzodiazepine B-CHED-MISC O-MISC
antagonist O-MISC B-DISO-MISC
flumazenil B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
unmask O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
mixed O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
benzodiazepine B-CHED-MISC O-MISC
intoxication O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

DESIGN O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Male O-MISC B-ACTI-MISC
Sprague O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Dawley O-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
received O-MISC B-CHED-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
IP O-MISC O-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
minutes O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
challenged O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
vehicle O-MISC O-MISC
or O-MISC B-ACTI-MISC
flumazenil B-CHED-MISC O-MISC
5 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
IP O-MISC B-PHEN-MISC
. O-MISC B-ACTI-MISC

Animal O-MISC B-DEVI-MISC
behavior O-MISC I-DEVI-MISC
, O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
death O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cortical O-MISC B-CONC-MISC
EEG O-MISC I-CONC-MISC
tracings O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

INTERVENTIONS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
flumazenil B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
after O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
1 O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
received O-MISC B-CHED-MISC
cocaine B-CHED-MISC O-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
vehicle O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Group O-MISC B-CHED-MISC
2 O-MISC I-CHED-MISC
received O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
vehicle O-MISC O-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
became O-MISC B-ACTI-MISC
somnolent O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
died O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Group O-MISC B-PHEN-MISC
3 O-MISC I-CHED-MISC
received O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
flumazenil B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
became O-MISC B-ACTI-MISC
somnolent O-MISC O-MISC
after O-MISC B-ACTI-MISC
diazepam B-CHED-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
active O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
flumazenil B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
4 O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
simultaneously O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
overt O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
detectable O-MISC I-DISO-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Group O-MISC B-CHED-MISC
5 O-MISC I-CHED-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
flumazenil B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
4 O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Group O-MISC B-PHEN-MISC
6 O-MISC B-UnknownType-MISC
received O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
flumazenil B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
4 O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
Flumazenil B-CHED-MISC O-MISC
can O-MISC B-ACTI-MISC
unmask O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
death O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
combined O-MISC B-CHED-MISC
cocaine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
intoxications O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Mechanisms O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
protective O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
free O-MISC O-MISC
radical O-MISC B-DISO-MISC
scavengers O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC I-ACTI-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Studies O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
examine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protective O-MISC B-PHEN-MISC
effects O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
free O-MISC O-MISC
radical O-MISC B-DISO-MISC
scavengers O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
gentamicin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
GM B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
GM B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
sc O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
induced O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
flow O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
RBF O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
inulin O-MISC I-DISO-MISC
clearance O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
CIn O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
tubular B-DISO-MISC I-GENE-MISC
damage I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
urinary O-MISC B-CHED-MISC
guanosine B-CHED-MISC O-MISC
3 I-CHED-MISC B-DISO-MISC
' I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
' I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
cyclic I-CHED-MISC B-DISO-MISC
monophosphate I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
cGMP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
excretion O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cortical O-MISC B-GEOG-MISC
renin O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
endothelin O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
contents O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
GM B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Superoxide B-CHED-MISC O-MISC
dismutase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
SOD O-MISC O-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
dimethylthiourea B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DMTU B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
lessened O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
GM B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
decrement O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
CIn O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
SOD O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
glomerular O-MISC B-OCCU-MISC
filtration O-MISC I-OCCU-MISC
rate O-MISC I-OCCU-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
RBF O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
urinary O-MISC B-CHED-MISC
cGMP B-CHED-MISC O-MISC
excretion O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
renin O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
endothelin O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
content O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

SOD O-MISC B-CONC-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
attenuate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tubular B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
DMTU B-CHED-MISC O-MISC
significantly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
tubular B-DISO-MISC I-GENE-MISC
damage I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
lipid O-MISC I-DISO-MISC
peroxidation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
hemodynamics O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
vasoactive O-MISC O-MISC
substances O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
SOD O-MISC O-MISC
nor O-MISC B-ACTI-MISC
DMTU B-CHED-MISC O-MISC
affected O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cortical O-MISC B-GEOG-MISC
GM B-CHED-MISC O-MISC
content O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
GM B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
SOD O-MISC O-MISC
and O-MISC B-ACTI-MISC
DMTU B-CHED-MISC O-MISC
have O-MISC B-ACTI-MISC
protective O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
GM B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protective O-MISC B-PHEN-MISC
effects O-MISC B-UnknownType-MISC
differ O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
SOD O-MISC O-MISC
and O-MISC B-ACTI-MISC
DMTU B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
superoxide B-CHED-MISC O-MISC
anions O-MISC B-DISO-MISC
play O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
critical O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
GM B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
renal O-MISC I-ACTI-MISC
vasoconstriction O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Cephalothin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
immune O-MISC I-ACTI-MISC
hemolytic B-DISO-MISC B-ANAT-MISC
anemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
developed O-MISC B-ACTI-MISC
Coombs O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
positive O-MISC B-ANAT-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
anemia I-DISO-MISC B-ANAT-MISC
while O-MISC B-ACTI-MISC
receiving O-MISC B-ACTI-MISC
cephalothin B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
cephalothin B-CHED-MISC B-DISO-MISC
IgG O-MISC B-DISO-MISC
antibody O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
detected O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
serum O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
eluates O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
erythrocytes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
nonimmunologic O-MISC I-DISO-MISC
binding O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
' O-MISC I-PHEN-MISC
s O-MISC I-PHEN-MISC
serum O-MISC O-MISC
proteins O-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
own O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cephalothin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
coated O-MISC B-CHED-MISC
normal O-MISC I-GENE-MISC
red O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Skin O-MISC B-CONC-MISC
tests O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
lymphocyte O-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
sensitized O-MISC B-PHEN-MISC
to O-MISC B-ACTI-MISC
cephalothin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
ampicillin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Careful O-MISC B-ACTI-MISC
investigation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
drug O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
anemias I-DISO-MISC B-ANAT-MISC
reveals O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
complexity O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
immune O-MISC I-DISO-MISC
mechanisms O-MISC B-CHED-MISC
involved O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Assessment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
DNA O-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
during O-MISC B-ACTI-MISC
hypertrophy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ability O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
cardiomyocytes O-MISC I-GENE-MISC
to O-MISC B-ACTI-MISC
synthesize O-MISC B-DEVI-MISC
DNA O-MISC O-MISC
in O-MISC B-ACTI-MISC
response O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
experimentally O-MISC B-CHED-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Isoproterenol B-CHED-MISC O-MISC
delivered O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
osmotic O-MISC B-OCCU-MISC
minipump O-MISC I-CONC-MISC
implantation O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
C3Heb O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
FeJ O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
area O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-CHED-MISC
DNA O-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
autoradiographic O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
cardiomyocytes O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
control O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
hypertrophic B-DISO-MISC I-ACTI-MISC
hearts I-DISO-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
survey O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
independent O-MISC B-CHED-MISC
inbred O-MISC I-ANAT-MISC
strains O-MISC I-PHEN-MISC
of O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
revealed O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
ventricular O-MISC B-CHED-MISC
cardiomyocyte O-MISC B-GEOG-MISC
nuclear O-MISC B-CHED-MISC
number O-MISC I-CHED-MISC
ranged O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
mononucleate O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
terminal O-MISC B-CHED-MISC
differentiation O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
influenced O-MISC B-CHED-MISC
directly O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
indirectly O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
genetic O-MISC I-DISO-MISC
background O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
capacity O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
reactive O-MISC I-DISO-MISC
DNA O-MISC I-LIVB-MISC
synthesis O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
subject O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
genetic O-MISC I-DISO-MISC
regulation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
strains O-MISC I-ANAT-MISC
of O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
comprising O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
extremes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nuclear O-MISC B-CHED-MISC
number O-MISC I-CHED-MISC
survey O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
mouse O-MISC I-PHEN-MISC
atrial O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
ventricular O-MISC B-CHED-MISC
cardiomyocytes O-MISC B-GEOG-MISC
do O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
synthesize O-MISC B-DEVI-MISC
DNA O-MISC O-MISC
in O-MISC B-ACTI-MISC
response O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Central O-MISC I-GENE-MISC
cardiovascular O-MISC B-GEOG-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
AVP B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
ANP O-MISC O-MISC
in O-MISC B-ACTI-MISC
normotensive O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
spontaneously O-MISC I-ANAT-MISC
hypertensive B-DISO-MISC I-PHEN-MISC
rats O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
purpose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
compare O-MISC B-DEVI-MISC
influence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
central O-MISC O-MISC
arginine B-CHED-MISC B-DISO-MISC
vasopressin I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
AVP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
atrial O-MISC O-MISC
natriuretic O-MISC B-DISO-MISC
peptide O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ANP O-MISC O-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
arterial O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
MAP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
HR O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
normotensive O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
WKY O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
spontaneously O-MISC I-ACTI-MISC
hypertensive B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SHR O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
series O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
experiments O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
WKY O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
SHR O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
chronically O-MISC B-CHED-MISC
instrumented O-MISC B-OBJC-MISC
with O-MISC B-ACTI-MISC
guide O-MISC B-OBJC-MISC
tubes O-MISC I-OBJC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lateral O-MISC I-GENE-MISC
ventricle O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
LV O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
arterial O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
venous O-MISC B-OBJC-MISC
catheters O-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

MAP O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
HR O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
monitored O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
injections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
vehicle O-MISC O-MISC
or O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
AVP B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
125 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ANP O-MISC O-MISC
. O-MISC B-ACTI-MISC

Sensitivity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
component O-MISC B-GEOG-MISC
of O-MISC I-LIVB-MISC
baroreflex O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
CCB O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
expressed O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
slope O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
regression O-MISC B-CHED-MISC
line O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
relationships O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
arterial O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
SAP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
HR O-MISC I-ACTI-MISC
period O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
HRp O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
phenylephrine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Phe B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
nitroprusside I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
SN B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CCB O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
measured O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
administration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
vehicle O-MISC O-MISC
, O-MISC B-ACTI-MISC
AVP B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
ANP O-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
peptides O-MISC O-MISC
together O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Increases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MAP O-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
LV O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
AVP B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
WKY O-MISC B-GENE-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
SHR O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

ANP O-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
MAP O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
strains O-MISC I-ANAT-MISC
as O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
vehicle O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
abolished O-MISC B-ACTI-MISC
AVP B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
MAP O-MISC I-ACTI-MISC
increase O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
WKY O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
SHR O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

CCB O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
WKY O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
SHR O-MISC I-ANAT-MISC
after O-MISC B-ACTI-MISC
LV O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
AVP B-CHED-MISC O-MISC
during O-MISC B-ACTI-MISC
SN B-CHED-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
SHR O-MISC I-ANAT-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
WKY O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
ANP O-MISC O-MISC
, O-MISC B-ACTI-MISC
AVP B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
ANP O-MISC O-MISC
+ O-MISC B-ACTI-MISC
AVP B-CHED-MISC O-MISC
decreased O-MISC B-CHED-MISC
CCB O-MISC I-DISO-MISC
during O-MISC B-ACTI-MISC
Phe B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
MAP O-MISC O-MISC
elevation O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
centrally O-MISC B-ACTI-MISC
applied O-MISC B-ACTI-MISC
AVP B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
ANP O-MISC O-MISC
exert O-MISC B-ACTI-MISC
differential O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
baroreflex O-MISC I-DISO-MISC
control O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
WKY O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
SHR O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
interaction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
peptides O-MISC O-MISC
in O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
regulation O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Cutaneous O-MISC B-CHED-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
warfarin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
like O-MISC B-DISO-MISC
anticoagulant O-MISC B-DISO-MISC
causing O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
intracerebral B-DISO-MISC I-ACTI-MISC
hemorrhage I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
intercerebral O-MISC B-ACTI-MISC
hematoma B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
coagulopathy B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
spread O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
type O-MISC B-DISO-MISC
rat O-MISC I-ANAT-MISC
poison O-MISC I-ACTI-MISC
around O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
house O-MISC B-GENE-MISC
weekly O-MISC B-CHED-MISC
using O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
bare O-MISC I-GENE-MISC
hands O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
washing O-MISC B-DEVI-MISC
post O-MISC B-CHED-MISC
application O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Percutaneous O-MISC B-OCCU-MISC
absorption O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
causing O-MISC B-ACTI-MISC
coagulopathy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
times O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
past O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
if O-MISC B-ACTI-MISC
protective O-MISC B-ACTI-MISC
measures O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
gloves O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
drug O-MISC B-ANAT-MISC
interaction O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
piroxicam B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
took O-MISC B-ACTI-MISC
occasionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
exacerbated O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
coagulopathy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Pediatric O-MISC B-CONC-MISC
heart O-MISC I-CONC-MISC
transplantation O-MISC I-CONC-MISC
without O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
maintenance O-MISC B-DEVI-MISC
steroids B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

From O-MISC B-ACTI-MISC
1986 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
February O-MISC B-ACTI-MISC
1993 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
aged O-MISC I-DISO-MISC
2 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
heart O-MISC B-CONC-MISC
transplantation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Indications O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
transplantation O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
prior O-MISC B-CONC-MISC
repair O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
71 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
hypertrophic B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
valvular B-DISO-MISC I-ACTI-MISC
heart I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC I-ACTI-MISC
cardiomyopathy B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
managed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
cyclosporine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
azathioprine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
prophylaxis O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
antilymphocyte O-MISC O-MISC
globulin O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Steroids B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
refractory O-MISC I-ACTI-MISC
rejection O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
weaning O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
attempted O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
generally O-MISC B-ACTI-MISC
successful O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
64 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
maintenance O-MISC B-DEVI-MISC
steroids B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
died O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
perioperative O-MISC B-CHED-MISC
period O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
died O-MISC I-DISO-MISC
4 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
later O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
deaths O-MISC I-DISO-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
rejection O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
infection B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Average O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Cumulative O-MISC B-CHED-MISC
survival O-MISC I-CHED-MISC
is O-MISC B-ACTI-MISC
88 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
rejection O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
monitored O-MISC B-CONC-MISC
noninvasively O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
postoperative O-MISC B-CHED-MISC
month O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
89 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
rejection O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Freedom O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
infections B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
83 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
month O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
65 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Cytomegalovirus B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
successfully O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
ganciclovir B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

No O-MISC I-ACTI-MISC
impairment O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
growth O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
underwent O-MISC B-ACTI-MISC
transplantation O-MISC B-CONC-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
undergone O-MISC B-ACTI-MISC
annual O-MISC B-CHED-MISC
catheterizations O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
sign O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
graft O-MISC I-ACTI-MISC
atherosclerosis B-DISO-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Seizures B-DISO-MISC I-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
disabled O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
lymphoproliferative B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
ABSTRACT O-MISC B-ACTI-MISC
TRUNCATED O-MISC B-ACTI-MISC
AT O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
WORDS O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC

Delirium B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
treatment O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
tricyclic O-MISC O-MISC
antidepressant O-MISC B-DISO-MISC
concentrations O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
established O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
reports O-MISC B-ACTI-MISC
exist O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
selective O-MISC O-MISC
serotonin B-CHED-MISC B-DISO-MISC
reuptake O-MISC B-DISO-MISC
inhibitors O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
SSRIs O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
toxic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
serum O-MISC B-CHED-MISC
concentration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
citalopram B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
600 O-MISC B-ACTI-MISC
nmol O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
increased O-MISC I-ACTI-MISC
somnolence B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
movement B-DISO-MISC I-ACTI-MISC
difficulties I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Widespread O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
delirium B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
linked O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-OCCU-MISC
blood O-MISC I-OCCU-MISC
levels O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
SSRIs O-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
hyperkinetic B-DISO-MISC I-ACTI-MISC
delirium B-DISO-MISC I-ACTI-MISC
connected O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
total O-MISC B-CHED-MISC
fluoxetine B-CHED-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
fluoxetine B-CHED-MISC O-MISC
plus O-MISC I-CONC-MISC
desmethylfluoxetine B-CHED-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Pulmonary B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
shock B-DISO-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
aracytine B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
C I-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
TNF O-MISC O-MISC
- O-MISC B-DISO-MISC
alpha O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
PAF O-MISC O-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
consecutive O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
Ara B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
C I-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
lymphomas B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
institution O-MISC B-PHYS-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
strikingly O-MISC B-ACTI-MISC
similar O-MISC B-CHED-MISC
syndrome O-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
perfusion O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
fever B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
diarrhea B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
shock B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
pulmonary B-DISO-MISC I-ACTI-MISC
edema I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
metabolic B-DISO-MISC B-CHED-MISC
acidosis I-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
weight B-DISO-MISC I-ACTI-MISC
gain I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
leukocytosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Thorough O-MISC B-CHED-MISC
bacteriological O-MISC B-CONC-MISC
screening O-MISC I-CONC-MISC
failed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
infection B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Sequential O-MISC B-CHED-MISC
biological O-MISC B-CHED-MISC
assays O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
IL O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
IL O-MISC O-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
TNF O-MISC O-MISC
and O-MISC B-ACTI-MISC
PAF O-MISC O-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
Ara B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
C I-CHED-MISC B-DISO-MISC
infusion O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
ten O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
syndrome O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

TNF O-MISC O-MISC
and O-MISC B-ACTI-MISC
PAF O-MISC O-MISC
activity O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
TNF O-MISC O-MISC
and O-MISC B-ACTI-MISC
PAF O-MISC O-MISC
are O-MISC B-ACTI-MISC
thought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
septic O-MISC I-ACTI-MISC
shock B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
adult B-DISO-MISC I-ANAT-MISC
respiratory I-DISO-MISC I-ACTI-MISC
distress I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
hypothesize O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
Ara B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
C I-CHED-MISC B-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
cytokine O-MISC O-MISC
release O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Protective O-MISC B-PHEN-MISC
effect O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
clentiazem B-CHED-MISC O-MISC
against O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
clentiazem B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
1 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
benzothiazepine I-CHED-MISC B-DISO-MISC
calcium B-CHED-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
cardiomyopathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-ACTI-MISC
chronic O-MISC B-CONC-MISC
epinephrine B-CHED-MISC I-CONC-MISC
infusion O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
died O-MISC I-DISO-MISC
within O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
ischemic B-DISO-MISC I-ACTI-MISC
lesions I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
fibrosis B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
ventricles O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
atrial O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
ventricular O-MISC B-GEOG-MISC
papillary O-MISC B-GEOG-MISC
muscle O-MISC B-GEOG-MISC
contractile O-MISC I-DISO-MISC
responses O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
compared O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Left O-MISC I-GENE-MISC
ventricular O-MISC B-GEOG-MISC
alpha O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
beta O-MISC I-GENE-MISC
adrenoceptor O-MISC B-GEOG-MISC
densities O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
clentiazem B-CHED-MISC O-MISC
prevented O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC I-ACTI-MISC
death O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
ventricular O-MISC I-ACTI-MISC
ischemic B-DISO-MISC B-ANAT-MISC
lesions I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
fibrosis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
manner O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Left O-MISC I-GENE-MISC
atrial O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
ventricular O-MISC B-GEOG-MISC
papillary O-MISC B-GEOG-MISC
muscle O-MISC B-GEOG-MISC
contractile O-MISC I-DISO-MISC
responses O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
compared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
clentiazem B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
combined O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
clentiazem B-CHED-MISC O-MISC
restored O-MISC B-CONC-MISC
left O-MISC I-GENE-MISC
atrial O-MISC B-GEOG-MISC
responses O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
left O-MISC I-GENE-MISC
ventricular O-MISC B-GEOG-MISC
papillary O-MISC I-LIVB-MISC
responses O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
hand O-MISC B-ACTI-MISC
clentiazem B-CHED-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
prevent O-MISC B-CHED-MISC
epinephrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
down O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
regulation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
and O-MISC B-ACTI-MISC
beta O-MISC O-MISC
adrenoceptors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Interestingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
clentiazem B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
infused O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
adrenergic O-MISC O-MISC
receptor O-MISC B-DISO-MISC
densities O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
ventricle O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Clentiazem B-CHED-MISC O-MISC
also O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
prevent O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
responses O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
clentiazem B-CHED-MISC O-MISC
partially O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
maximal O-MISC B-CHED-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
compared O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
clentiazem B-CHED-MISC O-MISC
attenuated O-MISC B-DEVI-MISC
epinephrine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiac B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adrenergic O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Kaliuretic O-MISC I-ACTI-MISC
effect O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
dopa I-CHED-MISC B-DISO-MISC
treatment O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
parkinsonian B-DISO-MISC O-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Hypokalemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
sometimes O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
dopa I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
parkinsonian B-DISO-MISC O-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
dopa I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
excretion O-MISC I-DISO-MISC
of O-MISC I-LIVB-MISC
potassium B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hypokalemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
normokalemic O-MISC B-CONC-MISC
patients O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
determination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
plasma O-MISC I-LIVB-MISC
flow O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
glomerular O-MISC B-CONC-MISC
filtration O-MISC I-CONC-MISC
rate O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
plasma O-MISC B-CHED-MISC
concentration O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
potassium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
urinary O-MISC I-GENE-MISC
excretion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
potassium B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
aldosterone B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
Dopa I-CHED-MISC B-DISO-MISC
intake O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
excretion O-MISC I-DISO-MISC
of O-MISC B-ANAT-MISC
potassium B-CHED-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sometimes O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
sodium B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypokalemic O-MISC I-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normokalemic O-MISC B-PHEN-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
prohibited O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
dopa O-MISC O-MISC
decarbodylase O-MISC B-DISO-MISC
inhibitor O-MISC O-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
why O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
occurred O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
others O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
aldosterone B-CHED-MISC I-DISO-MISC
production O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
effect O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
dopa I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Cocaine B-CHED-MISC O-MISC
induced O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
ischemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
ischemia I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ischemia B-DISO-MISC I-ACTI-MISC
probably O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
spasm I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
reversed O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
nitroglycerin B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
blocking O-MISC B-DISO-MISC
agents O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
monitored O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
ECG O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
freely O-MISC B-ACTI-MISC
moving O-MISC I-DISO-MISC
mice O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
model O-MISC B-OBJC-MISC
to O-MISC B-ACTI-MISC
test O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
protectors O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
laboratory O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
histology O-MISC B-PROC-MISC
is O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
commonly O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
monitoring O-MISC B-CONC-MISC
during O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
numbers O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
method O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
measure O-MISC B-CHED-MISC
ECG O-MISC B-CHED-MISC
values O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
freely O-MISC B-ACTI-MISC
moving O-MISC I-DISO-MISC
mice O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
telemetry O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
model O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
chronic O-MISC O-MISC
doxorubicin B-CHED-MISC B-DISO-MISC
administration O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ECG O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
freely O-MISC B-ACTI-MISC
moving O-MISC I-DISO-MISC
BALB O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
c O-MISC I-PHEN-MISC
mice O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ICRF B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
187 I-CHED-MISC B-DISO-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
protective O-MISC O-MISC
agent O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ST O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
significantly O-MISC B-ACTI-MISC
widened O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
ms O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
weekly O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
given O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
plus O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ECG O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
change O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
entire O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
sacrifice O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
enlarged O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
atria O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
hypertrophic B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
schedule O-MISC B-ACTI-MISC
exerted O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
toxicity B-DISO-MISC I-ACTI-MISC
than O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-ACTI-MISC
protective O-MISC O-MISC
agents O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protection O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
ICRF B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
187 I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CONC-MISC
schedule O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
general O-MISC B-ACTI-MISC
toxicity B-DISO-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
weekly O-MISC B-ACTI-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
given O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
plus O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
observation O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
schedule O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
' O-MISC B-ACTI-MISC
hearts O-MISC I-GENE-MISC
appeared O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
sacrifice O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
ICRF B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
187 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
provided O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
full O-MISC B-ACTI-MISC
protection O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
histology O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
model O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
enables O-MISC B-ACTI-MISC
monitoring O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
model O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
allows O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
testing O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
protectors O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
doxorubicin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
cardiotoxicity B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protection O-MISC I-ACTI-MISC
provided O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
ICRF B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
187 I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Epinephrine B-CHED-MISC I-ACTI-MISC
dysrhythmogenicity O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
enhanced O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
subtoxic O-MISC B-CHED-MISC
bupivacaine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Since O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
may O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
precipitate O-MISC B-ACTI-MISC
dysrhythmias B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
circulating O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
during O-MISC B-ACTI-MISC
regional O-MISC B-CONC-MISC
anesthesia O-MISC I-CONC-MISC
could O-MISC B-ACTI-MISC
potentiate O-MISC B-ACTI-MISC
dysrhythmogenic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
alters O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dysrhythmogenicity O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
conscious O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
dogs O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
dogs O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Forty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
conscious O-MISC I-ANAT-MISC
dogs O-MISC I-PHEN-MISC
received O-MISC B-CHED-MISC
10 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Seventeen O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
responded O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
VT B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
min O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
responders O-MISC I-ACTI-MISC
randomly O-MISC B-CHED-MISC
received O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
over O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
groups O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
caused O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
prodysrhythmic O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
than O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

VT B-DISO-MISC I-ACTI-MISC
appeared O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
fewer O-MISC B-CHED-MISC
dogs O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
later O-MISC B-CHED-MISC
time O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
sinoatrial O-MISC I-ACTI-MISC
beats O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
ectopies O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Epinephrine B-CHED-MISC O-MISC
shortened O-MISC B-CHED-MISC
QT O-MISC I-DISO-MISC
less O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
halothane B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
anesthetized O-MISC B-CONC-MISC
dogs O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
until O-MISC B-ACTI-MISC
VT B-DISO-MISC I-ACTI-MISC
appeared O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
injected O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
again O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prodysrhythmic O-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
to O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
mitigated O-MISC B-OCCU-MISC
by O-MISC B-ACTI-MISC
preceding O-MISC B-ACTI-MISC
bupivacaine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Bupivacaine B-CHED-MISC O-MISC
antagonizes O-MISC I-ACTI-MISC
epinephrine B-CHED-MISC I-ACTI-MISC
dysrhythmogenicity O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
conscious O-MISC I-ANAT-MISC
dogs O-MISC I-PHEN-MISC
susceptible O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
VT B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
dogs O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
postinfarct O-MISC I-ACTI-MISC
dysrhythmias B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
evidence O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
subtoxic O-MISC B-CHED-MISC
bupivacaine B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
enhances O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
dysrhythmogenicity O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
epinephrine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Milk B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
alkali I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
1 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
25 I-CHED-MISC B-DISO-MISC
( I-CHED-MISC B-DISO-MISC
OH I-CHED-MISC B-DISO-MISC
) I-CHED-MISC B-DISO-MISC
2D I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hypoparathyroidism B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Milk B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
alkali I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
ago O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
context O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
peptic B-DISO-MISC I-ACTI-MISC
ulcer I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
large O-MISC B-CHED-MISC
amounts O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
alkali B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
ulcer B-DISO-MISC I-ACTI-MISC
therapy O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
H O-MISC O-MISC
- O-MISC B-DISO-MISC
2 O-MISC B-DISO-MISC
blockers O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
omeprazole B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sucralfate B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
milk B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
alkali I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
decreased O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
classic O-MISC B-ACTI-MISC
triad O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hypercalcemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
alkalosis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
remains O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hallmark O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
syndrome O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Milk B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
alkali I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
can O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
occasionally O-MISC B-ACTI-MISC
life O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
threatening O-MISC B-ANAT-MISC
illness O-MISC I-ACTI-MISC
unless O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
appropriately O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
article O-MISC B-ACTI-MISC
presents O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hypoparathyroidism B-DISO-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
calcium B-CHED-MISC O-MISC
carbonate I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
calcitriol B-CHED-MISC O-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
admissions O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hospital O-MISC B-GENE-MISC
for O-MISC B-ACTI-MISC
milk B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
alkali I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
successfully O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
intravenous O-MISC B-CHED-MISC
pamidronate B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
admission O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
hydrocortisone B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
illustrates O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
pamidronate B-CHED-MISC O-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
valuable O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
tool O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
milk B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
alkali I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
presents O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
hypercalcemic B-DISO-MISC I-ACTI-MISC
emergency I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Famotidine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
delirium B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Famotidine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
histamine O-MISC O-MISC
H2 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
used O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
inpatient O-MISC I-ANAT-MISC
settings O-MISC I-PHYS-MISC
for O-MISC B-ACTI-MISC
prevention O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
stress O-MISC I-ACTI-MISC
ulcers B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
popularity O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
low O-MISC B-DEVI-MISC
cost O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
currently O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
H2 O-MISC O-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
antagonists O-MISC B-DISO-MISC
have O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
propensity O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
delirium B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
famotidine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
famotidine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
delirium B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
hospitalized O-MISC I-ANAT-MISC
patients O-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
cleared O-MISC I-ACTI-MISC
completely O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
removal O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
famotidine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pharmacokinetics O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
famotidine B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
reviewed O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
metabolism O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
seen O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
implications O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
famotidine B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
elderly O-MISC I-ANAT-MISC
persons O-MISC I-PHEN-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Encephalopathy B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
amitriptyline B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
: O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
serotonin B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
spectrum O-MISC I-ACTI-MISC
disorders O-MISC B-ANAT-MISC
? O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
describes O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
course O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amitriptyline B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
remission O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
unipolar B-DISO-MISC I-ACTI-MISC
depression I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
could O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
having O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
NMS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
serotonin B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
determinant O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
dopamine B-CHED-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
serotonin B-CHED-MISC I-ACTI-MISC
imbalance O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
NMS B-DISO-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
develops O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC I-CHED-MISC
antidepressants O-MISC O-MISC
indicates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
NMS B-DISO-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
SS B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
spectrum O-MISC I-ACTI-MISC
disorders O-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
with O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
antidopaminergic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
serotonergic O-MISC I-DISO-MISC
effects O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Genetic O-MISC B-CONC-MISC
separation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
growth O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
estrogen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
tumor B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
estrogen B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Fischer O-MISC O-MISC
344 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
F344 O-MISC O-MISC
) O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
induces O-MISC B-ACTI-MISC
growth O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
pituitary B-DISO-MISC B-ANAT-MISC
tumors I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Ten O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
diethylstilbestrol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DES B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
caused O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
F344 O-MISC I-ANAT-MISC
rat O-MISC I-PHEN-MISC
pituitaries O-MISC I-GENE-MISC
to O-MISC B-ACTI-MISC
grow O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
109 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SE O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
become O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
DES B-CHED-MISC B-OBJC-MISC
treatment O-MISC B-CONC-MISC
produced O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
growth O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
females O-MISC I-DISO-MISC
versus O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
females O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
morphological O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Brown O-MISC I-GENE-MISC
Norway O-MISC I-ORGA-MISC
( O-MISC B-ACTI-MISC
BN O-MISC B-ORGA-MISC
) O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
pituitaries O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
F1 O-MISC I-ANAT-MISC
hybrid O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
F344 O-MISC O-MISC
and O-MISC B-ACTI-MISC
BN O-MISC O-MISC
exhibited O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
pituitary O-MISC I-GENE-MISC
growth O-MISC I-DISO-MISC
after O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
DES B-CHED-MISC O-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
average O-MISC B-CHED-MISC
mass O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Surprisingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
F1 O-MISC I-ACTI-MISC
hybrid O-MISC B-ANAT-MISC
tumors B-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
hemoglobin O-MISC O-MISC
content O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
outward O-MISC B-CHED-MISC
appearance O-MISC B-CHED-MISC
identical O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
BN O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
growth O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
morphological O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
genes O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
DES B-CHED-MISC B-OBJC-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
pituitary O-MISC I-DISO-MISC
growth O-MISC I-LIVB-MISC
exhibited O-MISC B-ACTI-MISC
quantitative O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
additive O-MISC B-CHED-MISC
inheritance O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
phenotype O-MISC I-DISO-MISC
exhibited O-MISC B-ACTI-MISC
recessive O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
epistatic O-MISC I-DISO-MISC
inheritance O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
160 O-MISC B-ACTI-MISC
F2 O-MISC B-ACTI-MISC
pituitaries O-MISC I-GENE-MISC
exhibited O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
phenotype O-MISC I-DISO-MISC
; O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
160 O-MISC B-ACTI-MISC
F2 O-MISC B-ACTI-MISC
pituitaries O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
F344 O-MISC I-GENE-MISC
range O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
mass O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
31 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
phenotype O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
merely O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
consequence O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
extensive O-MISC B-CHED-MISC
growth O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hemorrhagic B-DISO-MISC I-ACTI-MISC
F2 O-MISC I-GENE-MISC
pituitaries O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
massive O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
regulate O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
neuronal O-MISC O-MISC
nitric B-CHED-MISC O-MISC
oxide I-CHED-MISC B-DISO-MISC
synthase O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
afferent O-MISC B-CHED-MISC
pathways O-MISC I-DISO-MISC
following O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
bladder B-DISO-MISC I-ACTI-MISC
irritation I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Immunocytochemical O-MISC B-CONC-MISC
techniques O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
examine O-MISC B-ACTI-MISC
alterations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
neuronal O-MISC O-MISC
nitric B-CHED-MISC B-DISO-MISC
oxide I-CHED-MISC B-DISO-MISC
synthase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
NOS O-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
pathways O-MISC B-GEOG-MISC
following O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
irritation B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
urinary I-DISO-MISC I-GENE-MISC
tract I-DISO-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Chemical O-MISC I-ACTI-MISC
cystitis B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
cyclophosphamide B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
metabolized O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
acrolein B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
irritant O-MISC O-MISC
eliminated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Injection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
perfusion O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
acute O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
increased O-MISC B-CHED-MISC
Fos O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
immunoreactivity O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
IR O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dorsal O-MISC I-GENE-MISC
commissure O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
dorsal O-MISC I-GENE-MISC
horn O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
autonomic O-MISC I-GENE-MISC
regions O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
spinal O-MISC I-GENE-MISC
segments O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
L1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
L2 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
L6 O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
S1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
afferent O-MISC B-CHED-MISC
inputs O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
urethra O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ureter O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Fos O-MISC O-MISC
- O-MISC B-DISO-MISC
IR O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
spinal O-MISC I-GENE-MISC
cord O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
changed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
receiving O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
CYP B-CHED-MISC I-ACTI-MISC
treatment O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
3rd O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
acutely O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
CYP B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
numbers O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NOS O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
IR O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
cell O-MISC I-GENE-MISC
profiles O-MISC B-GEOG-MISC
/ O-MISC B-ACTI-MISC
sections O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
L6 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
S1 O-MISC B-GEOG-MISC
dorsal O-MISC B-GEOG-MISC
root O-MISC B-GEOG-MISC
ganglia O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
DRG O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC B-CHED-MISC
CYP B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
significantly O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
002 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
bladder O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
numbers O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NOS O-MISC O-MISC
- O-MISC B-ACTI-MISC
immunoreactive O-MISC O-MISC
( O-MISC B-ACTI-MISC
IR O-MISC O-MISC
) O-MISC B-ACTI-MISC
afferent O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
L6 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
S1 O-MISC B-GEOG-MISC
DRG O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
L1 O-MISC B-ACTI-MISC
DRG O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
L2 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
L5 O-MISC B-ACTI-MISC
DRG O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Bladder O-MISC I-GENE-MISC
afferent O-MISC B-CHED-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
L6 O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
S1 O-MISC O-MISC
DRG O-MISC I-GENE-MISC
labeled O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
Fluorogold O-MISC O-MISC
( O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
microliters O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
injected O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
wall O-MISC B-GEOG-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
exhibit O-MISC B-ACTI-MISC
NOS O-MISC O-MISC
- O-MISC B-DISO-MISC
IR O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
animals O-MISC I-PHEN-MISC
; O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
CYP B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
percentage O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
bladder O-MISC I-GENE-MISC
afferent O-MISC B-CHED-MISC
neurons O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
NOS O-MISC O-MISC
- O-MISC B-DISO-MISC
IR O-MISC B-DISO-MISC
: O-MISC B-ACTI-MISC
L6 O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
S1 O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
neuronal O-MISC I-GENE-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
visceral O-MISC I-GENE-MISC
sensory O-MISC B-GEOG-MISC
pathways O-MISC B-GEOG-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
upregulated O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
chemical O-MISC B-OCCU-MISC
irritation O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
afferent O-MISC B-CHED-MISC
receptors O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urinary O-MISC I-GENE-MISC
tract O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
urinary O-MISC I-GENE-MISC
tract O-MISC B-GEOG-MISC
can O-MISC B-ACTI-MISC
initiate O-MISC B-CHED-MISC
chemical O-MISC B-OCCU-MISC
signals O-MISC I-OCCU-MISC
that O-MISC B-ACTI-MISC
alter O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
chemical O-MISC B-OCCU-MISC
properties O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
visceral O-MISC B-CHED-MISC
afferent O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
CD B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
832 I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC I-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
ischemia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
coronary B-DISO-MISC I-ACTI-MISC
stenosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
CD B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
832 I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
ISO B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
ischemia I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
coronary B-DISO-MISC I-ACTI-MISC
stenosis I-DISO-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC I-GENE-MISC
circumflex O-MISC B-GEOG-MISC
coronary O-MISC I-GENE-MISC
artery O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
findings O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
diltiazem B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
stenosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
periods O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
intracoronary O-MISC B-CHED-MISC
ISO B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
ng O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
maximal O-MISC B-CHED-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
rise O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
percentage O-MISC B-CHED-MISC
segmental O-MISC B-CHED-MISC
shortening O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
ST O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
segment O-MISC I-CHED-MISC
elevation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epicardial O-MISC I-ACTI-MISC
electrocardiogram O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC B-ACTI-MISC
ISO B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
stenosis B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
equihypotensive O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CD B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
832 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
diltiazem B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
infused O-MISC B-CHED-MISC
5 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
ISO B-CHED-MISC B-CONC-MISC
infusion O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
CD B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
832 I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
diltiazem B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
reduced O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
ISO B-CHED-MISC B-OCCU-MISC
infusion O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
CD B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
832 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
percentage O-MISC B-ACTI-MISC
segmental O-MISC B-CHED-MISC
shortening O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
115 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ST O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
segment O-MISC I-CHED-MISC
elevation O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
mV O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mV O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
ISO B-CHED-MISC B-CHED-MISC
infusion O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
stenosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Diltiazem B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
micrograms O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
percentage O-MISC B-CHED-MISC
segmental O-MISC B-CHED-MISC
shortening O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
63 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
ST O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
segment O-MISC I-CHED-MISC
elevation O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
mV O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
mV O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
ISO B-CHED-MISC B-CHED-MISC
infusion O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
stenosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
CD B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
832 I-CHED-MISC B-DISO-MISC
improves O-MISC I-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
ischemia I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
ISO B-CHED-MISC B-CONC-MISC
infusion O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
stenosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
chronotropic O-MISC B-CHED-MISC
property O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
CD B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
832 I-CHED-MISC B-DISO-MISC
plays O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beneficial O-MISC B-CHED-MISC
effects O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
CD B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
832 I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
recombinant O-MISC O-MISC
human O-MISC B-DISO-MISC
insulin O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
like O-MISC B-DISO-MISC
growth O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
puromycin B-CHED-MISC O-MISC
aminonucleoside I-CHED-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
recombinant O-MISC O-MISC
hGH O-MISC B-DISO-MISC
exacerbates O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
functional O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
structural O-MISC I-ACTI-MISC
injury O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
puromycin B-CHED-MISC O-MISC
aminonucleoside I-CHED-MISC B-ANAT-MISC
( O-MISC B-ANAT-MISC
PAN B-CHED-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
experimental O-MISC B-CHED-MISC
model O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
glomerular B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
whether O-MISC B-ACTI-MISC
recombinant O-MISC O-MISC
human O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
rh O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
IGF O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
safer O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
growth B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
PAN B-CHED-MISC I-ACTI-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
glomerulopathy B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
serial O-MISC B-ACTI-MISC
injections O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
PAN B-CHED-MISC O-MISC
over O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
wk O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Experimental O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
rhIGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
/ O-MISC B-ACTI-MISC
d O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
rats O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
vehicle O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

rhIGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
improved O-MISC B-ACTI-MISC
weight O-MISC I-ACTI-MISC
gain O-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
altering O-MISC B-ACTI-MISC
hematocrit O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Urinary O-MISC I-GENE-MISC
protein O-MISC O-MISC
excretion O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
unaltered O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
rhIGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
treatment O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
PAN B-CHED-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
wk O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inulin O-MISC O-MISC
clearance O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
rhIGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
08 O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
06 O-MISC B-ACTI-MISC
mL O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
PAN B-CHED-MISC I-ACTI-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
animals O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
improvement O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
GFR O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
enhanced O-MISC B-ACTI-MISC
glomerular B-DISO-MISC I-ACTI-MISC
hypertrophy I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
segmental O-MISC B-CHED-MISC
glomerulosclerosis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
tubulointerstitial B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cortical O-MISC B-GEOG-MISC
malondialdehyde B-CHED-MISC O-MISC
content O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
PAN B-CHED-MISC I-ACTI-MISC
nephropathy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
administration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
rhIGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
increased O-MISC B-CHED-MISC
IGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
GH O-MISC O-MISC
receptor O-MISC B-DISO-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
without O-MISC B-CHED-MISC
altering O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
steady O-MISC B-OCCU-MISC
state O-MISC I-OCCU-MISC
level O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
IGF O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
I O-MISC I-PROC-MISC
receptor O-MISC I-PROC-MISC
mRNA O-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
kidneys O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
rhIGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
administration O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
alter O-MISC B-ACTI-MISC
weight O-MISC I-ACTI-MISC
gain O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
proteinuria B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
GFR O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
glomerular O-MISC I-GENE-MISC
planar O-MISC B-GEOG-MISC
area O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
renal O-MISC I-GENE-MISC
cortical O-MISC B-GEOG-MISC
malondialdehyde B-CHED-MISC O-MISC
content O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
glomerular O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
tubulointerstitial B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
untreated O-MISC I-ACTI-MISC
animals O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

rhIGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
treatment O-MISC B-CONC-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
steady O-MISC B-OCCU-MISC
state O-MISC I-OCCU-MISC
renal O-MISC I-GENE-MISC
IGF O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
I O-MISC I-PROC-MISC
mRNA O-MISC O-MISC
level O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
modify O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
IGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
GH O-MISC O-MISC
receptors O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
rhIGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
improves O-MISC B-ACTI-MISC
growth O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
GFR O-MISC O-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
PAN B-CHED-MISC B-ANAT-MISC
nephropathy B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
unlike O-MISC B-ACTI-MISC
rhGH O-MISC O-MISC
, O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
rhIGF O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
worsen O-MISC I-ACTI-MISC
renal O-MISC I-GENE-MISC
functional O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
structural O-MISC I-ACTI-MISC
injury O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
model O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Nefiracetam B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DM B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
9384 I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
reverses O-MISC B-CHED-MISC
apomorphine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
amnesia B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
response O-MISC I-LIVB-MISC
: O-MISC B-ACTI-MISC
delayed O-MISC B-CHED-MISC
emergence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
memory O-MISC I-ACTI-MISC
retention O-MISC B-ANAT-MISC
effects O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Nefiracetam B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
pyrrolidone B-CHED-MISC O-MISC
derivative O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
attenuates O-MISC B-DEVI-MISC
scopolamine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
learning B-DISO-MISC I-DISO-MISC
and I-DISO-MISC B-ACTI-MISC
post I-DISO-MISC B-CONC-MISC
- I-DISO-MISC I-CONC-MISC
training I-DISO-MISC I-CONC-MISC
consolidation I-DISO-MISC I-ACTI-MISC
deficits I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Given O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
inhibits O-MISC B-DEVI-MISC
passive O-MISC I-ACTI-MISC
avoidance O-MISC B-ANAT-MISC
retention O-MISC B-CHED-MISC
when O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12h O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
training O-MISC I-CHED-MISC
period O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
ability O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
nefiracetam B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
attenuate O-MISC B-DEVI-MISC
amnesia B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
dopaminergic O-MISC I-ACTI-MISC
agonism O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
step O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
down O-MISC I-CONC-MISC
passive O-MISC I-DISO-MISC
avoidance O-MISC I-LIVB-MISC
paradigm O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
employed O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nefiracetam B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
alone O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12h O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
training O-MISC I-CHED-MISC
period O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
consolidation O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Co O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
nefiracetam B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
during O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
or O-MISC B-ACTI-MISC
10h O-MISC B-ACTI-MISC
thereafter O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
significant O-MISC B-ANAT-MISC
anti O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
amnesic O-MISC B-ANAT-MISC
effect O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
nefiracetam B-CHED-MISC O-MISC
during O-MISC B-ACTI-MISC
training O-MISC B-CONC-MISC
completely O-MISC B-ACTI-MISC
reversed O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
amnesia B-DISO-MISC I-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
apomorphine B-CHED-MISC O-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
10h O-MISC B-ACTI-MISC
post O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
training O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
converse O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
true O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dopaminergic O-MISC I-DISO-MISC
mechanism O-MISC I-LIVB-MISC
as O-MISC B-ACTI-MISC
nefiracetam B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
millimolar O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
failed O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
displace O-MISC B-CHED-MISC
either O-MISC B-ACTI-MISC
[ O-MISC O-MISC
3H O-MISC B-DISO-MISC
] O-MISC B-DISO-MISC
SCH B-CHED-MISC B-DISO-MISC
23390 I-CHED-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
[ O-MISC O-MISC
3H O-MISC B-DISO-MISC
] O-MISC B-DISO-MISC
spiperone B-CHED-MISC B-DISO-MISC
binding O-MISC B-DEVI-MISC
from O-MISC B-ACTI-MISC
D1 O-MISC O-MISC
or O-MISC B-ACTI-MISC
D2 O-MISC O-MISC
dopamine B-CHED-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
subtypes O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
nefiracetam B-CHED-MISC O-MISC
augments O-MISC B-CHED-MISC
molecular O-MISC I-DISO-MISC
processes O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
stages O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
events O-MISC B-DEVI-MISC
which O-MISC B-ACTI-MISC
ultimately O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
consolidation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
memory O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Phenytoin B-CHED-MISC I-ACTI-MISC
encephalopathy B-DISO-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
probable O-MISC B-CHED-MISC
idiosyncratic O-MISC I-ACTI-MISC
reaction O-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
phenytoin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DPH B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
seizures B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
mental O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Despite O-MISC B-ACTI-MISC
adequate O-MISC B-CHED-MISC
oral O-MISC B-CHED-MISC
dosage O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
DPH B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
daily O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
plasma O-MISC B-OCCU-MISC
level O-MISC I-OCCU-MISC
was O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
microgramg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
idiosyncratic O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
toxic O-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
allergic O-MISC I-ACTI-MISC
reaction O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
fact O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
free O-MISC B-ACTI-MISC
DPH B-CHED-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
retarded O-MISC B-CHED-MISC
morbilliform O-MISC I-ACTI-MISC
rash B-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
DPH B-CHED-MISC I-ACTI-MISC
treatment O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protidogram O-MISC O-MISC
was O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
intradermic O-MISC B-CONC-MISC
DPH B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
local O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC I-ANAT-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
starting O-MISC B-ACTI-MISC
DPH B-CHED-MISC I-ACTI-MISC
treatment O-MISC B-CONC-MISC
an O-MISC B-ACTI-MISC
unexpected O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
seizures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
EEG O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
mental O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
occurring O-MISC B-ACTI-MISC
simultaneously O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
alert O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
physician O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
eliminating O-MISC B-CHED-MISC
DPH B-CHED-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
therapeutic O-MISC B-CONC-MISC
regimen O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
plasma O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
are O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Prevention O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
endometrial B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
climacteric O-MISC I-ANAT-MISC
women O-MISC I-PHEN-MISC
receiving O-MISC B-ACTI-MISC
oestrogen B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
regimens O-MISC I-CONC-MISC
are O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
74 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
endometrial B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
850 O-MISC B-ACTI-MISC
climacteric O-MISC I-ANAT-MISC
women O-MISC I-PHEN-MISC
receiving O-MISC B-ACTI-MISC
oestrogen B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Cystic O-MISC I-ACTI-MISC
hyperplasia B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
unopposed O-MISC B-ACTI-MISC
oestrogen B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
without O-MISC B-ACTI-MISC
progestagen B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
courses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
norethisterone B-CHED-MISC O-MISC
daily O-MISC B-CHED-MISC
caused O-MISC B-ACTI-MISC
reversion O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cystic O-MISC I-ACTI-MISC
hyperplasia B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
atypical O-MISC I-ACTI-MISC
hyperplasia B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

4 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
endometrial B-DISO-MISC I-ACTI-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
referred O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
elsewhere O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
problems O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
inappropriate O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
unsupervised O-MISC B-CHED-MISC
unopposed O-MISC B-ACTI-MISC
oestrogen B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
difficulty O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
distinguishing O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
hyperplasia B-DISO-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
malignancy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Cyclical O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
oestrogen B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
progestagen B-CHED-MISC O-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
seem O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
endometrial B-DISO-MISC I-ACTI-MISC
hyperplasia I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
carcinoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Ninety O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
divided O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
groups O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
- O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
E O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
exercise O-MISC I-ANAT-MISC
control O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
EC O-MISC I-PHEN-MISC
) O-MISC I-PHEN-MISC
groups O-MISC I-PHEN-MISC
exercised O-MISC B-DEVI-MISC
daily O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
thirty O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
treadmill O-MISC B-GENE-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mph O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
grade O-MISC B-CHED-MISC
while O-MISC B-ACTI-MISC
animals O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sedentary O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
S O-MISC O-MISC
- O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
remained O-MISC B-ACTI-MISC
sedentary O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Eight O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
assigned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sedentary O-MISC B-CHED-MISC
control O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
SC O-MISC I-PHEN-MISC
) O-MISC I-PHEN-MISC
group O-MISC I-PHEN-MISC
which O-MISC B-ACTI-MISC
remained O-MISC B-ACTI-MISC
sedentary O-MISC B-CHED-MISC
throughout O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
experimental O-MISC B-CONC-MISC
period O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Forty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
final O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
period O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
S O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
I O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
E O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
I O-MISC I-CONC-MISC
animals O-MISC I-ANAT-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
subcutaneous O-MISC B-CHED-MISC
injection O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Animals O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
S O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
I O-MISC B-ANAT-MISC
group O-MISC I-ANAT-MISC
exhibited O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
Pp O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
than O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
E O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
I O-MISC B-ANAT-MISC
group O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Serum O-MISC I-GENE-MISC
CPK O-MISC O-MISC
activity O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
E O-MISC B-CONC-MISC
- O-MISC B-ANAT-MISC
I O-MISC B-ANAT-MISC
animals O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
S O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
I O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
EC O-MISC I-ACTI-MISC
groups O-MISC I-ANAT-MISC
twenty O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
injection O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-CHED-MISC
statistically O-MISC I-CHED-MISC
significant O-MISC I-CHED-MISC
differences O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
treated O-MISC B-CONC-MISC
groups O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
lesions O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
weight O-MISC I-LIVB-MISC
ratios O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC I-ACTI-MISC
indicated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
exercise O-MISC B-DEVI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
large O-MISC B-ACTI-MISC
dosages O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
isoproterenol B-CHED-MISC O-MISC
but O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
little O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
infarction B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Human O-MISC I-ANAT-MISC
corticotropin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
releasing O-MISC B-DISO-MISC
hormone O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
thyrotropin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
releasing O-MISC B-DISO-MISC
hormone O-MISC B-DISO-MISC
modulate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
hypercapnic B-DISO-MISC I-ACTI-MISC
ventilatory O-MISC I-DISO-MISC
response O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Human O-MISC O-MISC
corticotropin B-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
releasing O-MISC B-DISO-MISC
hormone O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
hCRH O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
thyrotropin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
releasing O-MISC B-DISO-MISC
hormone O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TRH O-MISC O-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
stimulate O-MISC B-OCCU-MISC
ventilation O-MISC I-DISO-MISC
after O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
single O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
we O-MISC B-ACTI-MISC
aimed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
clarify O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
peptides O-MISC O-MISC
act O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
altering O-MISC B-ACTI-MISC
central O-MISC B-CHED-MISC
chemosensitivity O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
CO2 B-CHED-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
rebreathing O-MISC I-CONC-MISC
tests O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
young O-MISC I-PHEN-MISC
volunteers O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
test O-MISC B-CONC-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
NaCl B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-CHED-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
test O-MISC B-CONC-MISC
200 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hCRH O-MISC O-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
TRH O-MISC O-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
Nine O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
received O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
NaCl B-CHED-MISC O-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
rebreathing O-MISC B-CONC-MISC
manoeuvres O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
CO2 B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
response O-MISC B-ANAT-MISC
curves O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
tests O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
subject O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hCRH O-MISC I-ACTI-MISC
group O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
parallel O-MISC B-ACTI-MISC
shift O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CO2 B-CHED-MISC O-MISC
- O-MISC I-LIVB-MISC
response O-MISC I-LIVB-MISC
curve O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
left O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
hCRH O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
occurred O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
TRH O-MISC I-ACTI-MISC
but O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
striking O-MISC B-DEVI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

hCRH O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
TRH O-MISC I-ACTI-MISC
caused O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CO2 B-CHED-MISC O-MISC
threshold O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
CO2 B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
response O-MISC B-ANAT-MISC
curves O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
nearly O-MISC B-ACTI-MISC
identical O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
additive O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
releasing O-MISC O-MISC
hormones O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypercapnic B-DISO-MISC B-CHED-MISC
ventilatory O-MISC I-DISO-MISC
response O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
presumably O-MISC B-ACTI-MISC
independent O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
central O-MISC I-ACTI-MISC
chemosensitivity O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Lamivudine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
suppressing O-MISC B-CHED-MISC
hepatitis B-DISO-MISC O-MISC
B I-DISO-MISC B-DISO-MISC
virus O-MISC B-DISO-MISC
DNA O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
hepatitis B-CHED-MISC O-MISC
B I-CHED-MISC B-DISO-MISC
surface I-CHED-MISC B-DISO-MISC
antigen I-CHED-MISC B-DISO-MISC
carriers O-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Lamivudine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
2 B-CHED-MISC O-MISC
' I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
' I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dideoxy I-CHED-MISC B-DISO-MISC
cytosine I-CHED-MISC B-DISO-MISC
analogue O-MISC O-MISC
that O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
potent O-MISC B-ACTI-MISC
inhibitory O-MISC B-DEVI-MISC
effects O-MISC I-LIVB-MISC
on O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ANAT-MISC
B I-DISO-MISC I-PHEN-MISC
virus O-MISC I-PHEN-MISC
replication O-MISC I-DISO-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
placebo O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-CONC-MISC
its O-MISC B-ACTI-MISC
effectiveness O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
hepatitis B-CHED-MISC O-MISC
B I-CHED-MISC B-DISO-MISC
surface I-CHED-MISC B-DISO-MISC
antigen I-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
HBsAg B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
carriers O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Forty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
HBsAg B-CHED-MISC I-DISO-MISC
carriers O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
randomized O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
receive O-MISC B-CHED-MISC
placebo O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
orally O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
dosages O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
daily O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
drug O-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
closely O-MISC B-CONC-MISC
monitored O-MISC I-CONC-MISC
clinically O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
biochemically O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
serologically O-MISC B-CHED-MISC
up O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
drug O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-CHED-MISC
lamivudine B-CHED-MISC O-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ANAT-MISC
B I-DISO-MISC I-PHEN-MISC
virus O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
HBV O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
DNA O-MISC B-CONC-MISC
values O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
slightly O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
011 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
005 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
still O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
94 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
suppression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
HBV O-MISC I-ACTI-MISC
DNA O-MISC B-ANAT-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fourth O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

HBV O-MISC B-CONC-MISC
DNA O-MISC I-CONC-MISC
values O-MISC B-CHED-MISC
returned O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
pretreatment O-MISC B-DEVI-MISC
levels O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cessation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hepatitis B-DISO-MISC I-ACTI-MISC
B I-DISO-MISC B-ANAT-MISC
e O-MISC B-ANAT-MISC
antigen O-MISC O-MISC
status O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
aminotransferase O-MISC B-OCCU-MISC
levels O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
course O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lamivudine B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
safe O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
suppression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
HBV O-MISC B-CONC-MISC
DNA O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
HBsAg B-CHED-MISC O-MISC
carriers O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
suppression O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
reversible O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Studies O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
lamivudine B-CHED-MISC O-MISC
administration O-MISC B-CONC-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
prolonged O-MISC B-CHED-MISC
suppression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
HBV O-MISC B-CONC-MISC
DNA O-MISC I-CONC-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
achieved O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Population O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
based O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
venous B-DISO-MISC I-ACTI-MISC
thromboembolism I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
various O-MISC B-ACTI-MISC
oral B-CHED-MISC O-MISC
contraceptives I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Four O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
published O-MISC B-ACTI-MISC
since O-MISC B-ACTI-MISC
December O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1995 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
venous B-DISO-MISC I-ACTI-MISC
thromboembolism I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
oral B-CHED-MISC O-MISC
contraceptives I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
OCs B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
containing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
third O-MISC O-MISC
- O-MISC B-DISO-MISC
generation O-MISC B-DISO-MISC
progestagens B-CHED-MISC B-DISO-MISC
gestodene B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
desogestrel B-CHED-MISC O-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
OCs B-CHED-MISC O-MISC
containing O-MISC B-ACTI-MISC
second O-MISC O-MISC
- O-MISC B-DISO-MISC
generation O-MISC B-DISO-MISC
progestagens B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
confounding O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
bias O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
design O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
re O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
examine O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
OC B-CHED-MISC I-ACTI-MISC
use O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
design O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
avoid O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bias O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
confounding O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
earlier O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
computer O-MISC B-CHED-MISC
records O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
143 O-MISC B-ACTI-MISC
general O-MISC B-PROC-MISC
practices O-MISC I-UnknownType-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
UK O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medical O-MISC B-CHED-MISC
records O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
540 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
born O-MISC I-DISO-MISC
between O-MISC B-ACTI-MISC
1941 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1981 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
deep B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
vein I-DISO-MISC B-ANAT-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
venous B-DISO-MISC I-ACTI-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
not O-MISC B-ACTI-MISC
otherwise O-MISC B-ACTI-MISC
specified O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
pulmonary O-MISC I-ACTI-MISC
embolus O-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
period O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
an O-MISC B-ACTI-MISC
anticoagulant O-MISC O-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cohort O-MISC B-CHED-MISC
analysis O-MISC I-CHED-MISC
to O-MISC B-ACTI-MISC
estimate O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
compare O-MISC B-DEVI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
main O-MISC B-ACTI-MISC
OC B-CHED-MISC B-OBJC-MISC
preparations O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nested O-MISC B-CONC-MISC
case O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
calculate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratios O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
different O-MISC B-CHED-MISC
types O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
OC B-CHED-MISC B-OBJC-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
adjustment O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
confounding O-MISC B-CHED-MISC
factors O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
matched O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
exact O-MISC B-ACTI-MISC
year O-MISC I-DISO-MISC
of O-MISC I-LIVB-MISC
birth O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
practice O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
current O-MISC B-CHED-MISC
use O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
OCs B-CHED-MISC B-OBJC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
logistic O-MISC B-PHEN-MISC
regression O-MISC B-UnknownType-MISC
model O-MISC B-UnknownType-MISC
that O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
body O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
mass O-MISC I-LIVB-MISC
index O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
number O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
cycles O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
change O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
OC B-CHED-MISC O-MISC
prescribed O-MISC B-CONC-MISC
within O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
event O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
previous O-MISC B-CHED-MISC
pregnancy O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
concurrent O-MISC B-CHED-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

FINDINGS O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
met O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inclusion O-MISC B-CHED-MISC
criteria O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
progestagen B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
only O-MISC B-CHED-MISC
OCs B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
83 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
combined O-MISC B-CHED-MISC
OCs B-CHED-MISC B-OBJC-MISC
, O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
recorded O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
deep B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
vein I-DISO-MISC B-ANAT-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
pulmonary O-MISC I-ACTI-MISC
thrombosis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
venous B-DISO-MISC I-ACTI-MISC
thrombosis I-DISO-MISC B-ANAT-MISC
not O-MISC B-ACTI-MISC
otherwise O-MISC B-ACTI-MISC
specified O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
crude O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
per O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
- O-MISC I-CHED-MISC
years O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
current O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
OC B-CHED-MISC B-OBJC-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
generation O-MISC I-CHED-MISC
OCs B-CHED-MISC B-OBJC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
96 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
third O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
generation O-MISC I-CHED-MISC
preparations O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
adjustment O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
third O-MISC B-CHED-MISC
- O-MISC I-OBJC-MISC
generation O-MISC I-OBJC-MISC
relative O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
- O-MISC I-OBJC-MISC
generation O-MISC I-OBJC-MISC
OCs B-CHED-MISC B-OBJC-MISC
was O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
04 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Logistic O-MISC B-CONC-MISC
regression O-MISC I-CONC-MISC
showed O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
significant O-MISC B-ANAT-MISC
difference O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
between O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
third O-MISC B-OBJC-MISC
- O-MISC I-OBJC-MISC
generation O-MISC I-OBJC-MISC
and O-MISC B-ACTI-MISC
second O-MISC B-OBJC-MISC
- O-MISC I-OBJC-MISC
generation O-MISC I-OBJC-MISC
OCs B-CHED-MISC I-OBJC-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
third O-MISC O-MISC
- O-MISC B-DISO-MISC
generation O-MISC B-DISO-MISC
progestagens B-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
desogestrel B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
ethinyloestradiol B-CHED-MISC O-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
users O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
gestodene B-CHED-MISC O-MISC
or O-MISC B-ACTI-MISC
desogestrel B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
ethinyloestradiol B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
second O-MISC O-MISC
- O-MISC B-DISO-MISC
generation O-MISC B-DISO-MISC
OCs B-CHED-MISC B-DISO-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reference O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratios O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
VTE B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
desogestrel B-CHED-MISC O-MISC
plus O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
g O-MISC B-ACTI-MISC
ethinyloestradiol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
66 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
third O-MISC O-MISC
- O-MISC B-DISO-MISC
generation O-MISC B-DISO-MISC
progestagens B-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

INTERPRETATION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
third O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
generation O-MISC I-OBJC-MISC
OCs B-CHED-MISC I-OBJC-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
second O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
generation O-MISC I-GEOG-MISC
products O-MISC I-GEOG-MISC
is O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
residual O-MISC B-ACTI-MISC
confounding O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
products O-MISC B-GENE-MISC
containing O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
ethinyloestradiol B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
desogestrel B-CHED-MISC O-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
micrograms O-MISC B-CHED-MISC
product O-MISC B-GENE-MISC
is O-MISC B-ACTI-MISC
biologically O-MISC B-ACTI-MISC
implausible O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
preferential O-MISC B-ACTI-MISC
prescribing O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
confounding O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
augments O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
electrographic O-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
but O-MISC B-ACTI-MISC
protects O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
brain B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
authors O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anticonvulsant O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC I-ACTI-MISC
seizure B-DISO-MISC I-ACTI-MISC
model O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Intraperitoneal O-MISC B-CHED-MISC
injection O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
tonic B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
clonic I-DISO-MISC I-ACTI-MISC
seizure I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Scopolamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
pentobarbital B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
behavioral O-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
but O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
electrical O-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
measured O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
hippocampal O-MISC B-CONC-MISC
EEG O-MISC I-CONC-MISC
appeared O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
group O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Scopolamine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
pentobarbital B-CHED-MISC I-GENE-MISC
blocked O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
electrographic O-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
treatment O-MISC B-CHED-MISC
augmented O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
electrographic O-MISC I-ACTI-MISC
seizure B-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Brain B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
examining O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
microscopically O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Pilocarpine B-CHED-MISC O-MISC
produced O-MISC B-ACTI-MISC
neuronal B-DISO-MISC I-DISO-MISC
death I-DISO-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
pyknotic O-MISC I-DISO-MISC
changes O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Pentobarbital B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
scopolamine B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
protected O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
though O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
MK B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
801 I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pyramidal O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
hippocampus O-MISC I-GENE-MISC
appeared O-MISC B-ACTI-MISC
darker O-MISC B-OCCU-MISC
than O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
granule O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dentate O-MISC I-GENE-MISC
gyrus O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-CHED-MISC
affected O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
status B-DISO-MISC I-ACTI-MISC
epilepticus I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
pilocarpine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
initiated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
cholinergic O-MISC B-CHED-MISC
overstimulation O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
propagated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
glutamatergic O-MISC I-DISO-MISC
transmission O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
elevation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
brain B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
through O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
excitatory O-MISC O-MISC
NMDA B-CHED-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Paclitaxel B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
folinic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
metastatic O-MISC I-ACTI-MISC
breast B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
BRE O-MISC O-MISC
- O-MISC B-DISO-MISC
26 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
Fluorouracil I-CHED-MISC B-DISO-MISC
plus O-MISC B-DISO-MISC
folinic B-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
Taxol B-CHED-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
Bristol O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
Myers O-MISC B-ACTI-MISC
Squibb O-MISC B-ACTI-MISC
Company O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Princeton O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
NJ O-MISC I-ORGA-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
salvage O-MISC B-CONC-MISC
therapies O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
metastatic O-MISC I-ACTI-MISC
breast B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Paclitaxel B-CHED-MISC O-MISC
and O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
fluorouracil I-CHED-MISC B-DISO-MISC
have O-MISC B-ACTI-MISC
additive O-MISC B-CHED-MISC
cytotoxicity B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
MCF O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
7 O-MISC B-GEOG-MISC
cell O-MISC B-GEOG-MISC
lines O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
phase O-MISC B-CONC-MISC
II O-MISC I-CONC-MISC
trial O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC O-MISC
175 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
hours O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
I O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
folinic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
300 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
hour O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
5 B-CHED-MISC B-ACTI-MISC
- I-CHED-MISC B-ACTI-MISC
fluorouracil I-CHED-MISC O-MISC
350 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
m2 O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
1 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
every O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
days O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
TFL O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
metastatic O-MISC I-ACTI-MISC
breast B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Analysis O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
minimum O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
192 O-MISC B-ACTI-MISC
cycles O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
TFL O-MISC O-MISC
: O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
cycles O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
grade O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
requiring O-MISC B-ACTI-MISC
hospitalization O-MISC B-CONC-MISC
; O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
cycles O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
required O-MISC B-ACTI-MISC
granulocyte B-CHED-MISC O-MISC
colony I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
stimulating I-CHED-MISC B-DISO-MISC
factor I-CHED-MISC B-DISO-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
neutropenia B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
required O-MISC B-ACTI-MISC
platelet O-MISC B-CONC-MISC
transfusions O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Grade O-MISC I-ACTI-MISC
3 O-MISC B-ANAT-MISC
/ O-MISC B-ACTI-MISC
4 O-MISC B-ANAT-MISC
nonhematologic O-MISC B-ANAT-MISC
toxicities B-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
uncommon O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
evaluable O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
complete O-MISC B-CHED-MISC
responses O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
partial O-MISC B-CHED-MISC
responses O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
53 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
overall O-MISC B-CHED-MISC
response O-MISC I-DISO-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
62 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
evaluable O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
prior O-MISC B-CHED-MISC
doxorubicin B-CHED-MISC O-MISC
exposure O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
responded O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
prior O-MISC B-CHED-MISC
doxorubicin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Plasma O-MISC I-GENE-MISC
paclitaxel B-CHED-MISC O-MISC
concentrations O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
completion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
paclitaxel B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
hours O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

TFL O-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
active O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
tolerated O-MISC B-ACTI-MISC
regimen O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
metastatic O-MISC I-ACTI-MISC
breast B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
proarrhythmia B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachyarrhythmias I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
prospectively O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
efficacy O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presumable O-MISC B-ACTI-MISC
risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
d B-CHED-MISC B-ACTI-MISC
, I-CHED-MISC B-ACTI-MISC
l I-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachyarrhythmias I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Eighty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
consecutive O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
artery I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
dilated B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
inducible O-MISC B-CHED-MISC
sustained O-MISC B-CHED-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
received O-MISC B-CHED-MISC
oral O-MISC I-GENE-MISC
d B-CHED-MISC B-ACTI-MISC
, I-CHED-MISC B-ACTI-MISC
l I-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachyarrhythmia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
loading O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
continuous O-MISC B-CONC-MISC
electrocardiographic O-MISC I-CONC-MISC
( O-MISC I-CONC-MISC
ECG O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
monitoring O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Those O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
prevented O-MISC B-ACTI-MISC
induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
discharged O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
and O-MISC B-ACTI-MISC
followed O-MISC B-CONC-MISC
up O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
outpatient O-MISC I-ANAT-MISC
basis O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Induction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachyarrhythmia I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
prevented O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachyarrhythmia I-DISO-MISC B-ANAT-MISC
remained O-MISC B-ACTI-MISC
inducible O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
tolerate O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
once O-MISC B-CHED-MISC
daily O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
torsades B-DISO-MISC I-GENE-MISC
de I-DISO-MISC B-ACTI-MISC
pointes I-DISO-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
oral O-MISC B-CONC-MISC
treatment O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
ECG O-MISC I-ACTI-MISC
[ O-MISC B-ACTI-MISC
sinus O-MISC I-GENE-MISC
- O-MISC I-CHED-MISC
cycle O-MISC I-CHED-MISC
length O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
SCL O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
QT O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
QTc O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
U O-MISC I-ACTI-MISC
wave O-MISC B-ANAT-MISC
] O-MISC B-ACTI-MISC
nor O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
parameters O-MISC I-ACTI-MISC
identified O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ACTI-MISC
pointes I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
46 O-MISC B-ACTI-MISC
vs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
328 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
53 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
day O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0017 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Risk O-MISC I-ACTI-MISC
factors O-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
torsades B-DISO-MISC B-ACTI-MISC
de I-DISO-MISC B-ACTI-MISC
pointes I-DISO-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
appearance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
U O-MISC I-ACTI-MISC
wave O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
049 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
gender O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
015 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
corrected O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
SCL O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
QT O-MISC I-DISO-MISC
interval O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
QTc O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
p O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

During O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nonfatal O-MISC I-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachycardia I-DISO-MISC B-ANAT-MISC
recurrence O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
died O-MISC I-ACTI-MISC
suddenly O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
patient O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
stable O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
had O-MISC B-ACTI-MISC
recurrent O-MISC B-CHED-MISC
torsades B-DISO-MISC B-ACTI-MISC
de I-DISO-MISC B-ACTI-MISC
pointes I-DISO-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
successful O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ACTI-MISC
pointes I-DISO-MISC I-GENE-MISC
occurred O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
even O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oral O-MISC O-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Pronounced O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
surface O-MISC B-ACTI-MISC
ECG O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
cycle O-MISC B-CHED-MISC
length O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
QT O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
QTc O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
relation O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
oral O-MISC B-CHED-MISC
d B-CHED-MISC B-ACTI-MISC
, I-CHED-MISC B-ACTI-MISC
l I-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
might O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
subgroup O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ANAT-MISC
pointes I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Other O-MISC B-ACTI-MISC
ECG O-MISC I-ACTI-MISC
parameters O-MISC I-ACTI-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
application O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
d B-CHED-MISC B-ACTI-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
torsades B-DISO-MISC I-ACTI-MISC
de I-DISO-MISC B-ACTI-MISC
pointes I-DISO-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Recurrence O-MISC B-CHED-MISC
rates O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
ventricular B-DISO-MISC I-ACTI-MISC
tachyarrhythmias I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
despite O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
suppression O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
arrhythmia B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
programmed O-MISC B-CONC-MISC
stimulation O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
programmed O-MISC B-CONC-MISC
electrical O-MISC I-CONC-MISC
stimulation O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
d B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
l I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
sotalol I-CHED-MISC B-DISO-MISC
seems O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
prognostic O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Chronic O-MISC I-ACTI-MISC
hyperprolactinemia B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
neurons O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
tuberoinfundibular O-MISC I-GENE-MISC
dopaminergic O-MISC B-GEOG-MISC
( O-MISC B-GEOG-MISC
TIDA O-MISC B-GEOG-MISC
) O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
inhibit O-MISC B-DEVI-MISC
prolactin O-MISC O-MISC
( O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
) O-MISC B-ACTI-MISC
secretion O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
young O-MISC B-CHED-MISC
animals O-MISC I-ANAT-MISC
this O-MISC B-ACTI-MISC
system O-MISC B-ACTI-MISC
responds O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
elevations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
PRL O-MISC O-MISC
by O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
its O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
responsiveness O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
lost O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
aging O-MISC I-DISO-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
chronically O-MISC B-CHED-MISC
high O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
PRL O-MISC B-CONC-MISC
levels O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
extended O-MISC B-CHED-MISC
periods O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
time O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
examine O-MISC I-ACTI-MISC
its O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
dopaminergic O-MISC I-GENE-MISC
systems O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Hyperprolactinemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
treatment O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
receptor O-MISC B-DISO-MISC
antagonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Palkovits O-MISC B-CONC-MISC
' O-MISC I-CONC-MISC
microdissection O-MISC I-CONC-MISC
technique O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
high O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
performance O-MISC I-CONC-MISC
liquid O-MISC I-CONC-MISC
chromatography O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
measure O-MISC B-CHED-MISC
neurotransmitter O-MISC O-MISC
concentrations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
areas O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
concentrations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
median O-MISC I-DISO-MISC
eminence O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
ME O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Nine O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
produced O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
DA B-CHED-MISC O-MISC
concentrations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ME O-MISC B-GENE-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
DA B-CHED-MISC O-MISC
response O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
lost O-MISC B-CHED-MISC
if O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
month O-MISC B-CHED-MISC
long O-MISC B-ACTI-MISC
haloperidol B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
month O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
long O-MISC B-ACTI-MISC
extremely O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
PRL O-MISC O-MISC
levels O-MISC B-CHED-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
implantation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
MMQ O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
under O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
capsule O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
change O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
DA B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
norepinephrine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
NE B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
serotonin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HT I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
metabolites O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
arcuate O-MISC I-GENE-MISC
nucleus O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
AN O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
medial O-MISC I-GENE-MISC
preoptic O-MISC B-GEOG-MISC
area O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
MPA O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
caudate O-MISC I-GENE-MISC
putamen O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
CP O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
substantia O-MISC I-GENE-MISC
nigra O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
SN O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
zona O-MISC I-GENE-MISC
incerta O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
ZI O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
except O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
hydroxyindoleacetic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
5 B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
HIAA I-CHED-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
AN O-MISC I-GENE-MISC
after O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
DA B-CHED-MISC O-MISC
concentrations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
AN O-MISC I-GENE-MISC
after O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
specifically O-MISC B-ACTI-MISC
affects O-MISC B-ACTI-MISC
TIDA O-MISC I-ACTI-MISC
neurons O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
vary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
depending O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
intensity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hyperprolactinemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
hypothalamic O-MISC I-GENE-MISC
dopamine B-CHED-MISC O-MISC
function O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
increases O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
PRL O-MISC O-MISC
secretion O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

Treatment O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
disseminated O-MISC B-CHED-MISC
necrotizing O-MISC I-ACTI-MISC
leukoencephalopathy B-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
characteristic O-MISC B-ACTI-MISC
contrast O-MISC B-CHED-MISC
enhancement O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
white O-MISC I-GENE-MISC
matter O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
describes O-MISC B-ACTI-MISC
unique O-MISC B-ACTI-MISC
contrast O-MISC B-CHED-MISC
enhancement O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
white O-MISC I-GENE-MISC
matter O-MISC B-GEOG-MISC
on O-MISC B-ACTI-MISC
T1 O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
weighted O-MISC I-CONC-MISC
magnetic O-MISC I-CONC-MISC
resonance O-MISC I-CONC-MISC
images O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
disseminated O-MISC B-CHED-MISC
necrotizing O-MISC I-ACTI-MISC
leukoencephalopathy B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
lymphoblastic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
treated O-MISC B-CHED-MISC
with O-MISC I-CONC-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
methotrexate B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
enhancement O-MISC B-DEVI-MISC
was O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
pronounced O-MISC B-ACTI-MISC
near O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
base O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
than O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vertex O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Necropsy O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
case O-MISC I-CHED-MISC
revealed O-MISC B-ACTI-MISC
loss B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ANAT-MISC
myelination I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
necrosis B-DISO-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
white O-MISC I-GENE-MISC
matter O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Possible O-MISC B-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
causing O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
leukoencephalopathy B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Thrombotic B-DISO-MISC I-ACTI-MISC
complications O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
promyelocytic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
all B-CHED-MISC B-CONC-MISC
- I-CHED-MISC I-CONC-MISC
trans I-CHED-MISC I-CONC-MISC
- I-CHED-MISC I-CONC-MISC
retinoic I-CHED-MISC I-CONC-MISC
acid I-CHED-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
occlusion B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
renal I-DISO-MISC I-GENE-MISC
vessels I-DISO-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
promyelocytic I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
APL B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
all B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
trans I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
retinoic I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ATRA B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
tranexamic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
APL B-DISO-MISC I-ACTI-MISC
patient O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
ATRA B-CHED-MISC O-MISC
alone O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
further O-MISC B-ACTI-MISC
supports O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
concern O-MISC B-ACTI-MISC
about O-MISC B-ACTI-MISC
thromboembolic B-DISO-MISC B-CHED-MISC
complications O-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
ATRA B-CHED-MISC B-CONC-MISC
therapy O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
APL B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
man O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
signs O-MISC I-ACTI-MISC
and O-MISC B-ANAT-MISC
symptoms O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
APL B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
protocol O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
ATRA B-CHED-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
completely O-MISC B-ACTI-MISC
reversible O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
remission O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
APL B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
achieved O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
discontinued O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
ATRA B-CHED-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
valid O-MISC B-ACTI-MISC
therapeutic O-MISC B-CHED-MISC
choice O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
APL B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
procoagulant O-MISC I-DISO-MISC
tendency O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-CHED-MISC
completely O-MISC I-CHED-MISC
corrected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Thrombotic B-DISO-MISC B-DEVI-MISC
events O-MISC I-DEVI-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
avoided O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
heparin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Pupillary O-MISC I-GENE-MISC
changes O-MISC B-CHED-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
stimulant O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
mania B-DISO-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
dependent O-MISC B-ANAT-MISC
man O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
subject O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
evaluating O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
anticraving O-MISC I-ACTI-MISC
efficacy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
stimulant O-MISC O-MISC
medication O-MISC O-MISC
diethylpropion B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
DEP B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
became O-MISC B-ACTI-MISC
manic B-DISO-MISC O-MISC
during O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
week O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
drug O-MISC O-MISC
. O-MISC B-ACTI-MISC

Pupillometric O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
while O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
DEP B-CHED-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
power O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pupillary B-DISO-MISC I-DISO-MISC
oscillation I-DISO-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
dramatically O-MISC B-ACTI-MISC
different O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
study O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
who O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
become O-MISC B-ACTI-MISC
manic B-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
power O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
pupillary B-DISO-MISC I-DISO-MISC
oscillation I-DISO-MISC I-LIVB-MISC
occurred O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
became O-MISC B-ACTI-MISC
fully O-MISC B-ACTI-MISC
manic B-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Such O-MISC B-ACTI-MISC
medication O-MISC O-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
changes O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
power O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pupillary B-DISO-MISC I-DISO-MISC
oscillation I-DISO-MISC I-LIVB-MISC
might O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
utility O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
identifying O-MISC B-CONC-MISC
persons O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
manic B-DISO-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
like O-MISC B-ANAT-MISC
adverse O-MISC B-ANAT-MISC
effects O-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
medical O-MISC B-CHED-MISC
use O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
psychomotor O-MISC O-MISC
stimulants O-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
sympathomimetic O-MISC O-MISC
agents O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Fetal O-MISC I-ACTI-MISC
risks O-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
warfarin B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
during O-MISC B-ACTI-MISC
pregnancy O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
mothers O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
heart O-MISC B-OBJC-MISC
valve O-MISC I-OBJC-MISC
prosthesis O-MISC I-OBJC-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
warfarin B-CHED-MISC O-MISC
during O-MISC B-ACTI-MISC
pregnancy O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
caesarean O-MISC B-CONC-MISC
section O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
done O-MISC B-ACTI-MISC
one O-MISC B-CHED-MISC
week O-MISC I-CHED-MISC
after O-MISC B-ACTI-MISC
replacement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
with O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
baby O-MISC I-ANAT-MISC
died O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
cerebral B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
pulmonary I-DISO-MISC I-ACTI-MISC
hemorrhage I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
mother O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
infant O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
caesarean O-MISC B-CONC-MISC
section O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
baby O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
warfarin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
embryopathy B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
nasal B-DISO-MISC I-ACTI-MISC
hypoplasia I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
stippled B-DISO-MISC I-ACTI-MISC
epiphyses I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
chondrodysplasia B-DISO-MISC I-ACTI-MISC
punctata I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Nasal B-DISO-MISC I-ACTI-MISC
hypoplasia I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
stippled B-DISO-MISC I-ACTI-MISC
epiphyses I-DISO-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
now O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
infants O-MISC I-ANAT-MISC
born O-MISC I-PHEN-MISC
to O-MISC B-ACTI-MISC
mothers O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
warfarin B-CHED-MISC O-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
trimester O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
causal O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
probable O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
view O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risks O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
mother O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
fetus O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
prosthetic O-MISC B-OBJC-MISC
cardiac O-MISC I-OBJC-MISC
valves O-MISC I-OBJC-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
recommended O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
therapeutic O-MISC B-CONC-MISC
abortion O-MISC I-CONC-MISC
be O-MISC B-ACTI-MISC
advised O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
mucosal O-MISC B-ANAT-MISC
potential O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
separating O-MISC B-ACTI-MISC
central O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
in O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
wanted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
test O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
assessment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
central O-MISC I-DISO-MISC
pain B-DISO-MISC I-ACTI-MISC
- O-MISC I-LIVB-MISC
related O-MISC I-LIVB-MISC
signal O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
chemo O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
somatosensory O-MISC I-LIVB-MISC
evoked O-MISC I-LIVB-MISC
potential O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
CSSEP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
concomitantly O-MISC B-CHED-MISC
recorded O-MISC B-ACTI-MISC
peripheral O-MISC I-DISO-MISC
signal O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
negative O-MISC I-DISO-MISC
mucosal O-MISC I-LIVB-MISC
potential O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
NMP O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
allows O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
separation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
central O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
experimental O-MISC B-ACTI-MISC
conditions O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
created O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
NSAIDs O-MISC O-MISC
had O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
phasic O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
tonic O-MISC I-ACTI-MISC
pain B-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
central O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
mechanisms O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
According O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
double O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
blind O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
randomised O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
controlled O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
threefold O-MISC B-ACTI-MISC
cross O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
over O-MISC I-CONC-MISC
design O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
males O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
females O-MISC I-DISO-MISC
; O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
26 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
, O-MISC B-ACTI-MISC
400 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
800 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Phasic O-MISC I-ACTI-MISC
pain B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
applied O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
means O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
short O-MISC B-ACTI-MISC
pulses O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
CO2 B-CHED-MISC O-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nasal O-MISC I-GENE-MISC
mucosa O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
stimulus O-MISC B-OCCU-MISC
duration O-MISC B-CHED-MISC
500 O-MISC B-ACTI-MISC
ms O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
interval O-MISC B-CHED-MISC
approximately O-MISC B-CHED-MISC
60 O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
tonic O-MISC I-ACTI-MISC
pain B-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nasal O-MISC I-GENE-MISC
cavity O-MISC B-GEOG-MISC
by O-MISC B-ACTI-MISC
means O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
dry O-MISC B-GENE-MISC
air O-MISC I-GEOG-MISC
of O-MISC B-ACTI-MISC
controlled O-MISC B-CHED-MISC
temperature O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
humidity O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
flow O-MISC B-OCCU-MISC
rate O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
degrees O-MISC B-ACTI-MISC
C O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
relative O-MISC B-CHED-MISC
humidity O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
145 O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
CSSEPs O-MISC O-MISC
as O-MISC B-ACTI-MISC
central O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
NMPs O-MISC I-DISO-MISC
as O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
correlates O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
response O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CO2 B-CHED-MISC O-MISC
stimuli O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

Additionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subjects O-MISC B-ACTI-MISC
rated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intensity O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
phasic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
tonic O-MISC I-ACTI-MISC
pain B-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
means O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
visual O-MISC B-CONC-MISC
analogue O-MISC I-CONC-MISC
scales O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
As O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
earlier O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
tonic O-MISC I-ACTI-MISC
pain B-DISO-MISC B-ANAT-MISC
but O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
relative O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
placebo O-MISC O-MISC
- O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
correlates O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
phasic O-MISC B-CHED-MISC
pain B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ibuprofen B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
interaction O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
stimuli O-MISC B-OCCU-MISC
under O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
special O-MISC B-ACTI-MISC
experimental O-MISC B-ACTI-MISC
conditions O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
behaviour O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
CSSEP O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
NMP O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pharmacological O-MISC B-OCCU-MISC
process O-MISC I-OCCU-MISC
underlying O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
phenomenon O-MISC B-OCCU-MISC
was O-MISC B-ACTI-MISC
localised O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
periphery O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
means O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
simultaneous O-MISC B-CHED-MISC
recording O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
interrelated O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
electrophysiologic O-MISC I-ACTI-MISC
correlates O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nociception O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
possible O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
separate O-MISC B-ACTI-MISC
central O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
NSAID O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
advantage O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
pain B-DISO-MISC I-ACTI-MISC
model O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
obtaining O-MISC B-ACTI-MISC
peripheral O-MISC I-ACTI-MISC
pain B-DISO-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
directly O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
invasive O-MISC I-CHED-MISC
technique O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Effect O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
Glucarates I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
antibiotic O-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
renal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Dehydrated B-DISO-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
regularly O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
failure I-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
single O-MISC B-CHED-MISC
injection O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
aminoglycoside B-CHED-MISC O-MISC
antibiotics O-MISC B-DISO-MISC
combined O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
dextran O-MISC O-MISC
or O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
antibiotics O-MISC O-MISC
only O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC B-CONC-MISC
administration O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
2 B-CHED-MISC O-MISC
, I-CHED-MISC B-DISO-MISC
5 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
di I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
O I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
acetyl I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
D I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
glucaro I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
1 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
4 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
6 I-CHED-MISC B-DISO-MISC
, I-CHED-MISC B-DISO-MISC
3 I-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
dilactone I-CHED-MISC B-DISO-MISC
protected O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
against O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
failure I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
kanamycin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
dextran O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
protective O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
prevalent O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
glucarates I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
saccharic B-CHED-MISC O-MISC
acid I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
hexauronic B-CHED-MISC O-MISC
acids I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
hexaaldonic B-CHED-MISC O-MISC
acids I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lesser O-MISC B-ACTI-MISC
degree O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hexaaldose O-MISC O-MISC
, O-MISC B-ACTI-MISC
sugar B-CHED-MISC O-MISC
alcohols I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
substances O-MISC O-MISC
inthe O-MISC B-DISO-MISC
TCA B-CHED-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
acidic O-MISC O-MISC
compounds O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
Glucarates I-CHED-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
peptide O-MISC O-MISC
antibiotics O-MISC B-DISO-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
aminoglycoside B-CHED-MISC O-MISC
antibitocis O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Dose O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
responses O-MISC I-OCCU-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protective O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
Glucarates I-CHED-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
glucarate I-CHED-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fixed O-MISC B-CHED-MISC
size O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
approximately O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
degree O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
protection O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
damages I-DISO-MISC B-ANAT-MISC
induced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
antibiotics O-MISC O-MISC
despite O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
disparities O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
administration O-MISC B-CHED-MISC
doses O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
antibiotics O-MISC O-MISC
. O-MISC B-ACTI-MISC

D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
Glucarates I-CHED-MISC B-DISO-MISC
had O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ability O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
prevent O-MISC B-CHED-MISC
renal B-DISO-MISC I-ACTI-MISC
damage I-DISO-MISC B-ANAT-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cure O-MISC B-CHED-MISC
it O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Rats O-MISC I-ANAT-MISC
excreted O-MISC I-DISO-MISC
acidic O-MISC I-GENE-MISC
urine O-MISC B-GEOG-MISC
when O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
spared O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
lesions I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
monosaccharides B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
effect O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
D B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
glucarates I-CHED-MISC B-DISO-MISC
against O-MISC B-ACTI-MISC
nephrotoxicity B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
antibiotics O-MISC O-MISC
was O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Acute O-MISC B-CHED-MISC
severe O-MISC B-ACTI-MISC
depression B-DISO-MISC B-ANAT-MISC
following O-MISC B-ACTI-MISC
peri O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
operative O-MISC I-CHED-MISC
ondansetron B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
woman O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
strong O-MISC B-ACTI-MISC
history O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
postoperative B-DISO-MISC I-ACTI-MISC
nausea I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
vomiting I-DISO-MISC I-ACTI-MISC
presented O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
abdominal O-MISC B-CONC-MISC
hysterectomy O-MISC I-CONC-MISC
3 O-MISC B-ACTI-MISC
months O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
anaesthetic O-MISC O-MISC
where O-MISC B-ACTI-MISC
ondansetron B-CHED-MISC O-MISC
prophylaxis O-MISC B-CONC-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
major B-DISO-MISC B-ACTI-MISC
depression I-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
almost O-MISC B-ACTI-MISC
immediately O-MISC B-ACTI-MISC
thereafter O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
serotonin B-CHED-MISC O-MISC
antagonist O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Nine O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
experienced O-MISC I-DISO-MISC
a O-MISC B-ACTI-MISC
self O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
limited O-MISC I-CHED-MISC
puerperal O-MISC B-CHED-MISC
depressive B-DISO-MISC I-ACTI-MISC
episode I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Anaesthesia O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
propofol B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
avoidance O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
serotonin B-CHED-MISC O-MISC
antagonists O-MISC B-DISO-MISC
provided O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nausea B-DISO-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
free O-MISC B-ANAT-MISC
postoperative O-MISC B-CHED-MISC
course O-MISC I-CHED-MISC
without O-MISC B-ACTI-MISC
exacerbation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Hypertensive B-DISO-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
stress O-MISC B-DISO-MISC
echocardiography O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
129 O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
stress O-MISC I-ACTI-MISC
echocardiographic O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hypertensive B-DISO-MISC I-ACTI-MISC
response O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
defined O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
BP O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
220 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
BP O-MISC I-LIVB-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
110 O-MISC B-ACTI-MISC
mm O-MISC B-ACTI-MISC
Hg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
response O-MISC I-ACTI-MISC
more O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
hypertension B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
resting O-MISC I-ACTI-MISC
systolic O-MISC I-DISO-MISC
and O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
BP O-MISC I-LIVB-MISC
before O-MISC B-ACTI-MISC
dobutamine B-CHED-MISC O-MISC
infusion O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Continuously O-MISC B-CHED-MISC
nebulized O-MISC B-CHED-MISC
albuterol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
severe O-MISC I-ACTI-MISC
exacerbations O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
asthma B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
retrospective O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
controlled O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
comparing O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
admitted O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
medical O-MISC B-GENE-MISC
intensive O-MISC I-GEOG-MISC
care O-MISC I-GEOG-MISC
unit O-MISC I-GEOG-MISC
with O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
exacerbations O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
asthma B-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
received O-MISC B-CHED-MISC
continuously O-MISC B-CHED-MISC
nebulized O-MISC B-CHED-MISC
albuterol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
CNA O-MISC O-MISC
) O-MISC B-ACTI-MISC
versus O-MISC B-ACTI-MISC
intermittent O-MISC O-MISC
albuterol B-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
INA O-MISC O-MISC
) O-MISC B-ACTI-MISC
treatments O-MISC B-CONC-MISC
is O-MISC B-ACTI-MISC
reported O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Forty O-MISC B-ACTI-MISC
matched O-MISC B-CHED-MISC
pairs O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
asthma B-DISO-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

CNA O-MISC O-MISC
was O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
hr O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
dysrhythmias I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
groups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Symptomatic O-MISC B-CHED-MISC
hypokalemia B-DISO-MISC I-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
occur O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

CNA O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rates O-MISC I-LIVB-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
reflect O-MISC B-ACTI-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
illness O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
intubation O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
similar O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
CNA O-MISC O-MISC
and O-MISC B-ACTI-MISC
INA O-MISC O-MISC
demonstrated O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
profiles O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
regard O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
safety O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
morbidity O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Paraplegia B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
intrathecal O-MISC B-CHED-MISC
methotrexate B-CHED-MISC O-MISC
: O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
literature O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
paraplegia B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intrathecal O-MISC B-CONC-MISC
instillation O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
methotrexate B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
discribed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ten O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
unusual O-MISC B-CHED-MISC
complication O-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
reviewed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
following O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
predispose O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
complication O-MISC I-ACTI-MISC
: O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
cerebrospinal O-MISC I-GENE-MISC
dynamics O-MISC B-OCCU-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
central B-DISO-MISC I-ACTI-MISC
nervous I-DISO-MISC B-ANAT-MISC
system I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
epidural O-MISC I-GENE-MISC
cerebrospinal O-MISC B-GEOG-MISC
leakage O-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
cerebrospinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
methothexate B-CHED-MISC O-MISC
concentration O-MISC B-CHED-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
cerebrospinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
dynamics O-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
inappropriately O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
methotrexate B-CHED-MISC O-MISC
doses O-MISC B-CHED-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
body O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
area O-MISC B-GEOG-MISC
calculations O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
children O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
neurotoxic B-DISO-MISC O-MISC
preservatives O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
commercially O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
methotrexate B-CHED-MISC O-MISC
preparations O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
diluents O-MISC O-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
methotrexate B-CHED-MISC O-MISC
diluents O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
unphysiologic O-MISC B-CHED-MISC
pH O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
ionic O-MISC B-CHED-MISC
content O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
osmolarity O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
methotrexate B-CHED-MISC O-MISC
contaminants O-MISC B-GENE-MISC
, O-MISC B-ACTI-MISC
local O-MISC B-CHED-MISC
folate B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cranial O-MISC B-CONC-MISC
irradiation O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
intrathecal O-MISC B-CHED-MISC
methotrexate B-CHED-MISC O-MISC
toxicity B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
unclear O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
employing O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
doses O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
methotrexate B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
central B-DISO-MISC I-ACTI-MISC
nervous I-DISO-MISC B-ANAT-MISC
system I-DISO-MISC B-ANAT-MISC
leukemia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
older O-MISC I-ANAT-MISC
children O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
adults O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
epidural O-MISC I-ACTI-MISC
leakage O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
preservative O-MISC O-MISC
- O-MISC B-DISO-MISC
free O-MISC B-DISO-MISC
methotrexate B-CHED-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
Elliott O-MISC B-CHED-MISC
' O-MISC I-CHED-MISC
s O-MISC I-CHED-MISC
B O-MISC I-CHED-MISC
Solution O-MISC I-CHED-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
intrathecal O-MISC B-CHED-MISC
administration O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Periodic O-MISC B-CHED-MISC
monitoring O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cerebruspinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
methotrexate B-CHED-MISC O-MISC
levels O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
predictive O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
neurotoxicity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Hyperosmolar B-DISO-MISC I-ACTI-MISC
nonketotic I-DISO-MISC B-ANAT-MISC
coma I-DISO-MISC B-ANAT-MISC
precipitated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-ACTI-MISC
nephrogenic B-DISO-MISC I-ACTI-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC I-ANAT-MISC
man O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
history O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
manic B-DISO-MISC I-ACTI-MISC
depression I-DISO-MISC B-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
lithium B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
admitted O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
hyperosmolar B-DISO-MISC I-ACTI-MISC
, I-DISO-MISC B-ACTI-MISC
nonketotic I-DISO-MISC I-ACTI-MISC
coma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
gave O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
polyuria B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
polydipsia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
urinalysis O-MISC I-DISO-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
for O-MISC B-ANAT-MISC
glucose B-CHED-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
recovery O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
hyperglycaemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
he O-MISC B-ACTI-MISC
remained O-MISC B-ACTI-MISC
polyuric B-DISO-MISC O-MISC
despite O-MISC B-ACTI-MISC
normal O-MISC B-OCCU-MISC
blood O-MISC I-OCCU-MISC
glucose B-CHED-MISC I-OCCU-MISC
concentrations O-MISC I-OCCU-MISC
; O-MISC B-ACTI-MISC
water O-MISC B-CONC-MISC
deprivation O-MISC I-CONC-MISC
testing O-MISC I-CONC-MISC
indicated O-MISC I-ACTI-MISC
nephrogenic B-DISO-MISC I-ACTI-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
lithium B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
hypothesize O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
type B-DISO-MISC I-ACTI-MISC
2 I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
polyuria B-DISO-MISC B-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
nephrogenic B-DISO-MISC I-ACTI-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
sufficient O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
precipitate O-MISC B-ACTI-MISC
hyperosmolar O-MISC I-ACTI-MISC
dehydration B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intracoronary O-MISC B-CONC-MISC
infusion O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
on O-MISC B-ACTI-MISC
left O-MISC I-DISO-MISC
ventricular O-MISC I-LIVB-MISC
systolic O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
dogs O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
large O-MISC B-CHED-MISC
amount O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
cocaine B-CHED-MISC O-MISC
causes O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
profound O-MISC B-CHED-MISC
deterioration B-DISO-MISC B-OCCU-MISC
of I-DISO-MISC B-ACTI-MISC
left I-DISO-MISC I-DISO-MISC
ventricular I-DISO-MISC I-LIVB-MISC
( I-DISO-MISC I-LIVB-MISC
LV I-DISO-MISC I-LIVB-MISC
) I-DISO-MISC I-LIVB-MISC
systolic I-DISO-MISC I-LIVB-MISC
function I-DISO-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
end O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
done O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
influence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
intracoronary O-MISC B-CHED-MISC
cocaine B-CHED-MISC O-MISC
concentration O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
systolic O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
diastolic O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
men O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
aged O-MISC I-DISO-MISC
39 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
72 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
referred O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
cardiac O-MISC B-CONC-MISC
catheterization O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
chest B-DISO-MISC I-ACTI-MISC
pain I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
systemic O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressure O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
derivative O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
dP O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
dt O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
volumes O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
ejection O-MISC B-CONC-MISC
fraction O-MISC B-ANAT-MISC
before O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
final O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
minutes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
minute O-MISC B-CHED-MISC
intracoronary O-MISC B-CONC-MISC
infusion O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
hydrochloride I-CHED-MISC B-DISO-MISC
1 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
min O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
variable O-MISC B-ACTI-MISC
changed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
saline O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC B-CHED-MISC
concentration O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
obtained O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
coronary O-MISC I-GENE-MISC
sinus O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SD O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
L O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
magnitude O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
cocaine B-CHED-MISC O-MISC
concentration O-MISC B-CHED-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
abusers O-MISC I-ANAT-MISC
dying O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC I-ACTI-MISC
intoxication O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Cocaine B-CHED-MISC O-MISC
induced O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
change O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
dP O-MISC I-LIVB-MISC
/ O-MISC B-ACTI-MISC
dt O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
end O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
volume O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
mean O-MISC I-ACTI-MISC
arterial O-MISC B-ANAT-MISC
pressures O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
end O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
end O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
systolic O-MISC I-LIVB-MISC
volume O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
LV O-MISC I-DISO-MISC
ejection O-MISC I-LIVB-MISC
fraction O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intracoronary O-MISC B-CHED-MISC
infusion O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
cocaine B-CHED-MISC O-MISC
sufficient O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
amount O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
achieve O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
drug O-MISC B-CHED-MISC
concentration O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
coronary O-MISC I-GENE-MISC
sinus O-MISC B-GEOG-MISC
blood O-MISC B-GEOG-MISC
causes O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
deterioration B-DISO-MISC B-OCCU-MISC
of I-DISO-MISC B-ACTI-MISC
LV I-DISO-MISC I-DISO-MISC
systolic I-DISO-MISC I-LIVB-MISC
and I-DISO-MISC B-ACTI-MISC
diastolic I-DISO-MISC I-DISO-MISC
performance I-DISO-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Ascending O-MISC I-ACTI-MISC
dose O-MISC B-ANAT-MISC
tolerance O-MISC B-ANAT-MISC
study O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
intramuscular O-MISC B-CHED-MISC
carbetocin B-CHED-MISC O-MISC
administered O-MISC B-CONC-MISC
after O-MISC B-ACTI-MISC
normal O-MISC I-ACTI-MISC
vaginal O-MISC B-ANAT-MISC
birth O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
tolerated O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
MTD O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
carbetocin B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
long O-MISC O-MISC
- O-MISC B-DISO-MISC
acting O-MISC B-DISO-MISC
synthetic O-MISC B-DISO-MISC
analogue O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
oxytocin B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
immediately O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
vaginal O-MISC B-CONC-MISC
delivery O-MISC I-CONC-MISC
at O-MISC I-CONC-MISC
term O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

MATERIALS O-MISC B-ACTI-MISC
AND O-MISC B-ACTI-MISC
METHODS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Carbetocin B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
intramuscular O-MISC B-CONC-MISC
injection O-MISC I-CONC-MISC
immediately O-MISC B-CHED-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
birth O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
infant O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
healthy O-MISC B-CHED-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
normal O-MISC I-ACTI-MISC
singleton O-MISC B-ANAT-MISC
pregnancies O-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
delivered O-MISC I-ACTI-MISC
vaginally O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
term O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Dosage O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
75 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
125 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
175 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
microg O-MISC B-CHED-MISC
carbetocin B-CHED-MISC O-MISC
were O-MISC B-ACTI-MISC
assigned O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
blocks O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
continual O-MISC B-CONC-MISC
reassessment O-MISC I-CONC-MISC
method O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
CRM O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
All O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
groups O-MISC B-CHED-MISC
consisted O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
except O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Recorded O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
limiting O-MISC I-CHED-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
hyper B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
or I-DISO-MISC B-ACTI-MISC
hypotension I-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
severe O-MISC I-ACTI-MISC
abdominal B-DISO-MISC B-ANAT-MISC
pain I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
vomiting B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
retained B-DISO-MISC B-CHED-MISC
placenta I-DISO-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Serious O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
blood B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
1000 O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
manual O-MISC B-CHED-MISC
placenta O-MISC I-GENE-MISC
removal O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
oxytocics O-MISC O-MISC
administration O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
blood O-MISC B-CONC-MISC
transfusion O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Maximum O-MISC B-CHED-MISC
blood B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
greatest O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
upper O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
levels O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
lowest O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
70 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
125 O-MISC B-ACTI-MISC
microg O-MISC B-CHED-MISC
dose O-MISC B-CHED-MISC
range O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
blood B-DISO-MISC I-ACTI-MISC
loss I-DISO-MISC B-ANAT-MISC
> O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
1000 O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
microg O-MISC I-ANAT-MISC
group O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
administration O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
oxytocics O-MISC O-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
blood O-MISC B-CONC-MISC
transfusion O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
groups O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
retained O-MISC B-CHED-MISC
placentae O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
found O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
MTD O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
calculated O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
carbetocin B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Heparin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
paradoxical O-MISC I-ACTI-MISC
thromboembolism B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
anticoagulant O-MISC O-MISC
drugs O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
development O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
remains O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
drug O-MISC O-MISC
of O-MISC B-ACTI-MISC
choice O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
anticoagulation O-MISC B-CONC-MISC
needs O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC O-MISC
are O-MISC B-ACTI-MISC
meritorious O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
side O-MISC I-ACTI-MISC
effects O-MISC B-ANAT-MISC
do O-MISC B-ACTI-MISC
exist O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Important O-MISC B-ACTI-MISC
untoward O-MISC B-PHEN-MISC
effects O-MISC I-DEVI-MISC
of O-MISC B-ACTI-MISC
heparin B-CHED-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
including O-MISC B-ACTI-MISC
heparin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
induced O-MISC B-ANAT-MISC
thrombocytopenia B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
heparin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
associated O-MISC B-ANAT-MISC
osteoporosis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
eosinophilia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
skin B-DISO-MISC I-ACTI-MISC
reactions I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
allergic B-DISO-MISC I-ACTI-MISC
reactions I-DISO-MISC B-ANAT-MISC
other O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
thrombocytopenia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
alopecia B-DISO-MISC I-ACTI-MISC
will O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
discussed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
article O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Nonopaque O-MISC B-ACTI-MISC
crystal O-MISC O-MISC
deposition O-MISC B-CHED-MISC
causing O-MISC B-ACTI-MISC
ureteric B-DISO-MISC I-ACTI-MISC
obstruction I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
HIV O-MISC I-ACTI-MISC
undergoing O-MISC B-ACTI-MISC
indinavir B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
unique O-MISC B-CHED-MISC
CT O-MISC B-CONC-MISC
features O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ureteric B-DISO-MISC I-GENE-MISC
calculi I-DISO-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
infected I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
receiving O-MISC B-CHED-MISC
indinavir B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
commonly O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
HIV O-MISC O-MISC
protease O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
urolithiasis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
Ureteric B-DISO-MISC I-ACTI-MISC
obstruction I-DISO-MISC B-ANAT-MISC
caused O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
precipitated O-MISC B-CHED-MISC
indinavir B-CHED-MISC O-MISC
crystals O-MISC O-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
difficult O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
diagnose O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
unenhanced O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
calculi O-MISC I-GENE-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
opaque O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
secondary O-MISC B-ACTI-MISC
signs O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
obstruction O-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
absent O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
minimal O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
sought O-MISC B-ACTI-MISC
carefully O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Images O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
contrast O-MISC O-MISC
material O-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
enable O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
ureteric B-DISO-MISC I-GENE-MISC
stones I-DISO-MISC B-GEOG-MISC
or I-DISO-MISC B-ACTI-MISC
obstruction I-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
HIV B-DISO-MISC I-ACTI-MISC
infection I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
receive O-MISC B-ACTI-MISC
indinavir B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Ischemic B-DISO-MISC I-ACTI-MISC
colitis I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
sumatriptan B-CHED-MISC O-MISC
use O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Sumatriptan B-CHED-MISC O-MISC
succinate I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
serotonin B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
5 B-CHED-MISC B-DISO-MISC
- I-CHED-MISC B-DISO-MISC
hydroxytryptamine I-CHED-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
agonist O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
antimigraine O-MISC O-MISC
drug O-MISC B-DISO-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
act O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
selectively O-MISC B-ACTI-MISC
constricting O-MISC B-CHED-MISC
intracranial O-MISC I-GENE-MISC
arteries O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
vasopressor O-MISC I-GENE-MISC
responses O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
distinct O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cranial O-MISC B-CHED-MISC
circulation O-MISC I-DISO-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
pulmonary O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
coronary O-MISC I-DISO-MISC
circulations O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Cases O-MISC B-CHED-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
published O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
coronary B-DISO-MISC I-ACTI-MISC
vasospasm I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
ischemia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-ACTI-MISC
infarction I-DISO-MISC B-ANAT-MISC
occurring O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
sumatriptan B-CHED-MISC O-MISC
use O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
serious O-MISC B-CHED-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ischemic B-DISO-MISC I-ACTI-MISC
colitis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
migraine B-DISO-MISC I-ACTI-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
sumatriptan B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Pallidotomy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gamma O-MISC B-CONC-MISC
knife O-MISC I-CONC-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
positive O-MISC I-DISO-MISC
experience O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

51 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
medically O-MISC B-CHED-MISC
refractory O-MISC I-CHED-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
underwent O-MISC B-ACTI-MISC
stereotactic O-MISC B-CONC-MISC
posteromedial O-MISC I-CONC-MISC
pallidotomy O-MISC I-CONC-MISC
between O-MISC B-ACTI-MISC
August O-MISC B-ACTI-MISC
1993 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
February O-MISC B-ACTI-MISC
1997 O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
bradykinesia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
rigidity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
L B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
DOPA I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pallidotomies O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Leksell O-MISC B-CONC-MISC
Gamma O-MISC I-CONC-MISC
Knife O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
standard O-MISC B-CHED-MISC
radiofrequency O-MISC B-CONC-MISC
( O-MISC I-CONC-MISC
RF O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
method O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CONC-MISC
assessment O-MISC I-CONC-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
blinded O-MISC B-CONC-MISC
ratings O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
Unified O-MISC B-CHED-MISC
Parkinson B-DISO-MISC I-CHED-MISC
' I-DISO-MISC I-CHED-MISC
s I-DISO-MISC I-CHED-MISC
Disease I-DISO-MISC I-CHED-MISC
Rating O-MISC I-CHED-MISC
Scale O-MISC I-CHED-MISC
( O-MISC I-CHED-MISC
UPDRS O-MISC I-CHED-MISC
) O-MISC I-CHED-MISC
scores O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
pre O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
postoperatively O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Mean O-MISC B-CONC-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
time O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
6 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
except O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

85 O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
dyskinesias B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
relieved O-MISC B-CONC-MISC
of O-MISC I-CONC-MISC
symptoms O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
regardless O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pallidotomies O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Gamma O-MISC B-CONC-MISC
Knife O-MISC I-CONC-MISC
or O-MISC B-ACTI-MISC
radiofrequency O-MISC B-CONC-MISC
methods O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

About O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
Gamma O-MISC B-OBJC-MISC
Knife O-MISC I-OBJC-MISC
and O-MISC B-ACTI-MISC
radiofrequency O-MISC B-CONC-MISC
groups O-MISC B-CHED-MISC
showed O-MISC B-ACTI-MISC
improvements O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
bradykinesia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
rigidity B-DISO-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
group O-MISC I-ANAT-MISC
neither O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Gamma O-MISC B-OBJC-MISC
Knife O-MISC I-OBJC-MISC
nor O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
radiofrequency O-MISC B-CONC-MISC
group O-MISC B-UnknownType-MISC
showed O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
improvements O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
UPDRS O-MISC B-CHED-MISC
scores O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Gamma O-MISC B-PHEN-MISC
Knife O-MISC B-UnknownType-MISC
group O-MISC B-UnknownType-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
homonymous B-DISO-MISC B-ACTI-MISC
hemianopsia I-DISO-MISC I-ACTI-MISC
9 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
following O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
radiofrequency O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
became O-MISC B-ACTI-MISC
transiently O-MISC B-ACTI-MISC
confused O-MISC B-ACTI-MISC
postoperatively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
complications O-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Gamma O-MISC B-CONC-MISC
Knife O-MISC I-CONC-MISC
pallidotomy O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
effective O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
radiofrequency O-MISC B-CONC-MISC
pallidotomy O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
controlling O-MISC B-OCCU-MISC
certain O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
Parkinson B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
s I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
practical O-MISC B-CHED-MISC
technique O-MISC B-CHED-MISC
available O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
take O-MISC B-ACTI-MISC
anticoagulants O-MISC O-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
bleeding B-DISO-MISC I-ACTI-MISC
diatheses O-MISC B-OCCU-MISC
or O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
systemic O-MISC B-CHED-MISC
medical O-MISC B-CHED-MISC
illnesses O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
viable O-MISC B-ACTI-MISC
option O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Centrally O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
cardiovascular O-MISC I-GENE-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
intracisternal O-MISC B-CHED-MISC
application O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
carbachol B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
response O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intracisternal O-MISC B-CHED-MISC
( O-MISC I-CHED-MISC
i O-MISC I-CHED-MISC
. O-MISC I-CHED-MISC
c O-MISC I-CHED-MISC
. O-MISC I-CHED-MISC
) O-MISC I-CHED-MISC
injection O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
carbachol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mug O-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
anesthetized O-MISC I-ACTI-MISC
rats O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
analyzed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
response O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intravenous O-MISC B-CONC-MISC
( O-MISC I-CONC-MISC
i O-MISC I-CONC-MISC
. O-MISC I-CONC-MISC
v O-MISC I-CONC-MISC
. O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
injection O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
guanethidine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
hexamethonium B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
phentolamine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
conversely O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
potentiated O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
desmethylimipramine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
propranolol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
v O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
selectively O-MISC B-ACTI-MISC
inhibited O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
enlargement B-DISO-MISC B-DEVI-MISC
of I-DISO-MISC B-ACTI-MISC
pulse I-DISO-MISC I-DISO-MISC
pressure I-DISO-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tachycardia B-DISO-MISC I-ACTI-MISC
following O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
carbachol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mug O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
hand O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
i O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
c O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC
carbachol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mug O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
completely O-MISC B-ACTI-MISC
blocked O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
i O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
atropine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
mug O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
hexamethonium B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
mug O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
i O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
c O-MISC I-PHEN-MISC
. O-MISC I-PHEN-MISC
chlorpromazine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
mug O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
potentiated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
i O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
c O-MISC I-PHEN-MISC
. O-MISC I-PHEN-MISC
desmethylimipramine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
mug O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
response O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
i O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
c O-MISC I-PHEN-MISC
. O-MISC I-PHEN-MISC
carbachol B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
mug O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
remained O-MISC B-ACTI-MISC
unchanged O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
sectioning O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
bilateral O-MISC B-CHED-MISC
cervical O-MISC I-GENE-MISC
vagal O-MISC B-GEOG-MISC
nerves O-MISC B-GEOG-MISC
but O-MISC B-ACTI-MISC
disappeared O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
sectioning O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
spinal O-MISC I-GENE-MISC
cord O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
C7 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
C8 O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

From O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
above O-MISC B-ACTI-MISC
result O-MISC B-CHED-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pressor O-MISC O-MISC
response O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
c O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
carbachol B-CHED-MISC O-MISC
ortral O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
peripheral O-MISC B-CHED-MISC
adrenergic O-MISC I-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sympathetic O-MISC I-GENE-MISC
trunk O-MISC B-GEOG-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
main O-MISC B-CHED-MISC
pathway O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
methylphenidate B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
probably O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
methylphenidate B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

She O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
defects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
supratentorial O-MISC B-CHED-MISC
brain O-MISC I-GENE-MISC
including O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basal O-MISC I-GENE-MISC
ganglia O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
striatum O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
multicystic B-DISO-MISC I-ACTI-MISC
encephalomalacia I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
perinatal O-MISC B-CHED-MISC
hypoxic B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
ischemic I-DISO-MISC B-ANAT-MISC
encephalopathy I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
considered O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
predisposing O-MISC B-CHED-MISC
factor O-MISC I-CHED-MISC
causing O-MISC B-ACTI-MISC
neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
dopaminergic O-MISC I-DISO-MISC
blockade O-MISC I-LIVB-MISC
mechanism O-MISC I-LIVB-MISC
generally O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
accepted O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
syndrome O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
methylphenidate B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
agonist O-MISC B-DISO-MISC
via O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
uptake O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
dopamine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
dopaminergic O-MISC I-GENE-MISC
systems O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brainstem O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
mainly O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
midbrain O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
spinal O-MISC I-GENE-MISC
cord O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
unlikely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
participate O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
this O-MISC B-ACTI-MISC
syndrome O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
relative O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminobutyric I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
ergic O-MISC I-ACTI-MISC
deficiency O-MISC B-ANAT-MISC
might O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
diazepam B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gamma B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
aminobutyric I-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
mimetic O-MISC O-MISC
agent O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
strikingly O-MISC B-ACTI-MISC
effective O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
neuroleptic B-DISO-MISC I-ACTI-MISC
malignant I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
probably O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
methylphenidate B-CHED-MISC O-MISC
. O-MISC B-ACTI-MISC

Differential O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
17alpha B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
ethinylestradiol I-CHED-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neutral O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
acidic O-MISC I-DISO-MISC
pathways O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
bile B-CHED-MISC I-DISO-MISC
salt I-CHED-MISC I-LIVB-MISC
synthesis O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
17alpha B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
ethinylestradiol I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
EE B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neutral O-MISC I-DISO-MISC
and O-MISC I-LIVB-MISC
acidic O-MISC I-LIVB-MISC
biosynthetic O-MISC I-LIVB-MISC
pathways O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
bile B-CHED-MISC I-DISO-MISC
salt I-CHED-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
BS B-CHED-MISC O-MISC
) O-MISC I-LIVB-MISC
synthesis O-MISC B-DEVI-MISC
were O-MISC B-ACTI-MISC
evaluated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
enterohepatic O-MISC I-GENE-MISC
circulation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
bile O-MISC I-DISO-MISC
diversion O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
BS B-CHED-MISC O-MISC
synthesis O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
purpose O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
bile B-CHED-MISC O-MISC
salt I-CHED-MISC B-DISO-MISC
pool O-MISC B-DISO-MISC
composition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
synthesis O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
individual O-MISC B-ACTI-MISC
BS B-CHED-MISC I-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
activities O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
expression O-MISC B-CHED-MISC
levels O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
cholesterol B-CHED-MISC O-MISC
7alpha O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
hydroxylase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CYP7A O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
sterol B-CHED-MISC O-MISC
27 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
hydroxylase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CYP27 O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
enzymes O-MISC O-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
BS B-CHED-MISC O-MISC
synthesis O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
EE B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
kg O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
days O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
vehicle O-MISC O-MISC
. O-MISC B-ACTI-MISC

BS B-CHED-MISC O-MISC
pool O-MISC B-CHED-MISC
size O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
BS B-CHED-MISC O-MISC
synthesis O-MISC B-DEVI-MISC
was O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
EE B-CHED-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Synthesis O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
cholate B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
EE B-CHED-MISC B-OCCU-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
chenodeoxycholate B-CHED-MISC O-MISC
was O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
Delta22 O-MISC O-MISC
- O-MISC B-ACTI-MISC
isomer O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
muricholate O-MISC B-DISO-MISC
contributed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pool O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
EE B-CHED-MISC B-OCCU-MISC
- O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
bile O-MISC I-GENE-MISC
after O-MISC B-ACTI-MISC
exhaustion O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pool O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
clear O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
BS B-CHED-MISC O-MISC
synthesis O-MISC B-DEVI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
bile O-MISC I-GENE-MISC
- O-MISC B-ANAT-MISC
diverted O-MISC B-ANAT-MISC
rats O-MISC I-ANAT-MISC
treated O-MISC B-CONC-MISC
with O-MISC I-CONC-MISC
EE B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
biliary O-MISC I-GENE-MISC
BS B-CHED-MISC O-MISC
composition O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
minimally O-MISC B-CHED-MISC
affected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Activity O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
CYP7A O-MISC O-MISC
was O-MISC B-ACTI-MISC
decreased O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
EE B-CHED-MISC O-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
intact O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
bile O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
diverted O-MISC B-ANAT-MISC
rats O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CYP27 O-MISC B-LIVB-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hepatic O-MISC I-GENE-MISC
mRNA O-MISC O-MISC
levels O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CYP7A O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
EE B-CHED-MISC B-OCCU-MISC
in O-MISC B-ACTI-MISC
bile O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
diverted O-MISC B-ANAT-MISC
rats O-MISC I-ANAT-MISC
only O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
CYP27 O-MISC B-LIVB-MISC
mRNA O-MISC O-MISC
levels O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
EE B-CHED-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mRNA O-MISC O-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sterol B-CHED-MISC O-MISC
12alpha O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
hydroxylase O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
lithocholate O-MISC O-MISC
6beta O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
hydroxylase O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
bile O-MISC I-DISO-MISC
diversion O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
suppressed O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
EE B-CHED-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
shows O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
17alpha B-CHED-MISC O-MISC
- I-CHED-MISC B-DISO-MISC
ethinylestradiol I-CHED-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
EE B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
intrahepatic B-DISO-MISC I-ACTI-MISC
cholestasis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
rats O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
selective O-MISC B-ACTI-MISC
inhibition O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
neutral O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
of O-MISC I-LIVB-MISC
bile B-CHED-MISC I-LIVB-MISC
salt I-CHED-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
BS B-CHED-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
synthesis O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Simultaneous O-MISC B-CHED-MISC
impairment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
enzymes O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BS B-CHED-MISC I-GENE-MISC
biosynthetic O-MISC I-DISO-MISC
pathways O-MISC I-LIVB-MISC
may O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
EE B-CHED-MISC B-OCCU-MISC
on O-MISC B-ACTI-MISC
BS B-CHED-MISC I-GENE-MISC
synthesis O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Glibenclamide B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
produced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
helodermin B-CHED-MISC B-CONC-MISC
assessed O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
helodermin B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
basic O-MISC B-ACTI-MISC
35 O-MISC O-MISC
- O-MISC B-DISO-MISC
amino B-CHED-MISC B-DISO-MISC
acid I-CHED-MISC B-DISO-MISC
peptide O-MISC B-DISO-MISC
isolated O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
venom O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lizard O-MISC I-GENE-MISC
salivary O-MISC I-GENE-MISC
gland O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
arterial O-MISC I-DISO-MISC
blood O-MISC I-LIVB-MISC
pressure O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
heart O-MISC I-DISO-MISC
rate O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
focusing O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
activation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
ATP B-CHED-MISC O-MISC
sensitive O-MISC B-CHED-MISC
K B-CHED-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
ATP B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
responses O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
vasoactive O-MISC O-MISC
intestinal O-MISC B-DISO-MISC
polypeptide O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
VIP O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Helodermin B-CHED-MISC O-MISC
produced O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dose O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dependent O-MISC I-CHED-MISC
manner O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
approximately O-MISC B-CHED-MISC
similar O-MISC B-CHED-MISC
potency O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
VIP O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Hypotension B-DISO-MISC I-ACTI-MISC
induced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
peptides O-MISC O-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
glibenclamide B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
abolished O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
levcromakalim B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
decrease O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
arterial O-MISC B-ANAT-MISC
blood O-MISC B-ANAT-MISC
pressure O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Oxyhemoglobin O-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
helodermin B-CHED-MISC O-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
shortened O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
duration O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
acetylcholine B-CHED-MISC O-MISC
( O-MISC B-ACTI-MISC
ACh B-CHED-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
produced O-MISC B-CHED-MISC
hypotension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
helodermin B-CHED-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
produced O-MISC B-ANAT-MISC
hypotension B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
partly O-MISC B-ACTI-MISC
attributable O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
glibenclamide B-CHED-MISC O-MISC
- O-MISC B-DISO-MISC
sensitive O-MISC B-DISO-MISC
K B-CHED-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
K B-CHED-MISC O-MISC
( O-MISC B-DISO-MISC
ATP B-CHED-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
presumably O-MISC B-ACTI-MISC
exist O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
arterial O-MISC I-GENE-MISC
smooth O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

EDRF O-MISC O-MISC
( O-MISC B-ACTI-MISC
endothelium O-MISC I-GENE-MISC
- O-MISC B-DISO-MISC
derived O-MISC B-DISO-MISC
relaxing O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
nitric B-CHED-MISC O-MISC
oxide I-CHED-MISC B-DISO-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
seem O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
play O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
role O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
peptide O-MISC O-MISC
- O-MISC B-ACTI-MISC
produced O-MISC B-ACTI-MISC
hypotension B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
efficacy O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
event O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
sustained O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
release O-MISC I-CHED-MISC
tablets O-MISC O-MISC
for O-MISC B-ACTI-MISC
cyclosporin B-CHED-MISC O-MISC
A I-CHED-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
hypertension B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
psoriasis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Thirteen O-MISC B-ACTI-MISC
psoriatic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hypertension B-DISO-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cyclosporin B-CHED-MISC O-MISC
A I-CHED-MISC B-DISO-MISC
therapy O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
treated O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
calcium B-CHED-MISC O-MISC
channel O-MISC B-DISO-MISC
blocker O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
release O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
antihypertensive O-MISC I-ACTI-MISC
effects O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
. O-MISC B-ACTI-MISC

Seven O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
exhibited O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
subclinical O-MISC I-ACTI-MISC
hypertensive B-DISO-MISC B-ANAT-MISC
state O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
cyclosporin B-CHED-MISC O-MISC
A I-CHED-MISC B-DISO-MISC
therapy O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
systolic O-MISC I-DISO-MISC
and O-MISC I-LIVB-MISC
diastolic O-MISC I-LIVB-MISC
blood O-MISC I-LIVB-MISC
pressures O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
significantly O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
weeks O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
therapy O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
blood O-MISC I-DISO-MISC
pressure O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
maintained O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
range O-MISC B-CHED-MISC
thereafter O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
adverse O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
during O-MISC B-ACTI-MISC
combined O-MISC B-ACTI-MISC
therapy O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
cyclosporin B-CHED-MISC O-MISC
A I-CHED-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
included O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increase O-MISC I-ACTI-MISC
in O-MISC B-ANAT-MISC
blood B-CHED-MISC B-ANAT-MISC
urea I-CHED-MISC I-CONC-MISC
nitrogen I-CHED-MISC I-CONC-MISC
levels O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
gingival B-DISO-MISC I-ACTI-MISC
hyperplasia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
findings O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
sustained O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
release O-MISC B-ACTI-MISC
nifedipine B-CHED-MISC O-MISC
is O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
hypertensive B-DISO-MISC I-ACTI-MISC
psoriatic B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
under O-MISC B-ACTI-MISC
long O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
term O-MISC I-CHED-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
cyclosporin B-CHED-MISC O-MISC
A I-CHED-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
monitored O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
gingival B-DISO-MISC I-ACTI-MISC
hyperplasia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Clustering O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ataxia B-DISO-MISC B-LIVB-MISC
- I-DISO-MISC I-PROC-MISC
telangiectasia I-DISO-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sporadic B-DISO-MISC B-CHED-MISC
T I-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
leukaemia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
recessive B-DISO-MISC I-ACTI-MISC
multi I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
system I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATM O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
at O-MISC B-ACTI-MISC
11q22 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
q23 O-MISC B-GEOG-MISC
( O-MISC B-GEOG-MISC
ref O-MISC B-GEOG-MISC
. O-MISC B-GEOG-MISC
3 O-MISC B-GEOG-MISC
) O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
cancer B-DISO-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
especially O-MISC B-ACTI-MISC
lymphoid B-DISO-MISC I-ACTI-MISC
neoplasias I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
substantially O-MISC B-ACTI-MISC
elevated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
long O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
chromosomal O-MISC I-ACTI-MISC
instability O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
analysing O-MISC B-CONC-MISC
tumour B-DISO-MISC O-MISC
DNA O-MISC B-DISO-MISC
from O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
sporadic B-DISO-MISC I-ACTI-MISC
T I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
prolymphocytic I-DISO-MISC B-ANAT-MISC
leukaemia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
T B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
PLL I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
clonal B-DISO-MISC I-ACTI-MISC
malignancy I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
similarities O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mature B-DISO-MISC B-CHED-MISC
T I-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
leukaemia I-DISO-MISC B-ANAT-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
A B-DISO-MISC I-GENE-MISC
- I-DISO-MISC B-GEOG-MISC
T I-DISO-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
ATM O-MISC I-ACTI-MISC
mutations O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
T B-DISO-MISC B-CONC-MISC
- I-DISO-MISC I-CONC-MISC
PLL I-DISO-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATM O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
pattern O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
A B-DISO-MISC I-GENE-MISC
- I-DISO-MISC B-GEOG-MISC
T I-DISO-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
frequent O-MISC B-ACTI-MISC
nucleotide O-MISC O-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
leukaemia B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
clustered O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
region O-MISC B-ACTI-MISC
corresponding O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kinase O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
conserved O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
ATM O-MISC O-MISC
- O-MISC B-DISO-MISC
related O-MISC B-DISO-MISC
proteins O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
yeast O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
Drosophila O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
amino O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
acid O-MISC I-LIVB-MISC
substitutions O-MISC I-LIVB-MISC
are O-MISC B-ACTI-MISC
predicted O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
interfere O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
ATP O-MISC I-DISO-MISC
binding O-MISC I-LIVB-MISC
or O-MISC B-ACTI-MISC
substrate O-MISC B-GENE-MISC
recognition O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
seventeen O-MISC B-ACTI-MISC
mutated O-MISC I-DISO-MISC
T B-DISO-MISC B-CONC-MISC
- I-DISO-MISC B-GEOG-MISC
PLL I-DISO-MISC B-GEOG-MISC
samples O-MISC B-GENE-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
A B-DISO-MISC B-LIVB-MISC
- I-DISO-MISC I-PROC-MISC
T I-DISO-MISC I-PROC-MISC
allele O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
detected O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
p53 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
tumour B-DISO-MISC O-MISC
suppressor O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
leukaemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Occasional O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
ATM O-MISC O-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
tumour B-DISO-MISC O-MISC
DNA O-MISC B-DISO-MISC
from O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
B B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
cell I-DISO-MISC B-ANAT-MISC
non I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
Hodgkins I-DISO-MISC B-ANAT-MISC
lymphomas I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
B B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
NHL I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
B B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
NHL I-DISO-MISC B-ANAT-MISC
cell O-MISC I-GENE-MISC
line O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
proportion O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
loss O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
function O-MISC B-ANAT-MISC
mutations O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
copy O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ATM O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mutated O-MISC I-ACTI-MISC
tumours B-DISO-MISC B-ANAT-MISC
establishes O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
inactivation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
sporadic B-DISO-MISC B-CHED-MISC
T I-DISO-MISC B-CONC-MISC
- I-DISO-MISC B-DISO-MISC
PLL I-DISO-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
ATM O-MISC O-MISC
acts O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tumour B-DISO-MISC O-MISC
suppressor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
constitutional O-MISC B-CHED-MISC
DNA O-MISC O-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
putative O-MISC B-ACTI-MISC
hereditary O-MISC B-CHED-MISC
predisposition O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
T B-DISO-MISC B-CONC-MISC
- I-DISO-MISC I-CONC-MISC
PLL I-DISO-MISC I-CONC-MISC
will O-MISC B-ACTI-MISC
require O-MISC B-CHED-MISC
further O-MISC B-ACTI-MISC
investigation O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Myotonic B-DISO-MISC O-MISC
dystrophy I-DISO-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
kinase O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
modulation O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Ca2 O-MISC I-DISO-MISC
+ O-MISC I-LIVB-MISC
homeostasis O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
skeletal O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
prevalent O-MISC B-ACTI-MISC
muscular B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
in O-MISC B-ANAT-MISC
adults O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
( O-MISC I-ACTI-MISC
CTG O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
n O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
repeat O-MISC B-ANAT-MISC
expansion O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
encoding O-MISC I-PROC-MISC
a O-MISC I-PROC-MISC
protein O-MISC B-LIVB-MISC
kinase O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
DM B-DISO-MISC O-MISC
protein O-MISC B-DISO-MISC
kinase O-MISC B-DISO-MISC
; O-MISC B-ACTI-MISC
DMPK O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
involves O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
cytoarchitecture O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
ion O-MISC I-DISO-MISC
homeostasis O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
obtain O-MISC B-ACTI-MISC
clues O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
biological O-MISC B-CHED-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
DMPK O-MISC O-MISC
in O-MISC B-ACTI-MISC
cellular O-MISC I-DISO-MISC
ion O-MISC I-LIVB-MISC
homeostasis O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
resting O-MISC I-ACTI-MISC
[ O-MISC I-LIVB-MISC
Ca2 O-MISC I-LIVB-MISC
+ O-MISC I-LIVB-MISC
] O-MISC I-LIVB-MISC
i O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
amplitude O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
shape O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
depolarization O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
Ca2 O-MISC O-MISC
+ O-MISC B-DISO-MISC
transients O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
content O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ATP O-MISC O-MISC
- O-MISC B-ACTI-MISC
driven O-MISC B-ACTI-MISC
ion O-MISC O-MISC
pumps O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
cultured O-MISC I-GENE-MISC
skeletal O-MISC B-GEOG-MISC
muscle O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
DMPK O-MISC B-LIVB-MISC
[ O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
/ O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
] O-MISC I-PROC-MISC
knockout O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
- O-MISC B-ACTI-MISC
differentiated O-MISC B-CHED-MISC
DMPK O-MISC O-MISC
[ O-MISC B-DISO-MISC
- O-MISC I-OCCU-MISC
/ O-MISC I-OCCU-MISC
- O-MISC B-DISO-MISC
] O-MISC B-DISO-MISC
myotubes O-MISC O-MISC
exhibit O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
resting O-MISC I-ACTI-MISC
[ O-MISC B-ANAT-MISC
Ca2 O-MISC I-LIVB-MISC
+ O-MISC I-LIVB-MISC
] O-MISC B-ANAT-MISC
i O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
do O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
myotubes O-MISC O-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
altered O-MISC B-CHED-MISC
open O-MISC B-ACTI-MISC
probability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
voltage O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
dependent O-MISC I-LIVB-MISC
l O-MISC O-MISC
- O-MISC B-DISO-MISC
type O-MISC B-DISO-MISC
Ca2 O-MISC O-MISC
+ O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Na O-MISC O-MISC
+ O-MISC B-DISO-MISC
channels O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
myotubes O-MISC I-GENE-MISC
exhibit O-MISC B-ACTI-MISC
smaller O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
slower O-MISC B-ACTI-MISC
Ca2 O-MISC I-DISO-MISC
+ O-MISC I-LIVB-MISC
responses O-MISC I-LIVB-MISC
upon O-MISC B-ACTI-MISC
triggering O-MISC B-CHED-MISC
by O-MISC I-CHED-MISC
acetylcholine O-MISC O-MISC
or O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
external O-MISC B-CHED-MISC
K O-MISC O-MISC
+ O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
Ca2 O-MISC O-MISC
+ O-MISC B-DISO-MISC
transients O-MISC B-CHED-MISC
partially O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
influx O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
extracellular O-MISC I-GENE-MISC
Ca2 O-MISC O-MISC
+ O-MISC B-DISO-MISC
through O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
l O-MISC O-MISC
- O-MISC B-DISO-MISC
type O-MISC B-DISO-MISC
Ca2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
channel O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
content O-MISC B-ACTI-MISC
nor O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
Na O-MISC O-MISC
+ O-MISC B-DISO-MISC
/ O-MISC B-DISO-MISC
K O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
ATPase O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
sarcoplasmic O-MISC O-MISC
reticulum O-MISC B-DISO-MISC
Ca2 O-MISC B-DISO-MISC
+ O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
ATPase O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
DMPK O-MISC O-MISC
absence O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
DMPK O-MISC O-MISC
is O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
modulating O-MISC B-PHEN-MISC
the O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
events O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
excitation O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
contraction O-MISC I-LIVB-MISC
coupling O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
skeletal O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Constitutional O-MISC B-CHED-MISC
RB1 O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
isolated O-MISC B-ACTI-MISC
unilateral B-DISO-MISC B-CHED-MISC
retinoblastoma I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
isolated O-MISC B-ACTI-MISC
unilateral B-DISO-MISC B-CHED-MISC
retinoblastoma I-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
development O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
initiated O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
inactivation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
alleles O-MISC B-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RB1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
can O-MISC B-ACTI-MISC
transmit O-MISC B-CHED-MISC
retinoblastoma B-DISO-MISC I-ACTI-MISC
predisposition O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
offspring O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
nature O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
constitutional O-MISC B-CHED-MISC
RB1 O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
isolated O-MISC B-ACTI-MISC
unilateral B-DISO-MISC B-CHED-MISC
retinoblastoma I-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
DNA O-MISC O-MISC
from O-MISC B-ACTI-MISC
peripheral O-MISC I-GENE-MISC
blood O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
tumors B-DISO-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
54 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
71 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
informative O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
loss O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
constitutional O-MISC I-DISO-MISC
heterozygosity O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
LOH O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
intragenic O-MISC B-LIVB-MISC
loci O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
uninformative O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
constitutional O-MISC I-ACTI-MISC
deletions O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
39 O-MISC B-ACTI-MISC
randomly O-MISC B-ACTI-MISC
selected O-MISC B-ACTI-MISC
tumors B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
SSCP O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
hetero O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
duplex O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
sequencing O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Southern O-MISC B-CONC-MISC
blot O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
91 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
tumors B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
LOH O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
tumors B-DISO-MISC I-ACTI-MISC
without O-MISC B-ACTI-MISC
LOH O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
56 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tumors B-DISO-MISC I-ACTI-MISC
without O-MISC B-ACTI-MISC
LOH O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
tumors B-DISO-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Thirty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
34 O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
structural O-MISC I-DISO-MISC
alterations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
hypermethylation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
tumors O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
detected O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
corresponding O-MISC B-ACTI-MISC
peripheral O-MISC I-GENE-MISC
blood O-MISC B-GEOG-MISC
DNA O-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
constitutional O-MISC B-CHED-MISC
DNA O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
reduced O-MISC B-CHED-MISC
expressivity O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
constitutional O-MISC B-CHED-MISC
mutation O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
age O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
somatic O-MISC I-ACTI-MISC
mosaicism O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
molecular O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
and O-MISC B-ACTI-MISC
RNA O-MISC O-MISC
from O-MISC B-ACTI-MISC
peripheral O-MISC I-GENE-MISC
blood O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
without O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
detectable O-MISC I-DISO-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
peripheral O-MISC I-GENE-MISC
blood O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
mosaicism O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
multifocal O-MISC I-ACTI-MISC
tumors B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
bilateral B-DISO-MISC I-ACTI-MISC
retinoblastoma I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
conclusion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
emphasize O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
manifestation O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
transmissibility O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
retinoblastoma B-DISO-MISC I-ACTI-MISC
depend O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nature O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
types O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
that O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hereditary B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
fifth I-DISO-MISC B-ACTI-MISC
component I-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
complement I-DISO-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

I O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
immunochemical O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
family O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
kindred O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
fifth I-DISO-MISC B-ACTI-MISC
component I-DISO-MISC I-GENE-MISC
of I-DISO-MISC B-GEOG-MISC
complement I-DISO-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
C5 O-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
proband O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
black O-MISC I-ANAT-MISC
female O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
systemic B-DISO-MISC I-ACTI-MISC
lupus I-DISO-MISC B-ANAT-MISC
erythematosus I-DISO-MISC B-ANAT-MISC
since O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
11 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
lacked O-MISC B-CHED-MISC
serum O-MISC B-CONC-MISC
hemolytic O-MISC I-CONC-MISC
complement O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
remission O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

C5 O-MISC O-MISC
was O-MISC B-ACTI-MISC
undetectable O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
by O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
immunodiffusion O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
hemolytic O-MISC B-CONC-MISC
assays O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Other O-MISC B-ACTI-MISC
complement O-MISC O-MISC
components O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
remission O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
lupus O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
C1 O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
C4 O-MISC O-MISC
, O-MISC B-ACTI-MISC
C2 O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
C3 O-MISC O-MISC
levels O-MISC B-CHED-MISC
fell O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
exacerbations O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
younger O-MISC B-CHED-MISC
half O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
sister O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
immunochemically O-MISC B-CHED-MISC
detectable O-MISC I-DISO-MISC
C5 O-MISC O-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
hemolytic O-MISC B-CONC-MISC
assay O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
exhibited O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
serum O-MISC I-GENE-MISC
C5 O-MISC B-CONC-MISC
level O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
concentrations O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
complement O-MISC O-MISC
components O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

C5 O-MISC O-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
members O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
approximately O-MISC B-CHED-MISC
half O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
normal O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
consistent O-MISC B-ACTI-MISC
with O-MISC I-CHED-MISC
autosomal O-MISC I-DISO-MISC
codominant O-MISC I-LIVB-MISC
inheritance O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
determining O-MISC B-ACTI-MISC
C5 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Normal O-MISC B-ACTI-MISC
hemolytic O-MISC I-ACTI-MISC
titers O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
restored O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
C5 B-DISO-MISC B-LIVB-MISC
- I-DISO-MISC I-PROC-MISC
deficient I-DISO-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
C5D B-DISO-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
sera O-MISC I-GENE-MISC
by O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
purified O-MISC B-CHED-MISC
human O-MISC O-MISC
C5 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
C5 O-MISC O-MISC
titrations O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
amounts O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
C5 O-MISC O-MISC
were O-MISC B-ACTI-MISC
assayed O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
dilutions O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
C5D B-DISO-MISC O-MISC
serum O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
curving O-MISC B-CHED-MISC
rather O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
linear O-MISC B-CHED-MISC
dose O-MISC I-CHED-MISC
- O-MISC I-CHED-MISC
response O-MISC I-CHED-MISC
plots O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
consistently O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
inhibitory O-MISC I-DISO-MISC
effect O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
dilutions O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
C5D B-DISO-MISC O-MISC
serum O-MISC I-GENE-MISC
contain O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
factor O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
factors O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
interfering O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
step O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hemolytic O-MISC B-CONC-MISC
assay O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
C5 O-MISC O-MISC
, O-MISC B-ACTI-MISC
rather O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
true O-MISC B-ACTI-MISC
C5 O-MISC O-MISC
inhibitor O-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
inactivator O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
interest O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
documentation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
membranous O-MISC I-ACTI-MISC
glomerulonephritis B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
vasculitis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
arthritis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
lacking O-MISC B-ACTI-MISC
C5 O-MISC O-MISC
( O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
biologic O-MISC I-DISO-MISC
functions O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
b O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
remarkable O-MISC B-ACTI-MISC
propensity O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
bacterial B-DISO-MISC I-ACTI-MISC
infections I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proband O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
periods O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
dose O-MISC I-CHED-MISC
or O-MISC B-ACTI-MISC
alternate O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
day O-MISC I-CONC-MISC
corticosteroid O-MISC I-CONC-MISC
therapy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Other O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C5D B-DISO-MISC I-ACTI-MISC
state O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
compatible O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
coagulation O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
capacity O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
mount O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
neutrophilic O-MISC I-GENE-MISC
leukocytosis O-MISC I-ACTI-MISC
during O-MISC B-ACTI-MISC
pyogenic B-DISO-MISC I-ACTI-MISC
infection I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
ankylosing B-DISO-MISC I-ACTI-MISC
spondylitis I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
twins O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
HLA O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
environment O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

OBJECTIVE O-MISC B-ACTI-MISC
To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relative O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
genetic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
environmental O-MISC B-CHED-MISC
factors O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
ankylosing B-DISO-MISC I-ACTI-MISC
spondylitis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
Twins O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
AS B-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Royal O-MISC B-GENE-MISC
National O-MISC I-GEOG-MISC
Hospital O-MISC I-GEOG-MISC
for O-MISC I-GEOG-MISC
Rheumatic B-DISO-MISC I-GEOG-MISC
Diseases I-DISO-MISC I-GEOG-MISC
database O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
radiographic O-MISC B-CONC-MISC
examinations O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
establish O-MISC B-ACTI-MISC
diagnoses O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
disease O-MISC B-CHED-MISC
severity O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
using O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
validated O-MISC B-ACTI-MISC
scoring O-MISC B-CHED-MISC
systems O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

HLA O-MISC O-MISC
typing O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
B27 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
B60 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
DR1 O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
polymerase O-MISC B-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
sequence O-MISC O-MISC
- O-MISC B-DISO-MISC
specific O-MISC B-DISO-MISC
primers O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
zygosity O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
microsatellite O-MISC I-DISO-MISC
markers O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Genetic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
environmental O-MISC B-CHED-MISC
variance O-MISC B-CHED-MISC
components O-MISC I-CHED-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
program O-MISC B-CHED-MISC
Mx O-MISC B-OBJC-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
twins O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
AS B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
Six O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
monozygotic O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
MZ O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
twin O-MISC B-DEVI-MISC
pairs O-MISC I-DEVI-MISC
were O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
concordant O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
B27 O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
dizygotic O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
DZ O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
twin O-MISC B-DEVI-MISC
pairs O-MISC I-DEVI-MISC
( O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
DZ O-MISC I-ACTI-MISC
twin O-MISC B-DEVI-MISC
pairs O-MISC I-DEVI-MISC
overall O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Nonsignificant O-MISC B-ACTI-MISC
increases O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
similarity O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
regard O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
disease O-MISC B-CHED-MISC
onset O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC B-CHED-MISC
severity O-MISC I-CHED-MISC
scores O-MISC I-CHED-MISC
assessed O-MISC B-DEVI-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
concordant O-MISC B-ACTI-MISC
MZ O-MISC I-ACTI-MISC
twins O-MISC I-ANAT-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
concordant O-MISC B-ACTI-MISC
DZ O-MISC I-ACTI-MISC
twins O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
B27 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
B60 O-MISC O-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
probands O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rate O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
concordance O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
increased O-MISC I-CHED-MISC
among O-MISC B-ACTI-MISC
DZ O-MISC I-ACTI-MISC
twin O-MISC I-ANAT-MISC
pairs O-MISC I-PHEN-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
co O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
twin O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
B27 O-MISC O-MISC
and O-MISC B-ACTI-MISC
DR1 O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Additive O-MISC B-CHED-MISC
genetic O-MISC B-CHED-MISC
effects O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
97 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
variance O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSION O-MISC B-ACTI-MISC
Susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
AS B-DISO-MISC O-MISC
is O-MISC B-ACTI-MISC
largely O-MISC B-ACTI-MISC
genetically O-MISC B-CONC-MISC
determined O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
environmental O-MISC I-DISO-MISC
trigger O-MISC I-LIVB-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
ubiquitous O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
B27 O-MISC B-DISO-MISC
accounts O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
minority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
overall O-MISC B-ACTI-MISC
genetic O-MISC I-DISO-MISC
susceptibility O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
AS B-DISO-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-ACTI-MISC
colocalization O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
BARD1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
proteins O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
discrete O-MISC B-ACTI-MISC
nuclear O-MISC B-LIVB-MISC
domains O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Germ O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
line O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
predispose O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
early O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
onset O-MISC B-ANAT-MISC
breast B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
ovarian I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
compromising O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
presumptive O-MISC B-CHED-MISC
function O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tumor B-DISO-MISC B-LIVB-MISC
suppressor O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
properties O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
polypeptides O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
understood O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
pattern O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
subcellular O-MISC I-GENE-MISC
localization O-MISC B-GEOG-MISC
suggest O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
cycle O-MISC I-LIVB-MISC
regulation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
resting O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
are O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
proliferate O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
steady O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
state O-MISC I-OCCU-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
late O-MISC B-CHED-MISC
G1 O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
reach O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
maximum O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
S O-MISC B-CHED-MISC
phase O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
S O-MISC I-GENE-MISC
phase O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
polypeptides O-MISC O-MISC
are O-MISC B-ACTI-MISC
hyperphosphorylated O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
accumulate O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
discrete O-MISC B-ACTI-MISC
subnuclear O-MISC B-CHED-MISC
foci O-MISC I-CHED-MISC
termed O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
BRCA1 O-MISC I-GENE-MISC
nuclear O-MISC B-ACTI-MISC
dots O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

" O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
associates O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
structurally O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
protein O-MISC O-MISC
termed O-MISC B-ACTI-MISC
BARD1 O-MISC O-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
steady O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
state O-MISC I-OCCU-MISC
levels O-MISC I-OCCU-MISC
of O-MISC B-ACTI-MISC
BARD1 O-MISC O-MISC
, O-MISC B-ACTI-MISC
unlike O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
, O-MISC B-ACTI-MISC
remain O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
constant O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
progression O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
immunostaining O-MISC B-CONC-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
BARD1 O-MISC O-MISC
resides O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
BRCA1 O-MISC I-GENE-MISC
nuclear O-MISC I-GENE-MISC
dots O-MISC I-GEOG-MISC
during O-MISC B-ACTI-MISC
S O-MISC B-CHED-MISC
phase O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
G1 O-MISC B-CHED-MISC
phase O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Nevertheless O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
BARD1 O-MISC O-MISC
polypeptides O-MISC O-MISC
are O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
exclusively O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nuclear O-MISC B-CHED-MISC
fractions O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
G1 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
S O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
phase O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
progression O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
S O-MISC B-CHED-MISC
phase O-MISC I-CHED-MISC
is O-MISC B-ACTI-MISC
accompanied O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
aggregation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
nuclear O-MISC B-CHED-MISC
BARD1 O-MISC O-MISC
polypeptides O-MISC B-DISO-MISC
into O-MISC B-ACTI-MISC
BRCA1 O-MISC I-GENE-MISC
nuclear O-MISC B-GENE-MISC
dots O-MISC I-GEOG-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-ACTI-MISC
colocalization O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
BARD1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
indicates O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
BARD1 O-MISC O-MISC
in O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-DISO-MISC
suppression O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Ethnic O-MISC I-ACTI-MISC
differences O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HFE O-MISC B-LIVB-MISC
codon O-MISC I-PROC-MISC
282 O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
Cys O-MISC B-LIVB-MISC
/ O-MISC I-PROC-MISC
Tyr O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
polymorphism O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Recent O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
hemochromatosis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HH B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
homozygosity O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Cys282Tyr O-MISC I-DISO-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HFE O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
located O-MISC I-DISO-MISC
4 O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
Mb O-MISC B-ACTI-MISC
telomeric O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Population O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
polymorphism O-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
facilitated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fact O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Cys282Tyr O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
creates O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Rsal O-MISC I-GENE-MISC
restriction O-MISC I-PROC-MISC
site O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
codon O-MISC B-LIVB-MISC
282 O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
Cys O-MISC B-LIVB-MISC
/ O-MISC I-PROC-MISC
Tyr O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
polymorphism O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
ethnic O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
agreement O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
Tyr O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
appeared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
absent O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Asiatic O-MISC I-ANAT-MISC
( O-MISC I-PHEN-MISC
Indian O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
) O-MISC I-PHEN-MISC
populations O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
highest O-MISC B-ACTI-MISC
allele O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Swedes O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Saamis O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Mordvinians O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
frequencies O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Tyr O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Comparisons O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
allele O-MISC B-CHED-MISC
frequencies O-MISC I-CHED-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
estimates O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
HH B-DISO-MISC I-ACTI-MISC
showed O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
disagreements O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RFLP O-MISC B-CHED-MISC
data O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Finns O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
newly O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
marker O-MISC I-DISO-MISC
provides O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
approach O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
screening O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
HH B-DISO-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
Tyr O-MISC B-DISO-MISC
allele O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
disorders O-MISC I-ACTI-MISC
including O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC

Autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
neurohypophyseal I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
encoding O-MISC B-DEVI-MISC
Gly23 O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
Val O-MISC O-MISC
in O-MISC B-ACTI-MISC
neurophysin O-MISC O-MISC
II O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
neurohypophyseal I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
ADNDI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inherited B-DISO-MISC B-CHED-MISC
disease I-DISO-MISC I-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
degeneration O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
magnocellular O-MISC I-GENE-MISC
neurons O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothalamus O-MISC I-GENE-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
decreased O-MISC I-ACTI-MISC
ability O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hormone O-MISC O-MISC
arginine O-MISC O-MISC
vasopressin O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
AVP O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Affected O-MISC I-ACTI-MISC
individuals O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
symptomatic O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
birth O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
insipidus I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
yr O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
genetic O-MISC B-LIVB-MISC
locus O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
AVP O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
neurophysin O-MISC I-PROC-MISC
II O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
NPII O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
ADNDI B-DISO-MISC I-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
signal O-MISC O-MISC
peptide O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prepro O-MISC O-MISC
- O-MISC B-DISO-MISC
AVP O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
NPII O-MISC B-DISO-MISC
precursor O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
NPII O-MISC O-MISC
itself O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
girl O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
similarly O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
younger O-MISC I-ANAT-MISC
brother O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
father O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
G1758 O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
T O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
encoding O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
amino O-MISC I-DISO-MISC
acid O-MISC I-LIVB-MISC
substitution O-MISC I-LIVB-MISC
Gly23 O-MISC I-LIVB-MISC
- O-MISC I-PROC-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
Val O-MISC I-LIVB-MISC
within O-MISC B-ACTI-MISC
NPII O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
restriction O-MISC B-CONC-MISC
endonuclease O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
T1 O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
weighted O-MISC I-CONC-MISC
magnetic O-MISC I-CONC-MISC
resonance O-MISC I-CONC-MISC
imaging O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fathers O-MISC I-GENE-MISC
pituitary O-MISC B-GEOG-MISC
gland O-MISC B-GEOG-MISC
demonstrates O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
attenuated O-MISC B-DEVI-MISC
posterior O-MISC I-GENE-MISC
pituitary O-MISC B-GEOG-MISC
bright O-MISC I-ACTI-MISC
spot O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
valuable O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
models O-MISC B-OBJC-MISC
of O-MISC B-ACTI-MISC
dominantly B-DISO-MISC B-CHED-MISC
inherited I-DISO-MISC B-CHED-MISC
neurodegeneration I-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
age O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
deleterious O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
magnocellular O-MISC I-GENE-MISC
neuron O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Frequent O-MISC B-ACTI-MISC
inactivation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PTEN O-MISC O-MISC
/ O-MISC B-DISO-MISC
MMAC1 O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
prostate B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Sporadic B-DISO-MISC I-ACTI-MISC
prostate I-DISO-MISC B-ANAT-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-CHED-MISC
male B-DISO-MISC I-DISO-MISC
cancer I-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Western O-MISC B-PHEN-MISC
world O-MISC B-UnknownType-MISC
, O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-CHED-MISC
genetic O-MISC I-DISO-MISC
events O-MISC I-LIVB-MISC
involved O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
progression O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
cancer B-DISO-MISC I-ACTI-MISC
remain O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
elucidated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Numerous O-MISC B-ACTI-MISC
cytogenetic O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
allelotype O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
loss O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
heterozygosity O-MISC B-ANAT-MISC
on O-MISC B-ACTI-MISC
chromosomal O-MISC I-ACTI-MISC
arm O-MISC B-ANAT-MISC
10q O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
sporadic B-DISO-MISC B-CHED-MISC
prostate I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Deletion O-MISC B-CONC-MISC
mapping O-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
unambiguously O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
region O-MISC B-LIVB-MISC
of O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
10q23 O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
minimal O-MISC B-ACTI-MISC
area O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
loss O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
tumor B-DISO-MISC B-LIVB-MISC
suppressor O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
PTEN O-MISC B-LIVB-MISC
/ O-MISC I-PROC-MISC
MMAC1 O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
isolated O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
region O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
chromosome O-MISC B-LIVB-MISC
10q23 O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
inactivated O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
prostate B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
cell O-MISC B-GEOG-MISC
lines O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
screened O-MISC B-CONC-MISC
80 O-MISC B-ACTI-MISC
prostate B-DISO-MISC I-ACTI-MISC
tumors I-DISO-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
microsatellite O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
chromosome O-MISC B-LIVB-MISC
10q23 O-MISC I-PROC-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
deleted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
then O-MISC B-ACTI-MISC
proceeded O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
sequence O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
entire O-MISC B-ACTI-MISC
PTEN O-MISC O-MISC
/ O-MISC B-ACTI-MISC
MMAC1 O-MISC O-MISC
coding O-MISC B-LIVB-MISC
region O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
deletion O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
intragenic O-MISC O-MISC
markers O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
10q23 O-MISC B-LIVB-MISC
loss O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
heterozygosity O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
identification O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
mutational O-MISC I-DISO-MISC
event O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
tumors B-DISO-MISC I-ACTI-MISC
establishes O-MISC B-ACTI-MISC
PTEN O-MISC O-MISC
/ O-MISC B-ACTI-MISC
MMAC1 O-MISC O-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
main O-MISC B-ACTI-MISC
inactivation O-MISC B-CHED-MISC
target O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
10q O-MISC B-LIVB-MISC
loss O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
sporadic B-DISO-MISC B-CHED-MISC
prostate I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Risk O-MISC B-CHED-MISC
reversals O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
predictive O-MISC B-CHED-MISC
testing O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
Huntington B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
predictive O-MISC B-CHED-MISC
testing O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
Huntington B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
linked O-MISC B-LIVB-MISC
polymorphic O-MISC I-PROC-MISC
DNA O-MISC I-PROC-MISC
markers O-MISC I-PROC-MISC
to O-MISC B-ACTI-MISC
estimate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
likelihood O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
inheriting O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
HD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Limits O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
accuracy O-MISC B-CHED-MISC
included O-MISC B-ACTI-MISC
recombination O-MISC I-DISO-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DNA O-MISC I-DISO-MISC
markers O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
pedigree O-MISC B-CHED-MISC
structure O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
DNA O-MISC I-GENE-MISC
samples O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
available O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
members O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

With O-MISC B-ACTI-MISC
direct O-MISC B-CHED-MISC
tests O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HD B-DISO-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
accuracy O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
obtained O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
linkage O-MISC B-CHED-MISC
approaches O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
requested O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
do O-MISC B-ACTI-MISC
so O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
test O-MISC B-CHED-MISC
individuals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

For O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
disparity O-MISC I-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tests O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
went O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Knowledge O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
reasons O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
results O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
impact O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
reversals O-MISC I-DEVI-MISC
on O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
counseling O-MISC B-CONC-MISC
team O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
assist O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
strategies O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prevention O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
where O-MISC B-ACTI-MISC
necessary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
management O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
reversal O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
predictive O-MISC B-CHED-MISC
testing O-MISC I-CHED-MISC
program O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
G301C O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
N O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
acetylgalactosamine O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
6 O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
sulfate O-MISC I-PROC-MISC
sulfatase O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
mucopolysaccharidosis B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Mucopolysaccharidosis B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MPS B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-DISO-MISC
recessive I-DISO-MISC B-ACTI-MISC
lysosomal I-DISO-MISC I-ACTI-MISC
storage I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
caused O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
genetic B-DISO-MISC B-CHED-MISC
defect I-DISO-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
N O-MISC O-MISC
- O-MISC B-DISO-MISC
acetylgalactosamine O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
6 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
sulfate O-MISC B-DISO-MISC
sulfatase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GALNS O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
Caucasians O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
characterize O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutational O-MISC I-DISO-MISC
spectrum O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
ethnic O-MISC I-ANAT-MISC
groups O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
GALNS O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
Colombian O-MISC I-ANAT-MISC
MPS B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
genetic O-MISC I-DISO-MISC
backgrounds O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
extensively O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
racial O-MISC B-CHED-MISC
origin O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
mitochondrial O-MISC O-MISC
DNA O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
mtDNA O-MISC O-MISC
) O-MISC B-ACTI-MISC
lineages O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
never O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
Colombian O-MISC I-ANAT-MISC
MPS B-DISO-MISC B-CONC-MISC
IVA I-DISO-MISC I-CONC-MISC
unrelated O-MISC I-ACTI-MISC
alleles O-MISC B-LIVB-MISC
account O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alleles O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
G301C O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
S162F O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
account O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
remaining O-MISC B-ACTI-MISC
F69V O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
skewed O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
G301C O-MISC O-MISC
in O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
Colombian O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
haplotype O-MISC I-DISO-MISC
analysis O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
restriction O-MISC I-DISO-MISC
fragment O-MISC I-CONC-MISC
length O-MISC I-CONC-MISC
polymorphisms O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
GALNS O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
G301C O-MISC B-LIVB-MISC
originated O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
ancestor O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Investigation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genetic O-MISC I-DISO-MISC
background O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
means O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mtDNA O-MISC O-MISC
lineages O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
native O-MISC I-ANAT-MISC
American O-MISC I-PHEN-MISC
descent O-MISC I-PHEN-MISC

Low O-MISC B-ACTI-MISC
frequency O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
germline O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
German O-MISC I-ANAT-MISC
breast B-DISO-MISC I-ACTI-MISC
/ I-DISO-MISC B-ANAT-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
German O-MISC I-ANAT-MISC
breast B-DISO-MISC I-ACTI-MISC
/ I-DISO-MISC B-ANAT-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
families O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
germline O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
germline O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
families O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
family O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
frameshift O-MISC I-DISO-MISC
mutation O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
nonsense O-MISC I-ACTI-MISC
mutation O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
site O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

8 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
general O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
age O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
disease O-MISC B-CHED-MISC
onset O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
harbouring O-MISC B-ACTI-MISC
causative O-MISC I-ACTI-MISC
mutations O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

3 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

4 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
harbouring O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
had O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
age O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
onset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

2 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
fraction O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
/ I-DISO-MISC B-ACTI-MISC
ovarian I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
families O-MISC I-ANAT-MISC
suggesting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
involvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
susceptibility O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
s O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC

Paternal O-MISC I-ACTI-MISC
transmission O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
myotonic I-DISO-MISC B-ANAT-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
paternally O-MISC I-ACTI-MISC
transmitted O-MISC B-ANAT-MISC
congenital B-DISO-MISC I-ACTI-MISC
myotonic I-DISO-MISC B-ANAT-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
proband O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mentally B-DISO-MISC I-ACTI-MISC
retarded I-DISO-MISC B-ANAT-MISC
male O-MISC I-DISO-MISC
who O-MISC B-ACTI-MISC
suffers O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
muscular B-DISO-MISC I-ACTI-MISC
weakness I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

He O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
respiratory O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
feeding O-MISC I-ACTI-MISC
difficulties O-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
birth O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

His O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
sibs O-MISC I-GENE-MISC
suffer O-MISC I-ACTI-MISC
from O-MISC B-ACTI-MISC
childhood O-MISC B-CHED-MISC
onset O-MISC B-CHED-MISC
DM B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Their O-MISC B-ACTI-MISC
late O-MISC B-CHED-MISC
father O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
around O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
paternal O-MISC I-ACTI-MISC
transmission O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
DM I-DISO-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
review O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
related O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
transmission O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
DM I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Decreased O-MISC I-ACTI-MISC
fertility O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
males O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
adult O-MISC I-ANAT-MISC
onset O-MISC B-CHED-MISC
DM B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
contraction O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
repeat O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
transmission O-MISC I-ACTI-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
absent O-MISC B-ANAT-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
paternal O-MISC B-CHED-MISC
transmission O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
DM I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Also O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fathers O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
congenitally O-MISC B-CHED-MISC
affected O-MISC B-CHED-MISC
children O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
shorter O-MISC B-CHED-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC B-ACTI-MISC
lengths O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
hence O-MISC B-ACTI-MISC
less O-MISC B-CHED-MISC
severe O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
symptoms O-MISC B-ANAT-MISC
than O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mothers O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
DM I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
paternal O-MISC B-CHED-MISC
transmission O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
DM I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
preferentially O-MISC B-ACTI-MISC
occurs O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
DM B-DISO-MISC I-ACTI-MISC
past O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
father O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
RB1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
child O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ectopic B-DISO-MISC B-CHED-MISC
intracranial I-DISO-MISC I-GENE-MISC
retinoblastoma I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
RB1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
mutation O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
child O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
ectopic B-DISO-MISC B-CHED-MISC
intracranial I-DISO-MISC I-GENE-MISC
retinoblastoma I-DISO-MISC I-ACTI-MISC
using O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
obtained O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pineal B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
retinal I-DISO-MISC I-ACTI-MISC
tumours I-DISO-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
nonsense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
17 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
codon O-MISC B-LIVB-MISC
556 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RB1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
homozygously O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
retinal B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
pineal I-DISO-MISC I-ACTI-MISC
tumours I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
heterozygously O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
constitutional O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
proving O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
germline O-MISC I-GENE-MISC
origin O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
paternally O-MISC B-CHED-MISC
derived O-MISC B-ACTI-MISC
RB1 O-MISC B-LIVB-MISC
allele O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
area O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
that O-MISC B-ACTI-MISC
encodes O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
protein O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
binding O-MISC I-PROC-MISC
region O-MISC I-PROC-MISC
known O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pocket O-MISC B-LIVB-MISC
region O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
retinoblastoma B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Low O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
beta O-MISC O-MISC
hexosaminidase O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
individuals O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
apparent O-MISC B-ACTI-MISC
deficiency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
enzyme O-MISC O-MISC
. O-MISC B-ACTI-MISC

Appreciable O-MISC B-ACTI-MISC
beta O-MISC O-MISC
hexosaminidase O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
hex O-MISC O-MISC
A O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
activity O-MISC I-DISO-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
cultured O-MISC I-GENE-MISC
skin O-MISC I-GENE-MISC
fibroblasts O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
melanoma B-DISO-MISC I-GENE-MISC
tissue O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
individuals O-MISC I-PHEN-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
having O-MISC B-ACTI-MISC
deficiency B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
hex I-DISO-MISC O-MISC
A I-DISO-MISC B-DISO-MISC
activity O-MISC I-DISO-MISC
indistinguishable O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Tay B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Sachs I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
TSD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Identification O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
quantitation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hex O-MISC O-MISC
A O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
amounting O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
beta O-MISC O-MISC
hexosaminidase O-MISC B-DISO-MISC
activity O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
cellulose O-MISC B-CONC-MISC
acetate O-MISC I-CONC-MISC
gel O-MISC I-CONC-MISC
electrophoresis O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
DEAE O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
cellulose O-MISC I-CONC-MISC
ion O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
exchange O-MISC I-CONC-MISC
chromatography O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
radial O-MISC B-CONC-MISC
immunodiffusion O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
radioimmunoassay O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Previous O-MISC B-ACTI-MISC
family O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
compound O-MISC I-DISO-MISC
heterozygotes O-MISC I-LIVB-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
TSD B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
allelic O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
mutant O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
postulated O-MISC B-CHED-MISC
rate O-MISC B-LIVB-MISC
mutant O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
code O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
amounts O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hex O-MISC O-MISC
A O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Heterozygotes O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
indistinguishable O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
heterozygotes O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
TSD B-DISO-MISC I-ACTI-MISC
mutant O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
direct O-MISC I-ACTI-MISC
visualization O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
quantitation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hex O-MISC O-MISC
A O-MISC B-DISO-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
methods O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
prevent O-MISC B-ACTI-MISC
false O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
positive O-MISC I-OCCU-MISC
prenatal O-MISC B-CONC-MISC
diagnosis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
TSD B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
fetuses O-MISC I-GENE-MISC
having O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
incomplete O-MISC B-CHED-MISC
hex B-DISO-MISC O-MISC
A I-DISO-MISC B-DISO-MISC
deficiency I-DISO-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
individuals O-MISC I-PHEN-MISC

The O-MISC B-ACTI-MISC
tumor B-DISO-MISC B-LIVB-MISC
suppressor O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
Smad4 O-MISC B-LIVB-MISC
/ O-MISC B-ACTI-MISC
Dpc4 O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
gastrulation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
anterior O-MISC B-CHED-MISC
development O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mouse O-MISC I-GENE-MISC
embryo O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SMAD4 O-MISC B-LIVB-MISC
/ O-MISC I-PROC-MISC
DPC4 O-MISC I-PROC-MISC
tumor B-DISO-MISC I-PROC-MISC
suppressor O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
key O-MISC B-ACTI-MISC
signal O-MISC O-MISC
transducer O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
TGFbeta O-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
pathways O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
pancreatic B-DISO-MISC I-ACTI-MISC
cancers I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Homozygous O-MISC I-DISO-MISC
Smad4 O-MISC B-LIVB-MISC
mutant O-MISC I-PROC-MISC
mice O-MISC I-PHEN-MISC
die O-MISC I-DISO-MISC
before O-MISC B-ACTI-MISC
day O-MISC B-CHED-MISC
7 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
embryogenesis O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Mutant O-MISC I-ACTI-MISC
embryos O-MISC I-GENE-MISC
have O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
size O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
fail O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
gastrulate O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
express O-MISC I-DISO-MISC
a O-MISC B-ACTI-MISC
mesodermal O-MISC I-DISO-MISC
marker O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
visceral O-MISC I-DISO-MISC
endoderm O-MISC I-DISO-MISC
development O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Growth B-DISO-MISC I-ACTI-MISC
retardation I-DISO-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Smad4 O-MISC O-MISC
- O-MISC B-ACTI-MISC
deficient O-MISC B-CHED-MISC
embryos O-MISC I-GENE-MISC
results O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
cell O-MISC I-DISO-MISC
proliferation O-MISC I-LIVB-MISC
rather O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
apoptosis O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Aggregation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mutant O-MISC B-LIVB-MISC
Smad4 O-MISC O-MISC
ES O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
with O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
tetraploid O-MISC I-GENE-MISC
morulae O-MISC B-GEOG-MISC
rescues O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gastrulation B-DISO-MISC I-DISO-MISC
defect I-DISO-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
Smad4 O-MISC O-MISC
is O-MISC B-ACTI-MISC
initially O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
differentiation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
visceral O-MISC I-GENE-MISC
endoderm O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gastrulation B-DISO-MISC I-DISO-MISC
defect I-DISO-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
epiblast O-MISC I-GENE-MISC
is O-MISC B-ACTI-MISC
secondary O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
non O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
cell O-MISC B-ACTI-MISC
autonomous O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Rescued O-MISC I-ACTI-MISC
embryos O-MISC I-GENE-MISC
show O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
anterior O-MISC I-GENE-MISC
truncations O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
Smad4 O-MISC O-MISC
in O-MISC B-ACTI-MISC
anterior O-MISC B-CHED-MISC
patterning O-MISC I-LIVB-MISC
during O-MISC B-ACTI-MISC
embryogenesis O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Prevalence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
p16 O-MISC O-MISC
and O-MISC B-ACTI-MISC
CDK4 O-MISC O-MISC
germline O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
melanoma B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
prone O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
France O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
French O-MISC B-PHYS-MISC
Familial B-DISO-MISC I-PHYS-MISC
Melanoma I-DISO-MISC I-PHYS-MISC
Study O-MISC I-PHYS-MISC
Group O-MISC I-PHYS-MISC
. O-MISC B-ACTI-MISC

Germline O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
p16 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
CDK4 O-MISC B-LIVB-MISC
genes O-MISC I-PROC-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
subset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
melanoma B-DISO-MISC I-ACTI-MISC
pedigrees O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
prevalence O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
searched O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
germline O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
French O-MISC B-ORGA-MISC
melanoma B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
prone O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
selected O-MISC B-ACTI-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
criteria O-MISC B-CHED-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
members O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
members O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
minor O-MISC B-CHED-MISC
criterion O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Sixteen O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
p16 O-MISC O-MISC
germline O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
families O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
germline O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
Arg24His O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CDK4 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
p16 O-MISC I-DISO-MISC
gene O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
sample O-MISC B-GENE-MISC
( O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
highest O-MISC B-ACTI-MISC
rates O-MISC B-CHED-MISC
yet O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CDK4 O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
worldwide O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
summary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
involvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
p16 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
familial B-DISO-MISC I-ACTI-MISC
melanoma I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
confirm O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CDK4 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
melanoma B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
predisposing O-MISC B-CHED-MISC
gene O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Progression O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC I-PROC-MISC
length O-MISC B-ACTI-MISC
heterogeneity O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
blood O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
genetic O-MISC B-CHED-MISC
basis O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expansion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unstable O-MISC I-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
34 O-MISC B-LIVB-MISC
UTR O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DM B-DISO-MISC B-LIVB-MISC
protein O-MISC I-PROC-MISC
kinase O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
on O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
19 O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
principal O-MISC B-ACTI-MISC
features O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
extraordinarily O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
mosaicism O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
extremely O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
degree O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
somatic O-MISC I-ACTI-MISC
instability O-MISC B-ANAT-MISC
both O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
tissues O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
instability O-MISC I-ACTI-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
biased O-MISC B-CHED-MISC
towards O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
expansion O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
continuous O-MISC B-CHED-MISC
throughout O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
life O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
features O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
nature O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
measured O-MISC B-ACTI-MISC
allele O-MISC B-CHED-MISC
size O-MISC I-CHED-MISC
between O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
clearly O-MISC B-ACTI-MISC
correlates O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
severity O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
earlier O-MISC B-CHED-MISC
age O-MISC I-CHED-MISC
of O-MISC I-CHED-MISC
onset O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
precise O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
measured O-MISC B-CHED-MISC
allele O-MISC B-CHED-MISC
length O-MISC I-CHED-MISC
cannot O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
accurate O-MISC B-CHED-MISC
predictor O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
age O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
onset O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
characterize O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dynamics O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC B-ANAT-MISC
somatic O-MISC I-ACTI-MISC
instability O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
repeat O-MISC B-LIVB-MISC
length O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
111 O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
varying O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
severity O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC B-LIVB-MISC
size O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
intervals O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
progression O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
size O-MISC B-CHED-MISC
heterogeneity O-MISC B-CHED-MISC
over O-MISC B-ACTI-MISC
time O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC I-ACTI-MISC
size O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
time O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
biased O-MISC B-ACTI-MISC
towards O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
expansion O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Attempts O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
mathematically O-MISC B-CHED-MISC
model O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
dynamics O-MISC B-OCCU-MISC
have O-MISC B-ACTI-MISC
proved O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
partially O-MISC B-ACTI-MISC
successful O-MISC B-ACTI-MISC
suggesting O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
specific O-MISC B-CHED-MISC
genetic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
environmental O-MISC B-CHED-MISC
factors O-MISC I-CHED-MISC
also O-MISC B-ACTI-MISC
play O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
mosaicism O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Aspartylglucosaminuria B-DISO-MISC I-ACTI-MISC
among O-MISC B-ACTI-MISC
Palestinian O-MISC I-ANAT-MISC
Arabs O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Aspartylglucosaminuria B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
AGU B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC I-ACTI-MISC
disorder B-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
glycoprotein I-DISO-MISC I-DISO-MISC
metabolism I-DISO-MISC I-LIVB-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
deficiency B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
lysosomal I-DISO-MISC I-GENE-MISC
enzyme I-DISO-MISC O-MISC
aspartylglucosaminidase I-DISO-MISC O-MISC
( O-MISC B-ACTI-MISC
AGA O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

AGU B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
inherited O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal O-MISC I-DISO-MISC
recessive O-MISC I-LIVB-MISC
trait O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
occurs O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
Finland O-MISC B-ORGA-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
founder O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

While O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
AGU B-DISO-MISC I-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Finnish O-MISC I-PHEN-MISC
origin O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
the O-MISC B-ACTI-MISC
disorder O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
originating O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
Palestinian O-MISC I-ANAT-MISC
Arabs O-MISC I-PHEN-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
region O-MISC B-ORGA-MISC
of O-MISC B-ACTI-MISC
Jerusalem O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
diagnosis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
AGU B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
difficult O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
particular O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
course O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
after O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
since O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
excrete O-MISC I-DISO-MISC
early O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
amounts O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aspartylglucosamine O-MISC O-MISC
in O-MISC B-ACTI-MISC
urine O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
biochemical O-MISC B-CONC-MISC
screening O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
easy O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
urine O-MISC B-CONC-MISC
chromatography O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Detection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
carriers O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ataxia B-DISO-MISC B-LIVB-MISC
- I-DISO-MISC I-PROC-MISC
telangiectasia I-DISO-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
ATM O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
by O-MISC B-ACTI-MISC
G2 O-MISC B-CHED-MISC
phase O-MISC I-CHED-MISC
chromosomal O-MISC I-ACTI-MISC
radiosensitivity O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
peripheral O-MISC I-GENE-MISC
blood O-MISC B-GEOG-MISC
lymphocytes O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
ATM O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
recessive I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
embraces O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
features O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
manifests O-MISC B-ACTI-MISC
extreme O-MISC B-ACTI-MISC
radiosensitivity O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
strong O-MISC B-ACTI-MISC
pre O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
disposition O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
malignancy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Heterozygotes O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATM O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
have O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
clinical O-MISC I-DISO-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
A B-DISO-MISC O-MISC
- I-DISO-MISC B-DISO-MISC
T I-DISO-MISC B-DISO-MISC
but O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
prone O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
moderate O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vitro O-MISC I-CHED-MISC
radiosensitivity O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
blind O-MISC B-ACTI-MISC
chromosomal O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
on O-MISC B-ACTI-MISC
G2 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
phase O-MISC B-GEOG-MISC
lymphocytes O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
A B-DISO-MISC I-DISO-MISC
- I-DISO-MISC I-LIVB-MISC
T I-DISO-MISC I-LIVB-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
obligate O-MISC I-ACTI-MISC
A B-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
heterozygotes O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
parents O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
controls O-MISC I-CHED-MISC
following O-MISC B-ACTI-MISC
X O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
irradiation O-MISC I-CONC-MISC
with O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
Gy O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
this O-MISC B-ACTI-MISC
cytogenetic O-MISC B-CHED-MISC
method O-MISC I-CHED-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tool O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
detection O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
ATM O-MISC O-MISC
carriers O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
A B-DISO-MISC O-MISC
- I-DISO-MISC B-DISO-MISC
T I-DISO-MISC B-DISO-MISC
homozygotes O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
heterozygotes O-MISC I-DISO-MISC
showed O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
radiation O-MISC B-OCCU-MISC
- O-MISC B-ACTI-MISC
induced O-MISC B-CHED-MISC
chromatid O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
relative O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
controls O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
G2 O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
phase O-MISC I-CONC-MISC
chromosomal O-MISC I-CONC-MISC
radiosensitivity O-MISC I-CONC-MISC
assay O-MISC I-CONC-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
detection O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
A B-DISO-MISC I-DISO-MISC
- I-DISO-MISC I-LIVB-MISC
T I-DISO-MISC I-LIVB-MISC
heterozygotes O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
molecular O-MISC B-CONC-MISC
genetic O-MISC I-CONC-MISC
analyses O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
test O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
value O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
familial B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
sporadic I-DISO-MISC I-ACTI-MISC
cancers I-DISO-MISC B-ANAT-MISC
aimed O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
determination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-ACTI-MISC
involvement O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ATM O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
tumor B-DISO-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
or O-MISC B-ACTI-MISC
development O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
identification O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
detection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
founder O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
effect O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATM O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
ethnic O-MISC I-ANAT-MISC
populations O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
facilitate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
evaluation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
ATM O-MISC O-MISC
heterozygotes O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
diseases O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
attempted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
define O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
frequencies O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
homozygotes O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
ethnic O-MISC I-ANAT-MISC
populations O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
genomic O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
cDNA O-MISC O-MISC
were O-MISC B-ACTI-MISC
characterized O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

Protein O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
truncation O-MISC I-CONC-MISC
testing O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
entire O-MISC B-ACTI-MISC
ATM O-MISC O-MISC
cDNA O-MISC B-DISO-MISC
detected O-MISC I-ACTI-MISC
92 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
66 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
truncating O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
140 O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
alleles O-MISC B-LIVB-MISC
screened O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
haplotyping O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
identical O-MISC B-CHED-MISC
mutations O-MISC I-DISO-MISC
indicates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
represent O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
ancestry O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
spontaneously O-MISC B-CHED-MISC
recurring O-MISC B-CHED-MISC
ATM O-MISC I-DISO-MISC
mutations O-MISC I-DISO-MISC
exist O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Assays O-MISC B-CONC-MISC
requiring O-MISC B-ACTI-MISC
minimal O-MISC B-ACTI-MISC
amounts O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
genomic O-MISC O-MISC
DNA O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
designed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
allow O-MISC B-ACTI-MISC
rapid O-MISC B-ACTI-MISC
screening O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
ethnic O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
rapid O-MISC B-ACTI-MISC
assays O-MISC B-CONC-MISC
detected O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Costa O-MISC I-ANAT-MISC
Rican O-MISC I-PHEN-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Norwegian O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Polish O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Italian O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
Amish O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
Mennonite O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
Irish O-MISC I-ANAT-MISC
English O-MISC B-CHED-MISC
backgrounds O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Additional O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
Utah O-MISC I-ANAT-MISC
Mormon O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
African O-MISC I-ANAT-MISC
American O-MISC I-PHEN-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
assays O-MISC B-CONC-MISC
should O-MISC B-ACTI-MISC
facilitate O-MISC B-ACTI-MISC
screening O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
A B-DISO-MISC I-DISO-MISC
- I-DISO-MISC I-LIVB-MISC
T I-DISO-MISC I-LIVB-MISC
heterozygotes O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
studied O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
von B-DISO-MISC B-LIVB-MISC
Hippel I-DISO-MISC I-PROC-MISC
- I-DISO-MISC I-PROC-MISC
Lindau I-DISO-MISC I-PROC-MISC
tumor I-DISO-MISC I-PROC-MISC
suppressor O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
is O-MISC B-ACTI-MISC
required O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
exit O-MISC B-CHED-MISC
upon O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
withdrawal O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
inactivation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
von B-DISO-MISC B-LIVB-MISC
Hippel I-DISO-MISC I-PROC-MISC
- I-DISO-MISC I-PROC-MISC
Lindau I-DISO-MISC I-PROC-MISC
( I-DISO-MISC I-PROC-MISC
VHL I-DISO-MISC I-PROC-MISC
) I-DISO-MISC I-PROC-MISC
tumor I-DISO-MISC I-PROC-MISC
suppressor O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
predisposes O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
individuals O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
VHL B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
sporadic B-DISO-MISC B-CHED-MISC
renal I-DISO-MISC I-ACTI-MISC
cell I-DISO-MISC B-ANAT-MISC
carcinomas I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
RCC B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
brain B-DISO-MISC I-ACTI-MISC
hemangioblastomas I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

VHL O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
negative O-MISC B-ANAT-MISC
786 O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
0 O-MISC B-ANAT-MISC
RCC B-DISO-MISC I-GENE-MISC
cells O-MISC I-GENE-MISC
are O-MISC B-ACTI-MISC
tumorigenic O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
nude O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
suppressed O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reintroduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
VHL B-DISO-MISC O-MISC
. O-MISC B-ACTI-MISC

Remarkably O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
occurs O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
affecting O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
growth O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
profile O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
culture O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
786 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
cell O-MISC I-GENE-MISC
line O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
fails O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
exit O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
upon O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
withdrawal O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
reintroduction O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
VHL B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
restores O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ability O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
VHL O-MISC O-MISC
- O-MISC B-ANAT-MISC
negative O-MISC B-ANAT-MISC
RCC B-DISO-MISC I-ANAT-MISC
cancer I-DISO-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
exit O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
enter O-MISC B-ACTI-MISC
G0 O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
quiescence O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
low O-MISC I-GENE-MISC
serum O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
VHL O-MISC O-MISC
- O-MISC B-ACTI-MISC
positive O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
VHL O-MISC O-MISC
- O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
RCC B-DISO-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
exit O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
cycle O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
contact O-MISC I-DISO-MISC
inhibition O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cyclin O-MISC O-MISC
- O-MISC B-DISO-MISC
dependent O-MISC B-DISO-MISC
kinase O-MISC B-DISO-MISC
inhibitor O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
p27 O-MISC O-MISC
, O-MISC B-ACTI-MISC
accumulates O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
withdrawal O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
VHL B-DISO-MISC O-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
stabilization O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protein O-MISC O-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
propose O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
loss O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
VHL B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
results O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
cellular O-MISC I-ACTI-MISC
defect O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-ACTI-MISC
growth O-MISC I-DISO-MISC
control O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
initiate O-MISC B-ACTI-MISC
tumor B-DISO-MISC I-ACTI-MISC
formation O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
corrected O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
reintroduction O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
VHL B-DISO-MISC O-MISC
, O-MISC B-ACTI-MISC
implicating O-MISC B-ACTI-MISC
VHL B-DISO-MISC O-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
tumor B-DISO-MISC O-MISC
suppressor O-MISC B-DISO-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
regulation O-MISC I-DISO-MISC
of O-MISC I-LIVB-MISC
cell O-MISC I-LIVB-MISC
cycle O-MISC I-LIVB-MISC
exit O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
its O-MISC B-ACTI-MISC
gatekeeper O-MISC I-DISO-MISC
function O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
kidney O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Piebaldism B-DISO-MISC I-ACTI-MISC
with O-MISC B-ANAT-MISC
deafness B-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
evidence O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
expanded O-MISC I-ACTI-MISC
syndrome O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
South O-MISC I-ANAT-MISC
African O-MISC I-PHEN-MISC
girl O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
Xhosa O-MISC I-ANAT-MISC
stock O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
piebaldism B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
profound O-MISC B-ACTI-MISC
congenital O-MISC I-ACTI-MISC
sensorineural B-DISO-MISC B-ANAT-MISC
deafness I-DISO-MISC B-ANAT-MISC
we O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
missense O-MISC I-DISO-MISC
substitution O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
highly O-MISC B-LIVB-MISC
conserved O-MISC I-PROC-MISC
residue O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intracellular O-MISC B-CHED-MISC
kinase O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
KIT O-MISC O-MISC
proto O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
oncogene O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
R796G O-MISC O-MISC
. O-MISC B-ACTI-MISC

Though O-MISC B-ACTI-MISC
auditory B-DISO-MISC I-ACTI-MISC
anomalies I-DISO-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
dominant O-MISC I-ACTI-MISC
white O-MISC B-ANAT-MISC
spotting O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
W O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
KIT O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
deafness B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
piebaldism B-DISO-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
sensorineural B-DISO-MISC I-ACTI-MISC
deafness I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
extends O-MISC B-ACTI-MISC
considerably O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phenotypic O-MISC I-DISO-MISC
range O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
piebaldism B-DISO-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
KIT O-MISC B-LIVB-MISC
gene O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
tightens O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
similarity O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
piebaldism B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
forms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Waardenburg B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Cycloheximide O-MISC O-MISC
facilitates O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
identification O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
aberrant O-MISC B-CHED-MISC
transcripts O-MISC O-MISC
resulting O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
site O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
COL17A1 O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
generalized O-MISC B-ACTI-MISC
atrophic B-DISO-MISC I-ACTI-MISC
benign I-DISO-MISC B-ANAT-MISC
epidermolysis I-DISO-MISC B-ANAT-MISC
bullosa I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
atrophic B-DISO-MISC B-ANAT-MISC
benign I-DISO-MISC B-ANAT-MISC
epidermolysis I-DISO-MISC B-ANAT-MISC
bullosa I-DISO-MISC B-ANAT-MISC
often O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
decreased O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
type O-MISC O-MISC
XVII O-MISC B-DISO-MISC
collagen O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transmembrane O-MISC O-MISC
hemidesmosomal O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
encoded O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
COL17A1 O-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
documents O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
site O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
COL17A1 O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
atrophic B-DISO-MISC B-ANAT-MISC
benign I-DISO-MISC B-ANAT-MISC
epidermolysis I-DISO-MISC B-ANAT-MISC
bullosa I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
applies O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
methodology O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
define O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
characterize O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
mRNA O-MISC O-MISC
splice O-MISC I-LIVB-MISC
variants O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Mutational O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
COL17A1 O-MISC B-LIVB-MISC
identified O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
maternally O-MISC I-DISO-MISC
inherited O-MISC I-LIVB-MISC
G O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
to O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
T O-MISC I-LIVB-MISC
transversion O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
position O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
exon O-MISC O-MISC
32 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
acceptor O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
site O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
formation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
aberrant O-MISC B-CHED-MISC
transcripts O-MISC O-MISC
present O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
extremely O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
levels O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
finding O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
cycloheximide O-MISC O-MISC
stabilized O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
COL17A1 O-MISC B-LIVB-MISC
transcripts O-MISC O-MISC
in O-MISC B-ACTI-MISC
keratinocytes O-MISC I-GENE-MISC
homozygous O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
frameshift O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
effects O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
site O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
on O-MISC B-ACTI-MISC
splicing O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
COL17A1 O-MISC B-LIVB-MISC
transcripts O-MISC O-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
reverse O-MISC B-CONC-MISC
transcriptase O-MISC I-CONC-MISC
polymerase O-MISC I-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
RNA O-MISC O-MISC
from O-MISC B-ACTI-MISC
keratinocytes O-MISC I-GENE-MISC
incubated O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
h O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
microg O-MISC B-ACTI-MISC
cycloheximide O-MISC O-MISC
per O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Using O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
approach O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
abnormally O-MISC O-MISC
spliced O-MISC I-DISO-MISC
transcript O-MISC O-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
contains O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
extra O-MISC B-ACTI-MISC
264 O-MISC B-LIVB-MISC
bases O-MISC I-PROC-MISC
upstream O-MISC I-PROC-MISC
from O-MISC B-ACTI-MISC
exon O-MISC O-MISC
32 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
premature O-MISC B-CHED-MISC
termination O-MISC B-LIVB-MISC
codon O-MISC B-LIVB-MISC
27 O-MISC I-PROC-MISC
bp O-MISC I-PROC-MISC
downstream O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cryptic O-MISC O-MISC
splice O-MISC B-LIVB-MISC
site O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
splice O-MISC B-LIVB-MISC
variants O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
skipping O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
exon O-MISC O-MISC
32 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
usefulness O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cycloheximide O-MISC O-MISC
treatment O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
evaluating O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
abnormal O-MISC I-ACTI-MISC
processing O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
mRNA O-MISC O-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
site O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
aberrant O-MISC B-CHED-MISC
splicing O-MISC I-DISO-MISC
often O-MISC B-ACTI-MISC
generates O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
premature O-MISC B-CHED-MISC
termination O-MISC I-PROC-MISC
codon O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
ii O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
transcripts O-MISC O-MISC
with O-MISC B-ACTI-MISC
premature O-MISC B-CHED-MISC
termination O-MISC I-CHED-MISC
codons O-MISC I-PROC-MISC
can O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
low O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
undetectable O-MISC I-DISO-MISC
levels O-MISC B-CHED-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
nonsense O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
mediated O-MISC I-LIVB-MISC
mRNA O-MISC O-MISC
decay O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
iii O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
transcripts O-MISC O-MISC
can O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
cycloheximide O-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
deletion O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
COL17A1 O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
Austrian O-MISC I-ANAT-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
atrophic B-DISO-MISC B-ANAT-MISC
benign I-DISO-MISC B-ANAT-MISC
epidermolysis I-DISO-MISC B-ANAT-MISC
bullosa I-DISO-MISC B-ANAT-MISC
represents O-MISC B-ACTI-MISC
propagation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
ancestral O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
atrophic B-DISO-MISC B-ANAT-MISC
benign I-DISO-MISC B-ANAT-MISC
epidermolysis I-DISO-MISC B-ANAT-MISC
bullosa I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
nonlethal O-MISC I-ACTI-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
junctional B-DISO-MISC I-ACTI-MISC
epidermolysis I-DISO-MISC B-ANAT-MISC
bullosa I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
blistering B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
nail B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
patchy B-DISO-MISC I-ACTI-MISC
alopecia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
dental B-DISO-MISC I-ACTI-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Skin B-DISO-MISC I-ACTI-MISC
fragility I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
encoding O-MISC B-DEVI-MISC
type O-MISC B-LIVB-MISC
XVII O-MISC I-PROC-MISC
collagen O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
COL17A1 O-MISC B-LIVB-MISC
) O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
Austrian O-MISC I-ANAT-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
generalized O-MISC I-ACTI-MISC
atrophic B-DISO-MISC B-ANAT-MISC
benign I-DISO-MISC B-ANAT-MISC
epidermolysis I-DISO-MISC B-ANAT-MISC
bullosa I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
share O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
COL17A1 O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Affected O-MISC I-ACTI-MISC
individuals O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
are O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
4003delTC O-MISC O-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
others O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
compound O-MISC I-ACTI-MISC
heterozygotes O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
4003delTC O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
families O-MISC B-CHED-MISC
signifies O-MISC B-ACTI-MISC
propagation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
ancestral O-MISC B-LIVB-MISC
allele O-MISC B-LIVB-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutational O-MISC I-DISO-MISC
hot O-MISC B-ACTI-MISC
spot O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
haplotypes O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
polymorphisms O-MISC I-DISO-MISC
both O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
flanking O-MISC B-ACTI-MISC
COL17A1 O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
intragenic O-MISC B-LIVB-MISC
polymorphisms O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
chosen O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
informativeness O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
2988 O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
C O-MISC O-MISC
that O-MISC B-ACTI-MISC
introduces O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
restriction O-MISC B-CHED-MISC
site O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
Eco0109 O-MISC B-LIVB-MISC
I O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
4003delTC O-MISC B-LIVB-MISC
alleles O-MISC I-PROC-MISC
showed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
haplotype O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
polymorphic O-MISC I-DISO-MISC
markers O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Fourteen O-MISC B-ACTI-MISC
microsatellite O-MISC B-LIVB-MISC
polymorphisms O-MISC I-PROC-MISC
were O-MISC B-ACTI-MISC
selected O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
heterozygosity O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
location O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
10q23 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
q25 O-MISC B-GEOG-MISC
near O-MISC B-ACTI-MISC
COL17A1 O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
families O-MISC B-CHED-MISC
shared O-MISC B-ACTI-MISC
microsatellite O-MISC B-LIVB-MISC
polymorphisms O-MISC I-PROC-MISC
covering O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
cM O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
others O-MISC B-ACTI-MISC
shared O-MISC B-ACTI-MISC
smaller O-MISC B-ACTI-MISC
regions O-MISC B-CHED-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
cross O-MISC I-ACTI-MISC
- O-MISC I-DEVI-MISC
over O-MISC I-DEVI-MISC
events O-MISC I-DEVI-MISC
during O-MISC B-ACTI-MISC
passage O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
through O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
generations O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
4003delTC O-MISC B-LIVB-MISC
occurs O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
ancestral O-MISC B-ACTI-MISC
allele O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
haptoglobin O-MISC O-MISC
- O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
deletion O-MISC I-LIVB-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
anhaptoglobinemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
allelic O-MISC I-ACTI-MISC
deletion O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
haptoglobin O-MISC B-LIVB-MISC
( O-MISC I-PROC-MISC
Hp O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
from O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
anhaptoglobinemia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Hp O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
cluster O-MISC I-PROC-MISC
consists O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
coding O-MISC B-LIVB-MISC
regions O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
chain O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
beta O-MISC O-MISC
chain O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
haptoglobin O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
Hp O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
chain O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
beta O-MISC O-MISC
chain O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
haptoglobin O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
related O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
Hpr O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
tandem O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
side O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Southern O-MISC B-CONC-MISC
blot O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
PCR O-MISC B-CONC-MISC
analyses O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
indicated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
individual O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
anhaptoglobinemia B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
deletion O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
deletion O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
promoter O-MISC O-MISC
region O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
Hp O-MISC O-MISC
to O-MISC B-ACTI-MISC
Hpr O-MISC O-MISC
alpha O-MISC B-DISO-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Hpr O-MISC O-MISC
beta O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Hpdel O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hypohaptoglobinemia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genotypes O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
Hp2 O-MISC O-MISC
/ O-MISC B-ACTI-MISC
Hpdel O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
genotypes O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
father O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
hypohaptoglobinemic B-DISO-MISC O-MISC
( O-MISC B-ACTI-MISC
Hp2 O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Hp2 O-MISC O-MISC
/ O-MISC B-ACTI-MISC
Hpdel O-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mother O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
Hp2 O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Hp1 O-MISC O-MISC
/ O-MISC B-ACTI-MISC
Hp2 O-MISC O-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
hypohaptoglobinemic B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
Hp2 O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Hp2 O-MISC O-MISC
/ O-MISC B-ACTI-MISC
Hpdel O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
child O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
Hp1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
Hp1 O-MISC O-MISC
/ O-MISC B-ACTI-MISC
Hpdel O-MISC O-MISC
, O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
anomalous O-MISC I-ACTI-MISC
inheritance O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
Hp O-MISC O-MISC
phenotypes O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
child O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Hp1 O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Hp2 O-MISC O-MISC
/ O-MISC B-ACTI-MISC
Hpdel O-MISC O-MISC
individuals O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
extremely O-MISC B-ACTI-MISC
low O-MISC B-CHED-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Hp O-MISC O-MISC
( O-MISC B-ACTI-MISC
mean O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
SD O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
049 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
043 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
64 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
07 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
healthy O-MISC I-ANAT-MISC
volunteers O-MISC I-PHEN-MISC
having O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
Hp2 O-MISC O-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC I-GENE-MISC
Hp O-MISC O-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Hp1 O-MISC O-MISC
/ O-MISC B-ACTI-MISC
Hpdel O-MISC O-MISC
was O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

50 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
approximately O-MISC B-CHED-MISC
half O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Hp O-MISC O-MISC
in O-MISC B-ACTI-MISC
control O-MISC B-ACTI-MISC
sera O-MISC I-GENE-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Hp1 O-MISC O-MISC
phenotype O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
26 O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
33 O-MISC B-ACTI-MISC
mg O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
ml O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gene O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dosage O-MISC I-CHED-MISC
effect O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
allele O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
Hp2 O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Hp2 O-MISC O-MISC
/ O-MISC B-ACTI-MISC
Hpdel O-MISC O-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
exons O-MISC O-MISC
, O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
DNA O-MISC B-CONC-MISC
sequencing O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
anhaptoglobinemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
anomalous O-MISC I-ACTI-MISC
inheritance O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
Hp O-MISC O-MISC
phenotypes O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
explained O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hypohaptoglobinemia B-DISO-MISC I-ACTI-MISC
remains O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC

ATM O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
families O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
British O-MISC B-ORGA-MISC
Isles O-MISC I-ORGA-MISC
: O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
mutant O-MISC B-LIVB-MISC
ATM O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
leukemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
spectrum O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
ATM O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
British O-MISC B-ORGA-MISC
Isles O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
ATM O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
identified O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
native O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
British O-MISC B-ORGA-MISC
Isles O-MISC I-ORGA-MISC
, O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
founder O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
conferred O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
milder O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
respect O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
cerebellar B-DISO-MISC I-ACTI-MISC
degeneration I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
cellular O-MISC I-GENE-MISC
features O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
A B-DISO-MISC B-LIVB-MISC
- I-DISO-MISC I-PROC-MISC
T I-DISO-MISC I-PROC-MISC
families O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
ATM O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
7271T O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
G O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
homozygotes O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
heterozygotes O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
relative O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
12 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0025 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
A B-DISO-MISC O-MISC
- I-DISO-MISC B-DISO-MISC
T I-DISO-MISC B-DISO-MISC
phenotype O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
terms O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
degree O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cerebellar B-DISO-MISC I-ACTI-MISC
degeneration I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
7271T O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
G O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
allows O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
full O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
length O-MISC B-ACTI-MISC
ATM O-MISC O-MISC
protein O-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
comparable O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
unaffected O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
leukemia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
preleukemic O-MISC I-ACTI-MISC
T O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
cell O-MISC B-ANAT-MISC
proliferation O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
Hodgkin B-DISO-MISC I-ACTI-MISC
lymphoma I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
mostly O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
childhood O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
wide O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ATM O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
types O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
in O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
frame O-MISC B-ANAT-MISC
deletions O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
25 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
A B-DISO-MISC I-GENE-MISC
- I-DISO-MISC B-GEOG-MISC
T I-DISO-MISC B-GEOG-MISC
patients O-MISC I-ANAT-MISC
carried O-MISC B-ACTI-MISC
in O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
frame O-MISC I-LIVB-MISC
deletions O-MISC I-LIVB-MISC
or O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
ATM O-MISC O-MISC
protein O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
DMPK O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
severely O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
hypermethylated O-MISC I-DISO-MISC
proximal O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
largely O-MISC B-ACTI-MISC
expanded O-MISC B-ACTI-MISC
CTG O-MISC O-MISC
repeat O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Using O-MISC B-ACTI-MISC
methylation O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
restriction O-MISC O-MISC
enzymes O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
characterized O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
methylation O-MISC I-DISO-MISC
pattern O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
side O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DMPK O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
affected O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
expansions O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
repetitive O-MISC B-LIVB-MISC
sequence O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
segment O-MISC I-PROC-MISC
analyzed O-MISC B-CONC-MISC
corresponds O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genomic O-MISC B-LIVB-MISC
SacI O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
HindIII O-MISC I-PROC-MISC
fragment O-MISC I-PROC-MISC
carrying O-MISC B-ACTI-MISC
exons O-MISC O-MISC
11 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
15 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
constitutive O-MISC B-ACTI-MISC
methylation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
intron O-MISC O-MISC
12 O-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
restriction O-MISC B-LIVB-MISC
sites O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
SacII O-MISC O-MISC
and O-MISC B-ACTI-MISC
HhaI O-MISC O-MISC
, O-MISC B-ACTI-MISC
localized O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
159 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
232 O-MISC B-ACTI-MISC
bp O-MISC I-DISO-MISC
upstream O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
sites O-MISC B-LIVB-MISC
of O-MISC B-ACTI-MISC
SacII O-MISC O-MISC
, O-MISC B-ACTI-MISC
HhaI O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
HpaII O-MISC O-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
region O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
unmethylated O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
individuals O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
young O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
severely O-MISC B-CHED-MISC
affected O-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
methylation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
restriction O-MISC B-LIVB-MISC
sites O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutated O-MISC I-DISO-MISC
allele O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
disease O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
congenital O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Preliminary O-MISC B-ACTI-MISC
in O-MISC B-CHED-MISC
vivo O-MISC I-CHED-MISC
footprinting O-MISC B-CONC-MISC
data O-MISC B-CHED-MISC
gave O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
protein O-MISC O-MISC
- O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
contact O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
at O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
Sp1 O-MISC O-MISC
consensus O-MISC B-DISO-MISC
binding O-MISC B-DISO-MISC
site O-MISC B-DISO-MISC
upstream O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
interaction O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hypermethylated O-MISC B-LIVB-MISC
DMPK O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC I-ACTI-MISC
gene O-MISC I-PROC-MISC
product O-MISC I-PROC-MISC
complexes O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
receptor O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
lowers O-MISC B-DEVI-MISC
its O-MISC B-ACTI-MISC
affinity O-MISC B-OCCU-MISC
for O-MISC B-ACTI-MISC
ligand O-MISC I-DISO-MISC
binding O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
reported O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
positional O-MISC B-CONC-MISC
cloning O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
candidate O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
for O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
hemochromatosis I-DISO-MISC B-ANAT-MISC
called O-MISC B-ACTI-MISC
HFE O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
gene O-MISC O-MISC
product O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
member O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
histocompatibility O-MISC B-DISO-MISC
complex O-MISC B-DISO-MISC
class O-MISC B-DISO-MISC
I O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
family O-MISC O-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
Cys O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
282 O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
Tyr O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
C282Y O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
85 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
chromosomes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
eliminates O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ability O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
to O-MISC B-ACTI-MISC
associate O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
beta2 O-MISC O-MISC
- O-MISC B-DISO-MISC
microglobulin O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
beta2m O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
prevents O-MISC B-ACTI-MISC
cell O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
surface O-MISC I-LIVB-MISC
expression O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
no O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
on O-MISC B-ACTI-MISC
beta2m O-MISC O-MISC
association O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
H63D O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
heterozygous O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C282Y O-MISC B-LIVB-MISC
mutant O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
report O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
cultured O-MISC B-CONC-MISC
293 O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
overexpressing O-MISC I-DISO-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
or O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
HFE O-MISC O-MISC
proteins O-MISC B-DISO-MISC
that O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
H63D O-MISC O-MISC
HFE O-MISC B-DISO-MISC
proteins O-MISC B-DISO-MISC
form O-MISC B-ACTI-MISC
stable O-MISC B-ACTI-MISC
complexes O-MISC O-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
receptor O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TfR O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
C282Y O-MISC I-ACTI-MISC
mutation O-MISC B-ANAT-MISC
nearly O-MISC B-ACTI-MISC
completely O-MISC B-ACTI-MISC
prevents O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
HFE O-MISC O-MISC
protein O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
TfR O-MISC O-MISC
. O-MISC B-ACTI-MISC

Studies O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
cell O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
transferrin O-MISC O-MISC
at O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
degrees O-MISC B-ACTI-MISC
C O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
overexpressed O-MISC I-DISO-MISC
wild O-MISC B-LIVB-MISC
- O-MISC B-DISO-MISC
type O-MISC I-PROC-MISC
HFE O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
decreases O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
affinity O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
TfR O-MISC O-MISC
for O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
overexpressed O-MISC I-DISO-MISC
H63D O-MISC O-MISC
protein O-MISC B-DISO-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
effect O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
providing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
consequence O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
H63D O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Addition O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
soluble O-MISC B-CHED-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
HFE O-MISC O-MISC
/ O-MISC B-ACTI-MISC
beta2m O-MISC B-LIVB-MISC
heterodimers O-MISC O-MISC
to O-MISC B-ACTI-MISC
cultured O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
also O-MISC B-ACTI-MISC
decreased O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
apparent O-MISC B-ACTI-MISC
affinity O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
TfR O-MISC O-MISC
for O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
ligand O-MISC O-MISC
under O-MISC B-ACTI-MISC
steady O-MISC B-OCCU-MISC
- O-MISC I-OCCU-MISC
state O-MISC I-OCCU-MISC
conditions O-MISC I-OCCU-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
293 O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
HeLa O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
degrees O-MISC B-ACTI-MISC
C O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
added O-MISC B-ACTI-MISC
soluble O-MISC B-CHED-MISC
complex O-MISC O-MISC
of O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
/ O-MISC B-ACTI-MISC
beta2m O-MISC O-MISC
inhibited O-MISC B-CHED-MISC
binding O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
to O-MISC B-ACTI-MISC
HeLa O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
TfR O-MISC O-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
concentration O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
manner O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Scatchard O-MISC B-CHED-MISC
plots O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
added O-MISC B-ACTI-MISC
heterodimer O-MISC O-MISC
substantially O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
affinity O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
TfR O-MISC O-MISC
for O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
establish O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
link O-MISC I-LIVB-MISC
between O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
key O-MISC B-ACTI-MISC
protein O-MISC O-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
iron O-MISC I-DISO-MISC
transport O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
TfR O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
raise O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
alterations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
regulatory O-MISC B-OCCU-MISC
mechanism O-MISC I-CHED-MISC
may O-MISC B-ACTI-MISC
play O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
hemochromatosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Genomic O-MISC I-DISO-MISC
organization O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
UBE3A O-MISC B-LIVB-MISC
/ O-MISC I-PROC-MISC
E6 O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
AP O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
pseudogenes O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
UBE3A O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
encodes O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
E6 O-MISC O-MISC
- O-MISC B-DISO-MISC
AP O-MISC B-DISO-MISC
ubiquitin O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
ligase O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
mutated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Angelman B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
15q11 O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
q13 O-MISC B-ANAT-MISC
deletions O-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
15 O-MISC B-GEOG-MISC
paternal O-MISC I-ACTI-MISC
uniparental B-DISO-MISC I-ACTI-MISC
disomy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Previous O-MISC B-ACTI-MISC
UBE3A O-MISC O-MISC
cDNA O-MISC B-DISO-MISC
analysis O-MISC I-CONC-MISC
has O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
coding O-MISC B-LIVB-MISC
region O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
approximately O-MISC B-CHED-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

6 O-MISC B-ACTI-MISC
kb O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
3 O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
untranslated O-MISC I-PROC-MISC
region O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
UTR O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
bp O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
whereas O-MISC B-ACTI-MISC
Northern O-MISC B-CONC-MISC
analysis O-MISC B-CONC-MISC
has O-MISC B-ACTI-MISC
indicated O-MISC B-ACTI-MISC
mRNA O-MISC O-MISC
sizes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
kb O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
additional O-MISC B-ACTI-MISC
cDNA O-MISC I-GENE-MISC
clones O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
kb O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
5 O-MISC O-MISC
- O-MISC B-DISO-MISC
UTR O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
kb O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
3 O-MISC O-MISC
- O-MISC B-DISO-MISC
UTR O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
established O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genomic O-MISC I-DISO-MISC
organization O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
UBE3A O-MISC O-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sequence O-MISC B-LIVB-MISC
of O-MISC B-ACTI-MISC
intron O-MISC O-MISC
- O-MISC B-DISO-MISC
exon O-MISC B-DISO-MISC
borders O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
mapped O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
homologous O-MISC I-DISO-MISC
processed O-MISC I-LIVB-MISC
pseudogenes O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
UBE3AP1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
UBE3AP2 O-MISC O-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
chromosomes O-MISC I-GENE-MISC
2 O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
21 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
genomic O-MISC I-DISO-MISC
organization O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
will O-MISC B-ACTI-MISC
form O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
imprinting O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
UBE3A O-MISC O-MISC
. O-MISC B-ACTI-MISC

Mutation O-MISC B-CONC-MISC
spectrum O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
genotype O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
phenotype O-MISC I-CONC-MISC
analyses O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
Cowden B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
Bannayan B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Zonana I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
hamartoma B-DISO-MISC I-ACTI-MISC
syndromes I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
germline O-MISC I-GENE-MISC
PTEN O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
tumour B-DISO-MISC B-LIVB-MISC
suppressor O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
PTEN O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
maps O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
10q23 O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

3 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
encodes O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
403 O-MISC B-ACTI-MISC
amino O-MISC O-MISC
acid O-MISC B-DISO-MISC
dual O-MISC B-DISO-MISC
specificity O-MISC B-DISO-MISC
phosphatase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
protein O-MISC O-MISC
tyrosine O-MISC B-DISO-MISC
phosphatase O-MISC B-DISO-MISC
; O-MISC B-ACTI-MISC
PTPase O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
play O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
broad O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
malignancy B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Somatic O-MISC B-CHED-MISC
PTEN O-MISC B-LIVB-MISC
deletions O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
sporadic B-DISO-MISC B-CHED-MISC
breast I-DISO-MISC I-GENE-MISC
, I-DISO-MISC B-ACTI-MISC
brain I-DISO-MISC I-GENE-MISC
, I-DISO-MISC B-ACTI-MISC
prostate I-DISO-MISC I-GENE-MISC
and I-DISO-MISC B-ACTI-MISC
kidney I-DISO-MISC I-GENE-MISC
cancer I-DISO-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
lines O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
primary O-MISC I-ACTI-MISC
tumours B-DISO-MISC B-ANAT-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
endometrial B-DISO-MISC I-ACTI-MISC
carcinomas I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
malignant B-DISO-MISC I-ACTI-MISC
melanoma I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
thyroid B-DISO-MISC I-ACTI-MISC
tumours I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
PTEN O-MISC B-LIVB-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
susceptibility O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
for O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
hamartoma B-DISO-MISC I-ACTI-MISC
syndromes I-DISO-MISC B-ANAT-MISC
Cowden B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CD B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
MIM O-MISC B-LIVB-MISC
158350 O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Bannayan B-DISO-MISC B-LIVB-MISC
- I-DISO-MISC I-PROC-MISC
Zonana I-DISO-MISC I-PROC-MISC
( I-DISO-MISC B-ACTI-MISC
BZS I-DISO-MISC B-LIVB-MISC
) I-DISO-MISC B-ACTI-MISC
or I-DISO-MISC B-ACTI-MISC
Ruvalcaba I-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Riley I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
Smith I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MIM O-MISC B-LIVB-MISC
153480 O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Constitutive O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
from O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
CD B-DISO-MISC I-ACTI-MISC
families O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
BZS B-DISO-MISC I-ANAT-MISC
families O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
screened O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
germline O-MISC I-GENE-MISC
PTEN O-MISC B-LIVB-MISC
mutations O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

PTEN O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
CD B-DISO-MISC I-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
nonsense O-MISC I-ACTI-MISC
point O-MISC B-ANAT-MISC
mutations O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
deletions O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
insertions O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
deletion O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
insertion O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
site O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
scattered O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
entire O-MISC B-ACTI-MISC
length O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
PTEN O-MISC O-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
exception O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
fourth O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
last O-MISC B-ACTI-MISC
exons O-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
hot O-MISC B-ACTI-MISC
spot O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
PTEN O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
CD B-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
5 O-MISC B-DISO-MISC
that O-MISC B-ACTI-MISC
contains O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PTPase O-MISC O-MISC
core O-MISC B-DISO-MISC
motif O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
43 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
CD B-DISO-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
exon O-MISC O-MISC
. O-MISC B-ACTI-MISC

Seven O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
core O-MISC B-CHED-MISC
motif O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
pointing O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
functional O-MISC B-CHED-MISC
significance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
region O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Germline O-MISC I-GENE-MISC
PTEN O-MISC O-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
BZS B-DISO-MISC I-ACTI-MISC
families O-MISC I-ANAT-MISC
studied O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Interestingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PTPase O-MISC O-MISC
core O-MISC B-DISO-MISC
motif O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
worthy O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
note O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
nonsense O-MISC I-DISO-MISC
point O-MISC I-LIVB-MISC
mutation O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
R233X O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
germline O-MISC I-GENE-MISC
DNA O-MISC O-MISC
from O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
CD B-DISO-MISC I-ACTI-MISC
families O-MISC I-PHEN-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
BZS B-DISO-MISC I-ANAT-MISC
family O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Genotype O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
phenotype O-MISC I-LIVB-MISC
studies O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
small O-MISC B-CHED-MISC
group O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
BZS B-DISO-MISC I-ANAT-MISC
families O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
genotype O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
phenotype O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
inthe O-MISC B-ACTI-MISC
group O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
CD B-DISO-MISC I-ACTI-MISC
families O-MISC I-ANAT-MISC
revealed O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
associations O-MISC B-ACTI-MISC
worthy O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
independent O-MISC B-CHED-MISC
analyses O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
association O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
group O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
CD B-DISO-MISC I-ACTI-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
/ O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
PTEN O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
breast O-MISC I-GENE-MISC
involvement O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
unaffected O-MISC B-CHED-MISC
versus O-MISC B-ACTI-MISC
benign O-MISC B-CHED-MISC
versus O-MISC B-ACTI-MISC
malignant O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Specifically O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
PTEN O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
malignant B-DISO-MISC I-ACTI-MISC
breast I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Secondly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
appeared O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
interdependent O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
upstream O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PTPase O-MISC B-CHED-MISC
core O-MISC I-CHED-MISC
motif O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
core O-MISC B-CHED-MISC
motif O-MISC B-CHED-MISC
containing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
involvement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
organ O-MISC I-GENE-MISC
systems O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
central O-MISC I-GENE-MISC
nervous O-MISC B-GEOG-MISC
system O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
thyroid O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
breast O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
skin O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
gastrointestinal O-MISC I-GENE-MISC
tract O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
would O-MISC B-ACTI-MISC
need O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
confirmed O-MISC B-CHED-MISC
by O-MISC I-CHED-MISC
studying O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
larger O-MISC B-CHED-MISC
number O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
CD B-DISO-MISC I-ACTI-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Molecular O-MISC I-DISO-MISC
defects O-MISC B-CHED-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
complement B-DISO-MISC O-MISC
component I-DISO-MISC B-DISO-MISC
C6 I-DISO-MISC B-DISO-MISC
deficiency I-DISO-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
African O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
American O-MISC I-PHEN-MISC
family O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Complement B-DISO-MISC I-ACTI-MISC
component I-DISO-MISC B-ANAT-MISC
C6 I-DISO-MISC B-ANAT-MISC
deficiency I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
C6D B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
African O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
American O-MISC I-PHEN-MISC
male O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
meningococcal B-DISO-MISC I-ACTI-MISC
meningitis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
father O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
brothers O-MISC I-ANAT-MISC
also O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
C6D B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
gave O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
history O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
meningitis B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
neisserial B-DISO-MISC I-ACTI-MISC
infection I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
exon O-MISC O-MISC
- O-MISC I-CONC-MISC
specific O-MISC I-CONC-MISC
polymerase O-MISC I-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PCR O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
single O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
strand O-MISC B-ANAT-MISC
conformation O-MISC B-ANAT-MISC
polymorphism O-MISC B-ANAT-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
screening O-MISC B-CONC-MISC
step O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
nucleotide O-MISC B-CONC-MISC
sequencing O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
target O-MISC B-ACTI-MISC
exons O-MISC O-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proband O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
compound O-MISC B-ACTI-MISC
heterozygote O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
C6 O-MISC I-DISO-MISC
gene O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1195delC O-MISC B-LIVB-MISC
located O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
7 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
while O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1936delG O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
12 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
C6D B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unrelated O-MISC I-ACTI-MISC
African O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
American O-MISC I-PHEN-MISC
individual O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
result O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
premature O-MISC I-ACTI-MISC
termination O-MISC B-ANAT-MISC
codons O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
C6 O-MISC B-LIVB-MISC
null O-MISC I-ACTI-MISC
alleles O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Allele O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
specific O-MISC I-CONC-MISC
PCR O-MISC I-CONC-MISC
indicated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
probands O-MISC I-ANAT-MISC
two O-MISC B-ACTI-MISC
brothers O-MISC I-ANAT-MISC
also O-MISC B-ACTI-MISC
inherited O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
1195delC O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
mother O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
1936delG O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
father O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

PAX6 O-MISC O-MISC
mutations O-MISC I-DISO-MISC
reviewed O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
PAX6 O-MISC O-MISC
are O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
aniridia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Peters B-DISO-MISC I-ACTI-MISC
anomaly I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
cataracts I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
keratitis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
isolated B-DISO-MISC B-CHED-MISC
foveal I-DISO-MISC I-ACTI-MISC
hypoplasia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
locus O-MISC B-LIVB-MISC
other O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
chromosome O-MISC B-LIVB-MISC
11p13 O-MISC I-PROC-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
aniridia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
PAX6 O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
clearly O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
responsible O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Twenty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
PAX6 O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
C O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
T O-MISC I-LIVB-MISC
changes O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
CpG O-MISC O-MISC
dinucleotides O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
splicing O-MISC B-CONC-MISC
errors O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
deletion O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
insertion O-MISC B-CHED-MISC
events O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
noticeably O-MISC B-ACTI-MISC
elevated O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
paired O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rest O-MISC B-LIVB-MISC
of O-MISC I-PROC-MISC
the O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Increased O-MISC B-CHED-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
homeodomain O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
accounted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypermutable O-MISC B-ACTI-MISC
CpG O-MISC O-MISC
dinucleotide O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
codon O-MISC B-LIVB-MISC
240 O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Very O-MISC B-ACTI-MISC
nearly O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
loss O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
function O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutant O-MISC B-LIVB-MISC
allele O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
exonic O-MISC I-DISO-MISC
substitutions O-MISC I-LIVB-MISC
result O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
nonsense O-MISC B-LIVB-MISC
codons O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
with O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
extraordinarily O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
sequence O-MISC B-LIVB-MISC
conservation O-MISC B-CHED-MISC
throughout O-MISC B-ACTI-MISC
evolution O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
presumed O-MISC B-ACTI-MISC
undiscovered O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
hypothesized O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
exist O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
unidentified O-MISC B-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Genetic O-MISC B-CHED-MISC
heterogeneity O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
penetrance O-MISC B-CHED-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
genes O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
Breast B-DISO-MISC I-ANAT-MISC
Cancer I-DISO-MISC I-PHEN-MISC
Linkage O-MISC I-PHEN-MISC
Consortium O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
contribution O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
to O-MISC B-ACTI-MISC
inherited B-DISO-MISC B-CHED-MISC
breast I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
linkage O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mutation O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
237 O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
collected O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Breast B-DISO-MISC I-ANAT-MISC
Cancer I-DISO-MISC I-PHEN-MISC
Linkage O-MISC I-PHEN-MISC
Consortium O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Families O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
included O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
regard O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
or I-DISO-MISC B-ACTI-MISC
other I-DISO-MISC B-ACTI-MISC
cancers I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Overall O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
linked O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
neither O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
[ O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
] O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
predisposition O-MISC B-LIVB-MISC
genes O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
81 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
families O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
others O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
BRCA2 O-MISC O-MISC
. O-MISC B-ACTI-MISC

Conversely O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
male B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
female I-DISO-MISC I-ACTI-MISC
breast I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
BRCA2 O-MISC O-MISC
( O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
largest O-MISC B-ACTI-MISC
proportion O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
67 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
was O-MISC B-ACTI-MISC
found O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
female O-MISC I-ACTI-MISC
breast B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
only O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
estimates O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
substantially O-MISC B-ANAT-MISC
affected O-MISC I-CHED-MISC
either O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
changing O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
assumed O-MISC B-ACTI-MISC
penetrance O-MISC B-CHED-MISC
model O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
BRCA1 O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
including O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
excluding O-MISC B-CHED-MISC
BRCA1 O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
data O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
that O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
standard O-MISC B-CHED-MISC
screening O-MISC I-CHED-MISC
methods O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
coding O-MISC B-LIVB-MISC
sequence O-MISC I-PROC-MISC
or O-MISC B-ACTI-MISC
splice O-MISC B-LIVB-MISC
sites O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
63 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
51 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
77 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
estimated O-MISC B-CONC-MISC
sensitivity O-MISC I-CONC-MISC
was O-MISC B-ACTI-MISC
identical O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
direct O-MISC B-CONC-MISC
sequencing O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
techniques O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
penetrance O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
was O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
maximizing O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LOD O-MISC B-CHED-MISC
score O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
penetrance O-MISC B-CHED-MISC
functions O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
estimated O-MISC B-CHED-MISC
cumulative O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
reached O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
9 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
50 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
43 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
70 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
corresponding O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
risks O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
50 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
CI O-MISC B-CHED-MISC
0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
70 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
lifetime O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
appears O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
carriers O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
suggestion O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
lower O-MISC B-CHED-MISC
risk O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
carriers O-MISC I-ACTI-MISC
< O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Eye B-DISO-MISC I-DISO-MISC
movement I-DISO-MISC I-LIVB-MISC
abnormalities I-DISO-MISC I-ACTI-MISC
correlate O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
genotype O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
autosomal O-MISC I-ACTI-MISC
dominant O-MISC B-ANAT-MISC
cerebellar B-DISO-MISC B-ANAT-MISC
ataxia I-DISO-MISC B-ANAT-MISC
type I-DISO-MISC B-ANAT-MISC
I I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
horizontal O-MISC I-DISO-MISC
eye O-MISC I-LIVB-MISC
movements O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
visually O-MISC I-ACTI-MISC
guided O-MISC I-LIVB-MISC
saccades O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
antisaccades O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
smooth O-MISC B-CHED-MISC
pursuit O-MISC I-DEVI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
subjects O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
forms O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
autosomal O-MISC I-ACTI-MISC
dominant O-MISC B-ANAT-MISC
cerebellar B-DISO-MISC B-ANAT-MISC
ataxias I-DISO-MISC B-ANAT-MISC
type I-DISO-MISC B-ANAT-MISC
I I-DISO-MISC B-ANAT-MISC
spinocerebellar B-DISO-MISC I-ACTI-MISC
ataxias I-DISO-MISC B-ANAT-MISC
1 I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
2 I-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
SCA1 B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
SCA2 B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
SCA3 B-DISO-MISC I-ACTI-MISC
/ O-MISC B-ANAT-MISC
Machado B-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
Joseph I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MJD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
SCA1 B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
saccade O-MISC I-DISO-MISC
amplitude O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
hypermetria B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
smooth O-MISC B-CHED-MISC
pursuit O-MISC I-DEVI-MISC
gain O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
SCA2 B-DISO-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
saccade O-MISC I-DISO-MISC
velocity O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
markedly O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
percentage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
errors O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
antisaccades O-MISC O-MISC
was O-MISC B-ACTI-MISC
greatly O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
significantly O-MISC B-ACTI-MISC
correlated O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
disease O-MISC B-CHED-MISC
onset O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
smooth O-MISC B-ACTI-MISC
pursuit O-MISC B-DEVI-MISC
gain O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
trinucleotide O-MISC O-MISC
repeats O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
SCA3 B-DISO-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
gaze B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ACTI-MISC
evoked I-DISO-MISC B-ANAT-MISC
nystagmus I-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
often O-MISC B-ACTI-MISC
present O-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
saccade O-MISC I-DISO-MISC
hypometria O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
smooth O-MISC B-ACTI-MISC
pursuit O-MISC B-DEVI-MISC
gain O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
markedly O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
criteria O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
saccade O-MISC I-DISO-MISC
amplitude O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
saccade O-MISC I-DISO-MISC
velocity O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
gaze B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
evoked I-DISO-MISC B-ANAT-MISC
nystagmus I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
permitted O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
correct O-MISC B-ACTI-MISC
assignment O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SCA1 B-DISO-MISC O-MISC
, O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
SCA2 B-DISO-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
93 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
SCA3 B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
genetically O-MISC B-CHED-MISC
confirmed O-MISC I-CHED-MISC
patient O-MISC I-ANAT-MISC
group O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
help O-MISC B-ACTI-MISC
orient O-MISC B-ACTI-MISC
diagnoses O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
SCA1 B-DISO-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
SCA2 B-DISO-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
SCA3 B-DISO-MISC B-LIVB-MISC
at O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
clinical O-MISC I-CONC-MISC
stages O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diseases O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Genetic O-MISC B-CHED-MISC
basis O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
molecular O-MISC I-DISO-MISC
mechanism O-MISC I-LIVB-MISC
for O-MISC B-ACTI-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Ventricular B-DISO-MISC I-ACTI-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
causes O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
sudden O-MISC I-ACTI-MISC
deaths O-MISC B-ANAT-MISC
each O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
USA O-MISC B-ORGA-MISC
alone O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
approximately O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
demonstrable O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
non O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
cardiac O-MISC B-ACTI-MISC
causes O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
account O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
episode O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
idiopathic B-DISO-MISC I-ACTI-MISC
ventricular I-DISO-MISC B-ANAT-MISC
fibrillation I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
IVF B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
distinct O-MISC B-ACTI-MISC
group O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
IVF B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
characteristic O-MISC B-ACTI-MISC
electrocardiographic O-MISC I-ACTI-MISC
pattern O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
small O-MISC I-ACTI-MISC
size O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
pedigrees O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sudden B-DISO-MISC I-ACTI-MISC
death I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
molecular O-MISC B-CONC-MISC
genetic O-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
IVF B-DISO-MISC I-ACTI-MISC
have O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
done O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Because O-MISC B-ACTI-MISC
IVF B-DISO-MISC I-ACTI-MISC
causes O-MISC B-ACTI-MISC
cardiac O-MISC I-ACTI-MISC
rhythm O-MISC B-ANAT-MISC
disturbance O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
investigated O-MISC B-CHED-MISC
whether O-MISC B-ACTI-MISC
malfunction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ion O-MISC O-MISC
channels O-MISC B-DISO-MISC
could O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disorder O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
studying O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cardiac O-MISC B-LIVB-MISC
sodium O-MISC I-PROC-MISC
channel O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
SCN5A O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
now O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
donor O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
frameshift O-MISC I-ACTI-MISC
mutation O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
coding O-MISC B-LIVB-MISC
region O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
SCN5A O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
IVF B-DISO-MISC I-ACTI-MISC
families O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
sodium O-MISC O-MISC
channels O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
recover O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
inactivation O-MISC B-CHED-MISC
more O-MISC B-ACTI-MISC
rapidly O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frameshift O-MISC I-DISO-MISC
mutation O-MISC I-DISO-MISC
causes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sodium O-MISC O-MISC
channel O-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
non O-MISC B-CHED-MISC
- O-MISC B-ANAT-MISC
functional O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
cardiac O-MISC I-GENE-MISC
ion O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
channel O-MISC I-PROC-MISC
genes O-MISC I-PROC-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
IVF B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Molecular O-MISC B-CHED-MISC
heterogeneity O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
mucopolysaccharidosis B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Australia O-MISC B-ORGA-MISC
and O-MISC B-ACTI-MISC
Northern O-MISC B-ORGA-MISC
Ireland O-MISC I-ORGA-MISC
: O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
mutations O-MISC I-DISO-MISC
including O-MISC B-ACTI-MISC
T312S O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
allele O-MISC B-LIVB-MISC
that O-MISC B-ACTI-MISC
confers O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mild O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Mucopolysaccharidosis B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MPS B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-DISO-MISC
recessive I-DISO-MISC B-ACTI-MISC
lysosomal I-DISO-MISC I-ACTI-MISC
storage I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
caused O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
genetic B-DISO-MISC B-CHED-MISC
defect I-DISO-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
N O-MISC O-MISC
- O-MISC B-DISO-MISC
acetylgalactosamine O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
6 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
sulfate O-MISC B-DISO-MISC
sulfatase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
GALNS O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Previous O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
British O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Irish O-MISC I-PHEN-MISC
population O-MISC I-ANAT-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I113F O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
among O-MISC B-ACTI-MISC
MPS B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
GALNS O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
from O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
MPS B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
Australia O-MISC B-ORGA-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
Northern O-MISC B-ORGA-MISC
Ireland O-MISC I-ORGA-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
phenotypes O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
intermediate O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
; O-MISC B-ACTI-MISC
mild O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
accounted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
unrelated O-MISC I-ACTI-MISC
alleles O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
T312S O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
found O-MISC B-ACTI-MISC
exclusively O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
milder O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
I113F O-MISC I-ANAT-MISC
that O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
I113F O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
T312S O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
accounted O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
unrelated O-MISC I-ACTI-MISC
alleles O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
residual O-MISC B-CHED-MISC
GALNS O-MISC O-MISC
activity O-MISC I-DISO-MISC
seen O-MISC B-ACTI-MISC
when O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
T312S O-MISC B-LIVB-MISC
mutant O-MISC I-PROC-MISC
cDNA O-MISC O-MISC
is O-MISC B-ACTI-MISC
overexpressed O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
cells O-MISC I-GENE-MISC
provides O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
explanation O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mild O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
distribution O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
relative O-MISC B-CHED-MISC
frequencies O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I113F O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
T312S O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
Australia O-MISC B-ORGA-MISC
corresponded O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Northern O-MISC B-ORGA-MISC
Ireland O-MISC I-ORGA-MISC
and O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
unique O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
introduced O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Australia O-MISC B-ORGA-MISC
by O-MISC B-ACTI-MISC
Irish O-MISC I-ANAT-MISC
migrants O-MISC I-PHEN-MISC
during O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
19th O-MISC B-ACTI-MISC
century O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Haplotype O-MISC I-DISO-MISC
analysis O-MISC B-CONC-MISC
using O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
RFLPs O-MISC O-MISC
provides O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I113F O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
originated O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
ancestor O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
identified O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
provide O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
extensive O-MISC B-ACTI-MISC
allelic O-MISC B-LIVB-MISC
heterogeneity O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
MPS B-DISO-MISC I-ACTI-MISC
IVA I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
British O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Irish O-MISC I-PHEN-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
transmission O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
Australia O-MISC B-ORGA-MISC
by O-MISC B-ACTI-MISC
British O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Irish O-MISC I-PHEN-MISC
migrants O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Identification O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
constitutional O-MISC B-CHED-MISC
WT1 O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
isolated O-MISC B-ACTI-MISC
diffuse B-DISO-MISC B-CHED-MISC
mesangial I-DISO-MISC I-ACTI-MISC
sclerosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
genotype O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
correlations O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
computerized O-MISC B-CHED-MISC
mutation O-MISC I-CHED-MISC
database O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Constitutional O-MISC I-ACTI-MISC
mutations O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
WT1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
encoding O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
zinc O-MISC O-MISC
- O-MISC B-DISO-MISC
finger O-MISC B-DISO-MISC
transcription O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
renal O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
gonadal O-MISC I-DISO-MISC
development O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Denys B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Drash I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DDS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
diffuse B-DISO-MISC I-ACTI-MISC
mesangial I-DISO-MISC B-ANAT-MISC
sclerosis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DMS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
pseudohermaphroditism B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
Wilms B-DISO-MISC I-ACTI-MISC
tumor I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
WT B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Most O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
DDS B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
lie O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
8 O-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
exon O-MISC O-MISC
9 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
encoding O-MISC B-DEVI-MISC
zinc O-MISC B-LIVB-MISC
finger O-MISC I-PROC-MISC
2 O-MISC I-PROC-MISC
or O-MISC B-ACTI-MISC
zinc O-MISC B-LIVB-MISC
finger O-MISC I-PROC-MISC
3 O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hot O-MISC B-CHED-MISC
spot O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
R394W O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
9 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
a O-MISC B-ACTI-MISC
series O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
24 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
isolated B-DISO-MISC I-ACTI-MISC
DMS I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
IDMS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
DDS B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
urogenital B-DISO-MISC I-ACTI-MISC
abnormalities I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
WT B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
WT1 O-MISC B-LIVB-MISC
heterozygous O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
IDMS B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
IDMS B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
WT1 O-MISC I-ACTI-MISC
mutations O-MISC B-ANAT-MISC
underwent O-MISC B-ACTI-MISC
normal O-MISC I-DISO-MISC
puberty O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
IDMS B-DISO-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
DDS B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

No O-MISC I-ACTI-MISC
WT1 O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
IDMS B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
genetic O-MISC I-DISO-MISC
heterogeneity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
analyzed O-MISC B-ACTI-MISC
genotype O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
correlations O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
constitution O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
WT1 O-MISC B-LIVB-MISC
mutation O-MISC I-LIVB-MISC
database O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
84 O-MISC B-ACTI-MISC
germ O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
line O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
compare O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
distribution O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
type O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
according O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
exons O-MISC O-MISC
8 O-MISC B-DISO-MISC
and O-MISC B-DISO-MISC
9 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
DMS B-DISO-MISC O-MISC
; O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
DMS B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
exon O-MISC O-MISC
8 O-MISC B-DISO-MISC
mutations O-MISC I-DISO-MISC
among O-MISC B-ACTI-MISC
46 O-MISC I-ACTI-MISC
, O-MISC B-ANAT-MISC
XY O-MISC B-ANAT-MISC
patients O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
phenotype O-MISC I-LIVB-MISC
than O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
46 O-MISC I-ACTI-MISC
, O-MISC B-ANAT-MISC
XY O-MISC B-ANAT-MISC
patients O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
sexual O-MISC I-ACTI-MISC
ambiguity O-MISC B-ANAT-MISC
or O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
phenotype O-MISC I-LIVB-MISC
; O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
statistically O-MISC B-CHED-MISC
significant O-MISC I-CHED-MISC
evidence O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
exons O-MISC O-MISC
8 O-MISC B-DISO-MISC
and O-MISC B-DISO-MISC
9 O-MISC B-DISO-MISC
preferentially O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
amino O-MISC O-MISC
acids O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
functions O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
185delAG O-MISC B-LIVB-MISC
BRCA1 O-MISC I-PROC-MISC
mutation O-MISC I-DISO-MISC
originated O-MISC B-ACTI-MISC
before O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dispersion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Jews O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diaspora O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Ashkenazim O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
185delAG O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
Ashkenazi O-MISC I-ANAT-MISC
Jews O-MISC I-PHEN-MISC
both O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
familial B-DISO-MISC I-ACTI-MISC
breast I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
ovarian I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
general O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
Ashkenazi O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
carriers O-MISC I-ACTI-MISC
share O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
allelic O-MISC B-CHED-MISC
pattern O-MISC I-CHED-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
locus O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
Ashkenazi O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
also O-MISC B-ACTI-MISC
occurs O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Iraqi O-MISC I-ANAT-MISC
Jews O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
allelic O-MISC B-LIVB-MISC
pattern O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
extended O-MISC B-CHED-MISC
our O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
Ashkenazi O-MISC B-ANAT-MISC
subsets O-MISC B-CHED-MISC
354 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Moroccan O-MISC I-ANAT-MISC
origin O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
200 O-MISC B-ACTI-MISC
Yemenites O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
Iranian O-MISC I-ANAT-MISC
Jews O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Heteroduplex O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
complemented O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
DNA O-MISC I-CONC-MISC
sequencing O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
abnormally O-MISC I-ACTI-MISC
migrating O-MISC B-ANAT-MISC
bands O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
employed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Moroccan O-MISC I-ANAT-MISC
origin O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
none O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Yemenites O-MISC I-ANAT-MISC
or O-MISC B-ACTI-MISC
Iranians O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
carrier O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
185delAG O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

BRCA1 O-MISC B-LIVB-MISC
allelic O-MISC B-CHED-MISC
patterns O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
determined O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
non O-MISC B-PHEN-MISC
- O-MISC B-UnknownType-MISC
Ashkenazi O-MISC B-UnknownType-MISC
185delAG O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
carriers O-MISC I-ACTI-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
/ I-DISO-MISC B-ANAT-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Ashkenazi O-MISC I-PHEN-MISC
individuals O-MISC I-PHEN-MISC
shared O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
Ashkenazi O-MISC I-DISO-MISC
haplotype O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
closely O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
pattern O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rest O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
displayed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
distinct O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
allelic O-MISC B-LIVB-MISC
pattern O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
185delAG O-MISC B-ACTI-MISC
BRCA1 O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
occurs O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Ashkenazi O-MISC I-PHEN-MISC
populations O-MISC I-PHEN-MISC
at O-MISC B-ACTI-MISC
rates O-MISC B-ACTI-MISC
comparable O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Ashkenazim O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Jewish O-MISC I-ANAT-MISC
185delAG O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
carriers O-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-CHED-MISC
allelic O-MISC B-LIVB-MISC
pattern O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
supporting O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
founder O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
notion O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
dating O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
origin O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
earlier O-MISC B-CHED-MISC
date O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
currently O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
different O-MISC B-CHED-MISC
allelic O-MISC B-CHED-MISC
pattern O-MISC I-CHED-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
locus O-MISC B-CHED-MISC
even O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
Jewish O-MISC I-ANAT-MISC
mutation O-MISC I-DISO-MISC
carriers O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
might O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
arose O-MISC B-ACTI-MISC
independently O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Crystal O-MISC O-MISC
structure O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC O-MISC
protein O-MISC B-DISO-MISC
HFE O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
characterization O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
interaction O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
receptor O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

HFE O-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
MHC O-MISC O-MISC
- O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
protein O-MISC O-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
mutated O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
iron B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
overload I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
hereditary B-DISO-MISC I-ACTI-MISC
hemochromatosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

HFE O-MISC O-MISC
binds O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
receptor O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
TfR O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
reduces O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
affinity O-MISC B-OCCU-MISC
for O-MISC B-ACTI-MISC
iron O-MISC O-MISC
- O-MISC B-ACTI-MISC
loaded O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
, O-MISC B-ACTI-MISC
implicating O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
in O-MISC B-ACTI-MISC
iron O-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

6 O-MISC B-ACTI-MISC
A O-MISC B-ACTI-MISC
crystal O-MISC O-MISC
structure O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
reveals O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
locations O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patch O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
histidines O-MISC O-MISC
that O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
pH O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
dependent O-MISC B-CHED-MISC
interactions O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
soluble O-MISC B-CHED-MISC
TfR O-MISC O-MISC
and O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
bind O-MISC I-DISO-MISC
tightly O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basic O-MISC B-CHED-MISC
pH O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cell O-MISC I-GENE-MISC
surface O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
acidic O-MISC B-CHED-MISC
pH O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
intracellular O-MISC I-GENE-MISC
vesicles O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

TfR O-MISC I-GENE-MISC
HFE O-MISC O-MISC
stoichiometry O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
differs O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
TfR O-MISC I-GENE-MISC
transferrin O-MISC O-MISC
stoichiometry O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
implying O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
different O-MISC B-CHED-MISC
mode O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
binding O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
and O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
to O-MISC B-ACTI-MISC
TfR O-MISC O-MISC
, O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
our O-MISC B-ACTI-MISC
demonstration O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
HFE O-MISC O-MISC
, O-MISC B-ACTI-MISC
transferrin O-MISC O-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
TfR O-MISC O-MISC
form O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
ternary O-MISC B-CHED-MISC
complex O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Identification O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Arg778Leu O-MISC I-DISO-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
Korean O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
R778L O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
A874V O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
L1083F O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2304delC O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
copper O-MISC O-MISC
- O-MISC B-DISO-MISC
transporting O-MISC B-DISO-MISC
enzyme O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
P O-MISC O-MISC
- O-MISC B-DISO-MISC
type O-MISC B-DISO-MISC
ATPase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ATP7B O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Korean O-MISC I-ANAT-MISC
Patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Arg778Leu O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
enzyme O-MISC O-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
unrelated O-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
studied O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
allele O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
considerably O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
Asian O-MISC I-ANAT-MISC
populations O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
single O-MISC I-ACTI-MISC
nucleotide O-MISC B-ANAT-MISC
deletion O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
2304delC O-MISC O-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Since O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
cDNA O-MISC O-MISC
nucleotide O-MISC B-DISO-MISC
2302 O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
2302insC O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
region O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATP7B O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
susceptible O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
rearrangements O-MISC I-LIVB-MISC
causing O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Disruption O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
splicing O-MISC I-DISO-MISC
regulated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
CUG O-MISC O-MISC
- O-MISC B-DISO-MISC
binding O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
CTG O-MISC B-CONC-MISC
expansion O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
3 O-MISC B-LIVB-MISC
untranslated O-MISC B-LIVB-MISC
region O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
model O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
RNAs O-MISC O-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expanded O-MISC B-CHED-MISC
allele O-MISC B-LIVB-MISC
create O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gain O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
function O-MISC B-ANAT-MISC
mutation O-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inappropriate O-MISC B-ACTI-MISC
binding O-MISC I-DISO-MISC
of O-MISC I-LIVB-MISC
proteins O-MISC I-LIVB-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CUG O-MISC O-MISC
repeats O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Data O-MISC B-CHED-MISC
presented O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
conserved O-MISC B-ACTI-MISC
heterogeneous O-MISC B-CHED-MISC
nuclear O-MISC O-MISC
ribonucleoprotein O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
CUG O-MISC O-MISC
- O-MISC B-DISO-MISC
binding O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CUG O-MISC O-MISC
- O-MISC B-DISO-MISC
BP O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
mediate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
trans O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
dominant O-MISC I-LIVB-MISC
effect O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RNA O-MISC O-MISC
. O-MISC B-ACTI-MISC

CUG O-MISC O-MISC
- O-MISC B-DISO-MISC
BP O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
bind O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
cardiac O-MISC O-MISC
troponin O-MISC B-DISO-MISC
T O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
cTNT O-MISC O-MISC
) O-MISC B-ACTI-MISC
pre O-MISC O-MISC
- O-MISC B-DISO-MISC
messenger O-MISC B-DISO-MISC
RNA O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
regulate O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
alternative O-MISC I-DISO-MISC
splicing O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Splicing O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
cTNT O-MISC O-MISC
was O-MISC B-ACTI-MISC
disrupted O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
striated O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
normal O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
expressing O-MISC I-DISO-MISC
transcripts O-MISC O-MISC
that O-MISC B-ACTI-MISC
contain O-MISC B-ACTI-MISC
CUG O-MISC O-MISC
repeats O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Altered O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC I-LIVB-MISC
genes O-MISC I-LIVB-MISC
regulated O-MISC B-ACTI-MISC
posttranscriptionally O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
CUG O-MISC O-MISC
- O-MISC B-DISO-MISC
BP O-MISC B-DISO-MISC
therefore O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Identification O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
nonsense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
substitution O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
vasopressin O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
neurophysin O-MISC I-PROC-MISC
II O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
Spanish O-MISC I-ANAT-MISC
kindreds O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
familial B-DISO-MISC I-ACTI-MISC
neurohypophyseal I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Familial B-DISO-MISC I-ACTI-MISC
neurohypophyseal I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
insipidus I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
FNDI B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
deficiency O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
antidiuretic O-MISC O-MISC
hormone O-MISC B-DISO-MISC
arginine O-MISC O-MISC
vasopressin O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
AVP O-MISC O-MISC
) O-MISC B-ACTI-MISC
encoded O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
AVP O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
neurophysin O-MISC I-PROC-MISC
II O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
AVP O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
NPII O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
on O-MISC B-ACTI-MISC
chromosome O-MISC B-LIVB-MISC
20p13 O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
analyzed O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
FNDI B-DISO-MISC I-ACTI-MISC
using O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
automated O-MISC B-CONC-MISC
fluorescent O-MISC I-CONC-MISC
, O-MISC I-CONC-MISC
solid O-MISC I-CONC-MISC
phase O-MISC I-CONC-MISC
, O-MISC I-CONC-MISC
single O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
stranded O-MISC I-CONC-MISC
DNA O-MISC I-CONC-MISC
sequencing O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
PCR O-MISC B-CONC-MISC
- O-MISC B-ACTI-MISC
amplified O-MISC B-OCCU-MISC
AVP O-MISC O-MISC
- O-MISC B-DISO-MISC
NPII O-MISC B-DISO-MISC
DNA O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
individuals O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
nonsense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
3 O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
consisting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
G O-MISC I-DISO-MISC
to O-MISC I-LIVB-MISC
T O-MISC I-LIVB-MISC
transition O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
nucleotide O-MISC O-MISC
2101 O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
produces O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
stop O-MISC B-OCCU-MISC
signal O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
codon O-MISC B-LIVB-MISC
82 O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
Glu O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
NPII O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
premature O-MISC I-DISO-MISC
termination O-MISC I-LIVB-MISC
eliminates O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
terminal O-MISC I-PROC-MISC
domain O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
NPII O-MISC O-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cysteine O-MISC O-MISC
residue O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
position O-MISC B-CHED-MISC
85 O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
involved O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
correct O-MISC B-ACTI-MISC
folding O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prohormone O-MISC O-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
G279A O-MISC O-MISC
substitution O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
position O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
1 O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
signal O-MISC O-MISC
peptide O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
individuals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
replaces O-MISC B-ACTI-MISC
Ala O-MISC O-MISC
with O-MISC B-ACTI-MISC
Thr O-MISC O-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
frequent O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
FNDI B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
thought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
reduce O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
efficiency O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cleavage O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
signal O-MISC O-MISC
peptidases O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Genetic O-MISC I-DISO-MISC
heterogeneity O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
Saethre B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Chotzen I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
TWIST O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
FGFR O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Thirty O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
features O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Saethre B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Chotzen I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
condition I-DISO-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
craniosynostosis B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
limb B-DISO-MISC I-ACTI-MISC
anomalies I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
screened O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
TWIST O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
FGFR2 O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
FGFR3 O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Nine O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
recurrent O-MISC B-CHED-MISC
TWIST O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Seven O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
FGFR3 O-MISC B-LIVB-MISC
P250R O-MISC B-ANAT-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
individual O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
FGFR2 O-MISC B-LIVB-MISC
VV269 O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
270 O-MISC I-PROC-MISC
deletion O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
date O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
detection O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
TWIST O-MISC B-LIVB-MISC
or O-MISC B-ACTI-MISC
FGFR O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
Saethre B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Chotzen I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
elsewhere O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
TWIST O-MISC B-LIVB-MISC
mutations O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

More O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
TWIST O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
now O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
phenotypic O-MISC I-DISO-MISC
features O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
third O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
TWIST O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
coronal B-DISO-MISC I-ACTI-MISC
synostosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
brachycephaly B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
low B-DISO-MISC I-ACTI-MISC
frontal I-DISO-MISC B-ANAT-MISC
hairline I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
facial B-DISO-MISC I-ACTI-MISC
asymmetry I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
ptosis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
hypertelorism B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
broad B-DISO-MISC I-ACTI-MISC
great I-DISO-MISC B-ANAT-MISC
toes I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
clinodactyly B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Significant O-MISC B-ACTI-MISC
intra O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
interfamilial O-MISC B-ACTI-MISC
phenotypic O-MISC I-DISO-MISC
variability O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
TWIST O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
FGFR O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
overlap O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
features O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
craniosynostotic B-DISO-MISC I-ACTI-MISC
condition I-DISO-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
Saethre B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Chotzen I-DISO-MISC B-ANAT-MISC
, I-DISO-MISC B-ACTI-MISC
Crouzon I-DISO-MISC I-ACTI-MISC
, I-DISO-MISC B-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
Pfeiffer I-DISO-MISC I-ACTI-MISC
syndromes I-DISO-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
support O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
TWIST O-MISC O-MISC
and O-MISC B-ACTI-MISC
FGFRs O-MISC O-MISC
are O-MISC B-ACTI-MISC
components O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
molecular O-MISC I-DISO-MISC
pathway O-MISC I-LIVB-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
modulation O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
craniofacial O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
limb O-MISC I-DISO-MISC
development O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Mutation O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
UBE3A O-MISC O-MISC
in O-MISC B-ACTI-MISC
Angelman B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Angelman B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
chromosome O-MISC B-PHEN-MISC
15q11 O-MISC B-UnknownType-MISC
- O-MISC B-UnknownType-MISC
q13 O-MISC B-UnknownType-MISC
deletions O-MISC B-UnknownType-MISC
of O-MISC B-ACTI-MISC
maternal O-MISC I-ACTI-MISC
origin O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
paternal O-MISC I-ACTI-MISC
uniparental B-DISO-MISC B-ANAT-MISC
disomy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ANAT-MISC
UPD B-DISO-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
15 O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
imprinting O-MISC I-ACTI-MISC
defects O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
UBE3A O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

UBE3A O-MISC O-MISC
encodes O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
ubiquitin O-MISC O-MISC
- O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
ligase O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
shows O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
imprinting O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
UBE3A O-MISC B-LIVB-MISC
coding O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
region O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
detected O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
SSCP O-MISC B-CONC-MISC
analysis O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
AS B-DISO-MISC I-ACTI-MISC
individuals O-MISC I-ANAT-MISC
or O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
identical O-MISC B-CHED-MISC
de O-MISC B-CHED-MISC
novo O-MISC I-CHED-MISC
5 O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
bp O-MISC I-LIVB-MISC
duplications O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
16 O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
unique O-MISC B-CHED-MISC
mutations O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
deletions O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
insertions O-MISC I-ACTI-MISC
predicted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
frameshifts O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
stop O-MISC B-LIVB-MISC
codon O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
predicted O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
insertion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
isoleucine O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hect O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
UBE3A O-MISC O-MISC
protein O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
functions O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
E2 O-MISC I-DISO-MISC
binding O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
ubiquitin O-MISC I-DISO-MISC
transfer O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Eight O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
familial O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
sporadic O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
familial O-MISC B-CHED-MISC
cases O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
sporadic O-MISC B-CHED-MISC
case O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
mosaicism O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
UBE3A O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mother O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
AS B-DISO-MISC I-ACTI-MISC
sons O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maternal O-MISC I-ANAT-MISC
grandfather O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
AS B-DISO-MISC I-ACTI-MISC
first O-MISC I-ANAT-MISC
cousins O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mother O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
AS B-DISO-MISC I-ACTI-MISC
daughter O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
frequencies O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
35 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
sporadic O-MISC I-ACTI-MISC
cases O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
80 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
familial O-MISC B-CHED-MISC
cases O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC I-ACTI-MISC
845 O-MISC B-ACTI-MISC
G O-MISC O-MISC
- O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
A O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
187 O-MISC B-ACTI-MISC
C O-MISC O-MISC
- O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
G O-MISC I-LIVB-MISC
mutations O-MISC I-DISO-MISC
: O-MISC B-ACTI-MISC
prevalence O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Caucasian O-MISC I-PHEN-MISC
populations O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Hemochromatosis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
inherited B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
iron I-DISO-MISC I-DISO-MISC
metabolism I-DISO-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
leads O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
untreated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
iron B-DISO-MISC I-ACTI-MISC
overload I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
premature B-DISO-MISC I-ACTI-MISC
death I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
HFE O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
characterization O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
has O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
contains O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
amino O-MISC I-DISO-MISC
acid O-MISC I-LIVB-MISC
substitutions O-MISC I-LIVB-MISC
- O-MISC B-ACTI-MISC
cDNA O-MISC O-MISC
nucleotides O-MISC O-MISC
845 O-MISC B-ACTI-MISC
G O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
A O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
C282Y O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
187 O-MISC B-ACTI-MISC
C O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
G O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
H63D O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Caucasians O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
affecting O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
300 O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
northern O-MISC I-ANAT-MISC
European O-MISC I-PHEN-MISC
origin O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
used O-MISC B-ACTI-MISC
PCR O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
restriction O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
enzyme O-MISC I-CONC-MISC
digestion O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
analyze O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
845 O-MISC B-ACTI-MISC
G O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
A O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
187 O-MISC B-ACTI-MISC
C O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
G O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
HLA O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
typed O-MISC I-PROC-MISC
samples O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Caucasian O-MISC I-PHEN-MISC
populations O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
comprising O-MISC B-ACTI-MISC
Australian O-MISC I-ANAT-MISC
Aboriginal O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Pacific O-MISC I-ANAT-MISC
Islanders O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Results O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
845 O-MISC B-ACTI-MISC
G O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
A O-MISC I-PROC-MISC
mutation O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
present O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
allele O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
32 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
conjunction O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
HLA O-MISC B-LIVB-MISC
haplotypes O-MISC I-DISO-MISC
common O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Caucasians O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
845 O-MISC B-ACTI-MISC
G O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
A O-MISC I-PROC-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
introduced O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
by O-MISC B-ACTI-MISC
Caucasian O-MISC I-ANAT-MISC
admixture O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

187 O-MISC B-ACTI-MISC
C O-MISC O-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
G O-MISC O-MISC
was O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
allele O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

68 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
populations O-MISC I-ANAT-MISC
analyzed O-MISC B-CONC-MISC
( O-MISC B-ACTI-MISC
Australian O-MISC I-ANAT-MISC
Aboriginal O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Australian O-MISC I-ANAT-MISC
Aboriginal O-MISC I-ANAT-MISC
samples O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
187 O-MISC B-ACTI-MISC
C O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
G O-MISC O-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
HLA O-MISC O-MISC
haplotypes O-MISC I-DISO-MISC
common O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Caucasians O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
introduced O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
recent O-MISC B-ACTI-MISC
admixture O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Chinese O-MISC I-ANAT-MISC
samples O-MISC B-GENE-MISC
analyzed O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
187 O-MISC B-ACTI-MISC
C O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
G O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
wide O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
HLA O-MISC B-LIVB-MISC
haplotypes O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
widespread O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
predate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
genetically O-MISC B-OCCU-MISC
restricted O-MISC B-CHED-MISC
845 O-MISC B-ACTI-MISC
G O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
A O-MISC I-PROC-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Genotype O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
correlations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
attenuated B-DISO-MISC B-CHED-MISC
adenomatous I-DISO-MISC I-ANAT-MISC
polyposis I-DISO-MISC I-PHEN-MISC
coli I-DISO-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Germ O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
line O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tumor B-DISO-MISC B-LIVB-MISC
suppressor O-MISC I-PROC-MISC
APC O-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
implicated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
attenuated B-DISO-MISC I-ANAT-MISC
adenomatous I-DISO-MISC I-PHEN-MISC
polyposis I-DISO-MISC I-PHEN-MISC
coli I-DISO-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
AAPC B-DISO-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
variant O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
familial B-DISO-MISC I-ACTI-MISC
adenomatous I-DISO-MISC B-ANAT-MISC
polyposis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
FAP B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

AAPC B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
occurrence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
colonic B-DISO-MISC I-ACTI-MISC
adenomas I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
later O-MISC B-ACTI-MISC
onset O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
> O-MISC B-ACTI-MISC
40 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
aim O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
was O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-DEVI-MISC
genotype O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
phenotype O-MISC I-LIVB-MISC
correlations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
AAPC B-DISO-MISC I-ACTI-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
protein O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
truncation O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
( O-MISC I-CONC-MISC
PTT O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
assay O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
entire O-MISC B-ACTI-MISC
coding O-MISC B-LIVB-MISC
region O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
screened O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
AAPC B-DISO-MISC I-ACTI-MISC
kindreds O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
phenotypic O-MISC I-ACTI-MISC
differences O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
germ O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
line O-MISC I-LIVB-MISC
APC B-DISO-MISC B-LIVB-MISC
mutations O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
kindreds O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
located O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
different O-MISC B-CHED-MISC
regions O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
end O-MISC B-CHED-MISC
spanning O-MISC B-ACTI-MISC
exons O-MISC O-MISC
4 O-MISC B-DISO-MISC
and O-MISC B-DISO-MISC
5 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
exon O-MISC O-MISC
9 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
distal O-MISC B-CHED-MISC
end O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Variability O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
adenomas I-DISO-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
apparent O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
region O-MISC B-CHED-MISC
1 O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
upper O-MISC B-CHED-MISC
- O-MISC B-GEOG-MISC
gastrointestinal O-MISC B-GEOG-MISC
manifestations O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
region O-MISC B-CHED-MISC
2 O-MISC I-CHED-MISC
or O-MISC B-ACTI-MISC
region O-MISC B-CHED-MISC
3 O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
adenomas B-DISO-MISC I-ACTI-MISC
tended O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
region O-MISC B-CHED-MISC
1 O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
AAPC B-DISO-MISC I-ACTI-MISC
kindreds O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
predominance O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
right O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
sided O-MISC I-CHED-MISC
colorectal B-DISO-MISC I-ACTI-MISC
adenomas I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
rectal B-DISO-MISC I-ACTI-MISC
polyp I-DISO-MISC B-ANAT-MISC
sparing O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

No O-MISC B-ACTI-MISC
desmoid B-DISO-MISC I-ACTI-MISC
tumors I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
kindreds O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
data O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
AAPC B-DISO-MISC I-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
location O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
partially O-MISC B-ACTI-MISC
predict O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
phenotypic O-MISC I-DISO-MISC
expression O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
should O-MISC B-ACTI-MISC
help O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
design O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
tailored O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
management O-MISC I-CONC-MISC
protocols O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
subset O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
FAP B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Wilms B-DISO-MISC I-ACTI-MISC
' I-DISO-MISC B-ANAT-MISC
tumor I-DISO-MISC B-ANAT-MISC
1 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Dax O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
modulate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
orphan O-MISC O-MISC
nuclear O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
SF O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
sex O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-CHED-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Products O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
steroidogenic O-MISC B-LIVB-MISC
factor O-MISC I-PROC-MISC
1 O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
SF O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
1 O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Wilms B-DISO-MISC B-LIVB-MISC
tumor I-DISO-MISC I-PROC-MISC
1 O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
WT1 O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
essential O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
mammalian O-MISC I-ANAT-MISC
gonadogenesis O-MISC I-DISO-MISC
prior O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
sexual O-MISC I-DISO-MISC
differentiation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
males O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
SF O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
participates O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
sexual O-MISC I-DISO-MISC
development O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
regulating O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
polypeptide O-MISC O-MISC
hormone O-MISC B-DISO-MISC
Mullerian O-MISC O-MISC
inhibiting O-MISC B-DISO-MISC
substance O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MIS O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
WT1 O-MISC O-MISC
- O-MISC B-ACTI-MISC
KTS O-MISC O-MISC
isoforms O-MISC O-MISC
associate O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
synergize O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
SF O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
to O-MISC B-ACTI-MISC
promote O-MISC B-DEVI-MISC
MIS O-MISC I-ACTI-MISC
expression O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
WT1 O-MISC B-LIVB-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
male B-DISO-MISC I-DISO-MISC
pseudohermaphroditism I-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
Denys B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Drash I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
fail O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
synergize O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
SF O-MISC I-ANAT-MISC
- O-MISC B-ANAT-MISC
1 O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Additionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
X O-MISC O-MISC
- O-MISC B-DISO-MISC
linked O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
candidate O-MISC B-ACTI-MISC
dosage O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
sensitive O-MISC B-CHED-MISC
sex O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
reversal O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
Dax O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
1 O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
antagonizes O-MISC I-DISO-MISC
synergy O-MISC I-DISO-MISC
between O-MISC B-ACTI-MISC
SF O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
WT1 O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
through O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
direct O-MISC B-CHED-MISC
interaction O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
SF O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
propose O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
WT1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
Dax O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
functionally O-MISC B-ACTI-MISC
oppose O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
testis O-MISC I-DISO-MISC
development O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
modulating O-MISC B-CHED-MISC
SF O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
transactivation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
mouse O-MISC I-ACTI-MISC
model O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
Prader B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Willi I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
imprinting O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
centre O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Imprinting O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
15q11 O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
q13 O-MISC B-GEOG-MISC
region O-MISC B-GEOG-MISC
involves O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
imprinting O-MISC I-GENE-MISC
centre O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
IC O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mapping O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
promoter O-MISC O-MISC
and O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
exon O-MISC O-MISC
of O-MISC B-ACTI-MISC
SNRPN O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Deletion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
IC O-MISC B-CHED-MISC
abolishes O-MISC B-ACTI-MISC
local O-MISC B-ACTI-MISC
paternally O-MISC B-CHED-MISC
derived O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
expression O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Prader B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Willi I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
created O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
deletion O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
understand O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mechanism O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
IC O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Mice O-MISC I-ANAT-MISC
harbouring O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
intragenic O-MISC B-LIVB-MISC
deletion O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
Snrpn O-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
phenotypically O-MISC I-DISO-MISC
normal O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
SNRPN O-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
sufficient O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
induce O-MISC B-CHED-MISC
PWS B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Mice O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
larger O-MISC B-ACTI-MISC
deletion O-MISC I-DISO-MISC
involving O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
Snrpn O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
putative O-MISC B-ACTI-MISC
PWS O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
IC O-MISC B-CHED-MISC
lack O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
imprinted O-MISC B-LIVB-MISC
genes O-MISC I-PROC-MISC
Zfp127 O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
mouse O-MISC B-LIVB-MISC
homologue O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
ZNF127 O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Ndn O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
Ipw O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
manifest O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
common O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC
infants O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
position O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
IC O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
coordinate O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC I-LIVB-MISC
genes O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
conserved O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
suitable O-MISC B-ACTI-MISC
model O-MISC B-OBJC-MISC
system O-MISC I-OBJC-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
molecular O-MISC I-DISO-MISC
mechanisms O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
imprinting O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
region O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genome O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATM O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
detected O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
: O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
preponderance O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
founder O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
4612del165 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
7883del5 O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ATM O-MISC B-LIVB-MISC
( O-MISC I-PROC-MISC
A O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
T O-MISC I-PROC-MISC
, O-MISC I-PROC-MISC
mutated O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
on O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
chromosome O-MISC I-GENE-MISC
11q22 O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

3 O-MISC B-LIVB-MISC
has O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
recessive B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
define O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
types O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
ATM O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
A B-DISO-MISC I-ANAT-MISC
- I-DISO-MISC I-PHEN-MISC
T I-DISO-MISC I-PHEN-MISC
patients O-MISC I-PHEN-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
look O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
mutational O-MISC B-LIVB-MISC
hotspots O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
reverse O-MISC O-MISC
- O-MISC B-DISO-MISC
transcribed O-MISC B-DISO-MISC
RNA O-MISC B-DISO-MISC
derived O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
ten O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
belonging O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
A B-DISO-MISC I-ANAT-MISC
- I-DISO-MISC I-PHEN-MISC
T I-DISO-MISC I-PHEN-MISC
families O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
for O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
restriction O-MISC B-CONC-MISC
endonuclease O-MISC I-CONC-MISC
fingerprinting O-MISC I-CONC-MISC
method O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
others O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
exon O-MISC I-DISO-MISC
skipping O-MISC I-LIVB-MISC
or O-MISC B-ACTI-MISC
premature O-MISC I-ACTI-MISC
protein O-MISC B-ANAT-MISC
truncation O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
predominant O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
mutants O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
alleles O-MISC B-LIVB-MISC
examined O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
deletions O-MISC I-DISO-MISC
involving O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
loss O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
exon O-MISC O-MISC
exon O-MISC O-MISC
7 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
exon O-MISC O-MISC
16 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
exon O-MISC O-MISC
33 O-MISC B-DISO-MISC
or O-MISC B-ACTI-MISC
exon O-MISC O-MISC
35 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
others O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
minute O-MISC I-ACTI-MISC
deletions O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
4649delA O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
33 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
7883del5 O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
55 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
4612del165 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
7883del5 O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
44 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutant O-MISC B-LIVB-MISC
alleles O-MISC B-LIVB-MISC
had O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
4612del165 O-MISC O-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
families O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
ascribed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
T O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
A O-MISC I-LIVB-MISC
substitution O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
splice O-MISC B-LIVB-MISC
donor O-MISC I-PROC-MISC
site O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
intron O-MISC O-MISC
33 O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Microsatellite O-MISC B-CONC-MISC
genotyping O-MISC I-CONC-MISC
around O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATM O-MISC B-LIVB-MISC
locus O-MISC I-PROC-MISC
also O-MISC B-ACTI-MISC
indicated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
haplotype O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
shared O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutant O-MISC B-LIVB-MISC
alleles O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
founder O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
predominant O-MISC B-ACTI-MISC
among O-MISC B-ACTI-MISC
Japanese O-MISC B-ORGA-MISC
ATM O-MISC B-LIVB-MISC
mutant O-MISC I-PROC-MISC
alleles O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

W474C O-MISC B-LIVB-MISC
amino O-MISC I-DISO-MISC
acid O-MISC I-LIVB-MISC
substitution O-MISC I-LIVB-MISC
affects O-MISC B-ACTI-MISC
early O-MISC B-ACTI-MISC
processing O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
alpha O-MISC B-CHED-MISC
- O-MISC I-PROC-MISC
subunit O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
hexosaminidase O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
subacute O-MISC I-ACTI-MISC
G B-DISO-MISC B-ANAT-MISC
( I-DISO-MISC B-ANAT-MISC
M2 I-DISO-MISC B-ANAT-MISC
) I-DISO-MISC B-ANAT-MISC
gangliosidosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HEXA O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
encoding O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
alpha O-MISC B-CHED-MISC
- O-MISC I-PROC-MISC
subunit O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
hexosaminidase O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Hex O-MISC O-MISC
A O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
abolish O-MISC B-CHED-MISC
Hex O-MISC O-MISC
A O-MISC B-DISO-MISC
enzyme O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
cause O-MISC B-ACTI-MISC
Tay B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Sachs I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
TSD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
infantile B-DISO-MISC I-ACTI-MISC
form I-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
G I-DISO-MISC I-ACTI-MISC
( I-DISO-MISC B-ANAT-MISC
M2 I-DISO-MISC B-ANAT-MISC
) I-DISO-MISC B-ANAT-MISC
gangliosidosis I-DISO-MISC B-ANAT-MISC
, I-DISO-MISC B-ACTI-MISC
Type I-DISO-MISC I-ACTI-MISC
1 I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Less O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
subacute O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
juvenile O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
onset O-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
chronic O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
adult O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
onset O-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
variants O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
broad O-MISC B-ACTI-MISC
spectrum O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
manifestations O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
residual O-MISC B-ACTI-MISC
levels O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Hex O-MISC O-MISC
A O-MISC B-DISO-MISC
enzyme O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
1422 O-MISC B-ACTI-MISC
G O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
C O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
amino O-MISC O-MISC
acid O-MISC B-DISO-MISC
W474C O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
substitution O-MISC B-DEVI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
position O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
exon O-MISC O-MISC
13 O-MISC B-DISO-MISC
of O-MISC B-DISO-MISC
HEXA O-MISC O-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC B-ANAT-MISC
Jewish O-MISC B-ANAT-MISC
proband O-MISC I-DISO-MISC
who O-MISC B-ACTI-MISC
manifested O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
subacute O-MISC B-CHED-MISC
variant O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
G B-DISO-MISC I-ACTI-MISC
( I-DISO-MISC B-ANAT-MISC
M2 I-DISO-MISC B-ANAT-MISC
) I-DISO-MISC B-ANAT-MISC
gangliosidosis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
second O-MISC B-ACTI-MISC
maternally O-MISC I-ACTI-MISC
inherited O-MISC I-LIVB-MISC
allele O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
infantile O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
4 O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
bp O-MISC I-PROC-MISC
insertion O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
+ O-MISC B-ACTI-MISC
TATC O-MISC B-LIVB-MISC
1278 O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
11 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Pulse O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
chase O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
using O-MISC B-ACTI-MISC
proband O-MISC B-CHED-MISC
fibroblasts O-MISC I-GENE-MISC
revealed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
W474C O-MISC O-MISC
- O-MISC B-ACTI-MISC
containing O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
subunit O-MISC B-DISO-MISC
precursor O-MISC O-MISC
was O-MISC B-ACTI-MISC
normally O-MISC B-ACTI-MISC
synthesized O-MISC B-DEVI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
phosphorylated O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
secreted O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mature O-MISC B-ACTI-MISC
lysosomal O-MISC I-GENE-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
subunit O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
detected O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

When O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
W474C O-MISC O-MISC
- O-MISC B-ACTI-MISC
containing O-MISC B-ACTI-MISC
alpha O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
subunit O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
transiently O-MISC I-DISO-MISC
co O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
expressed O-MISC I-LIVB-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
beta O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
subunit O-MISC I-PROC-MISC
to O-MISC B-ACTI-MISC
produce O-MISC B-ACTI-MISC
Hex O-MISC O-MISC
A O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
alphabeta O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
COS O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
7 O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mature O-MISC B-ACTI-MISC
alpha O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
subunit O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
level O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
much O-MISC B-ACTI-MISC
lower O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
alpha O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
subunit O-MISC I-PROC-MISC
transfections O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
cells O-MISC I-GENE-MISC
transfected O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alpha O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
subunit O-MISC I-PROC-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
infantile O-MISC I-ACTI-MISC
TSD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
precursor O-MISC B-CHED-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
W474C O-MISC O-MISC
alpha O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
subunit O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
accumulate O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
comparison O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
subunit O-MISC B-DISO-MISC
precursor O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
1422 O-MISC B-ACTI-MISC
G O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
C O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Hex B-DISO-MISC O-MISC
A I-DISO-MISC B-DISO-MISC
enzyme I-DISO-MISC B-DISO-MISC
deficiency I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proband O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
W474C O-MISC B-LIVB-MISC
substitution O-MISC I-DISO-MISC
clearly O-MISC B-ACTI-MISC
interferes O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
alpha O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
subunit O-MISC I-LIVB-MISC
processing O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
base O-MISC I-DISO-MISC
substitution O-MISC I-LIVB-MISC
falls O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
position O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
exon O-MISC O-MISC
13 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
aberrant O-MISC B-CHED-MISC
splicing O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
Hex B-DISO-MISC I-ACTI-MISC
A I-DISO-MISC B-ANAT-MISC
deficiency I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
proband O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
frequent O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
Pendred B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Pendred B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
recessive I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
childhood O-MISC I-CHED-MISC
deafness B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
goiter B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
century O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
recognition O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
syndrome O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
Vaughan O-MISC I-ANAT-MISC
Pendred O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
PDS O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
mapped O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
chromosome O-MISC B-LIVB-MISC
7q22 O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
q31 O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
encode O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
putative O-MISC O-MISC
sulfate O-MISC B-DISO-MISC
transporter O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
mutation O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PDS B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
Pendred B-DISO-MISC I-ANAT-MISC
families O-MISC I-PHEN-MISC
originating O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
countries O-MISC B-ORGA-MISC
and O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
include O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
single O-MISC I-ACTI-MISC
base O-MISC B-ANAT-MISC
deletions O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
site O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

One O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
L236P O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
state O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
consanguineous O-MISC I-ANAT-MISC
families O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
state O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
consanguineous O-MISC I-PHEN-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Another O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
( O-MISC I-LIVB-MISC
T416P O-MISC I-LIVB-MISC
) O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
state O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
state O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Pendred B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
consanguineous O-MISC I-PHEN-MISC
families O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
compound O-MISC I-DISO-MISC
heterozygotes O-MISC I-LIVB-MISC
for O-MISC B-ACTI-MISC
L236P O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
T416P O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
14 O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
analyzed O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
identification O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
frequent O-MISC B-ACTI-MISC
PDS B-DISO-MISC I-ACTI-MISC
mutations O-MISC I-ACTI-MISC
will O-MISC B-ACTI-MISC
facilitate O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
molecular O-MISC B-CONC-MISC
diagnosis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
Pendred B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Insertional O-MISC I-ACTI-MISC
mutation O-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
transposable O-MISC O-MISC
element O-MISC B-DISO-MISC
, O-MISC B-DISO-MISC
L1 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DMD B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
results O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
X B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
linked I-DISO-MISC B-ANAT-MISC
dilated I-DISO-MISC B-ANAT-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

X B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
linked I-DISO-MISC B-ANAT-MISC
dilated I-DISO-MISC B-ANAT-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
XLDCM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
dystrophinopathy B-DISO-MISC I-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
characterized O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
preferential O-MISC B-ACTI-MISC
myocardial B-DISO-MISC I-GENE-MISC
involvement I-DISO-MISC B-CHED-MISC
without O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
overt O-MISC B-ACTI-MISC
clinical O-MISC I-ACTI-MISC
signs O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
skeletal B-DISO-MISC I-ACTI-MISC
myopathy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
date O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Duchenne B-DISO-MISC B-LIVB-MISC
muscular I-DISO-MISC I-PROC-MISC
dystrophy I-DISO-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
DMD O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
XLDCM B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pathogenic O-MISC I-ACTI-MISC
correlation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cardiospecific O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
DMD O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
XLDCM B-DISO-MISC I-ACTI-MISC
phenotype O-MISC I-DISO-MISC
has O-MISC B-ACTI-MISC
remained O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
elucidated O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
identification O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
unique O-MISC B-ACTI-MISC
de O-MISC B-CHED-MISC
novo O-MISC I-CHED-MISC
L1 O-MISC O-MISC
insertion O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
muscle O-MISC I-GENE-MISC
exon O-MISC O-MISC
1 O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
DMD O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
XLDCM B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
insertion O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
5 O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
truncated O-MISC I-CHED-MISC
form O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
human O-MISC O-MISC
L1 O-MISC B-DISO-MISC
inversely O-MISC B-CHED-MISC
integrated O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
5 O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
untranslated O-MISC I-PROC-MISC
region O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
muscle O-MISC I-GENE-MISC
exon O-MISC O-MISC
1 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transcription O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
stability O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
muscle O-MISC I-GENE-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
dystrophin O-MISC O-MISC
transcripts O-MISC O-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
or O-MISC B-ACTI-MISC
Purkinje O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
form O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
probably O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
unique O-MISC B-CHED-MISC
site O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
integration O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
speculate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
insertion O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
L1 O-MISC B-ACTI-MISC
sequence O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
DMD O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
XLDCM B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Severe O-MISC B-ACTI-MISC
early O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
onset O-MISC B-ANAT-MISC
obesity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
adrenal B-DISO-MISC I-ACTI-MISC
insufficiency I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
red O-MISC I-ACTI-MISC
hair O-MISC B-ANAT-MISC
pigmentation O-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
POMC O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Sequential O-MISC B-CHED-MISC
cleavage O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
precursor O-MISC O-MISC
protein O-MISC B-DISO-MISC
pre O-MISC O-MISC
- O-MISC B-DISO-MISC
pro O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
opiomelanocortin O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
POMC O-MISC O-MISC
) O-MISC B-ACTI-MISC
generates O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
melanocortin O-MISC O-MISC
peptides O-MISC B-DISO-MISC
adrenocorticotrophin O-MISC O-MISC
( O-MISC B-ACTI-MISC
ACTH O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
melanocyte O-MISC O-MISC
- O-MISC B-DISO-MISC
stimulating O-MISC B-DISO-MISC
hormones O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
MSH O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
alpha O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
beta O-MISC O-MISC
and O-MISC B-ACTI-MISC
gamma O-MISC O-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
opioid O-MISC O-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
ligand O-MISC B-DISO-MISC
beta O-MISC O-MISC
- O-MISC B-DISO-MISC
endorphin O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

While O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
ACTH B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
OMIM O-MISC B-CHED-MISC
201400 O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inherited O-MISC B-CHED-MISC
POMC O-MISC B-LIVB-MISC
defect O-MISC B-CHED-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
so O-MISC B-ACTI-MISC
far O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Recent O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
animal O-MISC I-ANAT-MISC
models O-MISC I-PHEN-MISC
elucidated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
central O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
MSH O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
regulation O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
food O-MISC I-DISO-MISC
intake O-MISC I-LIVB-MISC
by O-MISC B-ACTI-MISC
activation O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
melanocortin O-MISC O-MISC
- O-MISC B-DISO-MISC
4 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
MC4 O-MISC O-MISC
- O-MISC B-DISO-MISC
R O-MISC B-DISO-MISC
; O-MISC B-ACTI-MISC
refs O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
linkage O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
obesity B-DISO-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
2 O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
close O-MISC B-ACTI-MISC
proximity O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
POMC O-MISC B-LIVB-MISC
locus O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
led O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proposal O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
POMC O-MISC O-MISC
with O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
obesity B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
dual O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
MSH O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
regulating O-MISC B-OCCU-MISC
food O-MISC I-DISO-MISC
intake O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
influencing O-MISC B-ACTI-MISC
hair O-MISC I-DISO-MISC
pigmentation O-MISC I-LIVB-MISC
predicts O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
defect O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
POMC O-MISC I-GENE-MISC
function O-MISC B-CHED-MISC
would O-MISC B-ACTI-MISC
include O-MISC B-ACTI-MISC
obesity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
alteration O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
pigmentation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
ACTH B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
observation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
symptoms O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
probands O-MISC I-ANAT-MISC
prompted O-MISC B-ACTI-MISC
us O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
search O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
within O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
POMC O-MISC B-LIVB-MISC
genes O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Patient O-MISC I-ANAT-MISC
1 O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
compound O-MISC B-ACTI-MISC
heterozygote O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
3 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
G7013T O-MISC O-MISC
, O-MISC B-ACTI-MISC
C7133delta O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
interfere O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
appropriate O-MISC B-ACTI-MISC
synthesis O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
ACTH O-MISC O-MISC
and O-MISC B-ACTI-MISC
alpha O-MISC O-MISC
- O-MISC B-DISO-MISC
MSH O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Patient O-MISC I-ANAT-MISC
2 O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
2 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
C3804A O-MISC O-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
abolishes O-MISC B-CHED-MISC
POMC O-MISC B-LIVB-MISC
translation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
represent O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
examples O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
genetic B-DISO-MISC B-CHED-MISC
defect I-DISO-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
POMC O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
define O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
monogenic B-DISO-MISC I-ACTI-MISC
endocrine I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
early O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
onset O-MISC B-ANAT-MISC
obesity B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
adrenal B-DISO-MISC I-ACTI-MISC
insufficiency I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
red O-MISC I-ACTI-MISC
hair O-MISC B-ANAT-MISC
pigmentation O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
European O-MISC B-ORGA-MISC
multicenter O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
phenylalanine B-DISO-MISC I-ACTI-MISC
hydroxylase I-DISO-MISC B-ANAT-MISC
deficiency I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
classification O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
105 O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
general O-MISC B-ACTI-MISC
system O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
genotype O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
based O-MISC B-ACTI-MISC
prediction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Phenylketonuria B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
PKU B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mild B-DISO-MISC I-ACTI-MISC
hyperphenylalaninemia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MHP B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
allelic B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
encoding O-MISC B-DEVI-MISC
phenylalanine O-MISC O-MISC
hydroxylase O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
PAH O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Previous O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
have O-MISC B-ACTI-MISC
suggested O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
highly O-MISC B-CHED-MISC
variable O-MISC B-CHED-MISC
metabolic O-MISC B-CHED-MISC
phenotypes O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
PAH B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-CHED-MISC
correlate O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
PAH O-MISC I-ACTI-MISC
genotypes O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
both O-MISC B-ACTI-MISC
causative O-MISC I-ACTI-MISC
mutations O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
686 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
European O-MISC B-ORGA-MISC
centers O-MISC B-GENE-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phenotypic O-MISC I-DISO-MISC
characteristics O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
297 O-MISC B-ACTI-MISC
functionally O-MISC B-CHED-MISC
hemizygous O-MISC I-DISO-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
105 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
assigned O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
arbitrary O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
categories O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
proposed O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
tested O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
simple O-MISC B-CHED-MISC
model O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
genotype O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
phenotypic O-MISC I-ACTI-MISC
outcome O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
matched O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
predicted O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
79 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
184 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
more O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
category O-MISC B-ACTI-MISC
away O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
expected O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
contributing O-MISC B-ACTI-MISC
centers O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proportion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
match O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
predicted O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
23 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
0001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
differences O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
methods O-MISC B-CHED-MISC
used O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
mutation O-MISC B-CONC-MISC
detection O-MISC I-CONC-MISC
or O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
classification O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
account O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
considerable O-MISC B-ACTI-MISC
proportion O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
genotype O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
phenotype O-MISC I-LIVB-MISC
inconsistencies O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAH O-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
genotype O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
main O-MISC B-ACTI-MISC
determinant O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
metabolic O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
PAH B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
classification O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
105 O-MISC B-ACTI-MISC
PAH O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
allow O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
prediction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
phenotype O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
genotypes O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
hyperphenylalaninemia B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
newborns O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Somatic O-MISC B-CHED-MISC
instability O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
transgenic O-MISC O-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
region O-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
dependent O-MISC B-CHED-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
correlated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relative O-MISC B-ACTI-MISC
intertissue O-MISC B-LIVB-MISC
transcription O-MISC I-DISO-MISC
levels O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
proliferative O-MISC I-ACTI-MISC
capacities O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
CTG O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
nexpansion O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
3 O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
untranslated O-MISC I-PROC-MISC
region O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
UTR O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DM O-MISC B-LIVB-MISC
protein O-MISC I-PROC-MISC
kinase O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
DMPK O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Major O-MISC B-ACTI-MISC
instability O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
large O-MISC B-CHED-MISC
expansions O-MISC I-DISO-MISC
between O-MISC B-ACTI-MISC
generations O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
mosaicism O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
good O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
repeat O-MISC B-CHED-MISC
size O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
leucocytes O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
severity O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
age O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
onset O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
trinucleotide O-MISC I-ACTI-MISC
repeat O-MISC B-ANAT-MISC
instability O-MISC B-ANAT-MISC
mechanisms O-MISC B-CHED-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
genetic B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
unknown O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
somatic O-MISC I-ACTI-MISC
instability O-MISC B-ANAT-MISC
by O-MISC B-ACTI-MISC
measuring O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC I-PROC-MISC
length O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
ages O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
tissues O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
transgenic O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
carrying O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
( O-MISC B-LIVB-MISC
CTG O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
55expansion O-MISC I-DISO-MISC
surrounded O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
kb O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
DM B-DISO-MISC I-GENE-MISC
region O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
small O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
pool O-MISC I-CONC-MISC
PCR O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
reproduce O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
intergenerational O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
instability O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
55 O-MISC B-ACTI-MISC
CTG O-MISC B-LIVB-MISC
repeat O-MISC B-LIVB-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
surrounding O-MISC B-ACTI-MISC
sequences O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
chromatin O-MISC I-DISO-MISC
environment O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
instability O-MISC I-ACTI-MISC
mechanisms O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tissues O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tendency O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
repeat O-MISC B-ACTI-MISC
length O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
mosaicism O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
increase O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
correlation O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
mutation O-MISC B-CHED-MISC
rate O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
tissue O-MISC I-DISO-MISC
proliferation O-MISC I-LIVB-MISC
capacity O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
mutation O-MISC B-CHED-MISC
rates O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
tissues O-MISC I-GENE-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
correlated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relative O-MISC B-ACTI-MISC
inter O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
tissue O-MISC B-GEOG-MISC
difference O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
transcriptional O-MISC I-DISO-MISC
levels O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
DMAHP O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
DMPK O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
59 O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
surrounding O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
repeat O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
retinoblastoma B-DISO-MISC I-ACTI-MISC
pedigree O-MISC B-CHED-MISC
showing O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
mild O-MISC B-CHED-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
tumor B-DISO-MISC O-MISC
phenotype O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
single O-MISC B-CONC-MISC
strand O-MISC I-CONC-MISC
conformation O-MISC I-CONC-MISC
polymorphism O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
to O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
27 O-MISC B-ACTI-MISC
exons O-MISC O-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RB1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
mild O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
retinoblastoma B-DISO-MISC I-ACTI-MISC
phenotype O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
affected O-MISC B-CHED-MISC
individuals O-MISC I-ANAT-MISC
developed O-MISC B-ACTI-MISC
unilateral B-DISO-MISC B-CHED-MISC
tumors I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
linkage O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
unaffected O-MISC B-CHED-MISC
mutation O-MISC I-DISO-MISC
carriers O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pedigree O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
band O-MISC B-ACTI-MISC
shift O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
SSCP O-MISC O-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
21 O-MISC B-DISO-MISC
which O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
converting O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cys O-MISC O-MISC
- O-MISC B-DISO-MISC
- O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
arg O-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
nucleotide O-MISC B-LIVB-MISC
position O-MISC I-PROC-MISC
28 O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
exon O-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
destroyed O-MISC B-DEVI-MISC
an O-MISC B-ACTI-MISC
NdeI O-MISC O-MISC
restriction O-MISC B-DISO-MISC
enzyme O-MISC O-MISC
site O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
members O-MISC I-PHEN-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
co O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
segregated O-MISC I-CHED-MISC
with O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
tumors B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
who O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
linkage O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
predicted O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
carry O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
predisposing O-MISC B-CHED-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
point O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
region O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
RB1 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
where O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
only O-MISC B-ACTI-MISC
modify O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
function O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
the O-MISC I-CHED-MISC
gene O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
raise O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
questions O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
genetic O-MISC B-CONC-MISC
counseling O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
distinctive O-MISC B-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Maternal B-DISO-MISC I-ACTI-MISC
disomy I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
Prader B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Willi I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
gamete O-MISC I-GENE-MISC
complementation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
familial O-MISC I-ACTI-MISC
translocation O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p25 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
q11 O-MISC I-GENE-MISC
. O-MISC B-GEOG-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Maternal B-DISO-MISC I-ACTI-MISC
uniparental I-DISO-MISC B-ANAT-MISC
disomy I-DISO-MISC I-CONC-MISC
( I-DISO-MISC B-ACTI-MISC
UPD I-DISO-MISC I-ACTI-MISC
) I-DISO-MISC B-ACTI-MISC
for I-DISO-MISC B-ACTI-MISC
chromosome I-DISO-MISC I-GENE-MISC
15 I-DISO-MISC B-GEOG-MISC
is O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
30 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Prader B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Willi I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unusual O-MISC B-CHED-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
maternal B-DISO-MISC I-ACTI-MISC
disomy I-DISO-MISC I-ACTI-MISC
15 I-DISO-MISC I-GENE-MISC
in O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
adjacent O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
segregation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
paternal O-MISC B-ACTI-MISC
t O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
15 O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
p25 O-MISC I-GENE-MISC
; O-MISC B-ACTI-MISC
q11 O-MISC I-GENE-MISC
. O-MISC B-GEOG-MISC
2 O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
simultaneous O-MISC B-CHED-MISC
maternal O-MISC I-ACTI-MISC
meiotic O-MISC I-DISO-MISC
nondisjunction O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
15 O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
J O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
B O-MISC I-PHEN-MISC
. O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
17 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
white O-MISC I-ANAT-MISC
male O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
47 O-MISC B-ACTI-MISC
chromosomes O-MISC I-GENE-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
supernumerary O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
paternal O-MISC I-GENE-MISC
der O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-GEOG-MISC
) O-MISC B-ACTI-MISC
consisting O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
short O-MISC I-GENE-MISC
arm O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proximal O-MISC I-GENE-MISC
long O-MISC B-GEOG-MISC
arm O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
15 O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
distal O-MISC I-GENE-MISC
chromosome O-MISC B-GEOG-MISC
arm O-MISC B-GEOG-MISC
3p O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
t O-MISC B-CHED-MISC
( O-MISC I-CHED-MISC
3 O-MISC I-CHED-MISC
; O-MISC B-ACTI-MISC
15 O-MISC I-CHED-MISC
) O-MISC I-CHED-MISC
was O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
balanced O-MISC B-CHED-MISC
state O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
father O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
sister O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Fluorescent O-MISC B-CONC-MISC
in O-MISC I-CONC-MISC
situ O-MISC I-CONC-MISC
hybridization O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC
critical O-MISC B-CHED-MISC
region O-MISC B-CHED-MISC
resided O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
derivative O-MISC I-GENE-MISC
chromosome O-MISC B-GEOG-MISC
3 O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
deletion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC
region O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-LIVB-MISC
pair O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
15s O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
J O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

B O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Methylation O-MISC I-DISO-MISC
analysis O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
exon O-MISC O-MISC
alpha O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
small O-MISC B-LIVB-MISC
nuclear O-MISC I-PROC-MISC
ribonucleoprotein O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
associated O-MISC I-PROC-MISC
polypeptide O-MISC I-PROC-MISC
N O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
SNRPN O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
showed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pattern O-MISC B-CHED-MISC
characteristic O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maternal O-MISC I-GENE-MISC
chromosome O-MISC B-GEOG-MISC
15 O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
J O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

B O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Maternal B-DISO-MISC I-ACTI-MISC
disomy I-DISO-MISC I-ACTI-MISC
was O-MISC B-ACTI-MISC
confirmed O-MISC B-CHED-MISC
by O-MISC I-CHED-MISC
polymerase O-MISC B-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
microsatellite O-MISC O-MISC
repeats O-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gamma O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
aminobutyric O-MISC I-PROC-MISC
acid O-MISC I-PROC-MISC
receptor O-MISC I-PROC-MISC
beta3 O-MISC I-PROC-MISC
subunit O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
GABRB3 O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
locus O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
niece O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
B O-MISC I-ANAT-MISC
. O-MISC I-PHEN-MISC
B O-MISC I-PHEN-MISC
. O-MISC I-PHEN-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
45 O-MISC B-ACTI-MISC
chromosomes O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
derivative O-MISC B-CHED-MISC
3 O-MISC I-CHED-MISC
but O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
der O-MISC O-MISC
( O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
consistent O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
that O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
haploinsufficiency O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
distal O-MISC B-CHED-MISC
3 O-MISC I-CHED-MISC
p O-MISC B-GEOG-MISC
. O-MISC B-GEOG-MISC

Uniparental B-DISO-MISC I-ACTI-MISC
disomy I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
unbalanced O-MISC B-ACTI-MISC
segregation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
non O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
Robertsonian O-MISC I-LIVB-MISC
translocations O-MISC I-LIVB-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
best O-MISC B-ACTI-MISC
interpreted O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
true O-MISC B-ACTI-MISC
gamete O-MISC I-GENE-MISC
complementation O-MISC I-DISO-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
maternal B-DISO-MISC I-ACTI-MISC
UPD I-DISO-MISC I-ACTI-MISC
15 I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
PWS B-DISO-MISC I-ACTI-MISC

Schwartz B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Jampel I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
type I-DISO-MISC B-ANAT-MISC
2 I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
Stuve B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Wiedemann I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
lumping O-MISC I-ACTI-MISC
" O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Recent O-MISC B-ACTI-MISC
studies O-MISC B-CONC-MISC
demonstrated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
existence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
genetically O-MISC B-CHED-MISC
distinct O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
lethal O-MISC I-ACTI-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Schwartz B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Jampel I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SJS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
myotonia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
skeletal B-DISO-MISC I-ACTI-MISC
dysplasia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
called O-MISC B-ACTI-MISC
SJS B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
2 I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
disorder O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
reminiscent O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
rare O-MISC B-CHED-MISC
condition O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Stuve B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Wiedemann I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
SWS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
comprises O-MISC B-ACTI-MISC
campomelia B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
birth O-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
skeletal B-DISO-MISC I-ACTI-MISC
dysplasia I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
contractures B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
early B-DISO-MISC I-ACTI-MISC
death I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
test O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
possible O-MISC B-ACTI-MISC
nosologic O-MISC B-CHED-MISC
identity O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
disorders O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
reviewed O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
literature O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
surviving O-MISC B-DEVI-MISC
patients O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
SJS B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
2 I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
10 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
SWS B-DISO-MISC I-ACTI-MISC
at O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
7 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
reported O-MISC B-CONC-MISC
as O-MISC B-ACTI-MISC
having O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
neonatal O-MISC I-ANAT-MISC
SJS B-DISO-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
SWS B-DISO-MISC I-ACTI-MISC
presented O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
combination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
prenatal O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
onset O-MISC I-CHED-MISC
neuromuscular B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
joint I-DISO-MISC B-ANAT-MISC
contractures I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
respiratory O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
feeding O-MISC I-ACTI-MISC
difficulties O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
tendency O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hyperthermia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
frequent O-MISC B-CHED-MISC
death O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
infancy O-MISC B-CHED-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
distinct O-MISC B-ACTI-MISC
campomelic B-DISO-MISC O-MISC
- I-DISO-MISC B-ACTI-MISC
metaphyseal I-DISO-MISC I-ACTI-MISC
skeletal I-DISO-MISC I-ACTI-MISC
dysplasia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
similarity O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
radiographic O-MISC B-OCCU-MISC
findings O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
so O-MISC B-ACTI-MISC
extensive O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
disorders O-MISC I-ACTI-MISC
appear O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
entity O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
follow O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
up O-MISC I-CONC-MISC
observation O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
identical O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
unique O-MISC B-CHED-MISC
pattern O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
bone B-DISO-MISC I-ACTI-MISC
dysplasia I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
SJS B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
2 I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
SWS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
surviving O-MISC B-DEVI-MISC
beyond O-MISC B-ACTI-MISC
infancy O-MISC B-CHED-MISC
adds O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
favor O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
identity O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
SWS B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
SJS B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
2 I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
disorder O-MISC I-ACTI-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
testable O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
molecular O-MISC B-CONC-MISC
methods O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
mouse O-MISC I-ACTI-MISC
model O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
severe O-MISC I-ACTI-MISC
von B-DISO-MISC I-ACTI-MISC
Willebrand I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
defects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
hemostasis O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
thrombosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

von B-DISO-MISC I-ACTI-MISC
Willebrand I-DISO-MISC B-ANAT-MISC
factor I-DISO-MISC B-ANAT-MISC
( I-DISO-MISC B-ANAT-MISC
vWf I-DISO-MISC B-ANAT-MISC
) I-DISO-MISC B-ANAT-MISC
deficiency I-DISO-MISC B-ANAT-MISC
causes O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
von B-DISO-MISC I-ACTI-MISC
Willebrand I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
generated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mouse O-MISC I-ACTI-MISC
model O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
gene O-MISC B-CONC-MISC
targeting O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

vWf B-DISO-MISC B-CHED-MISC
- I-DISO-MISC B-ACTI-MISC
deficient I-DISO-MISC B-CHED-MISC
mice O-MISC I-ANAT-MISC
appeared O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
birth O-MISC I-DISO-MISC
; O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
viable O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
fertile O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Neither O-MISC B-ACTI-MISC
vWf O-MISC O-MISC
nor O-MISC B-ACTI-MISC
vWf O-MISC O-MISC
propolypeptide O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
von B-DISO-MISC O-MISC
Willebrand I-DISO-MISC B-DISO-MISC
antigen O-MISC B-DISO-MISC
II O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
detectable O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
plasma O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
platelets O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
endothelial O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
mutant O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mutant O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
exhibited O-MISC B-ACTI-MISC
defects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
hemostasis O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
highly O-MISC B-CHED-MISC
prolonged O-MISC B-CHED-MISC
bleeding O-MISC I-ACTI-MISC
time O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
spontaneous O-MISC B-CHED-MISC
bleeding O-MISC I-ACTI-MISC
events O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
approximately O-MISC B-CHED-MISC
10 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
neonates O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
disease O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
factor O-MISC B-CHED-MISC
VIII O-MISC I-CHED-MISC
level O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
strongly O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
protection O-MISC I-ACTI-MISC
provided O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
vWf O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Defective O-MISC I-ACTI-MISC
thrombosis B-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
mutant O-MISC I-ANAT-MISC
mice O-MISC I-PHEN-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
evident O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
in O-MISC B-CONC-MISC
vivo O-MISC I-CONC-MISC
model O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
vascular B-DISO-MISC I-ACTI-MISC
injury I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
model O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
exteriorized O-MISC B-ACTI-MISC
mesentery O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
superfused O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
ferric O-MISC O-MISC
chloride O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
accumulation O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
fluorescently O-MISC B-CHED-MISC
labeled O-MISC I-CHED-MISC
platelets O-MISC I-GENE-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
intravital O-MISC B-CONC-MISC
microscopy O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mice O-MISC I-ANAT-MISC
very O-MISC B-ACTI-MISC
closely O-MISC B-ACTI-MISC
mimic O-MISC B-ACTI-MISC
severe O-MISC B-ACTI-MISC
human O-MISC I-ACTI-MISC
von B-DISO-MISC B-ANAT-MISC
Willebrand I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
will O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
very O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
investigating O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
vWf O-MISC O-MISC
in O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
physiology O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
models O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC O-MISC
contraceptives O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Hereditary B-DISO-MISC B-ACTI-MISC
Ovarian I-DISO-MISC B-ACTI-MISC
Cancer I-DISO-MISC B-ACTI-MISC
Clinical O-MISC B-ACTI-MISC
Study O-MISC I-PHEN-MISC
Group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
Women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
lifetime O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC O-MISC
contraceptives O-MISC B-DISO-MISC
protect O-MISC B-ACTI-MISC
against O-MISC B-CHED-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
general O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
protect O-MISC B-ACTI-MISC
against O-MISC B-CHED-MISC
hereditary B-DISO-MISC I-ACTI-MISC
forms I-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
ovarian I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
We O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
207 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
161 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
sisters O-MISC I-ANAT-MISC
as O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
case O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
control O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
carried O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pathogenic O-MISC I-ACTI-MISC
mutation O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
179 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
women O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
enrolled O-MISC B-ACTI-MISC
regardless O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
either O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Lifetime O-MISC B-CHED-MISC
histories O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
oral O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
contraceptive O-MISC B-ANAT-MISC
use O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
interview O-MISC B-DEVI-MISC
or O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
written O-MISC B-CHED-MISC
questionnaire O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
women O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
adjustment O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
year O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
birth O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
parity O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
adjusted O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
any O-MISC B-ACTI-MISC
past O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
oral O-MISC O-MISC
contraceptives O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
decreased O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
increasing O-MISC B-CHED-MISC
duration O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
use O-MISC I-CHED-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
trend O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
< O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
001 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
reduction O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Oral O-MISC O-MISC
- O-MISC B-ACTI-MISC
contraceptive O-MISC O-MISC
use O-MISC B-ACTI-MISC
protected O-MISC B-ACTI-MISC
against O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
both O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
carriers O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC I-ACTI-MISC
mutation O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
9 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
carriers O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA2 O-MISC I-ACTI-MISC
mutation O-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
odds O-MISC B-CHED-MISC
ratio O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
percent O-MISC B-ACTI-MISC
confidence O-MISC B-CHED-MISC
interval O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
Oral O-MISC O-MISC
- O-MISC B-DISO-MISC
contraceptive O-MISC B-DISO-MISC
use O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
women O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
pathogenic O-MISC I-ACTI-MISC
mutations O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
or O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC

A O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
family O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
adrenoleukodystrophy B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
codon O-MISC B-LIVB-MISC
291 O-MISC I-PROC-MISC
deletion O-MISC I-PROC-MISC
: O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
biochemical O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
genetic O-MISC B-CHED-MISC
report O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
family O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
adrenoleukodystrophy B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
ALD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
three O-MISC I-DISO-MISC
base O-MISC I-LIVB-MISC
pair O-MISC I-LIVB-MISC
deletion O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
delGAG O-MISC B-LIVB-MISC
291 O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ALD B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
variety O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

While O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
proband O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
1 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
having O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
intermediate O-MISC B-CHED-MISC
type O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
adult O-MISC I-GENE-MISC
cerebral O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
cerebello O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
brain O-MISC B-GEOG-MISC
stem O-MISC B-GEOG-MISC
forms O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
younger O-MISC I-ANAT-MISC
brother O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
nephew O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
childhood O-MISC B-CHED-MISC
ALD B-DISO-MISC I-ACTI-MISC
type O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Another O-MISC B-ACTI-MISC
nephew O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
1 O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
having O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
adolescent O-MISC I-ANAT-MISC
form O-MISC B-PROC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
tau O-MISC I-ACTI-MISC
level O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebrospinal O-MISC I-GENE-MISC
fluid O-MISC B-GEOG-MISC
( O-MISC B-ACTI-MISC
CSF O-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
1 O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Alzheimers B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
AD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

His O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
magnetic O-MISC B-CONC-MISC
resonance O-MISC I-CONC-MISC
image O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
MRI O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
showed O-MISC B-ACTI-MISC
abnormalities B-DISO-MISC I-ACTI-MISC
in I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
bilateral I-DISO-MISC I-GENE-MISC
cerebellar I-DISO-MISC B-GEOG-MISC
hemispheres I-DISO-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
stem O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebral O-MISC I-GENE-MISC
white O-MISC B-GEOG-MISC
matter O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
where O-MISC B-ACTI-MISC
marked O-MISC B-ACTI-MISC
reductions O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cerebral O-MISC I-ACTI-MISC
blood O-MISC B-ANAT-MISC
flow O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
oxygen O-MISC I-DISO-MISC
metabolism O-MISC I-LIVB-MISC
were O-MISC B-ACTI-MISC
clearly O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
positron O-MISC B-CONC-MISC
emission O-MISC I-CONC-MISC
tomography O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PET O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
2 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
autopsy O-MISC B-CONC-MISC
findings O-MISC I-ACTI-MISC
showed O-MISC B-ACTI-MISC
massive O-MISC I-ACTI-MISC
demyelination B-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
cerebral I-DISO-MISC I-GENE-MISC
white I-DISO-MISC B-GEOG-MISC
matter I-DISO-MISC B-GEOG-MISC
with O-MISC B-ACTI-MISC
sparing O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
U O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
fibers O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
compatible O-MISC B-CHED-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
childhood O-MISC B-CHED-MISC
ALD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Oleic O-MISC O-MISC
and O-MISC B-ACTI-MISC
erucic O-MISC O-MISC
acids O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
Lorenzos O-MISC O-MISC
Oil O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
administered O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
1 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
sufficient O-MISC B-ACTI-MISC
effectiveness O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
findings O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
delGAG291 O-MISC O-MISC
is O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Japanese O-MISC B-ORGA-MISC
ALD B-DISO-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
phenotypic O-MISC I-DISO-MISC
variations O-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
scale O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
limited O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
possibility O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
PET O-MISC B-CONC-MISC
can O-MISC B-ACTI-MISC
detect O-MISC I-ACTI-MISC
an O-MISC B-ACTI-MISC
insidious B-DISO-MISC B-CHED-MISC
lesion I-DISO-MISC I-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
undetectable O-MISC I-DISO-MISC
by O-MISC B-ACTI-MISC
computed O-MISC B-CONC-MISC
tomogram O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
CT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
MRI O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
level O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
tau O-MISC O-MISC
reflects O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
process O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
neuronal B-DISO-MISC I-ACTI-MISC
degeneration I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
ALD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Lorenzos O-MISC O-MISC
Oil O-MISC B-DISO-MISC
should O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
given O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
early O-MISC B-CHED-MISC
stage O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Nonsense O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
4 O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
complement O-MISC B-LIVB-MISC
C9 O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
complement B-DISO-MISC I-ACTI-MISC
C9 I-DISO-MISC B-ANAT-MISC
deficiency I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Deficiency B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
ninth I-DISO-MISC O-MISC
component I-DISO-MISC B-DISO-MISC
of I-DISO-MISC B-ACTI-MISC
human I-DISO-MISC B-DISO-MISC
complement I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
C9 O-MISC O-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
complement B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Japan O-MISC B-ORGA-MISC
but O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
countries O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
basis O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
C9 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
C9 B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ACTI-MISC
deficient I-DISO-MISC B-CHED-MISC
patients O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
suffered O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
meningococcal B-DISO-MISC I-ACTI-MISC
meningitis I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Direct O-MISC B-ACTI-MISC
sequencing O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
amplified O-MISC I-DISO-MISC
C9 O-MISC O-MISC
cDNA O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
revealed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nonsense O-MISC I-DISO-MISC
substitution O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
CGA O-MISC O-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
TGA O-MISC O-MISC
) O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
codon O-MISC B-LIVB-MISC
95 O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
4 O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
C9 B-DISO-MISC B-LIVB-MISC
- I-DISO-MISC B-ACTI-MISC
deficient I-DISO-MISC B-CHED-MISC
individuals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
allele O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
specific O-MISC B-CHED-MISC
polymerase O-MISC B-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
system O-MISC I-CONC-MISC
designed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
detect O-MISC I-ACTI-MISC
exclusively O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
alleles O-MISC B-LIVB-MISC
indicated O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
4 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
parents O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
2 O-MISC I-PHEN-MISC
were O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
codon O-MISC B-LIVB-MISC
95 O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
4 O-MISC B-DISO-MISC
might O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
Japanese O-MISC I-ACTI-MISC
C9 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

BRCA1 O-MISC O-MISC
required O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
transcription O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
coupled O-MISC I-LIVB-MISC
repair O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
oxidative O-MISC B-CHED-MISC
DNA O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ANAT-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
susceptibility O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
BRCA1 O-MISC B-LIVB-MISC
encodes O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
zinc O-MISC O-MISC
finger O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC
function O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Association O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
protein O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
repair O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
Rad51 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phosphorylation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
cellular O-MISC I-DISO-MISC
localization O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protein O-MISC O-MISC
after O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
to O-MISC I-CHED-MISC
DNA O-MISC O-MISC
- O-MISC B-DISO-MISC
damaging O-MISC B-DISO-MISC
agents O-MISC B-DISO-MISC
are O-MISC B-ACTI-MISC
consistent O-MISC B-ACTI-MISC
with O-MISC I-CHED-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
in O-MISC B-ACTI-MISC
DNA O-MISC I-DISO-MISC
repair O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
mouse O-MISC I-GENE-MISC
embryonic O-MISC B-GEOG-MISC
stem O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
deficient B-DISO-MISC B-CHED-MISC
in I-DISO-MISC B-ACTI-MISC
BRCA1 I-DISO-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
defective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ability O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
carry O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
transcription O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
coupled O-MISC I-LIVB-MISC
repair O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
oxidative O-MISC B-CHED-MISC
DNA O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
hypersensitive O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
ionizing O-MISC B-OCCU-MISC
radiation O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
hydrogen O-MISC O-MISC
peroxide O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
participates O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
directly O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
indirectly O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
transcription O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
coupled O-MISC I-LIVB-MISC
repair O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
oxidative O-MISC B-CHED-MISC
DNA O-MISC I-ACTI-MISC
damage O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Truncation O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transactivation O-MISC I-DISO-MISC
region O-MISC B-LIVB-MISC
of O-MISC B-ACTI-MISC
PAX6 O-MISC O-MISC
result O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
dominant O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
negative O-MISC B-ANAT-MISC
mutants O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

PAX6 O-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
transcription O-MISC O-MISC
factor O-MISC B-DISO-MISC
with O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
DNA O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
binding O-MISC I-PROC-MISC
domains O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
paired O-MISC B-LIVB-MISC
box O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
homeobox O-MISC O-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
proline O-MISC O-MISC
- O-MISC B-DISO-MISC
serine O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
threonine O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
PST O-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
rich O-MISC B-ACTI-MISC
transactivation O-MISC I-DISO-MISC
domain O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

PAX6 O-MISC O-MISC
regulates O-MISC B-ACTI-MISC
eye O-MISC I-DISO-MISC
development O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
animals O-MISC I-ANAT-MISC
ranging O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
jellyfish O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
Drosophila O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
humans O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Heterozygous O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
PAX6 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
result O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
aniridia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
Peters B-DISO-MISC I-ACTI-MISC
anomaly I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
keratitis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
familial B-DISO-MISC I-ACTI-MISC
foveal I-DISO-MISC B-ANAT-MISC
dysplasia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
believed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutated O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
PAX6 O-MISC O-MISC
produces O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inactive O-MISC O-MISC
protein O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
aniridia B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
genetic O-MISC I-ACTI-MISC
haploinsufficiency O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
truncation O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
occur O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
terminal O-MISC I-PROC-MISC
half O-MISC I-PROC-MISC
of O-MISC B-DISO-MISC
PAX6 O-MISC O-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Aniridia B-DISO-MISC I-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
proteins O-MISC O-MISC
that O-MISC B-ACTI-MISC
retain O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DNA O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
binding O-MISC I-PROC-MISC
domains O-MISC I-PROC-MISC
but O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
lost O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transactivation O-MISC I-DISO-MISC
domain O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
clear O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
mutants O-MISC I-ACTI-MISC
really O-MISC B-ACTI-MISC
behave O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
loss O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
- O-MISC B-ANAT-MISC
function O-MISC B-ANAT-MISC
mutants O-MISC I-ACTI-MISC
as O-MISC B-ACTI-MISC
predicted O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
haploinsufficiency O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Contrary O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
theory O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mutants O-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
dominant O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
negative O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
transient O-MISC B-CONC-MISC
transfection O-MISC B-CONC-MISC
assays O-MISC I-CONC-MISC
when O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
coexpressed O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
PAX6 O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dominant O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
negative O-MISC I-ACTI-MISC
effects O-MISC B-CHED-MISC
result O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
enhanced O-MISC B-ACTI-MISC
DNA O-MISC I-DISO-MISC
binding O-MISC I-LIVB-MISC
ability O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mutants O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Kinetic O-MISC B-OCCU-MISC
studies O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
binding O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
dissociation O-MISC I-DISO-MISC
revealed O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
truncation O-MISC B-LIVB-MISC
mutants O-MISC I-PROC-MISC
have O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
fold O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
affinity O-MISC B-OCCU-MISC
to O-MISC B-ACTI-MISC
various O-MISC B-ACTI-MISC
DNA O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
binding O-MISC I-PROC-MISC
sites O-MISC I-PROC-MISC
when O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
PAX6 O-MISC O-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
provide O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
insight O-MISC I-DISO-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
mutant O-MISC B-LIVB-MISC
PAX6 O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
aniridia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Reversal O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
hypertrophic B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
excellent O-MISC B-CHED-MISC
neuropsychologic O-MISC B-CHED-MISC
outcome O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
very B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
long I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
chain I-DISO-MISC B-ANAT-MISC
acyl I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
coenzyme I-DISO-MISC B-ANAT-MISC
A I-DISO-MISC B-ANAT-MISC
dehydrogenase I-DISO-MISC B-ANAT-MISC
deficiency I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Very B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
long I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
chain I-DISO-MISC B-ANAT-MISC
acyl I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
coenzyme I-DISO-MISC B-ANAT-MISC
A I-DISO-MISC B-ANAT-MISC
dehydrogenase I-DISO-MISC B-ANAT-MISC
( I-DISO-MISC B-ANAT-MISC
VLCAD I-DISO-MISC B-ANAT-MISC
) I-DISO-MISC B-ANAT-MISC
deficiency I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
disorder O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
fatty O-MISC I-DISO-MISC
acid O-MISC I-LIVB-MISC
beta O-MISC I-LIVB-MISC
oxidation O-MISC I-LIVB-MISC
that O-MISC B-ACTI-MISC
reportedly O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
rates O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
morbidity O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
mortality O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
outcome O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
- O-MISC B-ACTI-MISC
old O-MISC B-ACTI-MISC
girl O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
VLCAD B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
who O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
months O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
hypertrophic B-DISO-MISC I-ACTI-MISC
cardiomyopathy I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
hepatomegaly B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
encephalopathy B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
hypotonia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Biochemical O-MISC B-CONC-MISC
studies O-MISC B-CONC-MISC
indicated O-MISC B-ACTI-MISC
VLCAD B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
stable O-MISC B-ACTI-MISC
yet O-MISC B-ACTI-MISC
inactive O-MISC B-ACTI-MISC
enzyme O-MISC O-MISC
. O-MISC B-ACTI-MISC

Molecular O-MISC B-CONC-MISC
genetic O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
her O-MISC B-ACTI-MISC
VLCAD O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
revealed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
T1372C O-MISC B-LIVB-MISC
( O-MISC I-PROC-MISC
F458L O-MISC B-ANAT-MISC
) O-MISC B-ANAT-MISC
missense O-MISC B-ANAT-MISC
mutation O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
1668 O-MISC B-ACTI-MISC
ACAG O-MISC B-LIVB-MISC
1669 O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
site O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

After O-MISC B-ACTI-MISC
initial O-MISC B-ACTI-MISC
treatment O-MISC B-CONC-MISC
with O-MISC B-ACTI-MISC
intravenous O-MISC B-CHED-MISC
glucose O-MISC O-MISC
and O-MISC B-ACTI-MISC
carnitine O-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
has O-MISC B-ACTI-MISC
thrived O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
low O-MISC B-GENE-MISC
- O-MISC I-GEOG-MISC
fat O-MISC I-GEOG-MISC
diet O-MISC I-GEOG-MISC
supplemented O-MISC I-GEOG-MISC
with O-MISC B-ACTI-MISC
medium O-MISC O-MISC
- O-MISC B-DISO-MISC
chain O-MISC B-DISO-MISC
triglyceride O-MISC B-DISO-MISC
oil O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
carnitine O-MISC O-MISC
and O-MISC B-ACTI-MISC
avoidance O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
fasting O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Her O-MISC B-ACTI-MISC
ventricular O-MISC I-ACTI-MISC
hypertrophy O-MISC B-ANAT-MISC
resolved O-MISC I-ACTI-MISC
significantly O-MISC B-ACTI-MISC
over O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
year O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
cognitively O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
she O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
superior O-MISC B-ACTI-MISC
range O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC I-DISO-MISC
recognition O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
VLCAD B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
treatable O-MISC B-CONC-MISC
causes O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cardiomyopathy B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Cloning O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
member O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
low O-MISC O-MISC
- O-MISC B-DISO-MISC
density O-MISC B-DISO-MISC
lipoprotein O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
family O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
encoding O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
transmembrane O-MISC O-MISC
protein O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
DNA O-MISC B-CONC-MISC
sequence O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
insulin B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
dependent I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
mellitus I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
IDDM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
locus O-MISC B-LIVB-MISC
IDDM4 O-MISC B-LIVB-MISC
on O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
11q13 O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Based O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
chromosomal O-MISC I-GENE-MISC
position O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
candidate O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
conferring O-MISC B-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
termed O-MISC B-ACTI-MISC
low O-MISC O-MISC
- O-MISC B-DISO-MISC
density O-MISC B-DISO-MISC
lipoprotein O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
related O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
5 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
LRP5 O-MISC O-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
encodes O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
protein O-MISC O-MISC
of O-MISC B-ACTI-MISC
1615 O-MISC B-ACTI-MISC
amino O-MISC O-MISC
acids O-MISC B-DISO-MISC
that O-MISC B-ACTI-MISC
contains O-MISC B-ACTI-MISC
conserved O-MISC B-ACTI-MISC
modules O-MISC B-CHED-MISC
which O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
characteristic O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
low O-MISC O-MISC
- O-MISC B-DISO-MISC
density O-MISC B-DISO-MISC
lipoprotein O-MISC B-DISO-MISC
( O-MISC B-DISO-MISC
LDL O-MISC B-DISO-MISC
) O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
family O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
modules O-MISC I-DISO-MISC
include O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
putative O-MISC O-MISC
signal O-MISC B-DISO-MISC
peptide O-MISC B-DISO-MISC
for O-MISC B-ACTI-MISC
protein O-MISC I-DISO-MISC
export O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
epidermal O-MISC O-MISC
growth O-MISC B-DISO-MISC
factor O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
EGF O-MISC O-MISC
) O-MISC B-ACTI-MISC
repeats O-MISC B-LIVB-MISC
with O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
spacer O-MISC B-LIVB-MISC
domains O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
LDL O-MISC O-MISC
- O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
LDLR O-MISC O-MISC
) O-MISC B-ACTI-MISC
repeats O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
single O-MISC B-ACTI-MISC
transmembrane O-MISC I-PROC-MISC
spanning O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cytoplasmic O-MISC I-GENE-MISC
domain O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
encoded O-MISC O-MISC
protein O-MISC O-MISC
has O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
unique O-MISC B-ACTI-MISC
organization O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
EGF O-MISC O-MISC
and O-MISC B-ACTI-MISC
LDLR O-MISC O-MISC
repeats O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
LRP5 O-MISC O-MISC
likely O-MISC B-ACTI-MISC
represents O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
category O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
LDLR O-MISC O-MISC
family O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
LRP5 O-MISC O-MISC
cDNAs O-MISC O-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
isolated O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
encoded O-MISC B-DEVI-MISC
mature O-MISC B-ACTI-MISC
proteins O-MISC O-MISC
are O-MISC B-ACTI-MISC
95 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
identical O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
degree O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
evolutionary O-MISC I-DISO-MISC
conservation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
variants O-MISC B-LIVB-MISC
I1307K O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
E1317Q O-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
tumors I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
family O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Classical O-MISC B-CHED-MISC
familial B-DISO-MISC I-ACTI-MISC
adenomatous I-DISO-MISC B-ANAT-MISC
polyposis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
FAP B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
penetrance O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
predisposes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hundreds O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
thousands O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
adenomas I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
carcinoma I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
truncating O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
variant O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
FAP B-DISO-MISC O-MISC
is O-MISC B-ACTI-MISC
attenuated B-DISO-MISC B-ACTI-MISC
adenomatous I-DISO-MISC I-ANAT-MISC
polyposis I-DISO-MISC I-PHEN-MISC
coli I-DISO-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
germ O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
line O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
5 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
3 O-MISC B-LIVB-MISC
regions O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Attenuated B-DISO-MISC B-ACTI-MISC
adenomatous I-DISO-MISC I-ACTI-MISC
polyposis I-DISO-MISC B-ANAT-MISC
coli I-DISO-MISC I-ANAT-MISC
patients O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
multiple O-MISC B-ACTI-MISC
" O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
adenomas I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
typically O-MISC B-ACTI-MISC
fewer O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
florid O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
classical O-MISC B-ACTI-MISC
FAP B-DISO-MISC B-OCCU-MISC
. O-MISC B-ACTI-MISC

Another O-MISC B-ACTI-MISC
group O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
multiple O-MISC I-ACTI-MISC
adenomas B-DISO-MISC B-ANAT-MISC
has O-MISC B-ACTI-MISC
no O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
probably O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
variation O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
locus O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
loci O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
elsewhere O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genome O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
variant O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
APC B-DISO-MISC O-MISC
( O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
confers O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
tumors I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
multiple O-MISC I-ACTI-MISC
adenomas B-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Ashkenazim O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
set O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
164 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
multiple O-MISC B-CHED-MISC
colorectal B-DISO-MISC I-ACTI-MISC
adenomas I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
/ I-DISO-MISC B-ACTI-MISC
or I-DISO-MISC B-ACTI-MISC
carcinoma I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
analyzed O-MISC B-ACTI-MISC
codons O-MISC B-LIVB-MISC
1263 O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
1377 O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
exon O-MISC O-MISC
15G O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
for O-MISC B-ACTI-MISC
germ O-MISC B-CHED-MISC
- O-MISC I-PROC-MISC
line O-MISC I-CHED-MISC
variants O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Three O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
were O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Ashkenazi O-MISC I-ANAT-MISC
descent O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
germ O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
line O-MISC I-CONC-MISC
E1317Q O-MISC I-OCCU-MISC
missense O-MISC I-ACTI-MISC
variant O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
APC O-MISC O-MISC
that O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
; O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unusually O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
metaplastic B-DISO-MISC I-ACTI-MISC
polyps I-DISO-MISC B-ANAT-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
colorectum I-DISO-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
increasing O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
exist O-MISC B-ACTI-MISC
germ O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
line O-MISC I-LIVB-MISC
variants O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
that O-MISC B-ACTI-MISC
predispose O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
multiple O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
adenomas I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
carcinoma I-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
florid O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
classical O-MISC B-ACTI-MISC
FAP B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
possibly O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
importance O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
risk O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
general O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Genomic O-MISC B-LIVB-MISC
structure O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
congenital B-DISO-MISC B-LIVB-MISC
chloride I-DISO-MISC I-PROC-MISC
diarrhea I-DISO-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
CLD B-DISO-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Congenital B-DISO-MISC I-ACTI-MISC
chloride I-DISO-MISC B-ANAT-MISC
diarrhea I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CLD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
which O-MISC B-ACTI-MISC
encodes O-MISC B-DEVI-MISC
an O-MISC B-ACTI-MISC
intestinal O-MISC I-GENE-MISC
anion O-MISC O-MISC
transporter O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
genomic O-MISC I-DISO-MISC
organization O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
CLD B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
which O-MISC B-ACTI-MISC
spans O-MISC B-ACTI-MISC
approximately O-MISC B-ACTI-MISC
39kb O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
comprises O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
exons O-MISC O-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
exon O-MISC O-MISC
/ O-MISC B-ACTI-MISC
intron O-MISC O-MISC
boundaries O-MISC B-CHED-MISC
conform O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
GT O-MISC I-DISO-MISC
/ O-MISC B-ACTI-MISC
AG O-MISC I-LIVB-MISC
rule O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

An O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
putative O-MISC B-ACTI-MISC
promoter O-MISC B-LIVB-MISC
region O-MISC I-PROC-MISC
sequence O-MISC I-PROC-MISC
shows O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
putative O-MISC B-ACTI-MISC
TATA O-MISC O-MISC
box O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
predicts O-MISC B-CHED-MISC
multiple O-MISC B-CHED-MISC
transcription O-MISC O-MISC
factor O-MISC B-DISO-MISC
binding O-MISC B-DISO-MISC
sites O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
genomic O-MISC B-LIVB-MISC
structure O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
from O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
sources O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
multiple O-MISC B-ACTI-MISC
large O-MISC B-LIVB-MISC
- O-MISC B-DISO-MISC
insert O-MISC I-PROC-MISC
libaries O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
genomic O-MISC O-MISC
DNA O-MISC B-DISO-MISC
from O-MISC B-ACTI-MISC
Finnish O-MISC B-ORGA-MISC
CLD B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
controls O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Exon O-MISC O-MISC
- O-MISC B-DISO-MISC
specific O-MISC B-DISO-MISC
primers O-MISC B-DISO-MISC
developed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
will O-MISC B-ACTI-MISC
facilitate O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
screening O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Genomic O-MISC B-CONC-MISC
sequencing O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
BAC O-MISC O-MISC
clone O-MISC I-GENE-MISC
H O-MISC O-MISC
_ O-MISC B-DISO-MISC
RG364P16 O-MISC B-DISO-MISC
revealed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
homologous O-MISC I-PROC-MISC
gene O-MISC B-LIVB-MISC
3 O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CLD B-DISO-MISC I-ACTI-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
genomic O-MISC B-LIVB-MISC
structure O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Pendred B-DISO-MISC B-LIVB-MISC
syndrome I-DISO-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
PDS B-DISO-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
APCI1307K O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
cancer B-DISO-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
community O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
based O-MISC I-CONC-MISC
study O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
Ashkenazi O-MISC I-ANAT-MISC
Jews O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
APC O-MISC B-LIVB-MISC
are O-MISC B-ACTI-MISC
classically O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
familial B-DISO-MISC I-ACTI-MISC
adenomatous I-DISO-MISC B-ANAT-MISC
polyposis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
FAP B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
highly O-MISC B-CHED-MISC
penetrant O-MISC B-CHED-MISC
autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
multiple O-MISC I-ACTI-MISC
intestinal O-MISC B-ANAT-MISC
polyps B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
surgical O-MISC I-ACTI-MISC
intervention O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CRC B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

APC B-DISO-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tumour O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
suppressor O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
somatic O-MISC I-ACTI-MISC
loss O-MISC B-ANAT-MISC
occurs O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
tumours B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
germline O-MISC I-DISO-MISC
T O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
to O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
A O-MISC I-LIVB-MISC
transversion O-MISC I-LIVB-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC O-MISC B-LIVB-MISC
I1307K O-MISC I-PROC-MISC
allele O-MISC I-PROC-MISC
converts O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
sequence O-MISC B-LIVB-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
homopolymer O-MISC O-MISC
tract O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
A8 O-MISC O-MISC
) O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
genetically O-MISC I-ACTI-MISC
unstable O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
prone O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
somatic O-MISC I-ACTI-MISC
mutation O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
unselected O-MISC I-ACTI-MISC
Ashkenazi O-MISC B-PHEN-MISC
Jews O-MISC B-UnknownType-MISC
and O-MISC B-ACTI-MISC
higher O-MISC B-CHED-MISC
proportions O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
Ashkenazim O-MISC O-MISC
with O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
or O-MISC B-ACTI-MISC
personal O-MISC B-CHED-MISC
histories O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
CRC B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
ref O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
evaluate O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
genotyped O-MISC I-DISO-MISC
5 O-MISC B-LIVB-MISC
, O-MISC I-PROC-MISC
081 O-MISC I-PROC-MISC
Ashkenazi O-MISC B-PHEN-MISC
volunteers O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
community O-MISC B-CHED-MISC
survey O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
, I-DISO-MISC B-ACTI-MISC
breast I-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
other I-DISO-MISC B-ACTI-MISC
cancers I-DISO-MISC I-ACTI-MISC
were O-MISC B-ACTI-MISC
compared O-MISC B-DEVI-MISC
between O-MISC B-ACTI-MISC
genotyped O-MISC I-DISO-MISC
I1307K O-MISC I-LIVB-MISC
carriers O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
carriers O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
degree O-MISC B-ACTI-MISC
relatives O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Sperm O-MISC I-GENE-MISC
DNA O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Friedreich B-DISO-MISC I-ACTI-MISC
ataxia I-DISO-MISC B-ANAT-MISC
premutation O-MISC O-MISC
carrier O-MISC O-MISC
suggests O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
meiotic O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
mitotic O-MISC I-DISO-MISC
expansion O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
FRDA B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Friedreich B-DISO-MISC I-ACTI-MISC
ataxia I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
usually O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
expansion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
GAA O-MISC O-MISC
trinucleotide O-MISC B-DISO-MISC
repeat O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
intron O-MISC O-MISC
1 O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
FRDA B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Occasionally O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
fully O-MISC B-CHED-MISC
expanded O-MISC B-CHED-MISC
allele O-MISC B-LIVB-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
arise O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
premutation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
100 O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
triplet O-MISC B-LIVB-MISC
repeats O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sperm O-MISC I-GENE-MISC
DNA O-MISC B-GEOG-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
premutation O-MISC I-DISO-MISC
carrier O-MISC O-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
mans O-MISC I-GENE-MISC
leucocyte O-MISC B-GEOG-MISC
DNA O-MISC O-MISC
showed O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
allele O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
allele O-MISC B-LIVB-MISC
of O-MISC B-ACTI-MISC
approximately O-MISC B-CHED-MISC
100 O-MISC B-ACTI-MISC
repeats O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

His O-MISC B-ACTI-MISC
sperm O-MISC I-GENE-MISC
showed O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
expanded O-MISC B-CHED-MISC
allele O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
tight O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
centering O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
size O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
approximately O-MISC B-ACTI-MISC
320 O-MISC B-ACTI-MISC
trinucleotide O-MISC O-MISC
repeats O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

His O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
son O-MISC B-LIVB-MISC
has O-MISC B-ACTI-MISC
repeat O-MISC B-ACTI-MISC
sizes O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
1040 O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
540 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
expansion O-MISC I-DISO-MISC
occurs O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
stages O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-CHED-MISC
during O-MISC B-ACTI-MISC
meiosis O-MISC I-DISO-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
second O-MISC B-CHED-MISC
mitotic O-MISC I-DISO-MISC
expansion O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
informative O-MISC B-CHED-MISC
carrier O-MISC I-CHED-MISC
father O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
child O-MISC I-ANAT-MISC
transmissions O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
notable O-MISC B-ACTI-MISC
exception O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
premutation O-MISC B-CHED-MISC
carrier O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expansion O-MISC I-DISO-MISC
size O-MISC B-CHED-MISC
decreases O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
R496H O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
arylsulfatase O-MISC O-MISC
A O-MISC B-DISO-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
metachromatic B-DISO-MISC I-ACTI-MISC
leukodystrophy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Deficiency B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
arylsulfatase I-DISO-MISC O-MISC
A I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
ARSA O-MISC O-MISC
) O-MISC B-ACTI-MISC
enzyme O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
causes O-MISC B-ACTI-MISC
metachromatic B-DISO-MISC I-ACTI-MISC
leukodystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MLD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
ARSA O-MISC B-LIVB-MISC
gene O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
MLD B-DISO-MISC I-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
R496H O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
ARSA O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
proposed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cause O-MISC B-PHEN-MISC
of O-MISC B-ACTI-MISC
MLD B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
Draghia O-MISC B-ACTI-MISC
et O-MISC B-ACTI-MISC
al O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
1997 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
investigated O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
R496H O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
frequency O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
African O-MISC I-ANAT-MISC
American O-MISC I-PHEN-MISC
population O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
f O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
09 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
61 O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ARSA O-MISC B-LIVB-MISC
enzyme O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
subjects O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
R496H O-MISC I-ACTI-MISC
mutation O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
concluded O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
R496H O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
ARSA O-MISC B-LIVB-MISC
does O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
negatively O-MISC I-ACTI-MISC
influence O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
activity O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
ARSA O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
MLD B-DISO-MISC I-ACTI-MISC

Down O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
regulation O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
transmembrane O-MISC O-MISC
carbonic O-MISC O-MISC
anhydrases O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
cell I-DISO-MISC B-ANAT-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
cell O-MISC I-GENE-MISC
lines O-MISC B-GEOG-MISC
by O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
von B-DISO-MISC I-ACTI-MISC
Hippel I-DISO-MISC I-PHEN-MISC
- I-DISO-MISC I-PHEN-MISC
Lindau I-DISO-MISC I-PHEN-MISC
transgenes O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
discover O-MISC B-DEVI-MISC
genes O-MISC B-LIVB-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
von B-DISO-MISC O-MISC
Hippel I-DISO-MISC B-DISO-MISC
- I-DISO-MISC B-DISO-MISC
Lindau I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
VHL B-DISO-MISC O-MISC
) O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
mediated O-MISC B-ACTI-MISC
carcinogenesis O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
cell I-DISO-MISC B-ANAT-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
cell O-MISC I-GENE-MISC
lines O-MISC B-GEOG-MISC
stably O-MISC B-ACTI-MISC
transfected O-MISC I-DISO-MISC
with O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
VHL O-MISC O-MISC
- O-MISC B-ACTI-MISC
expressing O-MISC I-DISO-MISC
transgenes O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Large O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
scale O-MISC I-CONC-MISC
RNA O-MISC I-CONC-MISC
differential O-MISC I-CONC-MISC
display O-MISC I-CONC-MISC
technology O-MISC I-CONC-MISC
applied O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
cell O-MISC I-GENE-MISC
lines O-MISC B-GEOG-MISC
identified O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
differentially O-MISC B-ACTI-MISC
expressed O-MISC I-DISO-MISC
genes O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alpha O-MISC B-LIVB-MISC
carbonic O-MISC I-PROC-MISC
anhydrase O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
termed O-MISC B-ACTI-MISC
CA12 O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
deduced O-MISC B-ACTI-MISC
protein O-MISC B-LIVB-MISC
sequence O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
classified O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
pass O-MISC B-ACTI-MISC
transmembrane O-MISC I-GENE-MISC
CA O-MISC O-MISC
possessing O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
apparently O-MISC B-ACTI-MISC
intact O-MISC B-ACTI-MISC
catalytic O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
extracellular O-MISC I-GENE-MISC
CA O-MISC I-DISO-MISC
module O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Reintroduced O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
VHL B-DISO-MISC O-MISC
strongly O-MISC B-ACTI-MISC
inhibited O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
overexpression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CA12 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
parental O-MISC B-ACTI-MISC
renal B-DISO-MISC I-ACTI-MISC
cell I-DISO-MISC B-ANAT-MISC
carcinoma I-DISO-MISC B-ANAT-MISC
cell O-MISC I-GENE-MISC
lines O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Similar O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
obtained O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
CA9 O-MISC O-MISC
, O-MISC B-ACTI-MISC
encoding O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
transmembrane O-MISC I-GENE-MISC
CA O-MISC O-MISC
with O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
intact O-MISC B-ACTI-MISC
catalytic O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
domains O-MISC B-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
VHL B-DISO-MISC O-MISC
protein O-MISC B-DISO-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
regulation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
CA12 O-MISC O-MISC
expression O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
elongin O-MISC O-MISC
binding O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
alone O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
effectively O-MISC B-ACTI-MISC
regulate O-MISC I-DISO-MISC
CA9 O-MISC O-MISC
expression O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
mapped O-MISC B-CONC-MISC
CA12 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
CA9 O-MISC B-LIVB-MISC
loci O-MISC I-PROC-MISC
to O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
bands O-MISC B-GEOG-MISC
15q22 O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
17q21 O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

2 O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
regions O-MISC B-ACTI-MISC
prone O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
amplification O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
cancers B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Additional O-MISC B-ACTI-MISC
experiments O-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
needed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
define O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CA O-MISC O-MISC
IX O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
CA O-MISC O-MISC
XII O-MISC B-DISO-MISC
enzymes O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
regulation O-MISC B-OCCU-MISC
of O-MISC B-ACTI-MISC
pH O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
extracellular O-MISC B-OCCU-MISC
microenvironment O-MISC I-OCCU-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
impact O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
cell O-MISC I-DISO-MISC
growth O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
encoding O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
transmembrane O-MISC O-MISC
protein O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
mutated O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
diabetes B-DISO-MISC I-ACTI-MISC
mellitus I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
optic B-DISO-MISC I-ACTI-MISC
atrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
Wolfram B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Wolfram B-DISO-MISC I-ACTI-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
WFS B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
OMIM O-MISC B-CHED-MISC
222300 O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
recessive I-DISO-MISC B-ANAT-MISC
neurodegenerative I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
defined O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
young O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
onset O-MISC B-ANAT-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
immune O-MISC B-ANAT-MISC
insulin B-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
dependent I-DISO-MISC B-ANAT-MISC
diabetes I-DISO-MISC B-ANAT-MISC
mellitus I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
optic B-DISO-MISC I-ACTI-MISC
atrophy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Linkage O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
markers O-MISC I-DISO-MISC
on O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
4p O-MISC B-GEOG-MISC
was O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
families O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

On O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
basis O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
meiotic O-MISC O-MISC
recombinants O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
disease O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
associated O-MISC I-LIVB-MISC
haplotypes O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
WFS B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
localized O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
BAC O-MISC O-MISC
/ O-MISC B-DISO-MISC
P1 O-MISC B-DISO-MISC
contig O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
less O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
250 O-MISC B-ACTI-MISC
kb O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
gene O-MISC B-LIVB-MISC
( O-MISC B-ACTI-MISC
WFS1 O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
encoding O-MISC B-DEVI-MISC
a O-MISC B-ACTI-MISC
putative O-MISC O-MISC
transmembrane O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
individuals O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
WFS B-DISO-MISC B-LIVB-MISC
families O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
phenotype O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

WFS1 O-MISC B-LIVB-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
function O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
survival O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
islet O-MISC I-GENE-MISC
beta O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
neurons O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Stable O-MISC B-CHED-MISC
interaction O-MISC I-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
products O-MISC O-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
tumor B-DISO-MISC B-LIVB-MISC
suppressor O-MISC I-PROC-MISC
genes O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
mitotic O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
meiotic O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

BRCA1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
BRCA2 O-MISC O-MISC
account O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
familial O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
early O-MISC I-ACTI-MISC
onset O-MISC B-ANAT-MISC
breast B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ACTI-MISC
/ I-DISO-MISC B-ACTI-MISC
or I-DISO-MISC B-ACTI-MISC
ovarian I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
encode O-MISC B-ACTI-MISC
products O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
interact O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
hRAD51 O-MISC O-MISC
. O-MISC B-ACTI-MISC

Results O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
BRCA2 O-MISC O-MISC
coexist O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
biochemical O-MISC O-MISC
complex O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
colocalize O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
subnuclear O-MISC B-CHED-MISC
foci O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
somatic O-MISC I-GENE-MISC
cells O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
axial O-MISC B-CHED-MISC
elements O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
synaptonemal O-MISC I-GENE-MISC
complexes O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Like O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
RAD51 O-MISC O-MISC
, O-MISC B-ACTI-MISC
BRCA2 O-MISC O-MISC
relocates O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
PCNA O-MISC O-MISC
+ O-MISC B-DISO-MISC
replication O-MISC I-GENE-MISC
sites O-MISC B-GEOG-MISC
following O-MISC B-ACTI-MISC
exposure O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
S O-MISC I-GENE-MISC
phase O-MISC B-GEOG-MISC
cells O-MISC I-GENE-MISC
to O-MISC B-ACTI-MISC
hydroxyurea O-MISC O-MISC
or O-MISC B-ACTI-MISC
UV O-MISC B-OCCU-MISC
irradiation O-MISC I-OCCU-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
and O-MISC B-ACTI-MISC
BRCA2 O-MISC O-MISC
participate O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pathway O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
s O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
the O-MISC B-ACTI-MISC
activation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
double O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
strand O-MISC I-LIVB-MISC
break O-MISC I-LIVB-MISC
repair O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
homologous O-MISC I-DISO-MISC
recombination O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Dysfunction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
pathway O-MISC B-CHED-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
general O-MISC B-OCCU-MISC
phenomenon O-MISC I-OCCU-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
breast I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
/ I-DISO-MISC B-ACTI-MISC
or I-DISO-MISC B-ACTI-MISC
ovarian I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
Arg362Ser O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sterol O-MISC B-LIVB-MISC
27 O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
hydroxylase O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
CYP27 O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
: O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
effects O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
pre O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
mRNA O-MISC I-LIVB-MISC
splicing O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
enzyme O-MISC I-DISO-MISC
activity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
C O-MISC I-DISO-MISC
to O-MISC I-LIVB-MISC
A O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sterol O-MISC B-LIVB-MISC
27 O-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
hydroxylase O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
CYP27 O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
sequencing O-MISC B-CONC-MISC
amplified O-MISC I-DISO-MISC
CYP27 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
products O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
cerebrotendinous B-DISO-MISC I-ACTI-MISC
xanthomatosis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CTX B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
changed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
adrenodoxin O-MISC O-MISC
cofactor O-MISC O-MISC
binding O-MISC I-PROC-MISC
residue O-MISC I-PROC-MISC
362Arg O-MISC I-LIVB-MISC
to O-MISC I-PROC-MISC
362Ser O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
CGT O-MISC I-DISO-MISC
362Arg O-MISC I-LIVB-MISC
to O-MISC B-DISO-MISC
AGT O-MISC I-LIVB-MISC
362Ser O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
deficiency O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
sterol O-MISC O-MISC
27 O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
hydroxylase O-MISC I-LIVB-MISC
activity O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
confirmed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
mutant O-MISC B-LIVB-MISC
cDNA O-MISC O-MISC
into O-MISC B-ACTI-MISC
COS O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
1 O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Quantitative O-MISC B-CHED-MISC
analysis O-MISC I-CHED-MISC
showed O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
CYP27 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
mRNA O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
represented O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
level O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

As O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
occurred O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
penultimate O-MISC B-CHED-MISC
nucleotide O-MISC O-MISC
of O-MISC B-ACTI-MISC
exon O-MISC O-MISC
6 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
position O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
exon O-MISC O-MISC
6 O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
intron O-MISC B-DISO-MISC
6 O-MISC B-DISO-MISC
splice O-MISC O-MISC
site O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
hypothesized O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
may O-MISC B-ACTI-MISC
partially O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
splicing O-MISC I-DISO-MISC
efficiency O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
6 O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
alternative O-MISC I-DISO-MISC
splicing O-MISC I-LIVB-MISC
elsewhere O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
decreased O-MISC B-CHED-MISC
transcript O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Transfection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
constructed O-MISC B-ACTI-MISC
minigenes O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
into O-MISC B-ACTI-MISC
COS O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
1 O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
confirmed O-MISC I-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutant O-MISC I-ACTI-MISC
minigene O-MISC B-LIVB-MISC
was O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mRNA O-MISC O-MISC
species O-MISC B-DISO-MISC
alternatively O-MISC B-CHED-MISC
spliced O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
activated O-MISC O-MISC
cryptic O-MISC B-DISO-MISC
5 O-MISC B-DISO-MISC
splice O-MISC B-DISO-MISC
site O-MISC B-DISO-MISC
88 O-MISC B-ACTI-MISC
bp O-MISC B-ACTI-MISC
upstream O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
end O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
exon O-MISC O-MISC
6 O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C O-MISC I-DISO-MISC
to O-MISC I-LIVB-MISC
A O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
penultimate O-MISC B-CHED-MISC
nucleotide O-MISC O-MISC
of O-MISC B-ACTI-MISC
exon O-MISC O-MISC
6 O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CYP27 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
not O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
causes O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
deficiency B-DISO-MISC B-CHED-MISC
in I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
sterol I-DISO-MISC O-MISC
27 I-DISO-MISC I-DISO-MISC
- I-DISO-MISC I-LIVB-MISC
hydroxylase I-DISO-MISC I-LIVB-MISC
activity I-DISO-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
partially O-MISC B-ACTI-MISC
leads O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
pre O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
mRNA O-MISC I-LIVB-MISC
splicing O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
knowledge O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
regarding O-MISC B-ACTI-MISC
effects O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
pre O-MISC O-MISC
- O-MISC B-DISO-MISC
mRNA O-MISC B-DISO-MISC
splicing O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
2 O-MISC I-CHED-MISC
position O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
splice O-MISC O-MISC
site O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

ATM O-MISC O-MISC
germline O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
classical O-MISC B-ACTI-MISC
ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Dutch O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Germline O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATM O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
are O-MISC B-ACTI-MISC
responsible O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
recessive I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
ataxia B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
telangiectasia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
determined O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATM O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
spectrum O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
classical O-MISC B-ACTI-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
T I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
immigrant O-MISC I-ANAT-MISC
populations O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Dutch O-MISC I-ANAT-MISC
ethnic O-MISC I-PHEN-MISC
origin O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Both O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protein O-MISC B-CONC-MISC
truncation O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
PTT O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
restriction O-MISC B-CONC-MISC
endonuclease O-MISC I-CONC-MISC
fingerprinting O-MISC I-CONC-MISC
( O-MISC I-CONC-MISC
REF O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
method O-MISC I-CONC-MISC
were O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
detection O-MISC B-CONC-MISC
efficiency O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
identifying O-MISC B-ACTI-MISC
76 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
60 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Most O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
compound O-MISC I-ACTI-MISC
heterozygote O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Seventeen O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
distinct O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
deletions O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
point O-MISC I-ACTI-MISC
mutations O-MISC B-ANAT-MISC
frequently O-MISC B-ACTI-MISC
affecting O-MISC B-ACTI-MISC
splice O-MISC B-LIVB-MISC
sites O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

7 O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
kb O-MISC I-LIVB-MISC
genomic O-MISC I-LIVB-MISC
deletion O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
end O-MISC I-PROC-MISC
of O-MISC I-PROC-MISC
the O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
recombination O-MISC I-DISO-MISC
between O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
LINE O-MISC O-MISC
elements O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
frequently O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
Turkish O-MISC I-ANAT-MISC
A B-DISO-MISC O-MISC
- I-DISO-MISC B-DISO-MISC
T I-DISO-MISC B-DISO-MISC
individuals O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Turkish O-MISC I-ANAT-MISC
A B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC I-LIVB-MISC
T I-DISO-MISC B-ANAT-MISC
founder O-MISC I-DISO-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
founder O-MISC B-CHED-MISC
mutation O-MISC I-CHED-MISC
among O-MISC B-ACTI-MISC
relatively O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
ethnic O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
groups O-MISC I-PHEN-MISC
in O-MISC B-ACTI-MISC
Western O-MISC B-ORGA-MISC
Europe O-MISC I-ORGA-MISC
could O-MISC B-ACTI-MISC
indicate O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
carrier O-MISC I-CHED-MISC
frequency O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
such O-MISC B-ACTI-MISC
communities O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
Dutch O-MISC I-ANAT-MISC
ethnic O-MISC I-PHEN-MISC
origin O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
founder O-MISC B-CHED-MISC
effect O-MISC I-CHED-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
genetic O-MISC I-DISO-MISC
heterogeneity O-MISC I-LIVB-MISC
including O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
relative O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
percentage O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
splice O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
site O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
had O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
reflection O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
manifested O-MISC B-CHED-MISC
classical O-MISC B-ACTI-MISC
A B-DISO-MISC O-MISC
- I-DISO-MISC B-DISO-MISC
T I-DISO-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
cellular O-MISC I-GENE-MISC
radioresistant O-MISC B-CHED-MISC
DNA O-MISC I-DISO-MISC
synthesis O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Determination O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genomic O-MISC B-LIVB-MISC
structure O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
COL4A4 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
causing O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
recessive I-DISO-MISC B-ANAT-MISC
Alport I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Autosomal B-DISO-MISC I-ACTI-MISC
recessive I-DISO-MISC B-ANAT-MISC
Alport I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
hematuric B-DISO-MISC I-ACTI-MISC
glomerulonephritis I-DISO-MISC I-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
glomerular B-DISO-MISC I-GENE-MISC
basement I-DISO-MISC B-GEOG-MISC
membrane I-DISO-MISC B-GEOG-MISC
abnormalities I-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
either O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
COL4A3 O-MISC B-LIVB-MISC
or O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
COL4A4 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
encode O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
alpha3 O-MISC O-MISC
and O-MISC B-ACTI-MISC
alpha4 O-MISC O-MISC
type O-MISC B-DISO-MISC
IV O-MISC B-DISO-MISC
collagen O-MISC B-DISO-MISC
chains O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
date O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
mutation O-MISC B-CONC-MISC
screening O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
hampered O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
lack O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
genomic O-MISC B-LIVB-MISC
structure O-MISC I-PROC-MISC
information O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
here O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
complete O-MISC B-ACTI-MISC
characterization O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
exons O-MISC O-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
COL4A4 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
comprehensive O-MISC B-CHED-MISC
gene O-MISC B-CONC-MISC
screen O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subsequent O-MISC B-ACTI-MISC
detection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
diagnosed O-MISC I-ACTI-MISC
with O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
recessive I-DISO-MISC B-ANAT-MISC
Alport I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
a O-MISC B-ACTI-MISC
glycine O-MISC O-MISC
to O-MISC B-ACTI-MISC
alanine O-MISC I-DISO-MISC
substitution O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
collagenous O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
apparently O-MISC B-ACTI-MISC
silent O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
carriers O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
individuals O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
control O-MISC I-ANAT-MISC
individual O-MISC I-ANAT-MISC
homozygous O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
glycine O-MISC O-MISC
substitution O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

There O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
previous O-MISC B-ACTI-MISC
finding O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
glycine O-MISC O-MISC
substitution O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
any O-MISC B-ACTI-MISC
obvious O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
individuals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Founder O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
French O-MISC I-ANAT-MISC
Canadian O-MISC I-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
and I-DISO-MISC B-ANAT-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
four O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
each O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
- O-MISC B-ACTI-MISC
susceptibility O-MISC B-LIVB-MISC
genes O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
French O-MISC I-ACTI-MISC
Canadian O-MISC B-ANAT-MISC
breast B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
/ I-DISO-MISC B-ANAT-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
families O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
Quebec O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
founder O-MISC B-CHED-MISC
effects O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
independently O-MISC B-ACTI-MISC
ascertained O-MISC B-ACTI-MISC
French O-MISC I-ANAT-MISC
Canadian O-MISC I-ACTI-MISC
cancer B-DISO-MISC I-ANAT-MISC
families O-MISC I-PHEN-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
distribution O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
97 O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
twice O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
C4446T O-MISC I-ACTI-MISC
mutation O-MISC I-LIVB-MISC
was O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
found O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
8765delAG O-MISC I-PROC-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Together O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
41 O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
identified O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
odds O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
detection O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
mutations O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

7x O-MISC B-ACTI-MISC
greater O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
more O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
ovarian B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
present O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
odds O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
detection O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
mutations O-MISC B-ANAT-MISC
was O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

3x O-MISC B-ACTI-MISC
greater O-MISC B-CHED-MISC
if O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
five O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Interestingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
case O-MISC B-CHED-MISC
< O-MISC B-ACTI-MISC
36 O-MISC B-ACTI-MISC
years O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
strongly O-MISC B-ACTI-MISC
predictive O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
eight O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
screened O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Carriers O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
same O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
shared O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
haplotypes O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
mutant O-MISC B-LIVB-MISC
alleles O-MISC I-PROC-MISC
were O-MISC B-ACTI-MISC
likely O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
identical O-MISC B-CHED-MISC
by O-MISC B-ACTI-MISC
descent O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
founder O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
identification O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
BRCA2 O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
will O-MISC B-ACTI-MISC
facilitate O-MISC B-ACTI-MISC
carrier O-MISC B-CONC-MISC
detection O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
French O-MISC I-ACTI-MISC
Canadian O-MISC B-ANAT-MISC
breast B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
breast B-DISO-MISC I-ACTI-MISC
/ I-DISO-MISC B-ANAT-MISC
ovarian I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
families O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Are O-MISC B-ACTI-MISC
Dp71 O-MISC O-MISC
and O-MISC B-ACTI-MISC
Dp140 O-MISC O-MISC
brain O-MISC I-GENE-MISC
dystrophin O-MISC I-ACTI-MISC
isoforms O-MISC O-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
Duchenne B-DISO-MISC I-ACTI-MISC
muscular I-DISO-MISC B-ANAT-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
? O-MISC B-ACTI-MISC

Molecular O-MISC B-CONC-MISC
study O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
neuropsychological O-MISC B-CONC-MISC
analysis O-MISC B-CONC-MISC
were O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
concurrently O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
49 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
Duchenne B-DISO-MISC I-ACTI-MISC
muscular I-DISO-MISC B-ANAT-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DMD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
find O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
explanation O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
DMD B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Complete O-MISC B-ACTI-MISC
analysis O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dystrophin O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
define O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
localization O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
deletions O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
duplications O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
relation O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
DMD B-DISO-MISC I-ACTI-MISC
promoters O-MISC O-MISC
. O-MISC B-ACTI-MISC

Qualitative O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Dp71 O-MISC B-LIVB-MISC
transcript O-MISC O-MISC
and O-MISC B-ACTI-MISC
testing O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
first O-MISC B-ACTI-MISC
exon O-MISC O-MISC
of O-MISC B-ACTI-MISC
Dp140 O-MISC O-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
carried O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Neuropsychological O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
assessed O-MISC B-DEVI-MISC
verbal O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
visuospatial O-MISC I-DISO-MISC
intelligence O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
verbal O-MISC I-DISO-MISC
memory O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
reading O-MISC I-DISO-MISC
skills O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Comparison O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
psychometric O-MISC B-CONC-MISC
findings O-MISC I-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
deletions O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
duplications O-MISC I-DISO-MISC
that O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
localized O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
distal O-MISC B-CHED-MISC
part O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
seemed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
preferentially O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
altered O-MISC B-ACTI-MISC
Dp71 O-MISC B-LIVB-MISC
transcripts O-MISC O-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
deleted O-MISC I-DISO-MISC
Dp140 O-MISC B-LIVB-MISC
DNA O-MISC B-LIVB-MISC
sequences O-MISC I-PROC-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
severe O-MISC B-CHED-MISC
cerebral B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
sequences O-MISC B-LIVB-MISC
located O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
distal O-MISC B-CHED-MISC
part O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
particular O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
DMD B-DISO-MISC I-ACTI-MISC
isoforms O-MISC O-MISC
expressed O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
brain O-MISC I-GENE-MISC
may O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cognitive B-DISO-MISC I-ACTI-MISC
impairment I-DISO-MISC B-ANAT-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
DMD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

I1307K O-MISC B-LIVB-MISC
APC O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
hMLH1 O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Jewish O-MISC I-PHEN-MISC
family O-MISC I-PHEN-MISC
with O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
non I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
polyposis I-DISO-MISC B-ANAT-MISC
colorectal I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
describe O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
French O-MISC I-ANAT-MISC
Canadian O-MISC I-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
non I-DISO-MISC B-ANAT-MISC
- I-DISO-MISC B-ANAT-MISC
polyposis I-DISO-MISC B-ANAT-MISC
colorectal I-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HNPCC B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
kindred O-MISC I-ANAT-MISC
which O-MISC B-ACTI-MISC
carries O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
truncating O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
hMLH1 O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Interestingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
APC O-MISC I-PROC-MISC
polymorphism O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
polymorphism O-MISC I-DISO-MISC
has O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
self O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
reported O-MISC I-CONC-MISC
Ashkenazi O-MISC B-PHEN-MISC
Jewish O-MISC B-UnknownType-MISC
origins O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
addition O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
appears O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
no O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
polymorphism O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cancer B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Identification O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
mutation O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CPO O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
hereditary B-DISO-MISC I-ACTI-MISC
coproporphyria I-DISO-MISC B-ANAT-MISC
family O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Hereditary B-DISO-MISC I-ACTI-MISC
coproporphyria I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HCP B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
characterized O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
deficiency B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
coproporphyrinogen I-DISO-MISC O-MISC
oxidase I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CPO O-MISC O-MISC
) O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CPO O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Only O-MISC B-ACTI-MISC
11 O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
of O-MISC I-PROC-MISC
the O-MISC I-LIVB-MISC
gene O-MISC I-PROC-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
HCP B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
report O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
family O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Polymerase O-MISC B-CONC-MISC
chain O-MISC I-CONC-MISC
reaction O-MISC I-CONC-MISC
- O-MISC B-ACTI-MISC
single O-MISC B-LIVB-MISC
strand O-MISC I-LIVB-MISC
conformational O-MISC I-LIVB-MISC
polymorphism O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
direct O-MISC B-CONC-MISC
sequence O-MISC I-CONC-MISC
analyses O-MISC I-CONC-MISC
demonstrated O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
C O-MISC I-DISO-MISC
to O-MISC I-LIVB-MISC
T O-MISC I-LIVB-MISC
substitution O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
1 O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CPO O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
at O-MISC B-ACTI-MISC
nucleotide O-MISC B-LIVB-MISC
position O-MISC I-PROC-MISC
85 O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
lies O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
putative O-MISC B-ACTI-MISC
presequence O-MISC I-PROC-MISC
for O-MISC B-ACTI-MISC
targeting O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
mitochondria O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
changes O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
codon O-MISC B-LIVB-MISC
for O-MISC B-ACTI-MISC
glutamine O-MISC O-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
termination O-MISC I-GENE-MISC
codon O-MISC B-LIVB-MISC
at O-MISC B-ACTI-MISC
amino O-MISC B-LIVB-MISC
acid O-MISC I-PROC-MISC
position O-MISC B-CHED-MISC
29 O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

MaeI O-MISC B-CONC-MISC
restriction O-MISC I-CONC-MISC
analysis O-MISC B-CONC-MISC
showed O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
carriers O-MISC O-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
C O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
T O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
located O-MISC B-ACTI-MISC
within O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
recently O-MISC B-ACTI-MISC
proposed O-MISC B-ACTI-MISC
putative O-MISC B-LIVB-MISC
alternative O-MISC I-PROC-MISC
translation O-MISC I-PROC-MISC
initiation O-MISC I-PROC-MISC
codon O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
TIC O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
1 O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
supporting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
TIC O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
1 O-MISC I-PROC-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
real O-MISC B-ACTI-MISC
TIC O-MISC I-GENE-MISC
rather O-MISC B-ACTI-MISC
than O-MISC B-ACTI-MISC
TIC O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
2 O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Human B-DISO-MISC I-ANAT-MISC
complement I-DISO-MISC O-MISC
factor I-DISO-MISC B-DISO-MISC
H I-DISO-MISC B-ANAT-MISC
deficiency I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
hemolytic B-DISO-MISC I-ACTI-MISC
uremic I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
reports O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
cases O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
deficiency B-DISO-MISC B-CHED-MISC
in I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
human I-DISO-MISC I-ANAT-MISC
complement I-DISO-MISC O-MISC
regulatory I-DISO-MISC B-DISO-MISC
protein I-DISO-MISC B-DISO-MISC
Factor I-DISO-MISC B-DISO-MISC
H I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
FH O-MISC O-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
context O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acute B-DISO-MISC I-ACTI-MISC
renal I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
presenting O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
idiopathic O-MISC I-ACTI-MISC
hemolytic B-DISO-MISC B-ANAT-MISC
uremic I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HUS B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Two O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
exhibited O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
deficiency O-MISC B-CHED-MISC
characterized O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
150 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
kD O-MISC B-ACTI-MISC
form O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
Factor O-MISC O-MISC
H O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
immunoblotting O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
42 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
kD O-MISC B-ACTI-MISC
Factor O-MISC O-MISC
H O-MISC B-DISO-MISC
- O-MISC B-DISO-MISC
like O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
FHL O-MISC O-MISC
- O-MISC B-DISO-MISC
1 O-MISC B-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
FH O-MISC O-MISC
- O-MISC B-DISO-MISC
related O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
FHR O-MISC O-MISC
) O-MISC B-ACTI-MISC
bands O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Southern O-MISC B-CONC-MISC
blot O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
PCR O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
DNA O-MISC O-MISC
of O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
homozygous O-MISC I-ACTI-MISC
deficiency O-MISC B-ANAT-MISC
ruled O-MISC B-ACTI-MISC
out O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
deletion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
FH O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
underlying O-MISC B-ACTI-MISC
defect O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
deficiency O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
children O-MISC I-ANAT-MISC
presented O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
heterozygous O-MISC I-ACTI-MISC
deficiency O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
exhibited O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
immunoblotting O-MISC B-CONC-MISC
pattern O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
proteins O-MISC O-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
FH O-MISC O-MISC
family O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

Factor B-DISO-MISC I-ACTI-MISC
H I-DISO-MISC B-ANAT-MISC
deficiency I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
complement B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
HUS B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
observations O-MISC B-CONC-MISC
suggest O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
FH O-MISC O-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
FH O-MISC O-MISC
receptors O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
idiopathic O-MISC B-CHED-MISC
HUS B-DISO-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Further O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
ancient O-MISC B-CHED-MISC
mutation O-MISC I-DISO-MISC
underlying O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
from O-MISC B-ACTI-MISC
linkage O-MISC B-CONC-MISC
disequilibrium O-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
unstable O-MISC I-ACTI-MISC
( O-MISC B-DISO-MISC
CTG O-MISC I-PROC-MISC
) O-MISC B-DISO-MISC
n O-MISC B-DISO-MISC
repeat O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
copy O-MISC B-CHED-MISC
number O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
repeats O-MISC B-LIVB-MISC
on O-MISC B-ACTI-MISC
normal O-MISC B-ACTI-MISC
chromosomes O-MISC I-GENE-MISC
but O-MISC B-ACTI-MISC
amplified O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3000 O-MISC B-ACTI-MISC
copies O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
chromosomes O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Previous O-MISC B-ACTI-MISC
findings O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
Caucasian O-MISC I-ANAT-MISC
populations O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
founder O-MISC I-DISO-MISC
chromosome O-MISC I-GENE-MISC
raise O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
question O-MISC B-CHED-MISC
about O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
molecular O-MISC I-DISO-MISC
events O-MISC I-LIVB-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expansion O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
investigate O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
founder O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
exists O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
genotyped O-MISC I-DISO-MISC
families O-MISC I-ANAT-MISC
using O-MISC B-ACTI-MISC
polymorphic O-MISC B-LIVB-MISC
markers O-MISC I-PROC-MISC
near O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
( O-MISC B-LIVB-MISC
CTG O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
n O-MISC I-PROC-MISC
repeat O-MISC I-PROC-MISC
region O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
constructed O-MISC B-ACTI-MISC
haplotypes O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Six O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
haplotypes O-MISC I-DISO-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
alleles O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
always O-MISC B-ACTI-MISC
haplotype O-MISC I-DISO-MISC
A O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
find O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
origin O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
( O-MISC B-LIVB-MISC
CTG O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
n O-MISC I-PROC-MISC
repeat O-MISC B-ANAT-MISC
mutation O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
mechanism O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
expansion O-MISC B-OCCU-MISC
mutation O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
population O-MISC I-PHEN-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
90 O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
DM B-DISO-MISC I-ACTI-MISC
families O-MISC I-ANAT-MISC
comprising O-MISC B-ACTI-MISC
190 O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
130 O-MISC B-ACTI-MISC
unaffected O-MISC B-CHED-MISC
members O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
few O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
ancestral O-MISC B-OCCU-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
Caucasian O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
Japanese O-MISC I-ANAT-MISC
populations O-MISC I-ANAT-MISC
have O-MISC B-ACTI-MISC
originated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
expansion O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
ancestral O-MISC B-CHED-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
repeat O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
n O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
19 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
37 O-MISC B-ACTI-MISC
copies O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
support O-MISC B-ACTI-MISC
multistep O-MISC B-OBJC-MISC
models O-MISC B-OBJC-MISC
of O-MISC B-ACTI-MISC
triplet O-MISC I-ACTI-MISC
repeat O-MISC B-ANAT-MISC
expansion O-MISC B-ANAT-MISC
that O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
proposed O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
Friedreichs B-DISO-MISC I-ACTI-MISC
ataxia I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
basis O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
C6 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
western O-MISC B-ORGA-MISC
Cape O-MISC I-ORGA-MISC
, O-MISC B-ACTI-MISC
South O-MISC B-ORGA-MISC
Africa O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

Deficiency B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
sixth I-DISO-MISC B-ACTI-MISC
component I-DISO-MISC B-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
human I-DISO-MISC O-MISC
complement I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
C6 O-MISC O-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
number O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
western O-MISC B-ORGA-MISC
Cape O-MISC I-ORGA-MISC
, O-MISC B-ACTI-MISC
South O-MISC B-ORGA-MISC
Africa O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

Meningococcal B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
endemic O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Cape O-MISC B-ORGA-MISC
and O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
pedigrees O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
C6 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
C6Q0 O-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
ascertained O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
recurrent O-MISC B-PHEN-MISC
disease O-MISC B-UnknownType-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
sequenced O-MISC B-CONC-MISC
the O-MISC B-ACTI-MISC
expressed O-MISC I-DISO-MISC
exons O-MISC O-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C6 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
from O-MISC B-ACTI-MISC
selected O-MISC B-ACTI-MISC
cases O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
defects O-MISC B-CHED-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
deficiency O-MISC B-CHED-MISC
879delG O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
defect O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Cape O-MISC B-ORGA-MISC
and O-MISC B-ACTI-MISC
hitherto O-MISC B-CHED-MISC
unreported O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1195delC O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
1936delG O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
previously O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
African O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Americans O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
show O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
879delG O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
1195delC O-MISC B-LIVB-MISC
defects O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
characteristic O-MISC B-ACTI-MISC
C6 O-MISC I-DISO-MISC
/ O-MISC I-LIVB-MISC
C7 O-MISC I-LIVB-MISC
region O-MISC B-GEOG-MISC
DNA O-MISC I-DISO-MISC
marker O-MISC I-LIVB-MISC
haplotypes O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
variations O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
1936delG O-MISC B-CONC-MISC
defect O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
once O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Cape O-MISC B-ORGA-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
haplotype O-MISC I-DISO-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
deduced O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
data O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
haplotypes O-MISC I-DISO-MISC
indicate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
defects O-MISC B-CHED-MISC
account O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
defects O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
38 O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
C6Q0 O-MISC I-ANAT-MISC
individuals O-MISC I-ANAT-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
studied O-MISC B-CONC-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Cape O-MISC B-ORGA-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
879delG O-MISC O-MISC
defect O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
Dutch O-MISC I-ANAT-MISC
C6 B-DISO-MISC O-MISC
- I-DISO-MISC B-ACTI-MISC
deficient I-DISO-MISC B-CHED-MISC
kindreds O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
879delG O-MISC O-MISC
defect O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Cape O-MISC B-ORGA-MISC
probably O-MISC B-ACTI-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
come O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
The O-MISC B-ORGA-MISC
Netherlands O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Complement B-DISO-MISC B-CHED-MISC
C7 I-DISO-MISC B-LIVB-MISC
deficiency I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
defects O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
associated O-MISC B-ACTI-MISC
marker O-MISC I-DISO-MISC
haplotypes O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

Seven O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
molecular O-MISC O-MISC
bases O-MISC B-DISO-MISC
of O-MISC B-ACTI-MISC
C7 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
described O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
defects O-MISC B-CHED-MISC
involve O-MISC B-ACTI-MISC
single O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
nucleotide O-MISC I-LIVB-MISC
events O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
deletions O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
substitutions O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
alter O-MISC B-ACTI-MISC
splice O-MISC B-LIVB-MISC
sites O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
others O-MISC B-ACTI-MISC
codons O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

They O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
distributed O-MISC B-CHED-MISC
along O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C7 O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
predominantly O-MISC B-CHED-MISC
towards O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
end O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

All O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
compound O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
individuals O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
C6 O-MISC I-DISO-MISC
/ O-MISC I-LIVB-MISC
C7 O-MISC I-LIVB-MISC
marker O-MISC I-LIVB-MISC
haplotypes O-MISC I-LIVB-MISC
associated O-MISC B-ACTI-MISC
with O-MISC I-CHED-MISC
most O-MISC B-ACTI-MISC
C7 B-DISO-MISC B-LIVB-MISC
defects I-DISO-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
tabulated O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
genome O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
wide O-MISC I-CONC-MISC
search O-MISC B-DEVI-MISC
for O-MISC B-ACTI-MISC
chromosomal O-MISC B-LIVB-MISC
loci O-MISC I-PROC-MISC
linked O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
mental O-MISC I-DISO-MISC
health O-MISC I-LIVB-MISC
wellness O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
relatives O-MISC I-ANAT-MISC
at O-MISC I-PHEN-MISC
high O-MISC I-ACTI-MISC
risk O-MISC B-ANAT-MISC
for O-MISC B-ACTI-MISC
bipolar B-DISO-MISC I-ACTI-MISC
affective I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
among O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Old O-MISC B-PHEN-MISC
Order O-MISC B-UnknownType-MISC
Amish O-MISC B-UnknownType-MISC
. O-MISC B-ACTI-MISC

Bipolar B-DISO-MISC I-ACTI-MISC
affective I-DISO-MISC B-ANAT-MISC
disorder I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
BPAD B-DISO-MISC I-ACTI-MISC
; O-MISC B-ACTI-MISC
manic B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
depressive I-DISO-MISC B-ANAT-MISC
illness I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
episodes O-MISC I-ACTI-MISC
of O-MISC B-ANAT-MISC
mania B-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
hypomania B-DISO-MISC I-ACTI-MISC
interspersed O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
periods O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
depression B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Compelling O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
supports O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
genetic O-MISC B-CHED-MISC
component O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
develop O-MISC B-ACTI-MISC
BPAD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
date O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
linkage O-MISC B-CONC-MISC
studies O-MISC I-CONC-MISC
have O-MISC B-ACTI-MISC
attempted O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
identify O-MISC B-ACTI-MISC
chromosomal O-MISC I-GENE-MISC
loci O-MISC I-PROC-MISC
that O-MISC B-ACTI-MISC
cause O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
increase O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
BPAD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
could O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
protective O-MISC B-ACTI-MISC
alleles O-MISC B-LIVB-MISC
that O-MISC B-ACTI-MISC
prevent O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
reduce O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
developing O-MISC B-ACTI-MISC
BPAD B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
what O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
observed O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
genetic B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
mental O-MISC I-DISO-MISC
health O-MISC I-LIVB-MISC
wellness O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
psychiatric B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
our O-MISC B-ACTI-MISC
genome O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
wide O-MISC I-CONC-MISC
linkage O-MISC B-CONC-MISC
scan O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
several O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
multigeneration O-MISC B-CHED-MISC
Old O-MISC I-CHED-MISC
Order O-MISC I-CHED-MISC
Amish O-MISC I-CHED-MISC
pedigrees O-MISC I-CHED-MISC
exhibiting O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
extremely O-MISC B-CHED-MISC
high O-MISC B-CHED-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
BPAD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
strong O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
locus O-MISC B-LIVB-MISC
on O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
4p O-MISC B-GEOG-MISC
at O-MISC B-ACTI-MISC
D4S2949 O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
GENEHUNTER O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
PLUS O-MISC I-CHED-MISC
nonparametric O-MISC I-CHED-MISC
linkage O-MISC I-CHED-MISC
score O-MISC I-CHED-MISC
= O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
05 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
SIBPAL O-MISC B-CHED-MISC
Pempirical O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
< O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
suggestive O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
locus O-MISC B-LIVB-MISC
on O-MISC B-ACTI-MISC
chromosome O-MISC I-GENE-MISC
4q O-MISC B-GEOG-MISC
at O-MISC B-ACTI-MISC
D4S397 O-MISC I-GENE-MISC
( O-MISC B-ACTI-MISC
maximum O-MISC B-CHED-MISC
GENEHUNTER O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
PLUS O-MISC I-CHED-MISC
nonparametric O-MISC I-CHED-MISC
linkage O-MISC I-CHED-MISC
score O-MISC I-CHED-MISC
= O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
29 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
; O-MISC B-ACTI-MISC
SIBPAL O-MISC B-CHED-MISC
Pempirical O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
< O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
x O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
linked O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
mental O-MISC I-DISO-MISC
health O-MISC I-LIVB-MISC
wellness O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
findings O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
consistent O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
alleles O-MISC B-LIVB-MISC
could O-MISC B-ACTI-MISC
prevent O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
modify O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
manifestations O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
BPAD B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
perhaps O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
related O-MISC B-ACTI-MISC
affective B-DISO-MISC I-ACTI-MISC
disorders I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Segregation O-MISC I-ACTI-MISC
distortion O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Myotonic B-DISO-MISC I-ACTI-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal B-DISO-MISC I-ACTI-MISC
dominant I-DISO-MISC B-ANAT-MISC
disease I-DISO-MISC B-ANAT-MISC
which O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
typical O-MISC B-ACTI-MISC
pedigree O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
shows O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
generation O-MISC B-ACTI-MISC
anticipation O-MISC I-LIVB-MISC
cascade O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
infertility B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
myotonic I-DISO-MISC B-ANAT-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CDM B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disappearance O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
pedigree O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
concept O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
segregation O-MISC I-DISO-MISC
distortion O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
where O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
preferential O-MISC B-ACTI-MISC
transmission O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
larger O-MISC B-ACTI-MISC
allele O-MISC B-LIVB-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
locus O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
put O-MISC B-ACTI-MISC
forward O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
explain O-MISC B-ACTI-MISC
partially O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maintenance O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
survey O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
Northern O-MISC B-ORGA-MISC
Ireland O-MISC I-ORGA-MISC
, O-MISC B-ACTI-MISC
59 O-MISC B-ACTI-MISC
pedigrees O-MISC B-CHED-MISC
were O-MISC B-ACTI-MISC
ascertained O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Sibships O-MISC B-CHED-MISC
where O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
status O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
members O-MISC I-ANAT-MISC
had O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transmission O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
expansion O-MISC I-DISO-MISC
from O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
parents O-MISC I-ANAT-MISC
to O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
offspring O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Where O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transmitting O-MISC B-CHED-MISC
parent O-MISC I-ANAT-MISC
was O-MISC B-ACTI-MISC
male O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
58 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
offspring O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
affected O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
case O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
female O-MISC I-DISO-MISC
transmitting O-MISC I-ANAT-MISC
parent O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
68 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

Studies O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
meiotic O-MISC I-DISO-MISC
drive O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
have O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
transmission O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
larger O-MISC B-ACTI-MISC
allele O-MISC B-LIVB-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
locus O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
DM O-MISC I-ACTI-MISC
heterozygotes O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
CTGn O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
provides O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DM B-DISO-MISC I-ACTI-MISC
expansion O-MISC I-DISO-MISC
tends O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
transmitted O-MISC I-ACTI-MISC
preferentially O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

If O-MISC B-ACTI-MISC
untreated O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC I-ACTI-MISC
can O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
serious O-MISC I-ACTI-MISC
illness O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
early B-DISO-MISC I-ACTI-MISC
death I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
still O-MISC B-ACTI-MISC
substantially O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
diagnosed O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
cornerstone O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
screening O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
detection O-MISC I-CHED-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
measurement O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
transferrin O-MISC I-CONC-MISC
saturation O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
ferritin O-MISC I-CONC-MISC
level O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

Once O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
suspected O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
physicians O-MISC I-ANAT-MISC
must O-MISC B-ACTI-MISC
use O-MISC B-ACTI-MISC
serum O-MISC B-CONC-MISC
ferritin O-MISC I-CONC-MISC
levels O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
hepatic O-MISC I-GENE-MISC
iron O-MISC O-MISC
stores O-MISC B-DISO-MISC
on O-MISC B-ACTI-MISC
liver O-MISC I-GENE-MISC
biopsy O-MISC B-GEOG-MISC
specimens O-MISC B-GEOG-MISC
to O-MISC B-ACTI-MISC
assess O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
iron B-DISO-MISC I-ACTI-MISC
overload I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Liver O-MISC B-CONC-MISC
biopsy O-MISC I-CONC-MISC
is O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
establish O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
presence O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
cirrhosis B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
prognosis O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
management O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
DNA O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
based O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HFE O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
is O-MISC B-ACTI-MISC
commercially O-MISC B-ACTI-MISC
available O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
place O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
still O-MISC B-ACTI-MISC
being O-MISC B-ACTI-MISC
evaluated O-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

Currently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
useful O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
test O-MISC B-CHED-MISC
is O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
detection O-MISC B-CONC-MISC
of O-MISC B-ACTI-MISC
hemochromatosis B-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
members O-MISC I-PHEN-MISC
of O-MISC I-PHEN-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
proven O-MISC B-ACTI-MISC
case O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
crucial O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
diagnose O-MISC I-ACTI-MISC
hemochromatosis B-DISO-MISC I-ACTI-MISC
before O-MISC B-ACTI-MISC
hepatic B-DISO-MISC I-ACTI-MISC
cirrhosis I-DISO-MISC B-ANAT-MISC
develops O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
phlebotomy O-MISC B-CONC-MISC
therapy O-MISC I-CONC-MISC
can O-MISC B-ACTI-MISC
avert O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
chronic O-MISC I-ACTI-MISC
disease O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
can O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
normal O-MISC B-CHED-MISC
life O-MISC I-CHED-MISC
expectancy O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Prevalence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
APC B-DISO-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
variant O-MISC B-LIVB-MISC
in O-MISC B-ACTI-MISC
Israeli O-MISC I-ANAT-MISC
Jews O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
differing O-MISC B-ACTI-MISC
ethnic O-MISC I-ACTI-MISC
origin O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
& O-MISC B-ACTI-MISC
AIMS O-MISC B-ACTI-MISC
Israeli O-MISC I-ANAT-MISC
Jews O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
European O-MISC I-ANAT-MISC
birth O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
i O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
e O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
Ashkenazim O-MISC B-ORGA-MISC
, O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
highest O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
Israeli O-MISC I-ANAT-MISC
ethnic O-MISC I-ANAT-MISC
group O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
APC B-DISO-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
variant O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
American O-MISC I-ANAT-MISC
Jews O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
28 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
familial O-MISC I-ACTI-MISC
colorectal B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
cases O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
Jews O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
prevalence O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Israeli O-MISC I-ANAT-MISC
Jews O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
differing O-MISC B-ACTI-MISC
ethnic O-MISC I-ACTI-MISC
origin O-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-CHED-MISC
DNA O-MISC I-GENE-MISC
samples O-MISC B-GEOG-MISC
from O-MISC B-ACTI-MISC
500 O-MISC B-ACTI-MISC
unrelated O-MISC I-ACTI-MISC
Jews O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
European O-MISC I-ANAT-MISC
or O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
European O-MISC I-PHEN-MISC
origin O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
without O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
personal O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
family O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
neoplasia B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
examined O-MISC I-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
variant O-MISC I-PROC-MISC
by O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
allele O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
specific O-MISC I-CONC-MISC
oligonucleotide O-MISC I-CONC-MISC
( O-MISC I-CONC-MISC
ASO O-MISC I-CONC-MISC
) O-MISC I-CONC-MISC
method O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-ACTI-MISC
In O-MISC B-ACTI-MISC
persons O-MISC I-ANAT-MISC
at O-MISC B-ACTI-MISC
average O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
I1307K O-MISC O-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

0 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
120 O-MISC B-ACTI-MISC
European O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
188 O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
European O-MISC I-PHEN-MISC
Jews O-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
08 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
52 O-MISC B-ACTI-MISC
Ashkenazi O-MISC I-ANAT-MISC
Israelis O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
familial O-MISC I-ACTI-MISC
cancer B-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
02 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
not O-MISC I-ACTI-MISC
detected O-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
51 O-MISC B-ACTI-MISC
non O-MISC I-ANAT-MISC
- O-MISC I-PHEN-MISC
European O-MISC I-PHEN-MISC
Jews O-MISC I-PHEN-MISC
at O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
cancer B-DISO-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
. O-MISC B-ACTI-MISC

Colorectal B-DISO-MISC I-ACTI-MISC
neoplasia I-DISO-MISC B-ANAT-MISC
occurred O-MISC B-ACTI-MISC
personally O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
20 O-MISC B-ACTI-MISC
Ashkenazi O-MISC I-ANAT-MISC
I1307K O-MISC B-ANAT-MISC
carriers O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
8 O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
had O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
personal O-MISC I-ACTI-MISC
or O-MISC B-ACTI-MISC
family O-MISC I-ACTI-MISC
history O-MISC B-ANAT-MISC
of O-MISC B-ACTI-MISC
noncolonic O-MISC I-ACTI-MISC
neoplasia B-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
I1307K O-MISC B-LIVB-MISC
APC O-MISC I-PROC-MISC
variant O-MISC I-PROC-MISC
may O-MISC B-ACTI-MISC
represent O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
susceptibility O-MISC I-DISO-MISC
gene O-MISC I-LIVB-MISC
for O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
, I-DISO-MISC B-ACTI-MISC
or I-DISO-MISC B-ACTI-MISC
other I-DISO-MISC B-ACTI-MISC
, I-DISO-MISC B-ACTI-MISC
cancers I-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
Ashkenazi O-MISC I-ANAT-MISC
Jews O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
partially O-MISC B-ACTI-MISC
explains O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
higher O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
European O-MISC I-ANAT-MISC
Israelis O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Systematic O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
coproporphyrinogen O-MISC B-LIVB-MISC
oxidase O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
defects O-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
coproporphyria I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
update O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Hereditary B-DISO-MISC I-ACTI-MISC
coproporphyria I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
HC B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
acute O-MISC I-ACTI-MISC
hepatic B-DISO-MISC B-ANAT-MISC
porphyria I-DISO-MISC B-ANAT-MISC
with O-MISC B-ACTI-MISC
autosomal O-MISC I-DISO-MISC
dominant O-MISC I-LIVB-MISC
inheritance O-MISC I-LIVB-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
deficient B-DISO-MISC B-CHED-MISC
activity I-DISO-MISC B-DEVI-MISC
of I-DISO-MISC B-ACTI-MISC
coproporphyrinogen I-DISO-MISC O-MISC
III I-DISO-MISC B-DISO-MISC
oxidase I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
CPO O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Clinical O-MISC B-CHED-MISC
manifestations O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
are O-MISC B-ACTI-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
acute O-MISC B-CHED-MISC
attacks O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
neurological B-DISO-MISC I-ACTI-MISC
dysfunction I-DISO-MISC B-ANAT-MISC
often O-MISC B-ACTI-MISC
precipitated O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
drugs O-MISC O-MISC
, O-MISC B-ACTI-MISC
fasting O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
cyclical O-MISC B-ACTI-MISC
hormonal O-MISC I-ACTI-MISC
changes O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
infectious B-DISO-MISC I-ACTI-MISC
diseases I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Skin O-MISC I-ACTI-MISC
photosensitivity O-MISC B-ANAT-MISC
may O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
exons O-MISC O-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
exon O-MISC O-MISC
/ O-MISC B-ACTI-MISC
intron O-MISC O-MISC
boundaries O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
noncoding O-MISC B-LIVB-MISC
sequence O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CPO O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
were O-MISC B-ACTI-MISC
systematically O-MISC B-CHED-MISC
analyzed O-MISC B-CONC-MISC
by O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
exon O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
by O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
exon O-MISC I-CONC-MISC
denaturing O-MISC I-CONC-MISC
gradient O-MISC I-CONC-MISC
gel O-MISC I-CONC-MISC
electrophoresis O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
DGGE O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
strategy O-MISC B-ACTI-MISC
followed O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
direct O-MISC B-CONC-MISC
sequencing O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
HC B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
from O-MISC B-ACTI-MISC
France O-MISC B-ORGA-MISC
, O-MISC B-ACTI-MISC
Holland O-MISC B-ORGA-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
Czech O-MISC B-ORGA-MISC
Republic O-MISC I-ORGA-MISC
. O-MISC B-ACTI-MISC

Seven O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
polymorphisms O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
detected O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Among O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
two O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
G197W O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
W427R O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
nonsense O-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
Q306X O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
Q385X O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
small O-MISC B-ACTI-MISC
deletions O-MISC B-DEVI-MISC
( O-MISC B-ACTI-MISC
662de14bp O-MISC B-LIVB-MISC
; O-MISC B-ACTI-MISC
1168del3bp O-MISC B-LIVB-MISC
removing O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
glycine O-MISC O-MISC
at O-MISC B-ACTI-MISC
position O-MISC B-CHED-MISC
390 O-MISC I-CHED-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
splicing O-MISC I-DISO-MISC
mutation O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
IVS1 O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
15c O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
g O-MISC I-LIVB-MISC
) O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
creates O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
acceptor O-MISC B-LIVB-MISC
splice O-MISC I-PROC-MISC
site O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
significance O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
point O-MISC I-ACTI-MISC
mutations O-MISC B-ANAT-MISC
G197W O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
W427R O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
in O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
frame O-MISC B-ANAT-MISC
deletion O-MISC B-ANAT-MISC
390delGly O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
assessed O-MISC B-DEVI-MISC
by O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
respective O-MISC B-ACTI-MISC
expression O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
prokaryotic O-MISC I-GENE-MISC
system O-MISC B-GEOG-MISC
using O-MISC B-ACTI-MISC
site O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
directed O-MISC I-LIVB-MISC
mutagenesis O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
resulted O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dramatic O-MISC B-ACTI-MISC
decrease O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
CPO O-MISC I-ACTI-MISC
activity O-MISC B-DEVI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
polymorphisms O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
localized O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
noncoding O-MISC B-LIVB-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
gene O-MISC B-LIVB-MISC
1 O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
C O-MISC O-MISC
/ O-MISC I-LIVB-MISC
G O-MISC I-LIVB-MISC
polymorphism O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
promotor O-MISC B-LIVB-MISC
region O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
142 O-MISC B-ACTI-MISC
bp O-MISC B-ACTI-MISC
upstream O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
transcriptional O-MISC B-LIVB-MISC
initiation O-MISC I-PROC-MISC
site O-MISC I-PROC-MISC
( O-MISC B-ACTI-MISC
- O-MISC B-LIVB-MISC
142C O-MISC I-PROC-MISC
/ O-MISC I-PROC-MISC
G O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
bp O-MISC B-ACTI-MISC
deletion O-MISC B-ACTI-MISC
polymorphism O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
noncoding O-MISC B-LIVB-MISC
part O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
CPO O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
574 O-MISC B-ACTI-MISC
bp O-MISC B-ACTI-MISC
downstream O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
last O-MISC B-LIVB-MISC
base O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
normal O-MISC B-LIVB-MISC
termination O-MISC I-PROC-MISC
codon O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
+ O-MISC I-PROC-MISC
574 O-MISC I-PROC-MISC
delATTCTT O-MISC I-PROC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Five O-MISC B-ACTI-MISC
intragenic O-MISC B-LIVB-MISC
dimorphisms O-MISC B-CHED-MISC
are O-MISC B-ACTI-MISC
now O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
characterized O-MISC B-DEVI-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
high O-MISC B-ACTI-MISC
degree O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
allelic O-MISC B-LIVB-MISC
heterogeneity O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
HC B-DISO-MISC I-ACTI-MISC
is O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
seven O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
making O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
total O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
nineteen O-MISC B-ACTI-MISC
CPO O-MISC B-LIVB-MISC
gene B-DISO-MISC I-PROC-MISC
defects I-DISO-MISC B-CHED-MISC
reported O-MISC B-ACTI-MISC
so O-MISC B-ACTI-MISC
far O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Coincidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
arylsulfatase O-MISC B-LIVB-MISC
A O-MISC I-PROC-MISC
alleles O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
459 O-MISC I-PROC-MISC
+ O-MISC I-PROC-MISC
1G O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
A O-MISC I-PROC-MISC
within O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
metachromatic B-DISO-MISC I-ACTI-MISC
leukodystrophy I-DISO-MISC B-ANAT-MISC
: O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
basis O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
phenotypic O-MISC I-ACTI-MISC
heterogeneity O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
family O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
siblings O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
classical O-MISC B-ACTI-MISC
late O-MISC I-ACTI-MISC
infantile O-MISC B-ANAT-MISC
metachromatic B-DISO-MISC B-ANAT-MISC
leukodystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
MLD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
fatal O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
age O-MISC I-DISO-MISC
5 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
deficient O-MISC B-CHED-MISC
arylsulfatase O-MISC I-DISO-MISC
A O-MISC I-LIVB-MISC
( O-MISC B-ACTI-MISC
ARSA O-MISC O-MISC
) O-MISC B-ACTI-MISC
activity O-MISC I-LIVB-MISC
and O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
galactosylsulfatide O-MISC O-MISC
( O-MISC B-ACTI-MISC
GS O-MISC O-MISC
) O-MISC B-ACTI-MISC
excretion O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
other O-MISC B-ACTI-MISC
siblings O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
apparently O-MISC B-CHED-MISC
healthy O-MISC B-CHED-MISC
at O-MISC B-ACTI-MISC
12 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
years O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
father O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
apparently O-MISC B-CHED-MISC
healthy O-MISC B-CHED-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
presented O-MISC B-ACTI-MISC
ARSA O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
GS O-MISC B-PHYS-MISC
values O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
MLD B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Mutation O-MISC B-CONC-MISC
screening O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
sequence O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
disclosed O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
involvement O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
ARSA O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
being O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
molecular O-MISC B-CHED-MISC
basis O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
intrafamilial O-MISC I-ACTI-MISC
phenotypic O-MISC I-DISO-MISC
heterogeneity O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
late O-MISC I-ANAT-MISC
infantile O-MISC I-PHEN-MISC
patient O-MISC I-PHEN-MISC
inherited O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
mother O-MISC I-ANAT-MISC
the O-MISC B-ACTI-MISC
frequent O-MISC B-ACTI-MISC
0 O-MISC I-ACTI-MISC
- O-MISC I-LIVB-MISC
type O-MISC I-LIVB-MISC
mutation O-MISC I-LIVB-MISC
459 O-MISC I-LIVB-MISC
+ O-MISC I-LIVB-MISC
1G O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
A O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
his O-MISC B-ACTI-MISC
father O-MISC I-ANAT-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
single O-MISC I-ACTI-MISC
basepair O-MISC B-ANAT-MISC
microdeletion O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
guanine O-MISC O-MISC
at O-MISC B-ACTI-MISC
nucleotide O-MISC O-MISC
7 O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
1 O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
7delG O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
clinically O-MISC B-CHED-MISC
unaffected O-MISC B-CHED-MISC
siblings O-MISC I-ANAT-MISC
carried O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
maternal O-MISC I-ACTI-MISC
mutation O-MISC I-DISO-MISC
459 O-MISC I-LIVB-MISC
+ O-MISC I-LIVB-MISC
1G O-MISC I-PROC-MISC
> O-MISC I-PROC-MISC
A O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
their O-MISC B-ACTI-MISC
paternal O-MISC B-LIVB-MISC
allele O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
novel O-MISC B-CHED-MISC
cytosine O-MISC O-MISC
to O-MISC B-ACTI-MISC
thymidine O-MISC O-MISC
transition O-MISC I-LIVB-MISC
at O-MISC B-ACTI-MISC
nucleotide O-MISC O-MISC
2435 O-MISC B-DISO-MISC
in O-MISC B-ACTI-MISC
exon O-MISC O-MISC
8 O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
resulting O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
substitution O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
alanine O-MISC O-MISC
464 O-MISC B-DISO-MISC
by O-MISC B-ACTI-MISC
valine O-MISC O-MISC
( O-MISC B-ACTI-MISC
A464V O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
fathers O-MISC I-DISO-MISC
genotype O-MISC I-DISO-MISC
thus O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
7delG O-MISC I-ANAT-MISC
/ O-MISC I-PHEN-MISC
A464V O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

Mutation O-MISC I-DISO-MISC
A464V O-MISC B-LIVB-MISC
was O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
18 O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
MLD B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
50 O-MISC B-ACTI-MISC
controls O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

A464V O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
although O-MISC B-ACTI-MISC
clearly O-MISC B-ACTI-MISC
modifying O-MISC B-ACTI-MISC
ARSA O-MISC O-MISC
and O-MISC B-ACTI-MISC
GS O-MISC O-MISC
levels O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
apparently O-MISC B-ACTI-MISC
bears O-MISC B-ACTI-MISC
little O-MISC B-ACTI-MISC
significance O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
manifestation O-MISC B-CHED-MISC
of O-MISC I-CHED-MISC
MLD B-DISO-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
mimicking O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequent O-MISC B-ACTI-MISC
ARSA O-MISC O-MISC
pseudodeficiency O-MISC I-ACTI-MISC
allele O-MISC B-LIVB-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
demonstrate O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
genetic O-MISC B-CHED-MISC
conditions O-MISC B-CHED-MISC
MLD B-DISO-MISC I-ACTI-MISC
- O-MISC B-ACTI-MISC
like O-MISC B-ACTI-MISC
ARSA O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
GS O-MISC O-MISC
values O-MISC B-CHED-MISC
need O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
paralleled O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
disease O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
finding O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
serious O-MISC B-ACTI-MISC
diagnostic O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
prognostic O-MISC B-CHED-MISC
implications O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Moreover O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
further O-MISC B-ACTI-MISC
ARSA O-MISC B-LIVB-MISC
alleles O-MISC B-LIVB-MISC
functionally O-MISC B-CHED-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
A464V O-MISC I-ANAT-MISC
might O-MISC B-ACTI-MISC
exist O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
together O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
0 O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
type O-MISC B-ANAT-MISC
mutations O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
ARSA O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
GS O-MISC O-MISC
levels O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
clinical O-MISC B-CHED-MISC
outbreak O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
disease O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Human O-MISC I-ANAT-MISC
MLH1 O-MISC I-ACTI-MISC
deficiency O-MISC B-ANAT-MISC
predisposes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hematological B-DISO-MISC I-ACTI-MISC
malignancy I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
neurofibromatosis B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
1 I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Heterozygous O-MISC B-CHED-MISC
germ O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
line O-MISC I-LIVB-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
DNA O-MISC I-DISO-MISC
mismatch O-MISC I-LIVB-MISC
repair O-MISC I-PROC-MISC
genes O-MISC B-LIVB-MISC
lead O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
hereditary B-DISO-MISC B-CHED-MISC
nonpolyposis I-DISO-MISC I-ACTI-MISC
colorectal I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
disease O-MISC I-DISO-MISC
susceptibility O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
individuals O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
constitutionally O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
wild O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
type O-MISC I-PROC-MISC
alleles O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
unknown O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
offspring O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
nonpolyposis I-DISO-MISC B-ANAT-MISC
colorectal I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
family O-MISC I-ANAT-MISC
who O-MISC B-ACTI-MISC
developed O-MISC B-ACTI-MISC
hematological B-DISO-MISC I-ACTI-MISC
malignancy I-DISO-MISC B-ANAT-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
very O-MISC I-ACTI-MISC
early O-MISC B-ANAT-MISC
age O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
least O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
them O-MISC B-ACTI-MISC
displayed O-MISC B-ACTI-MISC
signs O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
neurofibromatosis B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
1 I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
NF1 B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

DNA O-MISC B-CONC-MISC
sequence O-MISC I-CONC-MISC
analysis O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
allele O-MISC B-LIVB-MISC
- O-MISC B-ACTI-MISC
specific O-MISC I-CHED-MISC
amplification O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
siblings O-MISC I-ANAT-MISC
revealed O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
MLH1 O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
( O-MISC B-ACTI-MISC
C676T O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
- O-MISC I-LIVB-MISC
> O-MISC I-LIVB-MISC
Arg226Stop O-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Thus O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
germ O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
line O-MISC I-LIVB-MISC
MLH1 O-MISC B-LIVB-MISC
mutation O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
consequent O-MISC B-ACTI-MISC
mismatch O-MISC I-DISO-MISC
repair O-MISC I-LIVB-MISC
deficiency O-MISC B-ANAT-MISC
results O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
mutator O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
characterized O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
leukemia B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
lymphoma B-DISO-MISC I-ACTI-MISC
associated O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
neurofibromatosis B-DISO-MISC I-ACTI-MISC
type I-DISO-MISC B-ANAT-MISC
1 I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
ancient O-MISC B-CHED-MISC
residues O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAX6 O-MISC O-MISC
paired O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
underlie O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
spectrum O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
congenital B-DISO-MISC I-ACTI-MISC
eye I-DISO-MISC B-ANAT-MISC
malformations I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
PAX6 O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
underlie O-MISC B-ACTI-MISC
aniridia B-DISO-MISC I-ACTI-MISC
( O-MISC B-ACTI-MISC
congenital B-DISO-MISC B-CHED-MISC
absence I-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
iris I-DISO-MISC I-GENE-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
dominant O-MISC B-ACTI-MISC
malformation B-DISO-MISC I-ACTI-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
eye I-DISO-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
spectrum O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
PAX6 O-MISC I-ACTI-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
aniridia B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
highly O-MISC B-ACTI-MISC
biased O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
92 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
reported O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
premature O-MISC I-ACTI-MISC
truncation O-MISC B-ANAT-MISC
of O-MISC B-ANAT-MISC
the O-MISC B-ANAT-MISC
protein O-MISC O-MISC
( O-MISC B-ACTI-MISC
nonsense O-MISC I-ACTI-MISC
, O-MISC B-ACTI-MISC
splicing O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
insertions O-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
deletions O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
just O-MISC B-ACTI-MISC
2 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
leading O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
substitution O-MISC I-DISO-MISC
of O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
amino O-MISC O-MISC
acid O-MISC B-DISO-MISC
by O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
extraordinary O-MISC B-ACTI-MISC
conservation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAX6 O-MISC O-MISC
protein O-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
amino O-MISC O-MISC
acid O-MISC B-DISO-MISC
level O-MISC B-CHED-MISC
amongst O-MISC B-ACTI-MISC
vertebrates O-MISC I-ANAT-MISC
predicts O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
should O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
fact O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
even O-MISC B-ACTI-MISC
though O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
hardly O-MISC B-ACTI-MISC
ever O-MISC B-ACTI-MISC
seen O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
aniridia B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
indicates O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
there O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
heavy O-MISC B-ACTI-MISC
ascertainment O-MISC B-ACTI-MISC
bias O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
selection O-MISC B-DEVI-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
for O-MISC B-ACTI-MISC
PAX6 O-MISC B-LIVB-MISC
mutation O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
missing O-MISC B-ACTI-MISC
PAX6 O-MISC B-LIVB-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
frequently O-MISC B-ACTI-MISC
may O-MISC B-ACTI-MISC
underlie O-MISC B-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
distinct O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
textbook O-MISC B-CHED-MISC
aniridia B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Here O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
present O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
novel O-MISC B-ACTI-MISC
PAX6 O-MISC B-LIVB-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
atypical O-MISC B-CHED-MISC
phenotypes O-MISC I-DISO-MISC
ectopia B-DISO-MISC I-ACTI-MISC
pupillae I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
displaced B-DISO-MISC I-ACTI-MISC
pupils I-DISO-MISC B-ANAT-MISC
) O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
congenital B-DISO-MISC I-ACTI-MISC
nystagmus I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
searching B-DISO-MISC B-ACTI-MISC
gaze I-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
association O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
more O-MISC B-ACTI-MISC
recognizable O-MISC B-ACTI-MISC
aniridia B-DISO-MISC I-ACTI-MISC
phenotypes O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Strikingly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
located O-MISC B-CHED-MISC
within O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
PAX6 O-MISC O-MISC
paired O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
affect O-MISC B-ACTI-MISC
amino O-MISC O-MISC
acids O-MISC B-DISO-MISC
which O-MISC B-ACTI-MISC
are O-MISC B-ACTI-MISC
highly O-MISC B-CHED-MISC
conserved O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
known O-MISC B-ACTI-MISC
paired O-MISC B-LIVB-MISC
domain O-MISC I-PROC-MISC
proteins O-MISC O-MISC
. O-MISC B-ACTI-MISC

Our O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
support O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
under O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
representation O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
missense O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
is O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
ascertainment O-MISC B-ACTI-MISC
bias O-MISC I-CHED-MISC
and O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
substantial O-MISC B-ACTI-MISC
burden O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
PAX6 B-DISO-MISC O-MISC
- I-DISO-MISC B-ACTI-MISC
related I-DISO-MISC B-ACTI-MISC
disease I-DISO-MISC I-ACTI-MISC
remains O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
uncovered O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
chromosomal O-MISC I-GENE-MISC
order O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
controlling O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
histocompatibility O-MISC O-MISC
complex O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
properdin O-MISC O-MISC
factor O-MISC B-DISO-MISC
B O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
deficiency B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
second I-DISO-MISC B-CHED-MISC
component I-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
complement I-DISO-MISC O-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
relationship O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
coding O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
to O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
coding O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
properdin O-MISC O-MISC
Factor O-MISC B-DISO-MISC
B O-MISC B-DISO-MISC
allotypes O-MISC I-DISO-MISC
and O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
deficiency B-DISO-MISC B-CHED-MISC
of I-DISO-MISC B-ACTI-MISC
the I-DISO-MISC B-ACTI-MISC
second I-DISO-MISC B-CHED-MISC
component I-DISO-MISC O-MISC
of I-DISO-MISC B-ACTI-MISC
complement I-DISO-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
C2 O-MISC O-MISC
) O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
studied O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
connective O-MISC I-ACTI-MISC
tissue O-MISC B-ANAT-MISC
disorders O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Patients O-MISC I-ANAT-MISC
were O-MISC B-ACTI-MISC
selected O-MISC B-ACTI-MISC
because O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
heterozygous O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
homozygous O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
C2 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

12 O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
matings O-MISC I-DISO-MISC
informative O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
C2 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
57 O-MISC B-ACTI-MISC
informative O-MISC B-CHED-MISC
meioses O-MISC B-OCCU-MISC
, O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
crossovers O-MISC B-ACTI-MISC
were O-MISC B-ACTI-MISC
noted O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C2 B-DISO-MISC B-LIVB-MISC
deficiency I-DISO-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HLA O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
B O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
recombinant O-MISC I-ANAT-MISC
fraction O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

035 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
lod O-MISC B-CHED-MISC
score O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
13 O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
linkage O-MISC B-CHED-MISC
between O-MISC B-ACTI-MISC
C2 B-DISO-MISC O-MISC
deficiency I-DISO-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
B O-MISC B-DISO-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
maximum O-MISC B-ACTI-MISC
likelihood O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recombinant O-MISC O-MISC
fraction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

04 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

18 O-MISC B-ACTI-MISC
families O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
21 O-MISC B-ACTI-MISC
informative O-MISC B-CHED-MISC
matings O-MISC I-DISO-MISC
for O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
properdin O-MISC O-MISC
Factor O-MISC B-DISO-MISC
B O-MISC B-DISO-MISC
allotype O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
B O-MISC B-DISO-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Of O-MISC B-ACTI-MISC
72 O-MISC B-ACTI-MISC
informative O-MISC B-CHED-MISC
meioses O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
recombinants O-MISC O-MISC
were O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
giving O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
recombinant O-MISC O-MISC
fraction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

042 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
lod O-MISC B-CHED-MISC
score O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
B O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
Factor O-MISC O-MISC
B O-MISC B-DISO-MISC
allotypes O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
calculated O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
maximum O-MISC B-ACTI-MISC
likelihood O-MISC B-CHED-MISC
value O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
recombinant O-MISC I-ANAT-MISC
fraction O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
0 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

04 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
crossover O-MISC B-CHED-MISC
was O-MISC B-ACTI-MISC
shown O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
occurred O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
for O-MISC B-ACTI-MISC
Factor O-MISC O-MISC
B O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
D O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
D O-MISC B-DISO-MISC
segregared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
HLA O-MISC O-MISC
- O-MISC B-DISO-MISC
A O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
B O-MISC O-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
studies O-MISC B-ACTI-MISC
suggest O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
for O-MISC B-ACTI-MISC
Factor O-MISC O-MISC
B O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
C2 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
are O-MISC B-ACTI-MISC
located O-MISC B-ACTI-MISC
outside O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
HLA O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
order O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
genese O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
HLA O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
A O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-LIVB-MISC
B O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
- O-MISC B-LIVB-MISC
D O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
Factor O-MISC B-LIVB-MISC
B O-MISC I-PROC-MISC
allotype O-MISC I-DISO-MISC
, O-MISC B-ACTI-MISC
C2 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
coding O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
C2 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
Factor O-MISC B-LIVB-MISC
B O-MISC B-DISO-MISC
allotypes O-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
approximately O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
5 O-MISC B-ACTI-MISC
centimorgans O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
HLA O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
A O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
HLA O-MISC B-LIVB-MISC
- O-MISC I-PROC-MISC
B O-MISC I-PROC-MISC
loci O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
apparent O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
recombinants O-MISC O-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Factor O-MISC B-LIVB-MISC
B O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
C2 B-DISO-MISC I-ACTI-MISC
deficiency I-DISO-MISC B-ANAT-MISC
gene O-MISC B-LIVB-MISC
suggests O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
genes O-MISC B-LIVB-MISC
lie O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
close O-MISC B-ACTI-MISC
proximity O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
another O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Distribution O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
emerin O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
lamins O-MISC I-ANAT-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
implications O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
Emery B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Dreifuss I-DISO-MISC B-ANAT-MISC
muscular I-DISO-MISC B-ANAT-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Emerin O-MISC O-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
nuclear O-MISC O-MISC
membrane O-MISC B-DISO-MISC
protein O-MISC B-DISO-MISC
which O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
missing O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
defective O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Emery B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Dreifuss I-DISO-MISC B-ANAT-MISC
muscular I-DISO-MISC B-ANAT-MISC
dystrophy I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
EDMD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

It O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
one O-MISC B-ACTI-MISC
member O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
family O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lamina O-MISC O-MISC
- O-MISC B-DISO-MISC
associated O-MISC B-DISO-MISC
proteins O-MISC B-DISO-MISC
which O-MISC B-ACTI-MISC
includes O-MISC B-ACTI-MISC
LAP1 O-MISC O-MISC
, O-MISC B-ACTI-MISC
LAP2 O-MISC O-MISC
and O-MISC B-ACTI-MISC
lamin O-MISC O-MISC
B O-MISC B-DISO-MISC
receptor O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
LBR O-MISC O-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
panel O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
16 O-MISC B-ACTI-MISC
monoclonal O-MISC O-MISC
antibodies O-MISC B-DISO-MISC
( O-MISC B-ACTI-MISC
mAbs O-MISC O-MISC
) O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
mapped O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
six O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
sites O-MISC B-CHED-MISC
throughout O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
molecule O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
phage O-MISC I-ANAT-MISC
- O-MISC B-ACTI-MISC
displayed O-MISC B-CHED-MISC
peptide O-MISC O-MISC
libraries O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
used O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
localize O-MISC B-CHED-MISC
emerin O-MISC O-MISC
in O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
rabbit O-MISC I-ANAT-MISC
heart O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

Several O-MISC B-ACTI-MISC
mAbs O-MISC O-MISC
against O-MISC B-ACTI-MISC
different O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
epitopes O-MISC O-MISC
did O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
recognize O-MISC B-ACTI-MISC
intercalated O-MISC I-GENE-MISC
discs O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
though O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
nuclei O-MISC I-GENE-MISC
strongly O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
at O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
rim O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
intranuclear O-MISC B-CHED-MISC
spots O-MISC I-CHED-MISC
or O-MISC B-ACTI-MISC
channels O-MISC O-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
polyclonal O-MISC O-MISC
rabbit O-MISC I-ANAT-MISC
antiserum O-MISC O-MISC
against O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
did O-MISC B-ACTI-MISC
recognize O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
nuclear O-MISC I-GENE-MISC
membrane O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
intercalated O-MISC I-GENE-MISC
discs O-MISC B-GEOG-MISC
but O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
after O-MISC B-ACTI-MISC
affinity O-MISC B-ACTI-MISC
purification O-MISC B-CHED-MISC
against O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
pure O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
band O-MISC B-ACTI-MISC
on O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
western O-MISC B-CONC-MISC
blot O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
stained O-MISC I-ACTI-MISC
only O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nuclear O-MISC I-GENE-MISC
membrane O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
results O-MISC B-ACTI-MISC
would O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
expected O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
immunostaining O-MISC B-CONC-MISC
at O-MISC B-ACTI-MISC
intercalated O-MISC I-GENE-MISC
discs O-MISC B-GEOG-MISC
were O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
product O-MISC B-GENE-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
gene O-MISC B-DISO-MISC
and O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
therefore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
cast O-MISC B-ACTI-MISC
some O-MISC B-ACTI-MISC
doubt O-MISC B-ACTI-MISC
upon O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
hypothesis O-MISC B-CHED-MISC
that O-MISC B-ACTI-MISC
cardiac B-DISO-MISC I-ACTI-MISC
defects I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
EDMD B-DISO-MISC B-CONC-MISC
are O-MISC B-ACTI-MISC
caused O-MISC B-ACTI-MISC
by O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
from O-MISC B-ACTI-MISC
intercalated O-MISC B-CHED-MISC
discs O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
was O-MISC B-ACTI-MISC
abundant O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
membranes O-MISC I-GENE-MISC
of O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
nuclei O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
it O-MISC B-ACTI-MISC
was O-MISC B-ACTI-MISC
absent O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
many O-MISC B-ACTI-MISC
non O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
myocyte O-MISC B-GEOG-MISC
cells O-MISC B-GEOG-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
distribution O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
was O-MISC B-ACTI-MISC
similar O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
lamin O-MISC B-LIVB-MISC
A O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
candidate O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
for O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
autosomal O-MISC I-DISO-MISC
form O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
EDMD B-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
contrast O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
lamin O-MISC O-MISC
B1 O-MISC B-DISO-MISC
was O-MISC B-ACTI-MISC
absent O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
cardiomyocyte O-MISC I-GENE-MISC
nuclei O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
showing O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
lamin O-MISC O-MISC
B1 O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
essential O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
localization O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nuclear O-MISC I-GENE-MISC
lamina O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Lamin O-MISC O-MISC
B1 O-MISC B-DISO-MISC
is O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
almost O-MISC B-ACTI-MISC
completely O-MISC B-ACTI-MISC
absent O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
skeletal O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
nuclei O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
EDMD B-DISO-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
additional O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
lamin O-MISC O-MISC
B1 O-MISC B-DISO-MISC
from O-MISC B-ACTI-MISC
heart O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
skeletal O-MISC I-GENE-MISC
muscle O-MISC B-GEOG-MISC
nuclei O-MISC I-GENE-MISC
which O-MISC B-ACTI-MISC
already O-MISC B-ACTI-MISC
lack O-MISC B-ACTI-MISC
emerin O-MISC O-MISC
may O-MISC B-ACTI-MISC
offer O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
alternative O-MISC B-CHED-MISC
explanation O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
why O-MISC B-ACTI-MISC
these O-MISC B-ACTI-MISC
tissues O-MISC I-GENE-MISC
are O-MISC B-ACTI-MISC
particularly O-MISC B-ACTI-MISC
affected O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Genetic O-MISC B-CONC-MISC
mapping O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
copper B-DISO-MISC I-ACTI-MISC
toxicosis I-DISO-MISC B-ANAT-MISC
locus O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
Bedlington O-MISC I-ANAT-MISC
terriers O-MISC I-PHEN-MISC
to O-MISC B-ACTI-MISC
dog O-MISC I-ANAT-MISC
chromosome O-MISC I-GENE-MISC
10 O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
region O-MISC I-DISO-MISC
syntenic O-MISC I-DISO-MISC
to O-MISC B-ACTI-MISC
human O-MISC I-GENE-MISC
chromosome O-MISC B-GEOG-MISC
region O-MISC B-GEOG-MISC
2p13 O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
p16 O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

Abnormal O-MISC I-ACTI-MISC
hepatic B-DISO-MISC I-GENE-MISC
copper I-DISO-MISC B-ANAT-MISC
accumulation I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
recognized O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
inherited B-DISO-MISC I-ACTI-MISC
disorder I-DISO-MISC B-ANAT-MISC
in O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
dog O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
major O-MISC B-ACTI-MISC
cause O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
hepatic B-DISO-MISC I-GENE-MISC
copper I-DISO-MISC O-MISC
accumulation I-DISO-MISC I-ACTI-MISC
in O-MISC B-ACTI-MISC
man O-MISC I-ANAT-MISC
is O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
dysfunctional O-MISC B-CHED-MISC
ATP7B O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
, O-MISC B-ACTI-MISC
causing O-MISC B-ACTI-MISC
Wilson B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
WD B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ATP7B O-MISC B-LIVB-MISC
genes O-MISC I-PROC-MISC
have O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
demonstrated O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
mouse O-MISC I-ANAT-MISC
and O-MISC B-ACTI-MISC
rat O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
ATP7B O-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
excluded O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
much O-MISC B-ACTI-MISC
rarer O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
copper B-DISO-MISC I-ACTI-MISC
overload I-DISO-MISC B-ANAT-MISC
disease O-MISC B-ANAT-MISC
non B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
Indian I-DISO-MISC B-ANAT-MISC
childhood I-DISO-MISC B-ANAT-MISC
cirrhosis I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
indicating O-MISC B-ACTI-MISC
genetic O-MISC I-DISO-MISC
heterogeneity O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

By O-MISC B-ACTI-MISC
investigating O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
autosomal O-MISC I-ACTI-MISC
recessive O-MISC B-ANAT-MISC
copper B-DISO-MISC B-ANAT-MISC
toxicosis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
CT B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
Bedlington O-MISC I-ANAT-MISC
terriers O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
new O-MISC B-ACTI-MISC
locus O-MISC B-LIVB-MISC
involved O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
progressive O-MISC B-CHED-MISC
liver B-DISO-MISC I-ACTI-MISC
disease I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
examined O-MISC B-ACTI-MISC
whether O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
WD B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
ATP7B O-MISC O-MISC
was O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
causative O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
CT B-DISO-MISC I-ACTI-MISC
by O-MISC B-ACTI-MISC
investigating O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
chromosomal O-MISC I-GENE-MISC
co O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
localization O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
ATP7B O-MISC O-MISC
and O-MISC B-ACTI-MISC
C04107 O-MISC O-MISC
, O-MISC B-ACTI-MISC
using O-MISC B-ACTI-MISC
fluorescence O-MISC B-CONC-MISC
in O-MISC I-CONC-MISC
situ O-MISC I-CONC-MISC
hybridization O-MISC I-CONC-MISC
( O-MISC B-ACTI-MISC
FISH O-MISC B-CONC-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

C04107 O-MISC O-MISC
is O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
anonymous O-MISC B-ACTI-MISC
microsatellite O-MISC O-MISC
marker O-MISC B-DISO-MISC
closely O-MISC B-ACTI-MISC
linked O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
CT B-DISO-MISC B-CONC-MISC
. O-MISC B-ACTI-MISC

However O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
BAC O-MISC O-MISC
clones O-MISC I-GENE-MISC
containing O-MISC B-ACTI-MISC
ATP7B O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
C04107 O-MISC B-LIVB-MISC
mapped O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
canine O-MISC I-ANAT-MISC
chromosome O-MISC I-GENE-MISC
regions O-MISC B-GEOG-MISC
CFA22q11 O-MISC I-GENE-MISC
and O-MISC B-ACTI-MISC
CFA10q26 O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
demonstrating O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
WD B-DISO-MISC B-LIVB-MISC
cannot O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
homologous O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
CT B-DISO-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
copper O-MISC O-MISC
transport O-MISC I-DISO-MISC
genes O-MISC B-LIVB-MISC
CTR1 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
CTR2 O-MISC B-LIVB-MISC
were O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
excluded O-MISC B-DEVI-MISC
as O-MISC B-ACTI-MISC
candidate O-MISC B-LIVB-MISC
genes O-MISC I-PROC-MISC
for O-MISC B-ACTI-MISC
CT B-DISO-MISC B-CONC-MISC
since O-MISC B-ACTI-MISC
they O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
mapped O-MISC B-CONC-MISC
to O-MISC B-ACTI-MISC
canine O-MISC I-ANAT-MISC
chromosome O-MISC I-GENE-MISC
region O-MISC B-GEOG-MISC
CFA11q22 O-MISC B-GEOG-MISC
. O-MISC B-ACTI-MISC

2 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
22 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

A O-MISC B-ACTI-MISC
transcribed O-MISC B-LIVB-MISC
sequence O-MISC I-PROC-MISC
identified O-MISC B-CHED-MISC
from O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
C04107 O-MISC O-MISC
- O-MISC B-ACTI-MISC
containing O-MISC B-ACTI-MISC
BAC O-MISC O-MISC
was O-MISC B-ACTI-MISC
found O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
homologous O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
expressed O-MISC I-LIVB-MISC
from O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
chromosome O-MISC B-GEOG-MISC
2p13 O-MISC B-GEOG-MISC
- O-MISC B-GEOG-MISC
p16 O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
region O-MISC B-ACTI-MISC
devoid O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
positional O-MISC B-LIVB-MISC
candidate O-MISC I-PROC-MISC
genes O-MISC I-PROC-MISC
. O-MISC B-ACTI-MISC

Molecular O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
205 O-MISC B-ACTI-MISC
families O-MISC B-CHED-MISC
: O-MISC B-ACTI-MISC
extended O-MISC B-CHED-MISC
genotype O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
phenotype O-MISC I-LIVB-MISC
correlations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
FAP B-DISO-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
evidence O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
amino O-MISC O-MISC
acid O-MISC B-DISO-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
predisposition O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

BACKGROUND O-MISC B-ACTI-MISC
/ O-MISC B-ACTI-MISC
AIMS O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
development O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
variable O-MISC B-ACTI-MISC
range O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
extracolonic O-MISC I-ACTI-MISC
manifestations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
familial B-DISO-MISC I-ACTI-MISC
adenomatous I-DISO-MISC B-ANAT-MISC
polyposis I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
FAP B-DISO-MISC I-ACTI-MISC
) O-MISC B-ACTI-MISC
is O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
result O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
dominant O-MISC B-ACTI-MISC
inheritance O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
adenomatous B-DISO-MISC I-ANAT-MISC
polyposis I-DISO-MISC I-PHEN-MISC
coli I-DISO-MISC I-PHEN-MISC
( O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
) O-MISC B-ACTI-MISC
gene O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
, O-MISC B-ACTI-MISC
direct O-MISC B-ACTI-MISC
mutation O-MISC B-CONC-MISC
analysis O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
performed O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
genotype O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
phenotype O-MISC I-LIVB-MISC
correlations O-MISC B-CHED-MISC
for O-MISC B-ACTI-MISC
nine O-MISC B-ACTI-MISC
extracolonic O-MISC I-GENE-MISC
manifestations O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
investigate O-MISC B-CHED-MISC
the O-MISC B-ACTI-MISC
incidence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
FAP O-MISC B-ANAT-MISC
colorectal B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

METHODS O-MISC B-ACTI-MISC
The O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
analysed O-MISC B-CONC-MISC
in O-MISC B-ACTI-MISC
190 O-MISC B-ACTI-MISC
unrelated O-MISC B-ACTI-MISC
FAP B-DISO-MISC B-OCCU-MISC
and O-MISC B-ACTI-MISC
15 O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
FAP O-MISC B-ANAT-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
using O-MISC B-ACTI-MISC
denaturing O-MISC B-CONC-MISC
gradient O-MISC I-CONC-MISC
gel O-MISC I-CONC-MISC
electrophoresis O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
protein O-MISC B-CONC-MISC
truncation O-MISC I-CONC-MISC
test O-MISC I-CONC-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
direct O-MISC B-CONC-MISC
sequencing O-MISC I-CONC-MISC
. O-MISC B-ACTI-MISC

RESULTS O-MISC B-OCCU-MISC
Chain O-MISC B-OCCU-MISC
terminating O-MISC I-OCCU-MISC
signals O-MISC I-OCCU-MISC
were O-MISC B-ACTI-MISC
only O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
belonging O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
FAP B-DISO-MISC B-OCCU-MISC
group O-MISC B-CHED-MISC
( O-MISC B-ACTI-MISC
105 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Amino O-MISC O-MISC
acid O-MISC B-DISO-MISC
changes O-MISC B-ANAT-MISC
were O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
four O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
whom O-MISC B-ACTI-MISC
belonged O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
non O-MISC B-ACTI-MISC
- O-MISC I-PHEN-MISC
FAP O-MISC I-PHEN-MISC
group O-MISC I-PHEN-MISC
of O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Genotype O-MISC I-DISO-MISC
- O-MISC B-ACTI-MISC
phenotype O-MISC I-DISO-MISC
correlations O-MISC B-CHED-MISC
identified O-MISC B-ACTI-MISC
significant O-MISC B-ACTI-MISC
differences O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nature O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
certain O-MISC B-ACTI-MISC
extracolonic O-MISC I-GENE-MISC
manifestations O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
FAP B-DISO-MISC I-ACTI-MISC
patients O-MISC I-ANAT-MISC
belonging O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
three O-MISC B-ACTI-MISC
mutation O-MISC I-DISO-MISC
subgroups O-MISC B-CHED-MISC
. O-MISC B-ACTI-MISC

CONCLUSIONS O-MISC B-ACTI-MISC
Extended O-MISC B-CHED-MISC
genotype O-MISC I-DISO-MISC
- O-MISC I-LIVB-MISC
phenotype O-MISC I-LIVB-MISC
correlations O-MISC B-CHED-MISC
made O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
study O-MISC B-CONC-MISC
may O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
potential O-MISC B-CHED-MISC
to O-MISC B-ACTI-MISC
determine O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
most O-MISC B-ACTI-MISC
appropriate O-MISC B-ACTI-MISC
surveillance O-MISC B-CONC-MISC
and O-MISC B-ACTI-MISC
prophylactic O-MISC B-CHED-MISC
treatment O-MISC B-CONC-MISC
regimens O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
mutations O-MISC I-DISO-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
life O-MISC I-ACTI-MISC
threatening O-MISC B-ANAT-MISC
conditions O-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

This O-MISC B-ACTI-MISC
study O-MISC B-ACTI-MISC
also O-MISC B-ACTI-MISC
provided O-MISC B-ACTI-MISC
evidence O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathological O-MISC B-CHED-MISC
nature O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
amino O-MISC O-MISC
acid O-MISC B-DISO-MISC
changes O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
APC O-MISC I-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
both O-MISC B-ACTI-MISC
FAP B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
non O-MISC I-ACTI-MISC
- O-MISC B-ANAT-MISC
FAP O-MISC B-ANAT-MISC
colorectal B-DISO-MISC B-ANAT-MISC
cancer I-DISO-MISC B-ANAT-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Inherited B-DISO-MISC B-CHED-MISC
colorectal I-DISO-MISC I-ACTI-MISC
polyposis I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
cancer B-DISO-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC O-MISC B-LIVB-MISC
I1307K O-MISC I-PROC-MISC
polymorphism O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

Germ O-MISC I-GENE-MISC
- O-MISC B-GEOG-MISC
line O-MISC B-GEOG-MISC
and O-MISC B-ACTI-MISC
somatic O-MISC B-CHED-MISC
truncating O-MISC I-DISO-MISC
mutations O-MISC I-LIVB-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
are O-MISC B-ACTI-MISC
thought O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
initiate O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
tumor I-DISO-MISC B-ANAT-MISC
formation O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
familial B-DISO-MISC I-ACTI-MISC
adenomatous I-DISO-MISC B-ANAT-MISC
polyposis I-DISO-MISC B-ANAT-MISC
syndrome I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
sporadic O-MISC B-CHED-MISC
colorectal O-MISC I-ACTI-MISC
carcinogenesis O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
respectively O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Recently O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
isoleucine O-MISC O-MISC
- O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
> O-MISC B-ACTI-MISC
lysine O-MISC O-MISC
polymorphism O-MISC I-DISO-MISC
at O-MISC B-ACTI-MISC
codon O-MISC B-LIVB-MISC
1307 O-MISC I-PROC-MISC
( O-MISC I-PROC-MISC
I1307K O-MISC I-PROC-MISC
) O-MISC I-PROC-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
gene O-MISC I-PROC-MISC
has O-MISC B-ACTI-MISC
been O-MISC B-ACTI-MISC
identified O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
6 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
7 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
Ashkenazi O-MISC I-ANAT-MISC
Jewish O-MISC I-PHEN-MISC
population O-MISC I-PHEN-MISC
. O-MISC B-ACTI-MISC

To O-MISC B-ACTI-MISC
assess O-MISC B-DEVI-MISC
the O-MISC B-ACTI-MISC
risk O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
common O-MISC B-ACTI-MISC
APC B-DISO-MISC B-LIVB-MISC
allelic O-MISC B-LIVB-MISC
variant O-MISC I-PROC-MISC
in O-MISC B-ACTI-MISC
colorectal O-MISC I-ACTI-MISC
carcinogenesis O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
analyzed O-MISC B-CONC-MISC
a O-MISC B-ACTI-MISC
large O-MISC B-ACTI-MISC
cohort O-MISC I-ANAT-MISC
of O-MISC B-ACTI-MISC
unselected O-MISC B-ACTI-MISC
Ashkenazi O-MISC B-PHEN-MISC
Jewish O-MISC B-UnknownType-MISC
subjects O-MISC I-ANAT-MISC
with O-MISC B-ACTI-MISC
adenomatous B-DISO-MISC I-ACTI-MISC
polyps I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
or O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
, I-DISO-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC O-MISC B-LIVB-MISC
I1307K O-MISC I-PROC-MISC
polymorphism O-MISC I-DISO-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
APC O-MISC B-LIVB-MISC
I1307K O-MISC I-PROC-MISC
allele O-MISC I-PROC-MISC
was O-MISC B-ACTI-MISC
identified O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
48 O-MISC B-ACTI-MISC
( O-MISC B-ACTI-MISC
10 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
476 O-MISC B-ACTI-MISC
patients O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
frequency O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
two O-MISC B-ACTI-MISC
separate O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
control O-MISC I-PHEN-MISC
groups O-MISC I-PHEN-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC O-MISC B-LIVB-MISC
I1307K O-MISC I-PROC-MISC
allele O-MISC B-LIVB-MISC
is O-MISC B-ACTI-MISC
associated O-MISC B-CHED-MISC
with O-MISC I-CHED-MISC
an O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
relative O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
of O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

5 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
1 O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

7 O-MISC B-ACTI-MISC
for O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
neoplasia I-DISO-MISC B-ANAT-MISC
( O-MISC B-ACTI-MISC
both O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
01 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

Furthermore O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
compared O-MISC B-ACTI-MISC
with O-MISC B-ACTI-MISC
noncarriers O-MISC I-ANAT-MISC
, O-MISC B-ACTI-MISC
APC O-MISC B-LIVB-MISC
I1307K O-MISC I-PROC-MISC
carriers O-MISC I-ACTI-MISC
had O-MISC B-ACTI-MISC
increased O-MISC B-CHED-MISC
numbers O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
adenomas B-DISO-MISC I-ACTI-MISC
and O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancers I-DISO-MISC B-ANAT-MISC
per O-MISC B-ACTI-MISC
patient O-MISC I-ANAT-MISC
( O-MISC B-ACTI-MISC
P O-MISC B-ACTI-MISC
= O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC
03 O-MISC B-ACTI-MISC
) O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
well O-MISC B-ACTI-MISC
as O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
younger O-MISC B-CHED-MISC
age O-MISC I-CHED-MISC
at O-MISC B-ACTI-MISC
diagnosis O-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

We O-MISC B-ACTI-MISC
conclude O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
APC O-MISC B-LIVB-MISC
I1307K O-MISC I-PROC-MISC
variant O-MISC I-PROC-MISC
leads O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
increased O-MISC B-ACTI-MISC
adenoma B-DISO-MISC I-ACTI-MISC
formation O-MISC B-CHED-MISC
and O-MISC B-ACTI-MISC
directly O-MISC B-ACTI-MISC
contributes O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
3 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
4 O-MISC B-ACTI-MISC
% O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
Ashkenazi O-MISC B-PHEN-MISC
Jewish O-MISC B-UnknownType-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

The O-MISC B-ACTI-MISC
estimated O-MISC B-ACTI-MISC
relative O-MISC B-CHED-MISC
risk O-MISC I-CHED-MISC
for O-MISC B-ACTI-MISC
carriers O-MISC I-ACTI-MISC
may O-MISC B-ACTI-MISC
justify O-MISC B-ACTI-MISC
specific O-MISC B-ACTI-MISC
clinical O-MISC B-CONC-MISC
screening O-MISC I-CONC-MISC
for O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
360 O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
000 O-MISC B-ACTI-MISC
Americans O-MISC I-ANAT-MISC
expected O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
harbor O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
allele O-MISC B-LIVB-MISC
, O-MISC B-ACTI-MISC
and O-MISC B-ACTI-MISC
genetic O-MISC B-CONC-MISC
testing O-MISC I-CONC-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
setting O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
long O-MISC B-CONC-MISC
- O-MISC I-CONC-MISC
term O-MISC I-CONC-MISC
- O-MISC I-CONC-MISC
outcome O-MISC I-CONC-MISC
studies O-MISC I-CONC-MISC
may O-MISC B-ACTI-MISC
impact O-MISC B-ACTI-MISC
significantly O-MISC B-CHED-MISC
on O-MISC B-ACTI-MISC
colorectal B-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
prevention O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
this O-MISC B-ACTI-MISC
population O-MISC I-ANAT-MISC
. O-MISC B-ACTI-MISC

Localization O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
BRCA1 O-MISC B-LIVB-MISC
and O-MISC B-ACTI-MISC
its O-MISC B-ACTI-MISC
loss O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
grade O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
non B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
inherited I-DISO-MISC B-ANAT-MISC
breast I-DISO-MISC B-ANAT-MISC
carcinomas I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Although O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
link O-MISC B-ACTI-MISC
between O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
tumour B-DISO-MISC I-PROC-MISC
- O-MISC I-PROC-MISC
suppressor O-MISC I-PROC-MISC
gene O-MISC I-PROC-MISC
and O-MISC B-ACTI-MISC
hereditary B-DISO-MISC I-ACTI-MISC
breast I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
ovarian I-DISO-MISC I-ACTI-MISC
cancer I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
established O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
role O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
if O-MISC B-ACTI-MISC
any O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
in O-MISC B-ACTI-MISC
non B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
familial I-DISO-MISC B-ANAT-MISC
cancers I-DISO-MISC B-ANAT-MISC
is O-MISC B-ACTI-MISC
unclear O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

BRCA1 O-MISC B-LIVB-MISC
mutations O-MISC I-DISO-MISC
are O-MISC B-ACTI-MISC
rare O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
sporadic B-DISO-MISC I-ACTI-MISC
cancers I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
but O-MISC B-ACTI-MISC
loss O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
resulting O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
expression O-MISC I-DISO-MISC
or O-MISC B-ACTI-MISC
incorrect O-MISC B-CHED-MISC
subcellular O-MISC B-CHED-MISC
localization O-MISC I-CHED-MISC
is O-MISC B-ACTI-MISC
postulated O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
be O-MISC B-ACTI-MISC
important O-MISC B-ACTI-MISC
in O-MISC B-ACTI-MISC
non B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC B-ANAT-MISC
familial I-DISO-MISC B-ANAT-MISC
breast I-DISO-MISC B-ANAT-MISC
and I-DISO-MISC B-ACTI-MISC
ovarian I-DISO-MISC I-ACTI-MISC
cancers I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Epigenetic O-MISC I-DISO-MISC
loss O-MISC I-LIVB-MISC
, O-MISC B-ACTI-MISC
however O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
has O-MISC B-ACTI-MISC
not O-MISC B-ACTI-MISC
received O-MISC B-ACTI-MISC
general O-MISC B-ACTI-MISC
acceptance O-MISC B-ACTI-MISC
due O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
controversy O-MISC B-ACTI-MISC
regarding O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
subcellular O-MISC I-GENE-MISC
localization O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
proteins O-MISC B-DISO-MISC
, O-MISC B-ACTI-MISC
reports O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
which O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
ranged O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
exclusively O-MISC B-ACTI-MISC
nuclear O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
conditionally O-MISC B-ACTI-MISC
nuclear O-MISC B-CHED-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
ER O-MISC I-GENE-MISC
/ O-MISC B-ACTI-MISC
golgi O-MISC I-GENE-MISC
, O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
cytoplasmic O-MISC I-GENE-MISC
invaginations O-MISC I-ACTI-MISC
into O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
nucleus O-MISC I-GENE-MISC
. O-MISC B-ACTI-MISC

In O-MISC B-ACTI-MISC
an O-MISC B-ACTI-MISC
attempt O-MISC B-DEVI-MISC
to O-MISC B-ACTI-MISC
resolve O-MISC B-CHED-MISC
this O-MISC B-ACTI-MISC
issue O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
we O-MISC B-ACTI-MISC
have O-MISC B-ACTI-MISC
comprehensively O-MISC B-CHED-MISC
characterized O-MISC B-DEVI-MISC
19 O-MISC B-ACTI-MISC
anti O-MISC O-MISC
- O-MISC B-DISO-MISC
BRCA1 O-MISC B-DISO-MISC
antibodies O-MISC B-DISO-MISC
. O-MISC B-ACTI-MISC

These O-MISC B-ACTI-MISC
reagents O-MISC O-MISC
detect O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
220 O-MISC B-ACTI-MISC
- O-MISC B-ACTI-MISC
kD O-MISC B-ACTI-MISC
protein O-MISC O-MISC
localized O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
discrete O-MISC B-ACTI-MISC
nuclear O-MISC B-CHED-MISC
foci O-MISC I-CHED-MISC
in O-MISC B-ACTI-MISC
all O-MISC B-ACTI-MISC
epithelial O-MISC I-GENE-MISC
cell O-MISC B-GEOG-MISC
lines O-MISC B-GEOG-MISC
, O-MISC B-ACTI-MISC
including O-MISC B-ACTI-MISC
those O-MISC B-ACTI-MISC
derived O-MISC B-ACTI-MISC
from O-MISC B-ACTI-MISC
breast B-DISO-MISC I-GENE-MISC
malignancies I-DISO-MISC I-ACTI-MISC
. O-MISC B-ACTI-MISC

Immunohistochemical O-MISC B-CONC-MISC
staining O-MISC I-CONC-MISC
of O-MISC B-ACTI-MISC
human O-MISC I-ANAT-MISC
breast O-MISC I-GENE-MISC
specimens O-MISC B-GEOG-MISC
also O-MISC B-ACTI-MISC
revealed O-MISC B-ACTI-MISC
BRCA1 O-MISC I-GENE-MISC
nuclear O-MISC B-ACTI-MISC
foci O-MISC B-CHED-MISC
in O-MISC B-ACTI-MISC
benign O-MISC I-ACTI-MISC
breast O-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
invasive B-DISO-MISC I-ACTI-MISC
lobular I-DISO-MISC B-ANAT-MISC
cancers I-DISO-MISC B-ANAT-MISC
and O-MISC B-ACTI-MISC
low B-DISO-MISC I-ACTI-MISC
- I-DISO-MISC I-CHED-MISC
grade I-DISO-MISC B-ANAT-MISC
ductal I-DISO-MISC I-ACTI-MISC
carcinomas I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC

Conversely O-MISC B-ACTI-MISC
, O-MISC B-ACTI-MISC
BRCA1 O-MISC O-MISC
expression O-MISC I-DISO-MISC
was O-MISC B-ACTI-MISC
reduced O-MISC B-CHED-MISC
or O-MISC B-ACTI-MISC
undetectable O-MISC I-DISO-MISC
in O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
majority O-MISC B-ACTI-MISC
of O-MISC B-ACTI-MISC
high O-MISC B-CHED-MISC
- O-MISC I-CHED-MISC
grade O-MISC I-CHED-MISC
, O-MISC B-ACTI-MISC
ductal B-DISO-MISC I-ACTI-MISC
carcinomas I-DISO-MISC B-ANAT-MISC
, O-MISC B-ACTI-MISC
suggesting O-MISC B-ACTI-MISC
that O-MISC B-ACTI-MISC
absence O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
BRCA1 O-MISC B-LIVB-MISC
may O-MISC B-ACTI-MISC
contribute O-MISC B-ACTI-MISC
to O-MISC B-ACTI-MISC
the O-MISC B-ACTI-MISC
pathogenesis O-MISC I-ACTI-MISC
of O-MISC B-ACTI-MISC
a O-MISC B-ACTI-MISC
significant O-MISC B-CHED-MISC
percentage O-MISC B-CHED-MISC
of O-MISC B-ACTI-MISC
sporadic B-DISO-MISC B-CHED-MISC
breast I-DISO-MISC I-ACTI-MISC
cancers I-DISO-MISC B-ANAT-MISC
. O-MISC B-ACTI-MISC
. O-MISC B-ACTI-MISC

